Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
ABCA7,ABCX,ENSG00000064687,ATP binding cassette subfamily A member 7,19,1040101-1065572,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA041564,Enhanced,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cell Junctions,"Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 25.3,Cell line enhanced,NA,HMC-1: 52.2
ABCC5,"EST277145, MOAT-C, MRP5, SMRP",ENSG00000114770,ATP binding cassette subfamily C member 5,3,183919934-184018015,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA044067, HPA052295",Uncertain,NA,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,"Liver cancer:6.78e-8 (unfavourable), Prostate cancer:3.40e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,stomach: 72.6,Expressed in all,NA,NA
ABI1,"ABI-1, E3B1, SSH3BP1",ENSG00000136754,Abl interactor 1,10,26746593-26861087,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB008375, HPA029973, HPA068407",Approved,NA,Supported,Plasma membrane<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 87.4,Expressed in all,NA,NA
ABLIM3,KIAA0843,ENSG00000173210,Actin binding LIM protein family member 3,5,149141483-149260542,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003245,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,Renal cancer:1.28e-4 (unfavourable),Mixed,Tissue enhanced,NA,parathyroid gland: 79.4,adipose tissue: 63.7,Cell line enhanced,NA,TIME: 84.5
ACOT13,"HT012, THEM2",ENSG00000112304,Acyl-CoA thioesterase 13,6,24667035-24705065,Predicted intracellular proteins,Evidence at protein level,HPA019881,Approved,NA,Approved,Cell Junctions,Ovarian cancer:2.53e-6 (favourable),Expressed in all,Expressed in all,NA,NA,kidney: 19.9,Expressed in all,NA,NA
ADAM22,MDC2,ENSG00000008277,ADAM metallopeptidase domain 22,7,87934143-88202889,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA050325,NA,NA,Approved,Cell Junctions,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 47.6,prostate: 18.2,Cell line enhanced,NA,Karpas-707: 58.7;SH-SY5Y: 81.7
ADGRL2,"KIAA0786, LEC1, LPHH1, LPHN2",ENSG00000117114,Adhesion G protein-coupled receptor L2,1,81306160-81992436,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA043447,NA,NA,Approved,Plasma membrane<br>Cell Junctions,"Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 73.2,Cell line enhanced,NA,AF22: 246.2;hTEC/SVTERT24-B: 124.0;SH-SY5Y: 176.4
AFDN,"AF-6, AF6, MLLT4",ENSG00000130396,"Afadin, adherens junction formation factor",6,167826922-167972023,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868",Approved,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,Breast cancer:7.43e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,esophagus: 110.7,Mixed,NA,NA
AGER,"RAGE, SCARJ1",ENSG00000204305,Advanced glycosylation end-product specific receptor,6,32180968-32184324,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB011682, HPA064436",Enhanced,NA,Approved,Nucleoli fibrillar center<br>Plasma membrane<br>Cell Junctions,"Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable)",Expressed in all,Tissue enriched,181,lung: 889.2,thyroid gland: 4.9,Cell line enhanced,NA,HEK93: 2.5;U-266/70: 2.6
AGO2,"CASC7, EIF2C2, hAGO2, LINC00980, Q10",ENSG00000123908,"Argonaute 2, RISC catalytic component",8,140520156-140635619,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB019309, HPA058075",Approved,NA,Supported,Nucleoplasm<br>Cell Junctions,"Renal cancer:1.82e-5 (unfavourable), Endometrial cancer:1.21e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 12.0,Expressed in all,NA,NA
AMOT,KIAA1071,ENSG00000126016,Angiomotin,X,112774503-112840815,Predicted intracellular proteins,Evidence at protein level,"HPA067290, HPA067853",Enhanced,NA,Supported,Nucleus<br>Cell Junctions,"Renal cancer:4.21e-9 (favourable), Lung cancer:3.94e-4 (favourable)",Expressed in all,Tissue enhanced,NA,epididymis: 177.9,seminal vesicle: 38.6,Cell line enhanced,NA,AF22: 24.7;HAP1: 28.1
AMOTL1,JEAP,ENSG00000166025,Angiomotin like 1,11,94706431-94876753,Predicted intracellular proteins,Evidence at protein level,HPA001196,Approved,NA,Supported,Cell Junctions<br>Cytosol,Renal cancer:5.03e-6 (favourable),Expressed in all,Expressed in all,NA,NA,prostate: 52.5,Mixed,NA,NA
AMOTL2,LCCP,ENSG00000114019,Angiomotin like 2,3,134355874-134375479,Predicted intracellular proteins,Evidence at protein level,HPA063027,NA,NA,Approved,Cell Junctions,Endometrial cancer:1.94e-4 (unfavourable),Expressed in all,Mixed,NA,NA,adipose tissue: 76.7,Cell line enhanced,NA,BEWO: 266.7
ANKRA2,NA,ENSG00000164331,Ankyrin repeat family A member 2,5,73552335-73565686,Predicted intracellular proteins,Evidence at protein level,HPA065263,NA,NA,Approved,Plasma membrane<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 26.2,Expressed in all,NA,NA
APOC3,NA,ENSG00000110245,Apolipoprotein C3,11,116829706-116833072,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA065365,NA,NA,Approved,Nucleoplasm<br>Nucleoli<br>Cell Junctions,"Renal cancer:6.87e-5 (unfavourable), Liver cancer:3.77e-4 (favourable)",Tissue enriched,Tissue enriched,7,liver: 8677.3,small intestine: 1178.4,Group enriched,17,CACO-2: 85.2;Hep G2: 190.9
AQP4,MIWC,ENSG00000171885,Aquaporin 4,18,26852038-26865818,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB005079, HPA014784, CAB058689",Enhanced,Supported,Supported,Plasma membrane<br>Cell Junctions,NA,Tissue enriched,Group enriched,16,cerebral cortex: 630.0;lung: 171.9,thyroid gland: 24.4,Cell line enhanced,NA,AF22: 2.4;RPTEC TERT1: 1.0
ARHGAP21,"ARHGAP10, KIAA1424",ENSG00000107863,Rho GTPase activating protein 21,10,24583609-24723668,Predicted intracellular proteins,Evidence at protein level,"HPA036610, HPA057861",Approved,NA,Supported,Plasma membrane<br>Cell Junctions<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 88.5,Mixed,NA,NA
ARHGAP28,"FLJ10312, KIAA1314",ENSG00000088756,Rho GTPase activating protein 28,18,6729718-6915716,Predicted intracellular proteins,Evidence at protein level,"HPA030413, HPA030414, HPA030415",Enhanced,NA,Supported,Cell Junctions,NA,Mixed,Tissue enhanced,NA,testis: 133.0,placenta: 40.9,Cell line enhanced,NA,AF22: 35.5;CACO-2: 31.8
ARL15,"ARFRP2, FLJ20051",ENSG00000185305,ADP ribosylation factor like GTPase 15,5,53883945-54310582,Predicted intracellular proteins,Evidence at protein level,"HPA044604, HPA063820",Uncertain,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,placenta: 44.8,Mixed,NA,NA
ARPC1A,"Arc40, SOP2Hs, SOP2L",ENSG00000241685,Actin related protein 2/3 complex subunit 1A,7,99325910-99366262,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA004334,Approved,NA,Approved,Cell Junctions<br>Cytosol,Liver cancer:4.70e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 130.9,Expressed in all,NA,NA
ARPC5,"ARC16, dJ127C7.3, p16-Arc",ENSG00000162704,Actin related protein 2/3 complex subunit 5,1,183620846-183635757,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA022013, HPA031972",Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol,"Renal cancer:1.21e-10 (unfavourable), Liver cancer:3.63e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,appendix: 201.3,Expressed in all,NA,NA
ARVCF,NA,ENSG00000099889,Armadillo repeat gene deleted in velocardiofacial syndrome,22,19969896-20016808,Predicted intracellular proteins,Evidence at protein level,"CAB016162, HPA055264, HPA063675",Enhanced,NA,Enhanced,Plasma membrane<br>Cell Junctions,Urothelial cancer:5.76e-6 (favourable),Expressed in all,Mixed,NA,NA,spleen: 8.8,Cell line enhanced,NA,K-562: 18.0;SCLC-21H: 21.2;SH-SY5Y: 14.7;U-2 OS: 16.4
ASGR1,CLEC4H1,ENSG00000141505,Asialoglycoprotein receptor 1,17,7173431-7179564,Predicted intracellular proteins,Evidence at protein level,"HPA011954, HPA012852",Enhanced,NA,Supported,Vesicles<br>Cell Junctions,NA,Tissue enriched,Tissue enriched,13,liver: 236.1,testis: 17.6,Cell line enriched,25,Hep G2: 331.3
ATP23,"KUB3, XRCC6BP1",ENSG00000166896,ATP23 metallopeptidase and ATP synthase assembly factor homolog,12,57941541-57957269,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035804, HPA043204",Uncertain,NA,Enhanced,Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Renal cancer:1.44e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 26.8,rectum: 5.5,Expressed in all,NA,NA
BRK1,"C3orf10, HSPC300, MDS027",ENSG00000254999,"BRICK1, SCAR/WAVE actin nucleating complex subunit",3,10115592-10127190,Predicted intracellular proteins,Evidence at protein level,HPA060391,NA,NA,Approved,Nuclear speckles<br>Cell Junctions,Liver cancer:5.76e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,fallopian tube: 225.0,Expressed in all,NA,NA
BUB1B-PAK6,NA,ENSG00000259288,BUB1B-PAK6 readthrough,15,40217428-40276396,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA031124,Uncertain,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions,NA,Not detected,Not detected,NA,NA,cerebral cortex: 0.1,Not detected,NA,NA
BVES,"HBVES, POP1, POPDC1",ENSG00000112276,Blood vessel epicardial substance,6,105096822-105137174,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA014788, HPA018176",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions,NA,Mixed,Tissue enhanced,NA,smooth muscle: 25.0,testis: 20.7,Cell line enhanced,NA,RH-30: 28.7;WM-115: 29.8
C11orf52,"FLJ25219, MGC14839",ENSG00000149300,Chromosome 11 open reading frame 52,11,111918032-111926872,Predicted intracellular proteins,Evidence at protein level,"HPA038387, HPA038388",Uncertain,NA,Enhanced,Cell Junctions,NA,Not detected,Mixed,NA,NA,kidney: 44.9,Cell line enhanced,NA,CAPAN-2: 19.2;RPTEC TERT1: 20.1;T-47d: 70.7
C16orf59,FLJ13909,ENSG00000162062,Chromosome 16 open reading frame 59,16,2460080-2464963,Predicted intracellular proteins,Evidence at protein level,"HPA051394, HPA055389",Approved,NA,Approved,Nucleoplasm<br>Cell Junctions,"Liver cancer:2.43e-5 (unfavourable), Lung cancer:7.58e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 5.5,"bone marrow,lymph node: 2.5",Mixed,NA,NA
C17orf62,"FLJ90469, MGC4368",ENSG00000178927,Chromosome 17 open reading frame 62,17,82442589-82450829,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045696,Uncertain,NA,Approved,Plasma membrane<br>Cell Junctions,Renal cancer:6.83e-11 (unfavourable),Expressed in all,Expressed in all,NA,NA,lymph node: 127.0,Expressed in all,NA,NA
C4orf19,FLJ11017,ENSG00000154274,Chromosome 4 open reading frame 19,4,37453941-37623495,Predicted intracellular proteins,Evidence at protein level,"HPA043458, HPA052894",Enhanced,NA,Supported,Cell Junctions,Renal cancer:1.49e-11 (favourable),Mixed,Mixed,NA,NA,rectum: 26.9,Group enriched,6,RT4: 70.0;SK-BR-3: 25.9;T-47d: 116.1
C8orf37,"BBS21, CORD16, FLJ30600, RP64",ENSG00000156172,Chromosome 8 open reading frame 37,8,95244919-95269201,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA024198,Approved,NA,Approved,Plasma membrane<br>Cell Junctions<br>Cytosol,Endometrial cancer:4.63e-4 (unfavourable),Expressed in all,Mixed,NA,NA,fallopian tube: 6.3,Mixed,NA,NA
C9orf3,"AOPEP, AP-O, APO, C90RF3, FLJ14675",ENSG00000148120,Chromosome 9 open reading frame 3,9,94726701-95087218,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004633, HPA072729",Approved,NA,Approved,Cell Junctions,Renal cancer:6.33e-5 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 50.0,Mixed,NA,NA
CABLES2,"C20orf150, dJ908M14.2, ik3-2",ENSG00000149679,Cdk5 and Abl enzyme substrate 2,20,62388632-62407285,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA052138,NA,NA,Approved,Nuclear bodies<br>Cell Junctions,"Renal cancer:1.24e-6 (unfavourable), Endometrial cancer:5.26e-5 (unfavourable)",Expressed in all,Tissue enriched,6,testis: 58.3,cerebral cortex: 9.0,Expressed in all,NA,NA
CADM1,"BL2, IGSF4, IGSF4A, Necl-2, NECL2, RA175, ST17, SYNCAM, SYNCAM1, TSLC1",ENSG00000182985,Cell adhesion molecule 1,11,115169218-115504957,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB037266,Enhanced,NA,Supported,Cell Junctions,Endometrial cancer:1.32e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 151.6,Cell line enhanced,NA,CACO-2: 245.0;WM-115: 185.3
CAMK2A,"CAMKA, CaMKIINalpha, KIAA0968",ENSG00000070808,Calcium/calmodulin dependent protein kinase II alpha,5,150219491-150290291,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004330, HPA051783, HPA051785, HPA053973",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Tissue enriched,Tissue enriched,9,cerebral cortex: 283.6,skeletal muscle: 33.3,Cell line enhanced,NA,SCLC-21H: 6.2;U-87 MG: 4.3
CAMK2B,"CAM2, CAMK2, CAMKB",ENSG00000058404,Calcium/calmodulin dependent protein kinase II beta,7,44217150-44334577,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB006849, HPA026307, HPA051783, HPA051785, HPA053973",Enhanced,Supported,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 214.1,skeletal muscle: 46.1,Cell line enriched,12,SCLC-21H: 88.9
CAMK2D,CAMKD,ENSG00000145349,Calcium/calmodulin dependent protein kinase II delta,4,113451032-113761927,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA026281, HPA051783, HPA051785, HPA053973",Approved,NA,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,heart muscle: 110.3,Mixed,NA,NA
CAMK2G,CAMKG,ENSG00000148660,Calcium/calmodulin dependent protein kinase II gamma,10,73812501-73874591,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040656, HPA051783, HPA051785, HPA053973",Approved,NA,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 119.0,Expressed in all,NA,NA
CCDC170,"bA282P11.1, C6orf97, FLJ23305",ENSG00000120262,Coiled-coil domain containing 170,6,151494030-151621193,Predicted intracellular proteins,Evidence at protein level,"HPA027114, HPA027185",Enhanced,NA,Approved,Golgi apparatus<br>Cell Junctions,Endometrial cancer:3.64e-4 (favourable),Mixed,Tissue enriched,6,fallopian tube: 53.5,thyroid gland: 9.4,Group enriched,6,MCF7: 7.9;T-47d: 5.5
CCDC66,DKFZp686C0433,ENSG00000180376,Coiled-coil domain containing 66,3,56557161-56621818,Predicted intracellular proteins,Evidence at protein level,HPA044185,Uncertain,NA,Approved,Cell Junctions<br>Midbody ring<br>Microtubule organizing center,NA,Expressed in all,Mixed,NA,NA,fallopian tube: 9.6,Expressed in all,NA,NA
CCDC85C,NA,ENSG00000205476,Coiled-coil domain containing 85C,14,99500180-99604026,Predicted intracellular proteins,Evidence at protein level,HPA058346,Uncertain,NA,Approved,Nuclear speckles<br>Cell Junctions,"Renal cancer:2.60e-5 (favourable), Endometrial cancer:1.44e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 31.1,Mixed,NA,NA
CD34,NA,ENSG00000174059,CD34 molecule,1,207880972-207911402,"CD markers, Predicted membrane proteins",Evidence at protein level,"CAB000018, HPA036722, HPA036723",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Cell Junctions,"Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 316.6,Group enriched,7,HUVEC TERT2: 53.6;MOLT-4: 53.1
CDH1,"CD324, UVO, uvomorulin",ENSG00000039068,Cadherin 1,16,68737225-68835548,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857",Enhanced,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cell Junctions,Renal cancer:2.06e-4 (favourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 475.1,thyroid gland: 266.2,Cell line enhanced,NA,BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9
CDH17,"cadherin, HPT-1",ENSG00000079112,Cadherin 17,8,94127171-94217303,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA023614, HPA023616, CAB025143, HPA026556",Enhanced,NA,Supported,Cell Junctions,NA,Group enriched,Group enriched,8,colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3,appendix: 37.5,Group enriched,6,CACO-2: 81.5;U-266/70: 121.0
CDH2,"CD325, CDHN, NCAD",ENSG00000170558,Cadherin 2,18,27950966-28177446,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000141, CAB018580, HPA058574, CAB078686",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions,NA,Expressed in all,Tissue enhanced,NA,heart muscle: 123.5;parathyroid gland: 126.2,adrenal gland: 87.3,Cell line enhanced,NA,AF22: 306.2;fHDF/TERT166: 367.9
CDH24,CDH11L,ENSG00000139880,Cadherin 24,14,23047062-23057538,Predicted membrane proteins,Evidence at protein level,HPA065233,NA,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Microtubule organizing center<br>Cytosol,Renal cancer:1.15e-4 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 8.5,Cell line enhanced,NA,SCLC-21H: 62.2
CDH3,"CDHP, PCAD",ENSG00000062038,Cadherin 3,16,68636189-68722616,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA001767, CAB002487",Enhanced,NA,Uncertain,Cell Junctions<br>Cytosol,"Pancreatic cancer:8.43e-4 (unfavourable), Lung cancer:8.53e-4 (unfavourable)",Mixed,Tissue enhanced,NA,skin: 31.9,ovary: 26.5,Cell line enhanced,NA,A-431: 89.4;HaCaT: 243.8;HBEC3-KT: 95.6;hTCEpi: 75.4;RPTEC TERT1: 88.7
CDK5,PSSALRE,ENSG00000164885,Cyclin dependent kinase 5,7,151053812-151058530,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB008909, HPA064535",Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 49.9,Expressed in all,NA,NA
CDK5RAP2,"C48, CEP215, FLJ10867, MCPH3",ENSG00000136861,CDK5 regulatory subunit associated protein 2,9,120388869-120580170,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035820, HPA046529",Approved,NA,Enhanced,Cell Junctions<br>Centrosome,NA,Expressed in all,Expressed in all,NA,NA,testis: 37.4,Expressed in all,NA,NA
CERCAM,"CEECAM1, CerCAM, GLT25D3",ENSG00000167123,Cerebral endothelial cell adhesion molecule,9,128411751-128437351,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021657, HPA051595",Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Cell Junctions,"Renal cancer:3.33e-16 (unfavourable), Urothelial cancer:3.30e-5 (unfavourable), Ovarian cancer:5.22e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 155.6,Mixed,NA,NA
CFAP206,"C6orf165, dJ382I10.1, FLJ25974",ENSG00000272514,Cilia and flagella associated protein 206,6,87407983-87464465,Predicted intracellular proteins,Evidence at protein level,"HPA044891, HPA072261",Approved,NA,Approved,Nucleoplasm<br>Cell Junctions,NA,Not detected,Group enriched,30,fallopian tube: 35.9;testis: 106.8,"lung,thyroid gland: 2.3",Cell line enhanced,NA,MCF7: 1.7;RPTEC TERT1: 2.0;T-47d: 4.2
CFB,"BF, BFD, H2-Bf",ENSG00000243649,Complement factor B,6,31945650-31952084,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA000951, HPA001817, HPA001832, CAB016381",Supported,NA,Approved,Endoplasmic reticulum<br>Vesicles<br>Cell Junctions,"Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable)",Expressed in all,Tissue enriched,21,liver: 285.9,stomach: 13.8,Cell line enhanced,NA,CAPAN-2: 6.6;fHDF/TERT166: 9.6;HSkMC: 14.1
CGN,KIAA1319,ENSG00000143375,Cingulin,1,151510510-151538692,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017193, HPA027586, HPA027587, HPA027657",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions,Renal cancer:5.84e-10 (favourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 73.4,small intestine: 61.9,Cell line enhanced,NA,CACO-2: 75.4;CAPAN-2: 52.0
CGNL1,"FLJ14957, JACOP, KIAA1749, PCING",ENSG00000128849,Cingulin like 1,15,57375967-57550727,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB013500, HPA056911, HPA069214",Enhanced,NA,Approved,Cell Junctions,"Renal cancer:1.37e-6 (favourable), Endometrial cancer:3.55e-4 (favourable), Liver cancer:5.58e-4 (favourable)",Expressed in all,Mixed,NA,NA,kidney: 73.1,Cell line enhanced,NA,AF22: 12.9;HUVEC TERT2: 43.8;TIME: 26.5
CHCHD7,"COX23, MGC2217",ENSG00000170791,Coiled-coil-helix-coiled-coil-helix domain containing 7,8,56211686-56218798,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA050783,Approved,NA,Approved,Cell Junctions<br>Aggresome,"Endometrial cancer:1.39e-6 (unfavourable), Renal cancer:9.47e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 61.6,Expressed in all,NA,NA
CLCA2,CLCRG2,ENSG00000137975,Chloride channel accessory 2,1,86424086-86456558,Predicted membrane proteins,Evidence at protein level,HPA047192,Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,NA,Group enriched,Group enriched,5,esophagus: 126.4;skin: 102.7,tonsil: 22.5,Cell line enhanced,NA,BEWO: 36.7;HBEC3-KT: 23.7;hTCEpi: 148.8
CLDN2,NA,ENSG00000165376,Claudin 2,X,106900164-106930861,Predicted membrane proteins,Evidence at protein level,"CAB002609, HPA051548",Enhanced,NA,Supported,Nucleoplasm<br>Cell Junctions,Thyroid cancer:1.70e-4 (favourable),Group enriched,Tissue enhanced,NA,gallbladder: 159.0;kidney: 171.8;seminal vesicle: 129.3,epididymis: 41.1,Group enriched,23,A549: 24.6;CACO-2: 18.2;RPTEC TERT1: 35.1
CLDN3,"C7orf1, CPE-R2, CPETR2, HRVP1, RVP1",ENSG00000165215,Claudin 3,7,73768997-73770270,"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002702, HPA014361",Supported,NA,Supported,Cell Junctions,Renal cancer:3.39e-5 (favourable),Mixed,Tissue enhanced,NA,colon: 87.7;small intestine: 119.5,duodenum: 55.0,Cell line enhanced,NA,MCF7: 175.3;PC-3: 44.1;SCLC-21H: 68.2;T-47d: 98.9
CLDN7,"CEPTRL2, CPETRL2, Hs.84359",ENSG00000181885,Claudin 7,17,7259903-7263983,"Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB013063, HPA014703, HPA073662",Enhanced,NA,Approved,Vesicles<br>Cell Junctions,"Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable)",Expressed in all,Mixed,NA,NA,small intestine: 350.1,Cell line enhanced,NA,BEWO: 162.4;CAPAN-2: 304.6;HaCaT: 644.4;MCF7: 198.9;SK-BR-3: 225.1
CLDN9,NA,ENSG00000213937,Claudin 9,16,3012456-3014505,Predicted membrane proteins,Evidence at protein level,HPA076613,NA,NA,Supported,Vesicles<br>Cell Junctions,"Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable)",Mixed,Tissue enhanced,NA,parathyroid gland: 3.2,bone marrow: 1.7,Cell line enhanced,NA,CAPAN-2: 5.5;MCF7: 16.8;SCLC-21H: 19.5
CLSTN2,"CDHR13, CS2, CSTN2, FLJ39113",ENSG00000158258,Calsyntenin 2,3,139935185-140577397,Predicted membrane proteins,Evidence at protein level,HPA031342,Approved,NA,Approved,Nucleoplasm<br>Nuclear membrane<br>Cell Junctions,NA,Tissue enriched,Tissue enhanced,NA,cerebral cortex: 34.6;ovary: 81.6,adipose tissue: 18.8,Cell line enhanced,NA,AF22: 5.2;SCLC-21H: 17.0;THP-1: 6.3
CMTR2,"AFT, FLJ11171, FTSJD1, MTr2",ENSG00000180917,Cap methyltransferase 2,16,71281389-71289715,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041700, HPA048265",Uncertain,NA,Approved,Nuclear speckles<br>Cell Junctions,Renal cancer:4.97e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 18.9,Expressed in all,NA,NA
COBL,KIAA0633,ENSG00000106078,Cordon-bleu WH2 repeat protein,7,51016212-51316818,Predicted intracellular proteins,Evidence at protein level,"HPA019033, HPA019167",Enhanced,NA,Approved,Plasma membrane<br>Cell Junctions,Renal cancer:5.21e-12 (favourable),Mixed,Mixed,NA,NA,parathyroid gland: 61.9,Cell line enhanced,NA,BEWO: 31.3;HeLa: 39.5;RPMI-8226: 32.2
COBLL1,KIAA0977,ENSG00000082438,Cordon-bleu WH2 repeat protein like 1,2,164653624-164843679,Predicted intracellular proteins,Evidence at protein level,"HPA044933, HPA053344",Enhanced,NA,Approved,Cell Junctions,Renal cancer:5.27e-13 (favourable),Expressed in all,Mixed,NA,NA,placenta: 77.1,Mixed,NA,NA
COLEC12,"CL-P1, SCARA4, SRCL",ENSG00000158270,Collectin subfamily member 12,18,316740-500722,Predicted membrane proteins,Evidence at protein level,"HPA047917, HPA071056",Enhanced,NA,Approved,Golgi apparatus<br>Vesicles<br>Cell Junctions,Thyroid cancer:8.10e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,placenta: 28.2,lung: 16.7,Cell line enhanced,NA,ASC TERT1: 16.8;BJ: 10.3;HSkMC: 14.5;U-2197: 29.2
COLQ,EAD,ENSG00000206561,Collagen like tail subunit of asymmetric acetylcholinesterase,3,15450133-15521751,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA045876,NA,NA,Approved,Plasma membrane<br>Cell Junctions,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 19.4,fallopian tube: 17.6,Cell line enhanced,NA,BEWO: 13.9;HDLM-2: 4.5;U-937: 5.9
CRB3,MGC17303,ENSG00000130545,"Crumbs 3, cell polarity complex component",19,6463777-6467221,Predicted membrane proteins,Evidence at protein level,HPA013835,Enhanced,NA,Supported,Cell Junctions,"Renal cancer:0.00e+0 (favourable), Urothelial cancer:8.06e-5 (favourable), Endometrial cancer:4.54e-4 (favourable)",Mixed,Mixed,NA,NA,duodenum: 37.4,Cell line enhanced,NA,A-431: 50.4;BEWO: 34.1;CACO-2: 31.7;HaCaT: 32.6
CTNNA1,CAP102,ENSG00000044115,Catenin alpha 1,5,138610967-138935034,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB021089, HPA046119, HPA063535",Approved,NA,Enhanced,Plasma membrane<br>Cell Junctions,"Renal cancer:7.34e-7 (favourable), Pancreatic cancer:8.02e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 217.1,Mixed,NA,NA
CTNNBIP1,"ICAT, MGC15093",ENSG00000178585,Catenin beta interacting protein 1,1,9848276-9910336,Predicted intracellular proteins,Evidence at protein level,HPA042617,NA,NA,Approved,Plasma membrane<br>Cell Junctions<br>Mitochondria,Endometrial cancer:5.68e-6 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 289.6,Expressed in all,NA,NA
CTNND2,"GT24, NPRAP",ENSG00000169862,Catenin delta 2,5,10971840-11904043,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA015077, CAB037339",Enhanced,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Cell Junctions,NA,Tissue enriched,Tissue enriched,18,cerebral cortex: 103.2,spleen: 5.6,Cell line enhanced,NA,AF22: 19.5;MCF7: 7.1;SK-BR-3: 4.4;U-266/84: 12.6
CTXN1,FLJ25968,ENSG00000178531,Cortexin 1,19,7924485-7926166,Predicted membrane proteins,Evidence at transcript level,HPA016669,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 100.4,endometrium: 22.7,Cell line enhanced,NA,AN3-CA: 86.1;NTERA-2: 70.2;SCLC-21H: 63.8;SH-SY5Y: 96.5
CXADR,CAR,ENSG00000154639,Coxsackie virus and adenovirus receptor,21,17512382-17593579,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA003342, CAB005103, HPA030411, HPA030412",Enhanced,NA,Enhanced,Plasma membrane<br>Cell Junctions,Head and neck cancer:3.50e-4 (favourable),Expressed in all,Mixed,NA,NA,skin: 59.1,Cell line enhanced,NA,CACO-2: 77.2;NTERA-2: 105.2;RT4: 82.7
CYP20A1,CYP-M,ENSG00000119004,Cytochrome P450 family 20 subfamily A member 1,2,203238940-203305611,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA055872, HPA058461",Uncertain,NA,Approved,Plasma membrane<br>Cell Junctions<br>Actin filaments,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 16.4,Mixed,NA,NA
DCAF13,"DKFZP564O0463, Gm83, HSPC064, WDSOF1",ENSG00000164934,DDB1 and CUL4 associated factor 13,8,103414714-103443453,Predicted intracellular proteins,Evidence at protein level,HPA044504,Uncertain,NA,Supported,Nucleus<br>Nucleoli<br>Cell Junctions<br>Centrosome<br>Cytosol,"Liver cancer:8.05e-6 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Breast cancer:4.06e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 58.8,Expressed in all,NA,NA
DCP2,NUDT20,ENSG00000172795,Decapping mRNA 2,5,112976702-113020970,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB011677, HPA057676",Approved,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Cytoplasmic bodies,"Renal cancer:2.66e-5 (unfavourable), Liver cancer:4.84e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 18.9,Expressed in all,NA,NA
DDB2,"DDBB, FLJ34321, UV-DDB2, XPE",ENSG00000134574,Damage specific DNA binding protein 2,11,47214465-47239240,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB025912, HPA058406",Enhanced,NA,Supported,Nucleoplasm<br>Cell Junctions,"Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,skin: 53.7,Expressed in all,NA,NA
DDR1,"CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6",ENSG00000204580,Discoidin domain receptor tyrosine kinase 1,6,30876421-30900156,"CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB010162, CAB025656, HPA057194",Approved,NA,Approved,Nucleoplasm<br>Cell Junctions,Renal cancer:3.31e-10 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 51.6,Cell line enhanced,NA,HaCaT: 80.3;RT4: 74.6;T-47d: 96.8
DHRS7B,"CGI-93, DKFZp566O084, MGC8916, SDR32C1",ENSG00000109016,Dehydrogenase/reductase 7B,17,21123364-21193265,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012132, HPA016873",Uncertain,NA,Approved,Plasma membrane<br>Cell Junctions<br>Cytosol,"Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 51.2,Expressed in all,NA,NA
DLG5,"KIAA0583, P-dlg",ENSG00000151208,Discs large MAGUK scaffold protein 5,10,77790791-77926526,Predicted intracellular proteins,Evidence at protein level,HPA001746,NA,NA,Supported,Cell Junctions,Liver cancer:5.38e-4 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 33.8,Mixed,NA,NA
DLX1,NA,ENSG00000144355,Distal-less homeobox 1,2,172084740-172089677,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA035666, HPA045884",Approved,NA,Approved,Nucleus<br>Vesicles<br>Cell Junctions,NA,Tissue enhanced,Tissue enhanced,NA,adrenal gland: 1.6;cerebral cortex: 5.0,prostate: 0.8,Cell line enhanced,NA,AN3-CA: 103.9
DNAJC18,MGC29463,ENSG00000170464,DnaJ heat shock protein family (Hsp40) member C18,5,139408588-139444491,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036538, HPA060154",Approved,NA,Supported,Cell Junctions,Pancreatic cancer:5.89e-4 (favourable),Mixed,Group enriched,5,cerebral cortex: 30.2;testis: 115.6,ovary: 13.8,Mixed,NA,NA
DOC2A,NA,ENSG00000149927,Double C2 domain alpha,16,30005509-30023270,Predicted intracellular proteins,Evidence at protein level,HPA065676,NA,NA,Uncertain,Nucleus<br>Nucleoli<br>Cell Junctions,NA,Tissue enhanced,Group enriched,9,cerebral cortex: 69.7;testis: 21.0,ovary: 5.2,Cell line enhanced,NA,BEWO: 12.9;SCLC-21H: 42.7;U-937: 14.1
DONSON,"B17, C21orf60, C2TA, DKFZP434M035",ENSG00000159147,Downstream neighbor of SON,21,33559542-33588708,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039558, HPA049033",Uncertain,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Ovarian cancer:2.17e-4 (favourable), Liver cancer:8.22e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 40.3,parathyroid gland: 15.4,Expressed in all,NA,NA
DPEP1,NA,ENSG00000015413,Dipeptidase 1 (renal),16,89613308-89638456,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"HPA009426, HPA012783",Enhanced,NA,Approved,Nucleus<br>Cell Junctions,Renal cancer:6.84e-4 (favourable),Tissue enriched,Tissue enhanced,NA,kidney: 262.6;small intestine: 418.9,pancreas: 92.8,Cell line enhanced,NA,Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
DPH1,"DPH2L, DPH2L1, OVCA1",ENSG00000108963,Diphthamide biosynthesis 1,17,2030110-2043430,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA069750,NA,NA,Approved,Nucleoplasm<br>Cell Junctions,Pancreatic cancer:1.78e-5 (favourable),Expressed in all,Expressed in all,NA,NA,fallopian tube: 31.5,Expressed in all,NA,NA
DSC3,"CDHF3, DSC, DSC1, DSC2, DSC4",ENSG00000134762,Desmocollin 3,18,30990008-31042815,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB037328, HPA049265, HPA073937",Enhanced,NA,Enhanced,Plasma membrane<br>Cell Junctions,Urothelial cancer:1.04e-5 (unfavourable),Tissue enhanced,Group enriched,12,esophagus: 119.1;skin: 454.8,tonsil: 24.8,Cell line enhanced,NA,HaCaT: 242.4;hTCEpi: 115.0;hTERT-HME1: 89.5
DSG2,CDHF5,ENSG00000046604,Desmoglein 2,18,31498043-31549008,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA004896, CAB025122",Enhanced,NA,Enhanced,Plasma membrane<br>Cell Junctions,"Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 251.3,rectum: 106.9,Cell line enhanced,NA,HaCaT: 233.0;hTERT-HME1: 159.3
DSP,"DPI, DPII, KPPS2, PPKS2",ENSG00000096696,Desmoplakin,6,7541575-7586717,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB037324, HPA045840, HPA054950",Enhanced,NA,Enhanced,Cell Junctions,"Renal cancer:1.53e-9 (favourable), Urothelial cancer:1.82e-4 (unfavourable)",Tissue enhanced,Group enriched,8,esophagus: 345.7;skin: 1016.4,placenta: 89.1,Cell line enhanced,NA,BEWO: 263.2;HaCaT: 265.1;hTCEpi: 482.9
DTNA,"D18S892E, DRP3, DTN, DTN-1, DTN-2, DTN-3",ENSG00000134769,Dystrobrevin alpha,18,34493290-34891844,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB015196, HPA071177",Enhanced,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Intermediate filaments,Renal cancer:2.64e-7 (favourable),Tissue enriched,Tissue enhanced,NA,cerebral cortex: 197.2,heart muscle: 101.8,Cell line enhanced,NA,NTERA-2: 42.7;SCLC-21H: 70.5;U-87 MG: 59.2
EDA2R,"EDA-A2R, EDAA2R, TNFRSF27, XEDAR",ENSG00000131080,Ectodysplasin A2 receptor,X,66595637-66639298,Predicted membrane proteins,Evidence at protein level,HPA054522,NA,NA,Approved,Cell Junctions,NA,Mixed,Mixed,NA,NA,thyroid gland: 9.5,Cell line enhanced,NA,HSkMC: 24.5;LHCN-M2: 26.7
EFCAB11,C14orf143,ENSG00000140025,EF-hand calcium binding domain 11,14,89794669-89954777,Predicted intracellular proteins,Evidence at transcript level,HPA051209,NA,NA,Approved,Cell Junctions<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,testis: 60.1,fallopian tube: 17.2,Expressed in all,NA,NA
ELFN1,PPP1R28,ENSG00000225968,Extracellular leucine rich repeat and fibronectin type III domain containing 1,7,1688119-1747954,Predicted membrane proteins,Evidence at protein level,HPA066382,NA,NA,Approved,Nucleoplasm<br>Cell Junctions,Liver cancer:9.68e-4 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 3.5;liver: 3.7,endometrium: 1.7,Cell line enhanced,NA,REH: 28.4;U-138 MG: 18.3;U-2 OS: 28.4;U-2197: 29.8
ELMO3,"CED-12, CED12, ELMO-3, FLJ13824",ENSG00000102890,Engulfment and cell motility 3,16,67199111-67204029,Predicted intracellular proteins,Evidence at protein level,HPA021484,Approved,NA,Approved,Plasma membrane<br>Cell Junctions,Renal cancer:2.77e-5 (favourable),Expressed in all,Mixed,NA,NA,skin: 39.3,Cell line enhanced,NA,BEWO: 31.7;CAPAN-2: 43.1;HaCaT: 41.1;T-47d: 42.8
ELOC,"SIII, TCEB1",ENSG00000154582,Elongin C,8,73939169-73972287,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA078113,NA,NA,Approved,Cell Junctions,Breast cancer:6.48e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 162.4,Expressed in all,NA,NA
EMC4,"FLJ90746, MGC24415, PIG17, TMEM85",ENSG00000128463,ER membrane protein complex subunit 4,15,34224999-34230156,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA026868, HPA053440",Approved,NA,Approved,Cell Junctions<br>Focal adhesion sites,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 122.1,Expressed in all,NA,NA
EPB41,"4.1R, EL1",ENSG00000159023,Erythrocyte membrane protein band 4.1,1,28887091-29120046,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA028076, HPA028412, HPA028414",Supported,NA,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,"Renal cancer:1.75e-6 (unfavourable), Endometrial cancer:4.58e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 50.6,Mixed,NA,NA
EPB41L2,4.1-G,ENSG00000079819,Erythrocyte membrane protein band 4.1 like 2,6,130839347-131063322,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005730, HPA006642",Supported,NA,Enhanced,Nucleus<br>Plasma membrane<br>Cell Junctions,"Liver cancer:2.41e-5 (unfavourable), Ovarian cancer:2.16e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 137.3,Mixed,NA,NA
EPHA2,ECK,ENSG00000142627,EPH receptor A2,1,16124337-16156087,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB010464,NA,NA,Supported,Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Tissue enhanced,NA,esophagus: 86.8,gallbladder: 44.5,Cell line enhanced,NA,PC-3: 211.2;WM-115: 253.0
F11R,"CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1",ENSG00000158769,F11 receptor,1,160995211-161021348,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB004671, HPA043616, HPA061700",Enhanced,NA,Supported,Cell Junctions<br>Microtubules,NA,Expressed in all,Expressed in all,NA,NA,lung: 95.0,Cell line enhanced,NA,HaCaT: 179.6
FAAP20,"C1orf86, FLJ31031",ENSG00000162585,Fanconi anemia core complex associated protein 20,1,2184461-2212720,Predicted intracellular proteins,Evidence at protein level,HPA038829,Uncertain,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Cell Junctions,"Pancreatic cancer:2.88e-4 (favourable), Liver cancer:4.57e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 13.0,Expressed in all,NA,NA
FAM126B,"HYCC2, MGC39518",ENSG00000155744,Family with sequence similarity 126 member B,2,200973718-201071671,Predicted intracellular proteins,Evidence at protein level,"HPA036166, HPA036167, HPA067307",Uncertain,NA,Supported,Nucleus<br>Cell Junctions,NA,Expressed in all,Mixed,NA,NA,cerebral cortex: 14.7,Expressed in all,NA,NA
FAM13A,"ARHGAP48, FAM13A1, KIAA0914",ENSG00000138640,Family with sequence similarity 13 member A,4,88725955-89111398,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038108, HPA038109",Uncertain,NA,Approved,Nucleoli<br>Cell Junctions<br>Cytosol,Urothelial cancer:4.28e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 114.4,Cell line enhanced,NA,ASC diff: 38.0
FBLIM1,"CAL, FBLP-1, migfilin",ENSG00000162458,Filamin binding LIM protein 1,1,15756607-15786594,Predicted intracellular proteins,Evidence at protein level,"HPA025287, HPA072750",Approved,NA,Enhanced,Nucleoli fibrillar center<br>Cell Junctions<br>Focal adhesion sites,"Cervical cancer:4.07e-4 (unfavourable), Melanoma:6.15e-4 (unfavourable), Renal cancer:8.64e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 101.8,Cell line enhanced,NA,HUVEC TERT2: 210.1;TIME: 323.6
FBLN7,"FLJ37440, TM14",ENSG00000144152,Fibulin 7,2,112138385-112188216,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA034992,NA,NA,Approved,Plasma membrane<br>Cell Junctions,NA,Mixed,Mixed,NA,NA,parathyroid gland: 18.7,Cell line enhanced,NA,AF22: 24.3;BJ hTERT+: 14.4;SCLC-21H: 18.6;SH-SY5Y: 13.4;U-2197: 23.6
FIBCD1,FLJ14810,ENSG00000130720,Fibrinogen C domain containing 1,9,130902438-130939286,Predicted intracellular proteins,Evidence at protein level,"HPA053898, HPA055353",Uncertain,NA,Supported,Cell Junctions,NA,Mixed,Tissue enhanced,NA,adrenal gland: 4.7;parathyroid gland: 8.6;testis: 5.3,cerebral cortex: 2.5,Cell line enhanced,NA,MCF7: 25.2;RPTEC TERT1: 18.5;U-2 OS: 17.4;U-251 MG: 11.7
FIGN,NA,ENSG00000182263,"Fidgetin, microtubule severing factor",2,163593396-163736012,Predicted intracellular proteins,Evidence at protein level,"HPA034987, HPA057919",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Mixed,Mixed,NA,NA,ovary: 5.1,Cell line enhanced,NA,AF22: 18.3
FLRT3,NA,ENSG00000125848,Fibronectin leucine rich transmembrane protein 3,20,14322988-14337616,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"CAB026166, HPA056033",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,"Renal cancer:1.49e-7 (favourable), Lung cancer:9.85e-5 (unfavourable), Pancreatic cancer:1.54e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,lung: 32.3,Cell line enhanced,NA,AF22: 32.9;hTCEpi: 45.3;WM-115: 75.5
FLT4,"PCL, VEGFR3",ENSG00000037280,Fms related tyrosine kinase 4,5,180601506-180649624,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB000099, HPA046519, HPA067906",Approved,NA,Enhanced,Nuclear speckles<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Mixed,NA,NA,spleen: 18.3,Cell line enhanced,NA,BEWO: 11.8;HEK93: 14.1;T-47d: 13.7;TIME: 12.7
FLVCR1,"AXPC1, FLVCR, MFSD7B, PCA",ENSG00000162769,Feline leukemia virus subgroup C cellular receptor 1,1,212858255-212899363,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA046646,Approved,NA,Approved,Cell Junctions,"Renal cancer:1.06e-5 (unfavourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)",Expressed in all,Tissue enhanced,NA,small intestine: 21.4,duodenum: 9.8,Expressed in all,NA,NA
FOXA2,HNF3B,ENSG00000125798,Forkhead box A2,20,22581005-22585455,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB001388, HPA066846",Enhanced,NA,Supported,Nucleoplasm<br>Cell Junctions,"Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable)",Mixed,Tissue enhanced,NA,"cervix, uterine: 21.4;lung: 20.5;stomach: 31.0",liver: 11.5,Cell line enhanced,NA,A549: 16.1;HBEC3-KT: 14.5;Hep G2: 19.5;PC-3: 24.0;SCLC-21H: 52.3
FRS2,"FRS2A, FRS2alpha, SNT-1, SNT1",ENSG00000166225,Fibroblast growth factor receptor substrate 2,12,69470349-69579789,Predicted intracellular proteins,Evidence at protein level,HPA038323,NA,NA,Approved,Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 27.6,Expressed in all,NA,NA
FZD2,NA,ENSG00000180340,Frizzled class receptor 2,17,44557459-44559570,"Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA057667,Uncertain,NA,Approved,Nucleus<br>Nuclear bodies<br>Cell Junctions,NA,Expressed in all,Mixed,NA,NA,placenta: 4.9,Mixed,NA,NA
GAS2L1,GAR22,ENSG00000185340,Growth arrest specific 2 like 1,22,29306582-29312785,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019858,Approved,NA,Approved,Plasma membrane<br>Cell Junctions,Renal cancer:8.44e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 32.1,Cell line enhanced,NA,U-138 MG: 75.8
GID8,"bA305P22.1, C20orf11, FLJ20602, TWA1",ENSG00000101193,GID complex subunit 8 homolog,20,62938119-62948475,Predicted intracellular proteins,Evidence at protein level,"HPA049929, HPA055047",Approved,NA,Supported,Nucleoplasm<br>Cell Junctions,"Renal cancer:3.22e-4 (favourable), Endometrial cancer:4.78e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 32.5,Expressed in all,NA,NA
GIPC1,"C19orf3, GIPC, GLUT1CBP, Hs.6454, NIP, RGS19IP1, SEMCAP, SYNECTIN, TIP-2",ENSG00000123159,GIPC PDZ domain containing family member 1,19,14477760-14496149,Predicted intracellular proteins,Evidence at protein level,"HPA043958, HPA061786",Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,esophagus: 103.9,Expressed in all,NA,NA
GJA1,"CX43, GJAL, ODD, ODDD, ODOD, SDTY3",ENSG00000152661,Gap junction protein alpha 1,6,121435692-121449727,"Cancer-related genes, Disease related genes, Predicted membrane proteins",Evidence at protein level,"CAB010753, HPA035097, HPA047551, HPA069245",Enhanced,Supported,Supported,Nucleoplasm<br>Vesicles<br>Cell Junctions,Stomach cancer:4.99e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 651.5,skin: 469.0,Cell line enhanced,NA,HUVEC TERT2: 306.6;NTERA-2: 370.8;U-87 MG: 348.4
GJB3,"CX31, DFNA2, EKV",ENSG00000188910,Gap junction protein beta 3,1,34781189-34786369,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA074472,NA,NA,Supported,Vesicles<br>Cell Junctions,"Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable)",Mixed,Tissue enhanced,NA,esophagus: 33.6;skin: 77.3,tonsil: 11.6,Cell line enhanced,NA,A-431: 76.8;CAPAN-2: 106.8;HaCaT: 87.5;HBEC3-KT: 60.8;hTCEpi: 98.5
GJB4,CX30.3,ENSG00000189433,Gap junction protein beta 4,1,34759741-34763724,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA055112,NA,NA,Supported,Cell Junctions,"Pancreatic cancer:3.24e-5 (unfavourable), Cervical cancer:5.48e-4 (favourable)",Group enriched,Tissue enriched,6,skin: 27.7,epididymis: 4.6,Cell line enhanced,NA,A-431: 4.0;HaCaT: 5.8;HBEC3-KT: 3.1;hTCEpi: 2.0;RPTEC TERT1: 1.9;RT4: 2.4
GJB6,"CX30, DFNA3, ED2, EDH, HED",ENSG00000121742,Gap junction protein beta 6,13,20221971-20232395,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA014846,NA,NA,Supported,Cell Junctions,NA,Tissue enhanced,Group enriched,5,bone marrow: 48.1;cerebral cortex: 39.4;esophagus: 150.1;skin: 32.1,tonsil: 12.2,Cell line enriched,9,RT4: 133.4
GJC1,"CX45, GJA7",ENSG00000182963,Gap junction protein gamma 1,17,44798448-44830816,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071788,NA,NA,Uncertain,Nucleoli<br>Cell Junctions<br>Cytosol,"Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,endometrium: 44.3;placenta: 51.5;smooth muscle: 49.2,seminal vesicle: 27.2,Mixed,NA,NA
GPATCH1,"ECGP, FLJ10206, FLJ38686, GPATC1",ENSG00000076650,G-patch domain containing 1,19,33080880-33130542,Predicted intracellular proteins,Evidence at protein level,"HPA043430, HPA043604",Approved,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,Endometrial cancer:8.20e-4 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 8.8,Expressed in all,NA,NA
GPR142,PGR2,ENSG00000257008,G protein-coupled receptor 142,17,74367407-74372622,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA031392,Uncertain,NA,Uncertain,Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Tissue enhanced,Not detected,NA,NA,appendix: 0.1,Not detected,NA,NA
GPR157,FLJ12132,ENSG00000180758,G protein-coupled receptor 157,1,9100305-9129170,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA028697,Uncertain,NA,Uncertain,Nucleoli<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 24.2,Cell line enhanced,NA,SK-BR-3: 46.8
GTF2F1,"BTF4, RAP74, TF2F1, TFIIF",ENSG00000125651,General transcription factor IIF subunit 1,19,6379569-6393981,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA022793, HPA028707, HPA070752",Supported,NA,Enhanced,Nucleus<br>Cell Junctions,"Endometrial cancer:8.39e-4 (favourable), Renal cancer:9.80e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 93.3,Expressed in all,NA,NA
HCAR2,"GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG",ENSG00000182782,Hydroxycarboxylic acid receptor 2,12,122701293-122703343,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA028660,Approved,NA,Approved,Cell Junctions,NA,Group enriched,Tissue enhanced,NA,spleen: 36.0,esophagus: 25.5,Cell line enriched,7,HaCaT: 105.3
HCAR3,"GPR109B, HCA3, HM74",ENSG00000255398,Hydroxycarboxylic acid receptor 3,12,122714756-122716892,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA028660,Approved,NA,Approved,Cell Junctions,NA,Mixed,Tissue enhanced,NA,bone marrow: 16.6;spleen: 21.7,appendix: 12.4,Group enriched,6,HaCaT: 8.1;RT4: 28.3
HLA-DPB1,HLA-DP1B,ENSG00000223865,"Major histocompatibility complex, class II, DP beta 1",6,33075926-33087201,Predicted membrane proteins,Evidence at protein level,"HPA011078, HPA058509",Approved,NA,Approved,Nucleus<br>Cell Junctions,Endometrial cancer:3.38e-4 (favourable),Expressed in all,Expressed in all,NA,NA,spleen: 170.6,Group enriched,7,HDLM-2: 102.6;REH: 48.0
HOXD4,"HOX4, HOX4B",ENSG00000170166,Homeobox D4,2,176151222-176153226,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA054383, HPA070349",Approved,NA,Enhanced,Nucleus<br>Cell Junctions,NA,Tissue enhanced,Tissue enhanced,NA,endometrium: 23.6;epididymis: 22.9,fallopian tube: 15.5,Cell line enhanced,NA,EFO-21: 11.0;HEK93: 25.9;RPTEC TERT1: 15.6
IGSF11,"BT-IgSF, CT119, Igsf13, MGC35227, VSIG3",ENSG00000144847,Immunoglobulin superfamily member 11,3,118900557-119146068,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA046377,Uncertain,NA,Approved,Nucleus<br>Cell Junctions<br>Cytosol,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 31.0;testis: 64.9,ovary: 20.1,Cell line enhanced,NA,A549: 7.2;SK-MEL-30: 26.9;U-266/70: 8.9;U-266/84: 10.2
IGSF23,NA,ENSG00000216588,Immunoglobulin superfamily member 23,19,44613630-44636781,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA051811, HPA054591",Uncertain,NA,Approved,Nucleus<br>Cell Junctions,Liver cancer:7.20e-6 (favourable),Tissue enriched,Group enriched,7,duodenum: 15.2;liver: 13.0;small intestine: 17.4,testis: 2.3,Cell line enhanced,NA,CACO-2: 9.0;Hep G2: 4.4;SiHa: 5.2
ILK,NA,ENSG00000166333,Integrin linked kinase,11,6603708-6610874,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004041, HPA048437",Enhanced,NA,Enhanced,Cell Junctions<br>Focal adhesion sites,Renal cancer:2.44e-4 (favourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 558.8,Expressed in all,NA,NA
IP6K2,IHPK2,ENSG00000068745,Inositol hexakisphosphate kinase 2,3,48688003-48740353,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007532, HPA070811",Approved,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions,"Breast cancer:1.25e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Lung cancer:2.95e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 131.1,Expressed in all,NA,NA
IQGAP1,"HUMORFA01, KIAA0051, p195, SAR1",ENSG00000140575,IQ motif containing GTPase activating protein 1,15,90388218-90502243,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013302, HPA014055",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions,Pancreatic cancer:5.67e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,endometrium: 120.4,Expressed in all,NA,NA
IREB2,IRP2,ENSG00000136381,Iron responsive element binding protein 2,15,78437431-78501456,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB032885, HPA040371, HPA068982",Uncertain,NA,Approved,Cell Junctions<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 48.0,Expressed in all,NA,NA
ITGA9,"ALPHA-RLC, ITGA4L, RLC",ENSG00000144668,Integrin subunit alpha 9,3,37452115-37823514,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA030609,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 34.7,Cell line enhanced,NA,CACO-2: 8.3;HEL: 7.3;SH-SY5Y: 12.3;WM-115: 6.1
ITGB4,CD104,ENSG00000132470,Integrin subunit beta 4,17,75721328-75757818,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002422, CAB005258, HPA036348, HPA036349",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions,"Pancreatic cancer:6.39e-4 (unfavourable), Lung cancer:7.18e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 84.3,Cell line enhanced,NA,CAPAN-2: 787.0;HaCaT: 304.0;HBEC3-KT: 550.4
ITGB6,NA,ENSG00000115221,Integrin subunit beta 6,2,160099666-160271888,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA023626, CAB073536",Approved,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Centrosome,Pancreatic cancer:5.03e-6 (unfavourable),Mixed,Tissue enhanced,NA,lung: 66.9,urinary bladder: 30.3,Cell line enhanced,NA,CAPAN-2: 122.2;RPTEC TERT1: 206.4
JUP,"CTNNG, DP3, DPIII, PDGB, PKGB",ENSG00000173801,Junction plakoglobin,17,41754604-41786931,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002139, HPA032047",Supported,NA,Enhanced,Vesicles<br>Plasma membrane<br>Cell Junctions,Renal cancer:2.06e-10 (favourable),Expressed in all,Group enriched,6,esophagus: 491.8;skin: 785.5,fallopian tube: 113.8,Cell line enhanced,NA,HaCaT: 960.4;RT4: 536.8
KCNK13,"K2p13.1, THIK-1, THIK1",ENSG00000152315,Potassium two pore domain channel subfamily K member 13,14,90061765-90185857,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at transcript level,HPA003514,Approved,NA,Approved,Nuclear speckles<br>Cell Junctions,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 14.6;testis: 14.4,kidney: 3.3,Cell line enhanced,NA,RT4: 1.4
KDF1,"C1orf172, FLJ34633, RP11-344H11.3",ENSG00000175707,Keratinocyte differentiation factor 1,1,26949562-26960406,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028639, HPA068312",Uncertain,NA,Supported,Nucleoplasm<br>Cell Junctions<br>Mitotic spindle,"Renal cancer:3.04e-13 (favourable), Urothelial cancer:4.40e-4 (favourable)",Mixed,Mixed,NA,NA,epididymis: 24.1,Cell line enhanced,NA,A-431: 22.4;BEWO: 20.8;CAPAN-2: 20.7;HaCaT: 19.6;HBEC3-KT: 21.9;hTCEpi: 28.4;SK-BR-3: 19.3
KIAA0895,NA,ENSG00000164542,KIAA0895,7,36324221-36390125,Predicted intracellular proteins,Evidence at transcript level,"HPA021036, HPA061066",Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,testis: 44.5,parathyroid gland: 23.9,Cell line enhanced,NA,SCLC-21H: 51.4
KIAA1257,NA,ENSG00000114656,KIAA1257,3,128909866-129002690,Predicted intracellular proteins,Evidence at transcript level,"HPA042811, HPA048445",Uncertain,NA,Approved,Cell Junctions<br>Cytosol,NA,Mixed,Tissue enriched,7,testis: 34.5,placenta: 5.1,Cell line enhanced,NA,AF22: 6.0;BEWO: 11.3;HL-60: 9.2;THP-1: 5.6
KIAA1462,JCAD,ENSG00000165757,KIAA1462,10,30012800-30115494,Predicted intracellular proteins,Evidence at protein level,HPA017956,Enhanced,NA,Supported,Vesicles<br>Cell Junctions,"Stomach cancer:2.01e-4 (unfavourable), Renal cancer:2.54e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 48.7,Cell line enhanced,NA,HUVEC TERT2: 25.1;TIME: 55.5
KIAA1522,NA,ENSG00000162522,KIAA1522,1,32741885-32774970,Predicted intracellular proteins,Evidence at protein level,"HPA032050, HPA032051, HPA064839",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,"Liver cancer:6.29e-7 (unfavourable), Renal cancer:1.29e-5 (favourable), Pancreatic cancer:8.25e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 72.8,Cell line enhanced,NA,CAPAN-2: 110.4
LDLRAD3,LRAD3,ENSG00000179241,Low density lipoprotein receptor class A domain containing 3,11,35943981-36232136,Predicted membrane proteins,Evidence at protein level,HPA038251,Approved,NA,Supported,Cell Junctions,"Renal cancer:5.05e-8 (unfavourable), Lung cancer:9.34e-6 (unfavourable), Urothelial cancer:2.14e-5 (unfavourable), Cervical cancer:2.24e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,breast: 23.0,Mixed,NA,NA
LMCD1,NA,ENSG00000071282,LIM and cysteine rich domains 1,3,8501707-8574673,Predicted intracellular proteins,Evidence at protein level,HPA024059,Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Renal cancer:8.66e-5 (unfavourable),Expressed in all,Mixed,NA,NA,skeletal muscle: 201.9,Cell line enhanced,NA,HSkMC: 90.7;hTEC/SVTERT24-B: 93.9
LMTK3,"KIAA1883, LMR3, PPP1R101, TYKLM3",ENSG00000142235,Lemur tyrosine kinase 3,19,48485271-48513189,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA040203, HPA077070",Enhanced,NA,Approved,Nucleoplasm<br>Cell Junctions,Renal cancer:3.18e-8 (favourable),Mixed,Group enriched,6,cerebral cortex: 20.3;parathyroid gland: 4.9,duodenum: 2.2,Cell line enhanced,NA,HMC-1: 6.1;SK-BR-3: 6.2;U-266/70: 5.9
LNX1,"LNX, MPDZ, PDZRN2",ENSG00000072201,Ligand of numb-protein X 1,4,53459301-53701405,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002235, HPA071091",Approved,NA,Supported,Cell Junctions<br>Cytosol,Renal cancer:3.08e-7 (favourable),Expressed in all,Mixed,NA,NA,placenta: 39.4,Mixed,NA,NA
LRRC34,MGC27085,ENSG00000171757,Leucine rich repeat containing 34,3,169793428-169812986,Predicted intracellular proteins,Evidence at protein level,HPA035747,Approved,NA,Approved,Cell Junctions<br>Microtubules<br>Cytokinetic bridge,NA,Mixed,Group enriched,8,fallopian tube: 12.2;testis: 26.8,cerebral cortex: 2.2,Cell line enhanced,NA,HEL: 7.6;HL-60: 7.2;NTERA-2: 8.7
MACF1,"ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA1251, MACF",ENSG00000127603,Microtubule-actin crosslinking factor 1,1,39081316-39487177,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA013713, HPA068064, HPA068103",Approved,NA,Supported,Plasma membrane<br>Cell Junctions<br>Actin filaments,Renal cancer:2.77e-5 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 137.2,Expressed in all,NA,NA
MAGI1,"AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3",ENSG00000151276,"Membrane associated guanylate kinase, WW and PDZ domain containing 1",3,65353525-66038834,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031851, HPA031852, HPA031853",Enhanced,NA,Enhanced,Nucleoplasm<br>Cell Junctions,Renal cancer:4.55e-8 (favourable),Expressed in all,Mixed,NA,NA,thyroid gland: 18.9,Cell line enhanced,NA,HEL: 32.4
MAGI3,MAGI-3,ENSG00000081026,"Membrane associated guanylate kinase, WW and PDZ domain containing 3",1,113390749-113685923,Predicted intracellular proteins,Evidence at protein level,"HPA007923, HPA008444",Approved,NA,Supported,Cell Junctions,"Renal cancer:2.60e-8 (favourable), Ovarian cancer:4.29e-4 (favourable)",Expressed in all,Mixed,NA,NA,lung: 20.9,Mixed,NA,NA
MAP2K4,"JNKK1, MEK4, MKK4, PRKMK4, SERK1",ENSG00000065559,Mitogen-activated protein kinase kinase 4,17,12020824-12143830,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB007751, HPA060074",Enhanced,NA,Approved,Nucleoplasm<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 64.0,Expressed in all,NA,NA
MAP3K12,"DLK, MEKK12, MUK, ZPK, ZPKP1",ENSG00000139625,Mitogen-activated protein kinase kinase kinase 12,12,53479669-53500063,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039936, HPA071996",Approved,NA,Approved,Nucleus<br>Cell Junctions,"Renal cancer:5.43e-10 (unfavourable), Pancreatic cancer:1.51e-4 (favourable)",Mixed,Mixed,NA,NA,gallbladder: 23.9,Cell line enhanced,NA,HHSteC: 46.6
MAPK15,"ERK7, ERK8",ENSG00000181085,Mitogen-activated protein kinase 15,8,143716259-143722458,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002704,NA,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Cytosol,NA,Mixed,Tissue enhanced,NA,fallopian tube: 43.7,parathyroid gland: 13.2,Cell line enhanced,NA,CAPAN-2: 6.9;HeLa: 10.4;MCF7: 11.8;T-47d: 12.5
MARVELD2,"DFNB49, FLJ30532, MRVLDC2, TRIC",ENSG00000152939,MARVEL domain containing 2,5,69415112-69444330,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018119, HPA061726",Uncertain,NA,Supported,Cell Junctions,Renal cancer:2.84e-13 (favourable),Mixed,Tissue enhanced,NA,thyroid gland: 19.7,small intestine: 8.7,Cell line enhanced,NA,BEWO: 30.0;CAPAN-2: 22.9;HaCaT: 17.6;RT4: 17.7;SCLC-21H: 32.0;T-47d: 18.4
MEIOC,"C17orf104, FLJ35848",ENSG00000180336,Meiosis specific with coiled-coil domain,17,44656404-44690308,Predicted intracellular proteins,Evidence at protein level,HPA027266,Enhanced,NA,Uncertain,Cell Junctions,NA,Not detected,Tissue enriched,52,testis: 86.2,cerebral cortex: 1.6,Cell line enhanced,NA,HAP1: 17.4;HMC-1: 22.4;SiHa: 10.1
MEPCE,"BCDIN3, FLJ20257, MePCE",ENSG00000146834,Methylphosphate capping enzyme,7,100428790-100434126,Predicted intracellular proteins,Evidence at protein level,"CAB026384, HPA051587",Supported,NA,Approved,Nucleoplasm<br>Cell Junctions,"Renal cancer:1.01e-10 (favourable), Endometrial cancer:6.01e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 87.8,Expressed in all,NA,NA
METTL9,DREV1,ENSG00000197006,Methyltransferase like 9,16,21597218-21657473,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA053588, HPA056347",Uncertain,NA,Approved,Nucleus<br>Cell Junctions<br>Cytosol,Liver cancer:8.71e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,kidney: 92.0,Expressed in all,NA,NA
MICALL1,"KIAA1668, MICAL-L1, MIRAB13",ENSG00000100139,MICAL like 1,22,37905657-37942822,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043480, HPA051956",Uncertain,NA,Supported,Cell Junctions<br>Microtubule organizing center<br>Cytosol,Liver cancer:3.08e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 51.2,Expressed in all,NA,NA
MIGA2,"C9orf54, FAM73B, FLJ00199, FLJ14596",ENSG00000148343,Mitoguardin 2,9,129036621-129072082,Predicted membrane proteins,Evidence at protein level,HPA041363,Approved,NA,Approved,Cell Junctions<br>Cytosol,Pancreatic cancer:3.04e-6 (favourable),Expressed in all,Mixed,NA,NA,small intestine: 15.5,Expressed in all,NA,NA
MLST8,"GbetaL, GBL, Lst8, Pop3",ENSG00000167965,"MTOR associated protein, LST8 homolog",16,2204248-2209416,Predicted intracellular proteins,Evidence at protein level,"CAB019935, HPA041841",Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Cell Junctions,Renal cancer:7.60e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 28.6,Expressed in all,NA,NA
MOAP1,"MAP-1, PNMA4",ENSG00000165943,Modulator of apoptosis 1,14,93182196-93184928,Predicted intracellular proteins,Evidence at protein level,HPA000939,Uncertain,NA,Approved,Nucleus<br>Cell Junctions,"Lung cancer:7.37e-9 (favourable), Renal cancer:3.15e-6 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 86.1,Expressed in all,NA,NA
MPP7,FLJ32798,ENSG00000150054,Membrane palmitoylated protein 7,10,28050993-28334486,Predicted intracellular proteins,Evidence at protein level,"HPA037597, HPA037598",Enhanced,NA,Supported,Cell Junctions,"Renal cancer:2.79e-14 (favourable), Lung cancer:5.88e-4 (favourable)",Mixed,Expressed in all,NA,NA,esophagus: 41.2,Cell line enhanced,NA,CACO-2: 37.3;T-47d: 83.8
MPZL2,"EVA, EVA1",ENSG00000149573,Myelin protein zero like 2,11,118253403-118264536,Predicted membrane proteins,Evidence at protein level,HPA060740,Approved,NA,Approved,Cell Junctions,"Pancreatic cancer:1.14e-4 (unfavourable), Thyroid cancer:1.62e-4 (favourable)",Expressed in all,Tissue enhanced,NA,esophagus: 209.1,urinary bladder: 118.1,Cell line enhanced,NA,CAPAN-2: 107.3;EFO-21: 123.8;HaCaT: 149.0;RT4: 257.4;TIME: 288.5
MRPL46,"C15orf4, LIECG2, P2ECSL",ENSG00000259494,Mitochondrial ribosomal protein L46,15,88459476-88467419,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA050166,Uncertain,NA,Supported,Nucleoplasm<br>Cell Junctions<br>Mitochondria,Renal cancer:2.09e-6 (favourable),Expressed in all,Expressed in all,NA,NA,adrenal gland: 50.3,Expressed in all,NA,NA
MRPS18B,"C6orf14, HSPC183, MRPS18-2, PTD017",ENSG00000204568,Mitochondrial ribosomal protein S18B,6,30617709-30626395,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA043485, HPA050334",Supported,NA,Supported,Cell Junctions<br>Mitochondria,Renal cancer:3.99e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 13.3,Expressed in all,NA,NA
MTFR1L,FAM54B,ENSG00000117640,Mitochondrial fission regulator 1 like,1,25818640-25832942,Predicted intracellular proteins,Evidence at protein level,"HPA027124, HPA027130",Approved,NA,Approved,Cell Junctions<br>Mitochondria,"Renal cancer:5.89e-12 (favourable), Endometrial cancer:6.81e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 150.7,Expressed in all,NA,NA
MTHFR,NA,ENSG00000177000,Methylenetetrahydrofolate reductase,1,11785723-11806920,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA063389,NA,NA,Approved,Cell Junctions,"Head and neck cancer:3.97e-5 (favourable), Pancreatic cancer:4.81e-5 (favourable), Liver cancer:1.19e-4 (unfavourable), Renal cancer:2.12e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 64.9,Expressed in all,NA,NA
MVD,MPD,ENSG00000167508,Mevalonate diphosphate decarboxylase,16,88651935-88663161,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041404, HPA048250",Uncertain,NA,Approved,Cell Junctions<br>Cytosol,Endometrial cancer:2.17e-4 (favourable),Expressed in all,Expressed in all,NA,NA,duodenum: 33.9,Expressed in all,NA,NA
NAMPT,"PBEF, PBEF1",ENSG00000105835,Nicotinamide phosphoribosyltransferase,7,106248285-106286326,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034349, HPA047776, HPA057722",Approved,NA,Approved,Nuclear speckles<br>Cell Junctions,"Renal cancer:2.49e-6 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable), Cervical cancer:4.78e-4 (unfavourable), Head and neck cancer:8.81e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,appendix: 778.1,Expressed in all,NA,NA
NECTIN2,"CD112, HVEB, PRR2, PVRL2, PVRR2",ENSG00000130202,Nectin cell adhesion molecule 2,19,44846175-44889228,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012759, CAB026138, HPA073459",Enhanced,NA,Approved,Nucleoli fibrillar center<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,placenta: 111.4,Mixed,NA,NA
NEU1,NEU,ENSG00000204386,Neuraminidase 1,6,31857659-31862906,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015634, HPA021506",Approved,NA,Supported,Vesicles<br>Cell Junctions,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 14.3,Expressed in all,NA,NA
NHS,NA,ENSG00000188158,NHS actin remodeling regulator,X,17375420-17735994,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031497, HPA076257",Uncertain,NA,Supported,Cell Junctions,Endometrial cancer:1.68e-4 (favourable),Mixed,Mixed,NA,NA,endometrium: 7.9,Cell line enhanced,NA,EFO-21: 12.0;RPTEC TERT1: 14.5
NLGN3,"ASPGX1, AUTSX1, HNL3, KIAA1480",ENSG00000196338,Neuroligin 3,X,71144831-71171201,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA003183, HPA004066",Enhanced,NA,Supported,Golgi apparatus<br>Cell Junctions,NA,Tissue enriched,Tissue enhanced,NA,cerebral cortex: 62.2,seminal vesicle: 17.3,Cell line enhanced,NA,AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9
NLK,NA,ENSG00000087095,Nemo like kinase,17,28041737-28196381,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018192, HPA056511",Approved,NA,Supported,Nucleus<br>Nucleoli<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 52.4,Expressed in all,NA,NA
NLRX1,"CLR11.3, NOD9",ENSG00000160703,NLR family member X1,11,119166568-119184016,Predicted intracellular proteins,Evidence at protein level,HPA061516,Supported,NA,Supported,Plasma membrane<br>Cell Junctions<br>Mitochondria,"Renal cancer:2.59e-6 (favourable), Endometrial cancer:2.47e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 37.8,Mixed,NA,NA
NPNT,"EGFL6L, POEM",ENSG00000168743,Nephronectin,4,105894775-106004027,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA003711, HPA050203",Supported,NA,Approved,Nucleus<br>Cell Junctions<br>Cytosol,Renal cancer:8.28e-8 (favourable),Expressed in all,Tissue enhanced,NA,lung: 168.4;thyroid gland: 276.0,prostate: 136.5,Cell line enhanced,NA,BEWO: 27.8;HeLa: 22.2;RPTEC TERT1: 28.6;T-47d: 48.1
NR2C1,"TR2, TR2-11",ENSG00000120798,Nuclear receptor subfamily 2 group C member 1,12,95020229-95073703,"Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA035040, HPA035041, HPA067767",Enhanced,NA,Supported,Nucleus<br>Cell Junctions<br>Cytosol,"Renal cancer:1.03e-6 (unfavourable), Liver cancer:5.18e-5 (unfavourable), Urothelial cancer:5.62e-5 (favourable)",Expressed in all,Mixed,NA,NA,testis: 21.9,Expressed in all,NA,NA
NUMB,C14orf41,ENSG00000133961,"NUMB, endocytic adaptor protein",14,73275107-73463642,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA002874, CAB011478",Approved,NA,Enhanced,Cell Junctions<br>Cytosol,Renal cancer:2.32e-6 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 78.0,Expressed in all,NA,NA
OCLN,PPP1R115,ENSG00000197822,Occludin,5,69492292-69558104,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA005933, CAB013075, CAB068212, CAB068213, CAB068214",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions,Renal cancer:6.59e-11 (favourable),Mixed,Tissue enhanced,NA,thyroid gland: 78.7,lung: 39.8,Cell line enhanced,NA,CAPAN-2: 60.2;HaCaT: 48.8
PAK4,NA,ENSG00000130669,P21 (RAC1) activated kinase 4,19,39125770-39182816,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB025747, CAB044670, HPA070175, HPA072220",Uncertain,NA,Supported,Plasma membrane<br>Cell Junctions,"Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,prostate: 47.8,Expressed in all,NA,NA
PAK6,PAK5,ENSG00000137843,P21 (RAC1) activated kinase 6,15,40238759-40277487,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA031124,Approved,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions,NA,Not detected,Mixed,NA,NA,cerebral cortex: 28.6,Cell line enhanced,NA,CACO-2: 17.4;HaCaT: 28.5;hTCEpi: 13.9
PARD3,"ASIP, Baz, Bazooka, PAR3, PARD3A, PPP1R118",ENSG00000148498,Par-3 family cell polarity regulator,10,34109560-34815325,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA030443,Approved,NA,Enhanced,Cell Junctions,"Liver cancer:1.73e-5 (unfavourable), Urothelial cancer:4.41e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 68.7,Mixed,NA,NA
PARD3B,"ALS2CR19, PAR3beta, Par3L",ENSG00000116117,Par-3 family cell polarity regulator beta,2,204545793-205620162,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035283,Approved,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Cell Junctions,Renal cancer:2.67e-10 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 13.4,Cell line enhanced,NA,ASC diff: 12.1
PARD6A,"PAR-6, PAR-6A, PAR6alpha, TAX40, TIP-40",ENSG00000102981,Par-6 family cell polarity regulator alpha,16,67660946-67662778,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009733, HPA041551",Approved,NA,Supported,Cell Junctions<br>Actin filaments<br>Cytosol,"Renal cancer:3.08e-7 (favourable), Breast cancer:5.40e-4 (favourable)",Expressed in all,Tissue enhanced,NA,testis: 20.2,cerebral cortex: 12.1,Cell line enhanced,NA,REH: 24.9;SCLC-21H: 25.2
PARP8,"FLJ21308, pART16",ENSG00000151883,Poly(ADP-ribose) polymerase family member 8,5,50665899-50846522,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049183,Approved,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Midbody ring<br>Cytosol,Urothelial cancer:1.12e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 72.9,Cell line enhanced,NA,THP-1: 65.6
PATJ,"Cipp, INADL",ENSG00000132849,"PATJ, crumbs cell polarity complex component",1,61742477-62178675,Predicted intracellular proteins,Evidence at protein level,"HPA066352, HPA066960, HPA069079",Approved,NA,Supported,Cell Junctions<br>Microtubule organizing center<br>Cytosol,Renal cancer:1.47e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 35.6,Cell line enhanced,NA,A-431: 31.4
PCDH1,pc42,ENSG00000156453,Protocadherin 1,5,141853111-141879246,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA047720, HPA050538",Enhanced,NA,Approved,Nucleus<br>Nucleoli<br>Cell Junctions,"Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 40.3,Cell line enhanced,NA,CAPAN-2: 75.4;HaCaT: 95.1;RT4: 59.1;TIME: 60.2;WM-115: 51.1
PCDH7,"BH-Pcdh, PPP1R120",ENSG00000169851,Protocadherin 7,4,30720415-31146805,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011866, HPA046521",Uncertain,NA,Enhanced,Plasma membrane<br>Cell Junctions,"Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable)",Mixed,Mixed,NA,NA,cerebral cortex: 46.0,Cell line enhanced,NA,RH-30: 116.4;RT4: 51.9
PCDHA11,"CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11",ENSG00000249158,Protocadherin alpha 11,5,140868183-141012344,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA077160,NA,NA,Approved,Vesicles<br>Cell Junctions<br>Cytoplasmic bodies,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 7.6;parathyroid gland: 3.8,testis: 1.8,Cell line enhanced,NA,AN3-CA: 14.0;EFO-21: 7.3;T-47d: 5.0
PDGFRA,"CD140a, GAS9, PDGFR2",ENSG00000134853,Platelet derived growth factor receptor alpha,4,54229097-54298247,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA004947, CAB018143",Supported,NA,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,"Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 222.6,Cell line enhanced,NA,ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDLIM1,"CLIM1, CLP-36, CLP36, hCLIM1",ENSG00000107438,PDZ and LIM domain 1,10,95237572-95291024,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA017010, CAB072838, CAB072840",Approved,NA,Supported,Plasma membrane<br>Cell Junctions<br>Actin filaments,Endometrial cancer:1.14e-5 (favourable),Expressed in all,Expressed in all,NA,NA,small intestine: 273.0,Cell line enhanced,NA,HaCaT: 680.7
PEAR1,"FLJ00193, JEDI, MEGF12",ENSG00000187800,Platelet endothelial aggregation receptor 1,1,156893698-156916434,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035217,Approved,NA,Approved,Nucleoplasm<br>Cell Junctions<br>Centrosome,Renal cancer:4.31e-4 (unfavourable),Expressed in all,Mixed,NA,NA,placenta: 16.9,Cell line enhanced,NA,HBEC3-KT: 21.4;HUVEC TERT2: 43.6;TIME: 69.3
PGLYRP2,"PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like",ENSG00000161031,Peptidoglycan recognition protein 2,19,15468645-15498956,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB033468, HPA043568, HPA046311, HPA075237",Approved,NA,Approved,Cell Junctions,NA,Tissue enriched,Tissue enriched,17,liver: 133.2,testis: 7.8,Group enriched,8,MCF7: 5.7;T-47d: 6.8
PGS1,DKFZP762M186,ENSG00000087157,Phosphatidylglycerophosphate synthase 1,17,78378640-78425114,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA022526,Approved,NA,Approved,Vesicles<br>Cell Junctions<br>Intermediate filaments,"Renal cancer:1.16e-5 (unfavourable), Pancreatic cancer:7.33e-5 (favourable), Liver cancer:1.37e-4 (unfavourable), Prostate cancer:9.94e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 26.7,Expressed in all,NA,NA
PKP2,NA,ENSG00000057294,Plakophilin 2,12,32790745-32896840,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA014314, CAB037336, HPA056908",Enhanced,NA,Enhanced,Nucleoplasm<br>Cell Junctions,"Lung cancer:6.79e-4 (unfavourable), Colorectal cancer:8.55e-4 (favourable)",Mixed,Tissue enhanced,NA,fallopian tube: 114.2;heart muscle: 123.3,parathyroid gland: 50.6,Cell line enhanced,NA,CACO-2: 161.1
PKP3,NA,ENSG00000184363,Plakophilin 3,11,392614-404908,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012993, HPA062937",Enhanced,NA,Enhanced,Nucleoplasm<br>Cell Junctions<br>Cytosol,"Lung cancer:2.89e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable), Pancreatic cancer:3.93e-4 (unfavourable)",Mixed,Tissue enhanced,NA,esophagus: 98.2;skin: 148.2,duodenum: 31.4,Cell line enhanced,NA,A-431: 131.6;HaCaT: 174.9;SK-BR-3: 111.1
PKP4,p0071,ENSG00000144283,Plakophilin 4,2,158456964-158682879,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB037334, HPA066647, HPA070648",Approved,NA,Enhanced,Plasma membrane<br>Cell Junctions,"Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,kidney: 65.6,Expressed in all,NA,NA
PLEKHA6,"KIAA0969, PEPP3",ENSG00000143850,Pleckstrin homology domain containing A6,1,204218851-204377665,Predicted intracellular proteins,Evidence at protein level,"HPA028152, HPA054311",Approved,NA,Supported,Vesicles<br>Cell Junctions<br>Microtubule organizing center,Urothelial cancer:3.57e-4 (favourable),Expressed in all,Mixed,NA,NA,stomach: 40.6,Cell line enhanced,NA,BEWO: 88.4;CAPAN-2: 75.9;PC-3: 64.5;RT4: 62.5
PLEKHA7,DKFZp686M22243,ENSG00000166689,Pleckstrin homology domain containing A7,11,16777317-17014443,Predicted intracellular proteins,Evidence at protein level,"HPA038610, HPA066103",Approved,NA,Supported,Nucleus<br>Cell Junctions<br>Cytosol,Renal cancer:1.89e-15 (favourable),Mixed,Mixed,NA,NA,parathyroid gland: 50.8,Cell line enhanced,NA,CAPAN-2: 113.7;HaCaT: 75.7;RT4: 94.4
PLEKHG4,"ARHGEF44, DKFZP434I216, SCA4",ENSG00000196155,Pleckstrin homology and RhoGEF domain containing G4,16,67277510-67289499,Predicted intracellular proteins,Evidence at protein level,HPA055696,NA,NA,Approved,Cell Junctions,Renal cancer:6.72e-9 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 41.5,ovary: 18.8,Mixed,NA,NA
PLEKHG6,"FLJ10665, MYOGEF",ENSG00000008323,Pleckstrin homology and RhoGEF domain containing G6,12,6310436-6328506,Predicted intracellular proteins,Evidence at protein level,"HPA041459, HPA058230",Uncertain,NA,Supported,Cell Junctions<br>Centrosome,NA,Mixed,Tissue enhanced,NA,small intestine: 47.7,duodenum: 36.5,Cell line enhanced,NA,BEWO: 147.7;CACO-2: 41.4;RT4: 42.4
PLXNA3,"6.3, Plxn3, PLXN4, SEX, XAP-6",ENSG00000130827,Plexin A3,X,154458281-154477779,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA058989,NA,NA,Supported,Vesicles<br>Plasma membrane<br>Cell Junctions,NA,Expressed in all,Mixed,NA,NA,skin: 12.0,Mixed,NA,NA
PROM2,NA,ENSG00000155066,Prominin 2,2,95274453-95291308,Predicted membrane proteins,Evidence at protein level,"CAB046005, HPA063728",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,"Renal cancer:1.55e-6 (unfavourable), Breast cancer:2.16e-4 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable)",Mixed,Tissue enhanced,NA,skin: 71.1,esophagus: 44.6,Cell line enhanced,NA,A-431: 69.3;CAPAN-2: 119.5;HaCaT: 65.0;hTCEpi: 56.7;RT4: 66.9;SK-BR-3: 88.2
PRR15,NA,ENSG00000176532,Proline rich 15,7,29563811-29567295,Predicted intracellular proteins,Evidence at protein level,"HPA040996, HPA048121",Enhanced,NA,Uncertain,Vesicles<br>Cell Junctions,"Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable)",Mixed,Tissue enhanced,NA,"cervix, uterine: 91.4",colon: 79.1,Cell line enhanced,NA,CAPAN-2: 33.6;HaCaT: 39.3;SK-BR-3: 55.3
PSEN1,"AD3, FAD, PS1, S182",ENSG00000080815,Presenilin 1,14,73136418-73223691,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB006844, HPA030760, HPA067496",Approved,NA,Approved,Nucleus<br>Golgi apparatus<br>Cell Junctions,"Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 66.0,Expressed in all,NA,NA
PTPRB,PTPB,ENSG00000127329,"Protein tyrosine phosphatase, receptor type B",12,70515866-70637440,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB004782, HPA067868",Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cell Junctions,"Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable)",Expressed in all,Mixed,NA,NA,lung: 54.0,Cell line enhanced,NA,EFO-21: 22.9;HUVEC TERT2: 51.3;TIME: 74.1
PTPRK,R-PTP-kappa,ENSG00000152894,"Protein tyrosine phosphatase, receptor type K",6,127968779-128520674,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA054056, HPA054822",Uncertain,NA,Supported,Vesicles<br>Plasma membrane<br>Cell Junctions,"Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 27.8,Mixed,NA,NA
PTPRR,"EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ",ENSG00000153233,"Protein tyrosine phosphatase, receptor type R",12,70638073-70920843,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB011461, HPA011851, HPA071067",Uncertain,NA,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,Urothelial cancer:1.40e-5 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 20.8,endometrium: 9.0,Group enriched,11,HDLM-2: 18.5;RT4: 29.7;SH-SY5Y: 6.2
PVALB,D22S749,ENSG00000100362,Parvalbumin,22,36800684-36819479,Predicted intracellular proteins,Evidence at protein level,"CAB002515, HPA048536",Enhanced,Approved,Approved,Nucleoplasm<br>Nucleoli<br>Cell Junctions,NA,Group enriched,Tissue enriched,13,parathyroid gland: 547.2,kidney: 43.5,Cell line enriched,144,RPMI-8226: 558.1
PYM1,"PYM, WIBG",ENSG00000170473,"PYM homolog 1, exon junction complex associated factor",12,55901413-55932618,Predicted intracellular proteins,Evidence at protein level,"CAB012803, HPA039717, HPA046200",Supported,NA,Supported,Nucleus<br>Nucleoli<br>Cell Junctions<br>Cytosol,"Urothelial cancer:1.34e-4 (favourable), Liver cancer:3.05e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 50.6,Expressed in all,NA,NA
RAB25,CATX-8,ENSG00000132698,"RAB25, member RAS oncogene family",1,156061160-156070514,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA010872, CAB033645",Enhanced,NA,Uncertain,Cell Junctions<br>Cytosol,Renal cancer:1.38e-6 (favourable),Mixed,Tissue enhanced,NA,esophagus: 297.5,skin: 169.0,Cell line enhanced,NA,BEWO: 114.9;CAPAN-2: 103.6;MCF7: 128.3;RT4: 119.8;SK-BR-3: 179.2;T-47d: 210.8
RAB3B,NA,ENSG00000169213,"RAB3B, member RAS oncogene family",1,51907956-51990764,Predicted intracellular proteins,Evidence at protein level,"HPA003159, CAB023293",Enhanced,NA,Approved,Cell Junctions,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 8.2;prostate: 17.8,adrenal gland: 4.0,Cell line enhanced,NA,BJ: 105.7;TIME: 79.3
RAD51C,"FANCO, RAD51L2",ENSG00000108384,RAD51 paralog C,17,58692573-58735611,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA045198,NA,NA,Supported,Nucleus<br>Vesicles<br>Cell Junctions<br>Mitochondria<br>Cytosol,"Liver cancer:8.68e-5 (unfavourable), Pancreatic cancer:5.33e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 37.3,Expressed in all,NA,NA
RASA4B,NA,ENSG00000170667,RAS p21 protein activator 4B,7,102482445-102517781,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at transcript level,HPA043010,Uncertain,NA,Uncertain,Vesicles<br>Cell Junctions,NA,Not detected,Tissue enhanced,NA,skeletal muscle: 39.7,cerebral cortex: 15.7,Cell line enhanced,NA,SH-SY5Y: 14.3;U-138 MG: 18.0;U-2 OS: 16.6
RASAL1,RASAL,ENSG00000111344,RAS protein activator like 1,12,113098819-113136239,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA041650,Uncertain,NA,Approved,Plasma membrane<br>Cell Junctions<br>Cytosol,Endometrial cancer:3.26e-5 (unfavourable),Mixed,Tissue enriched,6,parathyroid gland: 118.8,cerebral cortex: 19.4,Cell line enhanced,NA,EFO-21: 18.2;REH: 20.3;RPMI-8226: 34.6;RPTEC TERT1: 14.4;U-698: 28.8
RASSF4,"AD037, MGC44914",ENSG00000107551,Ras association domain family member 4,10,44959407-44995891,Predicted intracellular proteins,Evidence at protein level,HPA038834,Approved,NA,Approved,Nucleus<br>Nucleoli<br>Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 71.4,Cell line enhanced,NA,RH-30: 158.1;U-937: 67.6;WM-115: 54.3
RGS19,"GAIP, RGSGAIP",ENSG00000171700,Regulator of G-protein signaling 19,20,64073181-64079988,Predicted intracellular proteins,Evidence at protein level,"HPA056384, HPA069984",Enhanced,NA,Supported,Nucleoli fibrillar center<br>Cell Junctions,"Renal cancer:2.06e-9 (unfavourable), Liver cancer:2.75e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,spleen: 53.7,lymph node: 39.8,Expressed in all,NA,NA
RP5-900K19.2,NA,ENSG00000284292,NA,7,99325879-99394653,Predicted intracellular proteins,Evidence at protein level,HPA004334,Uncertain,NA,Approved,Cell Junctions<br>Cytosol,NA,NA,Mixed,NA,NA,appendix: 3.3,Mixed,NA,NA
RPUSD1,"C16orf40, MGC19600, RLUCL",ENSG00000007376,RNA pseudouridylate synthase domain containing 1,16,784974-788397,Predicted intracellular proteins,Evidence at protein level,"HPA041144, HPA041938",Approved,NA,Approved,Nucleus<br>Golgi apparatus<br>Cell Junctions<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,appendix: 13.0,Expressed in all,NA,NA
RRP7A,CGI-96,ENSG00000189306,Ribosomal RNA processing 7 homolog A,22,42509968-42519802,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001586, HPA046768",Approved,NA,Approved,Nucleus<br>Nucleoli<br>Cell Junctions,Liver cancer:1.21e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,epididymis: 47.3,Expressed in all,NA,NA
RSC1A1,RS1,ENSG00000215695,Regulator of solute carriers 1,1,15659869-15661722,Predicted intracellular proteins,Evidence at protein level,"HPA027813, HPA028676",Approved,NA,Supported,Nucleoplasm<br>Cell Junctions,NA,Not detected,Mixed,NA,NA,smooth muscle: 5.3,Mixed,NA,NA
S100A14,"BCMP84, S100A15",ENSG00000189334,S100 calcium binding protein A14,1,153614255-153616986,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA027613,Enhanced,NA,Supported,Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Mixed,Tissue enhanced,NA,esophagus: 2205.9,skin: 591.6,Group enriched,9,A-431: 692.6;HaCaT: 944.8;HBEC3-KT: 1089.8;hTCEpi: 1601.4;SK-BR-3: 1180.8
S100A9,"60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14",ENSG00000163220,S100 calcium binding protein A9,1,153357854-153361027,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004193, CAB009441",Enhanced,NA,Supported,Nucleoplasm<br>Cell Junctions<br>Cytosol,"Liver cancer:1.13e-6 (unfavourable), Renal cancer:8.10e-4 (unfavourable)",Expressed in all,Group enriched,6,bone marrow: 20959.3;esophagus: 24239.1,tonsil: 3911.6,Cell line enriched,5,SK-BR-3: 1782.7
SAMD4A,"DKFZP434H0350, hSmaug1, KIAA1053, SAMD4, Smaug, SMG, SMGA",ENSG00000020577,Sterile alpha motif domain containing 4A,14,54567097-54793315,Predicted intracellular proteins,Evidence at protein level,"HPA043061, HPA065309",Approved,NA,Approved,Cell Junctions<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,testis: 102.6,skeletal muscle: 32.7,Mixed,NA,NA
SAPCD1,"C6orf26, NG23",ENSG00000228727,Suppressor APC domain containing 1,6,31762799-31764851,Predicted intracellular proteins,Evidence at transcript level,HPA071699,NA,NA,Approved,Vesicles<br>Cell Junctions,NA,Mixed,Tissue enhanced,NA,skin: 3.2,bone marrow: 1.0,Cell line enhanced,NA,HeLa: 2.5
SCAMP1,SCAMP37,ENSG00000085365,Secretory carrier membrane protein 1,5,78360583-78479071,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA044753, CAB079009",NA,Approved,Approved,Nucleoplasm<br>Vesicles<br>Cell Junctions,Renal cancer:1.92e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 69.2,Expressed in all,NA,NA
SCHIP1,SCHIP-1,ENSG00000151967,Schwannomin interacting protein 1,3,159839861-159897360,Predicted intracellular proteins,Evidence at protein level,"HPA003243, HPA069824",Uncertain,NA,Approved,Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Glioma:3.78e-4 (favourable),Tissue enriched,Tissue enhanced,NA,cerebral cortex: 102.8;heart muscle: 53.1,skeletal muscle: 25.5,Cell line enhanced,NA,AN3-CA: 45.4;HUVEC TERT2: 48.7;NTERA-2: 29.7;SH-SY5Y: 177.1
SCRIB,"KIAA0147, SCRB1, Vartul",ENSG00000180900,Scribbled planar cell polarity protein,8,143790920-143815379,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB015463, CAB022081, HPA023557, HPA064312",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Rods & Rings,NA,Expressed in all,Expressed in all,NA,NA,skin: 22.0,Expressed in all,NA,NA
SHKBP1,"PP203, Sb1",ENSG00000160410,SH3KBP1 binding protein 1,19,40576851-40591399,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041887,Uncertain,NA,Approved,Cell Junctions,NA,Expressed in all,Expressed in all,NA,NA,spleen: 53.4,Expressed in all,NA,NA
SHROOM2,APXL,ENSG00000146950,Shroom family member 2,X,9786456-9949443,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA051646, HPA061435",Approved,NA,Approved,Plasma membrane<br>Cell Junctions<br>Cytosol,Renal cancer:1.35e-7 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 11.8,Cell line enhanced,NA,WM-115: 22.8
SLC16A1,"MCT, MCT1",ENSG00000155380,Solute carrier family 16 member 1,1,112911847-112957013,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA003324, CAB017489, HPA071055, CAB079035",Enhanced,Supported,Enhanced,Plasma membrane<br>Cell Junctions,"Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 31.4,Mixed,NA,NA
SLC16A10,"MCT10, TAT1",ENSG00000112394,Solute carrier family 16 member 10,6,111087503-111231194,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA016860,Approved,NA,Approved,Vesicles<br>Cell Junctions,NA,Tissue enriched,Tissue enhanced,NA,placenta: 38.6,skin: 22.4,Cell line enhanced,NA,HAP1: 53.9;HEK93: 20.6;RPMI-8226: 30.8
SLC16A9,"C10orf36, FLJ43803, MCT9",ENSG00000165449,Solute carrier family 16 member 9,10,59650761-59736002,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA049286,Approved,NA,Approved,Nucleus<br>Cell Junctions,Renal cancer:2.56e-6 (favourable),Mixed,Tissue enhanced,NA,adrenal gland: 198.5;kidney: 201.0,spleen: 56.3,Cell line enhanced,NA,HAP1: 11.1;NTERA-2: 20.0;U-937: 14.6
SLC23A3,"FLJ31168, SVCT3, Yspl1",ENSG00000213901,Solute carrier family 23 member 3,2,219161465-219170095,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA019059,NA,NA,Approved,Nucleus<br>Cell Junctions,NA,Tissue enriched,Tissue enhanced,NA,kidney: 53.1;small intestine: 22.9,duodenum: 8.7,Cell line enhanced,NA,hTCEpi: 3.5
SLC26A9,NA,ENSG00000174502,Solute carrier family 26 member 9,1,205913048-205943460,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA051485,Enhanced,NA,Approved,Nucleus<br>Cell Junctions,Head and neck cancer:8.55e-5 (favourable),Tissue enhanced,Group enriched,5,lung: 11.4;salivary gland: 31.5;stomach: 30.8,tonsil: 4.8,Group enriched,12,CAPAN-2: 11.8;Hep G2: 3.4
SLC2A11,"GLUT10, GLUT11",ENSG00000133460,Solute carrier family 2 member 11,22,23856703-23886309,"Predicted membrane proteins, Transporters",Evidence at transcript level,"HPA042960, HPA071184",Uncertain,NA,Uncertain,Nucleus<br>Cell Junctions,"Renal cancer:5.77e-7 (favourable), Pancreatic cancer:3.83e-4 (favourable)",Mixed,Mixed,NA,NA,parathyroid gland: 10.9,Mixed,NA,NA
SLC2A12,"GLUT12, GLUT8",ENSG00000146411,Solute carrier family 2 member 12,6,133988697-134052636,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA031593, HPA031594",Approved,NA,Enhanced,Plasma membrane<br>Cell Junctions,NA,Tissue enriched,Tissue enhanced,NA,prostate: 43.3,endometrium: 16.1,Cell line enhanced,NA,CAPAN-2: 8.0;HaCaT: 6.1;U-2 OS: 10.1
SLC38A6,NAT-1,ENSG00000139974,Solute carrier family 38 member 6,14,60981114-61083733,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA018508,Approved,NA,Approved,Plasma membrane<br>Cell Junctions<br>Microtubules,"Liver cancer:9.47e-6 (unfavourable), Renal cancer:1.37e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 24.7,Mixed,NA,NA
SLC44A2,CTL2,ENSG00000129353,Solute carrier family 44 member 2,19,10602457-10644559,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA003228, HPA070799",Approved,NA,Approved,Vesicles<br>Cell Junctions,"Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 226.1,Mixed,NA,NA
SLC5A6,SMVT,ENSG00000138074,Solute carrier family 5 member 6,2,27199587-27212958,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA036958,Approved,NA,Approved,Cell Junctions,Renal cancer:3.60e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,epididymis: 81.3,Expressed in all,NA,NA
SLC5A7,"CHT1, hCHT",ENSG00000115665,Solute carrier family 5 member 7,2,107986523-108013994,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA046105,NA,NA,Approved,Nuclear bodies<br>Cell Junctions<br>Intermediate filaments,NA,Tissue enhanced,Mixed,NA,NA,thyroid gland: 2.0,Group enriched,21,RT4: 2.9;SCLC-21H: 1.2
SLC6A6,TAUT,ENSG00000131389,Solute carrier family 6 member 6,3,14402576-14489349,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA015028, HPA016488",Enhanced,NA,Approved,Cell Junctions<br>Cytosol,"Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,ovary: 50.8,Mixed,NA,NA
SLC7A2,"ATRC2, CAT-2, HCAT2",ENSG00000003989,Solute carrier family 7 member 2,8,17497088-17570573,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA009277,NA,NA,Supported,Plasma membrane<br>Cell Junctions,"Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 380.7,liver: 92.6,Cell line enhanced,NA,HHSteC: 171.6
SLC9A2,NHE2,ENSG00000115616,Solute carrier family 9 member A2,2,102619707-102711318,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA035121, HPA035122",Approved,NA,Supported,Cell Junctions,NA,Mixed,Tissue enhanced,NA,colon: 20.5;rectum: 23.3;stomach: 25.7,testis: 10.7,Cell line enhanced,NA,A-431: 8.9;RT4: 13.9;SK-BR-3: 11.4;T-47d: 18.0
SLC9B2,"FLJ23984, NHA2, NHEDC2",ENSG00000164038,Solute carrier family 9 member B2,4,103019868-103085829,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA047008,Uncertain,NA,Approved,Nucleoplasm<br>Cell Junctions,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 32.5,liver: 20.4,Mixed,NA,NA
SLCO4A1,"OATP-E, OATP4A1, SLC21A12",ENSG00000101187,Solute carrier organic anion transporter family member 4A1,20,62642445-62685785,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA030669, HPA030670",Uncertain,NA,Supported,Cell Junctions,Lung cancer:4.74e-4 (unfavourable),Expressed in all,Mixed,NA,NA,esophagus: 10.5,Cell line enhanced,NA,PC-3: 178.2;RPTEC TERT1: 137.9
SLIT3,"MEGF5, SLIL2, Slit-3, SLIT1, slit2",ENSG00000184347,Slit guidance ligand 3,5,168661733-169301129,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051630,Approved,NA,Supported,Cell Junctions,Renal cancer:2.45e-5 (unfavourable),Mixed,Mixed,NA,NA,parathyroid gland: 99.9,Cell line enhanced,NA,ASC diff: 212.7;fHDF/TERT166: 89.9;RT4: 80.4;SH-SY5Y: 77.7
SLX4,"BTBD12, FANCP, KIAA1784, KIAA1987",ENSG00000188827,SLX4 structure-specific endonuclease subunit,16,3581181-3611598,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA049421, HPA066238",Approved,NA,Supported,Nucleoplasm<br>Cell Junctions<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,testis: 12.7,lymph node: 4.9,Expressed in all,NA,NA
SMPD2,"ISC1, nSMase",ENSG00000135587,Sphingomyelin phosphodiesterase 2,6,109440763-109443919,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018110, HPA018125",Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cell Junctions,"Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable)",Expressed in all,Mixed,NA,NA,testis: 55.8,Expressed in all,NA,NA
SNRK,"FLJ20224, HSNFRK, KIAA0096",ENSG00000163788,SNF related kinase,3,43286512-43424764,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042163,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cell Junctions,"Renal cancer:9.41e-5 (favourable), Breast cancer:9.28e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,placenta: 47.8,Expressed in all,NA,NA
SNX32,"FLJ30934, SNX6B",ENSG00000172803,Sorting nexin 32,11,65833641-65856896,Predicted intracellular proteins,Evidence at protein level,HPA041775,Uncertain,NA,Uncertain,Cell Junctions<br>Focal adhesion sites,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 7.7,testis: 1.8,Cell line enhanced,NA,HHSteC: 3.0;HSkMC: 3.4;SH-SY5Y: 1.9;U-266/70: 4.3
SORL1,"C11orf32, gp250, LR11, LRP9, SorLA, SorLA-1",ENSG00000137642,Sortilin related receptor 1,11,121452203-121633693,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB011500, HPA031321",Uncertain,NA,Approved,Nucleoplasm<br>Cell Junctions,Renal cancer:1.80e-7 (favourable),Expressed in all,Mixed,NA,NA,"cervix, uterine: 67.8",Cell line enhanced,NA,CAPAN-2: 125.3;RT4: 81.2;U-698: 97.2
SPERT,"CBY2, NURIT",ENSG00000174015,Spermatid associated,13,45702311-45714559,Predicted intracellular proteins,Evidence at protein level,"HPA039359, HPA040046",Enhanced,NA,Approved,Plasma membrane<br>Cell Junctions,NA,Mixed,Tissue enriched,178,testis: 49.0,"fallopian tube,urinary bladder: 0.2",Not detected,NA,NA
SPN,"CD43, GPL115, LSN",ENSG00000197471,Sialophorin,16,29662979-29670876,"CD markers, Predicted membrane proteins",Evidence at protein level,"CAB002666, HPA055244",Enhanced,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cell Junctions,"Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable)",Expressed in all,Tissue enhanced,NA,bone marrow: 38.6;lung: 33.3,lymph node: 25.4,Cell line enhanced,NA,HEL: 209.9;HL-60: 167.0;HMC-1: 98.8;U-937: 115.3
SPTBN2,SCA5,ENSG00000173898,"Spectrin beta, non-erythrocytic 2",11,66685248-66729226,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009844, HPA039293, HPA043529",Enhanced,NA,Supported,Cell Junctions<br>Cytosol,Pancreatic cancer:3.14e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 73.0;skin: 59.3;testis: 48.4,parathyroid gland: 24.6,Cell line enhanced,NA,NTERA-2: 49.7;SCLC-21H: 59.4
SRCIN1,"KIAA1684, p140Cap, SNIP",ENSG00000277363,SRC kinase signaling inhibitor 1,17,38530016-38605930,Predicted intracellular proteins,Evidence at protein level,"HPA009701, HPA063795",Enhanced,NA,Approved,Cell Junctions,Urothelial cancer:1.76e-4 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 22.1,skin: 4.7,Cell line enriched,5,SCLC-21H: 14.7
SSX2IP,hMsd1,ENSG00000117155,SSX family member 2 interacting protein,1,84643707-84690803,Predicted intracellular proteins,Evidence at protein level,"HPA027306, HPA075946",Approved,NA,Approved,Cell Junctions,Colorectal cancer:1.45e-4 (favourable),Expressed in all,Tissue enhanced,NA,testis: 191.9,cerebral cortex: 45.8,Expressed in all,NA,NA
SYNPO2L,FLJ12921,ENSG00000166317,Synaptopodin 2 like,10,73644881-73663803,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA055192, HPA057142",Enhanced,NA,Approved,Nuclear speckles<br>Cell Junctions<br>Cytosol,NA,Group enriched,Group enriched,12,heart muscle: 168.4;skeletal muscle: 95.9,esophagus: 11.1,Cell line enhanced,NA,CACO-2: 3.4;HSkMC: 2.3;RH-30: 3.0;SK-BR-3: 2.5
SYT8,DKFZp434K0322,ENSG00000149043,Synaptotagmin 8,11,1828307-1837521,Predicted membrane proteins,Evidence at transcript level,HPA052700,Uncertain,NA,Approved,Nucleoplasm<br>Cell Junctions,NA,Tissue enhanced,Group enriched,5,gallbladder: 26.5;skin: 80.2;urinary bladder: 24.5,seminal vesicle: 8.6,Group enriched,6,CAPAN-2: 56.5;hTCEpi: 72.7;T-47d: 25.8
TBC1D24,"DFNA65, DFNB86, KIAA1171, TLDC6",ENSG00000162065,TBC1 domain family member 24,16,2475051-2509560,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA044712, HPA068080",Uncertain,NA,Supported,Plasma membrane<br>Cell Junctions,Breast cancer:3.22e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 23.0,Expressed in all,NA,NA
TCAF2,"FAM115C, FAM139A, FLJ40722",ENSG00000170379,TRPM8 channel associated factor 2,7,143620950-143730409,Predicted intracellular proteins,Evidence at protein level,"HPA038756, HPA038758",Uncertain,NA,Supported,Plasma membrane<br>Cell Junctions,"Renal cancer:4.17e-6 (unfavourable), Glioma:6.78e-5 (unfavourable)",Mixed,Mixed,NA,NA,placenta: 8.1,Cell line enhanced,NA,HDLM-2: 11.0;TIME: 15.8;U-87 MG: 14.1
TES,"DKFZP586B2022, TESS-2, TESTIN",ENSG00000135269,Testin LIM domain protein,7,116210493-116258783,Predicted intracellular proteins,Evidence at protein level,"HPA015269, HPA018123",Approved,NA,Supported,Plasma membrane<br>Cell Junctions<br>Focal adhesion sites<br>Cytosol,"Pancreatic cancer:1.20e-5 (unfavourable), Renal cancer:8.71e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 271.7,Cell line enhanced,NA,EFO-21: 215.5
TEX14,CT113,ENSG00000121101,"Testis expressed 14, intercellular bridge forming factor",17,58556678-58692055,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA030620, HPA077020",Enhanced,NA,Approved,Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol,NA,Mixed,Tissue enriched,43,testis: 48.9,bone marrow: 1.1,Cell line enhanced,NA,HDLM-2: 5.9;Karpas-707: 5.7;MCF7: 2.5
TIAM1,NA,ENSG00000156299,T-cell lymphoma invasion and metastasis 1,21,31118416-31559977,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010416, HPA034853",Uncertain,NA,Supported,Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cell Junctions<br>Cytokinetic bridge<br>Cytosol,NA,Mixed,Mixed,NA,NA,skin: 28.0,Cell line enhanced,NA,BEWO: 33.2;SCLC-21H: 38.3
TJP1,"DKFZp686M05161, MGC133289, ZO-1",ENSG00000104067,Tight junction protein 1,15,29699367-29968865,Predicted intracellular proteins,Evidence at protein level,"HPA001636, HPA001637, CAB010822",Enhanced,NA,Enhanced,Cell Junctions,Renal cancer:1.72e-4 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 49.6,Mixed,NA,NA
TJP2,"DFNA51, X104, ZO-2, ZO2",ENSG00000119139,Tight junction protein 2,9,69121264-69255208,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001813, CAB009228, HPA070714",Supported,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Renal cancer:1.78e-14 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 104.1,Mixed,NA,NA
TJP3,ZO-3,ENSG00000105289,Tight junction protein 3,19,3708109-3750813,Predicted intracellular proteins,Evidence at protein level,"CAB013244, HPA046863, HPA053337",Enhanced,NA,Enhanced,Nucleoplasm<br>Cell Junctions,"Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable)",Mixed,Tissue enhanced,NA,duodenum: 41.5;small intestine: 41.3,colon: 30.6,Cell line enhanced,NA,BEWO: 42.4;CAPAN-2: 39.5;SK-BR-3: 19.4;T-47d: 51.5
TM4SF5,NA,ENSG00000142484,Transmembrane 4 L six family member 5,17,4771884-4783213,Predicted membrane proteins,Evidence at protein level,HPA055674,NA,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,NA,Tissue enriched,Group enriched,5,duodenum: 176.7;small intestine: 168.8,liver: 33.3,Group enriched,13,CACO-2: 45.1;Hep G2: 64.9
TMEM141,MGC14141,ENSG00000244187,Transmembrane protein 141,9,136791355-136793257,Predicted membrane proteins,Evidence at protein level,"HPA014615, HPA050244",Approved,NA,Supported,Cell Junctions<br>Mitochondria,Renal cancer:6.63e-4 (favourable),Expressed in all,Expressed in all,NA,NA,prostate: 199.4,Expressed in all,NA,NA
TMEM164,"FLJ22679, RP13-360B22.2",ENSG00000157600,Transmembrane protein 164,X,110002631-110182734,Predicted membrane proteins,Evidence at protein level,HPA038784,Approved,NA,Approved,Vesicles<br>Cell Junctions,"Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lung: 26.7,Expressed in all,NA,NA
TMEM183A,C1orf37,ENSG00000163444,Transmembrane protein 183A,1,203007386-203024848,Predicted membrane proteins,Evidence at protein level,HPA072607,NA,NA,Approved,Nucleus<br>Plasma membrane<br>Cell Junctions,Liver cancer:2.62e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 59.1,Expressed in all,NA,NA
TMEM186,"C16orf51, DKFZP564K2062",ENSG00000184857,Transmembrane protein 186,16,8780384-8797648,Predicted membrane proteins,Evidence at protein level,"HPA018226, HPA063559",Uncertain,NA,Approved,Cell Junctions,Renal cancer:1.93e-8 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 23.0,Expressed in all,NA,NA
TMEM251,"C14orf109, DKFZP564F1123",ENSG00000153485,Transmembrane protein 251,14,93184951-93187089,Predicted membrane proteins,Evidence at transcript level,HPA048559,Uncertain,NA,Approved,Golgi apparatus<br>Cell Junctions,"Liver cancer:6.14e-7 (unfavourable), Renal cancer:1.10e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,prostate: 27.0,Expressed in all,NA,NA
TMPRSS2,PRSS10,ENSG00000184012,"Transmembrane protease, serine 2",21,41464551-41531116,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034493, HPA035787",Enhanced,NA,Supported,Nucleoplasm<br>Cell Junctions,"Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable)",Tissue enriched,Tissue enhanced,NA,prostate: 489.3,stomach: 142.6,Cell line enhanced,NA,CACO-2: 21.8;RT4: 50.4;SK-BR-3: 9.5
TNK1,NA,ENSG00000174292,Tyrosine kinase non receptor 1,17,7380534-7389774,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA012065, HPA056452",Uncertain,NA,Approved,Cell Junctions,"Urothelial cancer:1.52e-4 (favourable), Endometrial cancer:4.28e-4 (favourable), Renal cancer:6.40e-4 (favourable)",Mixed,Mixed,NA,NA,skin: 5.1,Cell line enhanced,NA,HaCaT: 8.0;T-47d: 6.9
TP53BP2,"53BP2, ASPP2, PPP1R13A",ENSG00000143514,Tumor protein p53 binding protein 2,1,223779899-223845972,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA021603, HPA050429",Supported,NA,Enhanced,Cell Junctions<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 34.6,Mixed,NA,NA
TPD52L1,"D53, hD53",ENSG00000111907,Tumor protein D52-like 1,6,125119049-125264407,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027915, HPA027916",Enhanced,NA,Approved,Plasma membrane<br>Cell Junctions<br>Cytosol,"Renal cancer:3.26e-4 (favourable), Thyroid cancer:3.97e-4 (favourable), Urothelial cancer:5.34e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,adrenal gland: 320.2,salivary gland: 126.1,Cell line enhanced,NA,AN3-CA: 249.0;hTCEpi: 169.3;MCF7: 277.5;RPTEC TERT1: 204.5
TRIM38,"RNF15, RORET",ENSG00000112343,Tripartite motif containing 38,6,25962802-25991226,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031685,Approved,NA,Approved,Plasma membrane<br>Cell Junctions<br>Centrosome,"Urothelial cancer:4.94e-9 (favourable), Thyroid cancer:8.20e-5 (favourable), Ovarian cancer:8.95e-5 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 19.7,Mixed,NA,NA
TSR2,"DT1P1A10, RP1-112K5.2, WGG1",ENSG00000158526,"TSR2, ribosome maturation factor",X,54440401-54445487,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA030514,Approved,NA,Approved,Nucleus<br>Nucleoli<br>Cell Junctions<br>Cytosol,Renal cancer:1.21e-6 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 88.4,Expressed in all,NA,NA
TSSK4,"C14orf20, STK22E",ENSG00000139908,Testis specific serine kinase 4,14,24205697-24208362,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA060660, HPA077103",Enhanced,NA,Approved,Cell Junctions,NA,Mixed,Tissue enhanced,NA,testis: 42.2,skin: 10.1,Mixed,NA,NA
UBALD1,FAM100A,ENSG00000153443,UBA like domain containing 1,16,4608883-4615027,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA066771,Approved,NA,Approved,Nucleus<br>Cell Junctions<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 23.8,Expressed in all,NA,NA
UBXN10,"FLJ25429, UBXD3",ENSG00000162543,UBX domain protein 10,1,20186085-20196048,Predicted intracellular proteins,Evidence at protein level,"HPA028555, HPA028564",Uncertain,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,"Glioma:1.64e-4 (unfavourable), Endometrial cancer:2.02e-4 (favourable)",Mixed,Tissue enhanced,NA,fallopian tube: 79.1,testis: 25.5,Group enriched,6,HEL: 2.5;HMC-1: 6.3;K-562: 7.6;SCLC-21H: 6.6
VASP,NA,ENSG00000125753,Vasodilator-stimulated phosphoprotein,19,45506579-45526983,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004612, HPA005724",Enhanced,NA,Supported,Plasma membrane<br>Cell Junctions<br>Focal adhesion sites,"Renal cancer:5.91e-7 (unfavourable), Liver cancer:3.49e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,appendix: 90.5,Expressed in all,NA,NA
VCAM1,CD106,ENSG00000162692,Vascular cell adhesion molecule 1,1,100719742-100739045,"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB000154, HPA034796, HPA069867",Enhanced,NA,Approved,Cell Junctions,"Head and neck cancer:7.19e-5 (favourable), Cervical cancer:3.82e-4 (favourable)",Tissue enriched,Tissue enriched,5,spleen: 549.1,lymph node: 109.7,Cell line enhanced,NA,HHSteC: 144.7;HSkMC: 83.9;hTEC/SVTERT24-B: 31.1;U-138 MG: 25.9
VPS13B,"CHS1, COH1",ENSG00000132549,Vacuolar protein sorting 13 homolog B,8,99013266-99877580,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA043865,NA,NA,Approved,Cell Junctions,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 14.7,Expressed in all,NA,NA
VPS36,"C13orf9, CGI-145, Eap45",ENSG00000136100,Vacuolar protein sorting 36 homolog,13,52412602-52450628,Predicted intracellular proteins,Evidence at protein level,"HPA039734, HPA043947",Approved,NA,Supported,Vesicles<br>Lysosomes<br>Plasma membrane<br>Cell Junctions,Renal cancer:9.91e-6 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 62.4,Expressed in all,NA,NA
VTCN1,"B7-H4, B7H4, B7S1, B7X, FLJ22418",ENSG00000134258,V-set domain containing T-cell activation inhibitor 1,1,117143587-117210960,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA054200,Approved,NA,Approved,Plasma membrane<br>Cell Junctions<br>Focal adhesion sites,NA,Group enriched,Tissue enhanced,NA,breast: 129.4;fallopian tube: 51.3,"cervix, uterine: 22.0",Group enriched,8,BEWO: 43.1;SK-BR-3: 182.1
WDPCP,"BBS15, C2orf86, fritz, hFrtz",ENSG00000143951,WD repeat containing planar cell polarity effector,2,63121383-63827843,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA044144,Uncertain,NA,Approved,Cell Junctions,NA,Mixed,Mixed,NA,NA,testis: 11.4,Expressed in all,NA,NA
WDR1,NA,ENSG00000071127,WD repeat domain 1,4,10074339-10116949,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB020804, HPA036434, HPA070293",Approved,NA,Supported,Plasma membrane<br>Cell Junctions,Renal cancer:1.73e-5 (favourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 308.6,Expressed in all,NA,NA
WRAP73,WDR8,ENSG00000116213,"WD repeat containing, antisense to TP73",1,3630767-3652761,Predicted intracellular proteins,Evidence at protein level,HPA026893,Uncertain,NA,Approved,Nucleoplasm<br>Cell Junctions,"Liver cancer:1.37e-4 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:3.49e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 20.4,Expressed in all,NA,NA
ZDHHC5,"KIAA1748, ZNF375",ENSG00000156599,Zinc finger DHHC-type containing 5,11,57667747-57701187,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014670,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Pancreatic cancer:6.74e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 87.5,Expressed in all,NA,NA
ZNF497,FLJ44773,ENSG00000174586,Zinc finger protein 497,19,58354357-58362848,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047872,Uncertain,NA,Approved,Nucleus<br>Cell Junctions,NA,Mixed,Mixed,NA,NA,fallopian tube: 8.1,Cell line enhanced,NA,HEK93: 18.3
ZNF536,KIAA0390,ENSG00000198597,Zinc finger protein 536,19,30228290-30713538,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA077341,NA,NA,Approved,Nucleus<br>Cell Junctions,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 19.0,thyroid gland: 5.3,Cell line enhanced,NA,HAP1: 11.4;SH-SY5Y: 31.3;WM-115: 12.5
ZNF688,NA,ENSG00000229809,Zinc finger protein 688,16,30569346-30572734,Predicted intracellular proteins,Evidence at transcript level,HPA048922,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,"Endometrial cancer:4.58e-5 (favourable), Lung cancer:3.24e-4 (favourable), Breast cancer:5.90e-4 (favourable), Pancreatic cancer:6.61e-4 (favourable), Cervical cancer:7.74e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 23.7,Expressed in all,NA,NA
AADAT,"KAT2, KATII, KYAT2",ENSG00000109576,Aminoadipate aminotransferase,4,170060222-170091699,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037502,Enhanced,NA,Approved,Vesicles<br>Plasma membrane,Colorectal cancer:5.59e-4 (favourable),Expressed in all,Tissue enhanced,NA,liver: 34.7,prostate: 23.4,Mixed,NA,NA
AAK1,"DKFZp686K16132, KIAA1048",ENSG00000115977,AP2 associated kinase 1,2,69457997-69674349,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA017931, HPA020289",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Ovarian cancer:3.19e-4 (unfavourable),Expressed in all,Tissue enriched,7,parathyroid gland: 389.6,thyroid gland: 59.4,Expressed in all,NA,NA
ABCA12,"DKFZP434G232, ICR2B, LI2",ENSG00000144452,ATP binding cassette subfamily A member 12,2,214931542-215138428,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA078239,NA,NA,Approved,Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Group enriched,6,breast: 7.7;skin: 25.2,tonsil: 2.5,Group enriched,6,hTCEpi: 28.4;SK-BR-3: 13.8;T-47d: 9.1
ABCB11,"ABC16, BSEP, PFIC-2, PFIC2, PGY4, SPGP",ENSG00000073734,ATP binding cassette subfamily B member 11,2,168922938-169031322,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA019035,Enhanced,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enriched,13,liver: 19.1,testis: 1.4,Not detected,NA,NA
ABCB4,"GBD1, MDR2, MDR3, PFIC-3, PGY3",ENSG00000005471,ATP binding cassette subfamily B member 4,7,87401697-87480435,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA049395, HPA053288",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites,NA,Tissue enriched,Tissue enriched,6,liver: 69.3,adrenal gland: 10.7,Group enriched,6,SH-SY5Y: 14.2;WM-115: 25.6
ABCB6,"EST45597, MTABC3, umat",ENSG00000115657,ATP binding cassette subfamily B member 6 (Langereis blood group),2,219209768-219218990,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA046723, HPA058011",Approved,NA,Enhanced,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Mitochondria<br>Cytosol,"Renal cancer:1.52e-7 (unfavourable), Liver cancer:9.45e-7 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 32.7,Mixed,NA,NA
ABCC1,"GS-X, MRP, MRP1",ENSG00000103222,ATP binding cassette subfamily C member 1,16,15949577-16143074,"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA002380,Uncertain,NA,Supported,Plasma membrane,"Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 18.6,Cell line enhanced,NA,EFO-21: 84.1
ABCC3,"cMOAT2, EST90757, MLP2, MOAT-D, MRP3",ENSG00000108846,ATP binding cassette subfamily C member 3,17,50634777-50692252,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB037136, HPA048483",Enhanced,NA,Approved,Plasma membrane,"Renal cancer:4.68e-6 (unfavourable), Pancreatic cancer:9.57e-4 (unfavourable)",Mixed,Mixed,NA,NA,adrenal gland: 20.7,Cell line enhanced,NA,A549: 69.8;CAPAN-2: 51.3
ABCC6,"ARA, EST349056, MLP1, MRP6, PXE, URG7",ENSG00000091262,ATP binding cassette subfamily C member 6,16,16148928-16223522,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038105,NA,NA,Supported,Plasma membrane,Liver cancer:3.82e-4 (favourable),Tissue enhanced,Tissue enhanced,NA,kidney: 16.9;liver: 23.4,duodenum: 13.0,Cell line enriched,6,Hep G2: 45.5
ABCG2,"ABCP, BCRP, CD338, EST157481, MXR",ENSG00000118777,ATP binding cassette subfamily G member 2 (Junior blood group),4,88090264-88231322,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB037299, HPA054719",Enhanced,NA,Enhanced,Nucleus<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,small intestine: 113.8,seminal vesicle: 55.9,Cell line enhanced,NA,A549: 47.2;BEWO: 80.5;RPMI-8226: 32.5
ABHD3,LABH3,ENSG00000158201,Abhydrolase domain containing 3,18,21650897-21704805,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010729,Approved,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane,Melanoma:8.52e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,rectum: 71.5,Cell line enhanced,NA,REH: 188.5;RPMI-8226: 159.6
ACIN1,"ACINUS, fSAP152, KIAA0670",ENSG00000100813,Apoptotic chromatin condensation inducer 1,14,23058564-23095614,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA000657,Supported,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:4.88e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 77.4,Expressed in all,NA,NA
ACKR3,"CMKOR1, CXCR7, GPR159, RDC1",ENSG00000144476,Atypical chemokine receptor 3,2,236567787-236582358,"Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA032003, HPA049718",Approved,NA,Supported,Vesicles<br>Plasma membrane,"Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 176.7,Cell line enhanced,NA,RT4: 248.8;SiHa: 100.8;U-2197: 297.4
ACLY,"ACL, ATPCL, CLATP",ENSG00000131473,ATP citrate lyase,17,41866908-41930542,"Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB007783, HPA022434, HPA022953, HPA022959, HPA028758",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Cervical cancer:1.79e-4 (unfavourable), Liver cancer:3.66e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,prostate: 100.5,Expressed in all,NA,NA
ACOT9,"ACATE2, CGI-16, MT-ACT48",ENSG00000123130,Acyl-CoA thioesterase 9,X,23702253-23766475,Predicted intracellular proteins,Evidence at protein level,HPA035533,Supported,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:3.23e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 46.9,Mixed,NA,NA
ACTN1,NA,ENSG00000072110,Actinin alpha 1,14,68874143-68979440,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004303, HPA006035",Approved,NA,Approved,Plasma membrane<br>Focal adhesion sites,"Renal cancer:9.08e-10 (unfavourable), Lung cancer:7.63e-5 (unfavourable), Head and neck cancer:2.49e-4 (unfavourable), Urothelial cancer:8.00e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 754.0,Mixed,NA,NA
ACTR6,"ARP6, FLJ13433",ENSG00000075089,ARP6 actin-related protein 6 homolog,12,100199122-100241865,Predicted intracellular proteins,Evidence at protein level,"HPA038587, HPA038588",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Liver cancer:7.70e-9 (unfavourable),Expressed in all,Mixed,NA,NA,testis: 16.2,Expressed in all,NA,NA
ADA,NA,ENSG00000196839,Adenosine deaminase,20,44619522-44652233,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001399, CAB004307, HPA023884",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.94e-14 (unfavourable), Endometrial cancer:1.23e-7 (unfavourable), Liver cancer:6.77e-5 (unfavourable), Lung cancer:2.20e-4 (unfavourable)",Expressed in all,Tissue enriched,13,duodenum: 487.7,lymph node: 36.5,Cell line enriched,9,MOLT-4: 1479.5
ADAM10,"CD156c, HsT18717, kuz, MADM",ENSG00000137845,ADAM metallopeptidase domain 10,15,58588807-58749978,"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB001709, HPA050670",Approved,NA,Supported,Vesicles<br>Plasma membrane,"Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 47.9,Expressed in all,NA,NA
ADAM12,"MCMPMltna, MLTN",ENSG00000148848,ADAM metallopeptidase domain 12,10,126012381-126388455,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA030866, HPA030867, HPA030868",Enhanced,NA,Supported,Plasma membrane,Renal cancer:2.39e-14 (unfavourable),Mixed,Tissue enriched,8,placenta: 237.2,"cervix, uterine: 29.7",Cell line enhanced,NA,fHDF/TERT166: 119.5;hTEC/SVTERT24-B: 94.3;U-2197: 86.6;U-251 MG: 71.0
ADAM28,"ADAM23, eMDCII, MDC-Lm, MDC-Ls",ENSG00000042980,ADAM metallopeptidase domain 28,8,24294040-24359018,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA074034,Enhanced,NA,Approved,Plasma membrane<br>Mitochondria,Endometrial cancer:3.17e-4 (favourable),Mixed,Tissue enhanced,NA,epididymis: 435.5,stomach: 104.6,Cell line enriched,10,CAPAN-2: 24.6
ADAM33,"C20orf153, dJ964F7.1, DKFZp434K0521",ENSG00000149451,ADAM metallopeptidase domain 33,20,3667965-3682246,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA067152, HPA071758",Approved,NA,Uncertain,Nuclear speckles<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,endometrium: 103.3,Cell line enhanced,NA,ASC diff: 55.2;ASC TERT1: 72.4;BJ: 31.3;BJ hTERT+: 51.1;fHDF/TERT166: 29.6;U-2197: 46.1
ADAMTS2,"ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP",ENSG00000087116,ADAM metallopeptidase with thrombospondin type 1 motif 2,5,179110851-179345430,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA028444,Uncertain,NA,Approved,Vesicles<br>Plasma membrane,Renal cancer:1.71e-8 (unfavourable),Expressed in all,Mixed,NA,NA,placenta: 14.7,Cell line enhanced,NA,HHSteC: 100.5;HSkMC: 69.6
ADAMTSL4,"DKFZP434K1772, TSRC1",ENSG00000143382,ADAMTS like 4,1,150549369-150560937,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA006279,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:4.35e-7 (unfavourable), Glioma:1.63e-4 (unfavourable), Colorectal cancer:1.86e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 88.9,lung: 32.3,Cell line enhanced,NA,ASC TERT1: 64.0;BEWO: 191.0;K-562: 60.1
ADAP1,"CENTA1, GCS1L",ENSG00000105963,ArfGAP with dual PH domains 1,7,897901-955407,Predicted intracellular proteins,Evidence at protein level,"HPA007033, HPA012049",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 80.4,colon: 37.9,Cell line enhanced,NA,A-431: 97.9;CAPAN-2: 69.1;HMC-1: 64.7;THP-1: 87.7
ADCK5,FLJ35454,ENSG00000173137,AarF domain containing kinase 5,8,144373101-144393242,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA025692, HPA028679",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,duodenum: 9.6,Mixed,NA,NA
ADD1,NA,ENSG00000087274,Adducin 1,4,2843857-2930076,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009794, HPA035873, HPA035874",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane,"Renal cancer:1.29e-7 (favourable), Pancreatic cancer:3.94e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 201.1,Expressed in all,NA,NA
ADD2,ADDB,ENSG00000075340,Adducin 2,2,70607618-70768225,Predicted intracellular proteins,Evidence at protein level,"CAB009796, HPA034509, HPA034510",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Group enriched,10,bone marrow: 40.2;cerebral cortex: 44.7,testis: 4.2,Cell line enhanced,NA,K-562: 41.5;NTERA-2: 86.7;SCLC-21H: 50.4;U-251 MG: 38.9
ADD3,ADDL,ENSG00000148700,Adducin 3,10,109996368-110135565,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB009797, HPA035696",Supported,NA,Supported,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 168.6,Cell line enhanced,NA,ASC diff: 215.0;ASC TERT1: 204.7
ADGRG2,"EDDM6, GPR64, HE6, TM7LN2",ENSG00000173698,Adhesion G protein-coupled receptor G2,X,18989309-19122637,"Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA001478, HPA050029",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enriched,6,epididymis: 1494.8,parathyroid gland: 240.0,Cell line enhanced,NA,A549: 5.4;BEWO: 7.0;NTERA-2: 6.3;SH-SY5Y: 6.9;U-2197: 13.5
ADH1A,ADH1,ENSG00000187758,"Alcohol dehydrogenase 1A (class I), alpha polypeptide",4,99276367-99291028,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009562, HPA047814, HPA060902",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Liver cancer:2.38e-4 (favourable),Tissue enriched,Tissue enriched,135,liver: 1367.7,gallbladder: 10.1,Cell line enhanced,NA,ASC diff: 3.7
ADH1B,ADH2,ENSG00000196616,"Alcohol dehydrogenase 1B (class I), beta polypeptide",4,99304964-99352760,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047814, HPA060902",Supported,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:7.87e-4 (unfavourable),Tissue enriched,Group enriched,6,adipose tissue: 1624.6;liver: 3000.2,lung: 388.5,Cell line enriched,7,ASC diff: 4511.9
ADH1C,ADH3,ENSG00000248144,"Alcohol dehydrogenase 1C (class I), gamma polypeptide",4,99336492-99353027,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047814, HPA060902",Supported,NA,Supported,Plasma membrane<br>Cytosol,"Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable)",Tissue enriched,Tissue enhanced,NA,duodenum: 508.1;liver: 888.0;stomach: 477.4,colon: 276.3,Cell line enhanced,NA,ASC TERT1: 2.5;HSkMC: 7.7
ADH7,ADH-4,ENSG00000196344,"Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide",4,99412261-99435737,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039695,Enhanced,NA,Supported,Plasma membrane<br>Cytosol,NA,Group enriched,Tissue enriched,6,esophagus: 215.5,tonsil: 34.5,Cell line enhanced,NA,HaCaT: 1.0
ADORA1,RDC7,ENSG00000163485,Adenosine A1 receptor,1,203090654-203167405,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA044383,NA,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 50.2;testis: 25.4,parathyroid gland: 18.9,Cell line enhanced,NA,CACO-2: 33.2;RH-30: 62.4;RPTEC TERT1: 23.7;SK-BR-3: 26.3
ADRA1B,NA,ENSG00000170214,Adrenoceptor alpha 1B,5,159916783-159972544,"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA074416,NA,NA,Supported,Plasma membrane,"Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable)",Mixed,Tissue enhanced,NA,cerebral cortex: 14.8;spleen: 17.0,ovary: 4.8,Cell line enhanced,NA,EFO-21: 12.8;TIME: 10.9;U-2 OS: 9.6
ADRM1,"ARM1, GP110, Rpn13",ENSG00000130706,Adhesion regulating molecule 1,20,62302093-62308862,Predicted intracellular proteins,Evidence at protein level,HPA042266,Supported,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:9.02e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 108.5,Expressed in all,NA,NA
ADSS,NA,ENSG00000035687,Adenylosuccinate synthase,1,244408494-244452134,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA024400,Enhanced,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 117.0,Expressed in all,NA,NA
AFAP1L2,"Em:AC005383.4, FLJ14564, KIAA1914, XB130",ENSG00000169129,Actin filament associated protein 1 like 2,10,114294824-114404756,Predicted intracellular proteins,Evidence at protein level,HPA037843,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.55e-5 (unfavourable), Pancreatic cancer:3.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,thyroid gland: 138.0,parathyroid gland: 94.7,Cell line enhanced,NA,A-431: 64.5;CAPAN-2: 68.1;EFO-21: 53.1;HaCaT: 87.3;RPMI-8226: 36.0;RPTEC TERT1: 45.2
AGRN,AGRIN,ENSG00000188157,Agrin,1,1020123-1056118,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA040090,Approved,NA,Supported,Plasma membrane<br>Cytosol,Liver cancer:4.62e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 33.2,Cell line enhanced,NA,EFO-21: 223.9
AHNAK,MGC5395,ENSG00000124942,AHNAK nucleoprotein,11,62433542-62556235,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019010, HPA019070, HPA026643",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Urothelial cancer:3.47e-6 (unfavourable), Pancreatic cancer:2.42e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 397.0,Mixed,NA,NA
AHNAK2,C14orf78,ENSG00000185567,AHNAK nucleoprotein 2,14,104937244-104978357,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA000878, HPA002940, HPA004145, HPA020111",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Pancreatic cancer:4.05e-6 (unfavourable), Urothelial cancer:2.23e-5 (unfavourable), Lung cancer:2.79e-5 (unfavourable)",Mixed,Tissue enriched,7,skin: 345.5,smooth muscle: 46.8,Cell line enhanced,NA,hTCEpi: 224.2
AKAP10,"D-AKAP2, MGC9414, PRKA10",ENSG00000108599,A-kinase anchoring protein 10,17,19904302-19978343,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA028901,Approved,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 26.2,Expressed in all,NA,NA
AKAP11,"AKAP220, DKFZp781I12161, FLJ11304, KIAA0629, PPP1R44, PRKA11",ENSG00000023516,A-kinase anchoring protein 11,13,42272153-42323267,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039089,Enhanced,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,Cervical cancer:9.26e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 51.6,Expressed in all,NA,NA
AKAP12,"AKAP250, SSeCKS",ENSG00000131016,A-kinase anchoring protein 12,6,151239999-151358557,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006344, CAB026379, HPA056230",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Lung cancer:6.34e-5 (unfavourable), Endometrial cancer:7.08e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 184.5,Cell line enhanced,NA,REH: 175.6
AKR1B10,"AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI",ENSG00000198074,Aldo-keto reductase family 1 member B10,7,134527592-134541408,Predicted intracellular proteins,Evidence at protein level,"HPA020280, CAB070163, HPA073633",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable)",Tissue enhanced,Tissue enhanced,NA,duodenum: 635.9;gallbladder: 283.3;small intestine: 387.2;stomach: 414.4,esophagus: 89.8,Group enriched,74,A549: 2731.1;Hep G2: 580.9
AKR1B15,NA,ENSG00000227471,Aldo-keto reductase family 1 member B15,7,134549136-134579875,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020280, HPA073633",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable)",Mixed,Tissue enriched,13,breast: 179.9,duodenum: 13.7,Group enriched,8,A549: 14.3;HDLM-2: 11.8;Hep G2: 7.6;NTERA-2: 3.2;SK-BR-3: 3.8;U-87 MG: 6.4
ALDH3A1,ALDH3,ENSG00000108602,Aldehyde dehydrogenase 3 family member A1,17,19737984-19748943,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB045957, HPA051150, HPA063783",Enhanced,NA,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,Head and neck cancer:7.55e-5 (favourable),Mixed,Group enriched,7,esophagus: 406.1;skin: 84.3;stomach: 207.2,tonsil: 31.0,Cell line enriched,21,A549: 4306.9
ALK,CD246,ENSG00000171094,Anaplastic lymphoma receptor tyrosine kinase,2,29192774-29921566,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010694,Approved,NA,Supported,Plasma membrane,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 2.7;testis: 2.0,adrenal gland: 0.5,Cell line enriched,6,SH-SY5Y: 28.3
ALOX15B,15-LOX-2,ENSG00000179593,"Arachidonate 15-lipoxygenase, type B",17,8039017-8049134,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010562,Enhanced,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,breast: 145.0;prostate: 115.3,lung: 26.1,Group enriched,15,HHSteC: 6.5;HSkMC: 11.9;hTCEpi: 25.0
ALOXE3,"E-LOX, eLOX3",ENSG00000179148,Arachidonate lipoxygenase 3,17,8095900-8119047,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023120, HPA078597",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enriched,16,skin: 36.5,breast: 2.2,Cell line enhanced,NA,A-431: 5.5;HBEC3-KT: 7.2;hTCEpi: 5.2;hTERT-HME1: 10.5;T-47d: 4.1
ALPI,NA,ENSG00000163295,"Alkaline phosphatase, intestinal",2,232456123-232460032,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA038764, HPA038765, HPA051699",Supported,NA,Approved,Plasma membrane,NA,Tissue enhanced,Group enriched,31,duodenum: 203.2;small intestine: 212.1,colon: 6.6,Cell line enriched,10,CACO-2: 5.9
ALPP,NA,ENSG00000163283,"Alkaline phosphatase, placental",2,232378534-232382889,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB026327, HPA038764, HPA038765, HPA051699",Enhanced,NA,Approved,Plasma membrane,Pancreatic cancer:4.33e-4 (unfavourable),Tissue enhanced,Group enriched,14,"cervix, uterine: 25.5;placenta: 45.5",fallopian tube: 2.5,Group enriched,6,HaCaT: 311.4;SiHa: 103.4
ALPPL2,NA,ENSG00000163286,"Alkaline phosphatase, placental like 2",2,232406843-232410714,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB020698, HPA038764, HPA038765, HPA051699",Supported,NA,Approved,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,fallopian tube: 1.5,lung: 0.7,Group enriched,29,BEWO: 6.5;CAPAN-2: 29.9;HaCaT: 22.2
ALS2CR12,NA,ENSG00000155749,Amyotrophic lateral sclerosis 2 chromosome region 12,2,201288271-201357398,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035793,NA,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Group enriched,5,fallopian tube: 15.0;testis: 31.8,lung: 4.2,Cell line enhanced,NA,U-2197: 4.3
AMACR,"P504S, RACE",ENSG00000242110,Alpha-methylacyl-CoA racemase,5,33986178-34008108,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB001809, HPA019527, HPA020912",Enhanced,NA,Supported,Vesicles<br>Plasma membrane,Colorectal cancer:7.11e-4 (favourable),Expressed in all,Expressed in all,NA,NA,kidney: 135.3,Expressed in all,NA,NA
AMDHD1,MGC35366,ENSG00000139344,Amidohydrolase domain containing 1,12,95943293-95968716,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039720,Uncertain,NA,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,NA,Tissue enriched,Tissue enhanced,NA,testis: 25.8,liver: 22.0,Cell line enhanced,NA,HMC-1: 57.9;Karpas-707: 44.7;SiHa: 44.1;U-266/84: 42.8
AMER1,"FAM123B, FLJ39827, RP11-403E24.2, WTX",ENSG00000184675,APC membrane recruitment protein 1,X,64185117-64205744,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA065214, HPA065265",Approved,NA,Supported,Nuclear bodies<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,ovary: 7.7,Mixed,NA,NA
AMIGO2,"ALI1, DEGA",ENSG00000139211,Adhesion molecule with Ig like domain 2,12,47075707-47079951,Predicted membrane proteins,Evidence at protein level,"HPA054004, HPA059601",Uncertain,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Pancreatic cancer:1.80e-4 (unfavourable),Expressed in all,Mixed,NA,NA,smooth muscle: 55.1,Cell line enhanced,NA,CAPAN-2: 184.4;fHDF/TERT166: 158.6;LHCN-M2: 167.5;RT4: 222.6;U-2 OS: 170.3
AMPH,NA,ENSG00000078053,Amphiphysin,7,38383704-38631567,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB008559, HPA019828, HPA019829",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Pancreatic cancer:9.96e-4 (favourable),Tissue enhanced,Tissue enriched,9,cerebral cortex: 83.7,"cervix, uterine: 8.9",Cell line enhanced,NA,ASC diff: 44.1;ASC TERT1: 26.4;BJ hTERT+ SV40 Large T+ RasG12V: 29.1;U-138 MG: 24.3
ANK2,LQT4,ENSG00000145362,Ankyrin 2,4,112818109-113383740,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA008007, CAB015178, HPA035970",Enhanced,NA,Supported,Plasma membrane,Renal cancer:2.41e-6 (unfavourable),Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 184.4,kidney: 125.1,Cell line enhanced,NA,RH-30: 60.5;SH-SY5Y: 33.1
ANK3,NA,ENSG00000151150,Ankyrin 3,10,60026298-60733490,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013249, CAB015179, HPA038455, HPA055643",Approved,NA,Approved,Plasma membrane,Renal cancer:8.88e-16 (favourable),Mixed,Expressed in all,NA,NA,parathyroid gland: 283.9,Cell line enhanced,NA,RT4: 40.1
ANKEF1,"ANKRD5, dJ839B4.6, FLJ21669",ENSG00000132623,Ankyrin repeat and EF-hand domain containing 1,20,9986126-10058303,Predicted intracellular proteins,Evidence at protein level,HPA041151,Approved,NA,Approved,Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Thyroid cancer:1.58e-4 (unfavourable), Lung cancer:1.81e-4 (unfavourable), Renal cancer:4.44e-4 (favourable)",Mixed,Tissue enhanced,NA,testis: 33.7,thyroid gland: 11.3,Mixed,NA,NA
ANKIB1,"DKFZP434A0225, KIAA1386",ENSG00000001629,Ankyrin repeat and IBR domain containing 1,7,92246234-92401384,Predicted intracellular proteins,Evidence at protein level,"HPA019358, HPA021780",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 46.3,Expressed in all,NA,NA
ANKLE2,"KIAA0692, Lem4, LEMD7",ENSG00000176915,Ankyrin repeat and LEM domain containing 2,12,132725503-132761888,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA003602, HPA074838",Uncertain,NA,Supported,Endoplasmic reticulum<br>Plasma membrane,"Renal cancer:1.90e-8 (unfavourable), Liver cancer:3.97e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 80.4,Expressed in all,NA,NA
ANKRD13A,"ANKRD13, NY-REN-25",ENSG00000076513,Ankyrin repeat domain 13A,12,109999186-110039763,Predicted intracellular proteins,Evidence at protein level,"HPA039488, HPA043218",Enhanced,NA,Supported,Plasma membrane,"Head and neck cancer:7.70e-6 (favourable), Ovarian cancer:6.77e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 113.4,Expressed in all,NA,NA
ANKRD42,"FLJ37874, PPP1R79, SARP",ENSG00000137494,Ankyrin repeat domain 42,11,83193739-83260694,Predicted intracellular proteins,Evidence at protein level,HPA039917,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,testis: 71.5,fallopian tube: 26.2,Expressed in all,NA,NA
ANKS1B,"AIDA-1, ANKS2, cajalin-2, EB-1",ENSG00000185046,Ankyrin repeat and sterile alpha motif domain containing 1B,12,98726457-99984654,Predicted intracellular proteins,Evidence at protein level,HPA044628,NA,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enriched,8,cerebral cortex: 111.9,testis: 14.0,Cell line enhanced,NA,AF22: 10.0;SCLC-21H: 13.0
ANO2,"C12orf3, TMEM16B",ENSG00000047617,Anoctamin 2,12,5531869-5946232,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036276, HPA057499",Supported,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,testis: 17.8,placenta: 5.9,Cell line enhanced,NA,BJ hTERT+: 7.8;HUVEC TERT2: 7.9;U-2 OS: 25.6
ANO6,"DKFZp313M0720, TMEM16F",ENSG00000177119,Anoctamin 6,12,45215987-45440404,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038958,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Breast cancer:7.56e-5 (unfavourable), Cervical cancer:3.82e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 91.1,Expressed in all,NA,NA
ANPEP,"CD13, gp150, LAP1, p150, PEPN",ENSG00000166825,"Alanyl aminopeptidase, membrane",15,89784889-89815401,"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002417, HPA004625",Enhanced,NA,Supported,Plasma membrane,NA,Expressed in all,Group enriched,9,duodenum: 2386.4;small intestine: 2133.7,kidney: 263.2,Cell line enhanced,NA,BJ hTERT+: 958.3;HUVEC TERT2: 770.8;TIME: 760.6;U-2197: 926.0
ANXA1,"ANX1, LPC1",ENSG00000135046,Annexin A1,9,73151757-73170393,"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA011271, HPA011272, CAB013023, CAB035987, CAB058693",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable)",Expressed in all,Tissue enriched,6,esophagus: 7548.8,tonsil: 1217.6,Mixed,NA,NA
ANXA13,ANX13,ENSG00000104537,Annexin A13,8,123680794-123737407,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA018535, HPA019569, HPA019650, CAB025135",Enhanced,NA,Supported,Plasma membrane,NA,Group enriched,Group enriched,5,duodenum: 296.6;fallopian tube: 92.7;gallbladder: 227.6;small intestine: 235.6,rectum: 39.2,Group enriched,16,A549: 25.3;HDLM-2: 13.7
AP2M1,"AP50, CLAPM1, mu2",ENSG00000161203,Adaptor related protein complex 2 mu 1 subunit,3,184174689-184184091,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036849, HPA069870",Uncertain,NA,Supported,Plasma membrane,"Renal cancer:7.45e-6 (unfavourable), Liver cancer:9.12e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 557.6,Expressed in all,NA,NA
APBB1,"Fe65, RIR",ENSG00000166313,Amyloid beta precursor protein binding family B member 1,11,6395124-6419414,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB022104, HPA038521, HPA038522",Approved,NA,Enhanced,Plasma membrane,"Renal cancer:7.44e-13 (favourable), Pancreatic cancer:1.86e-5 (favourable), Liver cancer:2.44e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 236.5,Cell line enhanced,NA,SCLC-21H: 81.4
APBB1IP,"INAG1, RIAM",ENSG00000077420,Amyloid beta precursor protein binding family B member 1 interacting protein,10,26438203-26567803,Predicted intracellular proteins,Evidence at protein level,"HPA017009, HPA063903",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Endometrial cancer:7.48e-4 (favourable),Expressed in all,Mixed,NA,NA,appendix: 61.2,Cell line enhanced,NA,REH: 169.0;U-698: 134.4
APMAP,"BSCv, C20orf3",ENSG00000101474,Adipocyte plasma membrane associated protein,20,24962925-24992979,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012863, HPA064700",Uncertain,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 323.5,Expressed in all,NA,NA
APOD,NA,ENSG00000189058,Apolipoprotein D,3,195568702-195584205,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA040520,Enhanced,NA,Approved,Plasma membrane,"Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable)",Expressed in all,Tissue enriched,7,breast: 4620.2,adipose tissue: 670.2,Cell line enhanced,NA,ASC diff: 1866.1;ASC TERT1: 1018.4;WM-115: 301.1
AQP1,"CHIP28, CO",ENSG00000240583,Aquaporin 1 (Colton blood group),7,30911694-30925516,"Blood group antigen proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB001707, HPA019206",Enhanced,NA,Supported,Plasma membrane,"Renal cancer:1.32e-8 (favourable), Head and neck cancer:6.52e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,kidney: 791.4,Cell line enhanced,NA,EFO-21: 37.4;SH-SY5Y: 15.9;U-2 OS: 19.3;WM-115: 72.2
AQP3,GIL,ENSG00000165272,Aquaporin 3 (Gill blood group),9,33441154-33447611,"Blood group antigen proteins, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA014924,Enhanced,NA,Supported,Nucleus<br>Plasma membrane,Cervical cancer:5.31e-4 (favourable),Expressed in all,Expressed in all,NA,NA,esophagus: 971.6,Cell line enhanced,NA,HaCaT: 113.2;HeLa: 108.6;RT4: 167.6;SK-BR-3: 112.0;U-266/70: 114.3;U-266/84: 148.6
AQP5,NA,ENSG00000161798,Aquaporin 5,12,49961870-49965681,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA065008,Enhanced,NA,Approved,Plasma membrane,Head and neck cancer:1.75e-5 (favourable),Tissue enhanced,Group enriched,8,salivary gland: 255.6;stomach: 53.3;testis: 176.4,breast: 21.1,Group enriched,9,CAPAN-2: 7.6;REH: 9.2
ARAP1,CENTD2,ENSG00000186635,"ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1",11,72685069-72793599,Predicted intracellular proteins,Evidence at protein level,"CAB020703, HPA070383",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:2.04e-5 (favourable), Thyroid cancer:6.41e-4 (favourable), Liver cancer:6.45e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 91.3,Expressed in all,NA,NA
ARF1,NA,ENSG00000143761,ADP ribosylation factor 1,1,228082660-228099212,Predicted intracellular proteins,Evidence at protein level,CAB007742,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:1.55e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 384.2,Expressed in all,NA,NA
ARHGAP18,"bA307O14.2, MacGAP",ENSG00000146376,Rho GTPase activating protein 18,6,129576132-129710225,Predicted intracellular proteins,Evidence at protein level,HPA031595,Approved,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,Pancreatic cancer:2.54e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,adrenal gland: 48.0,Cell line enhanced,NA,HMC-1: 344.1
ARHGAP19,"FLJ00194, MGC14258",ENSG00000213390,Rho GTPase activating protein 19,10,97222173-97292673,Predicted intracellular proteins,Evidence at protein level,"HPA035777, HPA043231",Uncertain,NA,Supported,Plasma membrane,Renal cancer:7.47e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 34.2,lymph node: 15.8,Expressed in all,NA,NA
ARHGAP22,RhoGAP2,ENSG00000128805,Rho GTPase activating protein 22,10,48446034-48656265,Predicted intracellular proteins,Evidence at protein level,"CAB020696, HPA040391, HPA064439",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:2.16e-8 (unfavourable),Mixed,Mixed,NA,NA,cerebral cortex: 8.0,Cell line enhanced,NA,LHCN-M2: 53.6;TIME: 56.1;U-87 MG: 81.1
ARHGAP23,KIAA1501,ENSG00000275832,Rho GTPase activating protein 23,17,38419280-38512392,Predicted intracellular proteins,Evidence at protein level,"HPA019818, HPA047291",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:5.38e-5 (unfavourable), Endometrial cancer:6.87e-5 (unfavourable), Pancreatic cancer:3.24e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 41.9,Cell line enhanced,NA,HaCaT: 260.4
ARHGAP24,"DKFZP564B1162, FilGAP, FLJ33877",ENSG00000138639,Rho GTPase activating protein 24,4,85475114-86002670,Predicted intracellular proteins,Evidence at protein level,HPA014288,Approved,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.67e-11 (favourable),Expressed in all,Expressed in all,NA,NA,kidney: 106.3,Cell line enhanced,NA,ASC diff: 75.0;HUVEC TERT2: 101.5;TIME: 70.7
ARHGAP29,PARG1,ENSG00000137962,Rho GTPase activating protein 29,1,94148988-94275068,Predicted intracellular proteins,Evidence at protein level,HPA026534,Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Centrosome<br>Cytosol,"Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:9.63e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 49.9,Cell line enhanced,NA,A-431: 194.8
ARHGAP33,"FLJ39019, SNX26, TCGAP",ENSG00000004777,Rho GTPase activating protein 33,19,35774532-35788822,Predicted intracellular proteins,Evidence at protein level,"HPA030117, HPA030118",Supported,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,Renal cancer:3.09e-8 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 25.8,Cell line enhanced,NA,HMC-1: 50.9
ARHGAP36,FLJ30058,ENSG00000147256,Rho GTPase activating protein 36,X,131058242-131089883,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA002064,Enhanced,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane,NA,Tissue enriched,Tissue enriched,19,adrenal gland: 137.8,cerebral cortex: 7.4,Cell line enriched,173,SH-SY5Y: 188.2
ARHGAP40,"C20orf95, dJ1100H13.4",ENSG00000124143,Rho GTPase activating protein 40,20,38601934-38651035,Predicted intracellular proteins,Evidence at protein level,"HPA042636, HPA042840",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol,Renal cancer:2.89e-4 (unfavourable),Mixed,Group enriched,7,breast: 38.1;epididymis: 43.7;esophagus: 12.6;seminal vesicle: 11.3;skin: 53.8,prostate: 4.4,Cell line enhanced,NA,BEWO: 8.0;HBEC3-KT: 9.7;RPTEC TERT1: 8.8;SK-BR-3: 9.5;T-47d: 14.4
ARHGDIG,RHOGDI-3,ENSG00000242173,Rho GDP dissociation inhibitor gamma,16,268727-283010,Predicted intracellular proteins,Evidence at protein level,HPA078260,NA,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 131.1;duodenum: 44.2,small intestine: 17.9,Cell line enhanced,NA,HEK93: 24.6;MCF7: 27.2;SCLC-21H: 14.0;SH-SY5Y: 15.7
ARHGEF1,"LBCL2, P115-RHOGEF, SUB1.5",ENSG00000076928,Rho guanine nucleotide exchange factor 1,19,41883161-41930150,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009502, HPA012924, HPA060784",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 144.9,Expressed in all,NA,NA
ARHGEF11,"GTRAP48, KIAA0380, PDZ-RHOGEF",ENSG00000132694,Rho guanine nucleotide exchange factor 11,1,156934840-157045370,Predicted intracellular proteins,Evidence at protein level,"HPA011026, HPA012037, HPA014658",Enhanced,NA,Approved,Golgi apparatus<br>Plasma membrane,Pancreatic cancer:1.72e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 44.3,Mixed,NA,NA
ARHGEF12,"KIAA0382, LARG",ENSG00000196914,Rho guanine nucleotide exchange factor 12,11,120336914-120489936,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA018911, CAB025581",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:5.43e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 145.8,Mixed,NA,NA
ARHGEF15,"ARGEF15, FLJ13791, KIAA0915, MGC44868, Vsm-RhoGEF",ENSG00000198844,Rho guanine nucleotide exchange factor 15,17,8310241-8322516,Predicted intracellular proteins,Evidence at protein level,"HPA044443, HPA063495",NA,NA,Supported,Plasma membrane,NA,Expressed in all,Tissue enhanced,NA,adipose tissue: 37.2,lung: 30.7,Group enriched,41,HUVEC TERT2: 32.7;TIME: 42.4
ARHGEF26,"DKFZP434D146, SGEF",ENSG00000114790,Rho guanine nucleotide exchange factor 26,3,154121003-154257827,Predicted intracellular proteins,Evidence at protein level,"HPA017722, HPA049195",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:9.74e-4 (favourable),Expressed in all,Mixed,NA,NA,"cerebral cortex,lung: 15.0",Cell line enhanced,NA,U-251 MG: 16.6
ARHGEF28,"p190RhoGEF, RGNEF, RIP2",ENSG00000214944,Rho guanine nucleotide exchange factor 28,5,73626158-73941993,Predicted intracellular proteins,Evidence at protein level,HPA037602,Enhanced,NA,Approved,Plasma membrane<br>Microtubules<br>Cytosol,"Renal cancer:1.91e-6 (favourable), Cervical cancer:5.31e-4 (favourable), Urothelial cancer:8.98e-4 (favourable)",Mixed,Mixed,NA,NA,kidney: 33.7,Cell line enhanced,NA,hTERT-HME1: 75.2;LHCN-M2: 76.8;TIME: 48.7
ARHGEF5,"GEF5, P60, TIM, TIM1",ENSG00000050327,Rho guanine nucleotide exchange factor 5,7,144355288-144380632,Predicted intracellular proteins,Evidence at protein level,"HPA020980, HPA029504, HPA044188, HPA045619, HPA045699",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:3.28e-7 (favourable),Mixed,Mixed,NA,NA,thyroid gland: 42.8,Cell line enhanced,NA,A-431: 46.6
ARID2,"BAF200, DKFZp686G052, FLJ30619, KIAA1557",ENSG00000189079,AT-rich interaction domain 2,12,45729665-45908040,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA063044,NA,NA,Supported,Nucleoplasm<br>Plasma membrane,Head and neck cancer:5.75e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 47.3,Expressed in all,NA,NA
ARID4A,"RBBP1, RBP-1, RBP1",ENSG00000032219,AT-rich interaction domain 4A,14,58298385-58373887,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA048899,NA,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Head and neck cancer:1.91e-4 (favourable), Lung cancer:7.82e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 24.0,Expressed in all,NA,NA
ARID5B,"FLJ21150, MRF2",ENSG00000150347,AT-rich interaction domain 5B,10,61901300-62096944,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA015037,Uncertain,NA,Approved,Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,smooth muscle: 62.1,Cell line enhanced,NA,BJ hTERT+: 91.0
ARL4C,"ARL7, LAK",ENSG00000188042,ADP ribosylation factor like GTPase 4C,2,234493041-234497053,Predicted intracellular proteins,Evidence at protein level,HPA028927,Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:3.69e-8 (unfavourable), Endometrial cancer:2.90e-7 (unfavourable), Urothelial cancer:6.99e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 72.0,Cell line enhanced,NA,RPTEC TERT1: 234.1;U-2197: 158.1
ARMC12,"C6orf81, FLJ25390",ENSG00000157343,Armadillo repeat containing 12,6,35737032-35749079,Predicted intracellular proteins,Evidence at protein level,HPA030895,NA,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enriched,8,testis: 63.2,epididymis: 7.5,Cell line enhanced,NA,HSkMC: 4.9;MOLT-4: 4.0
ASAP1,"CENTB4, DDEF1, KIAA1249, PAP, ZG14P",ENSG00000153317,"ArfGAP with SH3 domain, ankyrin repeat and PH domain 1",8,130052104-130443660,Predicted intracellular proteins,Evidence at protein level,"HPA011136, CAB037292, HPA048565",Approved,NA,Approved,Plasma membrane<br>Centrosome<br>Cytosol,"Liver cancer:5.63e-8 (unfavourable), Renal cancer:1.50e-7 (unfavourable), Lung cancer:3.56e-5 (unfavourable), Endometrial cancer:5.81e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 56.0,Expressed in all,NA,NA
ASB5,NA,ENSG00000164122,Ankyrin repeat and SOCS box containing 5,4,176213673-176277571,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA028870,NA,NA,Approved,Plasma membrane,Head and neck cancer:5.67e-4 (unfavourable),Tissue enhanced,Tissue enhanced,NA,skeletal muscle: 75.7,prostate: 20.8,Cell line enriched,14,LHCN-M2: 986.5
ASGR2,CLEC4H2,ENSG00000161944,Asialoglycoprotein receptor 2,17,7101322-7115700,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014899, HPA015998",Enhanced,NA,Supported,Endoplasmic reticulum<br>Plasma membrane,NA,Tissue enriched,Tissue enriched,11,liver: 317.7,gallbladder: 28.1,Cell line enriched,7,Hep G2: 356.8
ASH2L,"ASH2, ASH2L1, ASH2L2, Bre2",ENSG00000129691,ASH2 like histone lysine methyltransferase complex subunit,8,38105242-38144076,Predicted intracellular proteins,Evidence at protein level,HPA042289,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:4.25e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 74.9,Expressed in all,NA,NA
ASIC1,"ACCN2, BNaC2, hBNaC2",ENSG00000110881,Acid sensing ion channel subunit 1,12,50057548-50083611,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA058870,NA,NA,Approved,Golgi apparatus<br>Plasma membrane,NA,Tissue enhanced,Tissue enriched,10,cerebral cortex: 56.8,parathyroid gland: 5.7,Cell line enhanced,NA,SH-SY5Y: 30.8
ASPM,"ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5",ENSG00000066279,Abnormal spindle microtubule assembly,1,197084128-197146694,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB017816,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:1.25e-4 (unfavourable), Endometrial cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.40e-4 (unfavourable), Lung cancer:2.41e-4 (unfavourable)",Mixed,Mixed,NA,NA,bone marrow: 9.3,Mixed,NA,NA
ASPSCR1,"ASPL, ASPS, TUG, UBXD9, UBXN9",ENSG00000169696,"ASPSCR1, UBX domain containing tether for SLC2A4",17,81976807-82017406,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA026749,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,"Renal cancer:1.26e-4 (unfavourable), Pancreatic cancer:2.67e-4 (favourable), Head and neck cancer:8.55e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 21.3,Expressed in all,NA,NA
ATG13,KIAA0652,ENSG00000175224,Autophagy related 13,11,46617527-46674818,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA039350,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:8.59e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 111.6,Expressed in all,NA,NA
ATG3,"APG3L, DKFZp564M1178, FLJ22125, MGC15201, PC3-96",ENSG00000144848,Autophagy related 3,3,112532509-112562046,Predicted intracellular proteins,Evidence at protein level,"CAB037260, HPA040471",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Liver cancer:9.35e-6 (unfavourable), Prostate cancer:1.59e-4 (unfavourable), Cervical cancer:6.82e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 154.8,Expressed in all,NA,NA
ATG7,"APG7L, DKFZp434N0735, GSA7",ENSG00000197548,Autophagy related 7,3,11272309-11557665,Predicted intracellular proteins,Evidence at protein level,"HPA007639, CAB018771",Supported,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Liver cancer:1.41e-4 (unfavourable), Renal cancer:9.55e-4 (favourable), Colorectal cancer:9.66e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 40.7,Expressed in all,NA,NA
ATIC,"AICARFT, IMPCHASE, PURH",ENSG00000138363,5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase,2,215311817-215349773,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013462, HPA021012",Supported,NA,Enhanced,Plasma membrane<br>Cytosol,"Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 44.8,Expressed in all,NA,NA
ATOX1,HAH1,ENSG00000177556,Antioxidant 1 copper chaperone,5,151742316-151772532,Predicted intracellular proteins,Evidence at protein level,HPA055036,NA,NA,Approved,Nucleoplasm<br>Plasma membrane,Pancreatic cancer:9.57e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 151.5,Expressed in all,NA,NA
ATP10D,"ATPVD, KIAA1487",ENSG00000145246,ATPase phospholipid transporting 10D (putative),4,47485288-47593486,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA050808,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:5.00e-8 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 22.5,Cell line enhanced,NA,HAP1: 43.0
ATP13A3,AFURS1,ENSG00000133657,ATPase 13A3,3,194402672-194498364,Predicted membrane proteins,Evidence at protein level,HPA029471,Approved,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.60e-4 (unfavourable), Renal cancer:1.63e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 149.3,Expressed in all,NA,NA
ATP1B3,"CD298, FLJ29027",ENSG00000069849,ATPase Na+/K+ transporting subunit beta 3,3,141876124-141926514,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB020697, HPA048963",Enhanced,NA,Supported,Plasma membrane,"Liver cancer:6.32e-6 (unfavourable), Renal cancer:1.29e-5 (unfavourable), Endometrial cancer:5.19e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,skin: 310.1,Expressed in all,NA,NA
ATP2B1,PMCA1,ENSG00000070961,ATPase plasma membrane Ca2+ transporting 1,12,89588049-89709300,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB005605, HPA011166, HPA012945",Enhanced,NA,Supported,Plasma membrane,Liver cancer:7.74e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 143.6,Expressed in all,NA,NA
ATP2B3,"CFAP39, CLA2, PMCA3, SCAX1",ENSG00000067842,ATPase plasma membrane Ca2+ transporting 3,X,153517676-153582939,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA001583,Enhanced,NA,Uncertain,Golgi apparatus<br>Plasma membrane,NA,Not detected,Group enriched,8,adrenal gland: 12.1;cerebral cortex: 19.0,fallopian tube: 2.0,Cell line enhanced,NA,SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9
ATP2B4,"ATP2B2, MXRA1, PMCA4",ENSG00000058668,ATPase plasma membrane Ca2+ transporting 4,1,203626561-203744081,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB016118, HPA040431",Enhanced,NA,Supported,Plasma membrane,Renal cancer:1.21e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 254.6,Expressed in all,NA,NA
ATP2C2,"KIAA0703, SPCA2",ENSG00000064270,ATPase secretory pathway Ca2+ transporting 2,16,84368527-84464187,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052262, HPA075812",Approved,NA,Approved,Plasma membrane<br>Focal adhesion sites,Endometrial cancer:6.20e-6 (favourable),Mixed,Tissue enhanced,NA,rectum: 38.4,skin: 30.0,Cell line enhanced,NA,MCF7: 18.7;RT4: 15.1;SK-BR-3: 24.6;T-47d: 10.4
ATP6AP1,"16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3",ENSG00000071553,ATPase H+ transporting accessory protein 1,X,154428632-154436516,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB015218,Uncertain,NA,Approved,Plasma membrane<br>Microtubules<br>Cytosol,"Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 209.7,Expressed in all,NA,NA
ATP6V0A2,"a2, ATP6a2, ATP6N1D, J6B7, Stv1, TJ6, TJ6M, TJ6s, Vph1",ENSG00000185344,ATPase H+ transporting V0 subunit a2,12,123712318-123761755,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA044279,Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,skin: 15.1,Expressed in all,NA,NA
ATP8A2,"ATPIB, ML-1",ENSG00000132932,ATPase phospholipid transporting 8A2,13,25372071-26025851,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA039926, HPA040033",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Mixed,Group enriched,6,cerebral cortex: 26.4;testis: 10.7,adrenal gland: 2.9,Cell line enhanced,NA,HMC-1: 19.3;SCLC-21H: 3.9
ATXN10,"E46L, FLJ37990, SCA10",ENSG00000130638,Ataxin 10,22,45671798-45845307,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049531,Approved,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 133.9,Expressed in all,NA,NA
ATXN3,"ATX3, JOS, MJD, SCA3",ENSG00000066427,Ataxin 3,14,92038652-92106621,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB021976, HPA024123, HPA069338",Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,testis: 18.6,Expressed in all,NA,NA
ATXN7L3,DKFZp761G2113,ENSG00000087152,Ataxin 7 like 3,17,44191805-44200113,Predicted intracellular proteins,Evidence at protein level,HPA064316,Supported,NA,Approved,Nuclear speckles<br>Plasma membrane,"Renal cancer:2.87e-4 (unfavourable), Liver cancer:4.03e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 83.8,Expressed in all,NA,NA
AVEN,PDCD12,ENSG00000169857,Apoptosis and caspase activation inhibitor,15,33866227-34039176,Predicted intracellular proteins,Evidence at protein level,HPA020863,Approved,NA,Approved,Plasma membrane<br>Actin filaments<br>Centrosome,Renal cancer:5.29e-10 (unfavourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 19.1,Expressed in all,NA,NA
AVPI1,"PP5395, VIP32, VIT32",ENSG00000119986,Arginine vasopressin induced 1,10,97677424-97687323,Predicted intracellular proteins,Evidence at protein level,HPA037649,Approved,NA,Approved,Nucleus<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,adrenal gland: 42.1,Cell line enhanced,NA,hTCEpi: 154.8;SK-MEL-30: 138.8;U-2197: 116.9
AXIN2,"DKFZp781B0869, MGC126582",ENSG00000168646,Axin 2,17,65528563-65561647,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB012283, CAB017783",Approved,NA,Uncertain,Nucleus<br>Plasma membrane<br>Cytosol,Pancreatic cancer:6.58e-4 (favourable),Expressed in all,Mixed,NA,NA,endometrium: 31.1,Cell line enhanced,NA,AF22: 26.9;CACO-2: 43.2;Hep G2: 53.5
B2M,NA,ENSG00000166710,Beta-2-microglobulin,15,44711477-44718877,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB002572, HPA006361",Enhanced,NA,Enhanced,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,lymph node: 5119.8,Expressed in all,NA,NA
BACE1,BACE,ENSG00000186318,Beta-secretase 1,11,117285207-117316259,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB016358,Approved,NA,Supported,Plasma membrane,Urothelial cancer:6.76e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,pancreas: 100.7,Mixed,NA,NA
BAG3,NA,ENSG00000151929,BCL2 associated athanogene 3,10,119651370-119677819,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA018493, HPA020586",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,skeletal muscle: 98.2,Mixed,NA,NA
BAIAP2,"BAP2, IRSp53",ENSG00000175866,BAI1 associated protein 2,17,81035122-81117432,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023310, HPA027421",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Urothelial cancer:7.58e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 124.7,Mixed,NA,NA
BAIAP2L1,IRTKS,ENSG00000006453,BAI1 associated protein 2 like 1,7,98291651-98401068,Predicted intracellular proteins,Evidence at protein level,"HPA019484, HPA021257, HPA023874, HPA029503",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,stomach: 55.2,Mixed,NA,NA
BANK1,"BANK, FLJ20706",ENSG00000153064,B-cell scaffold protein with ankyrin repeats 1,4,101411286-102074812,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA037002,Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Mixed,Group enriched,5,appendix: 45.9;lymph node: 96.8;spleen: 77.4;thyroid gland: 21.6;tonsil: 87.2,urinary bladder: 12.9,Cell line enhanced,NA,Daudi: 9.7;HEL: 9.5;HL-60: 7.6;U-266/70: 23.8
BASP1,"CAP-23, CAP23, NAP-22, NAP22",ENSG00000176788,Brain abundant membrane attached signal protein 1,5,17065598-17276843,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA045218, HPA050333",Enhanced,NA,Enhanced,Plasma membrane,"Renal cancer:5.25e-11 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 419.0;epididymis: 369.1,placenta: 130.6,Cell line enhanced,NA,HeLa: 555.7;SiHa: 845.8
BBOF1,"C14orf45, CCDC176",ENSG00000119636,Basal body orientation factor 1,14,74019353-74082863,Predicted intracellular proteins,Evidence at protein level,"HPA003090, HPA003136",Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Microtubule organizing center,Endometrial cancer:6.34e-4 (favourable),Expressed in all,Tissue enhanced,NA,testis: 70.0,fallopian tube: 35.8,Mixed,NA,NA
BCAR1,"CAS, CASS1, Crkas, P130Cas",ENSG00000050820,"BCAR1, Cas family scaffolding protein",16,75228187-75268053,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000443, HPA042282",Approved,Supported,Approved,Plasma membrane<br>Cytosol,"Renal cancer:4.55e-8 (favourable), Liver cancer:9.11e-5 (unfavourable), Lung cancer:1.24e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 41.0,Mixed,NA,NA
BCAR3,"NSP2, SH2D3B",ENSG00000137936,Breast cancer anti-estrogen resistance 3,1,93561786-93847150,Predicted intracellular proteins,Evidence at protein level,HPA014858,Approved,NA,Approved,Plasma membrane<br>Centrosome<br>Cytosol,"Renal cancer:3.08e-7 (favourable), Lung cancer:8.92e-7 (unfavourable), Pancreatic cancer:4.38e-4 (unfavourable), Liver cancer:5.42e-4 (unfavourable), Head and neck cancer:8.41e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 32.6,Mixed,NA,NA
BCORL1,"CXorf10, FLJ11362",ENSG00000085185,BCL6 corepressor-like 1,X,129981107-130058083,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA031775, HPA031777, HPA068568",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,"Endometrial cancer:2.20e-5 (unfavourable), Renal cancer:5.00e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 18.3,Cell line enhanced,NA,HAP1: 51.8
BEND6,"bA203B9.1, C6orf65, FLJ30162",ENSG00000151917,BEN domain containing 6,6,56955126-57027342,Predicted intracellular proteins,Evidence at protein level,"HPA031605, HPA052973",Enhanced,NA,Approved,Nucleus<br>Plasma membrane,NA,Tissue enriched,Tissue enriched,6,cerebral cortex: 39.2,"cervix, uterine: 6.6",Mixed,NA,NA
BFSP1,"CP115, CP94, filensin, LIFL-H",ENSG00000125864,Beaded filament structural protein 1,20,17493905-17569220,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA040748, HPA042038",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Endometrial cancer:1.39e-4 (favourable),Mixed,Mixed,NA,NA,testis: 6.5,Cell line enhanced,NA,RPTEC TERT1: 14.8
BFSP2,"CP47, CP49, LIFL-L, phakinin",ENSG00000170819,Beaded filament structural protein 2,3,133399995-133475222,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA038464, HPA062959",Enhanced,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Tissue enriched,Not detected,NA,NA,lymph node: 0.4,Group enriched,7,Daudi: 1.5;U-698: 1.7
BICD2,KIAA0699,ENSG00000185963,BICD cargo adaptor 2,9,92711363-92764812,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA023013, HPA024452",Enhanced,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.39e-4 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 69.2,Expressed in all,NA,NA
BLNK,"BASH, bca, BLNK-s, Ly57, SLP-65, SLP65",ENSG00000095585,B-cell linker,10,96191702-96271587,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB009333, CAB016291, HPA038309, HPA038310",Enhanced,NA,Supported,Plasma membrane<br>Cytoplasmic bodies,Urothelial cancer:2.67e-6 (favourable),Expressed in all,Mixed,NA,NA,spleen: 69.1,Group enriched,5,Daudi: 49.2;REH: 152.1;RPMI-8226: 63.9;U-698: 171.5
BLVRB,"FLR, SDR43U1",ENSG00000090013,Biliverdin reductase B,19,40447789-40465840,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041698, HPA041937",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Pancreatic cancer:3.90e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 338.3,Cell line enhanced,NA,A549: 442.0;K-562: 413.4
BMPR2,"BMPR-II, BMPR3, BRK-3, PPH1, T-ALK",ENSG00000204217,Bone morphogenetic protein receptor type 2,2,202376936-202567751,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA017385, HPA049014",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,placenta: 44.9,Mixed,NA,NA
BMX,"ETK, PSCTK3",ENSG00000102010,BMX non-receptor tyrosine kinase,X,15464246-15556529,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001048, CAB032495",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enriched,18,epididymis: 125.0,placenta: 6.9,Cell line enriched,125,HUVEC TERT2: 295.8
BOC,CDON2,ENSG00000144857,"BOC cell adhesion associated, oncogene regulated",3,113211003-113287459,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025806, HPA060778, HPA061787",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane,"Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable)",Mixed,Mixed,NA,NA,fallopian tube: 51.7,Cell line enhanced,NA,AN3-CA: 73.4;ASC diff: 77.9;BJ hTERT+: 34.1
BRPF1,BR140,ENSG00000156983,Bromodomain and PHD finger containing 1,3,9731729-9748018,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003359,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:3.20e-5 (unfavourable), Prostate cancer:5.28e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 26.3,Expressed in all,NA,NA
BST2,"CD317, tetherin",ENSG00000130303,Bone marrow stromal cell antigen 2,19,17402939-17405648,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA017060,Approved,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:3.56e-9 (unfavourable), Testis cancer:4.22e-4 (unfavourable), Breast cancer:6.69e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 586.7,Mixed,NA,NA
BTN2A1,"BT2.1, BTF1, BTN2.1",ENSG00000112763,Butyrophilin subfamily 2 member A1,6,26457904-26476621,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA019208,Approved,NA,Approved,Plasma membrane,"Urothelial cancer:4.52e-5 (favourable), Renal cancer:5.90e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 26.3,Expressed in all,NA,NA
BTRC,"beta-TrCP1, betaTrCP, bTrCP, bTrCP1, FBXW1A, Fwd1",ENSG00000166167,Beta-transducin repeat containing E3 ubiquitin protein ligase,10,101354033-101557321,Predicted intracellular proteins,Evidence at protein level,"HPA031156, CAB032986",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 34.0,Expressed in all,NA,NA
BZW2,"HSPC028, MST017, MSTP017",ENSG00000136261,Basic leucine zipper and W2 domains 2,7,16646131-16706523,Predicted intracellular proteins,Evidence at protein level,"HPA022813, HPA026709",Approved,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,"Liver cancer:7.86e-8 (unfavourable), Renal cancer:6.01e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,heart muscle: 173.5,Expressed in all,NA,NA
C10orf90,"bA422P15.2, FATS, FLJ32938",ENSG00000154493,Chromosome 10 open reading frame 90,10,126424997-126670446,Predicted intracellular proteins,Evidence at protein level,"HPA038648, HPA057599",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Tissue enriched,Group enriched,12,breast: 5.6;cerebral cortex: 15.3;salivary gland: 4.3;testis: 12.1,"adipose tissue,skin: 0.7",Group enriched,9,SK-MEL-30: 94.3;U-2197: 33.5;U-266/84: 18.9;U-87 MG: 36.2;WM-115: 29.4
C12orf73,"DKFZp547P055, FLJ13975",ENSG00000204954,Chromosome 12 open reading frame 73,12,103950202-103965708,Predicted secreted proteins,Evidence at protein level,HPA038883,Uncertain,NA,Approved,Plasma membrane<br>Centrosome<br>Mitochondria,"Urothelial cancer:1.61e-4 (favourable), Liver cancer:6.98e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 17.8,Expressed in all,NA,NA
C12orf76,FLJ40142,ENSG00000174456,Chromosome 12 open reading frame 76,12,110027028-110073686,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,"HPA039713, HPA042013",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments,"Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 105.7,Expressed in all,NA,NA
C14orf37,UT2,ENSG00000139971,Chromosome 14 open reading frame 37,14,57999735-58298139,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA001580, HPA001789",Enhanced,NA,Approved,Plasma membrane,NA,Mixed,Mixed,NA,NA,kidney: 8.8,Cell line enhanced,NA,AF22: 9.6;fHDF/TERT166: 8.4
C14orf93,FLJ12154,ENSG00000100802,Chromosome 14 open reading frame 93,14,22985908-23010166,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA002569,Approved,NA,Approved,Nucleus<br>Plasma membrane,Breast cancer:5.05e-4 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 21.7,Expressed in all,NA,NA
C16orf74,MGC17624,ENSG00000154102,Chromosome 16 open reading frame 74,16,85690084-85751129,Predicted intracellular proteins,Evidence at protein level,HPA049367,Uncertain,NA,Approved,Plasma membrane<br>Centrosome,"Pancreatic cancer:1.54e-5 (unfavourable), Head and neck cancer:1.71e-4 (unfavourable), Melanoma:4.08e-4 (unfavourable)",Mixed,Mixed,NA,NA,urinary bladder: 13.3,Cell line enhanced,NA,HBEC3-KT: 68.8;T-47d: 79.3
C17orf58,NA,ENSG00000186665,Chromosome 17 open reading frame 58,17,67991101-67996431,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA023036,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.31e-10 (unfavourable), Liver cancer:8.99e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 50.5,"cervix, uterine: 42.4",Expressed in all,NA,NA
C18orf21,"HsT3108, PNAS-124, PNAS-131",ENSG00000141428,Chromosome 18 open reading frame 21,18,35972083-35979286,Predicted intracellular proteins,Evidence at protein level,"HPA065505, HPA067322",Uncertain,NA,Approved,Nucleoli<br>Plasma membrane,"Liver cancer:1.38e-6 (unfavourable), Ovarian cancer:1.81e-6 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 59.6,Expressed in all,NA,NA
C19orf33,"H2RSP, IMUP, IMUP-1, IMUP-2",ENSG00000167644,Chromosome 19 open reading frame 33,19,38304161-38305009,Predicted intracellular proteins,Evidence at protein level,"HPA054406, HPA059696",Uncertain,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:5.05e-4 (unfavourable), Lung cancer:5.42e-4 (unfavourable)",Mixed,Mixed,NA,NA,esophagus: 177.8,Cell line enhanced,NA,A-431: 535.8;A549: 841.0;CAPAN-2: 498.9;PC-3: 484.7
C19orf38,HIDE1,ENSG00000214212,Chromosome 19 open reading frame 38,19,10836575-10869790,Predicted membrane proteins,Evidence at protein level,"HPA012150, HPA055027",NA,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:1.75e-7 (unfavourable), Cervical cancer:2.43e-4 (favourable)",Expressed in all,Tissue enhanced,NA,bone marrow: 62.8,spleen: 17.4,Cell line enhanced,NA,U-937: 39.3
C19orf48,MGC13170,ENSG00000167747,Chromosome 19 open reading frame 48,19,50797704-50804929,Predicted intracellular proteins,Evidence at transcript level,HPA042000,Uncertain,NA,Approved,Plasma membrane,Liver cancer:8.80e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,prostate: 84.5,Expressed in all,NA,NA
C19orf71,LOC100128569,ENSG00000183397,Chromosome 19 open reading frame 71,19,3539154-3544030,Predicted intracellular proteins,Evidence at protein level,HPA048654,Uncertain,NA,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,"Renal cancer:2.02e-5 (favourable), Pancreatic cancer:2.03e-5 (favourable), Head and neck cancer:2.35e-4 (favourable)",Tissue enriched,Mixed,NA,NA,testis: 29.5,Cell line enhanced,NA,HeLa: 52.4;WM-115: 167.8
C1orf116,"FLJ36507, MGC2742, MGC4309, SARG",ENSG00000182795,Chromosome 1 open reading frame 116,1,207018521-207032756,Predicted intracellular proteins,Evidence at protein level,"HPA011888, HPA011889",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:1.01e-5 (favourable),Mixed,Tissue enhanced,NA,esophagus: 112.4;lung: 109.2;prostate: 82.0,stomach: 54.9,Group enriched,5,A-431: 50.3;CAPAN-2: 87.3;HaCaT: 108.7;HBEC3-KT: 85.0;hTCEpi: 44.4;hTERT-HME1: 26.3;RPTEC TERT1: 42.8
C1orf27,"FLJ20505, odr-4, TTG1",ENSG00000157181,Chromosome 1 open reading frame 27,1,186375838-186421378,Predicted membrane proteins,Evidence at protein level,"HPA015988, HPA031352",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,Ovarian cancer:9.92e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 76.3,Expressed in all,NA,NA
C1orf35,"MGC4174, MMTAG2",ENSG00000143793,Chromosome 1 open reading frame 35,1,228100726-228105411,Predicted intracellular proteins,Evidence at protein level,HPA046175,Approved,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,"Renal cancer:1.79e-6 (unfavourable), Ovarian cancer:7.38e-4 (favourable), Colorectal cancer:7.71e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 14.3,Expressed in all,NA,NA
C1orf54,FLJ23221,ENSG00000118292,Chromosome 1 open reading frame 54,1,150268200-150280916,Predicted secreted proteins,Evidence at transcript level,"HPA026518, HPA043874",Approved,NA,Approved,Plasma membrane,Renal cancer:2.43e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 76.0,Cell line enhanced,NA,AF22: 61.4;AN3-CA: 87.4;ASC TERT1: 75.6;HSkMC: 63.9;HUVEC TERT2: 73.1
C1orf74,"FLJ25078, URLC4",ENSG00000162757,Chromosome 1 open reading frame 74,1,209779208-209784559,Predicted intracellular proteins,Evidence at protein level,HPA028496,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Cervical cancer:8.52e-6 (unfavourable),Expressed in all,Mixed,NA,NA,lymph node: 5.0,Mixed,NA,NA
C1QBP,"gC1Q-R, gC1qR, HABP1, p32, SF2p32",ENSG00000108561,Complement C1q binding protein,17,5432777-5448830,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA026483,Supported,NA,Approved,Plasma membrane<br>Mitochondria,NA,Expressed in all,Expressed in all,NA,NA,rectum: 157.0,Expressed in all,NA,NA
C2orf72,LOC257407,ENSG00000204128,Chromosome 2 open reading frame 72,2,231037490-231049719,Predicted intracellular proteins,Evidence at protein level,HPA044962,Uncertain,NA,Approved,Nucleus<br>Plasma membrane,"Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)",Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 2.8;colon: 2.9;liver: 4.7,stomach: 1.3,Cell line enhanced,NA,BEWO: 8.2;CACO-2: 1.7;EFO-21: 2.9
C3orf14,HT021,ENSG00000114405,Chromosome 3 open reading frame 14,3,62318973-62336213,Predicted intracellular proteins,Evidence at transcript level,HPA048286,Approved,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:4.33e-5 (favourable),Expressed in all,Mixed,NA,NA,breast: 62.2,Cell line enhanced,NA,MCF7: 415.8
C3orf38,MGC26717,ENSG00000179021,Chromosome 3 open reading frame 38,3,88149743-88168729,Predicted intracellular proteins,Evidence at protein level,"HPA034736, HPA034737",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Ovarian cancer:3.55e-4 (favourable), Prostate cancer:4.12e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 59.0,Expressed in all,NA,NA
C4orf22,NA,ENSG00000197826,Chromosome 4 open reading frame 22,4,80335720-80963756,Predicted intracellular proteins,Evidence at transcript level,HPA043383,Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Group enriched,23,fallopian tube: 30.6;testis: 47.6,lung: 1.7,Cell line enhanced,NA,A-431: 1.1;BJ: 1.4;SCLC-21H: 1.2
C7orf43,FLJ10925,ENSG00000146826,Chromosome 7 open reading frame 43,7,100154420-100158715,Predicted intracellular proteins,Evidence at protein level,"HPA019359, HPA029463, HPA029464",Approved,NA,Enhanced,Vesicles<br>Plasma membrane<br>Microtubule organizing center,Pancreatic cancer:6.19e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 33.1,Expressed in all,NA,NA
C8orf33,FLJ20989,ENSG00000182307,Chromosome 8 open reading frame 33,8,145052378-145056030,Predicted intracellular proteins,Evidence at protein level,"HPA024812, HPA026104",Approved,NA,Uncertain,Nucleoplasm<br>Plasma membrane,"Breast cancer:2.77e-4 (unfavourable), Liver cancer:8.95e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 26.2,Expressed in all,NA,NA
C8orf4,"hTC-1, TC-1, TC1",ENSG00000176907,Chromosome 8 open reading frame 4,8,40153455-40155308,Predicted intracellular proteins,Evidence at protein level,HPA027188,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,placenta: 233.9,Cell line enhanced,NA,AF22: 130.7;BJ hTERT+: 107.2;EFO-21: 81.1;HeLa: 56.7;RPTEC TERT1: 49.9
C9,NA,ENSG00000113600,Complement C9,5,39284262-39424868,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB002151, HPA029577",Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enriched,120,liver: 728.9,epididymis: 6.0,Cell line enhanced,NA,U-698: 1.4
CA14,NA,ENSG00000118298,Carbonic anhydrase 14,1,150257159-150265078,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008482,Approved,NA,Approved,Plasma membrane,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 10.6;seminal vesicle: 21.2,skeletal muscle: 9.4,Group enriched,23,AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
CA9,"CAIX, MN",ENSG00000107159,Carbonic anhydrase 9,9,35673856-35681159,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB005100, CAB017107, HPA055207",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)",Mixed,Tissue enhanced,NA,gallbladder: 36.0;stomach: 93.6,small intestine: 14.5,Group enriched,11,A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9
CACNA1E,"BII, CACH6, CACNL1A6, Cav2.3",ENSG00000198216,Calcium voltage-gated channel subunit alpha1 E,1,181413102-181808084,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA042515, CAB079032",NA,Approved,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,NA,Mixed,Tissue enriched,8,cerebral cortex: 10.3,adrenal gland: 1.3,Cell line enhanced,NA,CACO-2: 1.2;U-266/70: 1.5
CALCRL,"CGRPR, CRLR",ENSG00000064989,Calcitonin receptor like receptor,2,187343129-187448460,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA008070, HPA046515",Uncertain,NA,Supported,Plasma membrane,NA,Expressed in all,Tissue enhanced,NA,lung: 114.3,adipose tissue: 76.8,Cell line enhanced,NA,HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7
CALD1,"CDM, H-CAD, L-CAD",ENSG00000122786,Caldesmon 1,7,134744252-134970728,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000006, HPA008066, HPA017330",Enhanced,NA,Enhanced,Plasma membrane<br>Actin filaments,"Renal cancer:1.84e-5 (unfavourable), Melanoma:3.73e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,seminal vesicle: 1289.8,smooth muscle: 1185.8,Cell line enhanced,NA,fHDF/TERT166: 910.7
CALML5,CLSP,ENSG00000178372,Calmodulin like 5,10,5498697-5499555,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA040725,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:2.59e-5 (favourable),Group enriched,Group enriched,8,salivary gland: 260.7;skin: 650.6,breast: 55.6,Cell line enriched,24,A-431: 355.7
CALN1,NA,ENSG00000183166,Calneuron 1,7,71779491-72447151,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036278, HPA036708",Approved,NA,Uncertain,Vesicles<br>Plasma membrane,NA,Mixed,Group enriched,5,adrenal gland: 14.7;cerebral cortex: 46.4,testis: 6.0,Cell line enhanced,NA,Karpas-707: 33.8;NTERA-2: 6.0;REH: 6.4;SCLC-21H: 7.8;U-2 OS: 7.6
CAP2,NA,ENSG00000112186,"CAP, adenylate cyclase-associated protein, 2 (yeast)",6,17393216-17557792,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA050530, HPA054147",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 125.1;skeletal muscle: 220.8,heart muscle: 70.1,Mixed,NA,NA
CAPS,"CAPS1, MGC126562",ENSG00000105519,Calcyphosine,19,5911707-5915877,Predicted intracellular proteins,Evidence at protein level,HPA043520,Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:7.63e-5 (favourable), Head and neck cancer:8.60e-4 (favourable)",Tissue enriched,Tissue enriched,10,fallopian tube: 448.7,lung: 45.1,Cell line enhanced,NA,SK-BR-3: 46.0
CASKIN2,"ANKS5B, FLJ21609, KIAA1139",ENSG00000177303,CASK interacting protein 2,17,75500261-75515583,Predicted intracellular proteins,Evidence at protein level,"HPA071906, HPA075184",Enhanced,NA,Enhanced,Plasma membrane,"Renal cancer:4.83e-8 (favourable), Pancreatic cancer:2.47e-5 (favourable)",Expressed in all,Mixed,NA,NA,lung: 29.0,Mixed,NA,NA
CASP4,"ICE(rel)II, ICH-2, TX",ENSG00000196954,Caspase 4,11,104942866-104969436,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027588, CAB037167",Approved,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:3.27e-11 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 71.8,Mixed,NA,NA
CAV3,"LGMD1C, LQT9, VIP-21, VIP21",ENSG00000182533,Caveolin 3,3,8733800-8841808,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB017518, CAB018557, HPA054488",Enhanced,NA,Supported,Vesicles<br>Plasma membrane,NA,Tissue enhanced,Group enriched,6,heart muscle: 14.0;skeletal muscle: 63.3,esophagus: 6.0,Group enriched,15,LHCN-M2: 19.0;RH-30: 91.1
CBWD1,NA,ENSG00000172785,COBW domain containing 1,9,121038-179147,Predicted intracellular proteins,Evidence at transcript level,"HPA042759, HPA042813",Approved,NA,Approved,Plasma membrane,NA,Mixed,Expressed in all,NA,NA,adrenal gland: 44.8,Mixed,NA,NA
CBWD2,NA,ENSG00000136682,COBW domain containing 2,2,113437691-113496189,Predicted intracellular proteins,Evidence at transcript level,"HPA042759, HPA042813",Approved,NA,Approved,Plasma membrane,Endometrial cancer:3.22e-5 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 18.9,Expressed in all,NA,NA
CBWD3,bA561O23.1,ENSG00000196873,COBW domain containing 3,9,68232003-68300015,Predicted intracellular proteins,Evidence at transcript level,"HPA042759, HPA042813",Uncertain,NA,Approved,Plasma membrane,NA,Not detected,Expressed in all,NA,NA,appendix: 25.1,Expressed in all,NA,NA
CBWD5,NA,ENSG00000147996,COBW domain containing 5,9,65668805-65734041,Predicted intracellular proteins,Evidence at transcript level,"HPA042759, HPA042813",Approved,NA,Approved,Plasma membrane,NA,Mixed,Expressed in all,NA,NA,breast: 22.0,Expressed in all,NA,NA
CBWD7,NA,ENSG00000215126,COBW domain containing 7,9,41131306-41199261,Predicted intracellular proteins,Evidence at transcript level,"HPA042759, HPA042813",Approved,NA,Approved,Plasma membrane,NA,Not detected,Tissue enhanced,NA,adrenal gland: 4.9,"breast,seminal vesicle: 2.7",Cell line enhanced,NA,PC-3: 25.0
CC2D1A,"FLJ20241, MRT3",ENSG00000132024,Coiled-coil and C2 domain containing 1A,19,13906201-13930879,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA005436, CAB015220",Supported,NA,Supported,Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,Head and neck cancer:7.02e-4 (favourable),Expressed in all,Expressed in all,NA,NA,duodenum: 35.6,Expressed in all,NA,NA
CCBE1,"FLJ30681, KIAA1983",ENSG00000183287,Collagen and calcium binding EGF domains 1,18,59430940-59697380,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041361, HPA041374",Uncertain,NA,Enhanced,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,ovary: 40.6,"cervix, uterine: 16.0",Cell line enhanced,NA,BJ hTERT+ SV40 Large T+ RasG12V: 91.8;HBF TERT88: 109.2;hTERT-HME1: 117.8;LHCN-M2: 146.3
CCDC107,MGC31967,ENSG00000159884,Coiled-coil domain containing 107,9,35658290-35661511,Predicted membrane proteins,Evidence at protein level,"HPA016857, HPA050442",NA,NA,Enhanced,Nucleoplasm<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 63.7,Expressed in all,NA,NA
CCDC112,MGC39633,ENSG00000164221,Coiled-coil domain containing 112,5,115267188-115296831,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045120, HPA050621",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:1.51e-6 (unfavourable),Expressed in all,Tissue enriched,6,testis: 73.7,cerebral cortex: 13.1,Expressed in all,NA,NA
CCDC115,"ccp1, FLJ30131, MGC12981",ENSG00000136710,Coiled-coil domain containing 115,2,130338241-130342349,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA034598,Approved,NA,Supported,Vesicles<br>Plasma membrane,Breast cancer:7.59e-4 (favourable),Expressed in all,Expressed in all,NA,NA,ovary: 55.5,Expressed in all,NA,NA
CCDC124,NA,ENSG00000007080,Coiled-coil domain containing 124,19,17933016-17943991,Predicted intracellular proteins,Evidence at protein level,"HPA041708, HPA046765",Supported,NA,Enhanced,Plasma membrane<br>Cytosol,Liver cancer:1.68e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 72.4,Expressed in all,NA,NA
CCDC144NL,MGC87631,ENSG00000205212,"Coiled-coil domain containing 144 family, N-terminal like",17,20836447-20896140,Predicted intracellular proteins,Evidence at transcript level,HPA023457,Uncertain,NA,Approved,Nucleus<br>Plasma membrane,NA,Not detected,Tissue enriched,7,testis: 4.3,"endometrium,prostate,seminal vesicle: 0.5",Cell line enriched,6,U-2 OS: 32.3
CCDC15,FLJ13215,ENSG00000149548,Coiled-coil domain containing 15,11,124954121-125041489,Predicted intracellular proteins,Evidence at transcript level,"HPA040450, HPA041738",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,5,testis: 18.9,breast: 3.5,Mixed,NA,NA
CCDC154,"C16orf29, LOC645811",ENSG00000197599,Coiled-coil domain containing 154,16,1434383-1444556,Predicted intracellular proteins,Evidence at protein level,"HPA041158, HPA043535, HPA048237",Uncertain,NA,Approved,Golgi apparatus<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,testis: 6.5,spleen: 2.5,Group enriched,5,A-431: 8.2;SCLC-21H: 37.5
CCDC24,MGC45441,ENSG00000159214,Coiled-coil domain containing 24,1,43991359-43996528,Predicted intracellular proteins,Evidence at protein level,"HPA035424, HPA061710",Uncertain,NA,Enhanced,Plasma membrane<br>Cytosol,"Breast cancer:3.06e-5 (favourable), Liver cancer:1.70e-4 (unfavourable), Head and neck cancer:3.18e-4 (favourable)",Expressed in all,Tissue enhanced,NA,fallopian tube: 18.3,testis: 15.2,Cell line enhanced,NA,CAPAN-2: 11.7
CCDC62,"CT109, ERAP75, FLJ40344, TSP-NY",ENSG00000130783,Coiled-coil domain containing 62,12,122774327-122827528,Predicted intracellular proteins,Evidence at protein level,"HPA039021, HPA058741",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Not detected,Tissue enriched,146,testis: 116.0,spleen: 0.7,Cell line enhanced,NA,U-2 OS: 3.0
CCDC69,"DKFZP434C171, FLJ13705",ENSG00000198624,Coiled-coil domain containing 69,5,151181052-151224145,Predicted intracellular proteins,Evidence at protein level,"HPA043648, HPA052896",Uncertain,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Actin filaments,Breast cancer:3.21e-4 (favourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 112.8,Cell line enhanced,NA,ASC diff: 80.3;Daudi: 136.8;U-266/70: 89.8;U-698: 84.7
CCDC8,"3M3, DKFZp564K0322, PPP1R20",ENSG00000169515,Coiled-coil domain containing 8,19,46410372-46413584,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA041993,Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:1.72e-5 (favourable),Mixed,Tissue enhanced,NA,ovary: 45.3,fallopian tube: 37.6,Cell line enhanced,NA,AN3-CA: 20.7;RH-30: 24.3
CCDC81,"FLJ16339, FLJ23514",ENSG00000149201,Coiled-coil domain containing 81,11,86374736-86423109,Predicted intracellular proteins,Evidence at protein level,"HPA040745, HPA040827",Uncertain,NA,Uncertain,Plasma membrane,NA,Tissue enhanced,Group enriched,10,fallopian tube: 46.1;testis: 11.0,endometrium: 2.7,Cell line enhanced,NA,BJ: 2.9;HBF TERT88: 1.8
CCDC83,"CT148, FLJ42119, MGC34732",ENSG00000150676,Coiled-coil domain containing 83,11,85855101-85920021,Predicted intracellular proteins,Evidence at transcript level,"HPA039707, HPA039882",NA,NA,Uncertain,Nucleus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,148,testis: 63.5,"cerebral cortex,endometrium: 0.4",Cell line enriched,8,MCF7: 2.1
CCDC93,FLJ10996,ENSG00000125633,Coiled-coil domain containing 93,2,117915478-118014133,Predicted intracellular proteins,Evidence at protein level,HPA054183,Approved,NA,Supported,Vesicles<br>Plasma membrane,"Liver cancer:2.97e-6 (unfavourable), Thyroid cancer:9.66e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 24.9,Expressed in all,NA,NA
CCDC97,"FLJ40267, MGC20255",ENSG00000142039,Coiled-coil domain containing 97,19,41310189-41324883,Predicted intracellular proteins,Evidence at protein level,"HPA043320, HPA043572",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:1.09e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 59.0,Expressed in all,NA,NA
CCNT2,NA,ENSG00000082258,Cyclin T2,2,134918235-134959342,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005559,Supported,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.25e-5 (unfavourable), Prostate cancer:2.44e-4 (unfavourable), Urothelial cancer:3.28e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 28.7,Expressed in all,NA,NA
CCNYL1,FLJ40432,ENSG00000163249,Cyclin Y like 1,2,207711540-207761839,Predicted intracellular proteins,Evidence at protein level,HPA046825,Approved,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,testis: 30.4,Expressed in all,NA,NA
CCSAP,"C1orf96, CSAP, FLJ41471",ENSG00000154429,"Centriole, cilia and spindle associated protein",1,229321005-229343294,Predicted intracellular proteins,Evidence at protein level,"HPA028402, HPA043443",Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Microtubule ends,"Renal cancer:4.50e-13 (unfavourable), Liver cancer:1.41e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 54.0,placenta: 18.6,Expressed in all,NA,NA
CCT3,"Cctg, TRIC5",ENSG00000163468,Chaperonin containing TCP1 subunit 3,1,156308968-156367873,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006543,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Liver cancer:3.87e-7 (unfavourable), Renal cancer:6.34e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 206.2,Expressed in all,NA,NA
CD163,"M130, MM130, SCARI1",ENSG00000177575,CD163 molecule,12,7470813-7503893,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002432, HPA046404, HPA051974",Enhanced,NA,Approved,Plasma membrane,Ovarian cancer:7.27e-4 (unfavourable),Expressed in all,Mixed,NA,NA,appendix: 220.1,Cell line enhanced,NA,HSkMC: 1.2
CD164L2,NA,ENSG00000174950,CD164 molecule like 2,1,27379176-27383380,Predicted membrane proteins,Evidence at protein level,HPA062915,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:1.64e-5 (favourable),Mixed,Tissue enhanced,NA,fallopian tube: 46.3,skin: 10.7,Cell line enhanced,NA,CAPAN-2: 3.5;HaCaT: 1.6;HBEC3-KT: 1.4;hTCEpi: 2.0;SK-BR-3: 1.9
CD200R1,"CD200R, HCRTR2, MOX2R, OX2R",ENSG00000163606,CD200 receptor 1,3,112921209-112975122,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA068512,NA,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,spleen: 14.5,placenta: 10.2,Cell line enriched,8,HEL: 26.4
CD248,"CD164L1, TEM1",ENSG00000174807,CD248 molecule,11,66314487-66317044,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA051856,Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:2.69e-7 (unfavourable),Expressed in all,Tissue enhanced,NA,adipose tissue: 136.8,placenta: 96.7,Cell line enhanced,NA,ASC diff: 336.6;ASC TERT1: 336.4;BJ hTERT+: 268.5;fHDF/TERT166: 348.4;HSkMC: 374.9;U-2197: 735.8
CD2AP,CMS,ENSG00000198087,CD2 associated protein,6,47477789-47627263,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA003267, HPA003326, CAB004352",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Pancreatic cancer:5.53e-5 (unfavourable), Urothelial cancer:7.57e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 65.8,Expressed in all,NA,NA
CD33,"FLJ00391, p67, SIGLEC-3, SIGLEC3",ENSG00000105383,CD33 molecule,19,51225064-51243860,"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB011442, HPA035832, HPA064807",Approved,NA,Supported,Nucleus<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,spleen: 33.1,bone marrow: 20.9,Cell line enhanced,NA,HEL: 77.8;HL-60: 92.6;HMC-1: 72.6;RPMI-8226: 43.3;THP-1: 45.3;U-937: 66.2
CD38,NA,ENSG00000004468,CD38 molecule,4,15778275-15853230,"Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002493, HPA022132, CAB025255, HPA052381",Enhanced,NA,Supported,Plasma membrane,Endometrial cancer:9.68e-4 (favourable),Expressed in all,Mixed,NA,NA,seminal vesicle: 27.6,Cell line enhanced,NA,Daudi: 91.6;Karpas-707: 24.9;MOLT-4: 26.4;REH: 23.7;U-266/70: 20.4
CD4,NA,ENSG00000010610,CD4 molecule,12,6786858-6820808,"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000011, HPA004252, HPA004472, CAB068180",Enhanced,NA,Supported,Plasma membrane,"Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 549.0,spleen: 220.5,Group enriched,5,HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
CD44,"CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1",ENSG00000026508,CD44 molecule (Indian blood group),11,35138870-35232402,"Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000112, CAB000316, HPA005785",Enhanced,NA,Enhanced,Golgi apparatus<br>Plasma membrane,Renal cancer:1.78e-8 (unfavourable),Expressed in all,Expressed in all,NA,NA,skin: 530.1,Mixed,NA,NA
CD46,"MCP, MGC26544, MIC10, TLX, TRA2.10",ENSG00000117335,CD46 molecule,1,207752057-207795513,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB010401, HPA016903",Enhanced,NA,Approved,Plasma membrane,"Cervical cancer:8.54e-5 (unfavourable), Stomach cancer:2.38e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 489.1,Expressed in all,NA,NA
CD47,"IAP, MER6, OA3",ENSG00000196776,CD47 molecule,3,108043298-108091025,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB016055, HPA044659",Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane,"Thyroid cancer:7.29e-5 (favourable), Renal cancer:1.69e-4 (unfavourable), Endometrial cancer:2.44e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lung: 204.6,Expressed in all,NA,NA
CD48,"BCM1, BLAST, hCD48, mCD48, SLAMF2",ENSG00000117091,CD48 molecule,1,160678746-160711851,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002497, HPA055146",Enhanced,NA,Supported,Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)",Expressed in all,Tissue enhanced,NA,lymph node: 311.4;spleen: 213.1;tonsil: 226.0,appendix: 148.5,Cell line enhanced,NA,Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7
CD79B,"B29, IGB",ENSG00000007312,CD79b molecule,17,63928740-63932354,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA009178, CAB009751",Enhanced,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,Head and neck cancer:2.35e-4 (favourable),Expressed in all,Group enriched,5,appendix: 91.1;lymph node: 311.5;spleen: 157.4;tonsil: 189.1,bone marrow: 36.1,Group enriched,17,Daudi: 751.6;REH: 317.0;U-698: 986.5
CD81,"TAPA-1, TAPA1, TSPAN28",ENSG00000110651,CD81 molecule,11,2376177-2397419,"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002507, HPA007234",Supported,NA,Supported,Plasma membrane,"Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 2273.0,Cell line enhanced,NA,ASC diff: 2031.3
CD8B,CD8B1,ENSG00000172116,CD8b molecule,2,86815339-86861924,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB004353, HPA029164",Enhanced,NA,Supported,Plasma membrane,"Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)",Mixed,Tissue enhanced,NA,"cervix, uterine: 60.8;lymph node: 39.6",parathyroid gland: 22.7,Cell line enriched,50,RPMI-8226: 837.8
CD9,"BA2, MIC3, MRP-1, P24, TSPAN29",ENSG00000010278,CD9 molecule,12,6199715-6238271,"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB002490,Supported,NA,Supported,Plasma membrane,"Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 1013.7,Cell line enhanced,NA,CAPAN-2: 1447.3;TIME: 1977.3
CD93,"C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4",ENSG00000125810,CD93 molecule,20,23079349-23086340,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA009300, HPA012368",Enhanced,NA,Approved,Vesicles<br>Plasma membrane,Renal cancer:2.74e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 197.1,Group enriched,5,HUVEC TERT2: 286.2;TIME: 357.8;U-937: 464.4
CD99L2,"CD99B, MIC2L1",ENSG00000102181,CD99 molecule like 2,X,150766337-150898816,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038782, HPA038783, HPA061400",Enhanced,NA,Supported,Plasma membrane,"Pancreatic cancer:2.74e-5 (favourable), Lung cancer:4.96e-4 (favourable), Urothelial cancer:8.74e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 143.5,Expressed in all,NA,NA
CDAN1,"CDA-I, CDAI",ENSG00000140326,Codanin 1,15,42723559-42737126,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039404, HPA040787",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Liver cancer:1.07e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,ovary: 15.2,Expressed in all,NA,NA
CDC42EP1,"Borg5, CEP1, MSE55",ENSG00000128283,CDC42 effector protein 1,22,37560447-37569405,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006379,Approved,NA,Supported,Plasma membrane<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,stomach: 106.6,Mixed,NA,NA
CDC42EP3,"BORG2, CEP3, UB1",ENSG00000163171,CDC42 effector protein 3,2,37641882-37738468,Predicted intracellular proteins,Evidence at protein level,"HPA034986, HPA061792",Approved,NA,Supported,Plasma membrane<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,prostate: 153.3,Cell line enhanced,NA,LHCN-M2: 504.9
CDC42EP4,"BORG4, CEP4, KAIA1777, MGC17125, MGC3740",ENSG00000179604,CDC42 effector protein 4,17,73283624-73312175,Predicted intracellular proteins,Evidence at protein level,"HPA023335, HPA024797",Approved,Supported,Enhanced,Plasma membrane<br>Actin filaments<br>Microtubules,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 101.8,Mixed,NA,NA
CDC42SE1,"SCIP1, SPEC1",ENSG00000197622,CDC42 small effector 1,1,151050971-151070325,Predicted intracellular proteins,Evidence at protein level,HPA027634,Approved,NA,Supported,Plasma membrane,Renal cancer:2.19e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 119.4,Expressed in all,NA,NA
CDH13,CDHH,ENSG00000140945,Cadherin 13,16,82626803-83800640,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001380, CAB025863",Enhanced,NA,Supported,Plasma membrane,Renal cancer:1.73e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,endometrium: 70.0,"cervix, uterine: 66.4",Cell line enhanced,NA,LHCN-M2: 185.2;U-138 MG: 276.1;U-87 MG: 239.0
CDH26,VR20,ENSG00000124215,Cadherin 26,20,59958427-60034011,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA015722, HPA047578",Uncertain,NA,Approved,Plasma membrane<br>Microtubules,"Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable)",Group enriched,Tissue enhanced,NA,prostate: 19.1,urinary bladder: 6.1,Cell line enriched,6,RT4: 42.4
CDH4,NA,ENSG00000179242,Cadherin 4,20,61252426-61940617,Predicted membrane proteins,Evidence at protein level,HPA015613,NA,NA,Enhanced,Plasma membrane,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 6.0;spleen: 4.8,seminal vesicle: 1.3,Cell line enhanced,NA,AF22: 11.0;hTERT-HME1: 11.2;U-2 OS: 20.6;U-251 MG: 29.8
CDIPT,"PIS, PIS1",ENSG00000103502,CDP-diacylglycerol--inositol 3-phosphatidyltransferase,16,29858357-29863736,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA056597,Approved,NA,Approved,Nucleoplasm<br>Nuclear membrane<br>Plasma membrane,Cervical cancer:9.40e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 112.7,Expressed in all,NA,NA
CDK16,"FLJ16665, PCTAIRE, PCTAIRE1, PCTGAIRE, PCTK1",ENSG00000102225,Cyclin dependent kinase 16,X,47217860-47229997,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000974, HPA001366, CAB016535",Approved,NA,Uncertain,Plasma membrane<br>Microtubules<br>Cytosol,Liver cancer:2.02e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 96.9,Expressed in all,NA,NA
CDV3,H41,ENSG00000091527,CDV3 homolog,3,133573730-133590261,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029761, HPA029762, HPA029763",Enhanced,NA,Enhanced,Nucleoli<br>Plasma membrane<br>Cytosol,Liver cancer:5.21e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,lymph node: 185.6,Expressed in all,NA,NA
CEACAM5,"CD66e, CEA",ENSG00000105388,Carcinoembryonic antigen related cell adhesion molecule 5,19,41708585-41729798,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000021, CAB000022, HPA011041, HPA019758",Enhanced,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,colon: 1012.7;rectum: 1086.0,appendix: 257.7,Cell line enriched,6,HaCaT: 11.8
CECR6,NA,ENSG00000183307,"Cat eye syndrome chromosome region, candidate 6",22,17116299-17121367,Predicted membrane proteins,Evidence at protein level,HPA068790,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Tissue enhanced,Group enriched,7,cerebral cortex: 15.0;prostate: 10.8,testis: 1.9,Cell line enhanced,NA,AF22: 5.9;SCLC-21H: 16.7;THP-1: 8.0;U-937: 7.7
CELSR1,"ADGRC1, CDHF9, FMI2, HFMI2, ME2",ENSG00000075275,Cadherin EGF LAG seven-pass G-type receptor 1,22,46360834-46537170,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052976, HPA060521",NA,NA,Supported,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,fallopian tube: 15.5,Cell line enhanced,NA,A549: 38.6;T-47d: 28.3
CENPJ,"BM032, CPAP, LAP, LIP1, MCPH6, Sas-4, SASS4, SCKL4",ENSG00000151849,Centromere protein J,13,24882284-24922889,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA060426,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Centrosome,Renal cancer:1.75e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 42.8,thyroid gland: 20.5,Expressed in all,NA,NA
CEP162,"C6orf84, KIAA1009, QN1",ENSG00000135315,Centrosomal protein 162,6,84124241-84227635,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030170, HPA030171, HPA030172, HPA030173",Supported,NA,Enhanced,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,testis: 15.7,Mixed,NA,NA
CEP170,"FAM68A, KAB, KIAA0470",ENSG00000143702,Centrosomal protein 170,1,243124428-243255348,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042151, HPA045597, HPA045787",Uncertain,NA,Enhanced,Plasma membrane<br>Centrosome<br>Cytosol,Renal cancer:1.30e-9 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 130.5,cerebral cortex: 44.7,Expressed in all,NA,NA
CEP295,KIAA1731,ENSG00000166004,Centrosomal protein 295,11,93661639-93730358,Predicted intracellular proteins,Evidence at protein level,"HPA038595, HPA038596, HPA038597",Approved,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 22.2,Expressed in all,NA,NA
CEP55,"C10orf3, CT111, FLJ10540",ENSG00000138180,Centrosomal protein 55,10,93496632-93529092,Predicted intracellular proteins,Evidence at protein level,HPA023430,Approved,NA,Supported,Plasma membrane<br>Midbody<br>Microtubule organizing center,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.20e-9 (unfavourable), Pancreatic cancer:2.66e-5 (unfavourable), Lung cancer:1.45e-4 (unfavourable), Stomach cancer:3.15e-4 (favourable)",Expressed in all,Tissue enhanced,NA,testis: 39.4,lymph node: 17.6,Mixed,NA,NA
CEP57L1,"bA487F23.2, C6orf182, MGC21731",ENSG00000183137,Centrosomal protein 57 like 1,6,109095110-109163932,Predicted intracellular proteins,Evidence at protein level,HPA040378,Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 47.6,Expressed in all,NA,NA
CEP89,"CCDC123, FLJ14640",ENSG00000121289,Centrosomal protein 89,19,32875925-32971991,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039382, HPA040056",NA,NA,Supported,Plasma membrane<br>Cytosol,Liver cancer:8.78e-5 (unfavourable),Expressed in all,Mixed,NA,NA,"fallopian tube,prostate: 14.5",Expressed in all,NA,NA
CFAP157,C9orf117,ENSG00000160401,Cilia and flagella associated protein 157,9,127706989-127716002,Predicted intracellular proteins,Evidence at protein level,"HPA021474, HPA021786",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Endometrial cancer:1.45e-4 (favourable),Mixed,Tissue enriched,8,fallopian tube: 94.5,lung: 12.0,Cell line enhanced,NA,A549: 5.9;SCLC-21H: 5.2
CFAP97,"DKFZp434F1728, hmw, KIAA1430",ENSG00000164323,Cilia and flagella associated protein 97,4,185159665-185209504,Predicted intracellular proteins,Evidence at protein level,"HPA049446, HPA053335",Approved,NA,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 67.7,Expressed in all,NA,NA
CFD,"ADN, DF, PFD",ENSG00000197766,Complement factor D,19,859643-863630,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA052799,NA,NA,Uncertain,Plasma membrane,"Pancreatic cancer:1.77e-4 (favourable), Renal cancer:7.09e-4 (unfavourable)",Expressed in all,Tissue enriched,7,adipose tissue: 378.5,breast: 52.5,Group enriched,6,ASC diff: 82.6;THP-1: 121.6
CFL2,NEM7,ENSG00000165410,Cofilin 2,14,34706769-34714823,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB037078, HPA045599",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Urothelial cancer:2.16e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 242.7,Expressed in all,NA,NA
CFLAR,"c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT",ENSG00000003402,CASP8 and FADD like apoptosis regulator,2,201116104-201176687,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019044, CAB022157, CAB025216",Uncertain,NA,Supported,Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,Head and neck cancer:2.79e-4 (favourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 159.9,Expressed in all,NA,NA
CH507-9B2.1,NA,ENSG00000277117,NA,21,5022493-5040666,Predicted membrane proteins,Evidence at protein level,HPA029179,NA,NA,Supported,Plasma membrane<br>Cytoplasmic bodies,NA,Mixed,Mixed,NA,NA,cerebral cortex: 11.2,Cell line enhanced,NA,BEWO: 20.4;REH: 15.6;SiHa: 15.3
CHD9,"BC022889, FLJ12178, KIAA0308",ENSG00000177200,Chromodomain helicase DNA binding protein 9,16,53055033-53329150,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042053, HPA049420",Approved,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.84e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 28.2,Expressed in all,NA,NA
CHIC2,BTL,ENSG00000109220,Cysteine rich hydrophobic domain 2,4,54009789-54064690,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA026782, HPA026784, HPA076603",Uncertain,NA,Enhanced,Vesicles<br>Plasma membrane,Renal cancer:1.56e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 63.2,Expressed in all,NA,NA
CHMP2A,"BC-2, CHMP2, VPS2, VPS2A",ENSG00000130724,Charged multivesicular body protein 2A,19,58551566-58555124,Predicted intracellular proteins,Evidence at protein level,"HPA041153, HPA042031",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 191.7,Expressed in all,NA,NA
CHRM3,NA,ENSG00000133019,Cholinergic receptor muscarinic 3,1,239386565-239915452,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA024106, HPA048036",Approved,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 15.7,esophagus: 8.4,Cell line enhanced,NA,RPMI-8226: 11.9;SH-SY5Y: 55.3;U-266/70: 16.6;U-266/84: 11.6
CHRNA1,CHRNA,ENSG00000138435,Cholinergic receptor nicotinic alpha 1 subunit,2,174747592-174787935,"Disease related genes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071554,Enhanced,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,prostate: 3.2;skeletal muscle: 7.2,colon: 1.5,Group enriched,23,LHCN-M2: 370.9;RH-30: 348.5
CHRNA5,NA,ENSG00000169684,Cholinergic receptor nicotinic alpha 5 subunit,15,78565520-78595269,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054381,Approved,NA,Approved,Plasma membrane<br>Focal adhesion sites,Lung cancer:3.64e-5 (unfavourable),Mixed,Mixed,NA,NA,gallbladder: 6.9,Mixed,NA,NA
CHRND,ACHRD,ENSG00000135902,Cholinergic receptor nicotinic delta subunit,2,232525993-232536667,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA056404, HPA065404",NA,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enriched,12,skeletal muscle: 9.6,prostate: 0.8,Cell line enriched,76,RH-30: 79.9
CIB1,"CIB, KIP, SIP2-28",ENSG00000185043,Calcium and integrin binding 1,15,90229975-90234047,Predicted intracellular proteins,Evidence at protein level,"CAB012991, HPA042413, HPA048825",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,Endometrial cancer:2.26e-5 (favourable),Expressed in all,Expressed in all,NA,NA,fallopian tube: 207.5,Expressed in all,NA,NA
CKAP5,"ch-TOG, KIAA0097, TOG, TOGp",ENSG00000175216,Cytoskeleton associated protein 5,11,46743048-46846308,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039377, HPA040375",Enhanced,NA,Supported,Nucleoli<br>Plasma membrane<br>Centrosome,Liver cancer:1.03e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 66.2,Expressed in all,NA,NA
CLCN5,"ClC-5, CLC5, DENTS, hCIC-K2, hClC-K2, NPHL1, NPHL2, XLRH, XRN",ENSG00000171365,Chloride voltage-gated channel 5,X,49922615-50099235,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000401, HPA003213",Uncertain,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:2.05e-8 (favourable), Pancreatic cancer:5.20e-4 (favourable)",Expressed in all,Tissue enhanced,NA,epididymis: 33.7;kidney: 52.0,placenta: 9.6,Cell line enhanced,NA,CACO-2: 44.1;RH-30: 76.7
CLCN6,"CLC-6, KIAA0046",ENSG00000011021,Chloride voltage-gated channel 6,1,11806096-11843144,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA032097,Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,cerebral cortex: 31.2,Expressed in all,NA,NA
CLDN23,CLDNL,ENSG00000253958,Claudin 23,8,8701938-8704106,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA070578,NA,NA,Uncertain,Nucleus<br>Plasma membrane,"Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable)",Expressed in all,Tissue enhanced,NA,colon: 23.7;stomach: 24.5,small intestine: 16.5,Cell line enhanced,NA,BEWO: 7.4
CLDN4,"CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8",ENSG00000189143,Claudin 4,7,73799542-73832693,"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB002610,Enhanced,NA,Supported,Plasma membrane,"Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable)",Mixed,Mixed,NA,NA,colon: 208.6,Cell line enhanced,NA,A-431: 285.9;BEWO: 354.2;CAPAN-2: 613.4;MCF7: 279.4;PC-3: 419.8;SK-BR-3: 439.0
CLEC2A,"INPE5792, KACL, PILAR, UNQ5792",ENSG00000188393,C-type lectin domain family 2 member A,12,9898673-9932381,Predicted membrane proteins,Evidence at protein level,"HPA048530, HPA072407",Approved,NA,Uncertain,Plasma membrane,NA,Tissue enhanced,Tissue enriched,14,skin: 67.7,breast: 4.7,Cell line enhanced,NA,BEWO: 5.9;fHDF/TERT166: 16.8;U-937: 42.5
CLEC5A,"CLECSF5, MDL-1",ENSG00000258227,C-type lectin domain family 5 member A,7,141927357-141947007,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA054137,NA,NA,Supported,Plasma membrane<br>Cytosol,Ovarian cancer:2.21e-4 (unfavourable),Mixed,Tissue enhanced,NA,appendix: 10.6;bone marrow: 27.4,lung: 4.9,Group enriched,29,HL-60: 33.0;U-937: 123.1
CLIC2,XAP121,ENSG00000155962,Chloride intracellular channel 2,X,155276211-155334657,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA047381, HPA060101",Uncertain,NA,Approved,Plasma membrane,Renal cancer:1.74e-5 (unfavourable),Expressed in all,Mixed,NA,NA,spleen: 62.8,Cell line enhanced,NA,HDLM-2: 85.0;K-562: 44.8;Karpas-707: 31.6;RPMI-8226: 54.1
CLIC5,DFNB102,ENSG00000112782,Chloride intracellular channel 5,6,45898451-46080395,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA074371,NA,NA,Supported,Nuclear speckles<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,lung: 116.1;skeletal muscle: 119.2,heart muscle: 76.0,Group enriched,7,CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5
CLTB,Lcb,ENSG00000175416,Clathrin light chain B,5,176392455-176416569,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003692, HPA036458",Approved,NA,Supported,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:7.89e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,esophagus: 242.7,Expressed in all,NA,NA
CLUL1,NA,ENSG00000079101,Clusterin like 1,18,596988-650334,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025264, HPA075240",Supported,NA,Approved,Endoplasmic reticulum<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,prostate: 13.9,thyroid gland: 11.5,Cell line enhanced,NA,Hep G2: 23.4
CMTM4,CKLFSF4,ENSG00000183723,CKLF like MARVEL transmembrane domain containing 4,16,66614750-66696707,Predicted membrane proteins,Evidence at protein level,"HPA014704, HPA023890",Enhanced,NA,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,Renal cancer:4.72e-9 (favourable),Expressed in all,Tissue enhanced,NA,thyroid gland: 64.1,parathyroid gland: 47.8,Mixed,NA,NA
CMTM7,"CKLFSF7, FLJ30992",ENSG00000153551,CKLF like MARVEL transmembrane domain containing 7,3,32391671-32483067,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA077409,NA,NA,Approved,Plasma membrane,"Renal cancer:1.00e-6 (unfavourable), Liver cancer:3.21e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,fallopian tube: 61.7,Mixed,NA,NA
CNKSR2,"CNK2, KIAA0902, KSR2",ENSG00000149970,Connector enhancer of kinase suppressor of Ras 2,X,21374418-21654695,Predicted intracellular proteins,Evidence at protein level,HPA001502,NA,NA,Approved,Golgi apparatus<br>Plasma membrane,NA,Tissue enhanced,Tissue enriched,9,cerebral cortex: 53.9,adrenal gland: 5.8,Cell line enhanced,NA,A549: 6.4;NTERA-2: 10.9;RH-30: 9.6
CNNM1,ACDP1,ENSG00000119946,Cyclin and CBS domain divalent metal cation transport mediator 1,10,99329099-99394330,Predicted membrane proteins,Evidence at protein level,HPA040408,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 10.2;testis: 16.8,ovary: 3.0,Cell line enhanced,NA,A549: 16.9;BJ hTERT+ SV40 Large T+ RasG12V: 10.6;HAP1: 8.6
CNNM4,"ACDP4, KIAA1592",ENSG00000158158,Cyclin and CBS domain divalent metal cation transport mediator 4,2,96760902-96811891,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA017732,Enhanced,NA,Uncertain,Plasma membrane<br>Actin filaments,"Ovarian cancer:8.75e-4 (unfavourable), Endometrial cancer:9.14e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,rectum: 36.9,Expressed in all,NA,NA
CNTD1,"CNTD, FLJ40137",ENSG00000176563,Cyclin N-terminal domain containing 1,17,42798792-42811587,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA023324,NA,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites,NA,Mixed,Tissue enriched,25,testis: 73.1,stomach: 2.9,Cell line enhanced,NA,A-431: 2.1;ASC diff: 1.0;SiHa: 1.3
COG3,SEC34,ENSG00000136152,Component of oligomeric golgi complex 3,13,45464898-45536630,Predicted secreted proteins,Evidence at protein level,"HPA040353, HPA054470",Approved,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,Ovarian cancer:9.53e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,prostate: 30.7,Expressed in all,NA,NA
COL16A1,NA,ENSG00000084636,Collagen type XVI alpha 1 chain,1,31652247-31704319,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027235, HPA027237",NA,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:4.00e-9 (unfavourable), Glioma:7.08e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,ovary: 181.5,Cell line enhanced,NA,ASC diff: 88.5;BJ hTERT+: 91.9;fHDF/TERT166: 81.2;U-2197: 87.0
COL17A1,"BP180, BPAG2",ENSG00000065618,Collagen type XVII alpha 1 chain,10,104031286-104086002,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043673, HPA052963",Enhanced,NA,Supported,Golgi apparatus<br>Plasma membrane,"Breast cancer:1.38e-4 (favourable), Pancreatic cancer:1.86e-4 (unfavourable)",Tissue enhanced,Tissue enriched,14,skin: 769.3,placenta: 53.1,Group enriched,6,CAPAN-2: 175.9;HaCaT: 403.2;HBEC3-KT: 525.2;hTCEpi: 673.0;hTERT-HME1: 604.3
COL6A2,NA,ENSG00000142173,Collagen type VI alpha 2 chain,21,46098097-46132849,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA007029, HPA030920, HPA038799",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:8.72e-14 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 472.0,Cell line enhanced,NA,ASC TERT1: 1480.1;BJ: 903.2;HHSteC: 946.3;HSkMC: 1105.7;U-138 MG: 1108.3
COMMD10,PTD002,ENSG00000145781,COMM domain containing 10,5,116084991-116412762,Predicted intracellular proteins,Evidence at protein level,"HPA045441, HPA075641",Approved,NA,Uncertain,Plasma membrane<br>Cytosol,"Stomach cancer:2.99e-4 (unfavourable), Thyroid cancer:6.93e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 46.8,Expressed in all,NA,NA
COMMD4,FLJ20452,ENSG00000140365,COMM domain containing 4,15,75335891-75343224,Predicted intracellular proteins,Evidence at protein level,HPA066957,Uncertain,NA,Supported,Nucleus<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,testis: 76.2,Expressed in all,NA,NA
COMTD1,FLJ23841,ENSG00000165644,Catechol-O-methyltransferase domain containing 1,10,75233969-75236030,Predicted intracellular proteins,Evidence at protein level,HPA042165,Approved,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.88e-4 (favourable),Expressed in all,Mixed,NA,NA,duodenum: 13.6,Cell line enhanced,NA,HEK93: 43.6;PC-3: 61.2
COPRS,"C17orf79, COPR5, HSA272196, TTP1",ENSG00000172301,Coordinator of PRMT5 and differentiation stimulator,17,31851864-31859337,Predicted intracellular proteins,Evidence at protein level,HPA052552,Approved,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,Liver cancer:3.69e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 268.0,Expressed in all,NA,NA
COQ7,"CAT5, CLK-1",ENSG00000167186,"Coenzyme Q7, hydroxylase",16,19067599-19080095,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA067252, HPA071922",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:8.23e-12 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 39.2,Expressed in all,NA,NA
CORIN,"ATC2, CRN, Lrp4, PRSC, TMPRSS10",ENSG00000145244,"Corin, serine peptidase",4,47593998-47838106,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA070941,NA,NA,Approved,Nuclear bodies<br>Plasma membrane<br>Actin filaments,NA,Mixed,Tissue enhanced,NA,heart muscle: 38.6,skin: 9.4,Group enriched,6,ASC diff: 7.2;ASC TERT1: 31.6
CORO1B,coronin-2,ENSG00000172725,Coronin 1B,11,67435510-67443821,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017616, HPA040113, HPA070456",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Endometrial cancer:1.65e-4 (favourable),Expressed in all,Expressed in all,NA,NA,prostate: 85.9,Mixed,NA,NA
CORO2A,"IR10, WDR2",ENSG00000106789,Coronin 2A,9,98120975-98192640,Predicted intracellular proteins,Evidence at protein level,"HPA041161, HPA041302",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:6.56e-4 (unfavourable),Mixed,Mixed,NA,NA,small intestine: 38.5,Cell line enhanced,NA,BEWO: 64.3;SK-BR-3: 33.9
CORO2B,"ClipinC, KIAA0925",ENSG00000103647,Coronin 2B,15,68578969-68727806,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA017960,Enhanced,NA,Approved,Plasma membrane<br>Focal adhesion sites,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 73.3;fallopian tube: 36.7,ovary: 17.9,Cell line enhanced,NA,ASC TERT1: 40.2;HSkMC: 30.2;hTEC/SVTERT24-B: 34.6;U-87 MG: 57.2
COX6B2,"COXVIB2, CT59, FLJ32865",ENSG00000160471,Cytochrome c oxidase subunit 6B2,19,55349306-55354814,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA035014,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Pancreatic cancer:9.70e-5 (unfavourable),Mixed,Tissue enriched,14,testis: 74.5,rectum: 5.2,Group enriched,6,CAPAN-2: 21.1;SCLC-21H: 11.9
CPPED1,"CSTP1, FLJ11151",ENSG00000103381,Calcineurin like phosphoesterase domain containing 1,16,12659799-12804017,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040938, HPA041970",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.62e-9 (favourable), Breast cancer:9.72e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 41.0,Cell line enhanced,NA,Hep G2: 97.8;HMC-1: 114.2
CREB3L1,OASIS,ENSG00000157613,CAMP responsive element binding protein 3 like 1,11,46277661-46321422,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,"HPA024069, CAB026151",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,"cervix, uterine: 66.0",Cell line enhanced,NA,fHDF/TERT166: 248.2
CREB5,"CRE-BPA, H_GS165L15.1",ENSG00000146592,CAMP responsive element binding protein 5,7,28299321-28825894,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA050020, HPA061622",NA,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,gallbladder: 18.6,Cell line enhanced,NA,HL-60: 49.5
CRIP2,"CRP2, ESP1",ENSG00000182809,Cysteine rich protein 2,14,105472962-105480170,Predicted intracellular proteins,Evidence at protein level,HPA042664,Approved,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,NA,Expressed in all,Tissue enhanced,NA,heart muscle: 315.6,fallopian tube: 115.7,Cell line enhanced,NA,MCF7: 206.8
CRK,NA,ENSG00000167193,"CRK proto-oncogene, adaptor protein",17,1420689-1463162,Predicted intracellular proteins,Evidence at protein level,"CAB010485, HPA068087",Approved,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 61.0,Expressed in all,NA,NA
CRLF3,"CREME9, CYTOR4",ENSG00000176390,Cytokine receptor like factor 3,17,30769388-30824776,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA007596,Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:1.31e-7 (unfavourable),Expressed in all,Mixed,NA,NA,lymph node: 39.3,Expressed in all,NA,NA
CROCC,"ROLT, rootletin",ENSG00000058453,"Ciliary rootlet coiled-coil, rootletin",1,16740273-16972979,Predicted intracellular proteins,Evidence at protein level,"HPA021191, HPA021762",Enhanced,NA,Supported,Plasma membrane<br>Centrosome,"Endometrial cancer:8.34e-5 (favourable), Lung cancer:7.92e-4 (favourable), Renal cancer:7.97e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 11.6,Mixed,NA,NA
CRTC1,"FLJ14027, KIAA0616, MECT1, TORC1",ENSG00000105662,CREB regulated transcription coactivator 1,19,18683677-18782333,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA022035,Approved,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.80e-5 (favourable), Renal cancer:3.83e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 23.7,Expressed in all,NA,NA
CRYAB,"CRYA2, HSPB5",ENSG00000109846,Crystallin alpha B,11,111908565-111923722,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002053, CAB040560, HPA057100",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable)",Group enriched,Tissue enhanced,NA,heart muscle: 3968.4,cerebral cortex: 1888.7,Cell line enhanced,NA,ASC diff: 1679.2;fHDF/TERT166: 650.9;U-138 MG: 315.9
CRYGD,CRYG4,ENSG00000118231,Crystallin gamma D,2,208121607-208124501,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA041269,NA,NA,Approved,Plasma membrane<br>Intermediate filaments<br>Cytokinetic bridge,NA,Tissue enhanced,Tissue enriched,13,ovary: 21.6,bone marrow: 1.6,Cell line enriched,17,HEL: 19.0
CRYL1,"GDH, lambda-CRY, MGC149525, MGC149526",ENSG00000165475,Crystallin lambda 1,13,20403667-20525857,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040403,Enhanced,NA,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane,"Renal cancer:2.30e-9 (favourable), Endometrial cancer:1.76e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,kidney: 338.1,Mixed,NA,NA
CSF1R,"C-FMS, CD115, CSFR, FMS",ENSG00000182578,Colony stimulating factor 1 receptor,5,150053291-150113372,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB008970, HPA012323",Uncertain,NA,Supported,Vesicles<br>Plasma membrane,"Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 147.7,Group enriched,6,BEWO: 118.6;SK-BR-3: 35.4
CSPG4,"HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16, NG2",ENSG00000173546,Chondroitin sulfate proteoglycan 4,15,75674322-75712848,Predicted membrane proteins,Evidence at protein level,"HPA002951, CAB016189, HPA042785, HPA050008",Approved,NA,Approved,Nucleus<br>Plasma membrane,"Renal cancer:7.60e-6 (unfavourable), Urothelial cancer:4.93e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,smooth muscle: 32.1,Cell line enhanced,NA,SK-MEL-30: 115.3;U-138 MG: 90.7;WM-115: 136.7
CST6,NA,ENSG00000175315,Cystatin E/M,11,66011841-66013505,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB019316, HPA044963",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enriched,9,skin: 213.2,breast: 24.9,Group enriched,6,A-431: 83.9;CAPAN-2: 228.1
CTNNB1,"armadillo, beta-catenin, CTNNB",ENSG00000168036,Catenin beta 1,3,41194837-41260096,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000108, CAB001950, HPA029159, HPA029160",Enhanced,NA,Enhanced,Plasma membrane,Colorectal cancer:7.54e-4 (favourable),Expressed in all,Expressed in all,NA,NA,placenta: 285.6,Expressed in all,NA,NA
CTNND1,"CTNND, KIAA0384, p120, p120cas, p120ctn",ENSG00000198561,Catenin delta 1,11,57753243-57819546,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003837, HPA015954, HPA015955",Enhanced,NA,Enhanced,Plasma membrane,"Pancreatic cancer:3.02e-4 (unfavourable), Renal cancer:3.54e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 196.2,Expressed in all,NA,NA
CTSF,"CATSF, CLN13",ENSG00000174080,Cathepsin F,11,66563463-66568841,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB002141, HPA031431, HPA055610",Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:8.92e-7 (favourable),Expressed in all,Expressed in all,NA,NA,ovary: 140.6,Cell line enhanced,NA,SK-MEL-30: 123.6
CTSV,"CTSL2, CTSU",ENSG00000136943,Cathepsin V,9,97029679-97039643,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB017112,Uncertain,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable)",Mixed,Tissue enhanced,NA,"cervix, uterine: 69.3;skin: 64.2;testis: 131.8",placenta: 25.9,Cell line enriched,7,BEWO: 563.7
CTTN,EMS1,ENSG00000085733,Cortactin,11,70398404-70436584,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011235, HPA057242",Supported,NA,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol,"Head and neck cancer:2.19e-6 (unfavourable), Liver cancer:4.45e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,gallbladder: 108.9,Cell line enhanced,NA,A-431: 778.5
CUTA,"ACHAP, C6orf82",ENSG00000112514,CutA divalent cation tolerance homolog,6,33416442-33418317,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016787, HPA064369",Uncertain,NA,Approved,Plasma membrane<br>Focal adhesion sites,Lung cancer:8.50e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 293.5,Expressed in all,NA,NA
CX3CL1,"ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1",ENSG00000006210,C-X3-C motif chemokine ligand 1,16,57372458-57385048,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB026192, HPA040361",Approved,NA,Supported,Plasma membrane,"Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 100.1,lung: 69.3,Cell line enhanced,NA,EFO-21: 28.0;HDLM-2: 78.9;Hep G2: 42.9;RPTEC TERT1: 27.3
CYFIP2,PIR121,ENSG00000055163,Cytoplasmic FMR1 interacting protein 2,5,157266079-157395595,Predicted intracellular proteins,Evidence at protein level,"CAB055519, HPA068106, HPA071459",Uncertain,NA,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,"Renal cancer:3.21e-12 (favourable), Endometrial cancer:2.42e-6 (unfavourable), Pancreatic cancer:1.18e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,kidney: 166.2,Cell line enhanced,NA,Daudi: 156.3;MOLT-4: 169.6
CYP24A1,"CP24, CYP24, P450-CC24",ENSG00000019186,Cytochrome P450 family 24 subfamily A member 1,20,54153449-54173973,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA022261, HPA063771",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Mitochondria,NA,Mixed,Tissue enhanced,NA,endometrium: 24.8;urinary bladder: 50.8,placenta: 14.1,Group enriched,13,A549: 372.2;Hep G2: 83.4
CYTH2,"ARNO, CTS18.1, cytohesin-2, PSCD2, PSCD2L, Sec7p-L, Sec7p-like",ENSG00000105443,Cytohesin 2,19,48469032-48482314,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB014872, HPA060662",Uncertain,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Liver cancer:1.19e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 31.2,Expressed in all,NA,NA
DAAM1,KIAA0666,ENSG00000100592,Dishevelled associated activator of morphogenesis 1,14,59188646-59371405,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA026605, HPA064789",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:3.77e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 52.1,Expressed in all,NA,NA
DAB2,DOC-2,ENSG00000153071,"DAB2, clathrin adaptor protein",5,39371675-39462300,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009314, HPA028888",Enhanced,NA,Enhanced,Nucleoli fibrillar center<br>Vesicles<br>Plasma membrane,"Liver cancer:7.38e-6 (unfavourable), Stomach cancer:9.67e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 321.8,Cell line enhanced,NA,fHDF/TERT166: 273.0;U-138 MG: 234.0
DAGLB,"DAGLBETA, KCCR13L",ENSG00000164535,Diacylglycerol lipase beta,7,6409126-6484190,Predicted membrane proteins,Evidence at protein level,HPA069377,NA,NA,Supported,Plasma membrane,"Ovarian cancer:7.18e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 20.6,Expressed in all,NA,NA
DBN1,D0S117E,ENSG00000113758,Drebrin 1,5,177456608-177474401,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA051452, HPA056940",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments,Renal cancer:8.28e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 82.9,Mixed,NA,NA
DCAF16,"C4orf30, FLJ20280",ENSG00000163257,DDB1 and CUL4 associated factor 16,4,17800655-17810758,Predicted intracellular proteins,Evidence at protein level,HPA042487,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Lung cancer:5.78e-4 (favourable), Liver cancer:6.40e-4 (unfavourable), Urothelial cancer:7.67e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 23.0,Expressed in all,NA,NA
DCBLD2,"CLCP1, ESDN",ENSG00000057019,"Discoidin, CUB and LCCL domain containing 2",3,98795941-98901689,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA016909,Approved,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:3.32e-5 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Stomach cancer:2.87e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 44.9,Cell line enhanced,NA,LHCN-M2: 647.4;U-87 MG: 568.7
DCHS1,"CDH25, CDHR6, FIB1, FLJ11790, KIAA1773, PCDH16",ENSG00000166341,Dachsous cadherin-related 1,11,6621323-6655854,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA017970, HPA050246",Approved,NA,Approved,Plasma membrane,Renal cancer:9.32e-4 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 29.6,Cell line enhanced,NA,AF22: 32.9;HUVEC TERT2: 39.1;REH: 21.3;SH-SY5Y: 34.2
DCHS2,"CDH27, CDHJ, CDHR7, FLJ20047, PCDH23, PCDHJ",ENSG00000197410,Dachsous cadherin-related 2,4,154232037-154491716,Predicted membrane proteins,Evidence at protein level,HPA064159,Uncertain,NA,Approved,Vesicles<br>Plasma membrane,NA,Not detected,Tissue enhanced,NA,endometrium: 1.9,testis: 1.7,Cell line enriched,6,U-2 OS: 9.2
DCTN6,WS-3,ENSG00000104671,Dynactin subunit 6,8,30156297-30183640,Predicted intracellular proteins,Evidence at protein level,"HPA024049, HPA024558",Approved,NA,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:5.42e-4 (favourable), Liver cancer:5.51e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 93.9,Expressed in all,NA,NA
DCUN1D2,"C13orf17, FLJ10704, FLJ20092",ENSG00000150401,Defective in cullin neddylation 1 domain containing 2,13,113455819-113490952,Predicted intracellular proteins,Evidence at protein level,HPA039349,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Pancreatic cancer:5.65e-5 (favourable),Expressed in all,Expressed in all,NA,NA,heart muscle: 66.6,Expressed in all,NA,NA
DDAH1,DDAH,ENSG00000153904,Dimethylarginine dimethylaminohydrolase 1,1,85318481-85578363,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006308,Enhanced,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:5.21e-6 (favourable), Colorectal cancer:5.99e-4 (favourable)",Expressed in all,Mixed,NA,NA,kidney: 121.4,Cell line enhanced,NA,SH-SY5Y: 122.6
DDIAS,"C11orf82, FLJ25416, FLJ38838, noxin",ENSG00000165490,DNA damage induced apoptosis suppressor,11,82899975-82958277,Predicted secreted proteins,Evidence at protein level,"HPA038540, HPA038541",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,testis: 20.0,skeletal muscle: 6.4,Mixed,NA,NA
DDIT4L,"REDD2, Rtp801L",ENSG00000145358,DNA damage inducible transcript 4 like,4,100185870-100190782,Predicted intracellular proteins,Evidence at protein level,HPA050903,NA,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Actin filaments,Endometrial cancer:5.77e-4 (favourable),Tissue enhanced,Tissue enhanced,NA,skeletal muscle: 113.3,"cervix, uterine: 33.2",Cell line enhanced,NA,ASC TERT1: 13.5;BJ: 25.0;fHDF/TERT166: 12.5;HSkMC: 10.7;RPTEC TERT1: 15.6
DDR2,"NTRKR3, TKT, TYRO10",ENSG00000162733,Discoidin domain receptor tyrosine kinase 2,1,162631373-162787400,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA070112,NA,NA,Supported,Plasma membrane<br>Actin filaments,Renal cancer:1.73e-7 (unfavourable),Expressed in all,Mixed,NA,NA,adrenal gland: 93.5,Cell line enhanced,NA,ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DDX60L,FLJ31033,ENSG00000181381,DEAD-box helicase 60-like,4,168356735-168537786,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043211, HPA055501",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:3.04e-5 (unfavourable), Renal cancer:2.94e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,bone marrow: 33.7,Mixed,NA,NA
DENND6B,"AFI1B, FAM116B, MGC33692",ENSG00000205593,DENN domain containing 6B,22,50309030-50327060,Predicted intracellular proteins,Evidence at protein level,"HPA018934, HPA021653, HPA029570",Uncertain,NA,Uncertain,Plasma membrane,"Endometrial cancer:5.93e-5 (favourable), Colorectal cancer:1.41e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,fallopian tube: 21.5,cerebral cortex: 12.0,Mixed,NA,NA
DFFA,"DFF-45, DFF1, DFF45, ICAD",ENSG00000160049,DNA fragmentation factor subunit alpha,1,10456522-10472526,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002679, HPA018859, HPA019938, HPA025230",Supported,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.57e-9 (favourable), Liver cancer:9.46e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 28.8,Expressed in all,NA,NA
DGKG,DAGK3,ENSG00000058866,Diacylglycerol kinase gamma,3,186105668-186362237,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036577,Approved,NA,Approved,Vesicles<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 21.4,placenta: 11.3,Cell line enhanced,NA,HDLM-2: 22.1;U-87 MG: 13.9
DHDDS,"DS, FLJ13102, HDS, RP59",ENSG00000117682,Dehydrodolichyl diphosphate synthase subunit,1,26432282-26471294,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026721, HPA026727",Uncertain,NA,Uncertain,Plasma membrane,Renal cancer:4.08e-7 (favourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 54.5,Expressed in all,NA,NA
DHPS,MIG13,ENSG00000095059,Deoxyhypusine synthase,19,12675717-12681902,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA014461, HPA029413",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 64.5,Expressed in all,NA,NA
DIAPH1,"DFNA1, hDIA1, LFHL1",ENSG00000131504,Diaphanous related formin 1,5,141515016-141619055,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004916, HPA076913",Approved,NA,Approved,Plasma membrane,"Renal cancer:1.29e-5 (favourable), Pancreatic cancer:7.81e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 73.6,Expressed in all,NA,NA
DIAPH3,"AN, AUNA1, DRF3, FLJ34705, NSDAN",ENSG00000139734,Diaphanous related formin 3,13,59665583-60163987,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA032151,NA,NA,Supported,Plasma membrane<br>Microtubules,"Lung cancer:3.72e-4 (unfavourable), Endometrial cancer:4.18e-4 (unfavourable), Colorectal cancer:9.04e-4 (favourable)",Mixed,Tissue enriched,7,testis: 34.0,placenta: 5.0,Mixed,NA,NA
DIS3L,"DIS3L1, FLJ38088, KIAA1955, MGC4562",ENSG00000166938,DIS3 like exosome 3'-5' exoribonuclease,15,66293217-66333898,Predicted intracellular proteins,Evidence at protein level,HPA041805,Approved,NA,Approved,Plasma membrane<br>Centrosome<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 25.6,Expressed in all,NA,NA
DLEU1,"BCMS, BCMS1, DLB1, LEU1, LINC00021, NCRNA00021, XTP6",ENSG00000176124,Deleted in lymphocytic leukemia 1,13,50082171-50723236,Predicted intracellular proteins,Evidence at protein level,"CAB017848, HPA039465",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,testis: 9.3,Expressed in all,NA,NA
DLG1,"dJ1061C18.1.1, DLGH1, hdlg, SAP-97, SAP97",ENSG00000075711,Discs large MAGUK scaffold protein 1,3,197042560-197299300,Predicted intracellular proteins,Evidence at protein level,"CAB016307, HPA069593",Supported,NA,Uncertain,Vesicles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 94.9,Expressed in all,NA,NA
DLG2,"chapsyn-110, PPP1R58, PSD-93, PSD93",ENSG00000150672,Discs large MAGUK scaffold protein 2,11,83455012-85627922,Predicted intracellular proteins,Evidence at protein level,"HPA021307, HPA023896, CAB072341",Enhanced,NA,Approved,Vesicles<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 72.8,thyroid gland: 25.8,Cell line enhanced,NA,BEWO: 7.6;NTERA-2: 5.5;SCLC-21H: 6.4;SH-SY5Y: 8.7;T-47d: 19.2
DMWD,"D19S593E, DMR-N9, gene59",ENSG00000185800,"Dystrophia myotonica, WD repeat containing",19,45782947-45792802,Predicted intracellular proteins,Evidence at protein level,"HPA068172, HPA069843",Approved,NA,Approved,Plasma membrane<br>Actin filaments,Liver cancer:1.47e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 39.7,Expressed in all,NA,NA
DNAAF1,"CILD13, FLJ25330, LRRC50, ODA7, swt",ENSG00000154099,Dynein axonemal assembly factor 1,16,84145287-84178767,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA041166, HPA074239",Enhanced,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,Endometrial cancer:2.14e-4 (favourable),Tissue enhanced,Group enriched,19,fallopian tube: 36.3;testis: 82.6,lung: 3.0,Cell line enhanced,NA,Hep G2: 1.4;Karpas-707: 3.6;PC-3: 1.4;U-266/70: 3.1;U-266/84: 2.0
DNAH17,"DNAHL1, DNEL2, FLJ40457",ENSG00000187775,Dynein axonemal heavy chain 17,17,78423697-78577394,Predicted intracellular proteins,Evidence at protein level,"HPA024354, HPA076261",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Tissue enhanced,Tissue enriched,21,testis: 10.3,skin: 0.4,Group enriched,5,HeLa: 3.2;MOLT-4: 1.9
DNAJA4,PRO1472,ENSG00000140403,DnaJ heat shock protein family (Hsp40) member A4,15,78264086-78282196,Predicted intracellular proteins,Evidence at protein level,"CAB004646, HPA041790",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.08e-7 (favourable), Glioma:8.35e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 95.4,Cell line enhanced,NA,CAPAN-2: 38.0;RT4: 67.8;SCLC-21H: 62.7;SiHa: 45.2
DNAJB13,"RSPH16A, TSARG6",ENSG00000187726,DnaJ heat shock protein family (Hsp40) member B13,11,73950319-73970366,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA052465, HPA061330",Enhanced,NA,Approved,Plasma membrane,Renal cancer:2.10e-6 (unfavourable),Tissue enhanced,Group enriched,7,fallopian tube: 76.0;testis: 19.1,"cervix, uterine,epididymis: 6.4",Cell line enhanced,NA,RPTEC TERT1: 3.3
DNAJB4,HLJ1,ENSG00000162616,DnaJ heat shock protein family (Hsp40) member B4,1,77979175-78017964,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004995, HPA028383, HPA028385",Approved,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:2.28e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 74.4,Cell line enhanced,NA,HUVEC TERT2: 150.2;LHCN-M2: 254.4
DNAJC6,"KIAA0473, PARK19",ENSG00000116675,DnaJ heat shock protein family (Hsp40) member C6,1,65248219-65415869,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA031182, HPA054917",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:2.81e-4 (favourable),Tissue enhanced,Tissue enriched,10,cerebral cortex: 162.8,adrenal gland: 15.6,Cell line enhanced,NA,HDLM-2: 58.7;HEL: 150.3;K-562: 59.3
DNAJC9,"JDD1, SB73",ENSG00000213551,DnaJ heat shock protein family (Hsp40) member C9,10,73183362-73248862,Predicted intracellular proteins,Evidence at protein level,"HPA035215, HPA035216",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane,"Prostate cancer:7.07e-5 (unfavourable), Lung cancer:3.26e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 37.4,Expressed in all,NA,NA
DOCK4,"FLJ34238, KIAA0716",ENSG00000128512,Dedicator of cytokinesis 4,7,111726110-112206411,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA071516,NA,NA,Approved,Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 31.9,lung: 27.7,Cell line enhanced,NA,hTEC/SVTERT24-B: 42.1;HUVEC TERT2: 67.4;TIME: 57.4
DPP3,NA,ENSG00000254986,Dipeptidyl peptidase 3,11,66480013-66509657,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035780, HPA035781",Approved,NA,Enhanced,Nuclear speckles<br>Plasma membrane<br>Cytosol,Stomach cancer:1.34e-4 (favourable),Expressed in all,Expressed in all,NA,NA,colon: 29.7,Expressed in all,NA,NA
DPYSL2,"CRMP2, DHPRP2, DRP-2, DRP2",ENSG00000092964,Dihydropyrimidinase like 2,8,26514022-26658178,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA002381, CAB018719",Supported,NA,Supported,Plasma membrane<br>Cytosol,Urothelial cancer:5.41e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 379.1,Mixed,NA,NA
DQX1,FLJ23757,ENSG00000144045,DEAQ-box RNA dependent ATPase 1,2,74518131-74526336,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039158,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,duodenum: 14.4;small intestine: 13.5,colon: 5.5,Cell line enhanced,NA,HBEC3-KT: 4.2;Hep G2: 11.5;hTCEpi: 4.3
DRP2,NA,ENSG00000102385,Dystrophin related protein 2,X,101219769-101264497,Predicted intracellular proteins,Evidence at protein level,HPA002949,NA,NA,Approved,Nuclear speckles<br>Plasma membrane,NA,Tissue enhanced,Tissue enriched,6,cerebral cortex: 12.3,prostate: 2.2,Cell line enhanced,NA,RH-30: 10.4;TIME: 15.0;U-87 MG: 4.3
DSEL,"C18orf4, FLJ11477, NCAG1",ENSG00000171451,Dermatan sulfate epimerase-like,18,67506582-67516980,Predicted membrane proteins,Evidence at protein level,HPA060942,NA,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Tissue enhanced,Mixed,NA,NA,cerebral cortex: 5.2,Cell line enhanced,NA,BJ: 31.6;LHCN-M2: 38.7;U-138 MG: 46.6
DUS1L,"DUS1, PP3111",ENSG00000169718,Dihydrouridine synthase 1 like,17,82057506-82065887,Predicted intracellular proteins,Evidence at protein level,HPA023384,Uncertain,NA,Approved,Plasma membrane,Renal cancer:5.89e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,skin: 99.0,Expressed in all,NA,NA
DUSP15,"bA243J16.5, bA243J16.6, C20orf57, FLJ20645, VHY",ENSG00000149599,Dual specificity phosphatase 15,20,31847637-31870747,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA076649,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:5.40e-7 (favourable),Mixed,Tissue enhanced,NA,testis: 77.1,parathyroid gland: 16.1,Cell line enhanced,NA,REH: 14.6;SH-SY5Y: 4.6
DXO,DOM3Z,ENSG00000204348,Decapping exoribonuclease,6,31969810-31972292,Predicted intracellular proteins,Evidence at protein level,HPA046708,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:4.77e-6 (unfavourable), Pancreatic cancer:5.87e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 5.7,Cell line enhanced,NA,AN3-CA: 10.2
DYSF,"FER1L1, LGMD2B",ENSG00000135636,Dysferlin,2,71453722-71686768,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002510, HPA017071, HPA021945",Enhanced,NA,Supported,Plasma membrane<br>Microtubule organizing center,NA,Expressed in all,Mixed,NA,NA,skeletal muscle: 32.8,Group enriched,6,HUVEC TERT2: 69.0;LHCN-M2: 62.5;RH-30: 75.9;TIME: 44.6
DYX1C1,"CILD25, DNAAF4, EKN1, FLJ37882",ENSG00000256061,Dyslexia susceptibility 1 candidate 1,15,55410525-55508234,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA051048,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,testis: 20.5,fallopian tube: 17.6,Mixed,NA,NA
ECSCR,"ARIA, ECSM2",ENSG00000249751,Endothelial cell surface expressed chemotaxis and apoptosis regulator,5,139448556-139462743,Predicted membrane proteins,Evidence at protein level,HPA063337,NA,NA,Enhanced,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,placenta: 96.7,Group enriched,104,EFO-21: 322.5;HUVEC TERT2: 736.2;TIME: 536.3
EDNRB,"ETB, HSCR, HSCR2",ENSG00000136160,Endothelin receptor type B,13,77895481-77919768,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB017842, HPA027546",Approved,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:7.20e-5 (favourable),Group enriched,Tissue enhanced,NA,placenta: 180.2,cerebral cortex: 88.8,Cell line enhanced,NA,AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
EEF1AKMT1,N6AMT2,ENSG00000150456,Eukaryotic translation elongation factor 1 alpha lysine methyltransferase 1,13,20728731-20773958,Predicted intracellular proteins,Evidence at protein level,"HPA040417, HPA042543",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Endometrial cancer:1.82e-4 (favourable),Expressed in all,Expressed in all,NA,NA,"endometrium,fallopian tube: 18.1",Mixed,NA,NA
EEF2,"EEF-2, EF2",ENSG00000167658,Eukaryotic translation elongation factor 2,19,3976056-3985469,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB007795, HPA040534, HPA057351",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Endometrial cancer:1.81e-6 (favourable), Renal cancer:1.25e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 1621.6,Expressed in all,NA,NA
EEPD1,KIAA1706,ENSG00000122547,Endonuclease/exonuclease/phosphatase family domain containing 1,7,36153149-36301543,Predicted intracellular proteins,Evidence at protein level,HPA053668,NA,NA,Approved,Nuclear speckles<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 27.1,Cell line enhanced,NA,HDLM-2: 16.9;PC-3: 20.8
EFCAB1,FLJ11767,ENSG00000034239,EF-hand calcium binding domain 1,8,48710789-48735311,Predicted intracellular proteins,Evidence at protein level,"HPA023527, HPA069955",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,fallopian tube: 149.8;testis: 47.1,ovary: 23.9,Cell line enhanced,NA,A-431: 5.8;ASC TERT1: 4.4;CAPAN-2: 2.8;SCLC-21H: 5.8
EFCAB2,"CFAP200, DRC8, MGC12458",ENSG00000203666,EF-hand calcium binding domain 2,1,244969705-245127164,Predicted intracellular proteins,Evidence at protein level,"HPA031206, HPA031207",Approved,NA,Approved,Plasma membrane<br>Cytosol,Thyroid cancer:6.51e-4 (unfavourable),Mixed,Expressed in all,NA,NA,fallopian tube: 57.7,Expressed in all,NA,NA
EFCAB7,"KIAA1799, RP4-534K7.1",ENSG00000203965,EF-hand calcium binding domain 7,1,63523372-63572693,Predicted intracellular proteins,Evidence at protein level,"HPA029611, HPA029612, HPA029613",Enhanced,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,Glioma:4.84e-4 (favourable),Mixed,Mixed,NA,NA,testis: 24.7,Expressed in all,NA,NA
EFHC1,"EJM, EJM1, FLJ10466",ENSG00000096093,EF-hand domain containing 1,6,52362123-52529886,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA035307,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,"Pancreatic cancer:2.33e-4 (favourable), Renal cancer:3.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,fallopian tube: 55.6,testis: 31.3,Cell line enhanced,NA,SCLC-21H: 22.6
EFNB1,"CFNS, Elk-L, EPLG2, LERK2",ENSG00000090776,Ephrin B1,X,68828997-68842147,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB031489, HPA067188",Uncertain,NA,Supported,Plasma membrane,"Endometrial cancer:3.32e-5 (unfavourable), Pancreatic cancer:4.29e-4 (unfavourable), Melanoma:8.68e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 37.8,Mixed,NA,NA
EFR3A,KIAA0143,ENSG00000132294,EFR3 homolog A,8,131904088-132013642,Predicted intracellular proteins,Evidence at protein level,"HPA022859, HPA023092, HPA023402",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 70.4,Expressed in all,NA,NA
EGFR,"ERBB, ERBB1",ENSG00000146648,Epidermal growth factor receptor,7,55019021-55211628,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534",Enhanced,NA,Enhanced,Plasma membrane,Urothelial cancer:2.04e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,placenta: 100.0,skin: 58.7,Cell line enriched,15,A-431: 4682.9
EHBP1,"KIAA0903, NACSIN",ENSG00000115504,EH domain binding protein 1,2,62673851-63046487,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035468, HPA035469",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Urothelial cancer:1.95e-8 (unfavourable), Lung cancer:9.03e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 68.0,Expressed in all,NA,NA
EHBP1L1,"DKFZp762C186, TANGERIN",ENSG00000173442,EH domain binding protein 1 like 1,11,65576038-65592650,Predicted intracellular proteins,Evidence at protein level,HPA039479,Approved,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,Renal cancer:1.45e-4 (unfavourable),Expressed in all,Mixed,NA,NA,skeletal muscle: 88.6,Mixed,NA,NA
EHD1,"FLJ42622, FLJ44618, H-PAST, HPAST1, PAST1",ENSG00000110047,EH domain containing 1,11,64851642-64888296,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049890, HPA049986, HPA066751, HPA067747",Approved,NA,Supported,Plasma membrane,Liver cancer:2.81e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 152.8,Expressed in all,NA,NA
EHD2,PAST2,ENSG00000024422,EH domain containing 2,19,47713343-47743134,Predicted intracellular proteins,Evidence at protein level,"HPA047394, HPA049890, HPA049986, HPA066751",Approved,NA,Supported,Plasma membrane,"Renal cancer:3.98e-4 (unfavourable), Ovarian cancer:8.75e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 208.8,smooth muscle: 111.7,Mixed,NA,NA
EHD3,PAST3,ENSG00000013016,EH domain containing 3,2,31234337-31269447,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049890, HPA049986, HPA066751",Approved,NA,Approved,Plasma membrane,Renal cancer:1.02e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 64.2,esophagus: 28.8,Cell line enhanced,NA,BJ: 68.8;BJ hTERT+: 162.4;HEL: 71.6
EHD4,PAST4,ENSG00000103966,EH domain containing 4,15,41895939-41972578,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049890, HPA049986, HPA052729, HPA066751",Approved,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 24.8,Cell line enhanced,NA,TIME: 140.3
EIF2B2,"EIF-2Bbeta, EIF2B",ENSG00000119718,Eukaryotic translation initiation factor 2B subunit beta,14,75002911-75012366,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA005841, CAB037105, HPA048028",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites,"Liver cancer:2.26e-6 (unfavourable), Renal cancer:2.95e-4 (favourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 19.2,Expressed in all,NA,NA
EIF5,NA,ENSG00000100664,Eukaryotic translation initiation factor 5,14,103333544-103345025,Predicted intracellular proteins,Evidence at protein level,"HPA000867, CAB004226",Supported,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:5.67e-7 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 174.0,Expressed in all,NA,NA
EIF5B,"DKFZp434I036, FLJ10524, IF2, KIAA0741",ENSG00000158417,Eukaryotic translation initiation factor 5B,2,99337353-99401326,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034648, HPA040095",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:7.15e-10 (unfavourable), Renal cancer:1.42e-6 (unfavourable), Ovarian cancer:8.99e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 67.5,Expressed in all,NA,NA
ELN,"SVAS, WBS, WS",ENSG00000049540,Elastin,7,74027789-74069907,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB010750, HPA018111, HPA056941",Supported,NA,Approved,Plasma membrane,Thyroid cancer:6.29e-4 (unfavourable),Expressed in all,Mixed,NA,NA,smooth muscle: 125.8,Cell line enhanced,NA,BJ: 121.3;fHDF/TERT166: 160.9;U-2197: 748.2
ENAH,"FLJ10773, MENA, NDPP1",ENSG00000154380,Enabled homolog (Drosophila),1,225486835-225653142,Predicted intracellular proteins,Evidence at protein level,"HPA028448, HPA028696",Enhanced,NA,Enhanced,Plasma membrane<br>Focal adhesion sites<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,smooth muscle: 81.3,Mixed,NA,NA
ENC1,"ENC-1, KLHL37, NRPB, PIG10, TP53I10",ENSG00000171617,Ectodermal-neural cortex 1,5,74627406-74641424,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA078061,NA,NA,Uncertain,Plasma membrane,"Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable)",Expressed in all,Tissue enriched,15,cerebral cortex: 461.4,gallbladder: 30.8,Mixed,NA,NA
ENKD1,"C16orf48, DKFZP434A1319",ENSG00000124074,Enkurin domain containing 1,16,67662945-67667265,Predicted intracellular proteins,Evidence at protein level,"HPA041163, HPA041478",Approved,NA,Supported,Plasma membrane<br>Centrosome<br>Cytosol,Endometrial cancer:1.68e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 32.7,Mixed,NA,NA
ENO1,"ENO1L1, MBP-1, MPB1, PPH",ENSG00000074800,Enolase 1,1,8861002-8879249,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB018614, HPA068284, HPA068721, CAB069394",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Liver cancer:1.30e-8 (unfavourable), Glioma:2.12e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,appendix: 768.2,Expressed in all,NA,NA
ENO2,NA,ENSG00000111674,Enolase 2,12,6913745-6923698,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000063, HPA068284, HPA068721, CAB073539, CAB079023",Enhanced,Supported,Supported,Plasma membrane<br>Cytosol,"Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable)",Expressed in all,Tissue enriched,7,cerebral cortex: 431.0,parathyroid gland: 64.8,Cell line enhanced,NA,U-87 MG: 368.8
ENO3,NA,ENSG00000108515,Enolase 3,17,4948092-4957131,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000793, HPA068284, HPA068721",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Colorectal cancer:7.33e-4 (unfavourable),Expressed in all,Tissue enriched,17,skeletal muscle: 5974.6,heart muscle: 350.1,Expressed in all,NA,NA
ENOX1,"cCNOX, CNOX, FLJ10094, PIG38",ENSG00000120658,Ecto-NOX disulfide-thiol exchanger 1,13,43213518-43786908,Predicted intracellular proteins,Evidence at protein level,HPA038355,Supported,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,testis: 16.3,cerebral cortex: 10.5,Cell line enhanced,NA,hTEC/SVTERT24-B: 17.3;RH-30: 23.3
EPB41L1,"4.1N, KIAA0338",ENSG00000088367,Erythrocyte membrane protein band 4.1 like 1,20,36091504-36232799,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA054104, HPA056817",Enhanced,NA,Supported,Plasma membrane,"Renal cancer:4.39e-10 (favourable), Endometrial cancer:6.46e-5 (unfavourable), Pancreatic cancer:9.30e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adrenal gland: 162.4,Cell line enhanced,NA,HaCaT: 212.9
EPB41L3,"4.1B, DAL1, KIAA0987",ENSG00000082397,Erythrocyte membrane protein band 4.1 like 3,18,5392381-5630700,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028605,Enhanced,NA,Enhanced,Plasma membrane,NA,Mixed,Expressed in all,NA,NA,testis: 115.0,Cell line enhanced,NA,SCLC-21H: 77.1;TIME: 134.0
EPB41L4A,NBL4,ENSG00000129595,Erythrocyte membrane protein band 4.1 like 4A,5,112142441-112419316,Predicted intracellular proteins,Evidence at protein level,HPA036580,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:3.65e-5 (favourable),Mixed,Expressed in all,NA,NA,parathyroid gland: 25.6,Cell line enhanced,NA,EFO-21: 28.6;HeLa: 23.8
EPB41L4B,EHM2,ENSG00000095203,Erythrocyte membrane protein band 4.1 like 4B,9,109171975-109320964,Predicted intracellular proteins,Evidence at protein level,HPA042862,Approved,NA,Approved,Plasma membrane<br>Cytosol,Breast cancer:1.02e-4 (unfavourable),Mixed,Mixed,NA,NA,thyroid gland: 74.8,Cell line enhanced,NA,BEWO: 30.5;hTCEpi: 36.0
EPB41L5,"BE37, FLJ12957, KIAA1548, YMO1, YRT",ENSG00000115109,Erythrocyte membrane protein band 4.1 like 5,2,120013005-120179119,Predicted intracellular proteins,Evidence at protein level,"HPA037563, HPA037564",Uncertain,NA,Supported,Plasma membrane,Renal cancer:2.28e-6 (favourable),Expressed in all,Mixed,NA,NA,testis: 56.5,Cell line enhanced,NA,MCF7: 63.7
EPCAM,"17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1",ENSG00000119888,Epithelial cell adhesion molecule,2,47345158-47387601,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB003809, HPA026761, CAB030012, CAB055098, HPA067463",Enhanced,NA,Supported,Plasma membrane,"Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable)",Mixed,Tissue enhanced,NA,rectum: 680.5;small intestine: 714.7,colon: 659.9,Cell line enhanced,NA,A-431: 382.2;CACO-2: 461.4;CAPAN-2: 680.1;SCLC-21H: 345.3
EPHB1,"EPHT2, Hek6",ENSG00000154928,EPH receptor B1,3,134597801-135260467,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067740,Enhanced,NA,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enhanced,NA,cerebral cortex: 23.7;testis: 20.5,thyroid gland: 11.9,Cell line enhanced,NA,HDLM-2: 59.3;HMC-1: 31.7
EPHB2,"DRT, EPHT3, ERK, Hek5, Tyro5",ENSG00000133216,EPH receptor B2,1,22710839-22921500,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB013647, HPA071200",Approved,NA,Supported,Nucleus<br>Plasma membrane,"Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)",Tissue enhanced,Mixed,NA,NA,rectum: 27.3,Cell line enhanced,NA,HUVEC TERT2: 71.2;TIME: 69.5
EPS8L2,"FLJ21935, FLJ22171, MGC3088",ENSG00000177106,EPS8 like 2,11,694438-727727,Predicted intracellular proteins,Evidence at protein level,HPA041143,Approved,NA,Supported,Plasma membrane<br>Cytosol,Glioma:1.80e-4 (unfavourable),Expressed in all,Mixed,NA,NA,small intestine: 110.4,Cell line enhanced,NA,A-431: 186.2;BEWO: 194.1;CAPAN-2: 171.1;SK-BR-3: 177.2
ERAP1,"A-LAP, ARTS-1, ERAAP1, KIAA0525, PILS-AP",ENSG00000164307,Endoplasmic reticulum aminopeptidase 1,5,96760810-96808100,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025095, HPA042317",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,placenta: 68.0,Expressed in all,NA,NA
ERBB2,"CD340, HER-2, HER2, NEU, NGL",ENSG00000141736,Erb-b2 receptor tyrosine kinase 2,17,39687914-39730426,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 124.5,Cell line enriched,22,SK-BR-3: 2343.7
ERBB3,"HER3, LCCS2",ENSG00000065361,Erb-b2 receptor tyrosine kinase 3,12,56079857-56103505,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025331, HPA045396",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments,NA,Expressed in all,Mixed,NA,NA,small intestine: 86.8,Cell line enhanced,NA,Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ERBIN,"ERBB2IP, LAP2",ENSG00000112851,Erbb2 interacting protein,5,65926475-66082549,Predicted intracellular proteins,Evidence at protein level,"HPA048606, HPA059863",Approved,NA,Supported,Nuclear speckles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,testis: 50.1,Expressed in all,NA,NA
ERC1,"CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2",ENSG00000082805,ELKS/RAB6-interacting/CAST family member 1,12,990509-1495933,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA019513, HPA019523, HPA024130",Approved,NA,Supported,Vesicles<br>Plasma membrane<br>Cytosol,Urothelial cancer:7.01e-4 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 17.1,Expressed in all,NA,NA
ETNK1,"EKI, EKI1",ENSG00000139163,Ethanolamine kinase 1,12,22625075-22690665,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA010712, HPA029407",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,stomach: 45.6,Expressed in all,NA,NA
ETS2,NA,ENSG00000157557,"ETS proto-oncogene 2, transcription factor",21,38805307-38824955,"Predicted intracellular proteins, RAS pathway related proteins, Transcription factors",Evidence at protein level,HPA003176,NA,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,spleen: 252.7,Cell line enhanced,NA,HEL: 249.9
EVA1A,"FAM176A, FLJ13391, TMEM166",ENSG00000115363,"Eva-1 homolog A, regulator of programmed cell death",2,75469302-75569722,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008055,Approved,NA,Supported,Vesicles<br>Plasma membrane,"Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable)",Mixed,Tissue enhanced,NA,liver: 98.9,lung: 31.1,Cell line enhanced,NA,U-138 MG: 109.1
EXOC1,"BM-102, FLJ10893, SEC3, SEC3L1, Sec3p",ENSG00000090989,Exocyst complex component 1,4,55853616-55905034,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA037706, HPA044873",Uncertain,NA,Approved,Plasma membrane<br>Microtubules<br>Cytosol,"Urothelial cancer:5.50e-5 (favourable), Liver cancer:2.63e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 39.7,Expressed in all,NA,NA
EXOC3L1,"EXOC3L, FLJ35539, FLJ35587",ENSG00000179044,Exocyst complex component 3 like 1,16,67184366-67190204,Predicted intracellular proteins,Evidence at transcript level,HPA029574,Uncertain,NA,Approved,Vesicles<br>Plasma membrane,NA,Expressed in all,Tissue enhanced,NA,spleen: 30.0,placenta: 8.4,Cell line enhanced,NA,HUVEC TERT2: 2.8;SCLC-21H: 7.6
EXOC7,"EXO70, Exo70p, KIAA1067, YJL085W",ENSG00000182473,Exocyst complex component 7,17,76081017-76121576,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA022840, HPA022842",Supported,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 102.7,Expressed in all,NA,NA
EZR,VIL2,ENSG00000092820,Ezrin,6,158765741-158819412,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004035, HPA021616, CAB047324, CAB075739",Enhanced,NA,Enhanced,Plasma membrane,"Renal cancer:9.56e-8 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 537.0,Expressed in all,NA,NA
F2RL1,"GPR11, PAR2",ENSG00000164251,F2R like trypsin receptor 1,5,76818933-76835315,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB012989, HPA014091",Approved,NA,Approved,Plasma membrane,"Renal cancer:5.86e-7 (favourable), Colorectal cancer:3.88e-4 (favourable), Head and neck cancer:5.88e-4 (unfavourable), Lung cancer:8.92e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,colon: 58.9,Cell line enhanced,NA,PC-3: 113.9;RPTEC TERT1: 152.3
FABP2,I-FABP,ENSG00000145384,Fatty acid binding protein 2,4,119317250-119322390,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034607, CAB047325, CAB047326",Enhanced,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,NA,Group enriched,Group enriched,12,duodenum: 261.4;small intestine: 554.5,rectum: 33.8,Not detected,NA,NA
FABP5,"E-FABP, KFABP, PA-FABP",ENSG00000164687,Fatty acid binding protein 5,8,81280363-81284777,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB017831, CAB040577, HPA051895",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:4.69e-10 (unfavourable),Expressed in all,Expressed in all,NA,NA,esophagus: 1664.2,Mixed,NA,NA
FAIM,"FAIM1, FLJ10582",ENSG00000158234,Fas apoptotic inhibitory molecule,3,138608606-138633376,Predicted intracellular proteins,Evidence at protein level,"HPA042440, HPA052209",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:3.96e-5 (unfavourable), Renal cancer:6.63e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 61.0,Mixed,NA,NA
FAM126A,"DRCTNNB1A, HCC, HYCC1, hyccin",ENSG00000122591,Family with sequence similarity 126 member A,7,22889371-23014130,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042873,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:6.04e-7 (unfavourable), Stomach cancer:5.99e-4 (unfavourable), Urothelial cancer:9.03e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 33.4,Mixed,NA,NA
FAM129A,"C1orf24, GIG39, NIBAN",ENSG00000135842,Family with sequence similarity 129 member A,1,184790724-184974550,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028172, HPA028231, HPA028657",Approved,NA,Supported,Plasma membrane<br>Cytosol,Urothelial cancer:4.52e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,heart muscle: 104.1,Mixed,NA,NA
FAM129B,"bA356B19.6, C9orf88, DKFZP434H0820, FLJ13518, FLJ22151, FLJ22298, MINERVA",ENSG00000136830,Family with sequence similarity 129 member B,9,127505339-127578989,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021284, HPA021417, HPA023261, HPA024312",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,esophagus: 362.3,Mixed,NA,NA
FAM163B,C9orf166,ENSG00000196990,Family with sequence similarity 163 member B,9,133578415-133586197,Predicted membrane proteins,Evidence at transcript level,HPA067336,Approved,NA,Approved,Nuclear bodies<br>Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enriched,6,cerebral cortex: 103.5,adrenal gland: 16.4,Cell line enriched,19,SH-SY5Y: 72.4
FAM171A1,"C10orf38, FLJ12884",ENSG00000148468,Family with sequence similarity 171 member A1,10,15211643-15371062,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA051345,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,"Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 73.2,Cell line enhanced,NA,TIME: 95.9
FAM193A,"C4orf8, RES4-22",ENSG00000125386,Family with sequence similarity 193 member A,4,2536631-2732565,Predicted intracellular proteins,Evidence at protein level,HPA043116,Approved,NA,Approved,Plasma membrane<br>Cytosol,Pancreatic cancer:4.80e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 30.2,Expressed in all,NA,NA
FAM210B,"C20orf108, dJ1167H4.1, DKFZP434A1114",ENSG00000124098,Family with sequence similarity 210 member B,20,56358915-56368663,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA042652,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.44e-10 (favourable), Lung cancer:4.26e-4 (favourable), Cervical cancer:5.44e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 131.4,Cell line enhanced,NA,SK-MEL-30: 224.0
FAM213B,"C1orf93, MGC26818",ENSG00000157870,Family with sequence similarity 213 member B,1,2586491-2591469,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006403,Approved,Approved,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.28e-4 (favourable), Liver cancer:1.62e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,small intestine: 14.6,Mixed,NA,NA
FAM222A,"C12orf34, FLJ14721",ENSG00000139438,Family with sequence similarity 222 member A,12,109714228-109770507,Predicted intracellular proteins,Evidence at protein level,HPA040181,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites<br>Mitochondria,"Cervical cancer:1.82e-5 (favourable), Pancreatic cancer:4.81e-4 (favourable), Stomach cancer:8.59e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 20.0;testis: 16.5,adrenal gland: 9.8,Cell line enriched,5,SH-SY5Y: 122.9
FAM45A,NA,ENSG00000119979,Family with sequence similarity 45 member A,10,119104086-119137984,Predicted intracellular proteins,Evidence at protein level,HPA041159,NA,NA,Approved,Plasma membrane<br>Centrosome<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 21.0,Expressed in all,NA,NA
FAM47E,"FLJ42946, LOC100129583",ENSG00000189157,Family with sequence similarity 47 member E,4,76214040-76283780,Predicted intracellular proteins,Evidence at transcript level,HPA053331,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,fallopian tube: 28.1,thyroid gland: 16.3,Mixed,NA,NA
FAM47E-STBD1,NA,ENSG00000272414,FAM47E-STBD1 readthrough,4,76251721-76311129,Predicted intracellular proteins,Evidence at transcript level,HPA053331,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Not detected,Mixed,NA,NA,adipose tissue: 33.2,Cell line enhanced,NA,Karpas-707: 24.7
FAM72A,"LMPIP, MGC57827, RP11-312O7.1, UGENE",ENSG00000196550,Family with sequence similarity 72 member A,1,206186179-206204414,Predicted intracellular proteins,Evidence at protein level,"HPA043271, HPA067321",Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,lymph node: 12.6,Expressed in all,NA,NA
FAM72B,RP11-439A17.6,ENSG00000188610,Family with sequence similarity 72 member B,1,121167646-121185539,Predicted intracellular proteins,Evidence at transcript level,"HPA043271, HPA067321",Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,lymph node: 9.7,tonsil: 6.2,Mixed,NA,NA
FAM72C,RP5-998N21.9,ENSG00000263513,Family with sequence similarity 72 member C,1,143955364-143971965,Predicted intracellular proteins,Evidence at transcript level,"HPA043271, HPA067321",Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,lymph node: 5.5;tonsil: 4.3,testis: 3.0,Mixed,NA,NA
FAM72D,NA,ENSG00000215784,Family with sequence similarity 72 member D,1,145096000-145112696,Predicted intracellular proteins,Evidence at transcript level,"HPA043271, HPA067321",Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,lymph node: 5.6,tonsil: 4.1,Mixed,NA,NA
FANCG,"FAG, XRCC9",ENSG00000221829,Fanconi anemia complementation group G,9,35073835-35080016,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB008105, HPA045335",Approved,NA,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:2.38e-7 (unfavourable), Liver cancer:2.02e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,fallopian tube: 8.7,Expressed in all,NA,NA
FARS2,"dJ236A3.1, FARS1",ENSG00000145982,"Phenylalanyl-tRNA synthetase 2, mitochondrial",6,5261044-5771580,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA018148, HPA028836",Approved,NA,Approved,Plasma membrane,"Renal cancer:1.24e-6 (favourable), Colorectal cancer:5.14e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 24.5,Expressed in all,NA,NA
FAS,"APO-1, APT1, CD95, FAS1, TNFRSF6",ENSG00000026103,Fas cell surface death receptor,10,88990582-89015785,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA027444,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,rectum: 32.9,Cell line enhanced,NA,Karpas-707: 104.1
FASN,"FAS, SDR27X1",ENSG00000169710,Fatty acid synthase,17,82078333-82098332,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005192, HPA006461, CAB015417, HPA056108",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 290.7,Expressed in all,NA,NA
FBLN2,NA,ENSG00000163520,Fibulin 2,3,13549131-13638422,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001934, CAB018622",Enhanced,NA,Supported,Plasma membrane,"Liver cancer:3.17e-4 (favourable), Endometrial cancer:9.48e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 142.2,Cell line enhanced,NA,ASC diff: 262.8;fHDF/TERT166: 204.8;HMC-1: 273.5;HSkMC: 161.5
FBLN5,"ARMD3, DANCE, EVEC, UP50",ENSG00000140092,Fibulin 5,14,91869412-91947987,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA000848, HPA000868, CAB025843",Supported,NA,Supported,Plasma membrane,Liver cancer:6.75e-4 (favourable),Expressed in all,Expressed in all,NA,NA,gallbladder: 221.0,Group enriched,6,ASC diff: 345.3;ASC TERT1: 182.9;BJ: 207.7;BJ hTERT+: 185.8;fHDF/TERT166: 343.2;HHSteC: 70.5;HSkMC: 175.5
FBP2,NA,ENSG00000130957,Fructose-bisphosphatase 2,9,94558720-94593793,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA012513, HPA055286",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enriched,8,skeletal muscle: 266.1,stomach: 32.7,Cell line enhanced,NA,BEWO: 3.9;MCF7: 2.4;SiHa: 3.0
FBRSL1,KIAA1545,ENSG00000112787,Fibrosin like 1,12,132489551-132585188,Predicted intracellular proteins,Evidence at protein level,HPA049880,Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Renal cancer:1.17e-4 (favourable), Urothelial cancer:7.21e-4 (favourable), Prostate cancer:9.82e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 16.9,Expressed in all,NA,NA
FBXL2,"FBL2, FBL3",ENSG00000153558,F-box and leucine rich repeat protein 2,3,33277025-33403662,Predicted intracellular proteins,Evidence at protein level,HPA061783,NA,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,Renal cancer:3.35e-4 (favourable),Mixed,Mixed,NA,NA,cerebral cortex: 5.8,Cell line enhanced,NA,CAPAN-2: 6.7
FBXO16,FBX16,ENSG00000214050,F-box protein 16,8,28348287-28490318,Predicted intracellular proteins,Evidence at transcript level,"HPA053955, HPA058676",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,Ovarian cancer:6.70e-5 (favourable),Mixed,Tissue enhanced,NA,epididymis: 22.4,thyroid gland: 12.1,Cell line enhanced,NA,AF22: 19.5
FBXO38,"Fbx38, FLJ13962, MOKA, SP329",ENSG00000145868,F-box protein 38,5,148383935-148442836,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA034821, HPA041444",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytokinetic bridge<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 30.8,Expressed in all,NA,NA
FBXO41,"Fbx41, KIAA1940",ENSG00000163013,F-box protein 41,2,73254682-73284431,Predicted intracellular proteins,Evidence at protein level,"HPA055246, HPA058386",NA,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:5.76e-4 (unfavourable)",Mixed,Tissue enhanced,NA,cerebral cortex: 38.3,parathyroid gland: 11.1,Cell line enhanced,NA,Daudi: 33.9
FCAR,CD89,ENSG00000186431,Fc fragment of IgA receptor,19,54874248-54890472,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA014050,Approved,NA,Supported,Plasma membrane,NA,Not detected,Tissue enriched,15,bone marrow: 12.3,appendix: 0.8,Not detected,NA,NA
FCGBP,FC(GAMMA)BP,ENSG00000275395,Fc fragment of IgG binding protein,19,39863323-39934626,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA003517, HPA003564",Enhanced,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytokinetic bridge,"Ovarian cancer:9.70e-6 (unfavourable), Head and neck cancer:1.28e-5 (favourable), Liver cancer:4.74e-5 (unfavourable), Thyroid cancer:4.27e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,colon: 166.7,"cervix, uterine: 83.5",Cell line enhanced,NA,A549: 2.7;RH-30: 6.8
FCHSD2,"KIAA0769, SH3MD3",ENSG00000137478,FCH and double SH3 domains 2,11,72836745-73142261,Predicted intracellular proteins,Evidence at protein level,"HPA038545, HPA038546",Uncertain,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites,Colorectal cancer:1.71e-4 (favourable),Expressed in all,Expressed in all,NA,NA,spleen: 64.1,Expressed in all,NA,NA
FFAR4,"GPR120, GPR129, O3FAR1, PGR4",ENSG00000186188,Free fatty acid receptor 4,10,93566665-93604480,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA042563,Uncertain,NA,Uncertain,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,colon: 8.4;rectum: 12.4,lung: 5.4,Cell line enhanced,NA,A549: 1.2;HaCaT: 2.0;NB-4: 1.6
FGD1,"FGDY, ZFYVE3",ENSG00000102302,"FYVE, RhoGEF and PH domain containing 1",X,54445454-54496166,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA000911,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Endometrial cancer:2.10e-4 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 9.5,Mixed,NA,NA
FGR,"c-fgr, p55c-fgr, SRC2",ENSG00000000938,"FGR proto-oncogene, Src family tyrosine kinase",1,27612064-27635277,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002024,Enhanced,NA,Approved,Plasma membrane<br>Aggresome,NA,Expressed in all,Tissue enhanced,NA,appendix: 85.6;bone marrow: 137.0;spleen: 90.6,lung: 56.3,Cell line enhanced,NA,Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7
FHIT,"AP3Aase, FRA3B",ENSG00000189283,Fragile histidine triad,3,59749310-61251459,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB002684, HPA018840, HPA018909",Enhanced,NA,Approved,Nucleoli fibrillar center<br>Plasma membrane,Renal cancer:1.36e-4 (favourable),Mixed,Expressed in all,NA,NA,kidney: 26.8,Cell line enhanced,NA,U-266/70: 27.6
FHL1,"bA535K18.1, FHL1B, FLH1A, KYO-T, MGC111107, SLIM1, XMPMA",ENSG00000022267,Four and a half LIM domains 1,X,136146702-136211359,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001040, HPA001391, CAB020817",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Urothelial cancer:2.11e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 3804.7,Cell line enhanced,NA,BJ hTERT+: 219.3
FILIP1,"FILIP, KIAA1275",ENSG00000118407,Filamin A interacting protein 1,6,75291859-75493738,Predicted intracellular proteins,Evidence at protein level,HPA053564,Enhanced,NA,Uncertain,Plasma membrane<br>Actin filaments,NA,Mixed,Tissue enhanced,NA,heart muscle: 35.3,smooth muscle: 19.5,Cell line enhanced,NA,EFO-21: 6.6;U-266/70: 5.3
FILIP1L,"DOC-1, GIP130",ENSG00000168386,Filamin A interacting protein 1 like,3,99830141-100114513,Predicted intracellular proteins,Evidence at protein level,HPA043133,Approved,NA,Approved,Plasma membrane,Renal cancer:9.40e-4 (unfavourable),Expressed in all,Mixed,NA,NA,smooth muscle: 217.1,Cell line enhanced,NA,HDLM-2: 74.0;TIME: 118.7
FKBP2,"FKBP-13, PPIase",ENSG00000173486,FK506 binding protein 2,11,64241003-64244132,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB025561, HPA049405",Enhanced,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 399.2,Expressed in all,NA,NA
FLAD1,"FAD1, PP591",ENSG00000160688,Flavin adenine dinucleotide synthetase 1,1,154983338-154993111,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028476, HPA028486, HPA028563",Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 28.5,Expressed in all,NA,NA
FLCN,"BHD, MGC17998, MGC23445",ENSG00000154803,Folliculin,17,17212212-17237188,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB015158, HPA028760",Supported,NA,Supported,Plasma membrane<br>Cytosol,Pancreatic cancer:4.49e-4 (favourable),Expressed in all,Expressed in all,NA,NA,endometrium: 30.8,Expressed in all,NA,NA
FLNA,"ABP-280, FLN, FLN1, OPD1, OPD2",ENSG00000196924,Filamin A,X,154348524-154374638,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB000356, HPA000368, HPA001016, HPA001115, HPA002925",Enhanced,Approved,Enhanced,Plasma membrane<br>Actin filaments<br>Cytosol,"Renal cancer:1.54e-6 (unfavourable), Urothelial cancer:3.88e-4 (unfavourable), Colorectal cancer:7.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 1051.0,Expressed in all,NA,NA
FLNB,"ABP-278, FH1, FLN1L, LRS1, TABP, TAP",ENSG00000136068,Filamin B,3,58008400-58172251,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA004747, HPA004886, CAB019322",Enhanced,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Actin filaments<br>Cytosol,"Renal cancer:3.45e-6 (favourable), Pancreatic cancer:8.45e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,prostate: 148.3,Expressed in all,NA,NA
FLNC,"ABP-280, ABPL, FLN2",ENSG00000128591,Filamin C,7,128830377-128859274,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA006135,Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Lung cancer:2.17e-5 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Glioma:2.14e-4 (unfavourable), Renal cancer:5.69e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,skeletal muscle: 384.7,smooth muscle: 160.7,Cell line enhanced,NA,BJ: 331.0;hTEC/SVTERT24-B: 190.2;U-2 OS: 169.5
FLOT1,NA,ENSG00000137312,Flotillin 1,6,30727709-30742733,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001393, CAB007766",Enhanced,NA,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,"Renal cancer:1.49e-4 (unfavourable), Ovarian cancer:3.06e-4 (favourable), Colorectal cancer:5.78e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 18.9",Expressed in all,NA,NA
FLT1,"FLT, VEGFR1",ENSG00000102755,Fms related tyrosine kinase 1,13,28300344-28495145,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA011740, HPA014290, CAB068189, CAB068190",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments,Renal cancer:2.19e-4 (unfavourable),Expressed in all,Tissue enriched,8,placenta: 622.5,thyroid gland: 81.9,Cell line enhanced,NA,BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
FMN2,NA,ENSG00000155816,Formin 2,1,240014348-240475189,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA050649,NA,NA,Approved,Plasma membrane<br>Actin filaments,NA,Group enriched,Group enriched,6,cerebral cortex: 53.8;parathyroid gland: 33.5,adrenal gland: 7.0,Cell line enhanced,NA,BJ: 60.2;fHDF/TERT166: 54.7;LHCN-M2: 63.8;U-138 MG: 48.9;WM-115: 77.8
FMNL2,"FHOD2, KIAA1902",ENSG00000157827,Formin like 2,2,152335237-152649834,Predicted intracellular proteins,Evidence at protein level,HPA005464,Enhanced,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Liver cancer:9.04e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 137.8,placenta: 82.9,Cell line enhanced,NA,BEWO: 184.8
FMNL3,"DKFZp762B245, MGC45819, WBP3",ENSG00000161791,Formin like 3,12,49636499-49708165,Predicted intracellular proteins,Evidence at protein level,"HPA002552, HPA023201",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:3.58e-5 (unfavourable),Expressed in all,Mixed,NA,NA,lymph node: 28.0,Mixed,NA,NA
FOXN3,"C14orf116, CHES1",ENSG00000053254,Forkhead box N3,14,89124871-89619149,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059209,Approved,NA,Approved,Nucleus<br>Plasma membrane,Renal cancer:9.58e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 111.0,Mixed,NA,NA
FRMD3,"EPB41L4O, MGC20553",ENSG00000172159,FERM domain containing 3,9,83242990-83538546,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017285,Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,"Thyroid cancer:1.79e-4 (favourable), Renal cancer:7.24e-4 (favourable)",Tissue enhanced,Tissue enhanced,NA,heart muscle: 56.5,skeletal muscle: 28.5,Cell line enhanced,NA,HEL: 21.0;RPMI-8226: 54.8;SCLC-21H: 32.9
FSCN1,"FLJ38511, p55, SNL",ENSG00000075618,Fascin actin-bundling protein 1,7,5592823-5606655,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000121, HPA005723, CAB035991, HPA050654",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 85.5,spleen: 54.6,Cell line enhanced,NA,BEWO: 579.4
FSD1L,"CCDC10, CSDUFD1, FSD1CL, FSD1NL",ENSG00000106701,Fibronectin type III and SPRY domain containing 1 like,9,105447796-105552433,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA035138,Approved,NA,Approved,Plasma membrane<br>Actin filaments,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 17.8,testis: 13.5,Mixed,NA,NA
FTCD,NA,ENSG00000160282,Formimidoyltransferase cyclodeaminase,21,46136262-46155567,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020073, HPA030928, HPA030929, HPA036114",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)",Tissue enriched,Group enriched,18,kidney: 100.2;liver: 184.7,testis: 7.7,Cell line enriched,24,Hep G2: 62.7
FUT2,"SE, Se2, SEC2, sej",ENSG00000176920,Fucosyltransferase 2,19,48695971-48705950,"Blood group antigen proteins, Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014402,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,Head and neck cancer:5.83e-4 (favourable),Mixed,Tissue enhanced,NA,duodenum: 51.4,stomach: 32.2,Cell line enriched,6,CAPAN-2: 68.6
FYN,"MGC45350, SLK, SYN",ENSG00000010810,"FYN proto-oncogene, Src family tyrosine kinase",6,111660332-111873452,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005034, CAB018387, HPA023887, HPA063770",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:1.43e-4 (unfavourable), Liver cancer:1.84e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 166.1,Cell line enhanced,NA,U-2197: 500.5
FZD1,DKFZp564G072,ENSG00000157240,Frizzled class receptor 1,7,91264364-91271326,"Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB013008,Approved,NA,Supported,Plasma membrane,Renal cancer:8.87e-7 (favourable),Expressed in all,Mixed,NA,NA,thyroid gland: 32.4,Mixed,NA,NA
FZD4,"CD344, EVR1",ENSG00000174804,Frizzled class receptor 4,11,86945679-86955391,"CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA042328, HPA074833",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:8.60e-5 (favourable),Expressed in all,Tissue enhanced,NA,adipose tissue: 127.3,seminal vesicle: 42.3,Cell line enhanced,NA,ASC diff: 43.7;Hep G2: 57.9;HUVEC TERT2: 78.0;TIME: 37.7
FZD6,Hfz6,ENSG00000164930,Frizzled class receptor 6,8,103298433-103332866,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA017991,Approved,NA,Approved,Plasma membrane,Pancreatic cancer:1.20e-6 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 45.5,Mixed,NA,NA
GAB2,KIAA0571,ENSG00000033327,GRB2 associated binding protein 2,11,78215297-78418348,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA000271, HPA001368, CAB022159",Enhanced,NA,Supported,Plasma membrane,Renal cancer:9.32e-5 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 35.5,Cell line enhanced,NA,SH-SY5Y: 66.1
GABRA5,NA,ENSG00000186297,Gamma-aminobutyric acid type A receptor alpha5 subunit,15,26866363-26949207,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA077031, CAB079022",NA,Supported,Supported,Plasma membrane,NA,Mixed,Tissue enriched,43,cerebral cortex: 81.6,esophagus: 1.8,Group enriched,10,A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
GADL1,NA,ENSG00000144644,Glutamate decarboxylase like 1,3,30726200-30894765,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039160, HPA040229",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Tissue enhanced,NA,skeletal muscle: 9.0,thyroid gland: 2.5,Cell line enhanced,NA,HAP1: 5.0
GAGE1,CT4.1,ENSG00000205777,G antigen 1,X,49589496-49608536,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,748,testis: 110.5,duodenum: 0.1,Group enriched,7,AN3-CA: 2552.7;K-562: 597.3
GAGE10,NA,ENSG00000215274,G antigen 10,X,49303669-49319844,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enhanced,NA,ovary: 1.1;testis: 1.4,fallopian tube: 0.7,Cell line enhanced,NA,AN3-CA: 2.3;WM-115: 1.0
GAGE12C,NA,ENSG00000237671,G antigen 12C,X,49532211-49539538,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,461,testis: 46.0,all non-specific tissues: 0.0,Group enriched,10,U-2 OS: 9.9;U-266/84: 25.6
GAGE12D,NA,ENSG00000227488,G antigen 12D,X,49541767-49549094,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,461,testis: 46.0,all non-specific tissues: 0.0,Group enriched,10,U-2 OS: 9.9;U-266/84: 25.6
GAGE12E,NA,ENSG00000216649,G antigen 12E,X,49551333-49558649,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,19,testis: 1.9,all non-specific tissues: 0.0,Cell line enhanced,NA,AN3-CA: 2.9;HeLa: 1.1;U-266/84: 1.4
GAGE12G,NA,ENSG00000215269,G antigen 12G,X,49570434-49577754,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,78,stomach: 7.8,all non-specific tissues: 0.0,Cell line enriched,7,AN3-CA: 898.2
GAGE12H,NA,ENSG00000224902,G antigen 12H,X,49579983-49587301,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,392,testis: 39.2,all non-specific tissues: 0.0,Group enriched,44,A-431: 47.0;U-266/84: 113.6
GAGE12J,GAGE11,ENSG00000224659,G antigen 12J,X,49322057-49329384,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,34,testis: 32.7,epididymis: 0.9,Group enriched,6,AN3-CA: 132.7;K-562: 134.5
GAGE13,GAGE12A,ENSG00000274274,G antigen 13,X,49331616-49338952,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,553,testis: 59.6,stomach: 0.1,Cell line enriched,6,AN3-CA: 685.8
GAGE2A,"CT4.2, GAGE2",ENSG00000189064,G antigen 2A,X,49589529-49596827,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,560,testis: 176.3,cerebral cortex: 0.3,Cell line enhanced,NA,Karpas-707: 62.0;T-47d: 279.0;WM-115: 324.4
GAGE2E,GAGE8,ENSG00000275113,G antigen 2E,X,49341192-49345922,Predicted intracellular proteins,Evidence at transcript level,HPA043232,Approved,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Not detected,Group enriched,60,stomach: 15.4;testis: 8.6,small intestine: 0.2,Group enriched,5,AN3-CA: 943.7;K-562: 455.5;T-47d: 231.8
GALE,SDR1E1,ENSG00000117308,UDP-galactose-4-epimerase,1,23795599-23800804,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007340,Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Thyroid cancer:2.68e-4 (favourable),Expressed in all,Expressed in all,NA,NA,stomach: 112.8,Expressed in all,NA,NA
GALNT10,GalNAc-T10,ENSG00000164574,Polypeptide N-acetylgalactosaminyltransferase 10,5,154190730-154420984,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA007525,Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,"Endometrial cancer:3.33e-6 (favourable), Ovarian cancer:5.69e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 81.7,Mixed,NA,NA
GAP43,"B-50, PP46",ENSG00000172020,Growth associated protein 43,3,115623324-115721490,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB004417, HPA013392, HPA015600",Enhanced,NA,Enhanced,Plasma membrane,NA,Tissue enriched,Tissue enriched,38,cerebral cortex: 345.9,appendix: 9.1,Group enriched,6,AF22: 34.3;NTERA-2: 74.0;SCLC-21H: 55.5;SH-SY5Y: 37.6;U-87 MG: 16.1
GAPDH,GAPD,ENSG00000111640,Glyceraldehyde-3-phosphate dehydrogenase,12,6533927-6538374,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005197, CAB016392, HPA040067, HPA061280",Supported,NA,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:6.25e-10 (unfavourable), Liver cancer:1.79e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skeletal muscle: 9869.6,Expressed in all,NA,NA
GAS2,NA,ENSG00000148935,Growth arrest specific 2,11,22625642-22813055,Predicted intracellular proteins,Evidence at protein level,HPA058904,Enhanced,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,Renal cancer:6.13e-4 (favourable),Tissue enhanced,Tissue enhanced,NA,liver: 20.4,kidney: 5.5,Group enriched,11,Hep G2: 29.5;Karpas-707: 61.6;SCLC-21H: 29.3;U-266/84: 21.3
GAS7,"KIAA0394, MGC1348",ENSG00000007237,Growth arrest specific 7,17,9910609-10198551,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA004838, HPA064678",Enhanced,NA,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,Urothelial cancer:6.89e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 154.7,"cervix, uterine: 47.6",Cell line enriched,11,WM-115: 526.3
GAS8,"DRC4, GAS11",ENSG00000141013,Growth arrest specific 8,16,90019629-90044975,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041311, HPA048238",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.09e-7 (favourable), Endometrial cancer:3.01e-4 (favourable), Pancreatic cancer:7.67e-4 (favourable)",Expressed in all,Mixed,NA,NA,fallopian tube: 30.0,Mixed,NA,NA
GBP4,Mpa2,ENSG00000162654,Guanylate binding protein 4,1,89181148-89198932,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030101, HPA062039",Enhanced,NA,Approved,Plasma membrane,"Renal cancer:1.30e-5 (unfavourable), Ovarian cancer:9.29e-5 (favourable)",Expressed in all,Mixed,NA,NA,lung: 46.9,Cell line enhanced,NA,CAPAN-2: 10.6;HEL: 11.8;REH: 10.2;RT4: 14.7;U-266/70: 12.3
GCA,GCL,ENSG00000115271,Grancalcin,2,162318840-162371595,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035033, HPA035034",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,bone marrow: 214.5,appendix: 88.0,Mixed,NA,NA
GCC1,"FLJ22035, GCC1P, GCC88, MGC20706",ENSG00000179562,GRIP and coiled-coil domain containing 1,7,127580618-127593611,Predicted intracellular proteins,Evidence at protein level,"HPA019369, HPA021323",Enhanced,NA,Enhanced,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 18.7,Expressed in all,NA,NA
GCLM,GLCLR,ENSG00000023909,Glutamate-cysteine ligase modifier subunit,1,93885205-93909456,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB009568, HPA023696, CAB040554",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:9.83e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 28.2,Expressed in all,NA,NA
GFOD1,"ADG-90, C6orf114, FLJ20330",ENSG00000145990,Glucose-fructose oxidoreductase domain containing 1,6,13357830-13487662,Predicted intracellular proteins,Evidence at protein level,HPA029096,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:2.29e-5 (unfavourable), Renal cancer:6.72e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 22.3,Cell line enhanced,NA,HEL: 28.5;HMC-1: 41.5
GFRA3,GFRa-3,ENSG00000146013,GDNF family receptor alpha 3,5,138252379-138274671,Predicted membrane proteins,Evidence at protein level,HPA020731,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,seminal vesicle: 8.1,Cell line enriched,21,SH-SY5Y: 33.1
GHR,GHBP,ENSG00000112964,Growth hormone receptor,5,42423777-42721878,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA045339, HPA057705",Enhanced,NA,Supported,Plasma membrane<br>Cytosol<br>Cytoplasmic bodies,Liver cancer:2.73e-6 (favourable),Mixed,Group enriched,6,adipose tissue: 91.4;liver: 110.5,prostate: 18.0,Group enriched,7,HSkMC: 15.4;T-47d: 52.5
GINM1,"C6orf72, dJ12G14.2",ENSG00000055211,Glycoprotein integral membrane 1,6,149566294-149591748,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017210, HPA041679",Approved,NA,Approved,Nucleoli fibrillar center<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 118.5,Expressed in all,NA,NA
GLIS2,NPHP7,ENSG00000126603,GLIS family zinc finger 2,16,4314761-4339597,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA056976,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:8.06e-6 (favourable), Endometrial cancer:1.59e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 9.7,Cell line enhanced,NA,U-2197: 35.6
GLO1,GLOD1,ENSG00000124767,Glyoxalase I,6,38675925-38703141,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB040541, CAB040542, HPA059791",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:5.21e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,prostate: 274.2,Cell line enriched,5,HMC-1: 2266.7
GLP2R,NA,ENSG00000065325,Glucagon like peptide 2 receptor,17,9822206-9892102,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022690, HPA049244",Supported,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,gallbladder: 19.3,duodenum: 10.1,Cell line enhanced,NA,A549: 15.1;HeLa: 54.7;SiHa: 8.7
GLRX,"GRX, GRX1",ENSG00000173221,Glutaredoxin,5,95751319-95823005,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB008634, HPA046431, CAB069419",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,kidney: 218.9,Expressed in all,NA,NA
GMIP,ARHGAP46,ENSG00000089639,GEM interacting protein,19,19629476-19643667,Predicted intracellular proteins,Evidence at protein level,"HPA042484, HPA045481",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:3.97e-5 (unfavourable), Stomach cancer:3.03e-4 (favourable), Urothelial cancer:5.15e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 46.7,Expressed in all,NA,NA
GNAI2,"GIP, GNAI2B",ENSG00000114353,G protein subunit alpha i2,3,50226292-50259355,Predicted intracellular proteins,Evidence at protein level,HPA007704,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Breast cancer:1.03e-4 (favourable),Expressed in all,Expressed in all,NA,NA,placenta: 330.6,Expressed in all,NA,NA
GNAQ,"G-ALPHA-q, GAQ",ENSG00000156052,G protein subunit alpha q,9,77716087-78031458,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB010036, HPA048886",Uncertain,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,Renal cancer:1.11e-7 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 84.9,Mixed,NA,NA
GNAS,"GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI",ENSG00000087460,GNAS complex locus,20,58839718-58911192,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB010337, HPA018122, HPA027478, HPA028386",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:3.49e-4 (unfavourable), Ovarian cancer:8.76e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 1473.9,Expressed in all,NA,NA
GNB1,NA,ENSG00000078369,G protein subunit beta 1,1,1785285-1891117,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA040736,Supported,NA,Approved,Golgi apparatus<br>Plasma membrane,Liver cancer:3.61e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 447.4,Expressed in all,NA,NA
GNB2,NA,ENSG00000172354,G protein subunit beta 2,7,100673531-100679174,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010032, HPA040736",Approved,NA,Enhanced,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,esophagus: 235.4,Expressed in all,NA,NA
GNB3,NA,ENSG00000111664,G protein subunit beta 3,12,6839954-6847393,"Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA040736,Approved,NA,Approved,Golgi apparatus<br>Plasma membrane,NA,Tissue enhanced,Mixed,NA,NA,smooth muscle: 3.8,Cell line enhanced,NA,NTERA-2: 12.8;U-698: 22.7
GNB4,NA,ENSG00000114450,G protein subunit beta 4,3,179396089-179451590,"Disease related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB018383, CAB018737, HPA040736",Enhanced,NA,Enhanced,Plasma membrane,Renal cancer:1.39e-6 (unfavourable),Expressed in all,Mixed,NA,NA,skin: 37.6,Mixed,NA,NA
GOLPH3L,GPP34R,ENSG00000143457,Golgi phosphoprotein 3 like,1,150646225-150697144,Predicted intracellular proteins,Evidence at protein level,HPA028558,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 51.4,Cell line enriched,6,U-698: 294.2
GPAT3,"AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324",ENSG00000138678,Glycerol-3-phosphate acyltransferase 3,4,83535914-83605875,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA029414, CAB033749",Approved,NA,Uncertain,Plasma membrane<br>Cytosol,"Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable)",Mixed,Tissue enhanced,NA,kidney: 89.9,duodenum: 40.7,Cell line enhanced,NA,CAPAN-2: 141.3;U-87 MG: 67.1;WM-115: 52.9
GPBP1,"DKFZp761C169, vasculin",ENSG00000062194,GC-rich promoter binding protein 1,5,57173948-57264679,Predicted intracellular proteins,Evidence at protein level,HPA037773,Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Urothelial cancer:4.15e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 138.7,Expressed in all,NA,NA
GPBP1L1,SP192,ENSG00000159592,GC-rich promoter binding protein 1 like 1,1,45627304-45688113,Predicted intracellular proteins,Evidence at protein level,HPA028593,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites,NA,Expressed in all,Expressed in all,NA,NA,testis: 107.1,Expressed in all,NA,NA
GPC1,glypican,ENSG00000063660,Glypican 1,2,240435671-240468078,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030571,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:5.78e-5 (unfavourable), Endometrial cancer:1.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,skin: 265.8,prostate: 67.5,Mixed,NA,NA
GPC3,"DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1",ENSG00000147257,Glypican 3,X,133535745-133985895,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006316,NA,NA,Approved,Plasma membrane,Stomach cancer:4.83e-4 (unfavourable),Expressed in all,Tissue enriched,6,placenta: 845.0,lung: 130.6,Group enriched,6,HAP1: 539.0;Hep G2: 1445.8
GPI,"AMF, NLK",ENSG00000105220,Glucose-6-phosphate isomerase,19,34359480-34402156,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB018655, HPA024305, CAB040563, HPA052171",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 314.1,Expressed in all,NA,NA
GPR1,NA,ENSG00000183671,G protein-coupled receptor 1,2,206175316-206218047,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010525,Uncertain,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,placenta: 5.6,esophagus: 2.7,Cell line enhanced,NA,HHSteC: 112.4;hTCEpi: 44.7
GPR156,"GABABL, PGR28",ENSG00000175697,G protein-coupled receptor 156,3,120164645-120285094,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA028642, HPA028644",Uncertain,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,testis: 5.0,fallopian tube: 1.8,Cell line enhanced,NA,SiHa: 3.8;U-2 OS: 2.0
GPR160,"GPCR1, GPCR150",ENSG00000173890,G protein-coupled receptor 160,3,170037929-170085403,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA006970,Approved,NA,Supported,Plasma membrane,"Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 435.1,small intestine: 109.0,Cell line enhanced,NA,THP-1: 130.2;U-266/70: 156.8
GPR173,SREB3,ENSG00000184194,G protein-coupled receptor 173,X,53049091-53080615,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA003905,NA,NA,Approved,Plasma membrane<br>Cytosol,"Endometrial cancer:2.88e-6 (unfavourable), Pancreatic cancer:2.33e-5 (favourable), Renal cancer:2.47e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 19.1,ovary: 8.9,Cell line enhanced,NA,HAP1: 10.2
GPR27,SREB1,ENSG00000170837,G protein-coupled receptor 27,3,71754050-71756496,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA029395,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Cytosol,"Ovarian cancer:1.21e-6 (favourable), Breast cancer:5.63e-4 (favourable)",Mixed,Tissue enhanced,NA,parathyroid gland: 46.5,cerebral cortex: 24.9,Cell line enhanced,NA,EFO-21: 17.2;HL-60: 14.7;NTERA-2: 30.5;SH-SY5Y: 12.3
GPR50,"H9, Mel1c",ENSG00000102195,G protein-coupled receptor 50,X,151176653-151181465,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA049862, HPA054678",Supported,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Mixed,Not detected,NA,NA,placenta: 0.6,Cell line enriched,7,HEK93: 4.8
GPR63,"PSP24(beta), PSP24B",ENSG00000112218,G protein-coupled receptor 63,6,96794126-96837463,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA039103,Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,testis: 4.6,Cell line enhanced,NA,HHSteC: 11.3;Karpas-707: 15.0
GPRC5A,"PEIG-1, RAI3, RAIG1, TIG1",ENSG00000013588,G protein-coupled receptor class C group 5 member A,12,12890782-12917937,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007928, HPA046526",Enhanced,NA,Enhanced,Vesicles<br>Plasma membrane,"Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable)",Mixed,Tissue enhanced,NA,lung: 302.0,thyroid gland: 91.3,Cell line enhanced,NA,CAPAN-2: 1167.5;SiHa: 520.3
GPRIN1,"GRIN1, KIAA1893",ENSG00000169258,G protein regulated inducer of neurite outgrowth 1,5,176595802-176610133,Predicted intracellular proteins,Evidence at protein level,"HPA036478, HPA070892",Enhanced,NA,Supported,Vesicles<br>Plasma membrane,"Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable)",Expressed in all,Tissue enriched,7,cerebral cortex: 27.8,duodenum: 3.8,Cell line enhanced,NA,HDLM-2: 52.6;SCLC-21H: 70.4
GRAMD1A,"FLJ90346, KIAA1533",ENSG00000089351,GRAM domain containing 1A,19,34994784-35026471,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008852, HPA012570",Approved,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:7.95e-12 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 36.5,Expressed in all,NA,NA
GRAMD1C,DKFZp434C0328,ENSG00000178075,GRAM domain containing 1C,3,113828182-113947174,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012316,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,Renal cancer:4.22e-15 (favourable),Mixed,Mixed,NA,NA,testis: 28.1,Cell line enhanced,NA,CAPAN-2: 11.4;HUVEC TERT2: 8.3
GRB7,NA,ENSG00000141738,Growth factor receptor bound protein 7,17,39737927-39747291,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB005226, HPA057084, CAB073538",Approved,NA,Supported,Plasma membrane,"Endometrial cancer:6.60e-7 (unfavourable), Renal cancer:8.23e-5 (favourable), Ovarian cancer:3.10e-4 (unfavourable), Pancreatic cancer:6.90e-4 (unfavourable)",Mixed,Mixed,NA,NA,fallopian tube: 35.1,Cell line enriched,8,SK-BR-3: 272.9
GRIK5,"GluK5, GRIK2, KA2",ENSG00000105737,Glutamate ionotropic receptor kainate type subunit 5,19,41998321-42069498,Predicted membrane proteins,Evidence at protein level,HPA074001,NA,NA,Supported,Nucleus<br>Plasma membrane,"Pancreatic cancer:7.23e-4 (favourable), Renal cancer:9.32e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 30.8;parathyroid gland: 22.1,testis: 18.8,Cell line enhanced,NA,HEL: 12.3;NTERA-2: 13.1;REH: 34.1;SCLC-21H: 12.1;SH-SY5Y: 24.1
GRK3,"ADRBK2, BARK2",ENSG00000100077,G protein-coupled receptor kinase 3,22,25564849-25729294,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000804,Uncertain,NA,Approved,Nucleus<br>Plasma membrane,Urothelial cancer:1.29e-4 (favourable),Expressed in all,Mixed,NA,NA,adipose tissue: 32.7,Cell line enhanced,NA,HDLM-2: 40.3;SH-SY5Y: 39.9
GRK5,GPRK5,ENSG00000198873,G protein-coupled receptor kinase 5,10,119207589-119459742,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB025579, HPA046838",Approved,NA,Supported,Nuclear membrane<br>Nuclear speckles<br>Plasma membrane,Renal cancer:2.38e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 78.5,Cell line enhanced,NA,BJ hTERT+: 68.5;HUVEC TERT2: 55.7
GRPR,"BB2, BB2R",ENSG00000126010,Gastrin releasing peptide receptor,X,16123556-16153021,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA069604,NA,NA,Enhanced,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,pancreas: 4.2,"breast,epididymis: 2.6",Group enriched,10,PC-3: 30.0;T-47d: 37.9;U-138 MG: 53.4
GSDMA,"FLJ39120, GSDM, GSDM1",ENSG00000167914,Gasdermin A,17,39953263-39977766,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA023313, HPA064826",Enhanced,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enriched,7,skin: 58.4,epididymis: 7.9,Cell line enhanced,NA,HBEC3-KT: 2.9;hTCEpi: 2.0;hTERT-HME1: 4.1
GSR,NA,ENSG00000104687,Glutathione-disulfide reductase,8,30678061-30727926,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001538, CAB008632",Approved,NA,Supported,Plasma membrane<br>Cytosol,"Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 79.3,Expressed in all,NA,NA
GTSE1,"B99, GTSE-1",ENSG00000075218,G2 and S-phase expressed 1,22,46296741-46330810,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029457, HPA060544",Uncertain,NA,Approved,Plasma membrane<br>Centrosome,"Liver cancer:1.90e-10 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:4.66e-4 (unfavourable)",Mixed,Tissue enhanced,NA,testis: 12.5,lymph node: 10.6,Mixed,NA,NA
GUCA1A,"C6orf131, COD3, CORD14, dJ139D8.6, GCAP, GCAP1, GUCA, GUCA1",ENSG00000048545,Guanylate cyclase activator 1A,6,42155406-42180056,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA005561,Supported,Approved,Uncertain,Plasma membrane,NA,Tissue enriched,Tissue enriched,19,testis: 30.0,cerebral cortex: 1.5,Group enriched,8,NTERA-2: 3.6;SH-SY5Y: 4.7
HAPLN3,"EXLD1, HsT19883",ENSG00000140511,Hyaluronan and proteoglycan link protein 3,15,88877288-88895626,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA039237,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:4.18e-13 (unfavourable),Expressed in all,Tissue enhanced,NA,appendix: 13.8;lymph node: 10.8,spleen: 4.0,Cell line enhanced,NA,HDLM-2: 29.8;U-2 OS: 31.7
HARBI1,"C11orf77, FLJ32675",ENSG00000180423,Harbinger transposase derived 1,11,46602861-46617909,Predicted intracellular proteins,Evidence at protein level,"HPA038671, HPA045457",Uncertain,NA,Enhanced,Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,testis: 21.7,parathyroid gland: 5.4,Expressed in all,NA,NA
HAS1,HAS,ENSG00000105509,Hyaluronan synthase 1,19,51713112-51723994,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA067602,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,adipose tissue: 27.0,appendix: 8.9,Group enriched,12,hTEC/SVTERT24-B: 27.0;U-87 MG: 110.6
HAUS4,"C14orf94, FLJ20424",ENSG00000092036,HAUS augmin like complex subunit 4,14,22946228-22957161,Predicted intracellular proteins,Evidence at protein level,"HPA029803, HPA071195",Approved,NA,Supported,Plasma membrane<br>Focal adhesion sites,Urothelial cancer:2.24e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,ovary: 61.9,Expressed in all,NA,NA
HAUS7,"UCHL5IP, UIP1",ENSG00000213397,HAUS augmin like complex subunit 7,X,153447666-153495516,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003614,NA,NA,Approved,Nucleoli<br>Plasma membrane<br>Centrosome<br>Cytosol,"Renal cancer:3.94e-4 (unfavourable), Cervical cancer:6.12e-4 (favourable)",Expressed in all,Mixed,NA,NA,skin: 64.1,Expressed in all,NA,NA
HCFC2,HCF-2,ENSG00000111727,Host cell factor C2,12,104064457-104106524,Predicted intracellular proteins,Evidence at protein level,HPA006227,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 17.1,Mixed,NA,NA
HCK,JTK9,ENSG00000101336,"HCK proto-oncogene, Src family tyrosine kinase",20,32052188-32101856,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005195, HPA063768",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:1.66e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,appendix: 149.6;spleen: 113.2,lung: 74.1,Group enriched,8,THP-1: 48.4;U-937: 161.1
HCLS1,"CTTNL, HS1",ENSG00000180353,Hematopoietic cell-specific Lyn substrate 1,3,121631399-121660927,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019143,Supported,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,spleen: 271.3,Cell line enhanced,NA,HMC-1: 319.6;U-266/70: 275.0;U-698: 256.8
HDAC8,"HDACL1, MRXS6, RPD3, WTS",ENSG00000147099,Histone deacetylase 8,X,72329516-72573103,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA048560,Supported,NA,Supported,Nucleus<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 27.1,Expressed in all,NA,NA
HELZ,"DHRC, HUMORF5, KIAA0054",ENSG00000198265,Helicase with zinc finger,17,67070438-67245989,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028276,Approved,NA,Approved,Nucleoli<br>Plasma membrane<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 32.9,Expressed in all,NA,NA
HENMT1,"C1orf59, FLJ30525, HEN1",ENSG00000162639,HEN1 methyltransferase homolog 1,1,108648290-108661526,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028464, HPA028497",Uncertain,NA,Approved,Plasma membrane<br>Focal adhesion sites,"Renal cancer:2.48e-5 (unfavourable), Cervical cancer:2.56e-4 (favourable), Colorectal cancer:9.95e-4 (favourable)",Expressed in all,Tissue enriched,9,testis: 128.3,lymph node: 14.8,Cell line enhanced,NA,U-937: 75.4
HERPUD1,"HERP, KIAA0025, Mif1, SUP",ENSG00000051108,Homocysteine inducible ER protein with ubiquitin like domain 1,16,56932048-56944863,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB037041, CAB037104, HPA040754, HPA041219",Approved,NA,Uncertain,Plasma membrane<br>Cytosol,Renal cancer:1.41e-9 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 358.8,Expressed in all,NA,NA
HIF1A,"bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8",ENSG00000100644,Hypoxia inducible factor 1 alpha subunit,14,61695513-61748259,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA000907, HPA001275, CAB017442",Supported,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,bone marrow: 292.4,Mixed,NA,NA
HIF3A,"bHLHe17, IPAS, MOP7, PASD7",ENSG00000124440,Hypoxia inducible factor 3 alpha subunit,19,46297046-46343433,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA041141,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Endometrial cancer:6.90e-9 (unfavourable),Mixed,Tissue enhanced,NA,placenta: 39.8,spleen: 19.9,Cell line enhanced,NA,ASC TERT1: 6.5;HHSteC: 16.0;HSkMC: 12.2;TIME: 13.1
HINT1,"HINT, PKCI-1, PRKCNH1",ENSG00000169567,Histidine triad nucleotide binding protein 1,5,131159027-131171735,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044577,Approved,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 173.9,Expressed in all,NA,NA
HIP1R,"FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655",ENSG00000130787,Huntingtin interacting protein 1 related,12,122834453-122862960,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB017187, HPA038135, HPA038136",Enhanced,NA,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:6.50e-7 (favourable), Urothelial cancer:7.26e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 53.1,Mixed,NA,NA
HLA-A,NA,ENSG00000206503,"Major histocompatibility complex, class I, A",6,29941260-29945884,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB078470,NA,NA,Supported,Golgi apparatus<br>Plasma membrane,"Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)",Expressed in all,Mixed,NA,NA,gallbladder: 340.9,Cell line enhanced,NA,A-431: 1127.9
HMGCS1,HMGCS,ENSG00000112972,3-hydroxy-3-methylglutaryl-CoA synthase 1,5,43289395-43313512,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB032907, HPA036913, HPA036914",Approved,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:3.87e-6 (favourable),Expressed in all,Expressed in all,NA,NA,liver: 208.7,Expressed in all,NA,NA
HMOX1,"bK286B10, HO-1",ENSG00000100292,Heme oxygenase 1,22,35380361-35394214,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000635, CAB017444",Enhanced,NA,Uncertain,Golgi apparatus<br>Plasma membrane,Liver cancer:1.59e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 428.5,Cell line enhanced,NA,BEWO: 701.9;U-138 MG: 414.7;U-87 MG: 399.9
HN1L,"C16orf34, FLJ13092, KIAA1426, L11",ENSG00000206053,Hematological and neurological expressed 1 like,16,1678256-1702280,Predicted intracellular proteins,Evidence at protein level,"HPA041888, HPA041908",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,"Endometrial cancer:7.85e-4 (favourable), Liver cancer:9.14e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 101.8,Expressed in all,NA,NA
HOMER3,HOMER-3,ENSG00000051128,Homer scaffolding protein 3,19,18929201-18941261,Predicted intracellular proteins,Evidence at protein level,"CAB032656, HPA040999, CAB079015",Enhanced,Supported,Supported,Plasma membrane<br>Cytosol<br>Cytoplasmic bodies,"Colorectal cancer:4.24e-5 (unfavourable), Liver cancer:4.93e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 150.5,Mixed,NA,NA
HPS3,"BLOC2S1, SUTAL",ENSG00000163755,"HPS3, biogenesis of lysosomal organelles complex 2 subunit 1",3,149129584-149173732,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046281, HPA052778",Approved,NA,Approved,Golgi apparatus<br>Plasma membrane,"Renal cancer:4.38e-4 (unfavourable), Liver cancer:6.04e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 22.0,Expressed in all,NA,NA
HRH1,NA,ENSG00000196639,Histamine receptor H1,3,11137093-11263557,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029740,Uncertain,NA,Supported,Plasma membrane<br>Cytosol,Pancreatic cancer:1.27e-5 (unfavourable),Mixed,Mixed,NA,NA,cerebral cortex: 12.4,Mixed,NA,NA
HSH2D,"ALX, FLJ14886, HSH2",ENSG00000196684,Hematopoietic SH2 domain containing,19,16134028-16158575,Predicted intracellular proteins,Evidence at protein level,HPA036616,NA,NA,Approved,Plasma membrane<br>Focal adhesion sites<br>Cytosol,"Renal cancer:6.49e-6 (unfavourable), Colorectal cancer:9.46e-6 (unfavourable), Urothelial cancer:3.47e-5 (favourable)",Mixed,Mixed,NA,NA,tonsil: 32.7,Cell line enhanced,NA,HMC-1: 49.9;NB-4: 88.6;RPMI-8226: 43.5;U-937: 106.3
HSPB1,"CMT2F, Hs.76067, Hsp25, HSP27, HSP28",ENSG00000106211,Heat shock protein family B (small) member 1,7,76302544-76304295,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000497, CAB004439, CAB047330, CAB047331, CAB047332",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Colorectal cancer:9.94e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,esophagus: 1615.3,Expressed in all,NA,NA
HSPG2,"perlecan, PRCAN, SJS1",ENSG00000142798,Heparan sulfate proteoglycan 2,1,21822245-21937297,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB009820, HPA018892, CAB020718",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Urothelial cancer:2.82e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 135.6,Cell line enhanced,NA,EFO-21: 257.0;HUVEC TERT2: 511.1;TIME: 402.8
HTR1B,"5-HT1B, 5-HT1DB, HTR1D2, S12",ENSG00000135312,5-hydroxytryptamine receptor 1B,6,77461753-77463773,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA028808,Enhanced,NA,Uncertain,Plasma membrane,NA,Mixed,Tissue enhanced,NA,placenta: 10.0;stomach: 4.7,cerebral cortex: 2.4,Group enriched,16,HUVEC TERT2: 68.8;TIME: 29.9
HTR7,5-HT7,ENSG00000148680,5-hydroxytryptamine receptor 7,10,90740823-90857698,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB022708, HPA073617",Approved,NA,Supported,Nuclear speckles<br>Plasma membrane<br>Cytosol,NA,Group enriched,Group enriched,8,parathyroid gland: 44.8;testis: 16.1,urinary bladder: 3.8,Cell line enhanced,NA,hTERT-HME1: 25.8;LHCN-M2: 11.4;WM-115: 12.9
HTRA1,"ARMD7, HtrA, IGFBP5-protease, PRSS11",ENSG00000166033,HtrA serine peptidase 1,10,122461525-122514908,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA036655,Enhanced,NA,Supported,Plasma membrane,"Renal cancer:7.90e-7 (unfavourable), Urothelial cancer:5.62e-6 (unfavourable), Glioma:8.66e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,ovary: 503.4,Cell line enhanced,NA,ASC diff: 1649.0;HSkMC: 1139.5;LHCN-M2: 1027.1;U-87 MG: 974.2
HUNK,NA,ENSG00000142149,Hormonally up-regulated Neu-associated kinase,21,31873315-32044633,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027295, HPA027372",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:7.48e-5 (favourable),Mixed,Mixed,NA,NA,placenta: 6.8,Cell line enhanced,NA,AF22: 13.3;BEWO: 15.9;RH-30: 17.7;SCLC-21H: 17.5;SiHa: 14.1
HYDIN,"CILD5, DKFZp434D0513, KIAA1864, PPP1R31",ENSG00000157423,"HYDIN, axonemal central pair apparatus protein",16,70807378-71230722,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA067155, HPA074129",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Tissue enhanced,NA,fallopian tube: 9.1;parathyroid gland: 5.4;testis: 6.4,epididymis: 2.6,Cell line enhanced,NA,RPTEC TERT1: 2.1;SiHa: 6.4
HYI,HT036,ENSG00000178922,Hydroxypyruvate isomerase (putative),1,43451003-43453989,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040092,Uncertain,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Urothelial cancer:2.72e-5 (favourable), Renal cancer:2.75e-5 (unfavourable), Colorectal cancer:4.96e-4 (unfavourable), Liver cancer:5.55e-4 (unfavourable), Breast cancer:9.18e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 81.4,Mixed,NA,NA
HYLS1,FLJ32915,ENSG00000198331,"HYLS1, centriolar and ciliogenesis associated",11,125883614-125900648,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA041210,Uncertain,NA,Supported,Plasma membrane<br>Cytosol,Liver cancer:1.92e-4 (unfavourable),Expressed in all,Tissue enriched,6,testis: 37.5,smooth muscle: 6.6,Mixed,NA,NA
ICAM1,"BB2, CD54",ENSG00000090339,Intercellular adhesion molecule 1,19,10270835-10286615,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA002126, CAB002142, HPA004877",Enhanced,NA,Uncertain,Plasma membrane<br>Cytosol,"Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lung: 255.9,Cell line enhanced,NA,Karpas-707: 302.5
ICOSLG,"B7-H2, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653",ENSG00000160223,Inducible T-cell costimulator ligand,21,44222991-44240966,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB026037, HPA029179",Uncertain,NA,Supported,Plasma membrane<br>Cytoplasmic bodies,NA,Not detected,Mixed,NA,NA,bone marrow: 10.3,Mixed,NA,NA
IFFO2,NA,ENSG00000169991,Intermediate filament family orphan 2,1,18904281-18956686,Predicted intracellular proteins,Evidence at transcript level,"HPA015987, HPA064603",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,skin: 72.4,Cell line enhanced,NA,HDLM-2: 129.1
IFIT5,RI58,ENSG00000152778,Interferon induced protein with tetratricopeptide repeats 5,10,89414586-89421001,Predicted intracellular proteins,Evidence at protein level,"HPA037957, HPA062180",Uncertain,NA,Supported,Vesicles<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 36.2,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+: 66.6;BJ hTERT+ SV40 Large T+ RasG12V: 82.7
IFRD1,"PC4, TIS7",ENSG00000006652,Interferon related developmental regulator 1,7,112422968-112481017,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA024122,Approved,NA,Approved,Plasma membrane<br>Cytosol,Ovarian cancer:5.45e-4 (favourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 129.9,Expressed in all,NA,NA
IGFL2,UNQ645,ENSG00000204866,IGF like family member 2,19,46143106-46161299,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA059137,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enriched,6,skin: 35.5,parathyroid gland: 6.1,Cell line enriched,33,CACO-2: 68.3
IKZF3,"Aiolos, ZNFN1A3",ENSG00000161405,IKAROS family zinc finger 3,17,39757715-39864188,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB017105, HPA024377",Enhanced,NA,Uncertain,Plasma membrane<br>Cytosol,"Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable)",Mixed,Tissue enhanced,NA,lymph node: 44.7;spleen: 31.7;tonsil: 39.2,appendix: 25.5,Cell line enhanced,NA,Daudi: 50.3;Karpas-707: 25.9;U-266/70: 32.8;U-266/84: 35.9;U-698: 78.2
IKZF5,"FLJ22973, Pegasus, ZNFN1A5",ENSG00000095574,IKAROS family zinc finger 5,10,122990806-123008817,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA015297, HPA051574",NA,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,bone marrow: 21.3,Expressed in all,NA,NA
IL12RB1,"CD212, IL12RB",ENSG00000096996,Interleukin 12 receptor subunit beta 1,19,18058995-18098944,"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA074414,NA,NA,Approved,Plasma membrane,"Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable)",Mixed,Tissue enhanced,NA,lymph node: 25.9,spleen: 20.6,Cell line enhanced,NA,Daudi: 13.1;HDLM-2: 28.9;Karpas-707: 36.8
IL12RB2,NA,ENSG00000081985,Interleukin 12 receptor subunit beta 2,1,67307364-67396900,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA024168,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,placenta: 11.8,cerebral cortex: 4.4,Cell line enhanced,NA,HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6
IL13,"ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600",ENSG00000169194,Interleukin 13,5,132656263-132661110,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA042421,NA,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,10,testis: 19.9,gallbladder: 2.0,Cell line enriched,226,HDLM-2: 38.1
IL15RA,"CD215, IL-15RA",ENSG00000134470,Interleukin 15 receptor subunit alpha,10,5943639-5978187,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB026215,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,"Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,gallbladder: 33.5,Cell line enhanced,NA,CAPAN-2: 59.4;HDLM-2: 70.4
IL16,"FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16",ENSG00000172349,Interleukin 16,15,81159575-81314058,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005247, HPA018467",Enhanced,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,lymph node: 154.4;tonsil: 124.0,spleen: 118.2,Cell line enhanced,NA,HEL: 26.3;HMC-1: 44.5;RPMI-8226: 34.9;U-266/70: 45.9;U-937: 27.4
IL21R,CD360,ENSG00000103522,Interleukin 21 receptor,16,27402162-27452042,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA042296,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,Head and neck cancer:7.29e-4 (favourable),Mixed,Tissue enhanced,NA,appendix: 15.8;lymph node: 28.8;tonsil: 17.4,spleen: 7.5,Cell line enhanced,NA,HDLM-2: 102.6;Karpas-707: 35.4;RH-30: 36.0;RPMI-8226: 42.7
IL6ST,"CD130, GP130",ENSG00000134352,Interleukin 6 signal transducer,5,55935095-55994993,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA010558, CAB025784",Uncertain,NA,Supported,Golgi apparatus<br>Plasma membrane,Renal cancer:5.05e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 329.8,Expressed in all,NA,NA
IL7R,CD127,ENSG00000168685,Interleukin 7 receptor,5,35852695-35879603,"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB010215,Approved,NA,Approved,Plasma membrane<br>Microtubule organizing center,NA,Expressed in all,Tissue enhanced,NA,appendix: 182.9;lymph node: 158.5,tonsil: 112.9,Cell line enhanced,NA,fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0
INTS12,"INT12, PHF22, SBBI22",ENSG00000138785,Integrator complex subunit 12,4,105682627-105895986,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA035772, HPA041814",Approved,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,Liver cancer:2.67e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 33.5,Expressed in all,NA,NA
IPCEF1,"KIAA0403, PIP3-E",ENSG00000074706,Interaction protein for cytohesin exchange factors 1,6,154154496-154356792,Predicted intracellular proteins,Evidence at protein level,"HPA028708, HPA028710",Approved,NA,Approved,Nucleoli<br>Nuclear speckles<br>Plasma membrane<br>Cytoplasmic bodies,NA,Mixed,Tissue enhanced,NA,thyroid gland: 66.3,cerebral cortex: 24.9,Cell line enhanced,NA,HMC-1: 17.9;THP-1: 7.2;U-937: 8.8
IQGAP2,NA,ENSG00000145703,IQ motif containing GTPase activating protein 2,5,76403249-76708132,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004241, HPA037403, HPA037404",Uncertain,NA,Approved,Vesicles<br>Plasma membrane,"Renal cancer:9.44e-12 (favourable), Liver cancer:5.65e-4 (favourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 126.8,testis: 92.1,Cell line enhanced,NA,CACO-2: 61.1;HMC-1: 186.1;RPMI-8226: 56.3
IRS1,HIRS-1,ENSG00000169047,Insulin receptor substrate 1,2,226731317-226799759,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005261, HPA046433",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 33.9,Mixed,NA,NA
ISLR,HsT17563,ENSG00000129009,Immunoglobulin superfamily containing leucine rich repeat,15,74173671-74176872,Predicted secreted proteins,Evidence at protein level,"HPA040326, HPA050811",Approved,NA,Approved,Golgi apparatus<br>Plasma membrane,Renal cancer:4.89e-8 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 198.8,Cell line enhanced,NA,ASC diff: 85.5;ASC TERT1: 46.5;fHDF/TERT166: 227.9;RPMI-8226: 63.5
ITGA3,"CD49c, GAP-B3, MSK18, VCA-2, VLA3a",ENSG00000005884,Integrin subunit alpha 3,17,50055968-50090481,"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008572, CAB018594",Enhanced,NA,Supported,Plasma membrane,"Pancreatic cancer:5.95e-5 (unfavourable), Head and neck cancer:1.36e-4 (unfavourable), Cervical cancer:6.75e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,lung: 99.0,Cell line enhanced,NA,U-87 MG: 917.0
ITGA4,CD49D,ENSG00000115232,Integrin subunit alpha 4,2,181457202-181536187,"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA074961,NA,NA,Approved,Plasma membrane,"Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable)",Mixed,Tissue enhanced,NA,spleen: 67.6,appendix: 49.6,Cell line enhanced,NA,fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
ITGA7,NA,ENSG00000135424,Integrin subunit alpha 7,12,55684568-55716043,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008427,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Urothelial cancer:9.59e-5 (unfavourable), Pancreatic cancer:1.75e-4 (favourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 154.7,smooth muscle: 136.8,Cell line enhanced,NA,ASC diff: 46.9;hTEC/SVTERT24-B: 66.1;SK-MEL-30: 38.6;U-87 MG: 57.9
ITGB1,"CD29, FNRB, GPIIA, MDF2, MSK12",ENSG00000150093,Integrin subunit beta 1,10,32900319-33005792,"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB003434, HPA059297, HPA069003",Enhanced,NA,Supported,Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites,"Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 1069.5,Expressed in all,NA,NA
ITGB2,"CD18, LFA-1, MAC-1, MFI7",ENSG00000160255,Integrin subunit beta 2,21,44885953-44931989,"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA008877, HPA016894",Enhanced,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,appendix: 239.2,Cell line enhanced,NA,EFO-21: 120.5;THP-1: 518.6;U-937: 447.2
ITGB5,NA,ENSG00000082781,Integrin subunit beta 5,3,124761948-124901418,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA001820, CAB022050",Approved,NA,Approved,Plasma membrane<br>Mitochondria,Pancreatic cancer:1.40e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 117.5,Cell line enhanced,NA,WM-115: 463.5
ITGB7,NA,ENSG00000139626,Integrin subunit beta 7,12,53191318-53207307,"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA042277,NA,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,spleen: 32.5,Group enriched,97,Karpas-707: 3399.5;RPMI-8226: 2658.1
ITGB8,NA,ENSG00000105855,Integrin subunit beta 8,7,20330702-20415754,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,"HPA027796, HPA027797",Supported,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.77e-4 (favourable),Mixed,Mixed,NA,NA,cerebral cortex: 30.8,Cell line enhanced,NA,AF22: 45.0;EFO-21: 54.7;RPTEC TERT1: 68.8;WM-115: 130.0
ITSN1,"ITSN, MGC134948, MGC134949, SH3D1A, SH3P17",ENSG00000205726,Intersectin 1,21,33642400-33899861,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018007,Approved,NA,Supported,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 61.5,Expressed in all,NA,NA
ITSN2,"KIAA1256, PRO2015, SH3D1B, SH3P18, SWA, SWAP",ENSG00000198399,Intersectin 2,2,24202864-24360714,Predicted intracellular proteins,Evidence at protein level,HPA036475,Approved,NA,Approved,Vesicles<br>Plasma membrane,Head and neck cancer:2.98e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 84.8,Expressed in all,NA,NA
IYD,"C6orf71, DEHAL1, dJ422F24.1",ENSG00000009765,Iodotyrosine deiodinase,6,150368892-150405969,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA059627,Enhanced,NA,Supported,Plasma membrane,Liver cancer:6.22e-4 (favourable),Tissue enriched,Tissue enriched,28,thyroid gland: 794.5,kidney: 27.9,Cell line enhanced,NA,CACO-2: 1.1;SK-BR-3: 2.4
JAG1,"AGS, AHD, AWS, CD339, HJ1, JAGL1",ENSG00000101384,Jagged 1,20,10637684-10674107,"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB010343, HPA021555",Enhanced,NA,Supported,Golgi apparatus<br>Plasma membrane,Pancreatic cancer:4.10e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 97.1,Cell line enhanced,NA,HBEC3-KT: 150.8;hTERT-HME1: 96.7;U-251 MG: 151.3
JAK2,JTK10,ENSG00000096968,Janus kinase 2,9,4984390-5128183,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013089, HPA040820, HPA043870",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites,NA,Expressed in all,Mixed,NA,NA,appendix: 28.1,Group enriched,6,ASC diff: 34.8;HDLM-2: 71.3;HEL: 140.3
JAM2,"C21orf43, CD322, JAM-B, JAMB, VE-JAM",ENSG00000154721,Junctional adhesion molecule 2,21,25639272-25717562,"CD markers, Predicted membrane proteins",Evidence at protein level,"HPA028789, HPA077346",NA,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Tissue enriched,Tissue enhanced,NA,placenta: 92.9,cerebral cortex: 34.2,Cell line enhanced,NA,AF22: 25.3;BJ hTERT+: 13.4;HDLM-2: 15.5;U-138 MG: 18.0;U-87 MG: 13.2
JMJD4,FLJ12517,ENSG00000081692,Jumonji domain containing 4,1,227730425-227735411,Predicted intracellular proteins,Evidence at protein level,"HPA027260, HPA052861",Uncertain,NA,Approved,Vesicles<br>Plasma membrane,Renal cancer:3.16e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 12.9,Expressed in all,NA,NA
KANK1,"ANKRD15, KANK, KIAA0172",ENSG00000107104,KN motif and ankyrin repeat domains 1,9,470291-746106,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005539, HPA056090",Approved,NA,Supported,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,smooth muscle: 55.8,Mixed,NA,NA
KANK3,"ANKRD47, FLJ46061",ENSG00000186994,KN motif and ankyrin repeat domains 3,19,8322584-8343262,Predicted intracellular proteins,Evidence at protein level,HPA051153,Approved,NA,Approved,Plasma membrane,Renal cancer:1.69e-5 (favourable),Expressed in all,Tissue enhanced,NA,spleen: 24.9,adipose tissue: 22.2,Cell line enhanced,NA,HUVEC TERT2: 6.8;TIME: 12.1;U-266/70: 4.5
KANSL2,"C12orf41, FLJ20436, NSL2",ENSG00000139620,KAT8 regulatory NSL complex subunit 2,12,48653401-48682238,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038497, HPA038498",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:4.32e-4 (favourable), Liver cancer:4.98e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 31.9,Expressed in all,NA,NA
KATNB1,NA,ENSG00000140854,Katanin regulatory subunit B1,16,57735730-57757250,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA041165, HPA041839",Enhanced,NA,Supported,Plasma membrane<br>Microtubules<br>Cytosol,"Liver cancer:3.93e-4 (unfavourable), Pancreatic cancer:8.44e-4 (favourable), Endometrial cancer:9.24e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 45.3,Expressed in all,NA,NA
KCNB2,Kv2.2,ENSG00000182674,Potassium voltage-gated channel subfamily B member 2,8,72537391-72938349,"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA065970,NA,NA,Approved,Nucleoli<br>Plasma membrane<br>Midbody,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 3.2;spleen: 3.3,"fallopian tube,testis: 0.7",Cell line enhanced,NA,HaCaT: 1.3;HDLM-2: 1.4;HEK93: 3.2;SCLC-21H: 3.4
KCNC2,Kv3.2,ENSG00000166006,Potassium voltage-gated channel subfamily C member 2,12,75040077-75209868,"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA019664, CAB022571",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,NA,Group enriched,Tissue enriched,11,cerebral cortex: 46.4,prostate: 4.3,Not detected,NA,NA
KCNH8,"elk3, Kv12.1",ENSG00000183960,Potassium voltage-gated channel subfamily H member 8,3,19148454-19535646,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA016586,NA,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 4.8,adrenal gland: 2.3,Cell line enhanced,NA,HAP1: 1.0;SH-SY5Y: 4.4
KCNJ15,"IRKK, Kir1.3, Kir4.2",ENSG00000157551,Potassium voltage-gated channel subfamily J member 15,21,38157034-38307357,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA016702,Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable)",Tissue enhanced,Tissue enhanced,NA,kidney: 261.3;thyroid gland: 216.3,lung: 63.4,Cell line enhanced,NA,ASC TERT1: 48.4;HBEC3-KT: 50.0;RPTEC TERT1: 51.4;RT4: 65.6
KCNK6,"K2p6.1, TWIK-2",ENSG00000099337,Potassium two pore domain channel subfamily K member 6,19,38319844-38332076,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"CAB022637, HPA040184",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,"Endometrial cancer:1.45e-6 (favourable), Renal cancer:1.04e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,endometrium: 22.6,Cell line enhanced,NA,HEL: 33.9;HMC-1: 35.7
KCNK7,K2p7.1,ENSG00000173338,Potassium two pore domain channel subfamily K member 7,11,65592855-65595996,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels",Evidence at transcript level,HPA077577,NA,NA,Approved,Plasma membrane,NA,Tissue enhanced,Tissue enriched,7,skin: 53.2,esophagus: 7.9,Cell line enhanced,NA,SCLC-21H: 8.4
KCNS3,Kv9.3,ENSG00000170745,Potassium voltage-gated channel modifier subfamily S member 3,2,17877847-18361616,"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA014864,Approved,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.53e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,lung: 35.5,skeletal muscle: 29.6,Cell line enhanced,NA,RH-30: 66.9;RT4: 38.5
KCNU1,"KCa5.1, Kcnma3, KCNMC1, Slo3",ENSG00000215262,Potassium calcium-activated channel subfamily U member 1,8,36784324-36936128,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA063317,NA,NA,Uncertain,Plasma membrane,NA,Tissue enhanced,Tissue enriched,28,testis: 13.5,"adipose tissue,epididymis: 0.4",Cell line enriched,6,HDLM-2: 7.3
KDR,"CD309, FLK1, VEGFR, VEGFR2",ENSG00000128052,Kinase insert domain receptor,4,55078477-55125589,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB004028,Enhanced,NA,Supported,Plasma membrane,Renal cancer:7.26e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,placenta: 119.2,thyroid gland: 54.7,Group enriched,9,HUVEC TERT2: 178.6;TIME: 148.0
KIAA0556,JBTS26,ENSG00000047578,KIAA0556,16,27550133-27780369,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA035089, HPA035090",Enhanced,NA,Approved,Nuclear speckles<br>Plasma membrane,Head and neck cancer:3.00e-4 (favourable),Expressed in all,Tissue enhanced,NA,fallopian tube: 47.6,thyroid gland: 26.7,Expressed in all,NA,NA
KIAA1324,"EIG121, maba1",ENSG00000116299,KIAA1324,1,109113679-109206781,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA029869, HPA070749",Enhanced,NA,Supported,Plasma membrane,"Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable)",Mixed,Mixed,NA,NA,"cervix, uterine: 129.0",Cell line enhanced,NA,MCF7: 21.5;SCLC-21H: 20.3;SK-BR-3: 15.8;T-47d: 68.2;U-87 MG: 13.3
KIAA1524,CIP2A,ENSG00000163507,KIAA1524,3,108549869-108589644,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039570,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Endometrial cancer:6.24e-5 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:9.18e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 10.3,Mixed,NA,NA
KIAA1958,FLJ39294,ENSG00000165185,KIAA1958,9,112486847-112669397,Predicted intracellular proteins,Evidence at protein level,HPA020625,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,ovary: 12.2,Mixed,NA,NA
KIF17,"KIAA1405, KIF17B, KIF3X, KLP-2, OSM-3",ENSG00000117245,Kinesin family member 17,1,20664014-20718017,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA032085,Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enriched,6,testis: 23.7,cerebral cortex: 3.8,Cell line enhanced,NA,hTERT-HME1: 3.0;U-2 OS: 2.4
KIF19,"FLJ37300, KIF19A",ENSG00000196169,Kinesin family member 19,17,74326210-74355820,Predicted intracellular proteins,Evidence at protein level,"HPA043638, HPA073303",Enhanced,NA,Approved,Plasma membrane<br>Actin filaments<br>Centrosome,NA,Mixed,Tissue enhanced,NA,fallopian tube: 19.0;spleen: 6.6,duodenum: 2.9,Cell line enriched,13,SCLC-21H: 5.1
KIF21A,"FEOM1, FLJ20052",ENSG00000139116,Kinesin family member 21A,12,39293228-39443390,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB022079, HPA058432",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:8.07e-8 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 75.0,fallopian tube: 54.6,Cell line enhanced,NA,SH-SY5Y: 199.8
KIF26A,"DKFZP434N178, KIAA1236",ENSG00000066735,Kinesin family member 26A,14,104138723-104180894,Predicted intracellular proteins,Evidence at protein level,"HPA046882, HPA060346",Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:7.78e-4 (unfavourable),Group enriched,Mixed,NA,NA,adipose tissue: 5.0,Cell line enhanced,NA,HeLa: 18.9;MCF7: 18.8;NTERA-2: 20.8;REH: 17.1;SCLC-21H: 22.6;SH-SY5Y: 41.6
KIF26B,FLJ10157,ENSG00000162849,Kinesin family member 26B,1,245154985-245709431,Predicted intracellular proteins,Evidence at protein level,"HPA027709, HPA028478, HPA028561, HPA028562",Enhanced,NA,Approved,Plasma membrane<br>Microtubules,Ovarian cancer:1.24e-4 (unfavourable),Mixed,Mixed,NA,NA,cerebral cortex: 2.3,Cell line enhanced,NA,HSkMC: 8.1;REH: 19.4;SH-SY5Y: 11.8;U-937: 8.1
KISS1R,"AXOR12, GPR54, HOT7T175",ENSG00000116014,KISS1 receptor,19,917287-921015,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071913,NA,NA,Supported,Vesicles<br>Plasma membrane,Renal cancer:3.33e-6 (unfavourable),Tissue enhanced,Tissue enriched,5,cerebral cortex: 1.2,"appendix,lymph node,placenta: 0.2",Cell line enhanced,NA,K-562: 14.0;RPMI-8226: 26.1;SCLC-21H: 8.9;SH-SY5Y: 21.3
KIT,"C-Kit, CD117, PBT, SCFR",ENSG00000157404,KIT proto-oncogene receptor tyrosine kinase,4,54657918-54740715,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB003288, HPA004471, CAB068253, CAB072867, HPA073252",Enhanced,Supported,Supported,Plasma membrane,Renal cancer:5.63e-4 (favourable),Mixed,Tissue enhanced,NA,breast: 133.6,thyroid gland: 78.7,Group enriched,14,HEL: 220.1;HMC-1: 434.1
KLC1,"hKLC1B, hKLC1G, hKLC1J, hKLC1N, hKLC1P, hKLC1R, hKLC1S, KLC, KNS2, KNS2A",ENSG00000126214,Kinesin light chain 1,14,103561896-103714249,Predicted intracellular proteins,Evidence at protein level,"CAB009798, HPA044617, HPA052450",Uncertain,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:6.75e-4 (favourable), Renal cancer:7.17e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 467.9,Expressed in all,NA,NA
KLC2,FLJ12387,ENSG00000174996,Kinesin light chain 2,11,66257294-66267860,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA040416, HPA040434",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Head and neck cancer:3.16e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 63.8,Expressed in all,NA,NA
KLF9,BTEB1,ENSG00000119138,Kruppel like factor 9,9,70384597-70414624,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029308,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:6.59e-6 (favourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 88.4,Cell line enhanced,NA,ASC TERT1: 58.2;HHSteC: 90.2
KLHL41,"KBTBD10, Krp1, SARCOSIN",ENSG00000239474,Kelch like family member 41,2,169509702-169526262,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021165, HPA021753, HPA021760",Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,NA,Group enriched,Tissue enriched,22,skeletal muscle: 1750.6,esophagus: 79.6,Group enriched,8,HSkMC: 15.5;LHCN-M2: 29.3;RH-30: 53.9
KLK10,"NES1, PRSSL1",ENSG00000129451,Kallikrein related peptidase 10,19,51012739-51020175,"Cancer-related genes, Enzymes, Predicted secreted proteins",Evidence at protein level,HPA017195,NA,NA,Uncertain,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)",Mixed,Tissue enhanced,NA,esophagus: 138.2;skin: 52.7,tonsil: 45.8,Group enriched,5,CAPAN-2: 200.9;HaCaT: 307.2
KLK7,"PRSS6, SCCE",ENSG00000169035,Kallikrein related peptidase 7,19,50976482-50984099,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA018994, CAB026342, HPA062126",Enhanced,NA,Supported,Nuclear membrane<br>Plasma membrane,"Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable)",Tissue enhanced,Group enriched,5,esophagus: 68.7;skin: 219.6,fallopian tube: 27.9,Group enriched,6,CAPAN-2: 7.1;HaCaT: 28.1
KLRC1,"CD159a, NKG2, NKG2-A, NKG2-B",ENSG00000134545,Killer cell lectin like receptor C1,12,10442264-10454685,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058052,NA,NA,Approved,Plasma membrane,NA,Mixed,Mixed,NA,NA,spleen: 9.9,Cell line enhanced,NA,HeLa: 3.5
KLRC2,"CD159c, NKG2-C",ENSG00000205809,Killer cell lectin like receptor C2,12,10426854-10442300,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058052,NA,NA,Approved,Plasma membrane,NA,Tissue enriched,Group enriched,6,cerebral cortex: 17.3;spleen: 8.1,stomach: 2.1,Cell line enhanced,NA,HEL: 5.2;HeLa: 11.9;HSkMC: 3.0;U-87 MG: 2.8
KLRK1,"CD314, D12S2489E, KLR, NKG2-D, NKG2D",ENSG00000213809,Killer cell lectin like receptor K1,12,10372353-10391874,"Cancer-related genes, CD markers, Predicted membrane proteins",Evidence at protein level,"CAB021896, HPA068877",Enhanced,NA,Supported,Plasma membrane,NA,Not detected,Tissue enhanced,NA,lymph node: 35.1;spleen: 52.8,tonsil: 16.2,Cell line enriched,8,U-698: 41.6
KMT2D,"ALR, CAGL114, MLL2, MLL4, TNRC21",ENSG00000167548,Lysine methyltransferase 2D,12,49018975-49059774,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA035977,Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 46.6,Expressed in all,NA,NA
KNTC1,"KIAA0166, ROD",ENSG00000184445,Kinetochore associated 1,12,122527246-122626396,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA025241,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:7.89e-8 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Head and neck cancer:8.69e-4 (favourable)",Expressed in all,Tissue enhanced,NA,testis: 43.4,bone marrow: 27.1,Expressed in all,NA,NA
KPTN,2E4,ENSG00000118162,"Kaptin, actin binding protein",19,47475144-47484268,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA041710, HPA041796",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Liver cancer:7.91e-6 (unfavourable), Renal cancer:7.82e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 7.9,Expressed in all,NA,NA
KRT75,K6HF,ENSG00000170454,Keratin 75,12,52424070-52434525,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019367, HPA076201",Supported,NA,Approved,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Not detected,NA,NA,breast: 0.9,Group enriched,8,PC-3: 33.1;U-2 OS: 48.9
KRT77,KRT1B,ENSG00000189182,Keratin 77,12,52689626-52703463,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA045934,Enhanced,NA,Approved,Nuclear membrane<br>Plasma membrane,NA,Mixed,Tissue enriched,12,skin: 308.7,breast: 26.2,Cell line enriched,33,HaCaT: 3.2
KRTAP25-1,KAP25.1,ENSG00000232263,Keratin associated protein 25-1,21,30289145-30289514,Predicted intracellular proteins,No evidence,HPA031438,Uncertain,NA,Approved,Nuclear membrane<br>Plasma membrane<br>Cytosol,NA,Not detected,Not detected,NA,NA,all non-specific tissues: 0.0,Not detected,NA,NA
L1CAM,"CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1",ENSG00000198910,L1 cell adhesion molecule,X,153861514-153909223,"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB010896,Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,"Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,NA,adrenal gland: 36.0;cerebral cortex: 66.9,seminal vesicle: 12.8,Cell line enhanced,NA,BJ hTERT+: 303.8;BJ hTERT+ SV40 Large T+ RasG12V: 195.5;HeLa: 182.1
LACE1,AFG1,ENSG00000135537,Lactation elevated 1,6,108294894-108526796,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA030154, HPA030155, HPA030659",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,testis: 17.3,parathyroid gland: 8.5,Mixed,NA,NA
LAIR1,CD305,ENSG00000167613,Leukocyte associated immunoglobulin like receptor 1,19,54351384-54370558,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011155,Enhanced,NA,Supported,Plasma membrane,Renal cancer:5.01e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,lymph node: 7.1,appendix: 4.2,Cell line enhanced,NA,HMC-1: 6.6;Karpas-707: 14.1;THP-1: 15.4
LAMA4,LAMA3,ENSG00000112769,Laminin subunit alpha 4,6,112108760-112254939,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA015693, CAB078156",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:2.00e-4 (unfavourable),Expressed in all,Mixed,NA,NA,smooth muscle: 146.3,Cell line enhanced,NA,ASC diff: 216.1;ASC TERT1: 333.0;HSkMC: 271.2;HUVEC TERT2: 340.0;TIME: 306.5
LAMC1,LAMB2,ENSG00000135862,Laminin subunit gamma 1,1,183023460-183145592,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001908, HPA001909, CAB004486, CAB078163",Enhanced,NA,Approved,Endoplasmic reticulum<br>Plasma membrane,Urothelial cancer:8.85e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,placenta: 332.9,smooth muscle: 147.5,Cell line enhanced,NA,ASC diff: 1091.5;HSkMC: 716.3
LAMTOR1,"C11orf59, FLJ20625, p18, p27RF-Rho, Pdro, Ragulator1",ENSG00000149357,"Late endosomal/lysosomal adaptor, MAPK and MTOR activator 1",11,72085895-72103387,Predicted intracellular proteins,Evidence at protein level,HPA002997,Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane,Liver cancer:3.63e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 143.2,Expressed in all,NA,NA
LAPTM4A,"HUMORF13, KIAA0108, LAPTM4, MBNT, Mtrp",ENSG00000068697,Lysosomal protein transmembrane 4 alpha,2,20032650-20052028,Predicted membrane proteins,Evidence at protein level,"HPA031402, HPA031404, HPA068554",Approved,NA,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,Pancreatic cancer:4.37e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 635.0,Expressed in all,NA,NA
LASP1,"Lasp-1, MLN50",ENSG00000002834,LIM and SH3 protein 1,17,38869859-38921770,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA012072, CAB022049",Enhanced,NA,Supported,Plasma membrane<br>Focal adhesion sites<br>Cytosol,"Liver cancer:2.41e-4 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,small intestine: 181.3,Expressed in all,NA,NA
LAT,LAT1,ENSG00000213658,Linker for activation of T-cells,16,28984826-28990783,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB002223, HPA011157, CAB012978",Enhanced,NA,Supported,Golgi apparatus<br>Plasma membrane,NA,Not detected,Tissue enhanced,NA,lymph node: 75.3,appendix: 31.8,Group enriched,8,HEL: 173.8;HMC-1: 690.0;MOLT-4: 227.5
LAX1,"FLJ20340, LAX",ENSG00000122188,Lymphocyte transmembrane adaptor 1,1,203765176-203776233,Predicted membrane proteins,Evidence at protein level,"HPA002461, HPA003887, CAB025358",Enhanced,NA,Enhanced,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,tonsil: 15.3,lymph node: 10.3,Cell line enhanced,NA,Karpas-707: 14.1;U-266/70: 18.2;U-266/84: 40.4;U-698: 14.6
LCP1,"CP64, L-PLASTIN, LC64P, PLS2",ENSG00000136167,Lymphocyte cytosolic protein 1,13,46125920-46211871,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019493, CAB020673",Enhanced,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,lymph node: 614.4,Cell line enhanced,NA,HDLM-2: 728.6;HL-60: 666.2;HMC-1: 741.0;U-698: 751.3
LCTL,"FLJ33279, KLG, KLPH",ENSG00000188501,Lactase like,15,66547179-66565979,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,HPA071640,NA,NA,Approved,Endoplasmic reticulum<br>Plasma membrane,NA,Group enriched,Mixed,NA,NA,cerebral cortex: 1.0,Cell line enhanced,NA,EFO-21: 5.3;NTERA-2: 5.2;U-2 OS: 15.2;U-251 MG: 5.3
LDB2,"CLIM1, LDB1",ENSG00000169744,LIM domain binding 2,4,16501541-16898809,Predicted intracellular proteins,Evidence at protein level,"CAB017544, HPA068634",Supported,NA,Supported,Nucleus<br>Nucleoli<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,endometrium: 108.3,Cell line enhanced,NA,HAP1: 35.5;HUVEC TERT2: 54.3;U-138 MG: 25.3
LENG1,NA,ENSG00000105617,Leukocyte receptor cluster member 1,19,54155161-54159882,Predicted intracellular proteins,Evidence at protein level,HPA043541,Uncertain,NA,Approved,Nucleus<br>Plasma membrane,"Renal cancer:3.72e-4 (favourable), Pancreatic cancer:8.12e-4 (favourable)",Expressed in all,Tissue enhanced,NA,spleen: 1.8,endometrium: 1.0,Cell line enhanced,NA,AF22: 3.2;HaCaT: 4.1;HDLM-2: 2.8;LHCN-M2: 2.3;U-87 MG: 3.1
LGALS3,"GALIG, LGALS2, MAC-2",ENSG00000131981,Galectin 3,14,55124110-55145413,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003162, CAB005191",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,colon: 871.1,Cell line enhanced,NA,SK-MEL-30: 1368.8
LGALS4,GAL4,ENSG00000171747,Galectin 4,19,38801671-38813364,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025653, HPA031184, HPA031185, HPA031186",Enhanced,NA,Uncertain,Plasma membrane,"Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)",Group enriched,Tissue enhanced,NA,colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5,gallbladder: 138.8,Cell line enhanced,NA,CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0
LGALS8,PCTA-1,ENSG00000116977,Galectin 8,1,236518000-236552981,Predicted intracellular proteins,Evidence at protein level,"HPA012734, HPA030491",Approved,NA,Approved,Plasma membrane,"Renal cancer:4.93e-7 (unfavourable), Lung cancer:9.40e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 101.6,Mixed,NA,NA
LGR6,FLJ14471,ENSG00000133067,Leucine rich repeat containing G protein-coupled receptor 6,1,202193901-202319781,"G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008556,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Glioma:2.00e-4 (unfavourable),Tissue enhanced,Tissue enhanced,NA,fallopian tube: 14.3,gallbladder: 9.6,Cell line enhanced,NA,A549: 15.6;CAPAN-2: 13.4;HaCaT: 7.3
LHX6,LHX6.1,ENSG00000106852,LIM homeobox 6,9,122202577-122229626,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA047854, HPA058319",Approved,NA,Uncertain,Nucleoli fibrillar center<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,cerebral cortex: 8.1,Cell line enhanced,NA,CACO-2: 10.9;NB-4: 11.6;PC-3: 11.4;U-87 MG: 9.4
LIMA1,EPLIN,ENSG00000050405,LIM domain and actin binding 1,12,50175788-50283546,Predicted intracellular proteins,Evidence at protein level,"HPA023871, HPA052645",Enhanced,NA,Enhanced,Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol,"Head and neck cancer:1.76e-6 (unfavourable), Renal cancer:2.79e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,rectum: 143.8,Expressed in all,NA,NA
LINGO1,"FLJ14594, LERN1, LRRN6A",ENSG00000169783,Leucine rich repeat and Ig domain containing 1,15,77613027-77820900,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA074653,Enhanced,NA,Approved,Plasma membrane,Renal cancer:3.23e-7 (unfavourable),Expressed in all,Tissue enriched,13,cerebral cortex: 130.8,placenta: 9.8,Cell line enhanced,NA,AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK93: 19.6;NTERA-2: 56.8
LMTK2,"AATYK2, BREK, cprk, KIAA1079, KPI-2, KPI2, LMR2, PPP1R100",ENSG00000164715,Lemur tyrosine kinase 2,7,98106885-98209633,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA010657, HPA041836",Uncertain,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol,"Renal cancer:1.12e-7 (favourable), Ovarian cancer:8.03e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 27.9,Expressed in all,NA,NA
LNX2,"MGC46315, PDZRN1",ENSG00000139517,Ligand of numb-protein X 2,13,27545911-27620404,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040698,Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:7.09e-13 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 23.3,Expressed in all,NA,NA
LONRF1,"FLJ23749, RNF191",ENSG00000154359,LON peptidase N-terminal domain and ring finger 1,8,12721894-12756073,Predicted intracellular proteins,Evidence at protein level,"HPA023584, HPA024814",Uncertain,NA,Approved,Plasma membrane<br>Centrosome<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,skin: 30.8,Cell line enhanced,NA,Karpas-707: 47.8;SCLC-21H: 45.0
LONRF3,"FLJ22612, RNF127",ENSG00000175556,LON peptidase N-terminal domain and ring finger 3,X,118974614-119018355,Predicted intracellular proteins,Evidence at protein level,"HPA050422, HPA061162",Uncertain,NA,Approved,Nucleus<br>Plasma membrane,Pancreatic cancer:4.32e-4 (unfavourable),Mixed,Mixed,NA,NA,thyroid gland: 12.6,Cell line enhanced,NA,K-562: 11.8;PC-3: 13.4;SiHa: 14.0
LPAR1,"edg-2, EDG2, Gpcr26, GPR26, LPA1, Mrec1.3, rec.1.3, vzg-1",ENSG00000198121,Lysophosphatidic acid receptor 1,9,110873263-111038458,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA050667,NA,NA,Approved,Nuclear speckles<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,"cervix, uterine: 91.5",Cell line enhanced,NA,ASC diff: 399.3;ASC TERT1: 236.2;BJ hTERT+: 345.8
LPAR3,"Edg-7, EDG7, HOFNH30, LP-A3, LPA3, RP4-678I3",ENSG00000171517,Lysophosphatidic acid receptor 3,1,84811602-84893213,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA013421,NA,NA,Supported,Plasma membrane,Ovarian cancer:4.31e-5 (favourable),Tissue enhanced,Tissue enhanced,NA,fallopian tube: 66.9,prostate: 23.3,Cell line enhanced,NA,HAP1: 22.1;HBEC3-KT: 18.9;hTCEpi: 20.1;NTERA-2: 23.5;PC-3: 24.6;SK-MEL-30: 19.8
LPAR4,"GPR23, LPA4, P2RY9, P2Y5-LIKE, P2Y9",ENSG00000147145,Lysophosphatidic acid receptor 4,X,78747709-78757094,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA046563, HPA054951, HPA055571",Uncertain,NA,Supported,Nuclear bodies<br>Vesicles<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,ovary: 4.5,cerebral cortex: 2.2,Cell line enhanced,NA,AF22: 9.2;NTERA-2: 15.2;RH-30: 6.2
LPAR6,"P2RY5, P2Y5",ENSG00000139679,Lysophosphatidic acid receptor 6,13,48389567-48444704,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA028934, HPA076273",Approved,NA,Supported,Vesicles<br>Plasma membrane,"Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,placenta: 100.9,Cell line enhanced,NA,AF22: 19.1;HUVEC TERT2: 26.4
LPIN2,KIAA0249,ENSG00000101577,Lipin 2,18,2916994-3013315,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB015223, HPA017857, HPA030550",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,Head and neck cancer:8.01e-4 (favourable),Expressed in all,Mixed,NA,NA,liver: 87.3,Mixed,NA,NA
LRCH2,KIAA1495,ENSG00000130224,Leucine rich repeats and calponin homology domain containing 2,X,115110616-115234072,Predicted intracellular proteins,Evidence at protein level,HPA003233,Approved,NA,Approved,Nucleoli<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,prostate: 13.8,Cell line enhanced,NA,HAP1: 22.2
LRP12,"FLJ12929, ST7",ENSG00000147650,LDL receptor related protein 12,8,104489231-104589024,Predicted membrane proteins,Evidence at protein level,HPA017245,Uncertain,NA,Approved,Nucleoli fibrillar center<br>Plasma membrane<br>Mitochondria,Endometrial cancer:2.67e-4 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 27.8,Mixed,NA,NA
LRRC15,LIB,ENSG00000172061,Leucine rich repeat containing 15,3,194355247-194369743,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA035503,Uncertain,NA,Approved,Vesicles<br>Plasma membrane,NA,Tissue enhanced,Mixed,NA,NA,"cervix, uterine: 4.7",Group enriched,8,fHDF/TERT166: 93.4;U-138 MG: 22.2;U-87 MG: 61.4
LRRC17,"H_RG318M05.3, P37NB",ENSG00000128606,Leucine rich repeat containing 17,7,102912991-102944949,Predicted secreted proteins,Evidence at protein level,HPA030139,NA,NA,Approved,Nucleoplasm<br>Nuclear speckles<br>Plasma membrane,"Renal cancer:4.12e-6 (unfavourable), Urothelial cancer:6.30e-4 (unfavourable)",Mixed,Tissue enhanced,NA,ovary: 99.1,gallbladder: 46.8,Group enriched,5,LHCN-M2: 1100.6;RH-30: 248.7
LRRC26,bA350O14.10,ENSG00000184709,Leucine rich repeat containing 26,9,137168758-137170051,Predicted membrane proteins,Evidence at protein level,HPA056312,Approved,NA,Supported,Nucleoli fibrillar center<br>Plasma membrane,"Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable)",Tissue enriched,Group enriched,7,colon: 10.2;prostate: 35.5;salivary gland: 26.5,small intestine: 3.5,Group enriched,10,REH: 18.9;RPMI-8226: 87.4
LRRC45,MGC20806,ENSG00000169683,Leucine rich repeat containing 45,17,82023302-82031151,Predicted intracellular proteins,Evidence at protein level,"HPA023372, HPA023382, HPA024768",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol,Renal cancer:1.54e-4 (unfavourable),Expressed in all,Mixed,NA,NA,fallopian tube: 8.3,Mixed,NA,NA
LRRC69,NA,ENSG00000214954,Leucine rich repeat containing 69,8,91101832-91219236,Predicted intracellular proteins,Evidence at transcript level,HPA046337,Uncertain,NA,Approved,Plasma membrane,NA,Mixed,Tissue enhanced,NA,testis: 5.2,skin: 2.0,Cell line enhanced,NA,HEK93: 5.7;U-266/70: 12.2;U-266/84: 6.6
LRRFIP2,HUFI-2,ENSG00000093167,LRR binding FLII interacting protein 2,3,37052656-37183689,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA035956, HPA042023",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments,Cervical cancer:6.31e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 130.8,Expressed in all,NA,NA
LRRIQ3,"LRRC44, MGC22773",ENSG00000162620,Leucine rich repeats and IQ motif containing 3,1,74026015-74198187,Predicted intracellular proteins,Evidence at protein level,HPA030799,Approved,NA,Supported,Plasma membrane,NA,Not detected,Tissue enriched,11,testis: 37.1,fallopian tube: 3.5,Mixed,NA,NA
LSP1,WP34,ENSG00000130592,Lymphocyte-specific protein 1,11,1852970-1892267,Predicted intracellular proteins,Evidence at protein level,"CAB017781, HPA019693, HPA071843",Enhanced,NA,Supported,Plasma membrane,"Endometrial cancer:2.54e-4 (favourable), Cervical cancer:3.56e-4 (favourable), Glioma:9.00e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 279.2,Cell line enhanced,NA,Daudi: 229.4;HDLM-2: 1037.0;RPMI-8226: 322.1
LSR,"ILDR3, LISCH7",ENSG00000105699,Lipolysis stimulated lipoprotein receptor,19,35248330-35267964,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA007270,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:8.09e-4 (favourable),Expressed in all,Expressed in all,NA,NA,stomach: 128.7,Cell line enhanced,NA,A-431: 435.7
LTB4R2,"BLT2, BLTR2, JULF2, NOP9",ENSG00000213906,Leukotriene B4 receptor 2,14,24305734-24312053,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022689, HPA029680, HPA072921",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,skin: 40.5,spleen: 10.3,Cell line enhanced,NA,HaCaT: 24.8
LUZP2,NA,ENSG00000187398,Leucine zipper protein 2,11,24496970-25082631,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039007, HPA046161",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Group enriched,Group enriched,5,adrenal gland: 8.6;cerebral cortex: 33.0,prostate: 3.8,Group enriched,6,HaCaT: 9.2;HAP1: 5.4
LY6K,"CT97, FLJ35226, HSJ001348",ENSG00000160886,Lymphocyte antigen 6 family member K,8,142700111-142705127,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA017770, CAB075742, CAB075743",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane,Lung cancer:9.17e-5 (unfavourable),Mixed,Tissue enhanced,NA,testis: 29.0,adipose tissue: 5.9,Cell line enhanced,NA,A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2
LYN,JTK8,ENSG00000254087,"LYN proto-oncogene, Src family tyrosine kinase",8,55879813-56014168,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001231, CAB004492",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane,Renal cancer:3.43e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,spleen: 161.1,appendix: 130.6,Cell line enhanced,NA,HEL: 215.0;HMC-1: 205.1
LYST,"CHS, CHS1",ENSG00000143669,Lysosomal trafficking regulator,1,235661041-235883640,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA053366, HPA055725",NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Microtubule organizing center,Renal cancer:5.27e-5 (unfavourable),Expressed in all,Mixed,NA,NA,bone marrow: 20.9,Cell line enhanced,NA,HDLM-2: 28.5;THP-1: 66.9;U-937: 29.8
LZTS1,FEZ1,ENSG00000061337,Leucine zipper tumor suppressor 1,8,20246165-20303963,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006294, HPA022046",Approved,NA,Approved,Nucleoli<br>Plasma membrane,"Renal cancer:9.28e-6 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable)",Expressed in all,Tissue enriched,10,parathyroid gland: 125.4,testis: 12.4,Cell line enhanced,NA,SK-MEL-30: 59.3;WM-115: 50.1
LZTS2,"KIAA1813, LAPSER1",ENSG00000107816,Leucine zipper tumor suppressor 2,10,100996618-101007836,Predicted intracellular proteins,Evidence at protein level,HPA044956,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:3.39e-4 (unfavourable), Colorectal cancer:8.23e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"endometrium,seminal vesicle: 57.9",Expressed in all,NA,NA
MADD,"DENN, KIAA0358, RAB3GEP",ENSG00000110514,MAP kinase activating death domain,11,47269161-47330031,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038568,Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 103.9,Expressed in all,NA,NA
MAMDC2,MGC21981,ENSG00000165072,MAM domain containing 2,9,70043581-70226970,Predicted secreted proteins,Evidence at protein level,"HPA021814, HPA022249",Uncertain,NA,Approved,Nuclear speckles<br>Plasma membrane,Thyroid cancer:7.78e-4 (unfavourable),Mixed,Mixed,NA,NA,endometrium: 60.6,Cell line enhanced,NA,ASC diff: 35.3;HHSteC: 44.9;LHCN-M2: 57.7;TIME: 54.7
MAP2K1,"MAPKK1, MEK1, PRKMK1",ENSG00000169032,Mitogen-activated protein kinase kinase 1,15,66386817-66492312,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB003834, HPA026430",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,Glioma:2.68e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 144.4,Expressed in all,NA,NA
MAP2K7,"Jnkk2, MKK7, PRKMK7",ENSG00000076984,Mitogen-activated protein kinase kinase 7,19,7903843-7914478,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001633, CAB004262, HPA064711",Supported,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Head and neck cancer:8.54e-5 (favourable), Urothelial cancer:1.56e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,spleen: 19.1,Expressed in all,NA,NA
MAP3K21,"KIAA1804, MLK4",ENSG00000143674,Mitogen-activated protein kinase kinase kinase 21,1,233327768-233385148,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007636,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,testis: 17.8,Cell line enhanced,NA,HEK93: 25.2
MAP3K6,"ASK2, MAPKKK6, MEKK6",ENSG00000142733,Mitogen-activated protein kinase kinase kinase 6,1,27355184-27366892,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051192,Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Actin filaments<br>Cytosol,"Glioma:1.73e-4 (unfavourable), Head and neck cancer:7.26e-4 (favourable), Liver cancer:8.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,skin: 114.9,esophagus: 41.2,Mixed,NA,NA
MAP4,NA,ENSG00000047849,Microtubule associated protein 4,3,47850690-48089272,"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038149, HPA038150",Enhanced,NA,Supported,Plasma membrane<br>Microtubules<br>Cytosol,Liver cancer:1.82e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 241.9,Expressed in all,NA,NA
MAP4K1,HPK1,ENSG00000104814,Mitogen-activated protein kinase kinase kinase kinase 1,19,38587641-38618882,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007419, CAB007754",Enhanced,NA,Uncertain,Nucleoplasm<br>Plasma membrane,"Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable)",Expressed in all,Tissue enhanced,NA,lymph node: 37.3;spleen: 23.8;tonsil: 27.2,appendix: 19.2,Cell line enhanced,NA,Daudi: 34.0;HDLM-2: 44.1;Karpas-707: 34.0;U-266/70: 28.3;U-266/84: 27.3;U-698: 41.0
MAP4K5,"GCKR, KHS, KHS1",ENSG00000012983,Mitogen-activated protein kinase kinase kinase kinase 5,14,50418501-50561126,Predicted intracellular proteins,Evidence at protein level,HPA036696,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,endometrium: 55.2,Expressed in all,NA,NA
MAP6,"FLJ41346, KIAA1878, MAP6-N, STOP",ENSG00000171533,Microtubule associated protein 6,11,75586918-75669120,Predicted intracellular proteins,Evidence at protein level,"CAB015442, CAB022600, HPA039061, HPA039062",Enhanced,NA,Uncertain,Plasma membrane,"Pancreatic cancer:3.41e-4 (favourable), Prostate cancer:9.15e-4 (favourable)",Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 68.1;fallopian tube: 65.5,parathyroid gland: 52.6,Group enriched,6,AF22: 37.3;CACO-2: 31.4;HDLM-2: 19.9;SCLC-21H: 73.4;SH-SY5Y: 33.6
MAPK8IP1,"IB1, JIP-1, JIP1, PRKM8IP",ENSG00000121653,Mitogen-activated protein kinase 8 interacting protein 1,11,45885651-45906465,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA058921, HPA070332",NA,NA,Enhanced,Plasma membrane,Renal cancer:1.23e-11 (favourable),Expressed in all,Tissue enriched,5,cerebral cortex: 177.1,parathyroid gland: 33.1,Cell line enhanced,NA,SCLC-21H: 89.8
MAPT,"DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau",ENSG00000186868,Microtubule associated protein tau,17,45894382-46028334,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000151, HPA048895, HPA069524, HPA069570, CAB072344",Enhanced,NA,Supported,Nuclear speckles<br>Plasma membrane,NA,Group enriched,Tissue enriched,8,cerebral cortex: 116.2,skeletal muscle: 13.7,Cell line enhanced,NA,HDLM-2: 37.4;SCLC-21H: 16.3;T-47d: 16.5
MARCH10,"FLJ35757, MARCH-X, RNF190",ENSG00000173838,Membrane associated ring-CH-type finger 10,17,62701314-62808344,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023322,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,7,testis: 144.4,fallopian tube: 20.5,Cell line enhanced,NA,BEWO: 2.5;EFO-21: 4.5;SCLC-21H: 9.7
MARCH7,"AXOT, MARCH-VII, RNF177",ENSG00000136536,Membrane associated ring-CH-type finger 7,2,159712457-159771027,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA014275, HPA022152",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.84e-4 (unfavourable), Liver cancer:2.41e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 113.1,Expressed in all,NA,NA
MARCKS,"80K-L, MACS, PKCSL",ENSG00000277443,Myristoylated alanine rich protein kinase C substrate,6,113857362-113863471,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB022062, HPA054820, HPA067595, HPA069443",Enhanced,NA,Approved,Nucleus<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,"Liver cancer:2.78e-8 (unfavourable), Renal cancer:4.85e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 218.8,Cell line enhanced,NA,AF22: 402.5
MARK2,"EMK1, PAR-1, PAR-1B, Par1b",ENSG00000072518,Microtubule affinity regulating kinase 2,11,63838928-63911019,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038790, HPA074905",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,"Liver cancer:1.30e-4 (unfavourable), Endometrial cancer:3.21e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 46.1,Expressed in all,NA,NA
MAS1L,"dJ994E9.2, MAS-L, MRG",ENSG00000204687,"MAS1 proto-oncogene like, G protein-coupled receptor",6,29486697-29487956,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA017983,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enhanced,NA,"cervix, uterine: 5.1",epididymis: 2.3,Not detected,NA,NA
MBP,NA,ENSG00000197971,Myelin basic protein,18,76978827-77133683,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002300, HPA049222, HPA064368",Enhanced,Supported,Approved,Plasma membrane,Renal cancer:4.48e-12 (favourable),Group enriched,Tissue enriched,29,cerebral cortex: 2930.7,parathyroid gland: 99.8,Cell line enhanced,NA,HL-60: 79.4;SK-MEL-30: 158.4
MCAM,"CD146, MUC18",ENSG00000076706,Melanoma cell adhesion molecule,11,119308529-119321521,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002147, HPA008848",Enhanced,NA,Enhanced,Plasma membrane,"Renal cancer:5.14e-4 (unfavourable), Cervical cancer:7.61e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 367.1,Cell line enhanced,NA,HUVEC TERT2: 935.6;TIME: 901.7;WM-115: 859.1
MCF2L2,"ARHGEF22, KIAA0861",ENSG00000053524,MCF.2 cell line derived transforming sequence-like 2,3,183178043-183428778,"Disease related genes, Predicted intracellular proteins",Evidence at transcript level,"HPA038946, HPA038947",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Group enriched,8,adrenal gland: 10.2;cerebral cortex: 17.2;parathyroid gland: 7.7;spleen: 3.5;testis: 4.7,prostate: 1.0,Cell line enhanced,NA,HDLM-2: 5.5;Karpas-707: 3.6;REH: 3.1
MCOLN1,"ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1",ENSG00000090674,Mucolipin 1,19,7522626-7534009,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA031763, CAB032637",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,spleen: 48.2,Expressed in all,NA,NA
MCTS1,MCT-1,ENSG00000232119,"MCTS1, re-initiation and release factor",X,120594010-120621074,Predicted intracellular proteins,Evidence at protein level,HPA001045,NA,NA,Supported,Plasma membrane<br>Cytosol,"Head and neck cancer:3.27e-5 (unfavourable), Renal cancer:4.35e-5 (unfavourable), Breast cancer:1.38e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 50.7,Expressed in all,NA,NA
MDGA1,"GPIM, MAMDC3",ENSG00000112139,MAM domain containing glycosylphosphatidylinositol anchor 1,6,37630679-37699306,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031235, HPA050382",Approved,NA,Supported,Golgi apparatus<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,parathyroid gland: 10.1,Mixed,NA,NA
ME1,NA,ENSG00000065833,Malic enzyme 1,6,83210389-83431071,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006493,Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.81e-7 (unfavourable), Liver cancer:4.57e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 54.1,Cell line enhanced,NA,CACO-2: 113.5
MEI1,"MGC40042, SPATA38",ENSG00000167077,Meiotic double-stranded break formation protein 1,22,41699499-41799456,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049240,Approved,NA,Uncertain,Nucleoplasm<br>Plasma membrane,Cervical cancer:1.59e-6 (favourable),Tissue enhanced,Tissue enhanced,NA,testis: 18.6,spleen: 10.7,Cell line enhanced,NA,HMC-1: 7.9;Karpas-707: 21.6;U-266/70: 24.1
MERTK,"c-Eyk, mer, RP38, Tyro12",ENSG00000153208,"MER proto-oncogene, tyrosine kinase",2,111898479-112029561,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036196, HPA075622",Approved,NA,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,"Renal cancer:4.43e-5 (favourable), Lung cancer:4.74e-4 (favourable)",Expressed in all,Mixed,NA,NA,adrenal gland: 77.2,Cell line enhanced,NA,CACO-2: 31.5;Hep G2: 27.2;HUVEC TERT2: 32.3
MET,"DFNB97, HGFR, RCCP2",ENSG00000105976,"MET proto-oncogene, receptor tyrosine kinase",7,116672390-116798386,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB005282, CAB018577, HPA055607",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 39.0,Mixed,NA,NA
METAP1,"KIAA0094, MAP1A, MetAP1A",ENSG00000164024,Methionyl aminopeptidase 1,4,98995620-99062813,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025485, HPA037997, HPA037998",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:2.28e-5 (unfavourable), Liver cancer:3.08e-5 (unfavourable), Renal cancer:1.72e-4 (favourable), Colorectal cancer:7.22e-4 (favourable), Urothelial cancer:9.31e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 77.3,Expressed in all,NA,NA
METAP2,"MAP2, MNPEP, p67",ENSG00000111142,Methionyl aminopeptidase 2,12,95473520-95515839,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013025, HPA019095",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Liver cancer:4.51e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 142.4,Expressed in all,NA,NA
METTL15,"FLJ33979, METT5D1",ENSG00000169519,Methyltransferase like 15,11,28108248-28527041,Predicted intracellular proteins,Evidence at protein level,HPA039885,NA,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Actin filaments,Renal cancer:7.95e-5 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 14.7,Expressed in all,NA,NA
METTL25,"C12orf26, FLJ22789",ENSG00000127720,Methyltransferase like 25,12,82358497-82479236,Predicted intracellular proteins,Evidence at protein level,"HPA039534, HPA041207",Uncertain,NA,Uncertain,Plasma membrane<br>Mitochondria<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,testis: 10.9,Mixed,NA,NA
MFAP1,NA,ENSG00000140259,Microfibrillar associated protein 1,15,43804492-43824802,Predicted intracellular proteins,Evidence at protein level,HPA042370,Uncertain,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.04e-9 (favourable), Liver cancer:2.50e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 50.2,Expressed in all,NA,NA
MFSD2A,"FLJ14490, MFSD2",ENSG00000168389,Major facilitator superfamily domain containing 2A,1,39955112-39969968,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA043107,Uncertain,NA,Approved,Plasma membrane<br>Cytosol<br>Cytoplasmic bodies,"Renal cancer:4.22e-6 (unfavourable), Urothelial cancer:2.33e-4 (favourable)",Mixed,Tissue enhanced,NA,epididymis: 116.7;seminal vesicle: 110.9,testis: 63.4,Cell line enhanced,NA,THP-1: 112.5
MIB1,"DIP-1, KIAA1323, MIB, ZZANK2, ZZZ6",ENSG00000101752,Mindbomb E3 ubiquitin protein ligase 1,18,21704957-21870957,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019100, CAB037044",Approved,NA,Approved,Nuclear membrane<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 24.2,Expressed in all,NA,NA
MICAL3,KIAA0819,ENSG00000243156,"Microtubule associated monooxygenase, calponin and LIM domain containing 3",22,17787649-18024559,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000639, HPA003421, HPA034882",Uncertain,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 71.2,Expressed in all,NA,NA
MICALCL,FLJ14966,ENSG00000133808,MICAL C-terminal like,11,12276080-12359144,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039895, HPA040438",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,skin: 17.3;testis: 13.4,lung: 10.3,Cell line enhanced,NA,HBEC3-KT: 18.3;RT4: 12.1;U-2 OS: 9.9
MISP,"C19orf21, Caprice, DKFZp686H18209, MISP1",ENSG00000099812,Mitotic spindle positioning,19,751126-764318,Predicted intracellular proteins,Evidence at protein level,"HPA049511, HPA062232",Enhanced,NA,Enhanced,Plasma membrane<br>Focal adhesion sites,NA,Tissue enhanced,Group enriched,6,colon: 94.7;duodenum: 173.3;rectum: 52.6;small intestine: 217.1,stomach: 21.6,Cell line enhanced,NA,A549: 110.0;HaCaT: 79.4;hTCEpi: 59.7;SK-BR-3: 101.1
MKLN1,TWA2,ENSG00000128585,Muskelin 1,7,131110096-131496636,Predicted intracellular proteins,Evidence at protein level,"HPA022817, HPA041810",Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,prostate: 26.0,Expressed in all,NA,NA
MKRN3,"D15S9, MGC88288, RNF63, ZFP127, ZNF127",ENSG00000179455,Makorin ring finger protein 3,15,23565678-23630075,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029494,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Glioma:9.23e-4 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 5.9;placenta: 4.1;testis: 3.6,epididymis: 1.1,Cell line enhanced,NA,K-562: 22.8
MLF2,NTN4,ENSG00000089693,Myeloid leukemia factor 2,12,6747996-6767475,Predicted intracellular proteins,Evidence at protein level,"HPA010811, HPA010859",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 272.5,Expressed in all,NA,NA
MMACHC,"cblC, DKFZP564I122",ENSG00000132763,"Methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria",1,45500053-45513382,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA027394, HPA027399, HPA027402",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,liver: 8.9,Expressed in all,NA,NA
MMP10,STMY2,ENSG00000166670,Matrix metallopeptidase 10,11,102770503-102780628,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,CAB002159,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Urothelial cancer:7.12e-4 (favourable),Tissue enhanced,Tissue enriched,40,endometrium: 443.1,appendix: 11.1,Cell line enhanced,NA,BJ: 10.0;HUVEC TERT2: 12.6;SCLC-21H: 5.6
MMP15,"MT2-MMP, MTMMP2, SMCP-2",ENSG00000102996,Matrix metallopeptidase 15,16,58025566-58046901,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002611, HPA040390",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable)",Expressed in all,Tissue enhanced,NA,thyroid gland: 70.1,placenta: 39.3,Cell line enhanced,NA,BEWO: 86.0;WM-115: 73.7
MMP24,MT5-MMP,ENSG00000125966,Matrix metallopeptidase 24,20,35226654-35277000,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at transcript level,HPA049280,NA,NA,Approved,Nucleoli<br>Plasma membrane,Renal cancer:8.17e-11 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 10.6,lung: 7.0,Cell line enhanced,NA,A549: 32.8;CACO-2: 46.1;RPTEC TERT1: 18.5;U-2 OS: 18.9
MOCS1,MOCOD,ENSG00000124615,Molybdenum cofactor synthesis 1,6,39899578-39934551,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA045783, HPA058177, HPA075505",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Cervical cancer:1.07e-5 (unfavourable), Pancreatic cancer:6.07e-5 (favourable)",Expressed in all,Mixed,NA,NA,placenta: 60.3,Cell line enhanced,NA,CACO-2: 38.2
MPHOSPH8,"HSMPP8, mpp8",ENSG00000196199,M-phase phosphoprotein 8,13,19633681-19673459,Predicted intracellular proteins,Evidence at protein level,"HPA039701, HPA040035",Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,ovary: 63.5,Expressed in all,NA,NA
MPHOSPH9,MPP9,ENSG00000051825,M-phase phosphoprotein 9,12,123152320-123244014,Predicted intracellular proteins,Evidence at protein level,HPA037485,Approved,NA,Uncertain,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,testis: 22.7,Expressed in all,NA,NA
MPI,NA,ENSG00000178802,Mannose phosphate isomerase,15,74890005-74902219,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007200,Approved,NA,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:2.39e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 52.3,Expressed in all,NA,NA
MPP5,"FLJ12615, PALS1",ENSG00000072415,Membrane palmitoylated protein 5,14,67241109-67335819,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000993, HPA063890",Enhanced,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.71e-12 (favourable), Liver cancer:5.62e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 43.9,Expressed in all,NA,NA
MPV17L2,"FKSG24, MGC12972",ENSG00000254858,MPV17 mitochondrial inner membrane protein like 2,19,18193182-18196948,Predicted membrane proteins,Evidence at protein level,HPA043111,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:2.30e-4 (favourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 16.3,Expressed in all,NA,NA
MPZL1,"FLJ21047, PZR",ENSG00000197965,Myelin protein zero like 1,1,167721192-167791919,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA026966, HPA063538",Approved,NA,Supported,Vesicles<br>Plasma membrane,"Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,breast: 111.6,Expressed in all,NA,NA
MR1,HLALS,ENSG00000153029,"Major histocompatibility complex, class I-related",1,181033425-181061938,"FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA048304,NA,NA,Supported,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 28.2,Mixed,NA,NA
MRGPRF,"GPR140, GPR168, MGC21621, mrgF",ENSG00000172935,MAS related GPR family member F,11,69004395-69013409,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA028811,Approved,NA,Supported,Nuclear membrane<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,smooth muscle: 78.8,Cell line enhanced,NA,ASC diff: 43.0;BJ: 31.1;BJ hTERT+: 74.9;BJ hTERT+ SV40 Large T+: 31.7;U-2197: 40.5
MRNIP,"C5orf45, DKFZp686L2452, LOC51149, MGC65027, MGC78537",ENSG00000161010,MRN complex interacting protein,5,179835133-179862173,Predicted intracellular proteins,Evidence at protein level,HPA043975,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:2.64e-5 (unfavourable),Expressed in all,Mixed,NA,NA,fallopian tube: 13.8,Mixed,NA,NA
MRPL42,"HSPC204, MRP-L31, MRPL31, MRPS32, PTD007, RPML31",ENSG00000198015,Mitochondrial ribosomal protein L42,12,93467488-93516213,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA039398,Approved,NA,Supported,Plasma membrane<br>Mitochondria,"Liver cancer:7.49e-4 (unfavourable), Urothelial cancer:8.12e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 57.2,Expressed in all,NA,NA
MRPL44,"FLJ12701, FLJ13990",ENSG00000135900,Mitochondrial ribosomal protein L44,2,223957404-223967714,"Disease related genes, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA038147, HPA038148",Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Mitochondria,"Liver cancer:1.29e-4 (unfavourable), Renal cancer:2.02e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,kidney: 37.5,Expressed in all,NA,NA
MS4A1,"B1, Bp35, CD20, MS4A2",ENSG00000156738,Membrane spanning 4-domains A1,11,60455752-60470760,"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB000015, HPA014341, HPA014391",Enhanced,NA,Supported,Plasma membrane,Breast cancer:4.34e-5 (favourable),Mixed,Group enriched,15,appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8,urinary bladder: 38.3,Group enriched,19,Daudi: 534.8;U-698: 258.0
MSN,NA,ENSG00000147065,Moesin,X,65588377-65741931,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047338",Enhanced,NA,Enhanced,Plasma membrane,Renal cancer:1.60e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 420.9,Mixed,NA,NA
MTCP1,"P13MTCP1, p8MTCP1",ENSG00000214827,Mature T-cell proliferation 1,X,155061622-155147937,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA032040,NA,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:4.52e-8 (unfavourable),Mixed,Mixed,NA,NA,testis: 8.7,Mixed,NA,NA
MTM1,NA,ENSG00000171100,Myotubularin 1,X,150568619-150673322,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA010008, HPA010665",Approved,NA,Supported,Plasma membrane,Renal cancer:7.40e-7 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 27.3,Expressed in all,NA,NA
MTPN,"GCDP, MYOTROPHIN, V-1",ENSG00000105887,Myotrophin,7,135926761-135977353,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019735,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:1.19e-4 (unfavourable), Pancreatic cancer:3.05e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 193.6,Expressed in all,NA,NA
MUC20,"FLJ14408, KIAA1359",ENSG00000176945,"Mucin 20, cell surface associated",3,195720882-195741123,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042249,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:1.57e-4 (favourable),Mixed,Mixed,NA,NA,colon: 10.4,Cell line enriched,7,SK-BR-3: 20.9
MURC,"cavin-4, CAVIN4",ENSG00000170681,Muscle related coiled-coil protein,9,100578079-100587906,Predicted intracellular proteins,Evidence at protein level,"HPA020973, HPA020987, HPA021021",Enhanced,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,NA,Tissue enhanced,Group enriched,9,heart muscle: 34.8;skeletal muscle: 103.8,prostate: 7.4,Cell line enhanced,NA,NTERA-2: 9.6;SCLC-21H: 17.1
MYB,c-myb,ENSG00000118513,"MYB proto-oncogene, transcription factor",6,135181315-135219173,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,CAB017704,Approved,NA,Approved,Nucleus<br>Plasma membrane,"Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable)",Tissue enhanced,Tissue enhanced,NA,breast: 26.3;rectum: 29.1,colon: 25.2,Cell line enhanced,NA,HL-60: 173.9;MOLT-4: 321.7;REH: 222.8;THP-1: 230.7;U-937: 145.8
MYH11,"SMHC, SMMHC",ENSG00000133392,Myosin heavy chain 11,16,15703172-15857033,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002302, HPA014539, HPA015310",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Liver cancer:1.10e-5 (favourable),Tissue enhanced,Tissue enhanced,NA,seminal vesicle: 1381.0;smooth muscle: 1022.0,prostate: 899.8,Cell line enhanced,NA,BEWO: 1.7;NB-4: 1.2;U-698: 3.4
MYH9,"DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA",ENSG00000100345,Myosin heavy chain 9,22,36281281-36388018,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001644, CAB015386, HPA064783",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,spleen: 308.5,Expressed in all,NA,NA
MYL4,"ALC1, AMLC, GT1, PRO1957",ENSG00000198336,Myosin light chain 4,17,47200446-47223679,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA046859, HPA051884, HPA063034",Enhanced,NA,Approved,Plasma membrane,NA,Group enriched,Tissue enriched,21,heart muscle: 1686.3,bone marrow: 79.9,Group enriched,20,HEL: 495.8;K-562: 118.9
MYLK,"MLCK, MLCK1, MYLK1, smMLCK",ENSG00000065534,Myosin light chain kinase,3,123610049-123884331,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB020789, HPA031677, HPA048055",Enhanced,NA,Enhanced,Plasma membrane<br>Actin filaments,"Renal cancer:2.04e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 3002.5,Cell line enhanced,NA,BJ: 144.8;BJ hTERT+: 209.1;fHDF/TERT166: 165.3;RPTEC TERT1: 207.7
MYO10,KIAA0799,ENSG00000145555,Myosin X,5,16661914-16936276,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB015224, HPA024223",Enhanced,NA,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:2.75e-4 (favourable), Cervical cancer:4.35e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 68.3,Mixed,NA,NA
MYO1B,myr1,ENSG00000128641,Myosin IB,2,191245185-191425389,Predicted intracellular proteins,Evidence at protein level,"HPA013607, HPA060144",Approved,NA,Enhanced,Plasma membrane,Renal cancer:2.36e-5 (unfavourable),Expressed in all,Mixed,NA,NA,liver: 130.2,Cell line enhanced,NA,hTERT-HME1: 276.9
MYO1C,myr2,ENSG00000197879,Myosin IC,17,1464098-1492812,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA001768, HPA005924, CAB037023",Enhanced,NA,Enhanced,Nuclear bodies<br>Plasma membrane,Lung cancer:5.22e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 192.4,Mixed,NA,NA
MYO3A,DFNB30,ENSG00000095777,Myosin IIIA,10,25934267-26212527,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA048951, HPA051893",Approved,NA,Supported,Plasma membrane<br>Actin filaments<br>Cytoplasmic bodies,NA,Mixed,Tissue enriched,9,testis: 6.8,skin: 0.8,Cell line enhanced,NA,CAPAN-2: 2.0;HEK93: 2.2;SCLC-21H: 2.3;U-2 OS: 3.7;U-698: 8.6
MYO5B,KIAA1119,ENSG00000167306,Myosin VB,18,49822813-50195093,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040593, HPA040902, HPA069773",Enhanced,NA,Approved,Plasma membrane,"Renal cancer:1.45e-11 (favourable), Pancreatic cancer:2.26e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,small intestine: 67.6,Cell line enhanced,NA,HaCaT: 88.6;RH-30: 147.5
MYO9A,"FLJ11061, FLJ13244, MGC71859",ENSG00000066933,Myosin IXA,15,71822289-72118577,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039812, HPA040071",Approved,NA,Approved,Plasma membrane,Renal cancer:2.14e-4 (favourable),Mixed,Tissue enhanced,NA,testis: 51.5,thyroid gland: 22.1,Expressed in all,NA,NA
MYOF,"FER1L3, KIAA1207",ENSG00000138119,Myoferlin,10,93306429-93482317,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014245,Enhanced,NA,Supported,Vesicles<br>Plasma membrane,Pancreatic cancer:1.40e-4 (unfavourable),Expressed in all,Mixed,NA,NA,"cervix, uterine: 101.2",Mixed,NA,NA
MYSM1,KIAA1915,ENSG00000162601,"Myb like, SWIRM and MPN domains 1",1,58654739-58700092,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA054291, HPA067133",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,Head and neck cancer:5.09e-5 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 11.2,Mixed,NA,NA
N4BP2,B3BP,ENSG00000078177,NEDD4 binding protein 2,4,40056826-40158252,Predicted intracellular proteins,Evidence at protein level,"HPA036770, HPA042607",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Centrosome,NA,Expressed in all,Mixed,NA,NA,endometrium: 5.6,Cell line enhanced,NA,MOLT-4: 20.8
NAB1,NA,ENSG00000138386,NGFI-A binding protein 1,2,190646746-190692766,Predicted intracellular proteins,Evidence at protein level,HPA002738,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,Pancreatic cancer:1.01e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,skin: 80.6,Expressed in all,NA,NA
NAIF1,"bA379C10.2, C9orf90, DKFZp762G199",ENSG00000171169,Nuclear apoptosis inducing factor 1,9,128061233-128068206,Predicted intracellular proteins,Evidence at protein level,"HPA054898, HPA064931",NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.02e-5 (favourable), Renal cancer:8.30e-5 (favourable), Liver cancer:1.61e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 4.6,Expressed in all,NA,NA
NAP1L2,"BPX, MGC26243",ENSG00000186462,Nucleosome assembly protein 1 like 2,X,73212299-73214848,Predicted intracellular proteins,Evidence at protein level,"HPA054050, HPA057065",NA,NA,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,Pancreatic cancer:5.41e-4 (favourable),Mixed,Tissue enriched,5,cerebral cortex: 90.1,"parathyroid gland,prostate: 17.8",Cell line enhanced,NA,EFO-21: 15.7;NTERA-2: 18.1;U-2197: 13.6;U-266/84: 21.9
NAPG,NA,ENSG00000134265,NSF attachment protein gamma,18,10525905-10552761,Predicted intracellular proteins,Evidence at protein level,"HPA008208, HPA011389",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:8.14e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 50.5,Expressed in all,NA,NA
NARFL,"FLJ21988, HPRN, IOP1, NAR1, PRN",ENSG00000103245,Nuclear prelamin A recognition factor like,16,729753-741329,Predicted intracellular proteins,Evidence at protein level,HPA040851,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Cervical cancer:1.32e-5 (favourable), Renal cancer:9.83e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 19.3,Expressed in all,NA,NA
NCAM1,"CD56, NCAM",ENSG00000149294,Neural cell adhesion molecule 1,11,112961247-113278436,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000142, CAB018071, HPA039835",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)",Tissue enriched,Tissue enhanced,NA,cerebral cortex: 334.9,heart muscle: 87.5,Cell line enhanced,NA,RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9
NCAM2,"MGC51008, NCAM21",ENSG00000154654,Neural cell adhesion molecule 2,21,20998315-21543329,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA030900, HPA030901",Supported,NA,Supported,Nuclear bodies<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 68.8,adrenal gland: 15.8,Cell line enhanced,NA,T-47d: 86.4;WM-115: 22.5
NCK1,"NCK, NCKalpha",ENSG00000158092,NCK adaptor protein 1,3,136862208-136949823,Predicted intracellular proteins,Evidence at protein level,"CAB005063, HPA030766",Supported,NA,Enhanced,Plasma membrane<br>Cytosol,"Pancreatic cancer:9.14e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 48.8,Expressed in all,NA,NA
NCKAP1L,HEM1,ENSG00000123338,NCK associated protein 1 like,12,54497711-54548238,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA039490, HPA040772",Approved,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,spleen: 54.9,Cell line enhanced,NA,HL-60: 89.0;HMC-1: 98.8;THP-1: 81.4;U-937: 55.5
NCKAP5,"ERIH1, ERIH2, NAP5",ENSG00000176771,NCK associated protein 5,2,132671799-133568463,Predicted intracellular proteins,Evidence at protein level,"HPA034639, HPA044859",Uncertain,NA,Approved,Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,lung: 17.3,"cerebral cortex,kidney: 4.4",Cell line enriched,7,AF22: 45.7
NCKIPSD,"AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH",ENSG00000213672,NCK interacting protein with SH3 domain,3,48673844-48686364,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB019267, HPA050005",NA,NA,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable)",Expressed in all,Tissue enriched,9,parathyroid gland: 306.0,cerebral cortex: 35.0,Expressed in all,NA,NA
NCOA1,"bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1",ENSG00000084676,Nuclear receptor coactivator 1,2,24491914-24770702,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB019402, HPA070213, HPA070520",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 59.0,Expressed in all,NA,NA
NCS1,"FREQ, NCS-1",ENSG00000107130,Neuronal calcium sensor 1,9,130172578-130237304,Predicted intracellular proteins,Evidence at protein level,"CAB018587, HPA019713",Enhanced,Supported,Enhanced,Plasma membrane,"Liver cancer:1.11e-4 (unfavourable), Breast cancer:5.40e-4 (unfavourable), Thyroid cancer:8.25e-4 (unfavourable), Endometrial cancer:8.69e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 178.1,seminal vesicle: 92.3,Mixed,NA,NA
NDC1,"FLJ10407, NET3, TMEM48",ENSG00000058804,NDC1 transmembrane nucleoporin,1,53765460-53838860,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA069751, HPA070882",Approved,NA,Supported,Nuclear membrane<br>Plasma membrane<br>Actin filaments,"Liver cancer:7.52e-7 (unfavourable), Colorectal cancer:4.48e-5 (favourable), Pancreatic cancer:3.58e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,lymph node: 16.4,Expressed in all,NA,NA
NECTIN4,"LNIR, nectin-4, PRR4, PVRL4",ENSG00000143217,Nectin cell adhesion molecule 4,1,161070995-161089599,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA010775,Enhanced,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,esophagus: 45.9;skin: 79.5,"breast,placenta: 17.1",Cell line enhanced,NA,BEWO: 53.8;HaCaT: 32.5;SK-BR-3: 35.3;T-47d: 28.8
NEDD9,"CAS-L, CASS2, HEF1",ENSG00000111859,"Neural precursor cell expressed, developmentally down-regulated 9",6,11183298-11382348,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009720, HPA038768, HPA039270",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,lung: 103.4,Cell line enhanced,NA,EFO-21: 129.1
NEO1,"HsT17534, IGDCC2, NGN, NTN1R2",ENSG00000067141,Neogenin 1,15,73051710-73305206,"Cancer-related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB009320, HPA027804, HPA027805, HPA027806",Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,Renal cancer:4.39e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 102.7,Mixed,NA,NA
NF2,"ACN, BANF, merlin, SCH",ENSG00000186575,Neurofibromin 2,22,29603556-29698598,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003097, CAB005385",Supported,NA,Enhanced,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:2.89e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 58.7,Expressed in all,NA,NA
NFE2L2,NRF2,ENSG00000116044,"Nuclear factor, erythroid 2 like 2",2,177227595-177392697,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA002990, CAB020317, HPA043438",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:2.26e-4 (favourable),Expressed in all,Expressed in all,NA,NA,esophagus: 267.1,Expressed in all,NA,NA
NGEF,ARHGEF27,ENSG00000066248,Neuronal guanine nucleotide exchange factor,2,232878686-233013272,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008160,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,adrenal gland: 66.5;cerebral cortex: 151.4,duodenum: 42.8,Cell line enhanced,NA,A-431: 46.9;HDLM-2: 42.0;PC-3: 52.8;T-47d: 30.2
NGFR,"CD271, p75NTR, TNFRSF16",ENSG00000064300,Nerve growth factor receptor,17,49495293-49515017,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB000143, CAB001995, HPA004765",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,Urothelial cancer:3.40e-4 (unfavourable),Expressed in all,Mixed,NA,NA,adipose tissue: 32.4,Group enriched,8,RH-30: 193.0;WM-115: 221.3
NID2,NA,ENSG00000087303,Nidogen 2,14,52004803-52069228,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA052460, HPA058772",Enhanced,NA,Supported,Plasma membrane,"Urothelial cancer:2.78e-4 (unfavourable), Stomach cancer:7.34e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 88.5,thyroid gland: 54.1,Cell line enhanced,NA,ASC diff: 198.6;BJ: 133.5;HHSteC: 134.5;HSkMC: 435.7
NKTR,p104,ENSG00000114857,Natural killer cell triggering receptor,3,42600614-42648741,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022120, HPA051576",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.05e-5 (favourable), Head and neck cancer:1.26e-4 (favourable), Renal cancer:5.02e-4 (unfavourable), Prostate cancer:6.01e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 24.3,Expressed in all,NA,NA
NKX2-8,"Nkx2-9, NKX2.8, NKX2H",ENSG00000136327,NK2 homeobox 8,14,36580579-36582607,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA062879,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,testis: 3.1,lung: 0.6,Cell line enhanced,NA,HaCaT: 4.6;PC-3: 2.8;SiHa: 1.3
NLGN1,KIAA1070,ENSG00000169760,Neuroligin 1,3,173396284-174286644,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006572, HPA006680",Approved,NA,Uncertain,Nuclear bodies<br>Plasma membrane,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 25.4,testis: 12.5,Cell line enhanced,NA,fHDF/TERT166: 20.1;HUVEC TERT2: 20.7;RH-30: 25.4;WM-115: 26.7
NMB,"MGC17211, MGC2277, MGC3936",ENSG00000197696,Neuromedin B,15,84655129-84658563,Predicted secreted proteins,Evidence at protein level,CAB019302,Approved,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane,"Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 46.2;cerebral cortex: 47.2,thyroid gland: 14.8,Cell line enhanced,NA,A-431: 46.7
NMBR,"BB1, BB1R",ENSG00000135577,Neuromedin B receptor,6,142058330-142088799,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA026665,NA,NA,Supported,Plasma membrane<br>Cytosol,NA,Not detected,Group enriched,5,fallopian tube: 1.4;testis: 2.6,cerebral cortex: 0.3,Not detected,NA,NA
NMT1,NMT,ENSG00000136448,N-myristoyltransferase 1,17,45051610-45109016,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022949, HPA022963",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Liver cancer:4.94e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 58.6,Expressed in all,NA,NA
NMT2,NA,ENSG00000152465,N-myristoyltransferase 2,10,15102584-15168693,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001303,Approved,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 39.4,Cell line enhanced,NA,TIME: 123.2
NOS1,"nNOS, NOS",ENSG00000089250,Nitric oxide synthase 1,12,117208142-117452170,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002167, HPA058312",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,skeletal muscle: 12.9,cerebral cortex: 3.0,Cell line enhanced,NA,HaCaT: 4.0;RH-30: 9.0;RPTEC TERT1: 4.4
NOTCH2,NA,ENSG00000134250,Notch 2,1,119911553-120069626,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048743,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,"Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 46.7",Mixed,NA,NA
NPFFR2,"GPR74, NPFF2, NPGPR",ENSG00000056291,Neuropeptide FF receptor 2,4,72031804-72148067,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA026825,NA,NA,Approved,Plasma membrane<br>Actin filaments,NA,Mixed,Tissue enhanced,NA,placenta: 2.3;seminal vesicle: 4.6,epididymis: 1.1,Group enriched,11,NTERA-2: 9.2;RPTEC TERT1: 9.0;SH-SY5Y: 14.9;U-2 OS: 14.5
NPL,"C1orf13, DHDPS1, NPL1",ENSG00000135838,N-acetylneuraminate pyruvate lyase,1,182789293-182830384,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028345,NA,NA,Approved,Vesicles<br>Plasma membrane,"Renal cancer:6.63e-4 (unfavourable), Liver cancer:8.05e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 63.8,Mixed,NA,NA
NPR1,"ANPa, ANPRA, GUCY2A, NPRA",ENSG00000169418,Natriuretic peptide receptor 1,1,153678637-153693992,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA031087,NA,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,"Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 72.0;fallopian tube: 58.2,placenta: 25.4,Cell line enriched,6,ASC diff: 107.2
NPTXR,NA,ENSG00000221890,Neuronal pentraxin receptor,22,38818452-38843982,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA001079,Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:2.85e-4 (unfavourable), Cervical cancer:3.93e-4 (favourable)",Expressed in all,Tissue enriched,13,cerebral cortex: 176.4,prostate: 13.3,Cell line enhanced,NA,SCLC-21H: 36.6;U-87 MG: 86.8
NRP2,VEGF165R2,ENSG00000118257,Neuropilin 2,2,205681990-205798133,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA039980, HPA054974",Enhanced,NA,Supported,Vesicles<br>Plasma membrane,"Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,smooth muscle: 84.4,Cell line enhanced,NA,CAPAN-2: 119.6;U-251 MG: 195.9
NRXN1,"Hs.22998, KIAA0578",ENSG00000179915,Neurexin 1,2,49918505-51225575,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA071400,NA,NA,Approved,Nucleoli<br>Plasma membrane,NA,Tissue enriched,Tissue enriched,12,cerebral cortex: 154.0,seminal vesicle: 12.9,Cell line enriched,9,SCLC-21H: 42.8
NSD1,"ARA267, FLJ22263, KMT3B, STO",ENSG00000165671,Nuclear receptor binding SET domain protein 1,5,177133025-177300215,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA048431, HPA070333, HPA073705",Supported,NA,Supported,Nucleus<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,testis: 43.2,Mixed,NA,NA
NSFL1C,"dJ776F14.1, p47, UBX1, UBXD10, UBXN2C",ENSG00000088833,NSFL1 cofactor,20,1442162-1473842,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047108, HPA050628",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:1.29e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,fallopian tube: 35.4,Expressed in all,NA,NA
NT5E,"CALJA, CD73, eN, eNT, NT5",ENSG00000135318,5'-nucleotidase ecto,6,85449584-85495791,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA017357,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,"cervix, uterine: 172.7",smooth muscle: 106.3,Cell line enhanced,NA,LHCN-M2: 772.3;U-87 MG: 800.0
NTNG1,"KIAA0976, Lmnt1",ENSG00000162631,Netrin G1,1,107140007-107483458,Predicted secreted proteins,Evidence at protein level,HPA065954,NA,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 8.6,seminal vesicle: 6.7,Cell line enhanced,NA,ASC TERT1: 34.3;fHDF/TERT166: 19.6;RPTEC TERT1: 20.8;U-138 MG: 22.6;U-87 MG: 25.0
NTNG2,"KIAA1857, Lmnt2, NTNG1",ENSG00000196358,Netrin G2,9,132161676-132244534,Predicted secreted proteins,Evidence at protein level,"HPA061242, HPA065089, HPA071290",Approved,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytokinetic bridge<br>Midbody ring<br>Cytosol,Prostate cancer:6.06e-4 (favourable),Mixed,Group enriched,6,bone marrow: 26.5;cerebral cortex: 18.5;parathyroid gland: 16.3;prostate: 10.0,spleen: 3.1,Cell line enhanced,NA,HMC-1: 14.1;NB-4: 24.3;U-937: 7.7
NTSR1,NTR,ENSG00000101188,Neurotensin receptor 1,20,62708837-62762771,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA050299,NA,NA,Supported,Plasma membrane,NA,Tissue enhanced,Not detected,NA,NA,cerebral cortex: 0.5,Cell line enriched,6,PC-3: 53.5
NUDCD3,"KIAA1068, NudCL",ENSG00000015676,NudC domain containing 3,7,44379121-44490880,Predicted intracellular proteins,Evidence at protein level,"HPA019136, HPA019528, HPA019529",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:9.16e-4 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 12.4,Expressed in all,NA,NA
NUDT16L1,SDOS,ENSG00000168101,Nudix hydrolase 16 like 1,16,4693694-4695859,Predicted intracellular proteins,Evidence at protein level,"HPA044186, HPA063605",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.02e-6 (favourable), Lung cancer:2.79e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,prostate: 30.1,Expressed in all,NA,NA
NUP35,MP44,ENSG00000163002,Nucleoporin 35,2,183117513-183161680,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA018401, HPA018410, HPA018441",Enhanced,NA,Supported,Nucleoplasm<br>Nuclear membrane<br>Plasma membrane,"Ovarian cancer:3.45e-4 (favourable), Liver cancer:5.02e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 44.4,Expressed in all,NA,NA
NUP58,"KIAA0410, NUP45, NUPL1",ENSG00000139496,Nucleoporin 58,13,25301524-25349800,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA039360,Approved,NA,Approved,Plasma membrane<br>Mitochondria<br>Cytosol,"Cervical cancer:2.57e-4 (unfavourable), Liver cancer:3.56e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 87.0,Expressed in all,NA,NA
NUS1,"C6orf68, MGC7199, NgBR, TANGO14",ENSG00000153989,NUS1 dehydrodolichyl diphosphate synthase subunit,6,117675502-117710640,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA027504,Supported,NA,Approved,Vesicles<br>Plasma membrane,Cervical cancer:6.99e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 92.2",Expressed in all,NA,NA
OAS3,NA,ENSG00000111331,2'-5'-oligoadenylate synthetase 3,12,112938352-112973249,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041253, HPA041372",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:2.23e-5 (unfavourable),Expressed in all,Mixed,NA,NA,spleen: 33.4,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+: 251.3;BJ hTERT+ SV40 Large T+ RasG12V: 285.0
OBSCN,"ARHGEF30, KIAA1556, KIAA1639, UNC89",ENSG00000154358,"Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF",1,228208130-228378874,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA021186,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Endometrial cancer:1.64e-4 (unfavourable),Mixed,Tissue enriched,7,skeletal muscle: 301.1,heart muscle: 45.7,Mixed,NA,NA
ODC1,ODC,ENSG00000115758,Ornithine decarboxylase 1,2,10439968-10448504,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001536, CAB035996",Approved,NA,Approved,Plasma membrane<br>Cytosol,Liver cancer:3.07e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 242.0,Expressed in all,NA,NA
OGT,"FLJ23071, HRNT1, MGC22921, O-GLCNAC",ENSG00000147162,O-linked N-acetylglucosamine (GlcNAc) transferase,X,71533083-71575897,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA030751, HPA030752, HPA030753, HPA030754, CAB034099",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane,"Urothelial cancer:6.85e-7 (favourable), Renal cancer:2.36e-6 (unfavourable), Head and neck cancer:1.97e-4 (favourable), Endometrial cancer:8.33e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 83.2,Expressed in all,NA,NA
OLIG2,"BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17",ENSG00000205927,Oligodendrocyte transcription factor 2,21,33025845-33029196,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003254, CAB019381",Enhanced,NA,Uncertain,Nucleoplasm<br>Plasma membrane,NA,Tissue enriched,Tissue enriched,245,cerebral cortex: 91.0,duodenum: 0.3,Cell line enhanced,NA,HMC-1: 46.5;NB-4: 25.3;THP-1: 23.2;WM-115: 10.9
OLR1,"CLEC8A, LOX-1, SCARE1",ENSG00000173391,Oxidized low density lipoprotein receptor 1,12,10158301-10172138,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA050798,NA,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,Head and neck cancer:8.24e-5 (unfavourable),Expressed in all,Group enriched,6,appendix: 41.3;cerebral cortex: 32.7;lung: 146.3;placenta: 160.9,bone marrow: 15.8,Cell line enhanced,NA,CACO-2: 102.6;HHSteC: 104.1;SiHa: 261.9;SK-BR-3: 72.4
OPHN1,"ARHGAP41, MRX60, OPN1",ENSG00000079482,Oligophrenin 1,X,68042344-68433913,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA002919,Approved,NA,Approved,Nucleus<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,cerebral cortex: 20.1,Mixed,NA,NA
OPRK1,"KOR, OPRK",ENSG00000082556,Opioid receptor kappa 1,8,53225716-53251697,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022595, HPA067549",Uncertain,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Group enriched,7,cerebral cortex: 3.6;prostate: 2.8;testis: 1.3,"placenta,skeletal muscle: 0.3",Group enriched,7,AF22: 4.5;U-937: 17.3
OR2C3,"OR2C4, OR2C5P, OST742",ENSG00000196242,Olfactory receptor family 2 subfamily C member 3,1,247530132-247533839,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA053920, HPA058578",Uncertain,NA,Enhanced,Plasma membrane,NA,Not detected,Expressed in all,NA,NA,parathyroid gland: 27.0,Expressed in all,NA,NA
OR8S1,NA,ENSG00000197376,Olfactory receptor family 8 subfamily S member 1,12,48507354-48529897,"G-protein coupled receptors, Predicted membrane proteins",No evidence,HPA045595,Uncertain,NA,Approved,Plasma membrane,NA,Not detected,Not detected,NA,NA,testis: 0.1,Not detected,NA,NA
ORC1,"HSORC1, ORC1L, PARC1",ENSG00000085840,Origin recognition complex subunit 1,1,52372829-52404459,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA027450,Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Colorectal cancer:1.74e-5 (favourable), Liver cancer:3.22e-5 (unfavourable), Melanoma:3.69e-4 (unfavourable)",Mixed,Tissue enhanced,NA,bone marrow: 17.9,lymph node: 7.9,Mixed,NA,NA
OSBPL10,NA,ENSG00000144645,Oxysterol binding protein like 10,3,31657890-32077580,Predicted intracellular proteins,Evidence at protein level,HPA003636,NA,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:1.51e-4 (favourable), Pancreatic cancer:3.14e-4 (unfavourable), Urothelial cancer:4.85e-4 (unfavourable)",Mixed,Mixed,NA,NA,testis: 32.1,Cell line enhanced,NA,hTERT-HME1: 61.7;RPTEC TERT1: 64.6
OSBPL6,ORP6,ENSG00000079156,Oxysterol binding protein like 6,2,178194481-178402891,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA032131,Enhanced,NA,Approved,Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 15.5,skin: 9.2,Cell line enhanced,NA,HEL: 43.7
OSCP1,"C1orf102, NOR1",ENSG00000116885,Organic solute carrier partner 1,1,36415827-36450451,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA028436, HPA052655",Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,"Renal cancer:2.18e-6 (favourable), Endometrial cancer:6.88e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 126.7,Mixed,NA,NA
OSGEP,"GCPL1, KAE1, OSGEP1, PRSMG1",ENSG00000092094,O-sialoglycoprotein endopeptidase,14,20446411-20455105,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039751,Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane,"Renal cancer:4.64e-6 (unfavourable), Breast cancer:1.48e-4 (favourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 12.7,Expressed in all,NA,NA
OSR2,FLJ90037,ENSG00000164920,Odd-skipped related transciption factor 2,8,98944403-98952104,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052425, HPA063486",Uncertain,NA,Approved,Nucleus<br>Plasma membrane,Head and neck cancer:2.44e-5 (favourable),Mixed,Tissue enhanced,NA,endometrium: 205.3;fallopian tube: 144.6,ovary: 102.9,Cell line enriched,13,ASC diff: 372.1
OTULIN,"FAM105B, FLJ34884",ENSG00000154124,OTU deubiquitinase with linear linkage specificity,5,14664664-14699711,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA051074,Uncertain,NA,Approved,Plasma membrane<br>Mitochondria,Renal cancer:2.59e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 17.1,Expressed in all,NA,NA
OXGR1,"aKGR, GPR80, GPR99, P2RY15, P2Y15",ENSG00000165621,Oxoglutarate receptor 1,13,96985719-96994730,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA067673,NA,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,breast: 5.1,kidney: 4.6,Cell line enhanced,NA,RT4: 2.6;SK-BR-3: 1.1;U-2 OS: 1.7
P3H3,"GRCB, HSU47926, LEPREL2",ENSG00000110811,Prolyl 3-hydroxylase 3,12,6828410-6839851,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA043695,Approved,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:1.64e-4 (unfavourable), Pancreatic cancer:4.91e-4 (favourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 11.7,endometrium: 6.2,Cell line enhanced,NA,BJ: 33.3
PACSIN2,SDPII,ENSG00000100266,Protein kinase C and casein kinase substrate in neurons 2,22,42835412-43015145,Predicted intracellular proteins,Evidence at protein level,"HPA049854, HPA056520",Enhanced,NA,Supported,Nuclear speckles<br>Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:1.09e-13 (favourable), Liver cancer:7.33e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 95.3,Expressed in all,NA,NA
PACSIN3,SDPIII,ENSG00000165912,Protein kinase C and casein kinase substrate in neurons 3,11,47177525-47186443,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039480, HPA043904",Approved,Approved,Supported,Plasma membrane<br>Cytosol,Ovarian cancer:2.09e-4 (favourable),Expressed in all,Tissue enhanced,NA,skeletal muscle: 164.2,heart muscle: 93.6,Mixed,NA,NA
PAFAH1B2,NA,ENSG00000168092,Platelet activating factor acetylhydrolase 1b catalytic subunit 2,11,117144267-117176894,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA051836,Approved,NA,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:7.79e-5 (unfavourable), Lung cancer:3.07e-4 (unfavourable), Ovarian cancer:4.25e-4 (favourable), Liver cancer:9.44e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 68.2,Expressed in all,NA,NA
PAG1,"CBP, PAG",ENSG00000076641,Phosphoprotein membrane anchor with glycosphingolipid microdomains 1,8,80967810-81112068,Predicted intracellular proteins,Evidence at protein level,"HPA001632, HPA066527",Uncertain,NA,Supported,Vesicles<br>Plasma membrane,"Renal cancer:1.24e-6 (unfavourable), Testis cancer:6.82e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 23.0,Cell line enhanced,NA,Daudi: 25.3;HMC-1: 40.0;SK-MEL-30: 28.4
PAIP1,NA,ENSG00000172239,Poly(A) binding protein interacting protein 1,5,43526267-43557758,Predicted intracellular proteins,Evidence at protein level,"HPA073653, HPA076187",Approved,NA,Approved,Plasma membrane<br>Cytosol,Pancreatic cancer:4.79e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 153.0,Expressed in all,NA,NA
PAK1,NA,ENSG00000149269,P21 (RAC1) activated kinase 1,11,77321707-77474635,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA003565, CAB005312",Enhanced,Supported,Enhanced,Plasma membrane<br>Cytosol,"Glioma:9.48e-5 (unfavourable), Colorectal cancer:5.87e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 184.2,Mixed,NA,NA
PALLD,"CGI-151, KIAA0992, SIH002",ENSG00000129116,"Palladin, cytoskeletal associated protein",4,168497066-168928457,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA035905, CAB070159",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,Urothelial cancer:3.28e-4 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 444.9,Cell line enhanced,NA,LHCN-M2: 240.0
PALM,KIAA0270,ENSG00000099864,Paralemmin,19,708939-748329,Predicted intracellular proteins,Evidence at protein level,"HPA041713, HPA049578",Approved,NA,Enhanced,Nucleus<br>Plasma membrane,"Renal cancer:5.44e-4 (favourable), Pancreatic cancer:9.81e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 84.8,adipose tissue: 53.1,Cell line enhanced,NA,AN3-CA: 28.0;EFO-21: 25.9;REH: 46.8;SH-SY5Y: 33.4
PALM2,NA,ENSG00000243444,Paralemmin 2,9,109640788-109946703,Predicted intracellular proteins,Evidence at protein level,HPA074153,NA,NA,Approved,Plasma membrane,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 9.8,liver: 3.6,Cell line enhanced,NA,RH-30: 19.4
PALM3,NA,ENSG00000187867,Paralemmin 3,19,14053365-14059159,Predicted intracellular proteins,Evidence at protein level,"HPA052794, HPA056119",Enhanced,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane,Endometrial cancer:7.87e-4 (unfavourable),Mixed,Mixed,NA,NA,kidney: 15.7,Cell line enhanced,NA,AN3-CA: 35.4;CACO-2: 34.5;HAP1: 35.4;NTERA-2: 24.5
PALMD,"C1orf11, FLJ20271, PALML",ENSG00000099260,Palmdelphin,1,99645943-99694541,Predicted intracellular proteins,Evidence at protein level,"HPA017959, HPA030549",Supported,NA,Supported,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,"Head and neck cancer:5.90e-5 (favourable), Endometrial cancer:9.42e-4 (favourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 141.1,placenta: 60.5,Cell line enhanced,NA,HUVEC TERT2: 126.3;TIME: 174.6;U-87 MG: 88.7
PANX1,"MRS1, PX1, UNQ2529",ENSG00000110218,Pannexin 1,11,94128928-94181972,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA016930,Uncertain,NA,Enhanced,Plasma membrane,"Renal cancer:1.49e-7 (unfavourable), Lung cancer:7.09e-5 (unfavourable), Endometrial cancer:1.13e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 19.5,Expressed in all,NA,NA
PANX2,"hPANX2, PX2",ENSG00000073150,Pannexin 2,22,50170731-50180294,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004624, HPA039117",Enhanced,NA,Approved,Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 8.7,seminal vesicle: 2.1,Cell line enhanced,NA,HDLM-2: 15.5;Hep G2: 13.2;SCLC-21H: 11.5
PAPPA,"ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1",ENSG00000182752,Pappalysin 1,9,116153804-116402322,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001667, CAB016724",Enhanced,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,7,placenta: 104.5,parathyroid gland: 14.8,Cell line enhanced,NA,ASC diff: 34.3;HSkMC: 99.9;U-138 MG: 35.8
PAQR8,"C6orf33, LMPB1, MPRB",ENSG00000170915,Progestin and adipoQ receptor family member 8,6,52361421-52407777,Predicted membrane proteins,Evidence at protein level,HPA064625,NA,NA,Supported,Golgi apparatus<br>Plasma membrane,"Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 64.9,Cell line enhanced,NA,Hep G2: 28.4
PARD6G,"PAR-6G, PAR6gamma",ENSG00000178184,Par-6 family cell polarity regulator gamma,18,80157232-80247546,Predicted intracellular proteins,Evidence at protein level,HPA047017,Uncertain,NA,Approved,Plasma membrane,Liver cancer:3.19e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,skin: 44.9,thyroid gland: 30.0,Cell line enhanced,NA,HMC-1: 31.8;U-2 OS: 30.2
PARP6,pART17,ENSG00000137817,Poly(ADP-ribose) polymerase family member 6,15,72241181-72272999,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026991,Approved,NA,Approved,Plasma membrane,"Renal cancer:8.02e-8 (unfavourable), Cervical cancer:3.17e-5 (favourable), Colorectal cancer:3.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 46.9,Mixed,NA,NA
PAWR,"par-4, PAR4",ENSG00000177425,Pro-apoptotic WT1 regulator,12,79574979-79691097,Predicted intracellular proteins,Evidence at protein level,"HPA012640, CAB020779",Approved,NA,Enhanced,Plasma membrane<br>Actin filaments,NA,Expressed in all,Mixed,NA,NA,endometrium: 45.4,Mixed,NA,NA
PCBD2,"DCOH2, DCOHM",ENSG00000132570,Pterin-4 alpha-carbinolamine dehydratase 2,5,134904906-135007959,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036428,Uncertain,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 16.1,Expressed in all,NA,NA
PCDH17,"PCDH68, PCH68",ENSG00000118946,Protocadherin 17,13,57631810-57729311,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026817,Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:3.31e-5 (unfavourable),Mixed,Tissue enhanced,NA,cerebral cortex: 25.8;spleen: 33.8,lung: 18.3,Cell line enhanced,NA,AF22: 13.8;HEK93: 8.1;U-87 MG: 5.1
PCDHA1,NA,ENSG00000204970,Protocadherin alpha 1,5,140786136-141012347,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035969,Enhanced,NA,Approved,Plasma membrane,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 2.8;testis: 1.4,adrenal gland: 0.4,Cell line enriched,6,T-47d: 8.6
PCDHA4,"CNR1, CNRN1, CRNR1, PCDH-ALPHA4",ENSG00000204967,Protocadherin alpha 4,5,140806929-141012344,Predicted membrane proteins,Evidence at protein level,"HPA043180, HPA073478",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 4.4,gallbladder: 2.5,Cell line enhanced,NA,A549: 5.9;AF22: 6.1;EFO-21: 5.0;T-47d: 5.1
PCDHB11,"ME2, PCDH-BETA11",ENSG00000197479,Protocadherin beta 11,5,141199582-141203779,Predicted membrane proteins,Evidence at transcript level,HPA045042,Uncertain,NA,Approved,Plasma membrane,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 8.2,endometrium: 2.5,Cell line enhanced,NA,AN3-CA: 5.1;EFO-21: 7.4
PCDHB12,PCDH-BETA12,ENSG00000120328,Protocadherin beta 12,5,141208697-141212571,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA045042,Uncertain,NA,Approved,Plasma membrane,NA,Mixed,Mixed,NA,NA,endometrium: 3.6,Cell line enhanced,NA,EFO-21: 2.8;RH-30: 3.1
PCDHB16,"KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a",ENSG00000272674,Protocadherin beta 16,5,141181399-141186399,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014668,NA,NA,Approved,Vesicles<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 10.8,ovary: 7.3,Cell line enhanced,NA,AN3-CA: 15.6;U-138 MG: 35.8
PCDHB4,PCDH-BETA4,ENSG00000081818,Protocadherin beta 4,5,141121799-141125623,Predicted membrane proteins,Evidence at transcript level,HPA014466,Approved,NA,Uncertain,Plasma membrane<br>Intermediate filaments<br>Cytosol,NA,Mixed,Mixed,NA,NA,endometrium: 8.9,Group enriched,6,SCLC-21H: 10.2;SH-SY5Y: 6.2
PCDHB6,PCDH-BETA6,ENSG00000113211,Protocadherin beta 6,5,141150022-141153287,Predicted membrane proteins,Evidence at transcript level,HPA029566,Uncertain,NA,Uncertain,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:5.52e-4 (unfavourable),Mixed,Tissue enhanced,NA,parathyroid gland: 7.1,testis: 3.5,Cell line enhanced,NA,EFO-21: 15.4;SH-SY5Y: 7.4;T-47d: 5.0;U-2197: 7.0;WM-115: 10.2
PCDHGA1,PCDH-GAMMA-A1,ENSG00000204956,"Protocadherin gamma subfamily A, 1",5,141330571-141512981,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580, HPA036547",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 3.2,testis: 1.3,Cell line enhanced,NA,LHCN-M2: 3.7;T-47d: 6.9
PCDHGA10,PCDH-GAMMA-A10,ENSG00000253846,"Protocadherin gamma subfamily A, 10",5,141412987-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,5,cerebral cortex: 28.0,placenta: 5.1,Cell line enhanced,NA,AF22: 14.4;T-47d: 18.5
PCDHGA11,PCDH-GAMMA-A11,ENSG00000253873,"Protocadherin gamma subfamily A, 11",5,141421047-141512979,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,"cerebral cortex,placenta: 3.2",Cell line enhanced,NA,ASC diff: 16.8;ASC TERT1: 18.5;SK-MEL-30: 16.7;WM-115: 43.4
PCDHGA12,"CDH21, FIB3, KIAA0588, PCDH-GAMMA-A12",ENSG00000253159,"Protocadherin gamma subfamily A, 12",5,141430589-141512979,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Mixed,NA,NA,cerebral cortex: 8.1,Cell line enhanced,NA,BJ: 8.3;BJ hTERT+: 13.2;fHDF/TERT166: 18.9;HSkMC: 12.6
PCDHGA2,PCDH-GAMMA-A2,ENSG00000081853,"Protocadherin gamma subfamily A, 2",5,141338760-141512979,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580, HPA038625",Approved,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,cerebral cortex: 8.4,Cell line enhanced,NA,ASC TERT1: 4.3;BJ: 3.0;fHDF/TERT166: 3.3
PCDHGA3,PCDH-GAMMA-A3,ENSG00000254245,"Protocadherin gamma subfamily A, 3",5,141343829-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 6.5,ovary: 3.1,Group enriched,7,AF22: 7.0;BJ: 2.0;EFO-21: 5.4
PCDHGA4,PCDH-GAMMA-A4,ENSG00000262576,"Protocadherin gamma subfamily A, 4",5,141355025-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,cerebral cortex: 5.7,Cell line enhanced,NA,ASC TERT1: 5.2;U-87 MG: 5.9
PCDHGA5,"CDH-GAMMA-A5, ME3, PCDH-GAMMA-A5",ENSG00000253485,"Protocadherin gamma subfamily A, 5",5,141364232-141512979,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Mixed,NA,NA,cerebral cortex: 3.8,Group enriched,6,ASC diff: 10.8;ASC TERT1: 4.3
PCDHGA6,PCDH-GAMMA-A6,ENSG00000253731,"Protocadherin gamma subfamily A, 6",5,141373914-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,"endometrium,ovary: 3.8",Cell line enhanced,NA,SCLC-21H: 11.4;WM-115: 12.0
PCDHGA7,PCDH-GAMMA-A7,ENSG00000253537,"Protocadherin gamma subfamily A, 7",5,141382739-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 7.4,thyroid gland: 3.3,Cell line enhanced,NA,BJ hTERT+: 17.1;SH-SY5Y: 19.7
PCDHGA8,"KIAA0327, PCDH-GAMMA-A8",ENSG00000253767,"Protocadherin gamma subfamily A, 8",5,141390157-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Not detected,Not detected,NA,NA,thyroid gland: 0.7,Not detected,NA,NA
PCDHGA9,PCDH-GAMMA-A9,ENSG00000261934,"Protocadherin gamma subfamily A, 9",5,141402932-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 9.6,endometrium: 4.1,Cell line enhanced,NA,EFO-21: 3.4;TIME: 3.7;U-87 MG: 5.0
PCDHGB1,PCDH-GAMMA-B1,ENSG00000254221,"Protocadherin gamma subfamily B, 1",5,141350102-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580, HPA076182",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Focal adhesion sites<br>Midbody<br>Cytosol,NA,Mixed,Tissue enriched,11,cerebral cortex: 23.8,endometrium: 2.0,Cell line enhanced,NA,ASC diff: 8.8;T-47d: 8.1
PCDHGB2,PCDH-GAMMA-B2,ENSG00000253910,"Protocadherin gamma subfamily B, 2",5,141360042-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580, HPA077526",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enriched,Mixed,NA,NA,cerebral cortex: 6.5,Cell line enhanced,NA,ASC diff: 9.2
PCDHGB3,PCDH-GAMMA-B3,ENSG00000262209,"Protocadherin gamma subfamily B, 3",5,141370264-141512979,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580, HPA035823",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,endometrium: 1.5,Cell line enhanced,NA,ASC diff: 7.2;ASC TERT1: 5.9;TIME: 4.5
PCDHGB4,"CDH20, FIB2, PCDH-GAMMA-B4",ENSG00000253953,"Protocadherin gamma subfamily B, 4",5,141387698-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,placenta: 4.3,Cell line enhanced,NA,BJ hTERT+: 35.5;TIME: 18.0
PCDHGB5,PCDH-GAMMA-B5,ENSG00000276547,"Protocadherin gamma subfamily B, 5",5,141397987-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 19.8,thyroid gland: 7.6,Cell line enhanced,NA,ASC diff: 45.6;ASC TERT1: 34.8;BJ hTERT+ SV40 Large T+: 27.3;BJ hTERT+ SV40 Large T+ RasG12V: 31.8
PCDHGB6,PCDH-GAMMA-B6,ENSG00000253305,"Protocadherin gamma subfamily B, 6",5,141408021-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 20.8,parathyroid gland: 11.9,Cell line enhanced,NA,AF22: 15.8;EFO-21: 5.1
PCDHGB7,"ME6, PCDH-GAMMA-B7",ENSG00000254122,"Protocadherin gamma subfamily B, 7",5,141417645-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Mixed,NA,NA,ovary: 10.2,Cell line enhanced,NA,AN3-CA: 80.7;HSkMC: 19.4
PCDHGC3,"PC-43, PC43, PCDH-GAMMA-C3, PCDH2",ENSG00000240184,"Protocadherin gamma subfamily C, 3",5,141475947-141512979,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580, HPA077289",Approved,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,"Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable)",Group enriched,Tissue enhanced,NA,cerebral cortex: 376.0,"cervix, uterine: 93.8",Cell line enhanced,NA,U-138 MG: 264.5;WM-115: 404.1
PCDHGC4,PCDH-GAMMA-C4,ENSG00000242419,"Protocadherin gamma subfamily C, 4",5,141484997-141512979,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008755, HPA010580",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enriched,11,cerebral cortex: 16.3,adrenal gland: 1.4,Cell line enhanced,NA,REH: 8.3;SCLC-21H: 8.7;SH-SY5Y: 15.1
PCDHGC5,PCDH-GAMMA-C5,ENSG00000240764,"Protocadherin gamma subfamily C, 5",5,141489121-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580, HPA051540",Uncertain,NA,Approved,Nucleus<br>Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Group enriched,Tissue enriched,43,cerebral cortex: 50.6,smooth muscle: 1.1,Cell line enhanced,NA,U-138 MG: 14.5;U-251 MG: 5.4;U-87 MG: 8.8
PCLO,"ACZ, DKFZp779G1236, KIAA0559",ENSG00000186472,Piccolo presynaptic cytomatrix protein,7,82754013-83162930,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015858, HPA029579, CAB079012",Approved,Approved,Approved,Nuclear speckles<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 17.4,parathyroid gland: 9.8,Group enriched,36,REH: 239.6;U-2 OS: 298.6
PCMTD1,FLJ10883,ENSG00000168300,Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1,8,51817575-51899186,Predicted intracellular proteins,Evidence at protein level,"HPA025696, HPA061444",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 186.8,Expressed in all,NA,NA
PDAP1,"HASPP28, PAP, PAP1",ENSG00000106244,PDGFA associated protein 1,7,99392048-99408829,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB021103, HPA050294, HPA060836",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,Liver cancer:6.67e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 37.3,Expressed in all,NA,NA
PDCD7,"ES18, HES18",ENSG00000090470,Programmed cell death 7,15,65117379-65133836,Predicted intracellular proteins,Evidence at protein level,HPA049388,Approved,NA,Approved,Nucleoli<br>Plasma membrane,Renal cancer:1.00e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 30.7,Expressed in all,NA,NA
PDE4A,DPDE2,ENSG00000065989,Phosphodiesterase 4A,19,10416773-10469631,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB017632, HPA043310, HPA076091",Uncertain,NA,Supported,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 34.0,Cell line enhanced,NA,HMC-1: 32.2
PDE4D,DPDE3,ENSG00000113448,Phosphodiesterase 4D,5,58969038-60522120,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045895,Approved,NA,Approved,Nuclear membrane<br>Plasma membrane<br>Cytosol,Renal cancer:4.00e-5 (favourable),Mixed,Mixed,NA,NA,bone marrow: 47.7,Cell line enhanced,NA,A549: 56.1;AN3-CA: 65.2;HeLa: 68.4
PDGFC,"fallotein, SCDGF",ENSG00000145431,Platelet derived growth factor C,4,156760454-156971394,"Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA009134,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.35e-5 (favourable), Stomach cancer:3.05e-4 (unfavourable), Urothelial cancer:3.17e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 40.6,endometrium: 16.8,Cell line enhanced,NA,fHDF/TERT166: 47.4;U-138 MG: 41.4
PDHX,"DLDBP, E3BP, OPDX, PDX1, proX",ENSG00000110435,Pyruvate dehydrogenase complex component X,11,34915829-35020591,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038484, HPA038485",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Mitochondria,Renal cancer:1.83e-5 (favourable),Expressed in all,Expressed in all,NA,NA,heart muscle: 53.3,Expressed in all,NA,NA
PDLIM5,"Enh, LIM",ENSG00000163110,PDZ and LIM domain 5,4,94451857-94668227,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB013511, HPA016740, HPA020026",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites,NA,Tissue enriched,Expressed in all,NA,NA,heart muscle: 424.8,Expressed in all,NA,NA
PDZD2,"KIAA0300, PDZK3",ENSG00000133401,PDZ domain containing 2,5,31639410-32110931,Predicted intracellular proteins,Evidence at protein level,"CAB020784, HPA036503, HPA036504, HPA064387",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,ovary: 18.3,Cell line enhanced,NA,BEWO: 8.1;SiHa: 12.6;SK-BR-3: 8.1
PDZD8,"bA129M16.2, FLJ34427, PDZK8",ENSG00000165650,PDZ domain containing 8,10,117277274-117375467,Predicted secreted proteins,Evidence at protein level,"HPA015716, HPA051610",Uncertain,NA,Approved,Nucleoli fibrillar center<br>Plasma membrane,Pancreatic cancer:6.10e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 46.5,Expressed in all,NA,NA
PEBP1,"HCNP, PBP, PEBP, RKIP",ENSG00000089220,Phosphatidylethanolamine binding protein 1,12,118135858-118145584,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA008819, CAB013493, HPA063904",Enhanced,NA,Supported,Plasma membrane,"Renal cancer:2.15e-13 (favourable), Pancreatic cancer:1.52e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 1642.0,Expressed in all,NA,NA
PFAS,"FGARAT, KIAA0361, PURL",ENSG00000178921,Phosphoribosylformylglycinamidine synthase,17,8247618-8270491,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA022140, HPA022886",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,Liver cancer:9.19e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,lymph node: 11.6,Expressed in all,NA,NA
PFDN1,PFD1,ENSG00000113068,Prefoldin subunit 1,5,140245039-140303121,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006499,Approved,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,Liver cancer:8.81e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 106.3,Expressed in all,NA,NA
PGAP3,"CAB2, MGC9753, PER1, PERLD1, PP1498",ENSG00000161395,Post-GPI attachment to proteins 3,17,39671122-39696797,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA016591,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 35.6,Cell line enhanced,NA,SK-BR-3: 99.2
PGLYRP4,"PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67",ENSG00000163218,Peptidoglycan recognition protein 4,1,153330120-153348840,Predicted secreted proteins,Evidence at protein level,CAB025879,NA,NA,Approved,Vesicles<br>Plasma membrane,NA,Group enriched,Group enriched,6,esophagus: 5.8;skin: 18.2,tonsil: 2.1,Cell line enhanced,NA,HaCaT: 3.4;HDLM-2: 2.4;Karpas-707: 1.4
PGRMC2,"DG6, PMBP",ENSG00000164040,Progesterone receptor membrane component 2,4,128269237-128288829,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041172, HPA058652",Approved,NA,Approved,Nuclear bodies<br>Plasma membrane<br>Cytosol,"Endometrial cancer:3.62e-4 (favourable), Renal cancer:9.60e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,small intestine: 133.4,Expressed in all,NA,NA
PHACTR1,"dJ257A7.2, KIAA1733, RPEL1",ENSG00000112137,Phosphatase and actin regulator 1,6,12716805-13290484,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA029755, HPA029756, HPA029757",Enhanced,NA,Uncertain,Plasma membrane,Renal cancer:5.48e-6 (unfavourable),Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 26.6,bone marrow: 15.6,Cell line enhanced,NA,HMC-1: 33.9;U-266/70: 72.3;U-266/84: 46.3
PHACTR4,"FLJ13171, PPP1R124",ENSG00000204138,Phosphatase and actin regulator 4,1,28369582-28500369,Predicted intracellular proteins,Evidence at protein level,HPA028985,Approved,NA,Approved,Plasma membrane<br>Intermediate filaments<br>Cytosol,Head and neck cancer:1.05e-4 (favourable),Expressed in all,Expressed in all,NA,NA,esophagus: 35.7,Expressed in all,NA,NA
PHF20L1,"CGI-72, FLJ13649, FLJ21615, MGC64923, TDRD20B",ENSG00000129292,PHD finger protein 20-like 1,8,132775358-132848807,Predicted intracellular proteins,Evidence at protein level,"HPA025060, HPA028417",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 38.1,Expressed in all,NA,NA
PHGDH,"PDG, PGDH, SERA",ENSG00000092621,Phosphoglycerate dehydrogenase,1,119659798-119744215,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003681, HPA021241, HPA024031, CAB068216",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 216.7,skin: 115.9,Mixed,NA,NA
PHLDB2,"FLJ21791, LL5b, LL5beta",ENSG00000144824,Pleckstrin homology like domain family B member 2,3,111732497-111976517,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA035146, HPA035147",Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 59.0,Mixed,NA,NA
PHLDB3,FLJ40193,ENSG00000176531,Pleckstrin homology like domain family B member 3,19,43474954-43504935,Predicted intracellular proteins,Evidence at protein level,HPA043425,Approved,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:6.36e-6 (favourable), Renal cancer:4.11e-5 (unfavourable), Stomach cancer:5.77e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 24.6,Mixed,NA,NA
PHOSPHO1,NA,ENSG00000173868,Phosphoethanolamine/phosphocholine phosphatase,17,49223362-49230766,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA053016, HPA065025",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments,NA,Mixed,Tissue enhanced,NA,spleen: 20.4;testis: 41.1,bone marrow: 12.4,Cell line enhanced,NA,Daudi: 4.3;EFO-21: 3.6;HDLM-2: 4.0
PI3,"cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14",ENSG00000124102,Peptidase inhibitor 3,20,45174876-45176544,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB009449, HPA017737",Enhanced,NA,Approved,Plasma membrane,"Renal cancer:1.94e-8 (unfavourable), Ovarian cancer:3.84e-6 (unfavourable), Pancreatic cancer:6.89e-4 (unfavourable), Breast cancer:6.94e-4 (favourable)",Tissue enhanced,Group enriched,15,esophagus: 2285.4;tonsil: 1739.8,appendix: 133.6,Group enriched,7,EFO-21: 78.9;HaCaT: 92.0;PC-3: 163.0
PI4KA,"PI4K-ALPHA, pi4K230, PIK4CA",ENSG00000241973,Phosphatidylinositol 4-kinase alpha,22,20707691-20859417,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009092, HPA075515",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,"Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 113.6,Expressed in all,NA,NA
PIGB,NA,ENSG00000069943,Phosphatidylinositol glycan anchor biosynthesis class B,15,55318960-55355648,Predicted membrane proteins,Evidence at protein level,HPA039929,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 22.8,Expressed in all,NA,NA
PIGN,"MDC4, PIG-N",ENSG00000197563,Phosphatidylinositol glycan anchor biosynthesis class N,18,61905255-62187118,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039922, HPA040374",Approved,NA,Supported,Plasma membrane<br>Cytosol,Colorectal cancer:6.51e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 33.4,Expressed in all,NA,NA
PIGW,"FLJ37433, Gwt1",ENSG00000277161,Phosphatidylinositol glycan anchor biosynthesis class W,17,36535020-36539310,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA023499,NA,NA,Approved,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,appendix: 5.1,Expressed in all,NA,NA
PIK3AP1,"BCAP, FLJ35564",ENSG00000155629,Phosphoinositide-3-kinase adaptor protein 1,10,96593312-96720514,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB026136, HPA038452",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,spleen: 85.6,lymph node: 72.0,Cell line enhanced,NA,Daudi: 60.8;REH: 166.9;THP-1: 62.4;U-698: 79.5;U-937: 74.4
PIK3CG,NA,ENSG00000105851,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma",7,106865278-106907145,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069976,NA,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,bone marrow: 28.1,lymph node: 22.0,Cell line enhanced,NA,HMC-1: 30.6;MOLT-4: 44.8;U-266/70: 53.9;U-937: 40.5
PIP4K2A,"PIP5K2A, PIP5KIIA, PIP5KIIalpha",ENSG00000150867,Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha,10,22534849-22714555,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA065440, HPA068771",Supported,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.46e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 144.3,Expressed in all,NA,NA
PIP5K1A,NA,ENSG00000143398,Phosphatidylinositol-4-phosphate 5-kinase type 1 alpha,1,151197949-151249536,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029366,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:4.16e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 67.8,Expressed in all,NA,NA
PIRT,NA,ENSG00000233670,Phosphoinositide interacting regulator of transient receptor potential channels,17,10822475-10838445,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA042337,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enhanced,NA,adrenal gland: 3.1;cerebral cortex: 2.6;rectum: 2.7,colon: 2.1,Not detected,NA,NA
PITPNM3,"ACKR6, CORD5, NIR1, RDGBA3",ENSG00000091622,PITPNM family member 3,17,6451264-6556494,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA022432, HPA059005",Enhanced,NA,Approved,Plasma membrane,Head and neck cancer:3.67e-6 (favourable),Mixed,Tissue enhanced,NA,spleen: 76.8,ovary: 33.7,Cell line enhanced,NA,HaCaT: 15.7;hTCEpi: 36.7
PKD2L2,TRPP5,ENSG00000078795,"Polycystin 2 like 2, transient receptor potential cation channel",5,137887968-137942747,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at transcript level,"HPA041903, HPA043634",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,12,testis: 14.9,"adrenal gland,thyroid gland: 1.2",Mixed,NA,NA
PKN2,"Pak-2, PRK2, PRKCL2, STK7",ENSG00000065243,Protein kinase N2,1,88684222-88836255,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034861, HPA057913",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Intermediate filaments<br>Cytosol,Colorectal cancer:5.67e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 48.8,Expressed in all,NA,NA
PLAA,"DOA1, FLJ11281, FLJ12699, PLA2P, PLAP",ENSG00000137055,Phospholipase A2 activating protein,9,26904083-26947463,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005035, HPA020994, HPA020996",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Ovarian cancer:7.87e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 37.9,Mixed,NA,NA
PLAUR,"CD87, UPAR, URKR",ENSG00000011422,"Plasminogen activator, urokinase receptor",19,43646095-43670547,"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA050843, CAB073533",Uncertain,NA,Supported,Plasma membrane,"Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 428.5,Cell line enhanced,NA,U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6
PLCB1,"KIAA0581, PLC-I, PLC154",ENSG00000182621,Phospholipase C beta 1,20,8077251-8968360,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004275, CAB005334, HPA034743, HPA057910",Enhanced,NA,Approved,Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 68.3;parathyroid gland: 121.3,placenta: 28.2,Cell line enhanced,NA,Hep G2: 46.8
PLCD3,NA,ENSG00000161714,Phospholipase C delta 3,17,45108967-45133354,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA025711, HPA053665",Approved,NA,Approved,Plasma membrane,"Lung cancer:2.89e-6 (unfavourable), Thyroid cancer:4.28e-4 (favourable)",Expressed in all,Mixed,NA,NA,skeletal muscle: 29.7,Mixed,NA,NA
PLCD4,NA,ENSG00000115556,Phospholipase C delta 4,2,218607765-218637184,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009914, HPA038139, HPA038140",Enhanced,NA,Approved,Nuclear membrane<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,skeletal muscle: 38.4,testis: 9.7,Cell line enhanced,NA,SH-SY5Y: 21.8
PLD1,NA,ENSG00000075651,Phospholipase D1,3,171600405-171810950,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004527, HPA042396",Enhanced,NA,Approved,Plasma membrane,Urothelial cancer:4.76e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,gallbladder: 138.3,small intestine: 49.2,Cell line enhanced,NA,HUVEC TERT2: 49.2;TIME: 42.2
PLEKHA4,PEPP1,ENSG00000105559,Pleckstrin homology domain containing A4,19,48837097-48868632,Predicted intracellular proteins,Evidence at protein level,"HPA042978, HPA048473",Uncertain,NA,Approved,Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol,"Breast cancer:1.97e-4 (favourable), Liver cancer:8.68e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,ovary: 22.3,Cell line enhanced,NA,AN3-CA: 58.6;BJ hTERT+ SV40 Large T+ RasG12V: 48.0;SK-MEL-30: 57.7
PLEKHG3,"ARHGEF43, KIAA0599",ENSG00000126822,Pleckstrin homology and RhoGEF domain containing G3,14,64704102-64750247,Predicted intracellular proteins,Evidence at protein level,"HPA063455, HPA065323, HPA073702, HPA074734",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol,Renal cancer:7.39e-8 (favourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 53.5,Mixed,NA,NA
PLEKHH2,"KIAA2028, PLEKHH1L",ENSG00000152527,"Pleckstrin homology, MyTH4 and FERM domain containing H2",2,43637273-43767987,Predicted intracellular proteins,Evidence at protein level,HPA077225,NA,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Mixed,NA,NA,endometrium: 32.1,Mixed,NA,NA
PLEKHO2,"DKFZp761K2312, PLEKHQ1, PP1628, pp9099",ENSG00000241839,Pleckstrin homology domain containing O2,15,64841883-64868007,Predicted intracellular proteins,Evidence at protein level,HPA040055,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,spleen: 119.5,Mixed,NA,NA
PLIN4,"KIAA1881, S3-12",ENSG00000167676,Perilipin 4,19,4502180-4518465,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA044682, HPA054657",Enhanced,NA,Supported,Vesicles<br>Lipid droplets<br>Plasma membrane<br>Cytosol,"Endometrial cancer:2.31e-4 (unfavourable), Colorectal cancer:8.31e-4 (unfavourable)",Mixed,Tissue enriched,14,adipose tissue: 812.2,skeletal muscle: 59.1,Cell line enriched,7,ASC diff: 171.0
PLPP1,"LPP1, PAP-2a, PPAP2A",ENSG00000067113,Phospholipid phosphatase 1,5,55424854-55535050,"Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB033331, HPA047815",Enhanced,NA,Supported,Plasma membrane,"Stomach cancer:5.77e-4 (unfavourable), Liver cancer:6.06e-4 (favourable)",Expressed in all,Mixed,NA,NA,prostate: 339.9,Cell line enhanced,NA,ASC diff: 295.0;HMC-1: 201.8
PLPPR5,"LPPR5, PAP2, PAP2D, PRG5",ENSG00000117598,Phospholipid phosphatase related 5,1,98890245-99005032,Predicted membrane proteins,Evidence at transcript level,"HPA018072, HPA059085",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:6.22e-4 (unfavourable),Group enriched,Group enriched,11,cerebral cortex: 12.0;testis: 4.0,adrenal gland: 0.7,Group enriched,7,PC-3: 12.4;SH-SY5Y: 25.0
PLS3,T-plastin,ENSG00000102024,Plastin 3,X,115561174-115650861,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020433, HPA076083",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,"Head and neck cancer:6.07e-5 (unfavourable), Renal cancer:1.01e-4 (unfavourable), Thyroid cancer:3.72e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Urothelial cancer:7.04e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 293.0,Mixed,NA,NA
PLSCR1,MMTRA1B,ENSG00000188313,Phospholipid scramblase 1,3,146515180-146544864,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA068923, CAB070421",Approved,NA,Supported,Nucleus<br>Golgi apparatus<br>Plasma membrane,Endometrial cancer:1.35e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,appendix: 114.2,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+: 292.9;BJ hTERT+ SV40 Large T+ RasG12V: 404.0;SK-MEL-30: 418.1
PLXNA4,"DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B",ENSG00000221866,Plexin A4,7,132123332-132648688,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA029919, HPA052141, HPA075592",Approved,NA,Approved,Plasma membrane,Endometrial cancer:1.61e-6 (unfavourable),Tissue enhanced,Tissue enhanced,NA,"adipose tissue: 15.2;cervix, uterine: 12.5",cerebral cortex: 10.4,Cell line enhanced,NA,ASC diff: 17.3;HMC-1: 15.0;RH-30: 17.9;TIME: 46.9
PNCK,"CaMK1b, MGC45419",ENSG00000130822,Pregnancy up-regulated nonubiquitous CaM kinase,X,153669730-153689010,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007458,Approved,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.04e-6 (unfavourable),Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 40.5;seminal vesicle: 52.3,smooth muscle: 22.4,Cell line enriched,7,AN3-CA: 29.8
PODXL,"Gp200, PC, PCLP",ENSG00000128567,Podocalyxin like,7,131500262-131558217,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA002110, CAB016169, HPA045507, CAB062558, CAB068219, CAB068220",Enhanced,NA,Approved,Vesicles<br>Plasma membrane<br>Microtubule organizing center,Renal cancer:2.89e-4 (favourable),Expressed in all,Mixed,NA,NA,fallopian tube: 29.6,Cell line enhanced,NA,fHDF/TERT166: 106.7;NTERA-2: 181.6;TIME: 168.8
POLE,POLE1,ENSG00000177084,"DNA polymerase epsilon, catalytic subunit",12,132623753-132687365,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA058210, HPA067385",NA,NA,Enhanced,Nucleus<br>Plasma membrane,"Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 22.1,Expressed in all,NA,NA
PPEF1,"PPEF, PPP7CA",ENSG00000086717,Protein phosphatase with EF-hand domain 1,X,18675909-18827921,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA034577,Uncertain,NA,Uncertain,Plasma membrane<br>Cytokinetic bridge,NA,Mixed,Tissue enriched,7,testis: 26.4,cerebral cortex: 3.6,Cell line enhanced,NA,A549: 1.0;HeLa: 1.1
PPFIBP1,"hSGT2, hSgt2p, L2, SGT2",ENSG00000110841,PPFIA binding protein 1,12,27523431-27695564,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA001924,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:5.11e-7 (favourable), Pancreatic cancer:2.56e-4 (unfavourable), Lung cancer:5.11e-4 (unfavourable), Endometrial cancer:6.29e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 106.4,Mixed,NA,NA
PPL,NA,ENSG00000118898,Periplakin,16,4882507-4960741,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042550, HPA059859",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Ovarian cancer:2.76e-4 (unfavourable),Expressed in all,Group enriched,7,esophagus: 558.8;skin: 149.5,tonsil: 52.0,Cell line enhanced,NA,HaCaT: 168.9;SiHa: 108.6
PPM1A,"MGC9201, PP2CA, PP2Calpha",ENSG00000100614,"Protein phosphatase, Mg2+/Mn2+ dependent 1A",14,60245752-60299087,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029209,Approved,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:1.57e-9 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 100.1,Expressed in all,NA,NA
PPM1F,"CAMKP, CaMKPase, FEM-2, KIAA0015, POPX2",ENSG00000100034,"Protein phosphatase, Mg2+/Mn2+ dependent 1F",22,21919420-21952837,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030989, HPA030990",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:6.03e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 38.9,Expressed in all,NA,NA
PPP1CA,"PP-1A, PP1A, PP1alpha, PPP1A",ENSG00000172531,Protein phosphatase 1 catalytic subunit alpha,11,67398183-67421183,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB004545, HPA046833",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Thyroid cancer:1.17e-4 (favourable),Expressed in all,Expressed in all,NA,NA,lymph node: 166.4,Expressed in all,NA,NA
PPP1CB,"PP-1B, PP1B, PP1beta",ENSG00000213639,Protein phosphatase 1 catalytic subunit beta,2,28751640-28802940,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB022558, HPA065425, CAB069426",Supported,NA,Enhanced,Nucleus<br>Plasma membrane,Liver cancer:6.52e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,esophagus: 273.8,Expressed in all,NA,NA
PPP1R12B,"MGC131980, MGC87886, MYPT2, PP1bp55",ENSG00000077157,Protein phosphatase 1 regulatory subunit 12B,1,202348699-202592706,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA024171, HPA024640",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,endometrium: 366.8,Mixed,NA,NA
PPP1R16A,"MGC14333, MYPT3",ENSG00000160972,Protein phosphatase 1 regulatory subunit 16A,8,144477969-144502121,Predicted intracellular proteins,Evidence at protein level,HPA023755,Uncertain,NA,Approved,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,duodenum: 27.2,Mixed,NA,NA
PPP1R16B,"ANKRD4, KIAA0823, TIMAP",ENSG00000101445,Protein phosphatase 1 regulatory subunit 16B,20,38805705-38923024,Predicted intracellular proteins,Evidence at protein level,HPA049571,NA,NA,Supported,Nuclear speckles<br>Plasma membrane,"Head and neck cancer:7.87e-5 (favourable), Cervical cancer:2.11e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 50.9,lymph node: 44.2,Cell line enhanced,NA,Daudi: 40.9;HMC-1: 52.2;HUVEC TERT2: 29.7;U-266/70: 73.8;U-266/84: 29.1
PPP1R18,"KIAA1949, phostensin",ENSG00000146112,Protein phosphatase 1 regulatory subunit 18,6,30676389-30687895,Predicted intracellular proteins,Evidence at protein level,"HPA044745, HPA051000",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,"Renal cancer:1.11e-16 (unfavourable), Colorectal cancer:4.71e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,lymph node: 53.3,spleen: 35.1,Mixed,NA,NA
PPP1R9A,"FLJ20068, KIAA1222, Neurabin-I",ENSG00000158528,Protein phosphatase 1 regulatory subunit 9A,7,94907202-95296415,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027726, HPA075591",Uncertain,NA,Approved,Plasma membrane,"Renal cancer:8.63e-6 (favourable), Ovarian cancer:7.17e-4 (favourable)",Mixed,Mixed,NA,NA,cerebral cortex: 20.6,Mixed,NA,NA
PPP2R1B,"PP2A-Abeta, PR65B",ENSG00000137713,Protein phosphatase 2 scaffold subunit Abeta,11,111726908-111766427,Predicted intracellular proteins,Evidence at protein level,"CAB004034, HPA018908",Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Centrosome<br>Cytosol,Liver cancer:3.80e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 98.6,Expressed in all,NA,NA
PPP3R1,"CALNB1, CNB, CNB1",ENSG00000221823,"Protein phosphatase 3 regulatory subunit B, alpha",2,68178857-68256237,Predicted intracellular proteins,Evidence at protein level,"CAB005610, HPA047157",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Endometrial cancer:9.08e-6 (unfavourable), Renal cancer:1.70e-5 (unfavourable), Liver cancer:5.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 197.5,Expressed in all,NA,NA
PPP3R2,PPP3RL,ENSG00000188386,"Protein phosphatase 3 regulatory subunit B, beta",9,101591615-101595021,"FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA047157,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Tissue enriched,1372,testis: 137.1,all non-specific tissues: 0.0,Not detected,NA,NA
PPP4C,"PP4, PPX",ENSG00000149923,Protein phosphatase 4 catalytic subunit,16,30075978-30085377,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043837,Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 78.0,Expressed in all,NA,NA
PPP6R3,"C11orf23, DKFZp781E17107, DKFZp781E2374, DKFZp781O2362, FLJ11058, FLJ43065, KIAA1558, MGC125711, MGC125712, PP6R3, SAP190, SAPL, SAPLa, SAPS3",ENSG00000110075,Protein phosphatase 6 regulatory subunit 3,11,68460731-68615334,Predicted intracellular proteins,Evidence at protein level,"CAB017183, HPA038467, HPA038468",Enhanced,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,Testis cancer:8.23e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 93.8,Expressed in all,NA,NA
PPTC7,TA-PP2C,ENSG00000196850,PTC7 protein phosphatase homolog,12,110533245-110583320,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039335, HPA040614",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Ovarian cancer:1.43e-5 (unfavourable), Renal cancer:4.48e-5 (favourable), Pancreatic cancer:6.76e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 34.4,Expressed in all,NA,NA
PRAP1,UPA,ENSG00000165828,Proline rich acidic protein 1,10,133347146-133352683,Predicted secreted proteins,Evidence at protein level,"HPA038713, HPA052451",Supported,NA,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Group enriched,Group enriched,6,duodenum: 928.6;liver: 297.4;small intestine: 1097.7,kidney: 125.6,Group enriched,5,CACO-2: 18.2;Hep G2: 64.2
PRDX6,"1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX",ENSG00000117592,Peroxiredoxin 6,1,173477266-173488807,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006983, CAB008663",Supported,NA,Supported,Plasma membrane<br>Cytosol,"Head and neck cancer:1.23e-5 (unfavourable), Renal cancer:9.51e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 370.1,Expressed in all,NA,NA
PRICKLE3,LMO6,ENSG00000012211,Prickle planar cell polarity protein 3,X,49175264-49186528,Predicted intracellular proteins,Evidence at protein level,"HPA000998, HPA001442",Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Centrosome,"Renal cancer:5.73e-6 (unfavourable), Urothelial cancer:4.84e-5 (favourable)",Expressed in all,Mixed,NA,NA,skin: 11.7,Mixed,NA,NA
PRIMA1,PRIMA,ENSG00000175785,Proline rich membrane anchor 1,14,93718298-93788481,Predicted membrane proteins,Evidence at protein level,"HPA046671, HPA060047",Approved,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:2.62e-7 (unfavourable), Endometrial cancer:6.99e-5 (unfavourable)",Mixed,Mixed,NA,NA,smooth muscle: 11.7,Cell line enhanced,NA,HAP1: 5.8;SCLC-21H: 11.6;SH-SY5Y: 5.9
PRKCA,PKCA,ENSG00000154229,Protein kinase C alpha,17,66302636-66810743,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB003844, HPA006563, HPA006564, CAB016290",Enhanced,Approved,Enhanced,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,cerebral cortex: 45.0,Cell line enhanced,NA,U-87 MG: 157.3
PRKCDBP,"cavin-3, CAVIN3, HSRBC, MGC20400, SRBC",ENSG00000170955,Protein kinase C delta binding protein,11,6318946-6320647,Predicted intracellular proteins,Evidence at protein level,"HPA055136, HPA073327",Approved,NA,Approved,Plasma membrane,"Renal cancer:5.21e-6 (unfavourable), Cervical cancer:3.75e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 30.4,Cell line enhanced,NA,A-431: 88.2;BJ: 80.0;TIME: 91.9;U-87 MG: 101.1;WM-115: 110.6
PRKCH,"PKC-L, PKCL, PRKCL",ENSG00000027075,Protein kinase C eta,14,61187559-61550976,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026294, HPA053709",Approved,NA,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:8.55e-6 (favourable),Expressed in all,Expressed in all,NA,NA,lymph node: 61.7,Cell line enhanced,NA,BEWO: 78.7;HUVEC TERT2: 90.5;MOLT-4: 60.3;TIME: 58.5
PRKCZ,PKC2,ENSG00000067606,Protein kinase C zeta,1,2050470-2185395,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA021851,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.64e-9 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 99.7,placenta: 62.3,Cell line enhanced,NA,BEWO: 45.1
PRKD1,"PKC-mu, PKCM, PKD, PRKCM",ENSG00000184304,Protein kinase D1,14,29576479-30191898,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB018367, HPA029834",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.44e-5 (favourable), Thyroid cancer:2.91e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 50.3,prostate: 28.5,Mixed,NA,NA
PROSER2,"C10orf47, MGC35403",ENSG00000148426,Proline and serine rich 2,10,11823339-11872277,Predicted intracellular proteins,Evidence at protein level,HPA041337,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,placenta: 10.3,Cell line enhanced,NA,A-431: 74.3;CAPAN-2: 87.1
PRR7,MGC10772,ENSG00000131188,"Proline rich 7, synaptic",5,177446445-177456286,Predicted intracellular proteins,Evidence at transcript level,HPA046636,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Liver cancer:1.50e-4 (unfavourable), Renal cancer:1.98e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 8.1,bone marrow: 3.7,Mixed,NA,NA
PRRC2A,"BAT2, D6S51E, G2",ENSG00000204469,Proline rich coiled-coil 2A,6,31620720-31637771,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB026383, HPA046791, HPA066501",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,testis: 20.7,Cell line enhanced,NA,HBEC3-KT: 58.8;HEK93: 135.9;U-266/70: 57.4;U-266/84: 59.9;U-698: 54.2
PRRG1,PRGP1,ENSG00000130962,Proline rich and Gla domain 1,X,37349275-37457295,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA056029, HPA078129",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,"Renal cancer:2.05e-7 (favourable), Pancreatic cancer:1.22e-4 (unfavourable), Cervical cancer:4.65e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 21.6,Cell line enhanced,NA,RPTEC TERT1: 59.3
PRRT2,"DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC",ENSG00000167371,Proline rich transmembrane protein 2,16,29811382-29815892,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014447, HPA019203",Enhanced,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 98.1,ovary: 54.6,Cell line enhanced,NA,AF22: 26.4;REH: 19.4;U-138 MG: 18.0
PRRT3,FLJ33674,ENSG00000163704,Proline rich transmembrane protein 3,3,9945542-9952394,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA035127, HPA035128",Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 19.4;parathyroid gland: 27.8,fallopian tube: 12.2,Cell line enhanced,NA,MCF7: 17.7;SK-BR-3: 25.1
PRRT4,NA,ENSG00000224940,Proline rich transmembrane protein 4,7,128350325-128361685,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA046373, HPA052681",Uncertain,NA,Approved,Nucleoplasm<br>Peroxisomes<br>Plasma membrane,NA,Mixed,Group enriched,12,adipose tissue: 15.7;bone marrow: 41.2,cerebral cortex: 2.2,Cell line enriched,8,SH-SY5Y: 239.1
PRTG,"FLJ25756, IGDCC5",ENSG00000166450,Protogenin,15,55611546-55743090,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA032138,Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,thyroid gland: 18.2,testis: 6.7,Cell line enriched,6,AF22: 148.8
PRX,KIAA1620,ENSG00000105227,Periaxin,19,40393768-40413366,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA001868,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Tissue enhanced,NA,lung: 28.8,parathyroid gland: 9.4,Mixed,NA,NA
PSCA,NA,ENSG00000167653,Prostate stem cell antigen,8,142670308-142682724,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA030783, HPA056418",Approved,NA,Supported,Plasma membrane,Pancreatic cancer:5.60e-5 (unfavourable),Tissue enriched,Group enriched,8,prostate: 344.6;stomach: 1648.5;urinary bladder: 343.4,esophagus: 101.7,Cell line enhanced,NA,CAPAN-2: 18.6;HeLa: 27.5;RT4: 47.1
PSD,"EFA6, EFA6A, KIAA2011, PSD1, TYL",ENSG00000059915,Pleckstrin and Sec7 domain containing,10,102402617-102421539,Predicted intracellular proteins,Evidence at protein level,HPA059237,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 112.7,endometrium: 40.4,Cell line enhanced,NA,HSkMC: 5.6;SCLC-21H: 8.7;SH-SY5Y: 6.8
PSMC5,"p45, p45/SUG, S8, SUG-1, SUG1, TBP10, TRIP1",ENSG00000087191,"Proteasome 26S subunit, ATPase 5",17,63827152-63832026,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA017871, HPA064293",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:3.13e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 251.4,Expressed in all,NA,NA
PSMC6,p42,ENSG00000100519,"Proteasome 26S subunit, ATPase 6",14,52707172-52728587,Predicted intracellular proteins,Evidence at protein level,HPA042823,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 91.8,Expressed in all,NA,NA
PSMD9,"p27, Rpn4",ENSG00000110801,"Proteasome 26S subunit, non-ATPase 9",12,121888731-121918297,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040512, HPA044220",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Liver cancer:1.32e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 17.8,Expressed in all,NA,NA
PSTPIP2,NA,ENSG00000152229,Proline-serine-threonine phosphatase interacting protein 2,18,45983536-46072272,Predicted intracellular proteins,Evidence at protein level,"HPA040923, HPA040944",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Mitochondria,Renal cancer:2.39e-7 (unfavourable),Expressed in all,Tissue enhanced,NA,bone marrow: 47.2;spleen: 69.7,placenta: 17.3,Cell line enhanced,NA,HEL: 91.3;HMC-1: 95.2
PTAFR,NA,ENSG00000169403,Platelet activating factor receptor,1,28147166-28193936,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA027543,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Tissue enhanced,NA,appendix: 41.1,bone marrow: 26.2,Cell line enhanced,NA,HBEC3-KT: 26.0;HMC-1: 113.4
PTCHD4,"C6orf138, dJ402H5.2, FLJ41841",ENSG00000244694,Patched domain containing 4,6,47878028-48068689,Predicted membrane proteins,Evidence at transcript level,HPA041276,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.49e-6 (favourable),Group enriched,Mixed,NA,NA,seminal vesicle: 2.8,Cell line enhanced,NA,AF22: 17.0;BEWO: 22.0;Hep G2: 27.0;LHCN-M2: 15.3;TIME: 16.1;WM-115: 16.7
PTK2B,"CADTK, CAKB, FAK2, PTK, PYK2, RAFTK",ENSG00000120899,Protein tyrosine kinase 2 beta,8,27311482-27459391,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003850, HPA026091, HPA026276",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,"Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 91.1,Cell line enhanced,NA,REH: 128.1
PTK6,BRK,ENSG00000101213,Protein tyrosine kinase 6,20,63528001-63537370,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB032952, HPA036070, HPA036071",Approved,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,"Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)",Mixed,Tissue enhanced,NA,esophagus: 61.0;skin: 60.4,duodenum: 29.2,Cell line enhanced,NA,A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7
PTPN12,"PTP-PEST, PTPG1",ENSG00000127947,"Protein tyrosine phosphatase, non-receptor type 12",7,77537275-77640071,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007097,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:7.27e-6 (unfavourable), Cervical cancer:1.15e-4 (unfavourable), Pancreatic cancer:2.01e-4 (unfavourable), Liver cancer:8.78e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 107.2,Expressed in all,NA,NA
PTPN13,"PTP-BAS, PTP-BL, PTP1E, PTPL1",ENSG00000163629,"Protein tyrosine phosphatase, non-receptor type 13",4,86594315-86815171,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002213, HPA048888, HPA065290",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,skin: 65.9,Cell line enhanced,NA,AF22: 114.7
PTPN21,"PTPD1, PTPRL10",ENSG00000070778,"Protein tyrosine phosphatase, non-receptor type 21",14,88465778-88554733,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB011468, HPA073999",Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol,Renal cancer:3.16e-9 (favourable),Expressed in all,Mixed,NA,NA,skin: 34.5,Cell line enhanced,NA,RH-30: 34.1
PTPN22,"Lyp, Lyp1, Lyp2, PTPN8",ENSG00000134242,"Protein tyrosine phosphatase, non-receptor type 22",1,113813811-113871759,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004912, CAB012209, HPA013350",Approved,NA,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,bone marrow: 24.8,lymph node: 23.3,Cell line enhanced,NA,Daudi: 49.5;U-698: 25.4
PTPN4,PTPMEG,ENSG00000088179,"Protein tyrosine phosphatase, non-receptor type 4",2,119759631-119983818,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019351,Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Lung cancer:5.16e-4 (favourable),Expressed in all,Mixed,NA,NA,thyroid gland: 24.5,Mixed,NA,NA
PTPRM,"hR-PTPu, PTPRL1, RPTPU",ENSG00000173482,"Protein tyrosine phosphatase, receptor type M",18,7566782-8406861,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA003891, CAB022442, CAB022443",Supported,NA,Approved,Plasma membrane,"Cervical cancer:8.65e-5 (unfavourable), Urothelial cancer:1.07e-4 (favourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 91.6,Mixed,NA,NA
PTPRS,NA,ENSG00000105426,"Protein tyrosine phosphatase, receptor type S",19,5158495-5340803,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054747,NA,NA,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 70.7,Cell line enhanced,NA,AN3-CA: 112.7;HaCaT: 110.4
PTRF,"cavin-1, CAVIN1",ENSG00000177469,Polymerase I and transcript release factor,17,42402452-42423517,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049838, HPA074213",Supported,NA,Supported,Vesicles<br>Plasma membrane,"Urothelial cancer:5.87e-4 (unfavourable), Ovarian cancer:5.92e-4 (unfavourable), Colorectal cancer:6.36e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 343.1,Cell line enhanced,NA,BJ: 868.3;U-138 MG: 835.1
PURG,"PURG-A, PURG-B",ENSG00000172733,Purine rich element binding protein G,8,30995802-31033715,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047746,Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 6.6;testis: 4.8,endometrium: 2.6,Cell line enhanced,NA,AF22: 6.0;NTERA-2: 4.8;SH-SY5Y: 6.0
PVR,"CD155, HVED, Necl-5, NECL5, PVS, Tage4",ENSG00000073008,Poliovirus receptor,19,44643798-44663583,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012568,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,"Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 17.0,Cell line enhanced,NA,TIME: 147.4
PXDC1,C6orf145,ENSG00000168994,PX domain containing 1,6,3722614-3752026,Predicted intracellular proteins,Evidence at protein level,HPA019246,NA,NA,Approved,Plasma membrane,"Endometrial cancer:1.14e-4 (unfavourable), Colorectal cancer:3.64e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 82.7,Mixed,NA,NA
PXK,FLJ20335,ENSG00000168297,PX domain containing serine/threonine kinase like,3,58332880-58426126,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024068,Supported,NA,Supported,Plasma membrane<br>Microtubule organizing center<br>Cytosol,Lung cancer:5.68e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 124.5,Expressed in all,NA,NA
PYGL,NA,ENSG00000100504,Glycogen phosphorylase L,14,50857891-50944736,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000962, HPA004119",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 116.5,Mixed,NA,NA
RAB13,NA,ENSG00000143545,"RAB13, member RAS oncogene family",1,153981617-153986358,Predicted intracellular proteins,Evidence at protein level,HPA003996,Approved,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,prostate: 150.3,Mixed,NA,NA
RAB23,NA,ENSG00000112210,"RAB23, member RAS oncogene family",6,57186992-57222314,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA029135, HPA029136",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,smooth muscle: 110.0,Expressed in all,NA,NA
RAB26,NA,ENSG00000167964,"RAB26, member RAS oncogene family",16,2140803-2154165,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA075624,NA,NA,Uncertain,Vesicles<br>Plasma membrane<br>Centrosome,Cervical cancer:8.20e-5 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 21.1,liver: 11.4,Cell line enhanced,NA,A549: 18.3;HeLa: 14.7;SCLC-21H: 32.1;SK-BR-3: 18.7
RAB27B,NA,ENSG00000041353,"RAB27B, member RAS oncogene family",18,54717860-54895516,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017712, HPA019849",Enhanced,NA,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,Pancreatic cancer:2.13e-4 (unfavourable),Mixed,Tissue enhanced,NA,prostate: 31.7;stomach: 40.5,cerebral cortex: 24.3,Cell line enhanced,NA,HEL: 54.6;U-87 MG: 154.0
RAB3GAP2,"DKFZP434D245, KIAA0839, RAB3-GAP150, SPG69",ENSG00000118873,RAB3 GTPase activating non-catalytic protein subunit 2,1,220148293-220272454,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA026273, HPA027299",Approved,NA,Supported,Plasma membrane<br>Cytosol,Breast cancer:3.05e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 34.9,Expressed in all,NA,NA
RAB43,"ISY1, RAB11B, RAB41",ENSG00000172780,"RAB43, member RAS oncogene family",3,129087569-129122801,Predicted intracellular proteins,Evidence at protein level,"HPA046840, HPA060085",Enhanced,NA,Supported,Plasma membrane,NA,Mixed,Mixed,NA,NA,thyroid gland: 37.3,Mixed,NA,NA
RAB8A,"MEL, RAB8",ENSG00000167461,"RAB8A, member RAS oncogene family",19,16111629-16134234,Predicted intracellular proteins,Evidence at protein level,HPA041945,NA,NA,Supported,Nucleus<br>Plasma membrane,"Renal cancer:6.56e-5 (unfavourable), Thyroid cancer:1.71e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,small intestine: 64.5,Expressed in all,NA,NA
RABEPK,"bA65N13.1, RAB9P40",ENSG00000136933,Rab9 effector protein with kelch motifs,9,125200542-125234158,Predicted intracellular proteins,Evidence at protein level,"HPA023920, HPA067106",Enhanced,NA,Uncertain,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,liver: 30.6,Expressed in all,NA,NA
RAD52,NA,ENSG00000002016,"RAD52 homolog, DNA repair protein",12,912077-990053,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA028957,NA,NA,Approved,Nuclear speckles<br>Plasma membrane,Renal cancer:2.22e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 13.0,Expressed in all,NA,NA
RAI2,NA,ENSG00000131831,Retinoic acid induced 2,X,17800049-17861337,Predicted intracellular proteins,Evidence at protein level,HPA051054,Uncertain,NA,Approved,Plasma membrane,"Renal cancer:3.39e-14 (favourable), Pancreatic cancer:2.77e-4 (favourable)",Expressed in all,Mixed,NA,NA,fallopian tube: 79.1,Cell line enriched,9,ASC diff: 71.0
RALGAPA2,"AS250, C20orf74, dJ1049G11.4, KIAA1272, RapGAPalpha2",ENSG00000188559,Ral GTPase activating protein catalytic alpha subunit 2,20,20389552-20712488,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042707, HPA043622",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:3.77e-5 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 39.9,Group enriched,5,RT4: 88.7;SCLC-21H: 71.2
RAPH1,"ALS2CR18, ALS2CR9, KIAA1681",ENSG00000173166,Ras association (RalGDS/AF-6) and pleckstrin homology domains 1,2,203394345-203535410,Predicted intracellular proteins,Evidence at protein level,"HPA016744, HPA020027",Approved,NA,Approved,Nuclear bodies<br>Plasma membrane<br>Cytosol,NA,Mixed,Expressed in all,NA,NA,thyroid gland: 50.0,Mixed,NA,NA
RAPSN,"CMS1D, CMS1E, RNF205",ENSG00000165917,Receptor associated protein of the synapse,11,47437757-47449178,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA039475,Approved,NA,Approved,Plasma membrane<br>Centrosome<br>Cytosol,NA,Mixed,Tissue enriched,10,skeletal muscle: 30.0,placenta: 2.9,Group enriched,40,LHCN-M2: 47.4;RH-30: 226.0
RASAL2,nGAP,ENSG00000075391,RAS protein activator like 2,1,178094141-178484147,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA018805, HPA020453",Enhanced,NA,Approved,Plasma membrane<br>Focal adhesion sites,Urothelial cancer:2.05e-4 (unfavourable),Expressed in all,Mixed,NA,NA,esophagus: 19.4,Mixed,NA,NA
RASD1,"AGS1, DEXRAS1",ENSG00000108551,Ras related dexamethasone induced 1,17,17494437-17496395,Predicted intracellular proteins,Evidence at protein level,HPA047896,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 113.2,Cell line enhanced,NA,ASC diff: 48.2;REH: 65.3
RASD2,"MGC:4834, Rhes, TEM2",ENSG00000100302,RASD family member 2,22,35540868-35554001,Predicted intracellular proteins,Evidence at protein level,HPA005839,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:2.22e-5 (unfavourable),Mixed,Tissue enhanced,NA,seminal vesicle: 32.2,epididymis: 18.5,Cell line enhanced,NA,SK-BR-3: 4.2;U-2 OS: 3.3;U-87 MG: 3.9
RASGRP1,"CalDAG-GEFII, RASGRP",ENSG00000172575,RAS guanyl releasing protein 1,15,38488103-38565575,"Disease related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA039389,NA,NA,Supported,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 28.4;lymph node: 25.0,tonsil: 15.2,Cell line enhanced,NA,HDLM-2: 50.5;MOLT-4: 41.7
RASSF2,"CENP-34, KIAA0168",ENSG00000101265,Ras association domain family member 2,20,4780023-4823645,Predicted intracellular proteins,Evidence at protein level,HPA051200,Uncertain,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:7.82e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 148.5,lymph node: 68.8,Cell line enhanced,NA,HL-60: 59.0;NB-4: 60.4;U-937: 91.0
RASSF3,NA,ENSG00000153179,Ras association domain family member 3,12,64507001-64697567,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB022664, CAB034035, HPA038469",Supported,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,smooth muscle: 86.2,Expressed in all,NA,NA
RC3H1,"KIAA2025, RNF198, roquin, RP5-1198E17.5",ENSG00000135870,Ring finger and CCCH-type domains 1,1,173931214-174022297,Predicted intracellular proteins,Evidence at protein level,"HPA027428, HPA027434, HPA027448",Approved,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:7.96e-4 (unfavourable),Expressed in all,Mixed,NA,NA,bone marrow: 12.9,Mixed,NA,NA
RCCD1,MGC14386,ENSG00000166965,RCC1 domain containing 1,15,90954870-90963125,Predicted intracellular proteins,Evidence at protein level,"HPA039683, HPA040776",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 8.9,Mixed,NA,NA
RCSD1,"CapZIP, MGC21854, MK2S4",ENSG00000198771,RCSD domain containing 1,1,167630093-167706249,Predicted intracellular proteins,Evidence at protein level,HPA016597,Enhanced,NA,Uncertain,Nucleoplasm<br>Plasma membrane,Head and neck cancer:2.97e-4 (favourable),Expressed in all,Tissue enhanced,NA,lymph node: 107.2,spleen: 72.4,Cell line enhanced,NA,Daudi: 144.4;REH: 185.8;RPMI-8226: 96.4;U-266/70: 99.4;U-698: 91.2
RDX,DFNB24,ENSG00000137710,Radixin,11,110174880-110296722,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA000263, HPA000763, CAB037312",Enhanced,NA,Enhanced,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,adrenal gland: 198.2,Mixed,NA,NA
RECK,"hRECK, ST15",ENSG00000122707,Reversion inducing cysteine rich protein with kazal motifs,9,36036433-36124451,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB025109, HPA071729",Supported,NA,Supported,Plasma membrane,Stomach cancer:7.31e-4 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 21.4,Group enriched,5,ASC diff: 122.8;ASC TERT1: 99.6;BJ: 49.1;BJ hTERT+: 67.5;fHDF/TERT166: 40.1;HSkMC: 46.5;TIME: 32.3
RELL1,NA,ENSG00000181826,RELT like 1,4,37590800-37686376,Predicted membrane proteins,Evidence at protein level,HPA013377,Approved,NA,Supported,Plasma membrane<br>Microtubules,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 27.7,Cell line enhanced,NA,RH-30: 57.4
RELN,"PRO1598, RL",ENSG00000189056,Reelin,7,103471784-103989516,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA046512,NA,NA,Approved,Plasma membrane<br>Focal adhesion sites,NA,Tissue enhanced,Tissue enhanced,NA,liver: 17.8,cerebral cortex: 7.3,Cell line enhanced,NA,Hep G2: 43.5;PC-3: 11.6;SCLC-21H: 17.5;SH-SY5Y: 17.2;TIME: 29.6
REPS1,NA,ENSG00000135597,RALBP1 associated Eps domain containing 1,6,138903493-138988261,Predicted intracellular proteins,Evidence at protein level,"HPA029961, HPA029962",Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Liver cancer:9.47e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 66.1,Expressed in all,NA,NA
RET,"CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51",ENSG00000165731,Ret proto-oncogene,10,43077027-43130351,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002581, HPA008356, HPA008495, CAB018342",Approved,Supported,Supported,Vesicles<br>Plasma membrane<br>Cytosol,Endometrial cancer:5.02e-4 (unfavourable),Tissue enhanced,Tissue enriched,5,parathyroid gland: 154.5,adrenal gland: 29.8,Cell line enriched,5,SH-SY5Y: 404.3
RFLNB,"Cfm1, FAM101B, MGC45871, RefilinB",ENSG00000183688,Refilin B,17,439978-445939,Predicted intracellular proteins,Evidence at protein level,"HPA030879, HPA060388",Enhanced,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,Renal cancer:1.54e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,bone marrow: 49.3,placenta: 15.2,Cell line enhanced,NA,fHDF/TERT166: 74.0;HMC-1: 195.7
RFPL1,RNF78,ENSG00000128250,Ret finger protein like 1,22,29438583-29442455,Predicted intracellular proteins,Evidence at transcript level,"HPA048320, HPA072380",NA,NA,Approved,Nuclear speckles<br>Plasma membrane,NA,Not detected,Tissue enriched,8,cerebral cortex: 27.8,adrenal gland: 3.6,Cell line enhanced,NA,HDLM-2: 6.6;HMC-1: 2.3;Karpas-707: 2.0;SH-SY5Y: 3.5;THP-1: 2.2
RFPL2,RNF79,ENSG00000128253,Ret finger protein like 2,22,32190435-32203477,Predicted intracellular proteins,Evidence at transcript level,"HPA048320, HPA072380",NA,NA,Approved,Nuclear speckles<br>Plasma membrane,Prostate cancer:4.16e-4 (favourable),Tissue enriched,Tissue enriched,7,prostate: 5.8,cerebral cortex: 0.8,Not detected,NA,NA
RFPL3,NA,ENSG00000128276,Ret finger protein like 3,22,32354885-32361161,Predicted intracellular proteins,Evidence at protein level,"HPA048320, HPA072380",NA,NA,Approved,Nuclear speckles<br>Plasma membrane,NA,Not detected,Tissue enriched,13,testis: 3.6,prostate: 0.2,Not detected,NA,NA
RGP1,KIAA0258,ENSG00000107185,"RGP1 homolog, RAB6A GEF complex partner 1",9,35749287-35758575,Predicted intracellular proteins,Evidence at protein level,"HPA020414, HPA021085",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:8.55e-13 (favourable), Liver cancer:7.09e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 35.9,Expressed in all,NA,NA
RGS10,NA,ENSG00000148908,Regulator of G-protein signaling 10,10,119499828-119542708,Predicted intracellular proteins,Evidence at protein level,"CAB004559, HPA021305, HPA058485",Enhanced,Supported,Supported,Nucleus<br>Plasma membrane,"Renal cancer:4.20e-10 (unfavourable), Endometrial cancer:6.32e-4 (favourable), Cervical cancer:6.81e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 137.6,Cell line enhanced,NA,HMC-1: 456.7
RHOBTB2,"DBC2, KIAA0717",ENSG00000008853,Rho related BTB domain containing 2,8,22987417-23020199,Predicted intracellular proteins,Evidence at protein level,HPA060938,Approved,NA,Approved,Plasma membrane,Renal cancer:2.98e-4 (favourable),Expressed in all,Mixed,NA,NA,lung: 52.7,Expressed in all,NA,NA
RHOJ,"ARHJ, FLJ14445, RASL7B, TCL",ENSG00000126785,Ras homolog family member J,14,63204114-63293219,Predicted intracellular proteins,Evidence at protein level,HPA003050,Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,Renal cancer:1.31e-4 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 48.3,Cell line enhanced,NA,AF22: 64.5;HUVEC TERT2: 319.9;TIME: 83.9;WM-115: 109.1
RIF1,"FLJ10599, FLJ12870",ENSG00000080345,Replication timing regulatory factor 1,2,151409883-151508013,Predicted intracellular proteins,Evidence at protein level,"HPA036887, HPA036888",Supported,NA,Uncertain,Nucleus<br>Nuclear bodies<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,testis: 21.1,Expressed in all,NA,NA
RILPL1,FLJ39378,ENSG00000188026,Rab interacting lysosomal protein like 1,12,123470054-123533718,Predicted intracellular proteins,Evidence at protein level,HPA041314,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,heart muscle: 34.5,Mixed,NA,NA
RIMBP3,"KIAA1666, RIMBP3.1, RIMBP3A",ENSG00000275793,RIMS binding protein 3,22,18605815-18611919,Predicted intracellular proteins,Evidence at protein level,HPA001183,Supported,NA,Uncertain,Vesicles<br>Plasma membrane,NA,Not detected,Tissue enriched,37,testis: 45.4,parathyroid gland: 1.2,Mixed,NA,NA
RIMBP3B,NA,ENSG00000274600,RIMS binding protein 3B,22,21383374-21389478,Predicted intracellular proteins,Evidence at protein level,HPA001183,Supported,NA,Uncertain,Vesicles<br>Plasma membrane,NA,Not detected,Tissue enriched,26,testis: 12.1,parathyroid gland: 0.4,Cell line enhanced,NA,RH-30: 1.0;THP-1: 1.0
RIMBP3C,NA,ENSG00000183246,RIMS binding protein 3C,22,21545357-21551461,Predicted intracellular proteins,Evidence at protein level,HPA001183,Supported,NA,Uncertain,Vesicles<br>Plasma membrane,NA,Not detected,Tissue enriched,32,testis: 15.7,spleen: 0.4,Not detected,NA,NA
RIMS2,"KIAA0751, OBOE, RAB3IP3, RIM2",ENSG00000176406,Regulating synaptic membrane exocytosis 2,8,103500748-104256094,Predicted intracellular proteins,Evidence at protein level,"HPA046538, HPA066498, CAB079049",Enhanced,Supported,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,adrenal gland: 67.7;cerebral cortex: 45.0,"cervix, uterine: 11.5",Cell line enhanced,NA,Daudi: 10.2;RT4: 8.0;SCLC-21H: 28.6
RIOK2,FLJ11159,ENSG00000058729,RIO kinase 2,5,97160867-97183260,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005681,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 22.1,Expressed in all,NA,NA
RIOK3,SUDD,ENSG00000101782,RIO kinase 3,18,23452823-23486603,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001620, HPA024184",Approved,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol,"Pancreatic cancer:4.10e-4 (unfavourable), Prostate cancer:5.80e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 74.9,Expressed in all,NA,NA
RIPK1,RIP,ENSG00000137275,Receptor interacting serine/threonine kinase 1,6,3063991-3115187,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB010302, HPA015257",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Urothelial cancer:6.71e-4 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 26.1,Expressed in all,NA,NA
RND1,"ARHS, Rho6, RHOS",ENSG00000172602,Rho family GTPase 1,12,48857145-48865898,Predicted intracellular proteins,Evidence at protein level,HPA077800,NA,NA,Supported,Vesicles<br>Plasma membrane<br>Actin filaments,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 39.8;liver: 31.1,gallbladder: 23.6,Cell line enriched,6,SK-BR-3: 51.2
RNF114,"PSORS12, ZNF313",ENSG00000124226,Ring finger protein 114,20,49936336-49953892,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021184,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Endometrial cancer:8.10e-6 (unfavourable), Thyroid cancer:3.01e-4 (favourable), Liver cancer:3.11e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 149.2,Expressed in all,NA,NA
RNF145,FLJ31951,ENSG00000145860,Ring finger protein 145,5,159157409-159210053,Predicted membrane proteins,Evidence at protein level,HPA036562,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:1.64e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 109.0,Expressed in all,NA,NA
RNF146,"dactylidin, dJ351K20.1, DKFZp434O1427",ENSG00000118518,Ring finger protein 146,6,127266610-127288567,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027158, HPA027209",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:5.26e-5 (favourable), Renal cancer:7.32e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 94.6,Expressed in all,NA,NA
RNF149,FLJ90504,ENSG00000163162,Ring finger protein 149,2,101271219-101308701,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011424,Approved,NA,Approved,Vesicles<br>Plasma membrane,"Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,appendix: 67.8,Mixed,NA,NA
RNF165,"ARKL2, RNF111L2",ENSG00000141622,Ring finger protein 165,18,46326809-46463140,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041615, HPA047798",Uncertain,NA,Approved,Nucleus<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 9.3;parathyroid gland: 9.8,thyroid gland: 7.0,Cell line enhanced,NA,AF22: 13.9;SCLC-21H: 17.1;SH-SY5Y: 17.5
RNF166,"MGC14381, MGC2647",ENSG00000158717,Ring finger protein 166,16,88696495-88706421,Predicted intracellular proteins,Evidence at protein level,HPA042970,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:9.45e-6 (unfavourable), Pancreatic cancer:1.04e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 57.1,Expressed in all,NA,NA
RNF39,"HZFw1, LIRF",ENSG00000204618,Ring finger protein 39,6,30070266-30075887,Predicted intracellular proteins,Evidence at protein level,"CAB019278, HPA047115",Uncertain,NA,Uncertain,Vesicles<br>Plasma membrane<br>Centrosome,NA,Mixed,Tissue enhanced,NA,skin: 3.5,breast: 2.0,Cell line enhanced,NA,A-431: 1.1;U-266/84: 2.5
ROBO1,"DUTT1, FLJ21882, SAX3",ENSG00000169855,Roundabout guidance receptor 1,3,78597240-79767815,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB013524, HPA052968, HPA074461",Uncertain,NA,Enhanced,Plasma membrane,Liver cancer:9.88e-4 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 32.9,Mixed,NA,NA
ROBO4,"ECSM4, FLJ20798, MRB",ENSG00000154133,Roundabout guidance receptor 4,11,124883691-124898500,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA065212,NA,NA,Approved,Plasma membrane,"Liver cancer:4.85e-4 (favourable), Stomach cancer:8.73e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,spleen: 58.2,adipose tissue: 45.1,Group enriched,9,HUVEC TERT2: 203.4;TIME: 180.3
ROM1,"ROM, TSPAN23",ENSG00000149489,Retinal outer segment membrane protein 1,11,62611722-62615120,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028910,Supported,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:2.85e-6 (unfavourable), Lung cancer:2.20e-4 (favourable)",Tissue enriched,Tissue enhanced,NA,cerebral cortex: 25.4,ovary: 13.3,Mixed,NA,NA
RP11-192H23.4,NA,ENSG00000258472,NA,17,28455752-28614197,Predicted intracellular proteins,Evidence at protein level,HPA046590,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 2.2,lung: 1.2,Cell line enhanced,NA,A549: 2.3;PC-3: 1.1
RP11-298I3.5,NA,ENSG00000259132,NA,14,22946270-22982258,Predicted intracellular proteins,Evidence at protein level,HPA029803,Approved,NA,Approved,Plasma membrane<br>Focal adhesion sites,NA,Not detected,Mixed,NA,NA,skin: 9.3,Cell line enhanced,NA,Hep G2: 29.1
RP11-385D13.1,NA,ENSG00000251537,NA,17,15571491-15651653,Predicted intracellular proteins,Evidence at protein level,"HPA023623, HPA066431",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Not detected,Not detected,NA,NA,skin: 0.4,Cell line enhanced,NA,A549: 1.2;CAPAN-2: 1.0;HaCaT: 2.2
RP11-73M18.2,NA,ENSG00000256500,NA,14,103562962-103685924,Predicted intracellular proteins,Evidence at protein level,"HPA044617, HPA052450",Uncertain,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 21.5;testis: 21.6,skeletal muscle: 9.0,Expressed in all,NA,NA
RP2,"NM23-H10, NME10, TBCCD2",ENSG00000102218,Retinitis pigmentosa 2 (X-linked recessive),X,46836940-46882358,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA000234, HPA000909",Uncertain,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane,Liver cancer:7.97e-4 (unfavourable),Expressed in all,Mixed,NA,NA,placenta: 35.0,Expressed in all,NA,NA
RP5-877J2.1,NA,ENSG00000250424,NA,7,30852273-30923812,Predicted membrane proteins,Evidence at protein level,"HPA019206, HPA030130",Approved,NA,Approved,Plasma membrane,NA,Not detected,Tissue enhanced,NA,gallbladder: 1.5,fallopian tube: 1.2,Not detected,NA,NA
RPGRIP1L,"CORS3, FTM, JBTS7, KIAA1005, MKS5, NPHP8, PPP1R134",ENSG00000103494,RPGRIP1 like,16,53597683-53703938,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039405, HPA040530",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:5.95e-4 (unfavourable), Breast cancer:6.93e-4 (unfavourable)",Mixed,Tissue enhanced,NA,testis: 27.9,parathyroid gland: 19.3,Expressed in all,NA,NA
RPL36A,"L36A, RPL44",ENSG00000241343,Ribosomal protein L36a,X,101390824-101396154,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA063979, HPA077586",Uncertain,NA,Supported,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,Renal cancer:8.81e-11 (unfavourable),Expressed in all,Expressed in all,NA,NA,ovary: 3453.0,Expressed in all,NA,NA
RPL36A-HNRNPH2,NA,ENSG00000257529,RPL36A-HNRNPH2 readthrough,X,101391011-101412297,Predicted intracellular proteins,Evidence at transcript level,HPA077586,NA,NA,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,NA,Not detected,Mixed,NA,NA,ovary: 2.6,Cell line enhanced,NA,BJ: 10.0
RPL36AL,RPL36A,ENSG00000165502,Ribosomal protein L36a like,14,49618519-49620685,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA077586,NA,NA,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,Thyroid cancer:2.83e-4 (favourable),Expressed in all,Expressed in all,NA,NA,ovary: 529.4,Expressed in all,NA,NA
RPSA,"37LRP, LAMR1, LRP, p40, SA",ENSG00000168028,Ribosomal protein SA,3,39406689-39412542,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,CAB009561,Approved,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,ovary: 2084.6,Expressed in all,NA,NA
RRAD,"RAD, REM3",ENSG00000166592,"RRAD, Ras related glycolysis inhibitor and calcium channel regulator",16,66921679-66925644,Predicted intracellular proteins,Evidence at protein level,HPA041755,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,NA,Expressed in all,Tissue enhanced,NA,heart muscle: 98.8;skeletal muscle: 67.5,esophagus: 62.8,Group enriched,8,HDLM-2: 166.9;U-87 MG: 48.4
RSAD1,FLJ11164,ENSG00000136444,Radical S-adenosyl methionine domain containing 1,17,50478800-50485975,Predicted intracellular proteins,Evidence at protein level,"HPA022436, HPA022967",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Pancreatic cancer:5.04e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 36.7,Expressed in all,NA,NA
RSBN1L,"FLJ42526, FLJ45813, MGC71764",ENSG00000187257,Round spermatid basic protein 1 like,7,77696443-77783022,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA020406, HPA020413",Approved,NA,Supported,Nuclear speckles<br>Plasma membrane,Lung cancer:3.74e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 46.7,Expressed in all,NA,NA
RSPH3,"dJ111C20.1, RSHL2, RSP3",ENSG00000130363,Radial spoke 3 homolog,6,158972871-159000187,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039109, HPA040230",Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:2.19e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 26.4,Mixed,NA,NA
RTN4R,NOGOR,ENSG00000040608,Reticulon 4 receptor,22,20241415-20283246,Predicted membrane proteins,Evidence at protein level,CAB012443,NA,NA,Supported,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,Head and neck cancer:7.73e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 23.8,spleen: 5.0,Cell line enhanced,NA,NB-4: 24.1;REH: 48.8;SCLC-21H: 36.8
RYR2,"ARVC2, ARVD2, VTSIP",ENSG00000198626,Ryanodine receptor 2,1,237042205-237833988,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA020028,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,8,heart muscle: 65.9,cerebral cortex: 7.9,Cell line enhanced,NA,HDLM-2: 4.8;HEK93: 6.3;K-562: 2.0;NTERA-2: 2.5;U-937: 2.5
S100A13,NA,ENSG00000189171,S100 calcium binding protein A13,1,153618787-153631360,Predicted intracellular proteins,Evidence at protein level,"HPA019592, CAB025494",Approved,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,Renal cancer:1.97e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 331.5,Mixed,NA,NA
S100A16,"DT1P1A7, MGC17528, S100F",ENSG00000188643,S100 calcium binding protein A16,1,153606886-153613145,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA045841,Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,"Lung cancer:3.14e-5 (unfavourable), Renal cancer:3.91e-5 (unfavourable), Pancreatic cancer:2.04e-4 (unfavourable), Liver cancer:3.18e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,esophagus: 1489.4,skin: 394.6,Mixed,NA,NA
S100A2,"CAN19, S100L",ENSG00000196754,S100 calcium binding protein A2,1,153561108-153567890,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB002600, CAB047340, HPA062451",Enhanced,NA,Supported,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,Pancreatic cancer:2.04e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,esophagus: 1481.8,tonsil: 368.4,Cell line enhanced,NA,HBEC3-KT: 15305.5;RT4: 6706.3
S100A4,"18A2, 42A, CAPL, FSP1, MTS1, P9KA, PEL98",ENSG00000196154,S100 calcium binding protein A4,1,153543613-153550136,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002618, HPA007973, CAB027387, CAB058698, CAB068227, CAB068228",Enhanced,NA,Enhanced,Plasma membrane,"Head and neck cancer:4.03e-5 (favourable), Renal cancer:2.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lung: 990.6,Cell line enhanced,NA,BJ hTERT+: 4403.5;fHDF/TERT166: 3054.2
S100A6,"2A9, CABP, CACY, PRA",ENSG00000197956,S100 calcium binding protein A6,1,153534599-153536244,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002601, HPA007575, CAB040549, CAB047354",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Urothelial cancer:7.56e-4 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 1678.1,Cell line enhanced,NA,RPTEC TERT1: 7409.7
SAMHD1,"AGS5, HDDC1, Mg11, MOP-5, SBBI88",ENSG00000101347,SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1,20,36890229-36951843,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA047072,Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:5.12e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 133.3,Cell line enhanced,NA,ASC diff: 345.7;BJ hTERT+ SV40 Large T+: 170.4;BJ hTERT+ SV40 Large T+ RasG12V: 204.5
SAMSN1,"HACS1, NASH1, SASH2, SH3D6B, SLy2",ENSG00000155307,"SAM domain, SH3 domain and nuclear localization signals 1",21,14485228-14583402,Predicted intracellular proteins,Evidence at protein level,"HPA010645, HPA017055",Approved,NA,Enhanced,Plasma membrane,Renal cancer:4.52e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,appendix: 110.1;bone marrow: 123.6,spleen: 43.6,Cell line enhanced,NA,HEL: 244.0;K-562: 292.8;Karpas-707: 97.1
SASH3,"753P9, CXorf9, HACS2, SH3D6C, SLY",ENSG00000122122,SAM and SH3 domain containing 3,X,129779979-129795201,Predicted intracellular proteins,Evidence at protein level,HPA001085,Enhanced,NA,Approved,Plasma membrane,"Renal cancer:6.51e-5 (unfavourable), Endometrial cancer:3.15e-4 (favourable)",Expressed in all,Tissue enhanced,NA,lymph node: 136.7;spleen: 99.3;tonsil: 97.4,appendix: 80.4,Cell line enhanced,NA,Daudi: 116.3;MOLT-4: 95.0;NB-4: 56.4;REH: 79.9;U-698: 101.7;U-937: 90.0
SC5D,SC5DL,ENSG00000109929,Sterol-C5-desaturase,11,121292453-121308694,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA066283, HPA070248",Approved,NA,Approved,Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,"Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,liver: 193.5,Expressed in all,NA,NA
SCAMP4,FLJ33847,ENSG00000227500,Secretory carrier membrane protein 4,19,1905214-1926013,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA043284,Approved,NA,Approved,Golgi apparatus<br>Vesicles<br>Lipid droplets<br>Plasma membrane,"Endometrial cancer:4.40e-6 (favourable), Liver cancer:1.92e-5 (unfavourable), Renal cancer:3.56e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 59.3,Expressed in all,NA,NA
SCEL,"FLJ21667, MGC22531",ENSG00000136155,Sciellin,13,77535674-77645263,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039737, HPA040154",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.73e-5 (unfavourable), Pancreatic cancer:1.24e-4 (unfavourable), Endometrial cancer:4.07e-4 (unfavourable), Renal cancer:6.87e-4 (favourable)",Mixed,Tissue enhanced,NA,esophagus: 476.6;skin: 397.0,lung: 98.9,Cell line enhanced,NA,CAPAN-2: 28.9;HaCaT: 54.8;HBEC3-KT: 21.3;RPTEC TERT1: 89.6
SCIN,KIAA1905,ENSG00000006747,Scinderin,7,12570577-12660179,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020518, HPA024264",Enhanced,NA,Enhanced,Plasma membrane,Renal cancer:4.26e-8 (favourable),Tissue enhanced,Tissue enhanced,NA,placenta: 110.4,kidney: 52.0,Cell line enhanced,NA,RPTEC TERT1: 71.2;SK-BR-3: 76.9
SCN1A,"FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI",ENSG00000144285,Sodium voltage-gated channel alpha subunit 1,2,165989160-166149214,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA078664,NA,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane,NA,Tissue enriched,Group enriched,41,cerebral cortex: 10.3;fallopian tube: 2.9;lung: 2.2,"adrenal gland,placenta,testis: 0.1",Cell line enhanced,NA,AF22: 1.1;ASC TERT1: 4.4;Hep G2: 1.1
SCN9A,"ETHA, Nav1.7, NE-NA, NENA, PN1",ENSG00000169432,Sodium voltage-gated channel alpha subunit 9,2,166195185-166375993,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"CAB013679, HPA061843",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,Renal cancer:2.30e-5 (unfavourable),Mixed,Tissue enhanced,NA,testis: 9.1,placenta: 5.9,Cell line enhanced,NA,BJ: 20.5;BJ hTERT+: 13.6;HHSteC: 13.7
SCNN1D,"dNaCh, ENaCdelta",ENSG00000162572,Sodium channel epithelial 1 delta subunit,1,1280436-1292029,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026884,Enhanced,NA,Supported,Plasma membrane<br>Actin filaments,"Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable)",Mixed,Tissue enhanced,NA,testis: 13.8,cerebral cortex: 7.3,Mixed,NA,NA
SCNN1G,"ENaCgamma, SCNEG",ENSG00000166828,Sodium channel epithelial 1 gamma subunit,16,23182715-23216883,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071194,NA,NA,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:3.20e-7 (unfavourable),Tissue enhanced,Tissue enhanced,NA,"cervix, uterine: 24.6;kidney: 46.7",thyroid gland: 9.5,Group enriched,5,hTCEpi: 33.4;RT4: 17.1
SCUBE3,"CEGF3, FLJ34743",ENSG00000146197,"Signal peptide, CUB domain and EGF like domain containing 3",6,35214419-35253079,Predicted secreted proteins,Evidence at protein level,HPA040606,Uncertain,NA,Supported,Plasma membrane,Thyroid cancer:1.38e-4 (unfavourable),Tissue enhanced,Tissue enriched,7,thyroid gland: 49.4,seminal vesicle: 6.8,Cell line enhanced,NA,AF22: 27.2;ASC diff: 56.0;ASC TERT1: 76.2;HSkMC: 37.2;hTEC/SVTERT24-B: 32.0;U-138 MG: 30.4;WM-115: 26.3
SDC2,"CD362, fibroglycan, HSPG, HSPG1, SYND2",ENSG00000169439,Syndecan 2,8,96493351-96611780,"CD markers, Predicted membrane proteins",Evidence at protein level,"CAB025123, HPA044416",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 712.7,Cell line enhanced,NA,AF22: 646.8;U-138 MG: 309.2
SDC4,"amphiglycan, ryudocan, SYND4",ENSG00000124145,Syndecan 4,20,45325288-45348424,"Cancer-related genes, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA005716, CAB013240",Supported,NA,Approved,Golgi apparatus<br>Plasma membrane,"Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lung: 250.2,Mixed,NA,NA
SDE2,"C1orf55, FLJ35382",ENSG00000143751,SDE2 telomere maintenance homolog,1,225982702-225999331,Predicted intracellular proteins,Evidence at protein level,"HPA028467, HPA031255, HPA031256",Approved,NA,Approved,Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 21.1,Expressed in all,NA,NA
SDHB,"SDH, SDH1",ENSG00000117118,Succinate dehydrogenase complex iron sulfur subunit B,1,17018722-17054170,"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002868, CAB009822, CAB068233, CAB068234, CAB068235",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Mitochondria,Renal cancer:2.93e-7 (favourable),Expressed in all,Expressed in all,NA,NA,kidney: 215.2,Expressed in all,NA,NA
SDPR,"cavin-2, CAVIN2, PS-p68, SDR",ENSG00000168497,Serum deprivation response,2,191834302-191847255,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039325, HPA062122",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:8.45e-5 (favourable), Stomach cancer:3.69e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 165.9,Group enriched,6,fHDF/TERT166: 118.5;HEL: 101.3;HUVEC TERT2: 284.6;LHCN-M2: 440.0;TIME: 114.4
SEC16B,"LZTR2, PGPR-p117, RGPR, Sec16S",ENSG00000120341,"SEC16 homolog B, endoplasmic reticulum export factor",1,177923956-177984303,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054292, HPA072913",Enhanced,NA,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Actin filaments,NA,Not detected,Tissue enhanced,NA,duodenum: 28.2;small intestine: 30.9,liver: 18.8,Cell line enhanced,NA,CAPAN-2: 6.3;EFO-21: 5.1;HDLM-2: 5.3
SEMA3C,"SEMAE, SemE",ENSG00000075223,Semaphorin 3C,7,80742538-80922359,Predicted secreted proteins,Evidence at protein level,HPA042418,Uncertain,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:4.08e-5 (unfavourable), Head and neck cancer:5.72e-5 (unfavourable)",Mixed,Mixed,NA,NA,prostate: 103.0,Cell line enhanced,NA,T-47d: 248.8;U-2197: 317.7
SEMA3D,"coll-2, Sema-Z2",ENSG00000153993,Semaphorin 3D,7,84995553-85186855,Predicted intracellular proteins,Evidence at protein level,HPA037522,Uncertain,NA,Approved,Golgi apparatus<br>Plasma membrane,NA,Mixed,Group enriched,5,spleen: 66.2;thyroid gland: 76.6,prostate: 13.4,Cell line enhanced,NA,fHDF/TERT166: 22.0;HaCaT: 25.4;TIME: 36.0
SEMA4F,"SEMAM, SEMAW",ENSG00000135622,Ssemaphorin 4F,2,74654228-74683853,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA064095, HPA065969",Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Centrosome,"Renal cancer:9.74e-6 (unfavourable), Endometrial cancer:5.94e-5 (unfavourable), Glioma:3.18e-4 (unfavourable), Thyroid cancer:6.94e-4 (favourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 14.1,Mixed,NA,NA
SEMA6C,KIAA1869,ENSG00000143434,Semaphorin 6C,1,151131685-151146664,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,"HPA076150, HPA077625",NA,NA,Approved,Nucleoplasm<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,skeletal muscle: 111.3,testis: 33.8,Cell line enhanced,NA,AF22: 13.8;HUVEC TERT2: 20.6
SEMA6D,"FLJ11598, KIAA1479",ENSG00000137872,Semaphorin 6D,15,47184101-47774223,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA043109,NA,NA,Approved,Golgi apparatus<br>Plasma membrane,Renal cancer:5.96e-5 (favourable),Tissue enhanced,Tissue enhanced,NA,placenta: 63.6,small intestine: 44.3,Cell line enhanced,NA,BJ hTERT+: 12.7;SCLC-21H: 16.1;SH-SY5Y: 13.4
SEPT3,SEP3,ENSG00000100167,Septin 3,22,41976272-41998221,Predicted intracellular proteins,Evidence at protein level,"HPA003548, CAB017633",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments,Endometrial cancer:1.78e-4 (unfavourable),Tissue enhanced,Tissue enriched,11,cerebral cortex: 234.8,parathyroid gland: 21.5,Cell line enhanced,NA,AF22: 26.2;SCLC-21H: 84.0
SERPINB3,"HsT1196, SCC, SCCA1, T4-A",ENSG00000057149,Serpin family B member 3,18,63655197-63661963,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Pancreatic cancer:3.19e-4 (unfavourable),Tissue enhanced,Group enriched,7,"cervix, uterine: 298.5;esophagus: 848.0",urinary bladder: 87.5,Cell line enhanced,NA,HaCaT: 5.5;SiHa: 4.1;U-2197: 7.3
SFSWAP,"SFRS8, SWAP",ENSG00000061936,Splicing factor SWAP homolog,12,131711081-131799737,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039362, HPA040063",Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Renal cancer:3.33e-8 (unfavourable), Melanoma:1.10e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 18.1,Expressed in all,NA,NA
SGCE,DYT11,ENSG00000127990,Sarcoglycan epsilon,7,94585230-94656209,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA074790,NA,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles<br>Plasma membrane,"Head and neck cancer:1.61e-5 (unfavourable), Stomach cancer:1.35e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,ovary: 133.2,Mixed,NA,NA
SGK494,NA,ENSG00000167524,Uncharacterized serine/threonine-protein kinase SgK494,17,28607964-28614200,Predicted intracellular proteins,Evidence at protein level,HPA046590,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,testis: 10.5,Mixed,NA,NA
SH3BGR,21-GARP,ENSG00000185437,SH3 domain binding glutamate rich protein,21,39445855-39515506,Predicted intracellular proteins,Evidence at protein level,"CAB003685, HPA030690",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Group enriched,6,heart muscle: 100.8;skeletal muscle: 435.9,prostate: 41.4,Cell line enhanced,NA,U-87 MG: 100.6
SH3D21,"C1orf113, FLJ22938",ENSG00000214193,SH3 domain containing 21,1,36306387-36324886,Predicted intracellular proteins,Evidence at protein level,"HPA042212, HPA042456, HPA066168",Approved,NA,Approved,Nucleus<br>Plasma membrane,"Renal cancer:1.76e-6 (unfavourable), Breast cancer:2.60e-4 (favourable)",Mixed,Tissue enhanced,NA,small intestine: 22.2,skin: 15.5,Cell line enhanced,NA,HaCaT: 15.2
SHANK1,"SPANK-1, SSTRIP, synamon",ENSG00000161681,SH3 and multiple ankyrin repeat domains 1,19,50661827-50719450,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA032129, HPA032130",Uncertain,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enriched,24,cerebral cortex: 35.8,adrenal gland: 1.5,Cell line enhanced,NA,REH: 4.6;U-138 MG: 2.6;U-2 OS: 7.1
SHTN1,"KIAA1598, shootin-1, shootin1",ENSG00000187164,Shootin 1,10,116881482-117126586,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA037942, HPA037943",Enhanced,Approved,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 36.1,parathyroid gland: 18.7,Mixed,NA,NA
SIGLEC10,"MGC126774, PRO940, SIGLEC-10, SLG2",ENSG00000142512,Sialic acid binding Ig like lectin 10,19,51410021-51417803,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025807, HPA027093",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,Renal cancer:4.74e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,appendix: 48.4;spleen: 36.9,lymph node: 22.1,Cell line enhanced,NA,Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7
SIN3B,KIAA0700,ENSG00000127511,SIN3 transcription regulator family member B,19,16829400-16880353,Predicted intracellular proteins,Evidence at protein level,HPA050329,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,"Prostate cancer:3.58e-4 (unfavourable), Pancreatic cancer:4.37e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 112.3,Expressed in all,NA,NA
SIPA1,SPA1,ENSG00000213445,Signal-induced proliferation-associated 1,11,65638097-65650930,Predicted intracellular proteins,Evidence at protein level,"CAB020833, HPA039867",Enhanced,NA,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane,"Renal cancer:3.52e-6 (unfavourable), Colorectal cancer:9.42e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,spleen: 99.7,lymph node: 71.0,Expressed in all,NA,NA
SIPA1L1,"E6TP1, KIAA0440",ENSG00000197555,Signal induced proliferation associated 1 like 1,14,71320449-71741229,Predicted intracellular proteins,Evidence at protein level,HPA002875,Approved,NA,Approved,Plasma membrane<br>Actin filaments,Renal cancer:6.80e-8 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 47.0,Mixed,NA,NA
SKA3,"C13orf3, MGC4832, RAMA1",ENSG00000165480,Spindle and kinetochore associated complex subunit 3,13,21153595-21176602,Predicted intracellular proteins,Evidence at protein level,HPA039272,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,"Liver cancer:9.73e-6 (unfavourable), Pancreatic cancer:3.77e-4 (unfavourable), Melanoma:8.71e-4 (unfavourable)",Mixed,Tissue enhanced,NA,testis: 10.1,lymph node: 5.0,Mixed,NA,NA
SKAP1,"SCAP1, SKAP55",ENSG00000141293,Src kinase associated phosphoprotein 1,17,48133440-48430275,Predicted intracellular proteins,Evidence at protein level,"HPA002969, CAB025882, CAB055513",Enhanced,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Urothelial cancer:3.14e-4 (favourable), Breast cancer:5.07e-4 (favourable)",Mixed,Mixed,NA,NA,lymph node: 33.6,Cell line enhanced,NA,CAPAN-2: 26.1;HDLM-2: 14.7;HMC-1: 11.3;Karpas-707: 11.5;RPMI-8226: 13.6;RPTEC TERT1: 17.6;U-266/70: 11.0
SLC10A5,NA,ENSG00000253598,Solute carrier family 10 member 5,8,81693607-81696174,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA025966,Uncertain,NA,Approved,Plasma membrane,NA,Mixed,Mixed,NA,NA,liver: 3.0,Not detected,NA,NA
SLC12A2,"BSC, BSC2, NKCC1, PPP1R141",ENSG00000064651,Solute carrier family 12 member 2,5,128083766-128189688,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA020130, HPA063697",Approved,NA,Approved,Vesicles<br>Plasma membrane,"Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,rectum: 65.4,Expressed in all,NA,NA
SLC13A3,"NADC3, SDCT2",ENSG00000158296,Solute carrier family 13 member 3,20,46557823-46684467,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014333, HPA014353, HPA014736",Enhanced,NA,Supported,Plasma membrane,NA,Mixed,Tissue enriched,7,kidney: 431.7,placenta: 60.9,Cell line enhanced,NA,EFO-21: 17.7;Hep G2: 38.2
SLC16A2,"AHDS, DXS128, MCT7, MCT8, MRX22, XPCT",ENSG00000147100,Solute carrier family 16 member 2,X,74421461-74533917,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA072719,NA,NA,Approved,Plasma membrane,"Breast cancer:8.88e-5 (unfavourable), Renal cancer:1.83e-4 (unfavourable), Urothelial cancer:3.16e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adrenal gland: 24.0,Cell line enhanced,NA,BJ: 73.2
SLC16A3,"MCT3, MCT4",ENSG00000141526,Solute carrier family 16 member 3,17,82228397-82261129,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB017490, HPA021451",Approved,NA,Supported,Nuclear membrane<br>Plasma membrane,"Liver cancer:1.19e-7 (unfavourable), Renal cancer:3.71e-7 (unfavourable), Lung cancer:2.02e-5 (unfavourable), Cervical cancer:6.07e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skeletal muscle: 74.3,Mixed,NA,NA
SLC16A7,MCT2,ENSG00000118596,Solute carrier family 16 member 7,12,59596067-59789855,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA005911,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:8.85e-5 (favourable),Mixed,Mixed,NA,NA,"adipose tissue,heart muscle: 24.9",Mixed,NA,NA
SLC17A5,"AST, ISSD, NSD, SD, SIALIN, SIASD, SLD",ENSG00000119899,Solute carrier family 17 member 5,6,73593379-73654155,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA044479,NA,NA,Supported,Plasma membrane<br>Cytosol,Thyroid cancer:3.52e-4 (favourable),Expressed in all,Tissue enriched,9,parathyroid gland: 652.6,thyroid gland: 70.0,Expressed in all,NA,NA
SLC19A1,"FOLT, RFC1",ENSG00000173638,Solute carrier family 19 member 1,21,45493572-45544411,"Cancer-related genes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA024802,Approved,NA,Approved,Plasma membrane,"Renal cancer:1.07e-10 (unfavourable), Cervical cancer:4.15e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,duodenum: 22.0,Expressed in all,NA,NA
SLC1A5,"AAAT, ASCT2, M7V1, RDRC",ENSG00000105281,Solute carrier family 1 member 5,19,46774883-46788594,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA035239, HPA035240",Enhanced,NA,Enhanced,Plasma membrane,"Liver cancer:1.66e-8 (unfavourable), Renal cancer:1.18e-7 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 119.2,Expressed in all,NA,NA
SLC27A1,"ACSVL5, FATP, FATP1, FLJ00336, MGC71751",ENSG00000130304,Solute carrier family 27 member 1,19,17468769-17506168,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA076520,NA,NA,Approved,Plasma membrane<br>Mitochondria<br>Cytosol,Renal cancer:4.70e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 34.5,Cell line enhanced,NA,SK-MEL-30: 36.4
SLC2A1,"CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR",ENSG00000117394,Solute carrier family 2 member 1,1,42925375-42959173,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002759, HPA031345, HPA058494",Enhanced,Supported,Enhanced,Plasma membrane,"Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 293.0,skin: 59.3,Expressed in all,NA,NA
SLC2A14,"GLUT14, SLC2A3P3",ENSG00000173262,Solute carrier family 2 member 14,12,7812512-7891148,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA006539,Supported,NA,Approved,Plasma membrane,NA,Tissue enriched,Tissue enriched,35,testis: 148.8,ovary: 4.2,Cell line enhanced,NA,BEWO: 17.9;CACO-2: 25.7
SLC2A3,GLUT3,ENSG00000059804,Solute carrier family 2 member 3,12,7919230-7936275,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002763, HPA006539",Approved,NA,Approved,Plasma membrane,"Renal cancer:6.36e-8 (unfavourable), Stomach cancer:2.89e-5 (unfavourable), Colorectal cancer:8.58e-4 (unfavourable)",Tissue enriched,Tissue enhanced,NA,bone marrow: 271.2,placenta: 138.7,Group enriched,7,BEWO: 1387.7;CACO-2: 1315.8;NTERA-2: 293.2
SLC30A1,"ZNT1, ZRC1",ENSG00000170385,Solute carrier family 30 member 1,1,211571568-211578742,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA015275, HPA049000",Uncertain,NA,Supported,Vesicles<br>Plasma membrane,NA,Expressed in all,Mixed,NA,NA,liver: 47.3,Expressed in all,NA,NA
SLC31A2,"COPT2, CTR2, hCTR2",ENSG00000136867,Solute carrier family 31 member 2,9,113150942-113164137,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014861,Approved,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Intermediate filaments,NA,Mixed,Expressed in all,NA,NA,salivary gland: 169.9,Cell line enhanced,NA,hTCEpi: 59.3
SLC34A1,"NAPI-3, NPT2, NPTIIa, SLC11, SLC17A2",ENSG00000131183,Solute carrier family 34 member 1,5,177379235-177398848,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA051255,Approved,NA,Supported,Nuclear speckles<br>Plasma membrane<br>Mitotic spindle,NA,Tissue enriched,Tissue enriched,164,kidney: 161.7,liver: 0.9,Group enriched,12,HEL: 2.1;U-937: 1.2
SLC35F5,FLJ22004,ENSG00000115084,Solute carrier family 35 member F5,2,113705011-113756823,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA034828, HPA049229",Uncertain,NA,Uncertain,Plasma membrane,"Renal cancer:1.71e-5 (favourable), Cervical cancer:2.60e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 97.7,Expressed in all,NA,NA
SLC35G2,"DKFZp564K2464, MGC3295, TMEM22",ENSG00000168917,Solute carrier family 35 member G2,3,136818647-136855892,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052054, HPA064728",Approved,NA,Supported,Plasma membrane,Renal cancer:1.16e-7 (unfavourable),Mixed,Mixed,NA,NA,testis: 21.3,Cell line enhanced,NA,BJ hTERT+: 59.1
SLC36A4,"FLJ38932, PAT4",ENSG00000180773,Solute carrier family 36 member 4,11,93144171-93197964,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA017887,Enhanced,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 14.8,Mixed,NA,NA
SLC38A5,"JM24, SN2",ENSG00000017483,Solute carrier family 38 member 5,X,48458537-48470256,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA047411,Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:2.13e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,pancreas: 50.0,Cell line enhanced,NA,HBEC3-KT: 233.9;HeLa: 214.9;RPMI-8226: 374.4
SLC38A7,FLJ10815,ENSG00000103042,Solute carrier family 38 member 7,16,58665109-58685104,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA041777,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 34.7,Expressed in all,NA,NA
SLC39A10,"DKFZp564L2123, FLJ90515, KIAA1265",ENSG00000196950,Solute carrier family 39 member 10,2,195575977-195737702,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA036512, HPA036513, HPA066087",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 77.7;thyroid gland: 79.2,prostate: 30.8,Expressed in all,NA,NA
SLC39A14,"KIAA0062, NET34, ZIP14",ENSG00000104635,Solute carrier family 39 member 14,8,22367249-22434129,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA016508,Approved,NA,Approved,Endoplasmic reticulum<br>Golgi apparatus<br>Plasma membrane,"Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable)",Expressed in all,Mixed,NA,NA,liver: 203.0,Expressed in all,NA,NA
SLC3A2,"4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE",ENSG00000168003,Solute carrier family 3 member 2,11,62856102-62888875,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB010455, HPA017980",Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.48e-4 (unfavourable), Liver cancer:8.17e-4 (unfavourable), Renal cancer:8.22e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 431.9,Expressed in all,NA,NA
SLC40A1,"FPN1, HFE4, IREG1, MTP1, SLC11A3",ENSG00000138449,Solute carrier family 40 member 1,2,189560579-189583758,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA065634,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:8.55e-5 (favourable),Expressed in all,Expressed in all,NA,NA,spleen: 489.1,Group enriched,6,ASC diff: 336.9;CACO-2: 97.8;HEL: 380.0;HMC-1: 94.0;T-47d: 188.1
SLC41A3,FLJ20473,ENSG00000114544,Solute carrier family 41 member 3,3,126006355-126101561,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA045847,Approved,NA,Supported,Plasma membrane,"Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 77.4,Expressed in all,NA,NA
SLC43A1,"PB39, POV1, R00504",ENSG00000149150,Solute carrier family 43 member 1,11,57484534-57515786,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018813, HPA018826",Enhanced,NA,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,"Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,liver: 50.0,Mixed,NA,NA
SLC43A3,"DKFZp762A227, Eeg1, FOAP-13, PRO1659, SEEEG-1",ENSG00000134802,Solute carrier family 43 member 3,11,57406954-57427580,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA030551, HPA077244",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,Renal cancer:3.97e-13 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 122.3,Cell line enhanced,NA,WM-115: 524.5
SLC45A4,KIAA1126,ENSG00000022567,Solute carrier family 45 member 4,8,141207166-141308305,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA023154,Uncertain,NA,Approved,Plasma membrane,Renal cancer:1.73e-6 (favourable),Expressed in all,Mixed,NA,NA,testis: 21.0,Mixed,NA,NA
SLC46A1,"HCP1, MGC9564, PCFT",ENSG00000076351,Solute carrier family 46 member 1,17,28394756-28407197,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB011614,Approved,NA,Supported,Plasma membrane<br>Cytosol,Glioma:3.90e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,duodenum: 95.1,Cell line enhanced,NA,CACO-2: 169.5
SLC46A3,"DKFZp686A1775, FLJ42613",ENSG00000139508,Solute carrier family 46 member 3,13,28700064-28718970,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA039930,Uncertain,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,Lung cancer:7.09e-4 (favourable),Expressed in all,Expressed in all,NA,NA,small intestine: 87.7,Cell line enhanced,NA,RPTEC TERT1: 22.1
SLC4A1AP,"HLC3, kanadaptin",ENSG00000163798,Solute carrier family 4 member 1 adaptor protein,2,27663471-27694976,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA036679,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,"Liver cancer:3.76e-7 (unfavourable), Endometrial cancer:1.49e-4 (unfavourable), Urothelial cancer:1.79e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 62.0,Expressed in all,NA,NA
SLC4A2,"AE2, BND3L, EPB3L1, HKB3, NBND3",ENSG00000164889,Solute carrier family 4 member 2,7,151057210-151076527,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA019339,Enhanced,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,"Liver cancer:9.04e-6 (unfavourable), Renal cancer:1.26e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 89.3,Expressed in all,NA,NA
SLC4A7,"NBC3, SBC2, SLC4A6",ENSG00000033867,Solute carrier family 4 member 7,3,27372721-27484420,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB022494, HPA035857",Enhanced,NA,Supported,Plasma membrane<br>Focal adhesion sites<br>Cytosol,Renal cancer:7.91e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,duodenum: 57.7,breast: 23.8,Expressed in all,NA,NA
SLC5A3,"SMIT, SMIT1",ENSG00000198743,Solute carrier family 5 member 3,21,34073570-34106262,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA029791,NA,NA,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:1.98e-5 (unfavourable), Renal cancer:4.72e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,thyroid gland: 42.2,kidney: 33.1,Expressed in all,NA,NA
SLC7A5,"CD98, D16S469E, E16, LAT1, MPE16",ENSG00000103257,Solute carrier family 7 member 5,16,87830023-87869488,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052673, HPA056077",Approved,NA,Supported,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Lung cancer:2.43e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 90.3;testis: 84.3,bone marrow: 66.1,Expressed in all,NA,NA
SLC7A6,"KIAA0245, LAT-2, LAT3, y+LAT-2",ENSG00000103064,Solute carrier family 7 member 6,16,68264516-68301823,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA050713,Uncertain,NA,Approved,Vesicles<br>Plasma membrane,Urothelial cancer:1.84e-4 (unfavourable),Expressed in all,Mixed,NA,NA,adipose tissue: 35.7,Expressed in all,NA,NA
SLC8A1,NCX1,ENSG00000183023,Solute carrier family 8 member A1,2,40097270-40611053,"FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB022694, HPA070007",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,heart muscle: 78.0,seminal vesicle: 37.6,Cell line enhanced,NA,BJ: 24.4;fHDF/TERT166: 54.5
SLC9A1,"APNH, NHE1, PPP1R143",ENSG00000090020,Solute carrier family 9 member A1,1,27098815-27166981,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB022371, HPA048532, HPA052891",Enhanced,NA,Supported,Plasma membrane,"Glioma:6.32e-4 (unfavourable), Ovarian cancer:7.10e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,stomach: 65.5,Expressed in all,NA,NA
SLC9A3,NHE3,ENSG00000066230,Solute carrier family 9 member A3,5,473310-524332,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036493, HPA036669",Enhanced,NA,Supported,Plasma membrane,Melanoma:8.49e-4 (unfavourable),Mixed,Tissue enhanced,NA,colon: 80.9;gallbladder: 66.1;small intestine: 72.6,kidney: 57.3,Cell line enhanced,NA,HDLM-2: 30.4
SLC9A3R1,"EBP50, NHERF",ENSG00000109062,SLC9A3 regulator 1,17,74748652-74769353,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB001962, HPA009672, HPA027247",Enhanced,NA,Approved,Vesicles<br>Plasma membrane<br>Microtubule organizing center,Liver cancer:9.83e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,small intestine: 302.4,Expressed in all,NA,NA
SLC9A3R2,"E3KARP, NHERF-2, SIP-1, TKA-1",ENSG00000065054,SLC9A3 regulator 2,16,2025356-2039026,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA001672, HPA066520",Enhanced,NA,Supported,Plasma membrane,Endometrial cancer:1.03e-4 (favourable),Expressed in all,Mixed,NA,NA,lung: 160.8,Cell line enhanced,NA,MCF7: 234.6;PC-3: 259.8
SLC9A4,NHE4,ENSG00000180251,Solute carrier family 9 member A4,2,102473303-102533972,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA036096,Supported,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enriched,5,stomach: 51.3,kidney: 9.5,Cell line enhanced,NA,EFO-21: 1.3;HDLM-2: 2.2;RT4: 3.4
SLCO1A2,"OATP, OATP-A, OATP1A2, SLC21A3",ENSG00000084453,Solute carrier organic anion transporter family member 1A2,12,21264600-21419594,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA071152,NA,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 28.7,salivary gland: 6.6,Cell line enhanced,NA,NTERA-2: 16.5;RPMI-8226: 8.3;U-266/70: 18.6
SLCO1B3,"OATP1B3, OATP8, SLC21A8",ENSG00000111700,Solute carrier organic anion transporter family member 1B3,12,20810702-20916911,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004943, HPA050892",Enhanced,NA,Supported,Plasma membrane,NA,Tissue enhanced,Tissue enriched,7,liver: 138.9,"cervix, uterine: 19.5",Cell line enhanced,NA,A-431: 56.7;A549: 15.8;CAPAN-2: 11.0;PC-3: 16.0;U-2 OS: 15.2
SLIT1,"MEGF4, SLIL1, Slit-1, slit1, SLIT3",ENSG00000187122,Slit guidance ligand 1,10,96998038-97185920,Predicted secreted proteins,Evidence at protein level,HPA006879,NA,NA,Approved,Plasma membrane,NA,Group enriched,Tissue enriched,14,cerebral cortex: 60.0,thyroid gland: 4.2,Cell line enriched,11,MOLT-4: 64.7
SLITRK6,FLJ22774,ENSG00000184564,SLIT and NTRK like family member 6,13,85792790-85799488,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA014491, HPA014513",Uncertain,NA,Supported,Plasma membrane,Head and neck cancer:8.52e-4 (unfavourable),Tissue enhanced,Tissue enhanced,NA,urinary bladder: 19.6,prostate: 12.1,Group enriched,12,hTCEpi: 19.1;RT4: 76.0;WM-115: 21.9
SLK,"KIAA0204, se20-9, STK2",ENSG00000065613,STE20 like kinase,10,103967201-104029233,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA015757,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:2.77e-5 (unfavourable), Renal cancer:3.95e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 61.0,Expressed in all,NA,NA
SMAD1,"JV4-1, MADH1, MADR1",ENSG00000170365,SMAD family member 1,4,145481194-145558079,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,CAB005389,Approved,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 67.4,Cell line enhanced,NA,HUVEC TERT2: 94.6
SMAGP,"hSMAGP, MGC149453, MGC149454",ENSG00000170545,Small cell adhesion glycoprotein,12,51244558-51270890,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039711,Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane,"Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 145.7,esophagus: 83.3,Cell line enhanced,NA,BEWO: 126.2
SMAP1,"FLJ13159, SMAP-1",ENSG00000112305,Small ArfGAP 1,6,70667776-70862015,Predicted intracellular proteins,Evidence at protein level,HPA030574,Approved,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 51.5,Expressed in all,NA,NA
SMOC1,NA,ENSG00000198732,SPARC related modular calcium binding 1,14,69854131-70032366,"Disease related genes, Predicted secreted proteins",Evidence at protein level,"HPA004153, CAB034427",Approved,NA,Approved,Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 135.8,prostate: 66.2,Cell line enhanced,NA,AF22: 61.2;HeLa: 115.9;SiHa: 108.4;U-266/70: 48.2;U-87 MG: 61.4
SMPX,"DFN6, DFNX4",ENSG00000091482,"Small muscle protein, X-linked",X,21705972-21758163,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA077360,NA,NA,Approved,Plasma membrane,Head and neck cancer:3.04e-5 (unfavourable),Tissue enhanced,Group enriched,22,heart muscle: 456.2;skeletal muscle: 383.1,esophagus: 19.4,Cell line enhanced,NA,CACO-2: 1.2;Hep G2: 2.7;HSkMC: 3.0;Karpas-707: 2.2;U-266/70: 3.3;U-266/84: 1.2
SNAP23,"HsT17016, SNAP23A, SNAP23B",ENSG00000092531,Synaptosome associated protein 23,15,42491233-42545356,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA001214, CAB037083, CAB037317",Approved,NA,Supported,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,spleen: 86.7,Expressed in all,NA,NA
SNX9,"SDP1, SH3PX1, SH3PXD3A",ENSG00000130340,Sorting nexin 9,6,157700387-157945077,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031410, HPA057203",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,"Lung cancer:3.77e-4 (unfavourable), Cervical cancer:5.95e-4 (unfavourable), Renal cancer:9.95e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,gallbladder: 68.2,Mixed,NA,NA
SOCS5,"CIS6, Cish5, CISH6, KIAA0671, SOCS-5",ENSG00000171150,Suppressor of cytokine signaling 5,2,46698952-46763129,Predicted intracellular proteins,Evidence at protein level,"HPA020884, CAB025510",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Liver cancer:7.28e-4 (unfavourable), Ovarian cancer:7.53e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 31.1,Expressed in all,NA,NA
SOD1,"ALS, ALS1, IPOA",ENSG00000142168,Superoxide dismutase 1,21,31659622-31668931,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001401, CAB008670",Enhanced,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,liver: 768.9,Expressed in all,NA,NA
SORBS1,"CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12",ENSG00000095637,Sorbin and SH3 domain containing 1,10,95311771-95561414,Predicted intracellular proteins,Evidence at protein level,"HPA027559, HPA043084",Enhanced,NA,Supported,Plasma membrane<br>Focal adhesion sites<br>Centrosome,Breast cancer:2.84e-4 (favourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 320.1,Cell line enhanced,NA,CACO-2: 21.9;HMC-1: 39.4;SK-MEL-30: 30.9
SORCS1,sorCS1,ENSG00000108018,Sortilin related VPS10 domain containing receptor 1,10,106573663-107164534,Predicted membrane proteins,Evidence at protein level,HPA011948,Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 12.2;thyroid gland: 18.1,kidney: 4.8,Group enriched,12,RH-30: 78.2;SH-SY5Y: 111.4
SORT1,"Gp95, NT3",ENSG00000134243,Sortilin 1,1,109309568-109397951,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006889, CAB011498",Approved,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Colorectal cancer:7.74e-6 (favourable), Liver cancer:1.23e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 169.5,Mixed,NA,NA
SPAG16,"DKFZp666P1710, FLJ22724, PF20, WDR29",ENSG00000144451,Sperm associated antigen 16,2,213284379-214410501,Predicted intracellular proteins,Evidence at protein level,HPA037542,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:3.82e-4 (favourable), Prostate cancer:4.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 84.3,Mixed,NA,NA
SPATA12,NA,ENSG00000186451,Spermatogenesis associated 12,3,57060441-57075432,Predicted intracellular proteins,Evidence at transcript level,HPA043323,NA,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,54,testis: 23.0,"fallopian tube,lung: 0.4",Not detected,NA,NA
SPATC1L,C21orf56,ENSG00000160284,Spermatogenesis and centriole associated 1 like,21,46161148-46184476,Predicted intracellular proteins,Evidence at protein level,"HPA018979, HPA019165, HPA029394",Approved,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Pancreatic cancer:2.16e-4 (favourable),Expressed in all,Tissue enhanced,NA,testis: 11.7,prostate: 7.4,Cell line enhanced,NA,K-562: 33.7
SPG11,"FLJ21439, KIAA1840",ENSG00000104133,"SPG11, spatacsin vesicle trafficking associated",15,44562696-44663678,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040412, HPA040947",Approved,NA,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,Renal cancer:6.28e-5 (favourable),Expressed in all,Expressed in all,NA,NA,"parathyroid gland,thyroid gland: 48.3",Expressed in all,NA,NA
SPG20,"KIAA0610, TAHCCP1",ENSG00000133104,Spastic paraplegia 20 (Troyer syndrome),13,36301638-36370180,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039053, HPA039054",Approved,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 81.4,Mixed,NA,NA
SPHK1,SPHK,ENSG00000176170,Sphingosine kinase 1,17,76376584-76387860,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022829, HPA028761",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:5.14e-6 (unfavourable),Expressed in all,Mixed,NA,NA,gallbladder: 19.0,Mixed,NA,NA
SPINK13,"HESPINTOR, LiESP6, MGC149260, SPINK5L3",ENSG00000214510,"Serine peptidase inhibitor, Kazal type 13 (putative)",5,148268180-148286254,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA036456,Uncertain,NA,Approved,Nucleus<br>Plasma membrane,Renal cancer:4.03e-10 (unfavourable),Group enriched,Tissue enriched,8,epididymis: 309.7,seminal vesicle: 37.3,Cell line enriched,13,HeLa: 304.5
SPINT1,"HAI, MANSC2",ENSG00000166145,"Serine peptidase inhibitor, Kunitz type 1",15,40844018-40858207,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA006903, HPA031178",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 217.3,Cell line enhanced,NA,BEWO: 311.8;HaCaT: 333.0;RT4: 245.6;SK-BR-3: 418.2;T-47d: 251.3
SPINT2,"HAI-2, Kop",ENSG00000167642,"Serine peptidase inhibitor, Kunitz type 2",19,38244035-38292614,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA011101, CAB018969",Approved,NA,Uncertain,Plasma membrane<br>Intermediate filaments<br>Cytosol,Renal cancer:3.41e-4 (favourable),Expressed in all,Mixed,NA,NA,thyroid gland: 539.2,Cell line enhanced,NA,A-431: 736.5;CAPAN-2: 1060.7
SPPL2B,"IMP4, KIAA1532, PSL1",ENSG00000005206,Signal peptide peptidase like 2B,19,2328615-2354806,"Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB005592, HPA039292",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Centrosome,"Endometrial cancer:5.00e-5 (favourable), Pancreatic cancer:1.33e-4 (favourable), Renal cancer:6.45e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 49.1,Expressed in all,NA,NA
SPPL3,"DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4",ENSG00000157837,Signal peptide peptidase like 3,12,120762510-120904371,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA004194, HPA059958",Uncertain,NA,Supported,Vesicles<br>Plasma membrane,Liver cancer:1.29e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 84.1,Mixed,NA,NA
SPRED3,NA,ENSG00000188766,Sprouty related EVH1 domain containing 3,19,38388421-38399587,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA071521,NA,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 6.6,parathyroid gland: 2.6,Cell line enhanced,NA,TIME: 12.9
SRC,"ASV, c-src, SRC1",ENSG00000197122,"SRC proto-oncogene, non-receptor tyrosine kinase",20,37344685-37406050,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004023, HPA030875",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,"Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 43.6,Mixed,NA,NA
SRD5A3,"FLJ13352, SRD5A2L, SRD5A2L1",ENSG00000128039,Steroid 5 alpha-reductase 3,4,55346109-55373096,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA027006,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,gallbladder: 28.2,Expressed in all,NA,NA
SRPK1,SFRSK1,ENSG00000096063,SRSF protein kinase 1,6,35832966-35921342,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA016431, HPA056486",Approved,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,"Liver cancer:7.90e-6 (unfavourable), Pancreatic cancer:6.53e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 81.0,Expressed in all,NA,NA
SRPRB,"APMCF1, SR-beta",ENSG00000144867,SRP receptor beta subunit,3,133784033-133825772,Predicted membrane proteins,Evidence at protein level,HPA011173,Approved,NA,Approved,Plasma membrane,Liver cancer:3.12e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,epididymis: 52.0,Expressed in all,NA,NA
SRRM3,FLJ37078,ENSG00000177679,Serine/arginine repetitive matrix 3,7,76201900-76287288,Predicted intracellular proteins,Evidence at protein level,HPA019337,Uncertain,NA,Approved,Plasma membrane<br>Intermediate filaments<br>Microtubules,NA,Mixed,Group enriched,10,adrenal gland: 2.7;cerebral cortex: 8.5;testis: 1.8,stomach: 0.4,Group enriched,12,SCLC-21H: 12.8;SH-SY5Y: 8.5
SSFA2,"CS-1, KIAA1927, KRAP, SPAG13",ENSG00000138434,Sperm specific antigen 2,2,181891833-181930738,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034665, HPA039989",Uncertain,NA,Supported,Nucleus<br>Plasma membrane<br>Cytosol,"Renal cancer:2.91e-5 (favourable), Urothelial cancer:5.79e-5 (unfavourable), Pancreatic cancer:8.19e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 137.2,Mixed,NA,NA
SSH1,KIAA1298,ENSG00000084112,Slingshot protein phosphatase 1,12,108778192-108857590,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA019845,Uncertain,NA,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:5.80e-5 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 9.5,Expressed in all,NA,NA
SSH3,"FLJ10928, FLJ20515",ENSG00000172830,Slingshot protein phosphatase 3,11,67303448-67312607,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019949, HPA019957",Approved,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Actin filaments<br>Cytosol,Pancreatic cancer:2.89e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 37.5,Cell line enhanced,NA,RT4: 69.9
SSTR5,NA,ENSG00000162009,Somatostatin receptor 5,16,1078781-1080142,"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA066503,NA,NA,Supported,Plasma membrane,NA,Mixed,Tissue enhanced,NA,adrenal gland: 1.2,kidney: 0.5,Group enriched,15,Hep G2: 10.4;PC-3: 50.7
ST8SIA5,SIAT8E,ENSG00000101638,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5",18,46667821-46759257,Predicted membrane proteins,Evidence at protein level,"HPA043813, HPA046771",Approved,NA,Approved,Plasma membrane<br>Midbody,NA,Tissue enriched,Tissue enhanced,NA,adrenal gland: 5.5;cerebral cortex: 11.4,parathyroid gland: 3.4,Cell line enriched,7,WM-115: 121.0
STAB1,"CLEVER-1, FEEL-1, FELE-1, FEX1, KIAA0246, SCARH2, STAB-1",ENSG00000010327,Stabilin 1,3,52495338-52524495,Predicted membrane proteins,Evidence at protein level,HPA005434,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:3.88e-7 (unfavourable), Colorectal cancer:7.59e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 123.3,Group enriched,38,HUVEC TERT2: 86.2;NB-4: 93.1;TIME: 104.8
STAC,STAC1,ENSG00000144681,SH3 and cysteine rich domain,3,36380344-36548007,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA035143,Uncertain,NA,Uncertain,Nucleoplasm<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 23.4;prostate: 21.7,lung: 15.8,Cell line enhanced,NA,fHDF/TERT166: 34.6;HaCaT: 28.9;SH-SY5Y: 48.5;U-87 MG: 45.7
STAMBP,AMSH,ENSG00000124356,STAM binding protein,2,73828916-73873659,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035800, HPA035801",Uncertain,NA,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:4.70e-5 (unfavourable), Pancreatic cancer:5.79e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 39.1,Cell line enriched,11,LHCN-M2: 926.0
STAMBPL1,"ALMalpha, AMSH-FP, AMSH-LP, bA399O19.2, FLJ31524, KIAA1373",ENSG00000138134,STAM binding protein like 1,10,88879734-88975153,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040202,Uncertain,NA,Approved,Plasma membrane,Renal cancer:1.08e-5 (unfavourable),Mixed,Mixed,NA,NA,"adrenal gland,testis: 29.7",Mixed,NA,NA
STARD4,NA,ENSG00000164211,StAR related lipid transfer domain containing 4,5,111496033-111512590,Predicted intracellular proteins,Evidence at protein level,"HPA046177, HPA048081",Approved,NA,Approved,Plasma membrane,"Liver cancer:4.80e-5 (unfavourable), Renal cancer:5.89e-5 (unfavourable), Urothelial cancer:2.84e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,duodenum: 41.4,Mixed,NA,NA
STAT2,STAT113,ENSG00000170581,Signal transducer and activator of transcription 2,12,56341597-56360155,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB003858, HPA018888",Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.78e-13 (unfavourable), Endometrial cancer:4.75e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 47.9,Expressed in all,NA,NA
STIL,"MCPH7, SIL",ENSG00000123473,SCL/TAL1 interrupting locus,1,47250139-47314147,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA046543,NA,NA,Approved,Plasma membrane<br>Cytosol,Pancreatic cancer:1.33e-4 (unfavourable),Mixed,Mixed,NA,NA,testis: 12.9,Mixed,NA,NA
STIP1,"HOP, STI1",ENSG00000168439,Stress induced phosphoprotein 1,11,64185272-64204543,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017448, HPA039291, HPA044062",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Liver cancer:6.18e-8 (unfavourable), Head and neck cancer:1.23e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 220.4,Expressed in all,NA,NA
STK17A,DRAK1,ENSG00000164543,Serine/threonine kinase 17a,7,43582758-43626786,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA018138, HPA037979",Uncertain,NA,Approved,Nuclear speckles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,lymph node: 49.2,Expressed in all,NA,NA
STK17B,DRAK2,ENSG00000081320,Serine/threonine kinase 17b,2,196133566-196176503,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA034858,Enhanced,NA,Uncertain,Plasma membrane<br>Cytosol,Renal cancer:5.72e-8 (unfavourable),Expressed in all,Tissue enhanced,NA,bone marrow: 248.5,lymph node: 133.3,Expressed in all,NA,NA
STOM,"BND7, EPB7, EPB72",ENSG00000148175,Stomatin,9,121338988-121370304,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA010961, HPA011419",Approved,NA,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 463.6,Cell line enhanced,NA,ASC diff: 468.5;hTCEpi: 411.2
STOML2,"HSPC108, SLP-2",ENSG00000165283,Stomatin like 2,9,35099776-35103195,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB015944, HPA062016",Supported,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:3.00e-5 (favourable), Liver cancer:4.77e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 98.6,Expressed in all,NA,NA
STOML3,"Epb7.2l, SRO",ENSG00000133115,Stomatin like 3,13,38965925-38991066,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA012892, HPA071011",Enhanced,NA,Enhanced,Plasma membrane,Endometrial cancer:1.49e-4 (favourable),Tissue enhanced,Tissue enriched,18,fallopian tube: 50.3,lung: 2.8,Cell line enriched,33,AF22: 15.4
STX18,Ufe1,ENSG00000168818,Syntaxin 18,4,4415742-4542346,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA003019,Approved,NA,Approved,Plasma membrane,"Endometrial cancer:6.33e-8 (favourable), Colorectal cancer:2.84e-4 (favourable), Urothelial cancer:4.69e-4 (favourable), Renal cancer:7.03e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 180.1",Expressed in all,NA,NA
STX4,"p35-2, STX4A",ENSG00000103496,Syntaxin 4,16,31032889-31042975,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA001330,Approved,NA,Enhanced,Plasma membrane,"Renal cancer:2.88e-9 (unfavourable), Cervical cancer:3.65e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 64.5,Expressed in all,NA,NA
STXBP4,"MGC50337, Synip",ENSG00000166263,Syntaxin binding protein 4,17,54968727-55173632,Predicted intracellular proteins,Evidence at protein level,"CAB007760, HPA022138, HPA022888, HPA024227",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,parathyroid gland: 12.5,Mixed,NA,NA
STYK1,"DKFZp761P1010, NOK, SuRTK106",ENSG00000060140,Serine/threonine/tyrosine kinase 1,12,10618939-10674318,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040468, HPA048569",Uncertain,NA,Approved,Nucleus<br>Plasma membrane,NA,Mixed,Mixed,NA,NA,rectum: 17.4,Cell line enhanced,NA,CAPAN-2: 23.5;HUVEC TERT2: 20.0;TIME: 18.2
SUCLG1,NA,ENSG00000163541,Succinate-CoA ligase alpha subunit,2,84423523-84460045,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA036683, HPA036684",Enhanced,NA,Supported,Plasma membrane<br>Mitochondria,"Renal cancer:2.21e-8 (favourable), Endometrial cancer:5.23e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,kidney: 471.2,Expressed in all,NA,NA
SUCLG2,NA,ENSG00000172340,Succinate-CoA ligase GDP-forming beta subunit,3,67360460-67654614,"Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA046705, HPA051998",Enhanced,NA,Supported,Plasma membrane<br>Mitochondria,"Renal cancer:2.79e-10 (favourable), Colorectal cancer:1.08e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,colon: 168.2,Expressed in all,NA,NA
SUGT1,SGT1,ENSG00000165416,"SGT1 homolog, MIS12 kinetochore complex assembly cochaperone",13,52652709-52700909,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB015942, HPA043949",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Head and neck cancer:8.69e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 63.4,Expressed in all,NA,NA
SUMF2,DKFZp566I1024,ENSG00000129103,Sulfatase modifying factor 2,7,56064002-56080670,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA024040, CAB025743, HPA074892",Enhanced,NA,Uncertain,Vesicles<br>Plasma membrane,"Cervical cancer:6.58e-6 (unfavourable), Endometrial cancer:3.96e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 160.7,Expressed in all,NA,NA
SUPT6H,"KIAA0162, SPT6H",ENSG00000109111,"SPT6 homolog, histone chaperone",17,28662091-28702684,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012416, HPA036382",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Liver cancer:3.68e-5 (unfavourable), Renal cancer:4.36e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 62.1,Expressed in all,NA,NA
SUSD2,"BK65A6.2, FLJ22778",ENSG00000099994,Sushi domain containing 2,22,24181259-24189110,Predicted membrane proteins,Evidence at protein level,HPA004117,Enhanced,NA,Approved,Plasma membrane,Renal cancer:3.29e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,lung: 139.3,small intestine: 35.2,Cell line enriched,33,SK-BR-3: 622.4
SVIL,NA,ENSG00000197321,Supervillin,10,29457338-29736781,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010878, HPA020095, HPA020138",Approved,NA,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,Urothelial cancer:5.70e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 279.8,Cell line enhanced,NA,HaCaT: 106.2
SYCP2,SCP2,ENSG00000196074,Synaptonemal complex protein 2,20,59863563-59933655,Predicted intracellular proteins,Evidence at protein level,"HPA062401, HPA065613",NA,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Group enriched,Group enriched,8,breast: 17.7;testis: 76.9,prostate: 6.0,Cell line enhanced,NA,MOLT-4: 43.5;SiHa: 97.9;T-47d: 77.3
SYK,NA,ENSG00000165025,Spleen associated tyrosine kinase,9,90801787-90898549,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001384, CAB007773",Enhanced,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 96.0,Cell line enhanced,NA,Daudi: 89.3;HEL: 64.8;HL-60: 80.0;REH: 76.3
SYMPK,"SPK, SYM",ENSG00000125755,Symplekin,19,45815410-45863290,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041756, HPA042449",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 74.7,Expressed in all,NA,NA
SYNC,"SYNC1, SYNCOILIN",ENSG00000162520,"Syncoilin, intermediate filament protein",1,32680360-32703596,Predicted intracellular proteins,Evidence at protein level,HPA028311,Approved,NA,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,smooth muscle: 74.1,skeletal muscle: 36.1,Cell line enhanced,NA,BJ hTERT+: 65.1;fHDF/TERT166: 91.5;U-138 MG: 98.1;WM-115: 67.5
SYNGR3,NA,ENSG00000127561,Synaptogyrin 3,16,1989660-1994275,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB034278, HPA042842",Enhanced,NA,Approved,Plasma membrane,"Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable)",Mixed,Tissue enriched,7,cerebral cortex: 82.6,parathyroid gland: 12.6,Cell line enhanced,NA,HDLM-2: 45.7;HMC-1: 26.7;U-266/70: 30.7
SYT4,"HsT1192, KIAA1342",ENSG00000132872,Synaptotagmin 4,18,43267878-43277650,Predicted intracellular proteins,Evidence at protein level,HPA010574,Approved,NA,Supported,Vesicles<br>Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,adrenal gland: 20.4;cerebral cortex: 82.5,seminal vesicle: 11.3,Cell line enriched,10,SH-SY5Y: 251.0
SYTL2,"CHR11SYT, exophilin-4, FLJ20163, FLJ21219, KIAA1597, MGC102768, PPP1R151, SGA72M, SLP2",ENSG00000137501,Synaptotagmin like 2,11,85694224-85811159,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA039651,Approved,NA,Approved,Nucleus<br>Golgi apparatus<br>Plasma membrane,"Colorectal cancer:2.67e-4 (favourable), Urothelial cancer:9.07e-4 (favourable)",Mixed,Tissue enhanced,NA,stomach: 120.5,rectum: 81.4,Cell line enhanced,NA,RH-30: 170.2;RPTEC TERT1: 95.1
SYVN1,"DER3, HRD1",ENSG00000162298,Synoviolin 1,11,65121780-65134533,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA005480, HPA024300, CAB037030",Enhanced,NA,Supported,Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane,Head and neck cancer:6.88e-4 (favourable),Expressed in all,Expressed in all,NA,NA,tonsil: 73.8,Expressed in all,NA,NA
TACC2,AZU-1,ENSG00000138162,Transforming acidic coiled-coil containing protein 2,10,121989174-122254545,Predicted intracellular proteins,Evidence at protein level,"HPA031020, HPA031021, HPA061394",Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:2.50e-10 (favourable), Thyroid cancer:8.45e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skeletal muscle: 112.7,Mixed,NA,NA
TACR2,"NK2R, NKNAR, SKR, TAC2R",ENSG00000075073,Tachykinin receptor 2,10,69403903-69416867,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA076573,NA,NA,Approved,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,smooth muscle: 67.2,esophagus: 23.1,Cell line enhanced,NA,SK-MEL-30: 3.2;U-87 MG: 2.3
TACSTD2,"EGP-1, GA733-1, M1S1, TROP2",ENSG00000184292,Tumor-associated calcium signal transducer 2,1,58575423-58577773,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA043104, HPA055067, CAB072852",Enhanced,NA,Supported,Nucleoli<br>Vesicles<br>Plasma membrane,Renal cancer:3.99e-4 (favourable),Mixed,Tissue enhanced,NA,esophagus: 313.8,skin: 209.6,Cell line enhanced,NA,A-431: 502.8;CAPAN-2: 665.4;HaCaT: 672.0
TASP1,"C20orf13, dJ585I14.2, FLJ20212",ENSG00000089123,Taspase 1,20,13389392-13638940,Predicted intracellular proteins,Evidence at protein level,"HPA030824, HPA030825",Uncertain,NA,Approved,Plasma membrane,Thyroid cancer:6.78e-4 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 13.7,Mixed,NA,NA
TAZ,"BTHS, CMD3A, EFE, EFE2, G4.5, TAZ1, XAP-2",ENSG00000102125,Tafazzin,X,154411518-154421726,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039557,Approved,NA,Approved,Plasma membrane,"Renal cancer:1.22e-7 (unfavourable), Cervical cancer:5.70e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,"bone marrow,spleen: 20.8",Expressed in all,NA,NA
TBC1D10A,"AC004997.C22.2, EPI64, TBC1D10",ENSG00000099992,TBC1 domain family member 10A,22,30291990-30327046,Predicted intracellular proteins,Evidence at protein level,"HPA007725, HPA008142, HPA076041",Approved,NA,Enhanced,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,esophagus: 31.2,Expressed in all,NA,NA
TBC1D30,KIAA0984,ENSG00000111490,TBC1 domain family member 30,12,64781193-64881032,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039772, HPA040043",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Endometrial cancer:3.61e-5 (favourable), Lung cancer:5.08e-4 (favourable)",Mixed,Mixed,NA,NA,parathyroid gland: 12.5,Cell line enhanced,NA,MCF7: 33.4;RT4: 26.3;SCLC-21H: 35.3;SK-BR-3: 23.3
TBC1D9B,"GRAMD9B, KIAA0676",ENSG00000197226,TBC1 domain family member 9B,5,179862066-179907859,Predicted intracellular proteins,Evidence at protein level,HPA038350,Approved,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane,Thyroid cancer:3.99e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 30.3,Expressed in all,NA,NA
TBXA2R,NA,ENSG00000006638,Thromboxane A2 receptor,19,3594506-3606840,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA077366,NA,NA,Supported,Nuclear speckles<br>Plasma membrane,"Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 5.2,Cell line enhanced,NA,HeLa: 6.4;U-2197: 6.3
TCHP,"MGC10854, TpMs",ENSG00000139437,Trichoplein keratin filament binding,12,109900264-109983841,Predicted intracellular proteins,Evidence at protein level,"HPA038638, HPA061543",Supported,NA,Supported,Plasma membrane<br>Centrosome<br>Cytosol,Stomach cancer:5.52e-4 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 32.6,Expressed in all,NA,NA
TDO2,"TDO, TPH2",ENSG00000151790,"Tryptophan 2,3-dioxygenase",4,155854738-155920406,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039611,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Tissue enriched,Tissue enriched,18,liver: 278.3,appendix: 15.7,Group enriched,5,EFO-21: 7.3;HDLM-2: 14.7;U-87 MG: 8.6
TDP1,"FLJ11090, SCAN1",ENSG00000042088,Tyrosyl-DNA phosphodiesterase 1,14,89954939-90044768,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA071317,NA,NA,Supported,Nucleus<br>Plasma membrane,Liver cancer:8.99e-5 (unfavourable),Expressed in all,Mixed,NA,NA,testis: 40.6,Expressed in all,NA,NA
TEC,PSCTK4,ENSG00000135605,Tec protein tyrosine kinase,4,48135783-48269864,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005733, HPA024657",Approved,NA,Supported,Plasma membrane,Ovarian cancer:7.12e-4 (favourable),Mixed,Mixed,NA,NA,epididymis: 5.0,Cell line enhanced,NA,HEL: 11.8;HMC-1: 17.4;U-266/70: 15.1;U-266/84: 10.6
TEK,"CD202b, TIE-2, TIE2, VMCM, VMCM1",ENSG00000120156,TEK receptor tyrosine kinase,9,27109141-27230175,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB010359, HPA073265",Approved,NA,Supported,Plasma membrane<br>Microtubule organizing center,"Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)",Expressed in all,Tissue enhanced,NA,placenta: 65.9,lung: 42.6,Group enriched,8,HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
TEX9,NA,ENSG00000151575,Testis expressed 9,15,56244009-56445997,Predicted intracellular proteins,Evidence at protein level,HPA039415,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,fallopian tube: 44.5,Mixed,NA,NA
TGFBR1,"ACVRLK4, ALK-5, ALK5, ESS1, MSSE",ENSG00000106799,Transforming growth factor beta receptor 1,9,99104038-99154192,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002441, CAB031481, HPA056473",Uncertain,NA,Supported,Vesicles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,placenta: 69.8,Expressed in all,NA,NA
TGFBR2,MFS2,ENSG00000163513,Transforming growth factor beta receptor 2,3,30606502-30694142,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,CAB073537,NA,NA,Supported,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 292.3,Cell line enhanced,NA,ASC TERT1: 366.2;LHCN-M2: 371.8;TIME: 336.9
TGM2,TGC,ENSG00000198959,Transglutaminase 2,20,38127387-38166578,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002598, HPA021019, HPA029518",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.67e-7 (unfavourable), Pancreatic cancer:2.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,"cervix, uterine: 461.0",placenta: 319.8,Cell line enhanced,NA,CAPAN-2: 1300.3;EFO-21: 458.7;HUVEC TERT2: 559.8;TIME: 720.5
THBS1,"THBS, THBS-1, TSP, TSP-1, TSP1",ENSG00000137801,Thrombospondin 1,15,39581079-39599466,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB033678, HPA059756",Approved,NA,Approved,Plasma membrane,"Renal cancer:8.47e-5 (unfavourable), Stomach cancer:8.50e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,appendix: 573.9,Cell line enhanced,NA,fHDF/TERT166: 2033.2;HUVEC TERT2: 2095.4;TIME: 3015.4
THBS2,TSP2,ENSG00000186340,Thrombospondin 2,6,169215780-169254044,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB017716, HPA044304",Approved,NA,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,Renal cancer:3.77e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,gallbladder: 113.4,endometrium: 71.2,Cell line enhanced,NA,ASC diff: 282.6;ASC TERT1: 196.5;BJ hTERT+ SV40 Large T+ RasG12V: 134.9;hTEC/SVTERT24-B: 150.4
THY1,CD90,ENSG00000154096,Thy-1 cell surface antigen,11,119417378-119424985,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA003733, CAB068243, CAB068244",Enhanced,NA,Approved,Nucleus<br>Plasma membrane,"Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 421.8;smooth muscle: 434.2,gallbladder: 161.0,Cell line enhanced,NA,BJ: 643.3;BJ hTERT+: 686.4;fHDF/TERT166: 1040.5
TICAM1,"MGC35334, PRVTIRB, TICAM-1, TRIF",ENSG00000127666,Toll like receptor adaptor molecule 1,19,4815932-4831704,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042460,Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,"Lung cancer:3.48e-4 (unfavourable), Endometrial cancer:4.81e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 22.0,Mixed,NA,NA
TIGD7,Sancho,ENSG00000140993,Tigger transposable element derived 7,16,3298832-3305729,Predicted intracellular proteins,Evidence at protein level,"HPA041357, HPA041474",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,parathyroid gland: 14.7,Mixed,NA,NA
TLN1,"ILWEQ, TLN",ENSG00000137076,Talin 1,9,35696948-35732395,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002006, HPA004748",Supported,NA,Supported,Plasma membrane<br>Focal adhesion sites<br>Microtubule organizing center<br>Cytosol,"Colorectal cancer:5.56e-4 (unfavourable), Renal cancer:7.21e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 204.8,Expressed in all,NA,NA
TM2D2,BLP1,ENSG00000169490,TM2 domain containing 2,8,38988808-38996824,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA047152, HPA050547",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,"Colorectal cancer:1.71e-4 (favourable), Breast cancer:7.49e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 51.3,Expressed in all,NA,NA
TM4SF20,"FLJ22800, TCCE518",ENSG00000168955,Transmembrane 4 L six family member 20,2,227362156-227381995,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA051838, HPA063184, HPA065531",Uncertain,NA,Supported,Plasma membrane<br>Focal adhesion sites,NA,Group enriched,Group enriched,35,duodenum: 277.2;small intestine: 163.8,testis: 6.3,Cell line enhanced,NA,A549: 2.5;RPMI-8226: 1.2
TM4SF4,il-TMP,ENSG00000169903,Transmembrane 4 L six family member 4,3,149473974-149503281,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA046430,Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Group enriched,Group enriched,34,duodenum: 579.6;gallbladder: 1319.6;liver: 346.9;small intestine: 504.0,stomach: 20.2,Group enriched,6,A549: 19.4;RPTEC TERT1: 24.4
TMC5,FLJ13593,ENSG00000103534,Transmembrane channel like 5,16,19410496-19499113,Predicted membrane proteins,Evidence at protein level,"HPA040810, HPA042037",Enhanced,NA,Approved,Nucleus<br>Plasma membrane,Liver cancer:7.96e-4 (unfavourable),Mixed,Tissue enhanced,NA,small intestine: 59.1,duodenum: 45.4,Cell line enriched,6,CAPAN-2: 61.8
TMEM101,"FLJ23987, MGC4251",ENSG00000091947,Transmembrane protein 101,17,44011188-44023946,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039739,NA,NA,Approved,Nucleoplasm<br>Plasma membrane,"Renal cancer:4.10e-5 (favourable), Endometrial cancer:4.29e-4 (favourable), Liver cancer:7.10e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 158.8,Mixed,NA,NA
TMEM108,"CT124, MGC3040",ENSG00000144868,Transmembrane protein 108,3,133038391-133397792,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA063350,Uncertain,NA,Approved,Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 21.9;testis: 25.8,adrenal gland: 15.0,Cell line enhanced,NA,HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2
TMEM117,DKFZp434K2435,ENSG00000139173,Transmembrane protein 117,12,43835967-44389762,Predicted membrane proteins,Evidence at transcript level,"HPA039899, HPA046223",Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytokinetic bridge,Melanoma:3.94e-4 (unfavourable),Expressed in all,Mixed,NA,NA,seminal vesicle: 7.3,Mixed,NA,NA
TMEM139,FLJ90586,ENSG00000178826,Transmembrane protein 139,7,143279957-143288048,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036982, HPA036983",Approved,NA,Approved,Plasma membrane<br>Focal adhesion sites,"Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable)",Mixed,Tissue enhanced,NA,duodenum: 34.0;kidney: 34.6,small intestine: 20.7,Cell line enhanced,NA,CAPAN-2: 35.7;EFO-21: 26.3;RPTEC TERT1: 53.2;T-47d: 64.1
TMEM176B,"LR8, MS4B2",ENSG00000106565,Transmembrane protein 176B,7,150791285-150801360,Predicted membrane proteins,Evidence at protein level,HPA047509,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,liver: 845.2,Group enriched,13,HSkMC: 462.2;THP-1: 144.5
TMEM218,NA,ENSG00000150433,Transmembrane protein 218,11,125096545-125111763,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038489,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:1.93e-5 (unfavourable), Stomach cancer:5.50e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 21.9,Expressed in all,NA,NA
TMEM222,"C1orf160, DKFZP564D0478",ENSG00000186501,Transmembrane protein 222,1,27322145-27336400,Predicted membrane proteins,Evidence at protein level,"HPA016579, HPA059374",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 47.9,Expressed in all,NA,NA
TMEM229A,NA,ENSG00000234224,Transmembrane protein 229A,7,124030916-124033023,Predicted membrane proteins,Evidence at protein level,HPA056391,Uncertain,NA,Approved,Plasma membrane,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 7.1;duodenum: 8.6;testis: 10.4,small intestine: 4.4,Cell line enriched,46,SH-SY5Y: 141.7
TMEM245,"C9orf5, CG-2",ENSG00000106771,Transmembrane protein 245,9,109015152-109119945,Predicted membrane proteins,Evidence at protein level,HPA023892,Approved,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:4.46e-9 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 124.0,Expressed in all,NA,NA
TMEM254,"bA369J21.6, C10orf57, FLJ13263",ENSG00000133678,Transmembrane protein 254,10,80078646-80092557,Predicted membrane proteins,Evidence at protein level,"HPA029105, HPA072613",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,skin: 85.7,Mixed,NA,NA
TMEM258,C11orf10,ENSG00000134825,Transmembrane protein 258,11,61768501-61792802,Predicted membrane proteins,Evidence at protein level,HPA044602,Approved,NA,Approved,Plasma membrane<br>Cytosol,Ovarian cancer:4.37e-4 (favourable),Expressed in all,Expressed in all,NA,NA,epididymis: 437.6,Expressed in all,NA,NA
TMEM266,"C15orf27, FLJ38190",ENSG00000169758,Transmembrane protein 266,15,76059837-76229121,Predicted membrane proteins,Evidence at protein level,"HPA041921, HPA049425",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 1.9;skeletal muscle: 1.5,placenta: 1.2,Cell line enhanced,NA,NTERA-2: 1.0
TMEM268,"C9orf91, DKFZp547P234, FLJ38045",ENSG00000157693,Transmembrane protein 268,9,114611206-114646422,Predicted membrane proteins,Evidence at transcript level,HPA017199,Approved,NA,Approved,Plasma membrane<br>Cytosol,Endometrial cancer:3.61e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 22.3,Expressed in all,NA,NA
TMEM50A,SMP1,ENSG00000183726,Transmembrane protein 50A,1,25337917-25362361,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA065192,NA,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,"Endometrial cancer:8.64e-5 (favourable), Liver cancer:3.34e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,prostate: 71.2,Expressed in all,NA,NA
TMEM63B,"C6orf110, dJ421H19.2, DKFZp434P0531",ENSG00000137216,Transmembrane protein 63B,6,44126914-44155519,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA029249, HPA029250, HPA029251",Uncertain,NA,Enhanced,Plasma membrane<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,lung: 59.0,Expressed in all,NA,NA
TMEM97,MAC30,ENSG00000109084,Transmembrane protein 97,17,28319095-28328685,Predicted membrane proteins,Evidence at protein level,HPA044795,Approved,NA,Approved,Nuclear membrane<br>Plasma membrane<br>Cytosol,Renal cancer:1.24e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 110.0,Expressed in all,NA,NA
TMTC2,DKFZp762A217,ENSG00000179104,Transmembrane and tetratricopeptide repeat containing 2,12,82686880-83134870,Predicted membrane proteins,Evidence at protein level,"HPA026954, HPA026955",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments,Renal cancer:2.84e-5 (favourable),Mixed,Mixed,NA,NA,cerebral cortex: 16.4,Cell line enhanced,NA,AF22: 31.2;WM-115: 76.7
TNFRSF10D,"CD264, DcR2, TRAILR4, TRUNDD",ENSG00000173530,TNF receptor superfamily member 10d,8,23135588-23164030,"Cancer-related genes, CD markers, Predicted membrane proteins",Evidence at protein level,HPA070971,NA,NA,Approved,Plasma membrane<br>Actin filaments,Cervical cancer:1.70e-4 (unfavourable),Expressed in all,Mixed,NA,NA,gallbladder: 12.7,Cell line enhanced,NA,LHCN-M2: 208.5;WM-115: 234.5
TNFRSF11A,"CD265, FEO, LOH18CR1, PDB2, RANK",ENSG00000141655,TNF receptor superfamily member 11a,18,62325287-62391292,"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB010391, HPA027728, HPA047976",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,NA,Mixed,Tissue enhanced,NA,duodenum: 30.6,small intestine: 20.5,Cell line enhanced,NA,HDLM-2: 116.8;PC-3: 18.0;SCLC-21H: 24.0
TNFRSF12A,"CD266, FN14, TweakR",ENSG00000006327,TNF receptor superfamily member 12A,16,3018445-3022383,"Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA007853,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 199.0,Mixed,NA,NA
TNFRSF25,"APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR",ENSG00000215788,TNF receptor superfamily member 25,1,6461151-6466195,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA069834,NA,NA,Approved,Nucleus<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites,"Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,skin: 29.6,spleen: 12.1,Cell line enhanced,NA,HDLM-2: 24.6;RPMI-8226: 17.9
TNFRSF9,"4-1BB, CD137, ILA",ENSG00000049249,TNF receptor superfamily member 9,1,7915894-7943165,"Cancer-related genes, CD markers, Predicted membrane proteins",Evidence at protein level,HPA071425,NA,NA,Approved,Nucleoli<br>Plasma membrane,Renal cancer:2.69e-8 (unfavourable),Mixed,Tissue enhanced,NA,lymph node: 11.1;tonsil: 7.0,appendix: 5.2,Cell line enriched,8,HDLM-2: 92.4
TNNI2,"AMCD2B, DA2B, FSSV",ENSG00000130598,"Troponin I2, fast skeletal type",11,1838989-1841680,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB018697, HPA055938",Enhanced,NA,Approved,Plasma membrane<br>Intermediate filaments,NA,Group enriched,Tissue enriched,38,skeletal muscle: 5537.1,esophagus: 144.6,Cell line enhanced,NA,CAPAN-2: 62.9;hTCEpi: 145.7;T-47d: 23.3
TOLLIP,IL-1RAcPIP,ENSG00000078902,Toll interacting protein,11,1274371-1309654,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038621, HPA038622",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.11e-16 (favourable), Glioma:4.57e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 132.3,Expressed in all,NA,NA
TOM1,NA,ENSG00000100284,Target of myb1 membrane trafficking protein,22,35299275-35347994,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA000818, HPA001749",Approved,NA,Approved,Plasma membrane<br>Microtubule organizing center<br>Cytosol,"Endometrial cancer:2.20e-5 (favourable), Renal cancer:3.72e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 54.6,Expressed in all,NA,NA
TPRN,"C9orf75, DFNB79, FLJ90254",ENSG00000176058,Taperin,9,137191617-137204193,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA020899,Uncertain,NA,Approved,Plasma membrane,"Renal cancer:5.16e-9 (favourable), Cervical cancer:2.13e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,small intestine: 28.3,Mixed,NA,NA
TRAF7,"DKFZp586I021, MGC7807, RFWD1, RNF119",ENSG00000131653,TNF receptor associated factor 7,16,2155698-2178129,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041229,Approved,NA,Supported,Vesicles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,skin: 40.6,Expressed in all,NA,NA
TRAIP,"RNF206, TRIP",ENSG00000183763,TRAF interacting protein,3,49828599-49856574,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036261, HPA036262",Enhanced,NA,Supported,Plasma membrane<br>Cytosol,Liver cancer:8.77e-5 (unfavourable),Expressed in all,Mixed,NA,NA,testis: 11.3,Mixed,NA,NA
TRAPPC13,"C5orf44, FLJ13611, FLJ26957, MGC48585",ENSG00000113597,Trafficking protein particle complex 13,5,65624716-65666233,Predicted intracellular proteins,Evidence at protein level,HPA037777,Approved,NA,Approved,Nucleus<br>Plasma membrane,Renal cancer:8.66e-4 (favourable),Expressed in all,Expressed in all,NA,NA,prostate: 29.8,Expressed in all,NA,NA
TRDN,NA,ENSG00000186439,Triadin,6,123216339-123637093,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA038226, HPA058226",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,NA,Tissue enhanced,Group enriched,21,heart muscle: 273.5;skeletal muscle: 650.2,prostate: 22.2,Cell line enhanced,NA,MCF7: 1.4
TRIB1,"C8FW, GIG2, TRB1",ENSG00000173334,Tribbles pseudokinase 1,8,125430321-125438405,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA063982,NA,NA,Approved,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,bone marrow: 243.6,Cell line enhanced,NA,HEL: 173.6
TRIM16,EBBP,ENSG00000221926,Tripartite motif containing 16,17,15627960-15684311,Predicted intracellular proteins,Evidence at protein level,"HPA023623, HPA066431",Uncertain,NA,Supported,Plasma membrane<br>Cytosol,"Liver cancer:3.94e-4 (unfavourable), Urothelial cancer:6.71e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 117.8,Cell line enhanced,NA,A549: 255.9;HaCaT: 197.9
TRIM16L,TRIM70,ENSG00000108448,Tripartite motif containing 16-like,17,18697998-18736118,Predicted intracellular proteins,Evidence at protein level,HPA066431,NA,NA,Approved,Plasma membrane<br>Cytosol,"Thyroid cancer:2.29e-5 (unfavourable), Liver cancer:2.87e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 22.7,Cell line enhanced,NA,A549: 290.9;HeLa: 215.6
TRIM4,RNF87,ENSG00000146833,Tripartite motif containing 4,7,99876958-99919600,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019356, HPA029461",Approved,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:7.36e-6 (favourable),Expressed in all,Expressed in all,NA,NA,ovary: 50.6,Mixed,NA,NA
TRIM44,"DIPB, MC7",ENSG00000166326,Tripartite motif containing 44,11,35662805-35818007,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA049053, HPA057633",Approved,NA,Approved,Vesicles<br>Plasma membrane,Liver cancer:5.24e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 30.7,Mixed,NA,NA
TRIM71,"LIN-41, LIN41",ENSG00000206557,Tripartite motif containing 71,3,32818018-32897826,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038141, HPA038142",Uncertain,NA,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,NA,Tissue enriched,Tissue enriched,8,testis: 9.1,lung: 1.1,Group enriched,6,AF22: 31.1;BEWO: 91.3;CACO-2: 19.0;Hep G2: 43.4;NTERA-2: 84.2
TRIML2,"FLJ25801, SPRYD6",ENSG00000179046,Tripartite motif family like 2,4,188091273-188109603,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043838,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Tissue enriched,Group enriched,26,placenta: 5.9;testis: 3.4,"cerebral cortex,lung: 0.1",Cell line enhanced,NA,A549: 30.5;BEWO: 17.7;hTCEpi: 15.4;NTERA-2: 34.0
TRIP6,"MGC10556, MGC10558, MGC29959, MGC3837, MGC4423, OIP1, ZRP-1",ENSG00000087077,Thyroid hormone receptor interactor 6,7,100867138-100873454,Predicted intracellular proteins,Evidence at protein level,"CAB046454, CAB046460, HPA052813",Approved,NA,Supported,Plasma membrane<br>Focal adhesion sites<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 84.7,Mixed,NA,NA
TRMT1,"FLJ20244, TRM1",ENSG00000104907,TRNA methyltransferase 1,19,13104902-13117567,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041130, HPA041380",Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:9.87e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,lymph node: 26.6,Expressed in all,NA,NA
TRMT10B,"bA3J10.9, FLJ31455, RG9MTD3",ENSG00000165275,TRNA methyltransferase 10B,9,37753803-37778972,Predicted intracellular proteins,Evidence at transcript level,HPA021800,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,"Lung cancer:3.91e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable)",Expressed in all,Mixed,NA,NA,skin: 12.9,Expressed in all,NA,NA
TRMT13,"CCDC76, FLJ10287, FLJ11219",ENSG00000122435,TRNA methyltransferase 13 homolog,1,100133150-100150497,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028494,Approved,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,"Renal cancer:6.89e-6 (unfavourable), Liver cancer:5.81e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 29.5,Expressed in all,NA,NA
TRPM4,FLJ20041,ENSG00000130529,Transient receptor potential cation channel subfamily M member 4,19,49157741-49211836,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA041169,Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane,"Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable)",Expressed in all,Mixed,NA,NA,prostate: 29.4,Cell line enhanced,NA,RT4: 47.8
TRPV2,"VRL, VRL-1, VRL1",ENSG00000187688,Transient receptor potential cation channel subfamily V member 2,17,16415542-16437003,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA044993,Uncertain,NA,Supported,Plasma membrane,"Renal cancer:1.19e-6 (unfavourable), Testis cancer:5.53e-4 (unfavourable)",Tissue enriched,Mixed,NA,NA,lung: 44.1,Cell line enhanced,NA,fHDF/TERT166: 83.8;HMC-1: 77.5;SK-MEL-30: 73.0;TIME: 68.5
TRPV3,VRL3,ENSG00000167723,Transient receptor potential cation channel subfamily V member 3,17,3510502-3557995,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA069550,NA,NA,Approved,Plasma membrane<br>Centrosome<br>Cytosol,NA,Mixed,Tissue enhanced,NA,skin: 5.1;small intestine: 4.5,duodenum: 1.7,Cell line enhanced,NA,BEWO: 3.6;RH-30: 9.0;T-47d: 3.7
TSG101,"TSG10, VPS23",ENSG00000074319,Tumor susceptibility 101,11,18468336-18527232,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004283, HPA006161",Approved,NA,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,"Liver cancer:3.74e-6 (unfavourable), Renal cancer:5.52e-6 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 81.8,Expressed in all,NA,NA
TTC17,FLJ10890,ENSG00000052841,Tetratricopeptide repeat domain 17,11,43358932-43494933,Predicted intracellular proteins,Evidence at protein level,HPA038508,Approved,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:4.75e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 61.8,Expressed in all,NA,NA
TTC23,"FLJ12572, HCC-8",ENSG00000103852,Tetratricopeptide repeat domain 23,15,99136323-99251223,Predicted intracellular proteins,Evidence at protein level,"HPA039806, HPA040369",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Endometrial cancer:1.07e-4 (favourable), Breast cancer:3.17e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 24.3,Mixed,NA,NA
TTC7B,TTC7L1,ENSG00000165914,Tetratricopeptide repeat domain 7B,14,90524564-90816479,Predicted intracellular proteins,Evidence at protein level,"HPA058363, HPA059577",Enhanced,NA,Supported,Plasma membrane,Renal cancer:3.20e-6 (favourable),Mixed,Expressed in all,NA,NA,cerebral cortex: 72.6,Mixed,NA,NA
TTLL12,KIAA0153,ENSG00000100304,Tubulin tyrosine ligase like 12,22,43166622-43187133,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003054, CAB046029",Approved,NA,Approved,Plasma membrane<br>Cytosol,Liver cancer:2.84e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,esophagus: 74.3,Expressed in all,NA,NA
TTLL5,KIAA0998,ENSG00000119685,Tubulin tyrosine ligase like 5,14,75633625-75955078,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA032128,Uncertain,NA,Supported,Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enriched,5,testis: 104.0,parathyroid gland: 20.4,Expressed in all,NA,NA
TULP3,TUBL3,ENSG00000078246,Tubby like protein 3,12,2877223-2941140,Predicted intracellular proteins,Evidence at protein level,"HPA015285, HPA018496",Uncertain,NA,Supported,Nucleus<br>Nucleoli<br>Plasma membrane,"Liver cancer:7.97e-5 (unfavourable), Endometrial cancer:2.99e-4 (favourable), Renal cancer:7.18e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 46.5,Expressed in all,NA,NA
TWF2,"A6r, A6RP, PTK9L",ENSG00000247596,Twinfilin actin binding protein 2,3,52228610-52239260,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA053874,Uncertain,NA,Supported,Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,lymph node: 61.2,Expressed in all,NA,NA
TXNDC11,EFP1,ENSG00000153066,Thioredoxin domain containing 11,16,11679080-11742878,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041174, HPA041390",Supported,NA,Supported,Plasma membrane<br>Cytosol,"Endometrial cancer:2.12e-5 (favourable), Glioma:8.01e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 84.5,Expressed in all,NA,NA
TXNIP,"ARRDC6, EST01027, HHCPA78, THIF, VDUP1",ENSG00000265972,Thioredoxin interacting protein,1,145992435-145996600,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA031085, HPA053694",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 1576.7,Cell line enhanced,NA,ASC TERT1: 662.0;HSkMC: 921.1
TYW3,"C1orf171, FLJ40918",ENSG00000162623,TRNA-yW synthesizing protein 3 homolog,1,74733152-74766678,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029641,Approved,NA,Approved,Plasma membrane<br>Cytosol,Liver cancer:1.49e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,ovary: 32.6,Expressed in all,NA,NA
UAP1,"AgX, AGX1, SPAG2",ENSG00000117143,UDP-N-acetylglucosamine pyrophosphorylase 1,1,162561506-162599842,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA014659,Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:5.12e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 166.1,Expressed in all,NA,NA
UBA3,"hUba3, NAE2, UBE1C",ENSG00000144744,Ubiquitin like modifier activating enzyme 3,3,69054730-69080408,Predicted intracellular proteins,Evidence at protein level,"HPA034873, HPA034874, HPA065335",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol,Liver cancer:8.57e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 66.8,Expressed in all,NA,NA
UBA52,"CEP52, HUBCEP52, L40, MGC126879, MGC126881, MGC57125, RPL40",ENSG00000221983,Ubiquitin A-52 residue ribosomal protein fusion product 1,19,18571730-18577550,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA041344, HPA049132, HPA056624",Supported,NA,Approved,Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,ovary: 1914.0,Expressed in all,NA,NA
UBAC1,"GBDR1, KPC2, UBADC1",ENSG00000130560,UBA domain containing 1,9,135932969-135961380,Predicted intracellular proteins,Evidence at protein level,HPA005651,Approved,NA,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:3.58e-7 (favourable), Cervical cancer:4.34e-6 (favourable)",Expressed in all,Expressed in all,NA,NA,skeletal muscle: 88.7,Expressed in all,NA,NA
UBAP1,UBAP,ENSG00000165006,Ubiquitin associated protein 1,9,34179005-34252523,Predicted intracellular proteins,Evidence at protein level,"HPA019804, HPA041590",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,Renal cancer:7.49e-6 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 88.6,Expressed in all,NA,NA
UBASH3B,"KIAA1959, STS-1, TULA2",ENSG00000154127,Ubiquitin associated and SH3 domain containing B,11,122655675-122814473,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038605, HPA038607",Approved,NA,Approved,Plasma membrane,NA,Mixed,Tissue enhanced,NA,placenta: 19.6;spleen: 21.3,lung: 6.7,Cell line enhanced,NA,HEL: 108.5;HMC-1: 77.6
UBE2A,"HHR6A, RAD6A, UBC2",ENSG00000077721,Ubiquitin conjugating enzyme E2 A,X,119574467-119591083,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003875, HPA051765, HPA065898",NA,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:2.20e-6 (unfavourable), Cervical cancer:2.16e-4 (favourable), Head and neck cancer:9.07e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 76.5,Expressed in all,NA,NA
UBE2B,"HHR6B, RAD6B, UBC2",ENSG00000119048,Ubiquitin conjugating enzyme E2 B,5,134371179-134391992,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003875, HPA051765, HPA065898",NA,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,adrenal gland: 99.1,Expressed in all,NA,NA
UBE2C,UBCH10,ENSG00000175063,Ubiquitin conjugating enzyme E2 C,20,45812576-45816957,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB011464, HPA034569, CAB035990, HPA054975",Approved,NA,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.24e-6 (unfavourable), Pancreatic cancer:6.91e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,tonsil: 56.9,Mixed,NA,NA
UBE2D1,"E2(17)KB1, SFT, UBC4/5, UBCH5, UbcH5A",ENSG00000072401,Ubiquitin conjugating enzyme E2 D1,10,58334975-58370753,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003920,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:8.04e-6 (unfavourable), Liver cancer:5.58e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skeletal muscle: 47.8,Mixed,NA,NA
UBE2D2,"UBC4, UbcH5B",ENSG00000131508,Ubiquitin conjugating enzyme E2 D2,5,139526431-139628433,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA003920,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:9.63e-7 (unfavourable), Renal cancer:2.09e-5 (unfavourable), Colorectal cancer:5.09e-5 (favourable), Endometrial cancer:5.90e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 239.4,Expressed in all,NA,NA
UBE2D3,UbcH5C,ENSG00000109332,Ubiquitin conjugating enzyme E2 D3,4,102794383-102868896,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003920,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:4.51e-4 (favourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 300.9,Expressed in all,NA,NA
UBE2D4,HBUCE1,ENSG00000078967,Ubiquitin conjugating enzyme E2 D4 (putative),7,43926438-43956136,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003920,Approved,NA,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:4.86e-4 (favourable), Prostate cancer:5.77e-4 (favourable), Renal cancer:6.51e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 12.5,Expressed in all,NA,NA
UBE2QL1,FLJ25076,ENSG00000215218,Ubiquitin conjugating enzyme E2 Q family like 1,5,6448623-6494909,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057414,NA,NA,Supported,Nucleus<br>Plasma membrane,Renal cancer:6.81e-8 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 41.8,seminal vesicle: 10.4,Cell line enhanced,NA,Karpas-707: 29.4;PC-3: 32.0;SCLC-21H: 37.2;U-266/70: 57.9;U-266/84: 50.5
UBE2S,E2-EPF,ENSG00000108106,Ubiquitin conjugating enzyme E2 S,19,55399745-55407777,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB015228, HPA057150",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,"Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.00e-6 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 120.1,Expressed in all,NA,NA
UBE3C,"KIAA0010, KIAA10",ENSG00000009335,Ubiquitin protein ligase E3C,7,157138913-157269372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039915,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Mitochondria,Renal cancer:9.18e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 51.1,Expressed in all,NA,NA
UBQLN2,"Chap1, CHAP1/DSK2, Dsk2, LIC-2, N4BP4, PLIC-2, PLIC2, RIHFB2157",ENSG00000188021,Ubiquilin 2,X,56563639-56567868,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006431, CAB013481",Enhanced,NA,Enhanced,Plasma membrane<br>Cytosol,Liver cancer:2.29e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 53.7,Expressed in all,NA,NA
UBR2,"bA49A4.1, C6orf133, dJ392M17.3, KIAA0349",ENSG00000024048,Ubiquitin protein ligase E3 component n-recognin 2,6,42564062-42693504,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA027869, HPA027880",Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Ovarian cancer:1.65e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 30.5,Expressed in all,NA,NA
UBTD1,FLJ11807,ENSG00000165886,Ubiquitin domain containing 1,10,97498868-97571209,Predicted intracellular proteins,Evidence at protein level,HPA034825,Uncertain,NA,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Colorectal cancer:5.54e-4 (unfavourable),Expressed in all,Mixed,NA,NA,testis: 34.0,Mixed,NA,NA
UCP3,SLC25A9,ENSG00000175564,Uncoupling protein 3,11,74000281-74009435,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB010771, HPA072225",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Mixed,Tissue enriched,19,skeletal muscle: 71.2,testis: 3.8,Group enriched,5,HDLM-2: 13.8;RH-30: 3.3
UHRF1BP1L,KIAA0701,ENSG00000111647,UHRF1 binding protein 1 like,12,100028455-100142848,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039671, HPA040399",Uncertain,NA,Approved,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,cerebral cortex: 32.9,Expressed in all,NA,NA
ULBP1,RAET1I,ENSG00000111981,UL16 binding protein 1,6,149964007-149973710,Predicted membrane proteins,Evidence at protein level,"HPA007547, HPA071005",Enhanced,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,NA,Mixed,Tissue enhanced,NA,testis: 11.0,thyroid gland: 3.5,Cell line enhanced,NA,HAP1: 35.9
ULBP2,RAET1H,ENSG00000131015,UL16 binding protein 2,6,149942000-149949235,Predicted membrane proteins,Evidence at protein level,CAB018974,Approved,NA,Supported,Vesicles<br>Plasma membrane,"Glioma:3.69e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,"cerebral cortex,esophagus: 3.0",Cell line enhanced,NA,SiHa: 69.8
UNC5A,"KIAA1976, UNC5H1",ENSG00000113763,Unc-5 netrin receptor A,5,176810477-176880895,Predicted membrane proteins,Evidence at protein level,HPA071450,NA,NA,Approved,Plasma membrane<br>Cytosol,Endometrial cancer:2.23e-4 (unfavourable),Tissue enhanced,Group enriched,22,adrenal gland: 10.3;cerebral cortex: 35.4,lymph node: 1.0,Cell line enriched,14,SCLC-21H: 104.8
UNC79,KIAA1409,ENSG00000133958,Unc-79 homolog (C. elegans),14,93333219-93707876,Predicted membrane proteins,Evidence at protein level,HPA071881,NA,NA,Approved,Nucleus<br>Plasma membrane,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 5.2;testis: 3.0,adrenal gland: 1.0,Cell line enhanced,NA,REH: 3.9;SCLC-21H: 3.6;SH-SY5Y: 2.0;U-937: 1.2
UQCC1,"BFZB, C20orf44, CBP3, FLJ10850, UQCC",ENSG00000101019,Ubiquinol-cytochrome c reductase complex assembly factor 1,20,35302566-35412141,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA034875,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 43.4,Expressed in all,NA,NA
USP2,UBP41,ENSG00000036672,Ubiquitin specific peptidase 2,11,119355215-119381726,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006777, HPA007222",Approved,NA,Supported,Plasma membrane<br>Cytosol,Renal cancer:3.09e-11 (favourable),Expressed in all,Tissue enhanced,NA,testis: 119.4,skeletal muscle: 59.3,Cell line enhanced,NA,U-266/70: 43.2
USP20,KIAA1003,ENSG00000136878,Ubiquitin specific peptidase 20,9,129834698-129881838,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006287, HPA007008",Uncertain,Approved,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.54e-7 (favourable), Renal cancer:5.65e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Endometrial cancer:4.01e-4 (favourable), Cervical cancer:8.01e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 22.1,Expressed in all,NA,NA
USP21,"USP16, USP23",ENSG00000143258,Ubiquitin specific peptidase 21,1,161159450-161165723,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028397,Uncertain,Supported,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:9.50e-6 (unfavourable), Urothelial cancer:3.35e-5 (favourable), Liver cancer:1.68e-4 (unfavourable), Endometrial cancer:7.05e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 45.7,Expressed in all,NA,NA
USP4,"UNP, Unph",ENSG00000114316,Ubiquitin specific peptidase 4,3,49277831-49340712,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018499,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.29e-5 (favourable), Lung cancer:4.46e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 56.8,Expressed in all,NA,NA
UTP20,"1A6/DRIM, DRIM",ENSG00000120800,"UTP20, small subunit processome component",12,101280109-101386616,Predicted intracellular proteins,Evidence at protein level,HPA049341,NA,NA,Supported,Nucleoli<br>Plasma membrane,"Liver cancer:1.15e-5 (unfavourable), Renal cancer:8.87e-4 (favourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 12.2,Expressed in all,NA,NA
UTRN,"DMDL, DRP, DRP1",ENSG00000152818,Utrophin,6,144285701-144853034,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB016348, HPA018894",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:7.61e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 174.0,Cell line enhanced,NA,HAP1: 226.1
VANGL1,STB2,ENSG00000173218,VANGL planar cell polarity protein 1,1,115641953-115698224,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA025235, CAB076375",Approved,NA,Approved,Plasma membrane,"Colorectal cancer:7.53e-4 (favourable), Pancreatic cancer:7.89e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,fallopian tube: 19.4,Mixed,NA,NA
VCPIP1,"DUBA3, FLJ23132, KIAA1850, VCIP135",ENSG00000175073,Valosin containing protein interacting protein 1,8,66628487-66667217,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA023932,Uncertain,NA,Approved,Plasma membrane,NA,Expressed in all,Mixed,NA,NA,bone marrow: 13.1,Expressed in all,NA,NA
VIL1,"D2S1471, VIL",ENSG00000127831,Villin 1,2,218419092-218453295,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002452, HPA006884, HPA006885",Enhanced,NA,Enhanced,Plasma membrane,NA,Tissue enhanced,Group enriched,7,colon: 173.7;duodenum: 398.5;rectum: 199.6;small intestine: 480.0,gallbladder: 44.7,Group enriched,91,CACO-2: 628.4;Hep G2: 245.1
VPS50,"CCDC132, DKFZp313I2429, FLJ20097, KIAA1861, VPS54L",ENSG00000004766,"VPS50, EARP/GARPII complex subunit",7,93232340-93361121,Predicted intracellular proteins,Evidence at protein level,HPA026679,Approved,NA,Uncertain,Plasma membrane<br>Cytosol,"Renal cancer:1.35e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 25.4,Expressed in all,NA,NA
VPS8,"FLJ32099, KIAA0804",ENSG00000156931,"VPS8, CORVET complex subunit",3,184812143-185052614,Predicted intracellular proteins,Evidence at protein level,HPA036871,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 31.2,Expressed in all,NA,NA
VSIG4,Z39IG,ENSG00000155659,V-set and immunoglobulin domain containing 4,X,66021738-66040125,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA003903, CAB026000",Approved,NA,Uncertain,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:1.95e-6 (unfavourable), Colorectal cancer:1.34e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lung: 243.4,Not detected,NA,NA
VWA5B1,FLJ32784,ENSG00000158816,Von Willebrand factor A domain containing 5B1,1,20290919-20354894,Predicted intracellular proteins,Evidence at protein level,"HPA027496, HPA028405, HPA064829",Enhanced,NA,Approved,Plasma membrane<br>Mitochondria<br>Cytosol,NA,Mixed,Tissue enhanced,NA,testis: 5.0,epididymis: 1.6,Cell line enriched,10,SCLC-21H: 1.4
VWA7,"C6orf27, G7c, NG37",ENSG00000204396,Von Willebrand factor A domain containing 7,6,31765590-31777294,Predicted secreted proteins,Evidence at transcript level,"HPA046954, HPA054262",Approved,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:4.35e-8 (favourable),Mixed,Tissue enhanced,NA,fallopian tube: 9.1,parathyroid gland: 1.9,Cell line enhanced,NA,U-266/70: 1.0
WARS2,TrpRS,ENSG00000116874,"Tryptophanyl tRNA synthetase 2, mitochondrial",1,119031216-119140671,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069692,Enhanced,NA,Supported,Plasma membrane<br>Mitochondria,Renal cancer:1.45e-4 (favourable),Expressed in all,Expressed in all,NA,NA,fallopian tube: 15.2,Expressed in all,NA,NA
WASF2,"SCAR2, WAVE2",ENSG00000158195,WAS protein family member 2,1,27404226-27490158,Predicted intracellular proteins,Evidence at protein level,"CAB022632, HPA045288",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:5.29e-8 (unfavourable), Ovarian cancer:8.48e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 88.1,Expressed in all,NA,NA
WBP4,"FBP21, MGC117310",ENSG00000120688,WW domain binding protein 4,13,41061274-41084006,Predicted intracellular proteins,Evidence at protein level,"HPA038965, HPA058738",Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,Thyroid cancer:2.89e-4 (favourable),Expressed in all,Expressed in all,NA,NA,endometrium: 27.7,Expressed in all,NA,NA
WDFY3,"ALFY, KIAA0993, ZFYVE25",ENSG00000163625,WD repeat and FYVE domain containing 3,4,84669610-84966391,Predicted intracellular proteins,Evidence at protein level,"HPA042734, HPA048572",Approved,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:3.64e-5 (favourable), Stomach cancer:9.35e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 36.2,Mixed,NA,NA
WDR12,"FLJ10881, YTM1",ENSG00000138442,WD repeat domain 12,2,202874782-203014798,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036389,Uncertain,NA,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,Liver cancer:2.57e-6 (unfavourable),Expressed in all,Mixed,NA,NA,testis: 7.3,Expressed in all,NA,NA
WDR13,NA,ENSG00000101940,WD repeat domain 13,X,48590042-48608867,Predicted intracellular proteins,Evidence at protein level,HPA000913,Enhanced,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Microtubule organizing center,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 91.9,Expressed in all,NA,NA
WDR53,"MGC12928, MGC64882",ENSG00000185798,WD repeat domain 53,3,196554177-196568674,Predicted intracellular proteins,Evidence at protein level,"HPA016420, HPA019332",Approved,NA,Approved,Plasma membrane<br>Cytosol,"Liver cancer:1.57e-6 (unfavourable), Melanoma:3.09e-4 (unfavourable)",Expressed in all,Tissue enriched,6,testis: 112.5,parathyroid gland: 19.9,Expressed in all,NA,NA
WDR6,NA,ENSG00000178252,WD repeat domain 6,3,49007062-49015953,Predicted intracellular proteins,Evidence at protein level,HPA042622,Approved,NA,Supported,Plasma membrane<br>Cytosol,"Liver cancer:2.97e-6 (unfavourable), Renal cancer:4.52e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 204.8,Expressed in all,NA,NA
WDR66,"CaM-IP4, MGC33630",ENSG00000158023,WD repeat domain 66,12,121917862-122003927,Predicted intracellular proteins,Evidence at protein level,"HPA039902, HPA040005",Supported,NA,Uncertain,Plasma membrane<br>Cytosol,Endometrial cancer:3.11e-4 (favourable),Mixed,Tissue enhanced,NA,fallopian tube: 32.6;testis: 30.7,thyroid gland: 7.4,Cell line enhanced,NA,HBEC3-KT: 22.5;hTCEpi: 21.0;hTERT-HME1: 15.0
WIPF1,"WASPIP, WIP",ENSG00000115935,WAS/WASL interacting protein family member 1,2,174559572-174682916,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA003739, CAB009737, HPA070706",Enhanced,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.14e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,lymph node: 157.5,Cell line enhanced,NA,Karpas-707: 220.1
WNT8A,WNT8D,ENSG00000061492,Wnt family member 8A,5,138083892-138092365,Predicted secreted proteins,Evidence at transcript level,HPA038539,Uncertain,NA,Uncertain,Plasma membrane<br>Cytosol,NA,Tissue enriched,Not detected,NA,NA,testis: 0.7,Not detected,NA,NA
WWP1,"AIP5, DKFZP434D2111",ENSG00000123124,WW domain containing E3 ubiquitin protein ligase 1,8,86342738-86478420,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA023180,Approved,NA,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:5.45e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 183.6,Expressed in all,NA,NA
XIAP,"API3, BIRC4, hILP",ENSG00000101966,X-linked inhibitor of apoptosis,X,123859724-123913979,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB009203, HPA042428",Approved,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Breast cancer:9.21e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 35.4,Mixed,NA,NA
XIRP2,CMYA3,ENSG00000163092,Xin actin binding repeat containing 2,2,166888487-167259753,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034813, HPA074599",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Tissue enriched,Group enriched,22,heart muscle: 84.0;skeletal muscle: 301.6,prostate: 8.8,Cell line enhanced,NA,AN3-CA: 1.4;HUVEC TERT2: 3.5;U-2197: 2.7
XPC,"RAD4, XPCC",ENSG00000154767,"XPC complex subunit, DNA damage recognition and repair factor",3,14145147-14178783,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009932, HPA035707, HPA069673",Supported,NA,Enhanced,Nucleus<br>Plasma membrane,"Renal cancer:4.14e-7 (favourable), Urothelial cancer:2.46e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 52.4,Expressed in all,NA,NA
XPO6,"FLJ22519, KIAA0370, RANBP20",ENSG00000169180,Exportin 6,16,28097979-28211920,Predicted intracellular proteins,Evidence at protein level,HPA038246,Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,"Liver cancer:3.68e-4 (unfavourable), Urothelial cancer:8.80e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 93.8,Expressed in all,NA,NA
XRN1,SEP1,ENSG00000114127,5'-3' exoribonuclease 1,3,142306607-142448062,Predicted intracellular proteins,Evidence at protein level,"HPA035005, HPA035006",Approved,NA,Supported,Plasma membrane<br>Cytosol,Pancreatic cancer:9.43e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 22.2,Cell line enriched,5,RH-30: 137.9
YES1,"c-yes, HsT441, Yes",ENSG00000176105,"YES proto-oncogene 1, Src family tyrosine kinase",18,721588-812546,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004370, HPA026480",Approved,NA,Supported,Plasma membrane<br>Cytosol,Pancreatic cancer:2.46e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 62.0,Mixed,NA,NA
YIPF4,"FinGER4, MGC11061",ENSG00000119820,Yip1 domain family member 4,2,32277910-32316594,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017884,Supported,NA,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 19.0,Expressed in all,NA,NA
YOD1,"DKFZp451J1719, DUBA8, OTUD2",ENSG00000180667,YOD1 deubiquitinase,1,207043849-207052980,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028400, HPA028439",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,bone marrow: 37.1,esophagus: 27.8,Cell line enhanced,NA,HEL: 78.5;K-562: 55.5
YTHDC1,"KIAA1966, YT521, YT521-B",ENSG00000083896,YTH domain containing 1,4,68310387-68350089,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036462,Supported,NA,Approved,Nucleoplasm<br>Plasma membrane,Urothelial cancer:7.29e-5 (favourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 75.1,Expressed in all,NA,NA
ZBED3,MGC15435,ENSG00000132846,Zinc finger BED-type containing 3,5,77072072-77087323,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055995,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:1.68e-4 (favourable),Expressed in all,Mixed,NA,NA,thyroid gland: 18.8,Mixed,NA,NA
ZBTB33,"kaiso, WUGSC:H_DJ525N14.1, ZNF-kaiso, ZNF348",ENSG00000177485,Zinc finger and BTB domain containing 33,X,120250752-120258398,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA000755, CAB001980, HPA005732",Approved,NA,Enhanced,Nucleus<br>Plasma membrane<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 23.4,Expressed in all,NA,NA
ZBTB8OS,ARCH,ENSG00000176261,Zinc finger and BTB domain containing 8 opposite strand,1,32600172-32650903,Predicted intracellular proteins,Evidence at protein level,HPA046315,Approved,NA,Approved,Plasma membrane,"Renal cancer:7.11e-8 (unfavourable), Liver cancer:4.25e-4 (unfavourable), Melanoma:8.56e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 43.3,Expressed in all,NA,NA
ZCCHC16,"FLJ46608, Mar4, Mart4",ENSG00000187823,Zinc finger CCHC-type containing 16,X,112454500-112457112,Predicted intracellular proteins,Evidence at transcript level,HPA003272,Uncertain,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,NA,Group enriched,Not detected,NA,NA,kidney: 0.8,Not detected,NA,NA
ZCCHC5,"FLJ38865, Mar3, Mart3, ZHC5",ENSG00000179300,Zinc finger CCHC-type containing 5,X,78656069-78659328,Predicted intracellular proteins,Evidence at transcript level,"HPA051991, HPA053174, HPA075136",Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,NA,Not detected,Not detected,NA,NA,endometrium: 0.8,Cell line enhanced,NA,fHDF/TERT166: 1.4;HBF TERT88: 2.3;hTEC/SVTERT24-B: 1.7;RH-30: 2.0;U-251 MG: 1.3
ZDHHC20,FLJ25952,ENSG00000180776,Zinc finger DHHC-type containing 20,13,21372573-21459370,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA014483, HPA014702",Approved,NA,Uncertain,Vesicles<br>Plasma membrane<br>Mitochondria,"Renal cancer:1.01e-4 (unfavourable), Pancreatic cancer:6.55e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 60.5,Expressed in all,NA,NA
ZDHHC22,C14orf59,ENSG00000177108,Zinc finger DHHC-type containing 22,14,77131270-77142734,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA049471, HPA072213",NA,NA,Enhanced,Plasma membrane,NA,Tissue enriched,Tissue enriched,113,cerebral cortex: 64.2,testis: 0.5,Cell line enhanced,NA,AF22: 3.6;NTERA-2: 3.8;RH-30: 6.2;SCLC-21H: 8.2
ZFP41,"FLJ00028, FLJ38705, ZNF753",ENSG00000181638,ZFP41 zinc finger protein,8,143246821-143262705,Predicted intracellular proteins,Evidence at transcript level,"HPA047232, HPA056268",Uncertain,NA,Uncertain,Nucleus<br>Nucleoli<br>Plasma membrane,Liver cancer:3.46e-5 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 7.5,Mixed,NA,NA
ZFP90,"KIAA1954, NK10, ZNF756",ENSG00000184939,ZFP90 zinc finger protein,16,68530090-68576072,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029017,Uncertain,NA,Supported,Vesicles<br>Plasma membrane<br>Centrosome,Renal cancer:1.78e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 31.7,Mixed,NA,NA
ZFYVE28,KIAA1643,ENSG00000159733,Zinc finger FYVE-type containing 28,4,2269582-2418663,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038175, HPA057587",Approved,NA,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:1.35e-6 (favourable),Mixed,Mixed,NA,NA,cerebral cortex: 9.9,Mixed,NA,NA
ZGPAT,"dJ583P15.3, FLJ14972, GPATC6, GPATCH6, KIAA1847, MGC44880, ZC3H9, ZC3HDC9, ZIP",ENSG00000197114,Zinc finger CCCH-type and G-patch domain containing,20,63707465-63736142,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA056705,NA,NA,Supported,Nucleus<br>Plasma membrane,Head and neck cancer:6.17e-5 (favourable),Expressed in all,Expressed in all,NA,NA,liver: 27.5,Expressed in all,NA,NA
ZMYND10,"BLU, CILD22",ENSG00000004838,Zinc finger MYND-type containing 10,3,50341110-50346852,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035255,NA,NA,Approved,Plasma membrane<br>Cytosol,Renal cancer:6.75e-5 (favourable),Tissue enhanced,Group enriched,16,fallopian tube: 231.5;testis: 284.6,lung: 15.8,Cell line enhanced,NA,T-47d: 6.1;U-87 MG: 4.3
ZNF10,KOX1,ENSG00000256223,Zinc finger protein 10,12,133130575-133159465,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003204,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Plasma membrane,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 40.9,Mixed,NA,NA
ZNF18,"HDSG1, KOX11, Zfp535, ZKSCAN6, ZNF535, ZSCAN38",ENSG00000154957,Zinc finger protein 18,17,11977439-11997510,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA006144,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:3.06e-6 (unfavourable), Pancreatic cancer:5.12e-6 (favourable), Cervical cancer:6.32e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 22.3,Expressed in all,NA,NA
ZNF185,SCELL,ENSG00000147394,Zinc finger protein 185 (LIM domain),X,152914442-152973480,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000400, HPA016438",Enhanced,NA,Supported,Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol,"Pancreatic cancer:3.30e-5 (unfavourable), Lung cancer:1.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,epididymis: 400.1;esophagus: 278.4;seminal vesicle: 202.3,"cervix, uterine: 105.3",Cell line enhanced,NA,A-431: 108.1;EFO-21: 131.6;TIME: 192.3
ZNF2,"A1-5, Zfp661, ZNF661",ENSG00000275111,Zinc finger protein 2,2,95165432-95184317,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA041358,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Lung cancer:4.69e-5 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 6.4,Expressed in all,NA,NA
ZNF20,KOX13,ENSG00000132010,Zinc finger protein 20,19,12092843-12140407,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA020887,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,NA,Not detected,Mixed,NA,NA,testis: 9.3,Mixed,NA,NA
ZNF227,NA,ENSG00000131115,Zinc finger protein 227,19,44207547-44237268,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA030573,Uncertain,NA,Approved,Plasma membrane,Urothelial cancer:2.64e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 18.7,Mixed,NA,NA
ZNF229,NA,ENSG00000278318,Zinc finger protein 229,19,44417519-44448578,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA001494,Uncertain,NA,Approved,Vesicles<br>Plasma membrane,Renal cancer:8.43e-5 (favourable),Mixed,Tissue enhanced,NA,parathyroid gland: 6.7,"fallopian tube,thyroid gland: 3.1",Mixed,NA,NA
ZNF276,"CENP-Z, CENPZ, MGC45417, ZADT, ZFP276, ZNF477",ENSG00000158805,Zinc finger protein 276,16,89720400-89740903,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA021309, HPA022255",Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,Renal cancer:3.37e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 22.9,Expressed in all,NA,NA
ZNF277,"NRIF4, ZNF277P",ENSG00000198839,Zinc finger protein 277,7,112206588-112343096,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA027307,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:9.47e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 33.4,Expressed in all,NA,NA
ZNF337,dJ694B14.1,ENSG00000130684,Zinc finger protein 337,20,25674215-25696841,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA044303, HPA064219",Approved,NA,Approved,Nuclear speckles<br>Plasma membrane,Renal cancer:2.87e-6 (unfavourable),Mixed,Expressed in all,NA,NA,parathyroid gland: 27.9,Expressed in all,NA,NA
ZNF397,"MGC13250, ZNF47, ZSCAN15",ENSG00000186812,Zinc finger protein 397,18,35241030-35267133,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA026087,Uncertain,NA,Approved,Nucleoli<br>Plasma membrane<br>Microtubules<br>Cytosol,Pancreatic cancer:9.44e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 30.8,Mixed,NA,NA
ZNF407,"FLJ13839, FLJ20307, KIAA1703",ENSG00000215421,Zinc finger protein 407,18,74597870-75065671,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA028255, HPA041673",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:9.79e-5 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 9.0,Mixed,NA,NA
ZNF503,"FLJ45745, MGC2555, Nlz2",ENSG00000165655,Zinc finger protein 503,10,75397830-75401906,Predicted intracellular proteins,Evidence at protein level,HPA026848,Approved,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.97e-4 (favourable), Prostate cancer:3.50e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adrenal gland: 25.7,Cell line enhanced,NA,HEK93: 100.8;PC-3: 132.2
ZNF510,KIAA0972,ENSG00000081386,Zinc finger protein 510,9,96755865-96778129,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA049139,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:5.94e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 12.5,Expressed in all,NA,NA
ZNF511-PRAP1,NA,ENSG00000283496,ZNF511-PRAP1 readthrough,10,133309410-133352529,Predicted membrane proteins,Evidence at protein level,"HPA035360, HPA038713, HPA052451",Supported,NA,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,NA,NA,Tissue enhanced,NA,duodenum: 25.2;small intestine: 25.0,kidney: 10.7,Cell line enhanced,NA,Hep G2: 11.3
ZNF560,FLJ31986,ENSG00000198028,Zinc finger protein 560,19,9466507-9498607,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA045439, HPA063209",NA,NA,Supported,Nucleoplasm<br>Plasma membrane,NA,Tissue enriched,Tissue enriched,9,testis: 11.9,placenta: 1.2,Cell line enhanced,NA,HEL: 19.1;NTERA-2: 20.6
ZNF571,HSPC059,ENSG00000180479,Zinc finger protein 571,19,37554782-37594790,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA054762,NA,NA,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,NA,Mixed,Tissue enriched,6,thyroid gland: 130.6,parathyroid gland: 21.6,Mixed,NA,NA
ZNF598,FLJ00086,ENSG00000167962,Zinc finger protein 598,16,1997654-2009823,Predicted intracellular proteins,Evidence at protein level,"HPA041760, HPA041896",Approved,NA,Approved,Plasma membrane<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,spleen: 11.5,Expressed in all,NA,NA
ZNF599,FLJ30663,ENSG00000153896,Zinc finger protein 599,19,34758076-34773229,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA014701,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,NA,Mixed,Mixed,NA,NA,epididymis: 14.6,Mixed,NA,NA
ZNF646,KIAA0296,ENSG00000167395,Zinc finger protein 646,16,31074422-31084196,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA042364, HPA066468",Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:1.28e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 34.3,spleen: 10.8,Expressed in all,NA,NA
ZNF655,"VIK, VIK-1",ENSG00000197343,Zinc finger protein 655,7,99558406-99576453,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA029534, HPA050750",Uncertain,NA,Supported,Nucleoplasm<br>Plasma membrane,"Breast cancer:7.12e-4 (favourable), Melanoma:7.24e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 21.2,Mixed,NA,NA
ZNF706,HSPC038,ENSG00000120963,Zinc finger protein 706,8,101177878-101206193,Predicted intracellular proteins,Evidence at protein level,HPA042793,NA,NA,Approved,Plasma membrane,"Renal cancer:5.90e-11 (unfavourable), Endometrial cancer:3.12e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 159.9,Expressed in all,NA,NA
ZNF717,"X17, ZNF838",ENSG00000227124,Zinc finger protein 717,3,75709643-75785583,Predicted intracellular proteins,Evidence at transcript level,HPA044549,Uncertain,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane,NA,Mixed,Expressed in all,NA,NA,epididymis: 29.3,Cell line enhanced,NA,K-562: 73.1
ZNF783,DKFZp667J212,ENSG00000204946,Zinc finger family member 783,7,149262171-149297302,Predicted intracellular proteins,Evidence at protein level,HPA020375,Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Renal cancer:2.24e-7 (unfavourable), Urothelial cancer:4.11e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 9.2,Mixed,NA,NA
ZNF785,FLJ32130,ENSG00000197162,Zinc finger protein 785,16,30573740-30585771,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA030510,NA,NA,Approved,Nucleoplasm<br>Plasma membrane,"Pancreatic cancer:2.03e-5 (favourable), Lung cancer:8.99e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 11.7,Mixed,NA,NA
ZNF79,pT7,ENSG00000196152,Zinc finger protein 79,9,127424374-127445372,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA028977,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:6.04e-7 (favourable), Pancreatic cancer:5.42e-5 (favourable), Endometrial cancer:6.83e-5 (favourable), Lung cancer:5.96e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 11.4,Expressed in all,NA,NA
ZNF839,C14orf131,ENSG00000022976,Zinc finger protein 839,14,102317377-102342702,Predicted intracellular proteins,Evidence at protein level,HPA020434,Uncertain,NA,Approved,Nucleoplasm<br>Plasma membrane,"Pancreatic cancer:4.57e-4 (favourable), Renal cancer:5.00e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 37.2,Expressed in all,NA,NA
ZSCAN22,"HKR2, ZNF50",ENSG00000182318,Zinc finger and SCAN domain containing 22,19,58327019-58342332,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA006471,Uncertain,NA,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 3.3,Cell line enhanced,NA,HEK93: 13.4
ZSCAN29,"FLJ35867, Zfp690, ZNF690",ENSG00000140265,Zinc finger and SCAN domain containing 29,15,43358172-43371025,"Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,"HPA007241, HPA011109",Enhanced,NA,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,testis: 27.3,Expressed in all,NA,NA
ZSWIM1,"C20orf162, dJ337O18.5",ENSG00000168612,Zinc finger SWIM-type containing 1,20,45881227-45885266,Predicted intracellular proteins,Evidence at protein level,"HPA041147, HPA046751",Uncertain,NA,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:1.77e-4 (favourable), Liver cancer:5.47e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 9.3,Expressed in all,NA,NA
ZSWIM8,"4832404P21Rik, KIAA0913",ENSG00000214655,Zinc finger SWIM-type containing 8,10,73785582-73801797,Predicted intracellular proteins,Evidence at protein level,HPA041244,Approved,NA,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:5.61e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 63.2,Expressed in all,NA,NA
AACS,"ACSF1, FLJ12389, SUR-5",ENSG00000081760,Acetoacetyl-CoA synthetase,12,125065379-125143333,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA058815,Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,breast: 55.0,Expressed in all,NA,NA
AASS,"LKRSDH, LORSDH",ENSG00000008311,Aminoadipate-semialdehyde synthase,7,122075647-122144280,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020637, HPA020728, HPA020734",Enhanced,NA,Enhanced,Vesicles<br>Mitochondria,Liver cancer:9.81e-4 (favourable),Expressed in all,Mixed,NA,NA,ovary: 30.7,Cell line enhanced,NA,AN3-CA: 49.4;NTERA-2: 51.8
ABCA1,"ABC1, HDLDT1, TGD",ENSG00000165029,ATP binding cassette subfamily A member 1,9,104781002-104928237,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA057283, CAB069889",Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,adrenal gland: 38.0,Cell line enhanced,NA,U-87 MG: 76.7
ABCA13,"FLJ33876, FLJ33951",ENSG00000179869,ATP binding cassette subfamily A member 13,7,48171458-48647496,Predicted membrane proteins,Evidence at transcript level,HPA063601,NA,NA,Approved,Vesicles<br>Centrosome<br>Cytosol,NA,Mixed,Tissue enriched,10,bone marrow: 29.4,testis: 3.0,Cell line enhanced,NA,HDLM-2: 5.3;U-2 OS: 6.8
ABCB9,EST122234,ENSG00000150967,ATP binding cassette subfamily B member 9,12,122920951-122981649,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB033052, HPA035113, HPA035114",Approved,NA,Supported,Vesicles,Glioma:4.62e-4 (unfavourable),Mixed,Tissue enhanced,NA,testis: 23.8,cerebral cortex: 12.0,Mixed,NA,NA
ABCG1,ABC8,ENSG00000160179,ATP binding cassette subfamily G member 1,21,42199689-42297244,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA031470, HPA031471",Approved,NA,Supported,Golgi apparatus<br>Vesicles,Renal cancer:7.16e-6 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 43.5,Cell line enhanced,NA,MCF7: 25.3;MOLT-4: 25.1;SCLC-21H: 26.2
ABCG8,GBD4,ENSG00000143921,ATP binding cassette subfamily G member 8,2,43838964-43878466,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA019556,Uncertain,NA,Approved,Vesicles,NA,Tissue enriched,Group enriched,25,duodenum: 50.0;liver: 34.0;small intestine: 55.5,gallbladder: 1.8,Cell line enriched,44,Hep G2: 6.9
ABHD14A,"DKFZP564O243, DORZ1",ENSG00000248487,Abhydrolase domain containing 14A,3,51971426-51981199,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA038153, HPA056913",NA,NA,Enhanced,Vesicles,Lung cancer:4.72e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 51.0,Expressed in all,NA,NA
ABHD14A-ACY1,NA,ENSG00000114786,ABHD14A-ACY1 readthrough,3,51974706-51989183,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036174, HPA036175, HPA038153",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,small intestine: 1.7,kidney: 0.7,Cell line enhanced,NA,HUVEC TERT2: 1.3;SH-SY5Y: 1.3
ABHD17A,"C19orf27, FAM108A1, MGC5244",ENSG00000129968,Abhydrolase domain containing 17A,19,1876810-1885547,Predicted intracellular proteins,Evidence at protein level,"HPA043270, HPA047226",Uncertain,NA,Approved,Vesicles,"Pancreatic cancer:1.76e-5 (favourable), Endometrial cancer:1.73e-4 (favourable), Head and neck cancer:6.46e-4 (favourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 31.4,Mixed,NA,NA
ABHD5,"CGI-58, NCIE2",ENSG00000011198,Abhydrolase domain containing 5,3,43690113-43734371,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB020685, HPA035851, HPA035852",Approved,NA,Approved,Vesicles,"Renal cancer:9.17e-5 (favourable), Colorectal cancer:8.89e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 50.6,Expressed in all,NA,NA
ABHD6,NA,ENSG00000163686,Abhydrolase domain containing 6,3,58237506-58295693,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA017283, HPA073225",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.11e-11 (favourable), Colorectal cancer:1.13e-4 (favourable)",Expressed in all,Mixed,NA,NA,small intestine: 50.9,Mixed,NA,NA
ABT1,NA,ENSG00000146109,Activator of basal transcription 1,6,26596952-26600744,Predicted intracellular proteins,Evidence at protein level,HPA077039,NA,NA,Approved,Vesicles,"Ovarian cancer:1.89e-4 (favourable), Urothelial cancer:3.80e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 17.9,Expressed in all,NA,NA
AC240274.1,NA,ENSG00000271254,NA,Unmapped,4612-29626,Predicted intracellular proteins,Evidence at protein level,"HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Uncertain,NA,Approved,Vesicles,NA,NA,Expressed in all,NA,NA,testis: 73.9,Expressed in all,NA,NA
ACBD4,FLJ13322,ENSG00000181513,Acyl-CoA binding domain containing 4,17,45132600-45144181,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051772,Approved,NA,Approved,Nucleus<br>Vesicles,"Pancreatic cancer:4.64e-4 (favourable), Liver cancer:4.76e-4 (favourable), Urothelial cancer:6.53e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,duodenum: 30.3,Mixed,NA,NA
ACBD7,"bA455B2.2, FLJ38219",ENSG00000176244,Acyl-CoA binding domain containing 7,10,15077523-15088776,Predicted intracellular proteins,Evidence at protein level,"HPA043326, HPA062478",NA,NA,Approved,Vesicles<br>Cytosol,NA,Mixed,Tissue enriched,5,cerebral cortex: 40.5,testis: 7.7,Cell line enhanced,NA,MOLT-4: 29.4
ACE,"ACE1, CD143, DCP1",ENSG00000159640,Angiotensin I converting enzyme,17,63477061-63498380,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002426, CAB002921, HPA029298, HPA069790",Enhanced,NA,Approved,Vesicles,NA,Expressed in all,Tissue enhanced,NA,duodenum: 178.9;small intestine: 291.6,testis: 83.7,Cell line enhanced,NA,ASC TERT1: 44.4;HUVEC TERT2: 28.2
ACHE,YT,ENSG00000087085,Acetylcholinesterase (Cartwright blood group),7,100889994-100896974,"Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA019704, HPA027098",NA,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)",Mixed,Tissue enhanced,NA,skeletal muscle: 58.5,cerebral cortex: 14.1,Cell line enhanced,NA,BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
ACKR2,"CCBP2, CCR10, CCR9, CMKBR9, D6",ENSG00000144648,Atypical chemokine receptor 2,3,42804752-42887974,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA013819, HPA073493",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Mixed,Tissue enhanced,NA,placenta: 22.9,adipose tissue: 5.3,Cell line enhanced,NA,BEWO: 50.1;HEL: 15.5;SK-BR-3: 21.0
ACKR4,"CCBP2, CCR11, CCRL1, CCX-CKR, PPR1, VSHK1",ENSG00000129048,Atypical chemokine receptor 4,3,132597237-132618967,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA054926,NA,NA,Approved,Vesicles<br>Mitochondria,NA,Mixed,Mixed,NA,NA,duodenum: 19.1,Cell line enriched,6,BJ hTERT+: 281.6
ACOT8,"hACTE-III, hTE, NAP1, PTE-2, PTE1",ENSG00000101473,Acyl-CoA thioesterase 8,20,45841721-45857406,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB010261,Approved,NA,Supported,Vesicles<br>Mitochondria,Renal cancer:3.18e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 30.1,Expressed in all,NA,NA
ACOX1,PALMCOX,ENSG00000161533,Acyl-CoA oxidase 1,17,75941507-75979363,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB021094, HPA021192, HPA021195, HPA028759",Approved,NA,Enhanced,Nucleus<br>Vesicles,Renal cancer:5.25e-7 (favourable),Expressed in all,Expressed in all,NA,NA,liver: 98.4,Expressed in all,NA,NA
ACOX2,"BRCACOX, BRCOX, THCCox",ENSG00000168306,Acyl-CoA oxidase 2,3,58505136-58537319,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038280, HPA064845",Enhanced,NA,Supported,Vesicles<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,liver: 87.9,kidney: 42.5,Cell line enhanced,NA,ASC diff: 10.4;ASC TERT1: 17.4;fHDF/TERT166: 6.6;Hep G2: 7.0;HSkMC: 11.8
ACRBP,"CT23, OY-TES-1, SP32",ENSG00000111644,Acrosin binding protein,12,6638075-6647460,Predicted secreted proteins,Evidence at protein level,"HPA039081, HPA039082",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enriched,19,testis: 432.5,thyroid gland: 22.6,Cell line enhanced,NA,HMC-1: 5.8;U-266/70: 11.3;U-266/84: 7.3
ACSBG1,"BG1, BGM, FLJ30320, hBG1, hsBG, KIAA0631, MGC14352",ENSG00000103740,Acyl-CoA synthetase bubblegum family member 1,15,78167468-78245688,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041642, CAB045955, HPA058869",Approved,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 25.6;skin: 13.3,adrenal gland: 8.1,Cell line enhanced,NA,NTERA-2: 3.3
ACSS2,"ACAS2, AceCS, ACS, ACSA, dJ1161H23.1",ENSG00000131069,Acyl-CoA synthetase short-chain family member 2,20,34872146-34927962,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA004141,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.04e-4 (favourable),Expressed in all,Mixed,NA,NA,adipose tissue: 55.9,Mixed,NA,NA
ADAM15,MDC15,ENSG00000143537,ADAM metallopeptidase domain 15,1,155050566-155062775,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA011633, HPA072878",Uncertain,NA,Uncertain,Vesicles,"Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 72.6,Cell line enhanced,NA,PC-3: 305.3
ADAM19,MLTNB,ENSG00000135074,ADAM metallopeptidase domain 19,5,157395534-157575775,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA055537,NA,NA,Approved,Vesicles,Renal cancer:3.90e-12 (unfavourable),Expressed in all,Mixed,NA,NA,lymph node: 34.4,Cell line enhanced,NA,HDLM-2: 101.7;U-251 MG: 170.3
ADAM32,NA,ENSG00000197140,ADAM metallopeptidase domain 32,8,39106990-39284911,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA044156, HPA062151",Enhanced,NA,Approved,Nucleus<br>Vesicles,NA,Not detected,Tissue enriched,35,testis: 28.7,skin: 0.8,Cell line enhanced,NA,U-2 OS: 1.1
ADAM9,"CORD9, KIAA0021, MCMP, MDC9, Mltng",ENSG00000168615,ADAM metallopeptidase domain 9,8,38996869-39105144,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA004000,NA,NA,Approved,Endoplasmic reticulum<br>Vesicles,"Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 118.7,Expressed in all,NA,NA
ADAMTS19,NA,ENSG00000145808,ADAM metallopeptidase with thrombospondin type 1 motif 19,5,129460265-129738683,Predicted secreted proteins,Evidence at transcript level,"HPA056171, HPA058438",Uncertain,NA,Approved,Vesicles<br>Midbody,NA,Tissue enhanced,Group enriched,13,"cervix, uterine: 16.8;endometrium: 16.9;placenta: 5.4;smooth muscle: 9.2",adrenal gland: 0.9,Group enriched,7,MCF7: 12.3;SH-SY5Y: 37.6
ADAMTS7,"ADAM-TS7, DKFZp434H204",ENSG00000136378,ADAM metallopeptidase with thrombospondin type 1 motif 7,15,78759203-78811431,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA045284, HPA048453",Uncertain,NA,Supported,Vesicles,Stomach cancer:9.53e-4 (unfavourable),Mixed,Tissue enhanced,NA,endometrium: 7.2,heart muscle: 4.3,Cell line enriched,9,HMC-1: 229.5
ADAMTS9,KIAA1312,ENSG00000163638,ADAM metallopeptidase with thrombospondin type 1 motif 9,3,64515654-64688000,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA028567, HPA028577, HPA028601",Approved,NA,Approved,Endoplasmic reticulum<br>Vesicles,NA,Expressed in all,Tissue enhanced,NA,placenta: 45.1,adipose tissue: 32.1,Cell line enhanced,NA,RPTEC TERT1: 20.9;SH-SY5Y: 136.2;WM-115: 27.9
ADAMTSL2,KIAA0605,ENSG00000197859,ADAMTS like 2,9,133532164-133575519,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045634, HPA053812",Approved,NA,Approved,Vesicles,"Colorectal cancer:5.01e-4 (unfavourable), Pancreatic cancer:6.70e-4 (favourable)",Expressed in all,Tissue enhanced,NA,adrenal gland: 29.0,kidney: 11.2,Cell line enhanced,NA,Hep G2: 4.9;RPMI-8226: 6.9;SH-SY5Y: 31.9
ADAMTSL3,"KIAA1233, punctin-2",ENSG00000156218,ADAMTS like 3,15,83654086-84039842,Predicted secreted proteins,Evidence at protein level,"HPA034773, HPA034774",Approved,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,placenta: 14.9,Group enriched,6,EFO-21: 11.2;RPTEC TERT1: 10.6;TIME: 10.7;U-2 OS: 2.4
ADCYAP1R1,"PAC1, PAC1R, PACAPR",ENSG00000078549,ADCYAP receptor type I,7,31052461-31111479,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA030739, HPA049877",Enhanced,NA,Supported,Vesicles,Endometrial cancer:5.78e-4 (favourable),Tissue enriched,Tissue enhanced,NA,cerebral cortex: 137.1;fallopian tube: 46.8,"cervix, uterine: 20.7",Group enriched,6,AF22: 3.6;NTERA-2: 4.9;SCLC-21H: 4.8;SH-SY5Y: 7.8
ADGRE2,"CD312, EMR2",ENSG00000127507,Adhesion G protein-coupled receptor E2,19,14732393-14778541,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA055200,NA,NA,Uncertain,Vesicles,Renal cancer:4.35e-6 (unfavourable),Mixed,Tissue enhanced,NA,appendix: 27.0;spleen: 15.4,adipose tissue: 6.0,Cell line enhanced,NA,HEL: 10.6;HMC-1: 16.0;U-937: 11.8
ADGRG5,"GPR114, PGR27",ENSG00000159618,Adhesion G protein-coupled receptor G5,16,57542421-57591681,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA007133,Enhanced,NA,Approved,Nucleoplasm<br>Nuclear membrane<br>Vesicles,Cervical cancer:4.25e-4 (favourable),Mixed,Tissue enhanced,NA,lymph node: 11.2;tonsil: 8.8,"appendix,spleen: 5.9",Cell line enriched,8,HMC-1: 31.8
ADHFE1,"ADHFe1, FLJ32430",ENSG00000147576,"Alcohol dehydrogenase, iron containing 1",8,66430185-66471601,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023062,Enhanced,NA,Approved,Vesicles,"Renal cancer:4.55e-5 (favourable), Breast cancer:5.76e-5 (favourable), Liver cancer:9.90e-5 (favourable)",Mixed,Mixed,NA,NA,liver: 14.3,Cell line enhanced,NA,ASC diff: 1.1;RPTEC TERT1: 1.2
AEBP1,ACLP,ENSG00000106624,AE binding protein 1,7,44104361-44114562,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB009966, HPA047724, HPA063595, HPA064970",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:9.31e-9 (unfavourable), Glioma:1.10e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 300.4,Cell line enhanced,NA,BJ: 163.5;fHDF/TERT166: 162.3;WM-115: 116.5
AFTPH,"FLJ20080, FLJ23793, MGC33965, Nbla10388",ENSG00000119844,Aftiphilin,2,64524305-64593005,Predicted intracellular proteins,Evidence at protein level,"HPA034990, HPA034991",Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Cytosol,"Renal cancer:2.37e-5 (favourable), Urothelial cancer:1.83e-4 (favourable), Stomach cancer:8.44e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 65.7,Expressed in all,NA,NA
AGFG1,"HRB, RAB, RIP",ENSG00000173744,ArfGAP with FG repeats 1,2,227472152-227561214,Predicted intracellular proteins,Evidence at protein level,HPA008741,Approved,NA,Supported,Vesicles,"Liver cancer:7.31e-6 (unfavourable), Ovarian cancer:3.43e-5 (unfavourable), Lung cancer:1.85e-4 (unfavourable), Renal cancer:6.92e-4 (unfavourable), Cervical cancer:7.13e-4 (unfavourable), Glioma:7.89e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 169.2,Expressed in all,NA,NA
AGK,"FLJ10842, MULK",ENSG00000006530,Acylglycerol kinase,7,141551189-141655244,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA020959, HPA053471",Supported,NA,Supported,Vesicles<br>Mitochondria,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 26.9,Expressed in all,NA,NA
AGMO,"FLJ16237, TMEM195",ENSG00000187546,Alkylglycerol monooxygenase,7,15200318-15562015,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057900,NA,NA,Uncertain,Vesicles,NA,Tissue enriched,Tissue enhanced,NA,liver: 63.7,epididymis: 17.6,Cell line enhanced,NA,Karpas-707: 5.6;SCLC-21H: 3.8;WM-115: 15.2
AGPAT4,"dJ473J16.2, LPAAT-delta",ENSG00000026652,1-acylglycerol-3-phosphate O-acyltransferase 4,6,161129979-161274061,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA053287, HPA060525",Approved,NA,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles,"Cervical cancer:1.45e-4 (unfavourable), Renal cancer:4.08e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 24.7,placenta: 12.3,Cell line enhanced,NA,AF22: 25.4
AGR3,"BCMP11, hAG-3, HAG3, PDIA18",ENSG00000173467,"Anterior gradient 3, protein disulphide isomerase family member",7,16859405-16881987,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA053942,Enhanced,NA,Supported,Endoplasmic reticulum<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,fallopian tube: 354.7;small intestine: 259.5,rectum: 233.8,Cell line enriched,52,T-47d: 316.6
AGTPBP1,"CCP1, KIAA1035, Nna1",ENSG00000135049,ATP/GTP binding protein 1,9,85546539-85742029,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA057208,Approved,NA,Approved,Nucleoli<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,bone marrow: 39.2,Expressed in all,NA,NA
AGTR1,"AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R",ENSG00000144891,Angiotensin II receptor type 1,3,148697784-148743008,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA003596,Enhanced,NA,Uncertain,Vesicles,NA,Group enriched,Tissue enhanced,NA,placenta: 214.0,liver: 50.9,Cell line enhanced,NA,ASC diff: 127.9;BJ hTERT+ SV40 Large T+: 33.9;HBF TERT88: 54.9;HSkMC: 24.7
AGTRAP,ATRAP,ENSG00000177674,Angiotensin II receptor associated protein,1,11736084-11754802,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA044120,Approved,NA,Supported,Vesicles,Liver cancer:6.57e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,prostate: 92.6,Expressed in all,NA,NA
AGXT,"AGT, AGT1, AGXT1, PH1, SPAT, SPT",ENSG00000172482,Alanine-glyoxylate aminotransferase,2,240868479-240880502,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035370, HPA035371",Enhanced,NA,Supported,Vesicles,Liver cancer:5.92e-5 (favourable),Tissue enriched,Tissue enriched,58,liver: 611.6,kidney: 10.4,Cell line enhanced,NA,Hep G2: 5.6;SK-BR-3: 1.1
AHSA2,"AHA1, DKFZp564C236, Hch1",ENSG00000173209,Activator of HSP90 ATPase homolog 2,2,61177418-61191203,Predicted intracellular proteins,Evidence at protein level,HPA051137,Approved,NA,Approved,Vesicles<br>Microtubules<br>Cytokinetic bridge,"Renal cancer:4.11e-6 (unfavourable), Urothelial cancer:1.85e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 44.1,Expressed in all,NA,NA
AKAP9,"AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO",ENSG00000127914,A-kinase anchoring protein 9,7,91940867-92110673,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008548, CAB012909, HPA026109",Enhanced,NA,Enhanced,Golgi apparatus<br>Vesicles<br>Centrosome,Renal cancer:2.10e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 37.8,Expressed in all,NA,NA
AKT2,NA,ENSG00000105221,AKT serine/threonine kinase 2,19,40230317-40285536,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004204, HPA064521",Uncertain,NA,Supported,Nucleus<br>Vesicles<br>Cytosol,"Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 170.1,Expressed in all,NA,NA
ALDH1B1,"ALDH5, ALDHX",ENSG00000137124,Aldehyde dehydrogenase 1 family member B1,9,38392664-38398661,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021037,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Mitochondria,"Thyroid cancer:1.17e-5 (unfavourable), Renal cancer:2.05e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 178.4,Mixed,NA,NA
ALDOC,NA,ENSG00000109107,"Aldolase, fructose-bisphosphate C",17,28573115-28577264,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003282, CAB020828, HPA067442",Enhanced,Supported,Approved,Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol,"Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable)",Tissue enriched,Tissue enriched,7,cerebral cortex: 766.6,heart muscle: 111.2,Cell line enhanced,NA,RPMI-8226: 165.2;U-266/70: 119.9
AMBRA1,"DCAF3, FLJ20294, KIAA1736, WDR94",ENSG00000110497,Autophagy and beclin 1 regulator 1,11,46396414-46594125,Predicted intracellular proteins,Evidence at protein level,"CAB017825, HPA038535",Approved,NA,Approved,Vesicles<br>Mitochondria,Renal cancer:1.61e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 27.0,Expressed in all,NA,NA
AMH,MIS,ENSG00000104899,Anti-Mullerian hormone,19,2249309-2252073,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA066973,NA,NA,Approved,Vesicles<br>Aggresome,Colorectal cancer:9.21e-5 (unfavourable),Mixed,Tissue enriched,6,testis: 1.6,cerebral cortex: 0.2,Cell line enhanced,NA,HEK93: 15.7;NTERA-2: 6.5;REH: 6.4;SH-SY5Y: 8.2
ANAPC1,"APC1, MCPR, TSG24",ENSG00000153107,Anaphase promoting complex subunit 1,2,111766271-111884690,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036329, HPA036330, HPA042998",Approved,NA,Approved,Vesicles,Endometrial cancer:1.34e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 20.6,Expressed in all,NA,NA
ANAPC15,"APC15, C11orf51, DKFZP564M082, HSPC020",ENSG00000110200,Anaphase promoting complex subunit 15,11,72106378-72112780,Predicted intracellular proteins,Evidence at protein level,HPA036596,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Ovarian cancer:2.55e-4 (favourable), Liver cancer:4.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 77.6,Expressed in all,NA,NA
ANGPTL4,"ARP4, FIAF, HFARP, NL2, PGAR, pp1158",ENSG00000167772,Angiopoietin like 4,19,8363289-8374373,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA007879, CAB033770",Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.34e-5 (unfavourable), Colorectal cancer:7.53e-4 (unfavourable), Lung cancer:9.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 78.7,liver: 43.2,Cell line enhanced,NA,HBEC3-KT: 161.5;TIME: 92.8;U-138 MG: 64.0
ANKRD13B,FLJ25555,ENSG00000198720,Ankyrin repeat domain 13B,17,29589769-29614761,Predicted intracellular proteins,Evidence at protein level,"HPA051886, HPA063748",Uncertain,NA,Supported,Vesicles,"Renal cancer:5.92e-6 (unfavourable), Pancreatic cancer:7.58e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 25.9,testis: 17.6,Cell line enhanced,NA,SCLC-21H: 75.3;SH-SY5Y: 76.2
ANKRD2,ARPP,ENSG00000165887,Ankyrin repeat domain 2,10,97572499-97583884,Predicted intracellular proteins,Evidence at protein level,"HPA040842, HPA040884",Enhanced,NA,Enhanced,Vesicles,NA,Tissue enhanced,Group enriched,14,heart muscle: 35.9;skeletal muscle: 119.4,kidney: 5.6,Cell line enhanced,NA,A-431: 14.1;HaCaT: 11.0;RPTEC TERT1: 10.3
ANKRD26,"KIAA1074, THC2",ENSG00000107890,Ankyrin repeat domain 26,10,26991914-27100498,Predicted intracellular proteins,Evidence at protein level,"HPA040654, HPA041460",Approved,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 10.7,Expressed in all,NA,NA
ANKRD39,MGC41816,ENSG00000213337,Ankyrin repeat domain 39,2,96836611-96858095,Predicted intracellular proteins,Evidence at protein level,HPA042678,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:6.78e-9 (unfavourable), Pancreatic cancer:6.12e-5 (favourable), Colorectal cancer:2.26e-4 (unfavourable), Urothelial cancer:5.21e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 17.2,Expressed in all,NA,NA
ANKRD6,KIAA0957,ENSG00000135299,Ankyrin repeat domain 6,6,89433170-89633834,Predicted intracellular proteins,Evidence at protein level,"CAB020693, HPA035694, HPA064642",Enhanced,NA,Supported,Vesicles,NA,Mixed,Mixed,NA,NA,cerebral cortex: 23.7,Cell line enhanced,NA,AF22: 15.3;BEWO: 45.7;HAP1: 14.8
ANTXR1,"ATR, FLJ10601, FLJ21776, TEM8",ENSG00000169604,Anthrax toxin receptor 1,2,69013178-69249327,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054785,NA,NA,Uncertain,Vesicles,"Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 180.5,Cell line enhanced,NA,LHCN-M2: 286.7
ANXA10,ANX14,ENSG00000109511,Annexin A10,4,168092515-168187690,Predicted intracellular proteins,Evidence at protein level,HPA005469,Enhanced,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,Liver cancer:3.64e-6 (favourable),Group enriched,Tissue enriched,8,stomach: 459.7,urinary bladder: 60.6,Group enriched,8,PC-3: 118.8;RT4: 140.1
AP1B1,"ADTB1, AP105A, BAM22, CLAPB2",ENSG00000100280,Adaptor related protein complex 1 beta 1 subunit,22,29327680-29423179,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA065226, HPA068520",Approved,NA,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:7.24e-6 (favourable), Liver cancer:5.55e-5 (unfavourable), Cervical cancer:4.81e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 104.2,Expressed in all,NA,NA
AP1G1,"ADTG, CLAPG1",ENSG00000166747,Adaptor related protein complex 1 gamma 1 subunit,16,71729000-71809201,Predicted intracellular proteins,Evidence at protein level,"CAB009049, HPA041224",Approved,NA,Enhanced,Vesicles<br>Cytosol,Renal cancer:2.96e-8 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 88.8,Expressed in all,NA,NA
AP1M2,"AP1-mu2, HSMU1B, mu2",ENSG00000129354,Adaptor related protein complex 1 mu 2 subunit,19,10572671-10587315,Predicted intracellular proteins,Evidence at protein level,HPA054999,NA,NA,Supported,Vesicles,"Renal cancer:3.73e-6 (favourable), Endometrial cancer:2.07e-4 (favourable)",Mixed,Mixed,NA,NA,thyroid gland: 98.3,Cell line enhanced,NA,Hep G2: 212.3;MCF7: 206.6;U-2 OS: 174.7
AP1S1,"AP19, CLAPS1, EKV3, SIGMA1A, WUGSC:H_DJ0747G18.2",ENSG00000106367,Adaptor related protein complex 1 sigma 1 subunit,7,101154397-101161596,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA060945,Supported,NA,Supported,Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 107.0,Expressed in all,NA,NA
AP1S2,"MRX59, MRXS5, PGS, SIGMA1B",ENSG00000182287,Adaptor related protein complex 1 sigma 2 subunit,X,15825806-15855014,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA049894, HPA060945",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,"Ovarian cancer:5.53e-6 (favourable), Breast cancer:9.86e-4 (favourable)",Expressed in all,Tissue enriched,7,epididymis: 920.5,smooth muscle: 126.9,Expressed in all,NA,NA
AP1S3,NA,ENSG00000152056,Adaptor related protein complex 1 sigma 3 subunit,2,223751686-223838027,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA066782,Approved,NA,Supported,Vesicles,"Pancreatic cancer:2.08e-5 (unfavourable), Lung cancer:3.36e-5 (unfavourable)",Mixed,Tissue enhanced,NA,epididymis: 54.2,thyroid gland: 23.6,Cell line enhanced,NA,CACO-2: 130.6
AP2A1,"ADTAA, CLAPA1",ENSG00000196961,Adaptor related protein complex 2 alpha 1 subunit,19,49766968-49807113,Predicted intracellular proteins,Evidence at protein level,CAB004306,Approved,NA,Supported,Vesicles,"Renal cancer:2.83e-9 (unfavourable), Ovarian cancer:2.91e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 103.9,Expressed in all,NA,NA
AP2A2,"ADTAB, CLAPA2, DKFZP564D1864, HIP9, HYPJ, KIAA0899",ENSG00000183020,Adaptor related protein complex 2 alpha 2 subunit,11,924894-1012245,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017514, HPA043040",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:9.27e-5 (unfavourable), Pancreatic cancer:4.57e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 16.0,Mixed,NA,NA
AP2B1,"ADTB2, CLAPB1",ENSG00000006125,Adaptor related protein complex 2 beta 1 subunit,17,35578046-35726409,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB017631, HPA056733, HPA067983",Approved,NA,Supported,Vesicles,Renal cancer:2.62e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 265.4,Expressed in all,NA,NA
AP3S1,CLAPS3,ENSG00000177879,Adaptor related protein complex 3 sigma 1 subunit,5,115841481-115914081,Predicted intracellular proteins,Evidence at protein level,HPA049270,Uncertain,NA,Approved,Vesicles,"Renal cancer:9.57e-8 (unfavourable), Pancreatic cancer:1.13e-5 (unfavourable), Breast cancer:1.22e-4 (unfavourable), Glioma:5.30e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 90.3,Expressed in all,NA,NA
AP3S2,sigma3b,ENSG00000157823,Adaptor related protein complex 3 sigma 2 subunit,15,89830599-89894638,Predicted intracellular proteins,Evidence at transcript level,HPA049270,Uncertain,NA,Approved,Vesicles,Renal cancer:5.55e-16 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 77.7,Expressed in all,NA,NA
AP4B1,"BETA-4, SPG47",ENSG00000134262,Adaptor related protein complex 4 beta 1 subunit,1,113894748-113905201,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028162, HPA028652",Approved,NA,Approved,Vesicles,"Liver cancer:8.60e-7 (unfavourable), Renal cancer:3.73e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 19.2,Expressed in all,NA,NA
AP4S1,"AP47B, CLA20, SPG52",ENSG00000100478,Adaptor related protein complex 4 sigma 1 subunit,14,31025106-31096450,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA039963,Approved,NA,Supported,Vesicles,"Renal cancer:2.87e-6 (favourable), Lung cancer:7.44e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 33.1,Expressed in all,NA,NA
AP5B1,"AP-5, DKFZp761E198, PP1030",ENSG00000254470,Adaptor related protein complex 5 beta 1 subunit,11,65775893-65780802,Predicted intracellular proteins,Evidence at protein level,"HPA065739, HPA067880",Uncertain,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Renal cancer:2.31e-5 (favourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 25.1,Mixed,NA,NA
APBA3,"mint3, X11L2",ENSG00000011132,Amyloid beta precursor protein binding family A member 3,19,3750819-3761699,Predicted intracellular proteins,Evidence at protein level,HPA045577,Approved,NA,Approved,Vesicles,"Pancreatic cancer:1.51e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Head and neck cancer:4.91e-4 (favourable), Endometrial cancer:5.97e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 6.6,Mixed,NA,NA
APEX2,"APE2, APEXL2, XTH2, ZGRF2",ENSG00000169188,Apurinic/apyrimidinic endodeoxyribonuclease 2,X,55000357-55009057,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048577,NA,NA,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,"Liver cancer:6.13e-7 (unfavourable), Ovarian cancer:5.21e-4 (favourable), Cervical cancer:6.17e-4 (favourable), Urothelial cancer:6.63e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,skin: 14.3,Expressed in all,NA,NA
APLP2,"APPH, APPL2",ENSG00000084234,Amyloid beta precursor like protein 2,11,130069837-130144811,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA039319,Approved,NA,Approved,Vesicles,"Renal cancer:1.33e-9 (favourable), Thyroid cancer:2.90e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 1056.8,Expressed in all,NA,NA
APOA1,NA,ENSG00000118137,Apolipoprotein A1,11,116835751-116837950,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016778, HPA046715",Supported,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable)",Tissue enriched,Tissue enhanced,NA,liver: 8458.6;small intestine: 4128.6,duodenum: 1609.4,Cell line enriched,15,Hep G2: 1951.8
APOA4,NA,ENSG00000110244,Apolipoprotein A4,11,116820700-116823306,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001352, HPA002549, CAB068250, CAB068251, CAB068252",Enhanced,NA,Approved,Vesicles,NA,Tissue enriched,Group enriched,126,duodenum: 2211.8;small intestine: 3441.1,liver: 22.3,Cell line enhanced,NA,BEWO: 7.4;CACO-2: 6.6;Hep G2: 5.1;NB-4: 4.6;RPMI-8226: 8.2;SH-SY5Y: 11.1
APOB,NA,ENSG00000084674,Apolipoprotein B,2,21001429-21044073,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016070, HPA049793",Supported,NA,Supported,Vesicles<br>Cytosol,NA,Tissue enriched,Group enriched,120,duodenum: 182.8;liver: 618.9;small intestine: 333.2,adipose tissue: 3.1,Cell line enriched,25,Hep G2: 734.4
APOE,AD2,ENSG00000130203,Apolipoprotein E,19,44905754-44909393,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB008363, HPA065539, HPA068768, CAB069921",Enhanced,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,adrenal gland: 1801.1,Cell line enhanced,NA,ASC diff: 1276.1;Hep G2: 626.6;HSkMC: 991.4;SK-MEL-30: 1417.0
APOL4,APOLIV,ENSG00000100336,Apolipoprotein L4,22,36189124-36204840,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA049797, HPA055435",Approved,NA,Supported,Vesicles,"Urothelial cancer:2.40e-6 (favourable), Renal cancer:2.00e-5 (unfavourable), Ovarian cancer:3.45e-4 (favourable)",Expressed in all,Mixed,NA,NA,prostate: 26.7,Cell line enhanced,NA,BEWO: 19.1;HDLM-2: 103.0;K-562: 21.3;SCLC-21H: 56.9
APP,AD1,ENSG00000142192,Amyloid beta precursor protein,21,25880550-26171128,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB000157, HPA001462",Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,Renal cancer:2.79e-6 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 1203.4,Mixed,NA,NA
AQP11,NA,ENSG00000178301,Aquaporin 11,11,77589391-77610355,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA042879,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Ovarian cancer:9.89e-4 (favourable),Mixed,Tissue enhanced,NA,duodenum: 24.1;small intestine: 23.1,adrenal gland: 10.0,Cell line enhanced,NA,Hep G2: 7.7
ARC,"Arg3.1, KIAA0278",ENSG00000198576,Activity regulated cytoskeleton associated protein,8,142611044-142614472,Predicted intracellular proteins,Evidence at protein level,"HPA056430, CAB079013",NA,Supported,Approved,Vesicles<br>Microtubules,NA,Tissue enriched,Group enriched,7,adipose tissue: 14.2;adrenal gland: 13.4;cerebral cortex: 14.4;gallbladder: 3.3;seminal vesicle: 5.5,placenta: 1.4,Cell line enhanced,NA,HEK93: 9.2;SCLC-21H: 27.7;U-2 OS: 11.9;U-87 MG: 12.5
ARCN1,COPD,ENSG00000095139,Archain 1,11,118572390-118603033,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA037573, HPA044874",Approved,NA,Enhanced,Golgi apparatus<br>Vesicles,Liver cancer:2.97e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 144.4,Expressed in all,NA,NA
ARFGAP1,"ARF1GAP, bA261N11.3, FLJ10767",ENSG00000101199,ADP ribosylation factor GTPase activating protein 1,20,63272785-63289793,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA051019, HPA056273",Approved,NA,Supported,Nuclear membrane<br>Golgi apparatus<br>Vesicles,"Renal cancer:3.48e-7 (unfavourable), Pancreatic cancer:4.57e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 32.2,Expressed in all,NA,NA
ARFIP1,HSU52521,ENSG00000164144,ADP ribosylation factor interacting protein 1,4,152779937-152918463,Predicted intracellular proteins,Evidence at protein level,"CAB005080, HPA037375, HPA063759",Enhanced,NA,Supported,Nucleus<br>Golgi apparatus<br>Vesicles,"Renal cancer:2.83e-10 (favourable), Colorectal cancer:5.75e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 39.4,Expressed in all,NA,NA
ARHGAP1,"CDC42GAP, p50rhoGAP, RhoGAP",ENSG00000175220,Rho GTPase activating protein 1,11,46677080-46700615,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA004689, HPA008285",Approved,Approved,Supported,Vesicles,Liver cancer:2.14e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 116.2,Expressed in all,NA,NA
ARHGAP11B,"B'-T, FAM7B1",ENSG00000187951,Rho GTPase activating protein 11B,15,30624494-30772993,Predicted intracellular proteins,Evidence at protein level,HPA064479,Uncertain,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,bone marrow: 2.0,"lymph node,testis: 1.1",Mixed,NA,NA
ARHGAP15,BM046,ENSG00000075884,Rho GTPase activating protein 15,2,143091362-143768352,Predicted intracellular proteins,Evidence at protein level,HPA032125,Uncertain,NA,Uncertain,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:6.95e-5 (unfavourable),Mixed,Tissue enhanced,NA,lymph node: 65.4,spleen: 59.6,Cell line enhanced,NA,HEL: 77.1;HL-60: 97.4;MOLT-4: 65.5;NB-4: 59.8;THP-1: 85.7;U-698: 65.7
ARHGAP25,KIAA0053,ENSG00000163219,Rho GTPase activating protein 25,2,68679601-68826833,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035346, HPA061395",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.93e-4 (unfavourable), Cervical cancer:7.72e-4 (favourable)",Expressed in all,Tissue enhanced,NA,spleen: 89.6,lymph node: 81.2,Cell line enhanced,NA,HEL: 59.7;HMC-1: 225.1
ARHGAP30,FLJ00267,ENSG00000186517,Rho GTPase activating protein 30,1,161046946-161069970,Predicted intracellular proteins,Evidence at protein level,HPA036300,Uncertain,NA,Supported,Vesicles,Renal cancer:9.78e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,lymph node: 86.1;spleen: 80.6,appendix: 73.2,Cell line enhanced,NA,Daudi: 82.8;HL-60: 72.0;HMC-1: 106.5;U-266/70: 103.3
ARHGEF10L,"FLJ10521, KIAA1626",ENSG00000074964,Rho guanine nucleotide exchange factor 10 like,1,17539835-17697874,Predicted intracellular proteins,Evidence at protein level,"HPA026426, HPA026440, HPA028115",Approved,NA,Approved,Golgi apparatus<br>Vesicles<br>Cytosol,"Head and neck cancer:8.13e-5 (favourable), Renal cancer:5.65e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 29.7,Mixed,NA,NA
ARHGEF25,"GEFT, p63RhoGEF",ENSG00000240771,Rho guanine nucleotide exchange factor 25,12,57610180-57619379,Predicted intracellular proteins,Evidence at protein level,HPA052016,Uncertain,NA,Approved,Vesicles,Renal cancer:4.20e-7 (unfavourable),Expressed in all,Mixed,NA,NA,endometrium: 112.2,Cell line enhanced,NA,RH-30: 125.8;SH-SY5Y: 62.5
ARHGEF33,NA,ENSG00000214694,Rho guanine nucleotide exchange factor 33,2,38889880-38975449,Predicted intracellular proteins,Evidence at protein level,"HPA034661, HPA041051",Enhanced,NA,Supported,Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 10.6,ovary: 4.3,Cell line enhanced,NA,BEWO: 5.4;SiHa: 7.6
ARID3A,"BRIGHT, DRIL1",ENSG00000116017,AT-rich interaction domain 3A,19,925781-975934,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004793, HPA076330",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Pancreatic cancer:1.95e-5 (favourable), Renal cancer:3.22e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 33.4,testis: 9.7,Cell line enhanced,NA,BEWO: 199.1;K-562: 85.1
ARID4B,"BCAA, BRCAA1, RBP1L1, SAP180",ENSG00000054267,AT-rich interaction domain 4B,1,235131634-235328219,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA027333, HPA053692",Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:2.23e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 32.0,Expressed in all,NA,NA
ARL14EP,"ARF7EP, C11orf46, FLJ38968",ENSG00000152219,ADP ribosylation factor like GTPase 14 effector protein,11,30323051-30338227,Predicted intracellular proteins,Evidence at protein level,"HPA039634, HPA048127",Approved,NA,Approved,Nucleus<br>Vesicles<br>Focal adhesion sites<br>Cytosol,"Breast cancer:2.50e-5 (favourable), Liver cancer:5.26e-4 (unfavourable), Urothelial cancer:7.49e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 53.5,Expressed in all,NA,NA
ARL4D,ARF4L,ENSG00000175906,ADP ribosylation factor like GTPase 4D,17,43398959-43401137,Predicted intracellular proteins,Evidence at protein level,HPA060379,Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,"Endometrial cancer:1.16e-5 (favourable), Head and neck cancer:6.66e-4 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 62.5,Mixed,NA,NA
ARL6,"BBS3, RP55",ENSG00000113966,ADP ribosylation factor like GTPase 6,3,97764521-97801242,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA019361,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:2.53e-7 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 19.5,Cell line enhanced,NA,SCLC-21H: 28.0
ARMC8,"DKFZP434A043, GID5, HSPC056, VID28",ENSG00000114098,Armadillo repeat containing 8,3,138187248-138298389,Predicted intracellular proteins,Evidence at protein level,"HPA036996, HPA044869",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:8.90e-5 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable), Prostate cancer:2.15e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 38.2,Expressed in all,NA,NA
ARMCX4,"CXorf35, GASP4, MGC40053",ENSG00000196440,"Armadillo repeat containing, X-linked 4",X,101418287-101533459,Predicted intracellular proteins,Evidence at protein level,"HPA000429, HPA051930",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Pancreatic cancer:8.20e-5 (favourable),Mixed,Mixed,NA,NA,parathyroid gland: 14.3,Mixed,NA,NA
ARNTL,"bHLHe5, BMAL1, JAP3, MOP3, PASD3",ENSG00000133794,Aryl hydrocarbon receptor nuclear translocator like,11,13276652-13387266,"Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,"CAB045962, HPA050938",Supported,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,adrenal gland: 26.3,Mixed,NA,NA
ARPC1B,"ARC41, p40-ARC, p41-ARC",ENSG00000130429,Actin related protein 2/3 complex subunit 1B,7,99374249-99394801,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA004832,Approved,NA,Supported,Vesicles<br>Cytosol,"Renal cancer:1.62e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 251.5,Expressed in all,NA,NA
ARRB2,"ARR2, BARR2, DKFZp686L0365",ENSG00000141480,Arrestin beta 2,17,4710489-4721499,Predicted intracellular proteins,Evidence at protein level,HPA065681,NA,NA,Supported,Vesicles,"Prostate cancer:2.61e-5 (unfavourable), Cervical cancer:2.93e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 171.5,Expressed in all,NA,NA
ARSD,NA,ENSG00000006756,Arylsulfatase D,X,2903970-2929351,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA004694, HPA063835",Approved,NA,Approved,Vesicles<br>Lipid droplets,"Renal cancer:1.97e-5 (favourable), Endometrial cancer:5.21e-4 (favourable)",Expressed in all,Mixed,NA,NA,fallopian tube: 45.3,Cell line enhanced,NA,EFO-21: 23.1
ARSK,"DKFZp313G1735, TSULF",ENSG00000164291,Arylsulfatase family member K,5,95555074-95605064,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA042384,Approved,NA,Approved,Nucleus<br>Vesicles,Liver cancer:2.59e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 22.7,thyroid gland: 8.5,Expressed in all,NA,NA
ARV1,NA,ENSG00000173409,"ARV1 homolog, fatty acid homeostasis modulator",1,230978981-231000595,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA035709,Approved,NA,Approved,Vesicles,"Lung cancer:3.27e-5 (favourable), Colorectal cancer:1.33e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 61.9,Expressed in all,NA,NA
ASAP3,"CENTB6, DDEFL1, FLJ20199, UPLC1",ENSG00000088280,"ArfGAP with SH3 domain, ankyrin repeat and PH domain 3",1,23428563-23484568,Predicted intracellular proteins,Evidence at protein level,"HPA020537, HPA020546",Approved,NA,Supported,Nucleoplasm<br>Vesicles,"Renal cancer:5.12e-5 (favourable), Lung cancer:2.80e-4 (favourable), Endometrial cancer:5.56e-4 (unfavourable), Ovarian cancer:8.30e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 32.5,Cell line enhanced,NA,HSkMC: 27.9
ASB7,NA,ENSG00000183475,Ankyrin repeat and SOCS box containing 7,15,100602534-100651705,Predicted intracellular proteins,Evidence at protein level,HPA003300,Enhanced,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 12.5,Expressed in all,NA,NA
ASIP,"AGTIL, ASP",ENSG00000101440,Agouti signaling protein,20,34194569-34269344,Predicted secreted proteins,Evidence at protein level,HPA048636,Uncertain,NA,Supported,Vesicles,NA,Mixed,Group enriched,5,epididymis: 18.1;ovary: 7.4;skin: 5.7,breast: 2.0,Cell line enhanced,NA,CACO-2: 2.6
ASTN1,ASTN,ENSG00000152092,Astrotactin 1,1,176857302-177164973,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA074112,NA,NA,Approved,Golgi apparatus<br>Vesicles,NA,Tissue enriched,Group enriched,6,adrenal gland: 19.6;cerebral cortex: 66.8,ovary: 7.4,Cell line enhanced,NA,Karpas-707: 4.1;NTERA-2: 4.4;SCLC-21H: 3.2;U-2 OS: 3.6;U-266/84: 14.7
ATG2A,KIAA0404,ENSG00000110046,Autophagy related 2A,11,64894546-64917248,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA038715,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:4.79e-5 (favourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 39.0,Expressed in all,NA,NA
ATG9A,"APG9L1, FLJ22169",ENSG00000198925,Autophagy related 9A,2,219209772-219229717,Predicted membrane proteins,Evidence at protein level,HPA059551,Uncertain,NA,Supported,Vesicles,Liver cancer:2.18e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 113.1,Expressed in all,NA,NA
ATP11A,"ATPIH, ATPIS, KIAA1021",ENSG00000068650,ATPase phospholipid transporting 11A,13,112690329-112887168,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA035583, HPA035584",Approved,NA,Enhanced,Vesicles,Renal cancer:7.44e-4 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 59.1,Mixed,NA,NA
ATP13A1,"ATP13A, CGI-152, FLJ31858, KIAA1825",ENSG00000105726,ATPase 13A1,19,19645198-19663693,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA031798, HPA049717",Approved,NA,Approved,Vesicles,Renal cancer:6.51e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 52.5,Expressed in all,NA,NA
ATP6V0A1,"a1, ATP6N1, ATP6N1A, Stv1, Vph1, VPP1",ENSG00000033627,ATPase H+ transporting V0 subunit a1,17,42458844-42522611,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA022144,Enhanced,NA,Approved,Nuclear speckles<br>Golgi apparatus<br>Vesicles<br>Cytosol,"Renal cancer:1.28e-4 (favourable), Pancreatic cancer:2.05e-4 (favourable), Urothelial cancer:6.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 200.9,Mixed,NA,NA
ATP6V0D2,"ATP6D2, FLJ38708, VMA6",ENSG00000147614,ATPase H+ transporting V0 subunit d2,8,85987323-86154228,Predicted intracellular proteins,Evidence at protein level,"HPA055327, HPA058496",Enhanced,NA,Approved,Vesicles,Renal cancer:2.20e-6 (favourable),Tissue enriched,Tissue enriched,15,kidney: 59.4,rectum: 3.9,Cell line enhanced,NA,SCLC-21H: 2.3;SK-MEL-30: 2.6;U-87 MG: 4.8
ATP6V1A,"ATP6A1, ATP6V1A1, VA68, Vma1, VPP2",ENSG00000114573,ATPase H+ transporting V1 subunit A,3,113747019-113812056,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB006910, HPA035083, HPA035084",Approved,NA,Supported,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:3.82e-12 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 151.4,Expressed in all,NA,NA
ATP6V1B2,"ATP6B2, HO57, VATB, Vma2, VPP3",ENSG00000147416,ATPase H+ transporting V1 subunit B2,8,20197367-20226819,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA008147,Enhanced,NA,Supported,Vesicles,Renal cancer:8.41e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 304.2,Expressed in all,NA,NA
ATP7A,MNK,ENSG00000165240,ATPase copper transporting alpha,X,77910656-78050395,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA012887, HPA048107",Approved,NA,Supported,Golgi apparatus<br>Vesicles,Renal cancer:8.38e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 15.3,Mixed,NA,NA
ATP8A1,ATPIA,ENSG00000124406,ATPase phospholipid transporting 8A1,4,42408373-42657105,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA052935,Enhanced,NA,Supported,Vesicles,Renal cancer:5.54e-10 (favourable),Mixed,Tissue enhanced,NA,parathyroid gland: 68.8;thyroid gland: 66.6,cerebral cortex: 58.2,Cell line enhanced,NA,AN3-CA: 25.5;Daudi: 33.1
ATP8B4,"ATPIM, KIAA1939",ENSG00000104043,ATPase phospholipid transporting 8B4 (putative),15,49858238-50182817,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040254,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enhanced,NA,bone marrow: 23.0,endometrium: 9.3,Cell line enhanced,NA,HMC-1: 32.2;THP-1: 16.5;U-937: 60.0
ATXN7L2,"FLJ00381, MGC46534",ENSG00000162650,Ataxin 7 like 2,1,109483479-109492804,Predicted intracellular proteins,Evidence at protein level,"HPA029827, HPA054952",Uncertain,NA,Approved,Nucleoli<br>Vesicles<br>Cytosol,"Renal cancer:1.19e-8 (unfavourable), Endometrial cancer:7.65e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 4.4,Mixed,NA,NA
AUP1,NA,ENSG00000115307,Ancient ubiquitous protein 1,2,74526645-74529939,Predicted membrane proteins,Evidence at protein level,HPA007674,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:2.97e-9 (unfavourable), Liver cancer:2.29e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 58.2,Expressed in all,NA,NA
AXIN1,PPP1R49,ENSG00000103126,Axin 1,16,287440-352673,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB012987,Approved,NA,Supported,Nucleoli<br>Vesicles,Liver cancer:3.38e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 15.5,Expressed in all,NA,NA
AZIN1,"OAZI, OAZIN, ODC1L",ENSG00000155096,Antizyme inhibitor 1,8,102826357-102893864,Predicted intracellular proteins,Evidence at protein level,HPA027948,Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 133.4,Expressed in all,NA,NA
B3GALNT1,"B3GALT3, beta3Gal-T3, galT3, GLOB, P1",ENSG00000169255,"Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)",3,161083883-161105384,"Blood group antigen proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041204,NA,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 47.9,Cell line enhanced,NA,RT4: 111.0
B3GAT1,"CD57, GlcAT-P, HNK-1, LEU7, NK-1",ENSG00000109956,"Beta-1,3-glucuronyltransferase 1",11,134378504-134411918,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002500, CAB010893, HPA069468",Enhanced,NA,Supported,Vesicles,NA,Group enriched,Tissue enriched,11,cerebral cortex: 115.4,thyroid gland: 10.3,Cell line enhanced,NA,AF22: 22.9;HMC-1: 22.4;NTERA-2: 22.3;SH-SY5Y: 9.0
B3GNT2,"B3GN-T1, B3GN-T2, B3GNT-2, B3GNT1, BETA3GNT",ENSG00000170340,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2",2,62196113-62224731,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA005997,Approved,NA,Approved,Vesicles,Pancreatic cancer:1.62e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 51.0,Expressed in all,NA,NA
B4GALT2,beta4Gal-T2,ENSG00000117411,"Beta-1,4-galactosyltransferase 2",1,43978943-43991170,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007620, HPA047739",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,"Liver cancer:2.96e-5 (unfavourable), Renal cancer:3.62e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 49.4,Mixed,NA,NA
BAAT,BAT,ENSG00000136881,Bile acid-CoA:amino acid N-acyltransferase,9,101360417-101383519,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021251, HPA021330",Supported,NA,Uncertain,Vesicles,"Renal cancer:4.24e-7 (unfavourable), Liver cancer:4.97e-4 (favourable)",Tissue enriched,Tissue enriched,16,liver: 340.4,gallbladder: 21.1,Cell line enhanced,NA,A549: 1.8
BAG5,NA,ENSG00000166170,BCL2 associated athanogene 5,14,103556544-103562831,Predicted intracellular proteins,Evidence at protein level,HPA016429,Enhanced,NA,Supported,Vesicles,Renal cancer:1.58e-8 (favourable),Expressed in all,Tissue enriched,6,testis: 241.5,thyroid gland: 38.5,Expressed in all,NA,NA
BAMBI,NMA,ENSG00000095739,BMP and activin membrane bound inhibitor,10,28677342-28682939,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA010819, HPA010866",Approved,NA,Approved,Nucleoli fibrillar center<br>Vesicles<br>Lipid droplets,"Liver cancer:9.42e-6 (unfavourable), Renal cancer:5.25e-4 (favourable)",Expressed in all,Tissue enhanced,NA,ovary: 87.8,adrenal gland: 50.0,Cell line enhanced,NA,CACO-2: 120.2;SK-MEL-30: 134.8
BARX1,NA,ENSG00000131668,BARX homeobox 1,9,93951622-93955372,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055858,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Endometrial cancer:8.16e-6 (unfavourable), Head and neck cancer:1.02e-4 (unfavourable)",Tissue enhanced,Tissue enriched,7,stomach: 11.1,testis: 1.5,Group enriched,6,AN3-CA: 27.2;HMC-1: 61.1;NTERA-2: 20.7;THP-1: 19.2
BCAS1,"AIBC1, NABC1",ENSG00000064787,Breast carcinoma amplified sequence 1,20,53936777-54070594,Predicted intracellular proteins,Evidence at protein level,"CAB033558, HPA051816, HPA054745",Enhanced,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 108.7;stomach: 155.8,rectum: 80.7,Group enriched,6,RT4: 143.2;SK-BR-3: 277.9
BCL3,"BCL4, D19S37",ENSG00000069399,B-cell CLL/lymphoma 3,19,44747705-44760044,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB002051, HPA047514",Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Midbody,"Renal cancer:3.13e-14 (unfavourable), Melanoma:3.74e-4 (favourable), Glioma:5.58e-4 (unfavourable), Breast cancer:9.67e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,appendix: 30.1,Cell line enhanced,NA,HDLM-2: 55.4;SiHa: 65.8
BCL6B,"BAZF, ZBTB28, ZNF62",ENSG00000161940,B-cell CLL/lymphoma 6B,17,7023020-7030290,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA059147, HPA075112",Uncertain,NA,Approved,Vesicles,"Head and neck cancer:8.56e-5 (favourable), Renal cancer:4.04e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 34.6,Group enriched,14,HEL: 16.2;HMC-1: 46.5;HUVEC TERT2: 79.9;TIME: 30.9
BCL7A,BCL7,ENSG00000110987,BCL tumor suppressor 7A,12,122019422-122062044,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA019762,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.54e-6 (favourable), Liver cancer:2.04e-4 (unfavourable), Colorectal cancer:6.81e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 13.8,Cell line enhanced,NA,Daudi: 37.3;U-698: 41.3
BEND7,"C10orf30, FLJ40283",ENSG00000165626,BEN domain containing 7,10,13438484-13528974,Predicted intracellular proteins,Evidence at protein level,HPA037835,Uncertain,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,NA,Mixed,Mixed,NA,NA,thyroid gland: 40.9,Mixed,NA,NA
BICD1,NA,ENSG00000151746,BICD cargo adaptor 1,12,32106835-32383633,Predicted intracellular proteins,Evidence at protein level,HPA041309,Approved,NA,Approved,Vesicles,Renal cancer:2.33e-7 (unfavourable),Mixed,Mixed,NA,NA,ovary: 29.0,Mixed,NA,NA
BICDL1,"BICDR-1, CCDC64, FLJ26450",ENSG00000135127,BICD family like cargo adaptor 1,12,119989869-120094494,Predicted intracellular proteins,Evidence at protein level,HPA061116,Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Stomach cancer:1.21e-5 (favourable), Renal cancer:3.93e-5 (favourable), Head and neck cancer:3.15e-4 (favourable), Cervical cancer:6.50e-4 (favourable), Liver cancer:6.84e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,kidney: 73.9;skin: 58.6,epididymis: 45.6,Cell line enhanced,NA,hTCEpi: 35.3;SCLC-21H: 36.3
BIRC6,BRUCE,ENSG00000115760,Baculoviral IAP repeat containing 6,2,32357028-32618899,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA074409, HPA074738",NA,NA,Supported,Golgi apparatus<br>Vesicles<br>Mitotic spindle,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 31.4,Expressed in all,NA,NA
BLOC1S4,"BCAS4L, CNO, FLJ11230",ENSG00000186222,Biogenesis of lysosomal organelles complex 1 subunit 4,4,6716055-6717671,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA043840,Approved,NA,Approved,Vesicles<br>Cytosol,Liver cancer:1.06e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,ovary: 12.7,Expressed in all,NA,NA
BMP2,BMP2A,ENSG00000125845,Bone morphogenetic protein 2,20,6767664-6780280,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,"HPA058610, CAB078457",NA,NA,Enhanced,Vesicles,NA,Expressed in all,Mixed,NA,NA,thyroid gland: 31.2,Cell line enhanced,NA,CACO-2: 25.6;HeLa: 13.4;hTERT-HME1: 13.5;RT4: 19.5
BMP7,OP-1,ENSG00000101144,Bone morphogenetic protein 7,20,57168748-57266629,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA057757,NA,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,Endometrial cancer:2.91e-4 (unfavourable),Mixed,Tissue enhanced,NA,thyroid gland: 76.7,placenta: 36.8,Cell line enhanced,NA,Daudi: 124.6;MCF7: 154.9;SK-BR-3: 95.4;U-698: 163.1
BORCS8,MEF2BNB,ENSG00000254901,BLOC-1 related complex subunit 8,19,19176903-19192591,Predicted intracellular proteins,Evidence at protein level,HPA045700,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Pancreatic cancer:4.05e-5 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 17.3,Expressed in all,NA,NA
BPIFB2,"BPIL1, C20orf184, dJ726C3.2, LPLUNC2",ENSG00000078898,BPI fold containing family B member 2,20,33007600-33023709,"Plasma proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA049491, HPA060121",Enhanced,NA,Approved,Vesicles,Endometrial cancer:1.97e-5 (favourable),Group enriched,Group enriched,23,esophagus: 98.5;salivary gland: 90.5,"cervix, uterine: 4.0",Cell line enriched,418,Hep G2: 146.8
BRAF,BRAF1,ENSG00000157764,"B-Raf proto-oncogene, serine/threonine kinase",7,140719327-140924764,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001328, CAB004552, HPA071048",Approved,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 41.8,Expressed in all,NA,NA
BRINP2,"DBCCR1L2, FAM5B",ENSG00000198797,BMP/retinoic acid inducible neural specific 2,1,177171497-177282422,"Predicted secreted proteins, Transporters",Evidence at transcript level,"HPA050681, HPA061920",Uncertain,NA,Approved,Nucleoli<br>Vesicles,NA,Tissue enriched,Group enriched,10,adrenal gland: 11.5;cerebral cortex: 35.4,testis: 2.3,Group enriched,5,HDLM-2: 6.7;PC-3: 1.6;REH: 1.8;SCLC-21H: 7.3;SH-SY5Y: 1.4
BSG,"CD147, EMMPRIN, OK",ENSG00000172270,Basigin (Ok blood group),19,571277-583493,"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB002427, HPA036048, HPA074870",Enhanced,NA,Approved,Vesicles,"Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,heart muscle: 593.5,Expressed in all,NA,NA
BTAF1,"MOT1, TAF-172, TAF(II)170, TAF172, TAFII170",ENSG00000095564,B-TFIID TATA-box binding protein associated factor 1,10,91923769-92030325,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA070682,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:4.04e-5 (unfavourable), Head and neck cancer:5.07e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,skin: 59.8,Expressed in all,NA,NA
BTBD3,"dJ742J24.1, KIAA0952",ENSG00000132640,BTB domain containing 3,20,11890723-11926609,Predicted intracellular proteins,Evidence at protein level,"HPA041424, HPA042048",Uncertain,NA,Supported,Vesicles,"Liver cancer:2.51e-5 (unfavourable), Lung cancer:6.94e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 60.1,Cell line enhanced,NA,AN3-CA: 223.4;HeLa: 128.7
BTG2,"APRO1, MGC126063, MGC126064, PC3, TIS21",ENSG00000159388,BTG anti-proliferation factor 2,1,203305491-203309602,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA002355,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Breast cancer:8.53e-4 (favourable),Expressed in all,Expressed in all,NA,NA,ovary: 666.8,Cell line enhanced,NA,HMC-1: 140.5;U-266/70: 189.1
BTK,"AGMX1, ATK, IMD1, PSCTK1, XLA",ENSG00000010671,Bruton tyrosine kinase,X,101349447-101390796,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001198, HPA002028, CAB016689",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Tissue enhanced,NA,lymph node: 65.2;tonsil: 70.8,spleen: 52.7,Cell line enhanced,NA,Daudi: 147.2;HEL: 256.7;HMC-1: 868.2
BTN3A1,"BT3.1, BTF5, BTN3.1, CD277",ENSG00000026950,Butyrophilin subfamily 3 member A1,6,26402237-26415216,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012565,Approved,NA,Uncertain,Vesicles,"Renal cancer:4.15e-5 (unfavourable), Urothelial cancer:4.81e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,spleen: 112.6,Mixed,NA,NA
BTNL9,"BTN8, FLJ32535",ENSG00000165810,Butyrophilin like 9,5,181040225-181061523,Predicted membrane proteins,Evidence at protein level,HPA043429,NA,NA,Approved,Nuclear membrane<br>Vesicles,"Liver cancer:1.55e-9 (favourable), Endometrial cancer:7.51e-4 (unfavourable)",Mixed,Tissue enhanced,NA,adipose tissue: 166.9,lung: 55.8,Cell line enhanced,NA,U-2 OS: 5.7;U-698: 25.5
BZW1,"BZAP45, KIAA0005",ENSG00000082153,Basic leucine zipper and W2 domains 1,2,200810594-200827338,Predicted intracellular proteins,Evidence at protein level,"HPA047288, HPA053272",Uncertain,NA,Approved,Vesicles,"Cervical cancer:4.28e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 310.2,Expressed in all,NA,NA
C10orf10,"DEPP, FIG, Fseg",ENSG00000165507,Chromosome 10 open reading frame 10,10,44970981-44978810,Predicted secreted proteins,Evidence at protein level,"CAB013687, HPA037819",Uncertain,NA,Approved,Nucleus<br>Vesicles,Renal cancer:2.29e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 238.0,Cell line enhanced,NA,ASC diff: 98.2;HDLM-2: 98.9;HHSteC: 216.9;HSkMC: 146.6;HUVEC TERT2: 137.8
C10orf76,FLJ13114,ENSG00000120029,Chromosome 10 open reading frame 76,10,101845599-102056193,Predicted intracellular proteins,Evidence at protein level,"HPA050913, HPA053580",Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 26.4,Mixed,NA,NA
C11orf24,DM4E3,ENSG00000171067,Chromosome 11 open reading frame 24,11,68261335-68272001,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012748,Uncertain,NA,Uncertain,Nucleoplasm<br>Vesicles,"Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,small intestine: 65.9,Expressed in all,NA,NA
C11orf91,NA,ENSG00000205177,Chromosome 11 open reading frame 91,11,33698261-33700801,Predicted intracellular proteins,Evidence at protein level,"HPA047064, HPA050487",Uncertain,NA,Supported,Vesicles,NA,Not detected,Tissue enhanced,NA,adipose tissue: 5.8;gallbladder: 7.7;testis: 6.9,esophagus: 3.3,Cell line enhanced,NA,HBEC3-KT: 11.7;hTERT-HME1: 7.8;HUVEC TERT2: 6.8;TIME: 10.3;U-2197: 9.7
C12orf29,DKFZp434N2030,ENSG00000133641,Chromosome 12 open reading frame 29,12,88033846-88050160,Predicted intracellular proteins,Evidence at protein level,HPA039663,Uncertain,NA,Approved,Vesicles,Renal cancer:3.44e-4 (unfavourable),Expressed in all,Mixed,NA,NA,esophagus: 17.1,Expressed in all,NA,NA
C12orf75,"AGD3, OCC-1, OCC1",ENSG00000235162,Chromosome 12 open reading frame 75,12,105235290-105396097,Predicted intracellular proteins,Evidence at protein level,HPA065311,Uncertain,NA,Approved,Vesicles,"Renal cancer:1.69e-5 (favourable), Liver cancer:1.70e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,seminal vesicle: 138.7,prostate: 61.0,Expressed in all,NA,NA
C15orf38-AP3S2,NA,ENSG00000250021,C15orf38-AP3S2 readthrough,15,89834308-89912882,Predicted intracellular proteins,Evidence at protein level,"HPA040513, HPA047173, HPA049270, HPA052278",Uncertain,NA,Approved,Vesicles,NA,Not detected,Expressed in all,NA,NA,cerebral cortex: 19.5,Expressed in all,NA,NA
C15orf57,"CCDC32, MGC20481",ENSG00000128891,Chromosome 15 open reading frame 57,15,40528683-40565057,Predicted intracellular proteins,Evidence at protein level,HPA041688,Uncertain,NA,Approved,Nuclear speckles<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 35.2,Expressed in all,NA,NA
C15orf61,LOC145853,ENSG00000189227,Chromosome 15 open reading frame 61,15,67521068-67530143,Predicted intracellular proteins,Evidence at protein level,HPA062820,NA,NA,Approved,Nucleoli<br>Vesicles<br>Cytosol,Renal cancer:5.31e-5 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 11.0,Mixed,NA,NA
C16orf58,FLJ13868,ENSG00000140688,Chromosome 16 open reading frame 58,16,31489471-31509309,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA024406,Uncertain,NA,Approved,Nucleoplasm<br>Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 77.4,Expressed in all,NA,NA
C16orf72,"FLJ41272, PRO0149",ENSG00000182831,Chromosome 16 open reading frame 72,16,9091648-9121640,Predicted intracellular proteins,Evidence at protein level,"HPA041568, HPA067492",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Head and neck cancer:3.62e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 67.5,Expressed in all,NA,NA
C17orf51,"FLJ12977, FLJ31874, FLJ33618",ENSG00000212719,Chromosome 17 open reading frame 51,17,21524790-21574458,Predicted intracellular proteins,Evidence at protein level,HPA052106,Enhanced,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 16.6,testis: 8.2,Mixed,NA,NA
C17orf64,NA,ENSG00000141371,Chromosome 17 open reading frame 64,17,60392429-60431421,Predicted intracellular proteins,Evidence at protein level,HPA044415,Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Not detected,Tissue enriched,233,testis: 185.6,spleen: 0.7,Cell line enhanced,NA,MCF7: 4.4
C17orf80,"FLJ20721, HLC-8, MIG3, SPEP1",ENSG00000141219,Chromosome 17 open reading frame 80,17,73232233-73248947,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012896,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:9.02e-6 (unfavourable), Colorectal cancer:1.43e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 71.9,Expressed in all,NA,NA
C18orf32,FLJ23458,ENSG00000177576,Chromosome 18 open reading frame 32,18,49477250-49487252,Predicted membrane proteins,Evidence at protein level,HPA040921,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:8.89e-9 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 119.6,Expressed in all,NA,NA
C19orf60,"FLJ20850, FLJ30108, FLJ34606, FLJ37391",ENSG00000006015,Chromosome 19 open reading frame 60,19,18588685-18592336,Predicted intracellular proteins,Evidence at protein level,HPA043414,Approved,NA,Approved,Vesicles,Urothelial cancer:8.47e-4 (favourable),Expressed in all,Mixed,NA,NA,skeletal muscle: 22.2,Cell line enhanced,NA,PC-3: 78.2
C19orf81,NA,ENSG00000235034,Chromosome 19 open reading frame 81,19,50649445-50659310,Predicted intracellular proteins,Evidence at protein level,HPA060238,Enhanced,NA,Approved,Vesicles<br>Aggresome,NA,Tissue enhanced,Tissue enriched,11,testis: 5.3,"cerebral cortex,epididymis,prostate: 0.4",Cell line enhanced,NA,HEK93: 4.0;HMC-1: 1.3
C1orf53,NA,ENSG00000203724,Chromosome 1 open reading frame 53,1,197902647-197907367,Predicted intracellular proteins,Evidence at protein level,HPA065352,NA,NA,Approved,Vesicles<br>Aggresome,"Breast cancer:1.63e-4 (favourable), Endometrial cancer:3.78e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adrenal gland: 6.2,Mixed,NA,NA
C1QC,C1QG,ENSG00000159189,Complement C1q C chain,1,22643630-22648110,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001471, CAB009828",Supported,NA,Uncertain,Vesicles,Renal cancer:1.17e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 1285.6,Cell line enhanced,NA,RPMI-8226: 1.7
C1QTNF12,"ADIPOLIN, C1QDC2, CTRP12, FAM132A, MGC105127",ENSG00000184163,C1q and tumor necrosis factor related protein 12,1,1242446-1246722,Predicted secreted proteins,Evidence at protein level,HPA024107,Approved,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,duodenum: 6.9;small intestine: 7.3,colon: 2.1,Group enriched,5,EFO-21: 3.9;U-2 OS: 4.3
C1QTNF7,CTRP7,ENSG00000163145,C1q and tumor necrosis factor related protein 7,4,15339818-15446166,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB007055, HPA051797, HPA055392",Uncertain,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,"cervix, uterine: 36.4",Cell line enhanced,NA,ASC diff: 3.0;ASC TERT1: 2.1;HSkMC: 1.2
C20orf196,FLJ25067,ENSG00000171984,Chromosome 20 open reading frame 196,20,5750393-5863912,Predicted intracellular proteins,Evidence at transcript level,HPA040749,Approved,NA,Approved,Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles,Urothelial cancer:4.05e-5 (favourable),Expressed in all,Mixed,NA,NA,lymph node: 18.6,Expressed in all,NA,NA
C2CD4C,"FAM148C, KIAA1957, NLF3",ENSG00000183186,C2 calcium dependent domain containing 4C,19,405438-409170,Predicted intracellular proteins,Evidence at protein level,HPA055915,Uncertain,NA,Approved,Vesicles,NA,Tissue enhanced,Group enriched,6,adipose tissue: 2.6;cerebral cortex: 10.6;gallbladder: 4.4,endometrium: 0.9,Cell line enhanced,NA,HDLM-2: 5.9;NTERA-2: 6.2;SCLC-21H: 13.0;U-2 OS: 6.8
C2orf70,LOC339778,ENSG00000173557,Chromosome 2 open reading frame 70,2,26562582-26579532,Predicted intracellular proteins,Evidence at protein level,HPA062453,Enhanced,NA,Approved,Nuclear membrane<br>Vesicles,Pancreatic cancer:6.49e-4 (favourable),Mixed,Group enriched,6,fallopian tube: 12.0;stomach: 4.9;testis: 17.5,thyroid gland: 1.9,Cell line enhanced,NA,A-431: 3.6;CAPAN-2: 2.7;EFO-21: 1.8;RPTEC TERT1: 2.8
C4orf47,LOC441054,ENSG00000205129,Chromosome 4 open reading frame 47,4,185426249-185449826,Predicted intracellular proteins,Evidence at transcript level,HPA043662,Uncertain,NA,Approved,Vesicles,Renal cancer:4.75e-4 (unfavourable),Mixed,Tissue enhanced,NA,fallopian tube: 21.6;testis: 24.2,thyroid gland: 7.8,Cell line enhanced,NA,U-87 MG: 5.8
C5orf38,"CEI, IRX2NB",ENSG00000186493,Chromosome 5 open reading frame 38,5,2752131-2755397,Predicted intracellular proteins,Evidence at protein level,HPA073667,NA,NA,Enhanced,Golgi apparatus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,lung: 13.7;salivary gland: 13.0,skin: 8.5,Cell line enhanced,NA,BEWO: 79.2;hTCEpi: 32.4;SiHa: 37.3
C7orf61,IMAGE:4839025,ENSG00000185955,Chromosome 7 open reading frame 61,7,100456615-100464271,Predicted intracellular proteins,Evidence at protein level,HPA060395,Enhanced,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enriched,10,testis: 52.9,cerebral cortex: 5.2,Cell line enhanced,NA,HUVEC TERT2: 20.9;TIME: 12.0
C8orf44-SGK3,NA,ENSG00000270024,C8orf44-SGK3 readthrough,8,66667596-66860472,Predicted intracellular proteins,Evidence at transcript level,"HPA006699, HPA027146",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Not detected,Not detected,NA,NA,"cervix, uterine: 0.9",Cell line enhanced,NA,fHDF/TERT166: 1.3
C9orf84,FLJ32779,ENSG00000165181,Chromosome 9 open reading frame 84,9,111686173-111795008,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA032108,NA,NA,Approved,Vesicles<br>Cytosol,NA,Mixed,Tissue enriched,10,testis: 31.0,adrenal gland: 3.1,Cell line enhanced,NA,A-431: 4.3;SiHa: 5.3;U-2 OS: 23.4;U-266/84: 3.3
CA10,"CA-RPX, CARPX, HUCEP-15",ENSG00000154975,Carbonic anhydrase 10,17,51630313-52160017,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054825, HPA057837",Supported,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,"cerebral cortex: 56.7;cervix, uterine: 32.1",testis: 10.7,Cell line enhanced,NA,RT4: 1.6;SCLC-21H: 7.3
CA11,"CARP2, CARPX1",ENSG00000063180,Carbonic anhydrase 11,19,48637942-48646312,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041778,NA,NA,Approved,Vesicles<br>Microtubules,"Lung cancer:2.11e-5 (favourable), Pancreatic cancer:8.60e-5 (favourable), Cervical cancer:4.33e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 244.1,ovary: 49.5,Cell line enhanced,NA,AN3-CA: 39.9;SCLC-21H: 35.8
CA12,HsT18816,ENSG00000074410,Carbonic anhydrase 12,15,63321378-63382161,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA008773, CAB025181, CAB062549, CAB068179, HPA073203",Enhanced,NA,Approved,Nucleus<br>Vesicles,Pancreatic cancer:3.80e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,kidney: 308.4;skin: 168.3,rectum: 102.9,Cell line enhanced,NA,A549: 191.8;RT4: 180.0;T-47d: 269.1;U-138 MG: 295.7;U-87 MG: 352.6
CA13,"CAXIII, FLJ37995, MGC59868",ENSG00000185015,Carbonic anhydrase 13,8,85220587-85284073,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA024689, CAB025567",Enhanced,NA,Uncertain,Nucleus<br>Nucleoli<br>Vesicles,Renal cancer:9.40e-4 (favourable),Expressed in all,Mixed,NA,NA,small intestine: 16.5,Cell line enhanced,NA,HEL: 14.2
CA4,"CAIV, Car4, RP17",ENSG00000167434,Carbonic anhydrase 4,17,60149936-60170899,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011089, HPA017258",Enhanced,NA,Supported,Vesicles,NA,Mixed,Tissue enhanced,NA,colon: 253.5;rectum: 180.9,adipose tissue: 88.7,Not detected,NA,NA
CAAP1,"C9orf82, CAAP, FLJ13657",ENSG00000120159,Caspase activity and apoptosis inhibitor 1,9,26840685-26892804,Predicted intracellular proteins,Evidence at protein level,"HPA020404, HPA024029, HPA024100",Uncertain,NA,Approved,Vesicles,"Renal cancer:7.94e-9 (favourable), Ovarian cancer:1.27e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 49.6,Mixed,NA,NA
CAB39L,"bA103J18.3, FLJ12577, MO2L",ENSG00000102547,Calcium binding protein 39 like,13,49308650-49444126,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003686, HPA045954",Uncertain,NA,Approved,Vesicles,"Renal cancer:1.94e-13 (favourable), Ovarian cancer:2.28e-4 (unfavourable), Prostate cancer:7.91e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,prostate: 66.2,Cell line enhanced,NA,CACO-2: 32.9;RT4: 33.1
CACNA1H,Cav3.2,ENSG00000196557,Calcium voltage-gated channel subunit alpha1 H,16,1153121-1221772,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA039125,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable)",Expressed in all,Tissue enhanced,NA,ovary: 44.9,seminal vesicle: 39.1,Cell line enhanced,NA,A549: 16.1;AN3-CA: 23.5;MCF7: 36.8;T-47d: 13.0
CACNA2D2,KIAA0558,ENSG00000007402,Calcium voltage-gated channel auxiliary subunit alpha2delta 2,3,50362799-50504244,"FDA approved drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA034771, HPA071829",Enhanced,NA,Approved,Vesicles,"Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable)",Tissue enhanced,Tissue enriched,6,lung: 72.9,testis: 12.4,Cell line enriched,8,SH-SY5Y: 201.7
CACNB3,CACNLB3,ENSG00000167535,Calcium voltage-gated channel auxiliary subunit beta 3,12,48813794-48828941,"FDA approved drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA059515,NA,NA,Approved,Golgi apparatus<br>Vesicles,NA,Mixed,Mixed,NA,NA,endometrium: 40.0,Cell line enhanced,NA,U-937: 85.2
CADPS,"CAPS, CAPS1, KIAA1121, UNC-31",ENSG00000163618,Calcium dependent secretion activator,3,62398346-62875389,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA059328,Enhanced,NA,Approved,Vesicles,NA,Mixed,Group enriched,8,adrenal gland: 21.6;cerebral cortex: 94.1,heart muscle: 7.5,Cell line enhanced,NA,SCLC-21H: 23.2;SK-MEL-30: 7.0;U-698: 8.9;U-87 MG: 20.1
CADPS2,CAPS2,ENSG00000081803,Calcium dependent secretion activator 2,7,122318425-122886759,Predicted intracellular proteins,Evidence at protein level,HPA056398,NA,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:1.01e-7 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 45.7,Cell line enhanced,NA,HUVEC TERT2: 36.2;Karpas-707: 40.4
CALB1,CALB,ENSG00000104327,Calbindin 1,8,90058608-90095475,Predicted intracellular proteins,Evidence at protein level,"CAB002138, HPA023099, HPA056734",Enhanced,NA,Supported,Vesicles,Endometrial cancer:1.60e-4 (unfavourable),Mixed,Tissue enriched,15,kidney: 336.9,cerebral cortex: 22.5,Cell line enhanced,NA,A-431: 116.6;EFO-21: 179.9;NTERA-2: 72.7
CALCOCO2,"MGC17318, NDP52",ENSG00000136436,Calcium binding and coiled-coil domain 2,17,48830988-48866522,Predicted intracellular proteins,Evidence at protein level,"HPA022989, HPA023019, HPA023195",Enhanced,NA,Supported,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 249.4,Expressed in all,NA,NA
CALM1,"CALML2, CAMI, DD132, PHKD",ENSG00000198668,Calmodulin 1,14,90396502-90408261,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters",Evidence at protein level,"CAB018558, HPA044999",Supported,NA,Approved,Vesicles,"Urothelial cancer:2.38e-5 (unfavourable), Pancreatic cancer:5.62e-4 (favourable), Renal cancer:6.49e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 1325.6,Expressed in all,NA,NA
CAMLG,"CAML, GET2",ENSG00000164615,Calcium modulating ligand,5,134738501-134752160,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052636, HPA056472",Approved,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,Renal cancer:1.09e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 99.6,Expressed in all,NA,NA
CAPN8,nCL-2,ENSG00000203697,Calpain 8,1,223538007-223665734,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA073939,NA,NA,Approved,Nucleoplasm<br>Nuclear membrane<br>Vesicles,NA,Tissue enhanced,Tissue enriched,8,stomach: 286.5,rectum: 37.3,Cell line enriched,9,RT4: 62.5
CAPZB,NA,ENSG00000077549,Capping actin protein of muscle Z-line beta subunit,1,19338776-19485539,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031531, HPA056066",Approved,NA,Enhanced,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:1.85e-4 (unfavourable), Renal cancer:3.57e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 490.8,Expressed in all,NA,NA
CARD10,"BIMP1, CARMA3",ENSG00000100065,Caspase recruitment domain family member 10,22,37490362-37519542,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029359, HPA055612",Approved,NA,Approved,Vesicles<br>Intermediate filaments<br>Cytosol,"Liver cancer:7.73e-6 (unfavourable), Endometrial cancer:3.47e-4 (favourable)",Expressed in all,Mixed,NA,NA,small intestine: 39.9,Cell line enhanced,NA,U-2197: 76.9
CARF,"ALS2CR8, CaRF, FLJ21579, NYD-SP24",ENSG00000138380,Calcium responsive transcription factor,2,202912214-202987063,Predicted intracellular proteins,Evidence at protein level,"HPA034557, HPA043191",Approved,NA,Approved,Nucleoli fibrillar center<br>Vesicles<br>Cytosol,NA,Mixed,Mixed,NA,NA,testis: 37.0,Expressed in all,NA,NA
CASP10,MCH4,ENSG00000003400,Caspase 10,2,201182881-201229406,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003780, HPA017059",Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:6.05e-7 (unfavourable), Liver cancer:8.54e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 24.1,Cell line enhanced,NA,HUVEC TERT2: 21.4
CAT,NA,ENSG00000121691,Catalase,11,34438925-34472062,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB001515, HPA051282, HPA055838",Enhanced,NA,Supported,Vesicles<br>Cytosol,"Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,liver: 625.4,Cell line enhanced,NA,HL-60: 310.1
CATSPERB,"C14orf161, FLJ14298",ENSG00000133962,Cation channel sperm associated auxiliary subunit beta,14,91580696-91780707,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA035134,Uncertain,NA,Uncertain,Vesicles,NA,Mixed,Mixed,NA,NA,skin: 2.7,Cell line enhanced,NA,CAPAN-2: 1.1
CAV2,CAV,ENSG00000105971,Caveolin 2,7,116287380-116508541,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB013488, HPA044810",Enhanced,NA,Approved,Vesicles,"Head and neck cancer:5.80e-5 (unfavourable), Pancreatic cancer:1.21e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adipose tissue: 233.6,Mixed,NA,NA
CBS,HIP4,ENSG00000160200,Cystathionine-beta-synthase,21,43053191-43076943,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001223,Supported,NA,Approved,Nucleoli<br>Vesicles,NA,Mixed,Tissue enhanced,NA,liver: 56.6;ovary: 31.1,cerebral cortex: 19.8,Cell line enhanced,NA,HAP1: 171.2;HHSteC: 181.6
CBSL,NA,ENSG00000274276,Cystathionine-beta-synthase like,21,6444869-6468040,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001223,Supported,NA,Approved,Nucleoli<br>Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 45.9;liver: 27.3,thyroid gland: 22.2,Cell line enhanced,NA,AN3-CA: 123.4;NTERA-2: 245.4;SH-SY5Y: 82.5
CC2D1B,KIAA1836,ENSG00000154222,Coiled-coil and C2 domain containing 1B,1,52345723-52366193,Predicted intracellular proteins,Evidence at protein level,"HPA027500, HPA031426",Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,Liver cancer:1.45e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 18.7,Expressed in all,NA,NA
CCDC122,FLJ31846,ENSG00000151773,Coiled-coil domain containing 122,13,43823909-43879727,Predicted intracellular proteins,Evidence at protein level,"CAB034233, HPA054995, HPA061456",Approved,NA,Approved,Nucleus<br>Vesicles,NA,Mixed,Mixed,NA,NA,"prostate,thyroid gland: 7.9",Mixed,NA,NA
CCDC130,MGC10471,ENSG00000104957,Coiled-coil domain containing 130,19,13731760-13763296,Predicted intracellular proteins,Evidence at protein level,HPA056977,Approved,NA,Approved,Vesicles,"Head and neck cancer:7.83e-5 (favourable), Urothelial cancer:1.82e-4 (favourable), Renal cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.34e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,spleen: 24.7,Expressed in all,NA,NA
CCDC144A,"FLJ43983, KIAA0565",ENSG00000170160,Coiled-coil domain containing 144A,17,16689537-16777881,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA022996, HPA047220, HPA047851",Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Not detected,Tissue enhanced,NA,testis: 16.6,endometrium: 6.1,Mixed,NA,NA
CCDC146,KIAA1505,ENSG00000135205,Coiled-coil domain containing 146,7,77122434-77329533,Predicted intracellular proteins,Evidence at protein level,"HPA020082, HPA020105",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,Head and neck cancer:7.37e-4 (favourable),Expressed in all,Tissue enhanced,NA,fallopian tube: 57.6;testis: 39.3,thyroid gland: 13.8,Mixed,NA,NA
CCDC169-SOHLH2,C13orf38-SOHLH2,ENSG00000250709,CCDC169-SOHLH2 readthrough,13,36168794-36297842,Predicted intracellular proteins,Evidence at transcript level,HPA029182,NA,NA,Uncertain,Vesicles,NA,Not detected,Tissue enriched,28,testis: 19.5,seminal vesicle: 0.7,Cell line enhanced,NA,BEWO: 1.3;HL-60: 2.2;U-937: 1.7
CCDC190,"C1orf110, MGC48998",ENSG00000185860,Coiled-coil domain containing 190,1,162824458-162868815,Predicted intracellular proteins,Evidence at transcript level,"HPA028579, HPA028584, HPA028592",Uncertain,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,esophagus: 3.7;lung: 2.8,fallopian tube: 0.8,Cell line enhanced,NA,hTEC/SVTERT24-B: 3.9;HUVEC TERT2: 4.0;LHCN-M2: 6.0;TIME: 13.6;U-2197: 8.2
CCDC63,"FLJ35843, ODA5",ENSG00000173093,Coiled-coil domain containing 63,12,110846769-110907535,Predicted intracellular proteins,Evidence at protein level,HPA061568,NA,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,NA,Tissue enriched,Tissue enriched,28,testis: 29.6,heart muscle: 1.0,Cell line enriched,14,MCF7: 3.3
CCDC65,"CFAP250, CILD27, DRC2, FAP250, FLJ35732, NYD-SP28",ENSG00000139537,Coiled-coil domain containing 65,12,48904110-48931840,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA038520, HPA057573",Uncertain,NA,Approved,Vesicles<br>Microtubule organizing center,NA,Mixed,Group enriched,12,fallopian tube: 42.8;testis: 67.9,lung: 4.4,Mixed,NA,NA
CCDC74A,FLJ40345,ENSG00000163040,Coiled-coil domain containing 74A,2,131527675-131533666,Predicted intracellular proteins,Evidence at transcript level,HPA060727,NA,NA,Uncertain,Vesicles,"Renal cancer:1.70e-7 (unfavourable), Glioma:1.82e-4 (unfavourable), Testis cancer:4.92e-4 (favourable), Breast cancer:5.11e-4 (favourable)",Mixed,Tissue enhanced,NA,fallopian tube: 55.2;testis: 79.2,parathyroid gland: 27.2,Cell line enhanced,NA,NTERA-2: 28.4;SCLC-21H: 27.2
CCDC74B,DKFZp434E2321,ENSG00000152076,Coiled-coil domain containing 74B,2,130139287-130145134,Predicted intracellular proteins,Evidence at transcript level,HPA060727,NA,NA,Uncertain,Vesicles,"Renal cancer:1.55e-4 (unfavourable), Breast cancer:4.46e-4 (favourable)",Mixed,Tissue enhanced,NA,fallopian tube: 23.1;testis: 52.0,"cervix, uterine: 13.9",Cell line enhanced,NA,SCLC-21H: 12.3;SH-SY5Y: 15.8
CCL15,"HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3",ENSG00000275718,C-C motif chemokine ligand 15,17,35996440-36002038,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA058608,NA,NA,Approved,Golgi apparatus<br>Vesicles,Urothelial cancer:3.02e-4 (favourable),Tissue enhanced,Tissue enhanced,NA,duodenum: 21.5;rectum: 30.6;small intestine: 26.6,colon: 18.9,Cell line enriched,12,Hep G2: 22.7
CCL2,"GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF",ENSG00000108691,C-C motif chemokine ligand 2,17,34255218-34257203,"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB013676, HPA019163",Approved,NA,Approved,Golgi apparatus<br>Vesicles,Renal cancer:4.51e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,gallbladder: 411.3,Group enriched,5,BJ hTERT+: 1539.3;BJ hTERT+ SV40 Large T+ RasG12V: 503.9;HMC-1: 2137.8
CCZ1,"C7orf28A, CCZ1A, CGI-43",ENSG00000122674,"CCZ1 homolog, vacuolar protein trafficking and biogenesis associated",7,5898725-5926550,Predicted intracellular proteins,Evidence at protein level,"HPA045114, HPA050006",Uncertain,NA,Enhanced,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 77.0,Expressed in all,NA,NA
CCZ1B,"C7orf28B, DKFZP586I1023, H_NH0577018.2, MGC19819",ENSG00000146574,"CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated",7,6794134-6826770,Predicted intracellular proteins,Evidence at protein level,"HPA045114, HPA050006",Uncertain,NA,Enhanced,Vesicles,NA,Mixed,Expressed in all,NA,NA,parathyroid gland: 48.7,Expressed in all,NA,NA
CD14,NA,ENSG00000170458,CD14 molecule,5,140631728-140633701,"Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001887, HPA002127, CAB033631, CAB072865, CAB072866",Enhanced,NA,Supported,Vesicles,Renal cancer:6.80e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,appendix: 267.3,Cell line enhanced,NA,A549: 8.6;CACO-2: 12.0;SiHa: 18.3
CD24,CD24A,ENSG00000272398,CD24 molecule,6,106969831-106975627,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045879, CAB078471",NA,NA,Supported,Vesicles,"Breast cancer:2.44e-5 (unfavourable), Colorectal cancer:3.29e-4 (favourable), Liver cancer:7.58e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,thyroid gland: 2706.1,esophagus: 1402.0,Cell line enhanced,NA,NTERA-2: 984.0;RPTEC TERT1: 3501.8;SK-BR-3: 1014.5
CD276,"B7-H3, B7H3, B7RP-2",ENSG00000103855,CD276 molecule,15,73683966-73714518,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA009285, HPA017139, CAB017826",Enhanced,NA,Approved,Vesicles,"Renal cancer:6.31e-5 (unfavourable), Liver cancer:9.81e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 30.2,Cell line enhanced,NA,U-2197: 176.1
CD55,"CR, CROM, DAF, TC",ENSG00000196352,CD55 molecule (Cromer blood group),1,207321508-207386804,"Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA002190, CAB010454, HPA024386",Enhanced,NA,Uncertain,Vesicles<br>Midbody ring,Renal cancer:9.36e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 324.4,Cell line enhanced,NA,HMC-1: 495.0;U-2197: 364.6
CD59,"16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20",ENSG00000085063,CD59 molecule,11,33698261-33736445,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB001448, HPA026494",Supported,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 923.3,Cell line enhanced,NA,TIME: 2367.1;U-2197: 2401.2
CD63,"ME491, MLA1, TSPAN30",ENSG00000135404,CD63 molecule,12,55725323-55729707,"CD markers, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA010088, CAB026356",Supported,NA,Supported,Vesicles,Liver cancer:1.37e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,epididymis: 1743.5,Expressed in all,NA,NA
CD68,"DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1",ENSG00000129226,CD68 molecule,17,7579467-7582113,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000051, CAB000066, HPA048982, CAB072861, CAB072862",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,Renal cancer:1.14e-5 (unfavourable),Mixed,Expressed in all,NA,NA,lung: 532.4,Expressed in all,NA,NA
CD82,"IA4, KAI1, R2, ST6, TSPAN27",ENSG00000085117,CD82 molecule,11,44564427-44620363,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002508, HPA028900, HPA061418",Supported,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,esophagus: 131.5,Cell line enhanced,NA,HMC-1: 349.6;U-87 MG: 273.7
CD83,"BL11, HB15",ENSG00000112149,CD83 molecule,6,14117256-14136918,"CD markers, Predicted membrane proteins",Evidence at protein level,"CAB002509, HPA041454",Enhanced,NA,Approved,Vesicles,Renal cancer:3.49e-4 (favourable),Expressed in all,Tissue enhanced,NA,bone marrow: 130.9,tonsil: 64.1,Cell line enhanced,NA,Daudi: 54.6;HDLM-2: 64.1;U-698: 80.4
CDC25A,NA,ENSG00000164045,Cell division cycle 25A,3,48157146-48188402,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005855,NA,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,testis: 24.4,bone marrow: 9.3,Expressed in all,NA,NA
CDC25B,NA,ENSG00000101224,Cell division cycle 25B,20,3786772-3806121,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038892, HPA038893, HPA075215",Enhanced,NA,Supported,Vesicles<br>Mitotic spindle,"Renal cancer:2.94e-13 (unfavourable), Liver cancer:1.19e-4 (unfavourable), Endometrial cancer:4.76e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,lymph node: 56.6,Expressed in all,NA,NA
CDH12,"Br-cadherin, CDHB",ENSG00000154162,Cadherin 12,5,21750673-22853622,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA029325,Uncertain,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,"cerebral cortex: 3.6;cervix, uterine: 4.5;fallopian tube: 3.5",adrenal gland: 2.2,Group enriched,5,PC-3: 2.0;SCLC-21H: 3.7;U-2 OS: 1.3
CDK19,"bA346C16.3, CDC2L6, CDK11, KIAA1028",ENSG00000155111,Cyclin dependent kinase 19,6,110609978-110815958,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007053,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:4.72e-5 (unfavourable), Liver cancer:3.56e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,prostate: 42.4,Expressed in all,NA,NA
CDK5R1,"Nck5a, p35, p35nck5a",ENSG00000176749,Cyclin dependent kinase 5 regulatory subunit 1,17,32486619-32491256,Predicted intracellular proteins,Evidence at protein level,HPA000252,NA,NA,Supported,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enriched,7,cerebral cortex: 98.4,lymph node: 14.7,Cell line enhanced,NA,SCLC-21H: 62.8;SK-MEL-30: 30.8
CDKAL1,FLJ20342,ENSG00000145996,CDK5 regulatory subunit associated protein 1 like 1,6,20534457-21232404,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057474,NA,NA,Uncertain,Vesicles,Endometrial cancer:1.03e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 16.0,Cell line enriched,6,SCLC-21H: 222.3
CDKL1,KKIALRE,ENSG00000100490,Cyclin dependent kinase like 1,14,50329404-50416461,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA059605, HPA065919",Uncertain,NA,Enhanced,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,fallopian tube: 34.5,Mixed,NA,NA
CDKL3,NKIAMRE,ENSG00000006837,Cyclin dependent kinase like 3,5,134286350-134371047,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027751,NA,NA,Uncertain,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enriched,9,testis: 28.9,cerebral cortex: 3.2,Mixed,NA,NA
CDKN1B,"KIP1, P27KIP1",ENSG00000111276,Cyclin dependent kinase inhibitor 1B,12,12715058-12722371,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB003691, CAB021888, HPA059086",Approved,NA,Supported,Nucleus<br>Vesicles,"Liver cancer:3.25e-4 (unfavourable), Colorectal cancer:5.15e-4 (favourable), Renal cancer:8.39e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 73.1,Mixed,NA,NA
CEBPA,"C/EBP-alpha, CEBP",ENSG00000245848,CCAAT/enhancer binding protein alpha,19,33299934-33302564,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052734, HPA065037, HPA067937",Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 108.0,Cell line enhanced,NA,BEWO: 187.4;THP-1: 270.7;U-937: 100.7
CEBPZ,"CBF2, CTF2",ENSG00000115816,CCAAT/enhancer binding protein zeta,2,37201612-37231713,Predicted intracellular proteins,Evidence at protein level,HPA052065,Uncertain,NA,Approved,Nucleus<br>Vesicles,"Liver cancer:2.94e-5 (unfavourable), Endometrial cancer:5.07e-4 (unfavourable), Pancreatic cancer:8.13e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 67.3,Expressed in all,NA,NA
CECR2,KIAA1740,ENSG00000099954,"CECR2, histone acetyl-lysine reader",22,17359949-17558149,Predicted intracellular proteins,Evidence at protein level,HPA002943,Approved,NA,Approved,Nucleus<br>Vesicles,NA,Tissue enriched,Tissue enhanced,NA,cerebral cortex: 7.8,skeletal muscle: 7.5,Cell line enhanced,NA,AF22: 15.3;HAP1: 14.9;NTERA-2: 22.8;SCLC-21H: 11.9
CENPBD1,MGC16385,ENSG00000177946,CENPB DNA-binding domain containing 1,16,89969791-89972534,Predicted intracellular proteins,Evidence at transcript level,"HPA052759, HPA060522",Uncertain,NA,Approved,Nucleoli<br>Vesicles,Renal cancer:5.27e-11 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 11.1,Expressed in all,NA,NA
CEP295NL,"DDC8, KIAA1731NL",ENSG00000178404,CEP295 N-terminal like,17,78870910-78903217,Predicted intracellular proteins,Evidence at transcript level,"HPA023609, HPA024619, HPA025717",Uncertain,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,46,testis: 40.5,bone marrow: 0.8,Cell line enhanced,NA,BEWO: 1.4;U-2 OS: 2.0
CEP95,"CCDC45, DKFZp667E1824",ENSG00000258890,Centrosomal protein 95,17,64506588-64542461,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA023654, HPA052426, HPA052428, HPA061371",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Mitotic spindle<br>Centrosome,"Liver cancer:2.52e-5 (unfavourable), Renal cancer:5.76e-5 (unfavourable), Head and neck cancer:5.78e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 27.7,Expressed in all,NA,NA
CERK,"dA59H18.2, dA59H18.3, DKFZp434E0211, FLJ21430, FLJ23239, hCERK, KIAA1646, LK4",ENSG00000100422,Ceramide kinase,22,46684411-46738261,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA064699,NA,NA,Approved,Vesicles,"Urothelial cancer:1.58e-4 (unfavourable), Pancreatic cancer:2.35e-4 (favourable), Endometrial cancer:4.75e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,small intestine: 34.3,Mixed,NA,NA
CERS4,"FLJ12089, LASS4, Trh1",ENSG00000090661,Ceramide synthase 4,19,8206736-8262421,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033734, HPA054729",Uncertain,NA,Approved,Nucleus<br>Vesicles,"Lung cancer:3.45e-5 (favourable), Renal cancer:9.63e-5 (favourable), Cervical cancer:2.71e-4 (favourable), Head and neck cancer:7.83e-4 (favourable), Pancreatic cancer:8.05e-4 (favourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 80.8,Cell line enhanced,NA,NB-4: 63.0
CFAP73,"CCDC42B, MIA2",ENSG00000186710,Cilia and flagella associated protein 73,12,113149858-113159276,Predicted intracellular proteins,Evidence at protein level,HPA048539,Enhanced,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,"Cervical cancer:1.29e-4 (favourable), Endometrial cancer:5.52e-4 (favourable)",Tissue enhanced,Tissue enriched,9,fallopian tube: 60.1,lung: 6.9,Cell line enhanced,NA,Daudi: 3.1;T-47d: 2.4;U-698: 6.0
CFDP1,"BCNT, CENP-29, CP27, p97, SWC5, Yeti",ENSG00000153774,Craniofacial development protein 1,16,75293698-75433485,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041316, HPA048242",Approved,NA,Approved,Nucleoplasm<br>Vesicles,Head and neck cancer:9.63e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 111.6,Expressed in all,NA,NA
CFH,"ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS",ENSG00000000971,Complement factor H,1,196651878-196747504,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016385, CAB016769, HPA038922, HPA049176, HPA053326",Supported,NA,Approved,Vesicles,Renal cancer:1.92e-6 (unfavourable),Tissue enriched,Tissue enhanced,NA,liver: 839.5,gallbladder: 205.3,Cell line enhanced,NA,HHSteC: 100.0;RT4: 176.9
CFHR1,"CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2",ENSG00000244414,Complement factor H related 1,1,196819757-196832189,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA038915, HPA038922, HPA040726",Supported,NA,Approved,Vesicles,Liver cancer:8.71e-6 (favourable),Tissue enriched,Tissue enriched,147,liver: 1057.6,lymph node: 7.1,Cell line enhanced,NA,HL-60: 1.5;U-266/70: 1.9
CGRRF1,"CGR19, RNF197",ENSG00000100532,Cell growth regulator with ring finger domain 1,14,54509812-54539309,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA002930,Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,"Renal cancer:2.57e-8 (favourable), Liver cancer:6.84e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 33.8,Expressed in all,NA,NA
CHEK1,CHK1,ENSG00000149554,Checkpoint kinase 1,11,125625136-125676255,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044364,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 62.5;seminal vesicle: 52.6,testis: 22.1,Expressed in all,NA,NA
CHGA,NA,ENSG00000100604,Chromogranin A,14,92923080-92935293,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000023, HPA017369, CAB040544, CAB055506, CAB058688",Enhanced,NA,Supported,Vesicles,"Breast cancer:7.85e-5 (favourable), Liver cancer:2.40e-4 (unfavourable), Urothelial cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.07e-4 (favourable)",Tissue enhanced,Tissue enriched,9,parathyroid gland: 7061.6,adrenal gland: 818.1,Group enriched,156,SCLC-21H: 285.4;SH-SY5Y: 700.4
CHGB,"SCG1, SgI",ENSG00000089199,Chromogranin B,20,5911430-5925361,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008759, CAB009403, HPA012602",Enhanced,Supported,Enhanced,Vesicles,"Head and neck cancer:1.89e-4 (unfavourable), Pancreatic cancer:9.96e-4 (favourable)",Tissue enriched,Tissue enriched,26,adrenal gland: 4382.4,cerebral cortex: 168.3,Group enriched,25,SCLC-21H: 405.5;SH-SY5Y: 559.4
CHIC1,BRX,ENSG00000204116,Cysteine rich hydrophobic domain 1,X,73563200-73687102,Predicted membrane proteins,Evidence at protein level,"HPA026782, HPA052062",Uncertain,NA,Approved,Nuclear speckles<br>Vesicles<br>Cytosol,Renal cancer:2.75e-4 (favourable),Mixed,Mixed,NA,NA,cerebral cortex: 14.2,Mixed,NA,NA
CHP1,"CHP, p22, p24, Sid470p, SLC9A1BP",ENSG00000187446,Calcineurin like EF-hand protein 1,15,41230839-41281890,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006616,Approved,NA,Approved,Vesicles,"Renal cancer:2.79e-6 (favourable), Liver cancer:4.07e-6 (favourable), Endometrial cancer:9.63e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,colon: 110.9,Expressed in all,NA,NA
CHPF,"CHSY2, CSS2",ENSG00000123989,Chondroitin polymerizing factor,2,219538947-219543787,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035123,Approved,NA,Supported,Vesicles<br>Centrosome<br>Cytosol,"Cervical cancer:1.57e-4 (unfavourable), Head and neck cancer:1.68e-4 (unfavourable), Urothelial cancer:2.96e-4 (unfavourable), Glioma:9.56e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 77.2,Mixed,NA,NA
CHPT1,CPT1,ENSG00000111666,Choline phosphotransferase 1,12,101696947-101744140,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA067643,Approved,NA,Approved,Vesicles,Thyroid cancer:7.41e-4 (favourable),Expressed in all,Expressed in all,NA,NA,breast: 125.6,Expressed in all,NA,NA
CHST14,"D4ST-1, D4ST1, HD4ST",ENSG00000169105,Carbohydrate sulfotransferase 14,15,40470998-40474571,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA057697, HPA071601",Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,placenta: 38.8,Expressed in all,NA,NA
CHUK,"IkBKA, IKK-alpha, IKK1, IKKA, NFKBIKA, TCF16",ENSG00000213341,Conserved helix-loop-helix ubiquitous kinase,10,100188298-100229619,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA001402, CAB004240, CAB018564",Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:1.27e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 23.1,Expressed in all,NA,NA
CIC,KIAA0306,ENSG00000079432,Capicua transcriptional repressor,19,42268537-42295797,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB026388, HPA044341, HPA064725",Approved,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 54.9,Expressed in all,NA,NA
CITED4,NA,ENSG00000179862,Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 4,1,40861051-40862366,Predicted intracellular proteins,Evidence at protein level,HPA056434,Approved,NA,Approved,Vesicles,Endometrial cancer:4.38e-5 (favourable),Expressed in all,Mixed,NA,NA,breast: 20.5,Cell line enhanced,NA,RPTEC TERT1: 67.0;THP-1: 176.9
CKLF,"C32, CKLF1, CKLF3, CKLF4, HSPC224, UCK-1",ENSG00000217555,Chemokine like factor,16,66552563-66566251,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA062779,NA,NA,Approved,Vesicles,"Renal cancer:1.06e-9 (unfavourable), Liver cancer:5.67e-5 (unfavourable), Thyroid cancer:2.22e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 90.9,Expressed in all,NA,NA
CKS1B,"CKS1, ckshs1",ENSG00000173207,CDC28 protein kinase regulatory subunit 1B,1,154974653-154979249,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA003424, HPA030762",Approved,Supported,Approved,Nucleus<br>Vesicles<br>Mitochondria<br>Cytosol,"Renal cancer:6.03e-7 (unfavourable), Liver cancer:2.94e-5 (unfavourable), Melanoma:3.12e-5 (unfavourable), Thyroid cancer:4.87e-4 (favourable), Pancreatic cancer:6.13e-4 (unfavourable), Endometrial cancer:7.89e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 84.9,Expressed in all,NA,NA
CKS2,NA,ENSG00000123975,CDC28 protein kinase regulatory subunit 2,9,89311198-89316703,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA003424, HPA030762",Approved,Supported,Approved,Nucleus<br>Vesicles<br>Mitochondria<br>Cytosol,"Liver cancer:2.51e-6 (unfavourable), Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 341.7,lymph node: 122.6,Expressed in all,NA,NA
CLCF1,"BSF-3, BSF3, CISS2, CLC, NNT-1, NNT1, NR6",ENSG00000175505,Cardiotrophin-like cytokine factor 1,11,67364168-67374177,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA042444,Uncertain,NA,Approved,Nuclear bodies<br>Vesicles,NA,Expressed in all,Tissue enhanced,NA,gallbladder: 26.3,endometrium: 21.4,Cell line enhanced,NA,SiHa: 56.8
CLCN4,"ClC-4, CLC4",ENSG00000073464,Chloride voltage-gated channel 4,X,10156945-10237660,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA031313, HPA063637",Enhanced,NA,Approved,Vesicles,"Endometrial cancer:2.13e-5 (unfavourable), Pancreatic cancer:9.55e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 49.1;epididymis: 28.1,skeletal muscle: 14.6,Cell line enhanced,NA,HEL: 21.9;SCLC-21H: 28.6
CLDN14,DFNB29,ENSG00000159261,Claudin 14,21,36460621-36576569,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA054707,NA,NA,Uncertain,Vesicles,Liver cancer:1.53e-4 (favourable),Tissue enriched,Group enriched,11,kidney: 3.6;liver: 9.5,gallbladder: 0.6,Cell line enriched,18,HDLM-2: 205.9
CLEC16A,"Gop-1, KIAA0350",ENSG00000038532,C-type lectin domain family 16 member A,16,10944488-11182189,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035814, HPA035815, HPA061385",Approved,NA,Approved,Nucleus<br>Vesicles,Renal cancer:2.92e-6 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 60.3,Expressed in all,NA,NA
CLEC7A,"CD369, CLECSF12, dectin-1, hDectin-1, SCARE2",ENSG00000172243,C-type lectin domain family 7 member A,12,10116777-10130258,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043244, HPA050229",NA,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:1.31e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,appendix: 65.6,bone marrow: 53.3,Group enriched,15,Karpas-707: 144.0;U-266/84: 116.1
CLINT1,"CLINT, ENTH, EPNR, KIAA0171",ENSG00000113282,Clathrin interactor 1,5,157785743-157859175,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043280, HPA056947",Supported,NA,Supported,Nucleoplasm<br>Vesicles,"Renal cancer:8.88e-5 (favourable), Colorectal cancer:2.95e-4 (favourable), Thyroid cancer:6.77e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 171.0,Expressed in all,NA,NA
CLIP4,"FLJ21069, RSNL2",ENSG00000115295,CAP-Gly domain containing linker protein family member 4,2,29097705-29189643,Predicted intracellular proteins,Evidence at protein level,"HPA043366, HPA056246",Uncertain,NA,Enhanced,Vesicles,Renal cancer:1.83e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 55.8,Mixed,NA,NA
CLN6,"FLJ20561, HsT18960, nclf",ENSG00000128973,"Ceroid-lipofuscinosis, neuronal 6, late infantile, variant",15,68206992-68257211,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA066046, HPA074162",Approved,NA,Approved,Vesicles,Renal cancer:4.87e-4 (favourable),Expressed in all,Expressed in all,NA,NA,appendix: 19.8,Expressed in all,NA,NA
CLNK,MIST,ENSG00000109684,Cytokine dependent hematopoietic cell linker,4,10486395-10684865,Predicted intracellular proteins,Evidence at protein level,"HPA035671, HPA035672",Uncertain,NA,Uncertain,Vesicles,NA,Tissue enriched,Tissue enhanced,NA,kidney: 5.8,lymph node: 3.4,Group enriched,6,HDLM-2: 3.9;U-937: 1.6
CLPSL2,"C6orf126, dJ510O8.5, UNQ3045",ENSG00000196748,Colipase like 2,6,35776594-35779552,Predicted secreted proteins,Evidence at protein level,"HPA043460, HPA051655",Approved,NA,Uncertain,Vesicles,NA,Tissue enhanced,Tissue enriched,703,epididymis: 713.1,seminal vesicle: 1.0,Cell line enriched,6,T-47d: 6.6
CLTA,Lca,ENSG00000122705,Clathrin light chain A,9,36190856-36304781,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002665, HPA050918, HPA054667",Enhanced,NA,Enhanced,Vesicles<br>Endosomes<br>Lysosomes,"Liver cancer:9.46e-5 (unfavourable), Thyroid cancer:1.01e-4 (favourable), Breast cancer:5.64e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,placenta: 178.0,Expressed in all,NA,NA
CLTC,"CLTCL2, Hc",ENSG00000141367,Clathrin heavy chain,17,59619689-59696956,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010389, CAB011571, CAB017155, HPA059143",Approved,NA,Enhanced,Vesicles<br>Mitotic spindle<br>Cytosol,"Urothelial cancer:2.02e-4 (unfavourable), Liver cancer:5.54e-4 (unfavourable), Cervical cancer:7.35e-4 (unfavourable), Colorectal cancer:7.65e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 365.5,Expressed in all,NA,NA
CLTCL1,"CHC22, CLH22, CLTCL, CLTD",ENSG00000070371,Clathrin heavy chain like 1,22,19179473-19291716,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA075795,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,skeletal muscle: 24.1;testis: 49.4,bone marrow: 10.4,Cell line enhanced,NA,HMC-1: 56.9
CLUAP1,"CFAP22, FAP22, FLJ13297, IFT38, KIAA0643",ENSG00000103351,Clusterin associated protein 1,16,3500924-3539048,Predicted intracellular proteins,Evidence at protein level,"HPA036976, HPA044191",Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,Endometrial cancer:3.01e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 71.9,Mixed,NA,NA
CLUH,"CLU1, KIAA0664",ENSG00000132361,Clustered mitochondria homolog,17,2689386-2712663,Predicted intracellular proteins,Evidence at protein level,"HPA031505, HPA044346",Uncertain,NA,Supported,Nuclear bodies<br>Vesicles,Renal cancer:1.92e-5 (favourable),Expressed in all,Expressed in all,NA,NA,esophagus: 50.7,Expressed in all,NA,NA
CMTM5,"CKLFSF5, FLJ37521",ENSG00000166091,CKLF like MARVEL transmembrane domain containing 5,14,23376808-23379772,Predicted membrane proteins,Evidence at protein level,HPA052338,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,NA,Group enriched,Tissue enriched,20,cerebral cortex: 81.3,seminal vesicle: 4.1,Cell line enriched,6,HEL: 73.9
CNGB1,"CNCG2, CNCG3L, CNGB1B, GAR1, GARP, RCNC2, RCNCb, RP45",ENSG00000070729,Cyclic nucleotide gated channel beta 1,16,57882340-57971116,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA039159, HPA060355",NA,NA,Approved,Vesicles<br>Cytosol,NA,Tissue enriched,Tissue enhanced,NA,adrenal gland: 1.6,"appendix,cerebral cortex: 1.5",Cell line enhanced,NA,SCLC-21H: 2.6;SiHa: 3.1
CNIH1,"CNIH, CNIL, TGAM77",ENSG00000100528,Cornichon family AMPA receptor auxiliary protein 1,14,54423560-54441431,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA002544,Approved,NA,Approved,Vesicles,Urothelial cancer:8.95e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,liver: 119.4,Expressed in all,NA,NA
CNNM2,ACDP2,ENSG00000148842,Cyclin and CBS domain divalent metal cation transport mediator 2,10,102918293-103090221,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA059954, HPA071631",NA,NA,Enhanced,Vesicles,Renal cancer:2.39e-8 (favourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 33.6,placenta: 12.4,Expressed in all,NA,NA
CNPY4,"MGC40499, PRAT4B",ENSG00000166997,Canopy FGF signaling regulator 4,7,100119613-100125511,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA014166, HPA025240",Uncertain,NA,Approved,Vesicles,"Renal cancer:3.59e-5 (unfavourable), Liver cancer:3.99e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,endometrium: 34.8,Expressed in all,NA,NA
CNST,"C1orf71, FLJ32001, PPP1R64",ENSG00000162852,"Consortin, connexin sorting protein",1,246566444-246668584,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007225, HPA007226",Approved,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 26.3,Expressed in all,NA,NA
CNTF,HCNTF,ENSG00000242689,Ciliary neurotrophic factor,11,58622673-58625733,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019654,Uncertain,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,fallopian tube: 7.7,bone marrow: 4.3,Mixed,NA,NA
CNTNAP5,"caspr5, FLJ31966",ENSG00000155052,Contactin associated protein like 5,2,124025287-124915287,Predicted membrane proteins,Evidence at protein level,"HPA069095, HPA069356",NA,NA,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 5.8;gallbladder: 1.6,adrenal gland: 0.7,Cell line enhanced,NA,AF22: 1.1;SH-SY5Y: 2.8
COCH,"COCH-5B2, DFNA31, DFNA9",ENSG00000100473,Cochlin,14,30874514-30895065,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA065086,NA,NA,Approved,Vesicles,NA,Mixed,Group enriched,6,pancreas: 94.8;prostate: 79.0;seminal vesicle: 99.1,"cervix, uterine: 15.4",Cell line enhanced,NA,HEK93: 92.9;K-562: 114.9;NB-4: 71.8;SCLC-21H: 130.1
COG4,"COD1, DKFZP586E1519",ENSG00000103051,Component of oligomeric golgi complex 4,16,70480568-70523565,Predicted intracellular proteins,Evidence at protein level,"HPA040924, HPA042539",Approved,NA,Approved,Golgi apparatus<br>Vesicles,Liver cancer:1.64e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 49.1,Expressed in all,NA,NA
COL14A1,UND,ENSG00000187955,Collagen type XIV alpha 1 chain,8,120059780-120372036,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA023781,Uncertain,NA,Approved,Vesicles,"Renal cancer:5.79e-5 (unfavourable), Urothelial cancer:1.01e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,"cervix, uterine: 278.5",gallbladder: 207.5,Group enriched,7,ASC TERT1: 28.1;RH-30: 106.3
COL1A1,OI4,ENSG00000108821,Collagen type I alpha 1 chain,17,50183289-50201632,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008405, HPA011795",Uncertain,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:7.19e-12 (unfavourable), Lung cancer:4.43e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 1872.5",Cell line enhanced,NA,BJ: 2487.8;fHDF/TERT166: 3474.4;HSkMC: 1569.1;U-138 MG: 2286.9
COL22A1,NA,ENSG00000169436,Collagen type XXII alpha 1 chain,8,138588235-138914006,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA024830,Supported,NA,Supported,Endoplasmic reticulum<br>Vesicles,"Lung cancer:2.13e-6 (unfavourable), Glioma:3.62e-4 (unfavourable)",Mixed,Tissue enhanced,NA,adrenal gland: 9.7,prostate: 4.8,Group enriched,5,HDLM-2: 27.1;RT4: 9.7;SCLC-21H: 9.4;U-2 OS: 6.9
COL25A1,NA,ENSG00000188517,Collagen type XXV alpha 1 chain,4,108810721-109302657,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029107,NA,NA,Approved,Endoplasmic reticulum<br>Vesicles<br>Cytosol,NA,Mixed,Tissue enhanced,NA,testis: 20.4,adipose tissue: 7.5,Cell line enriched,6,HeLa: 37.1
COL26A1,"EMI6, EMID2, Emu2",ENSG00000160963,Collagen type XXVI alpha 1 chain,7,101362820-101559024,Predicted secreted proteins,Evidence at protein level,HPA027059,Approved,NA,Approved,Vesicles,Liver cancer:2.32e-5 (favourable),Group enriched,Tissue enhanced,NA,cerebral cortex: 10.2;parathyroid gland: 5.4,prostate: 3.1,Cell line enhanced,NA,AF22: 29.3;BEWO: 22.8;HAP1: 10.9;NTERA-2: 25.1
COL4A2,"DKFZp686I14213, FLJ22259",ENSG00000134871,Collagen type IV alpha 2 chain,13,110305812-110513027,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB010751, HPA029118",Enhanced,NA,Supported,Vesicles,"Renal cancer:3.49e-5 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 829.9,smooth muscle: 401.0,Cell line enhanced,NA,EFO-21: 1032.9;WM-115: 470.6
COL4A3,NA,ENSG00000169031,Collagen type IV alpha 3 chain,2,227164565-227314792,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042064,Approved,NA,Approved,Endoplasmic reticulum<br>Vesicles,Renal cancer:2.51e-7 (favourable),Group enriched,Tissue enhanced,NA,thyroid gland: 26.8,lung: 22.4,Cell line enhanced,NA,HeLa: 10.8;Karpas-707: 7.1;RPTEC TERT1: 8.3;U-266/70: 6.7
COL5A1,NA,ENSG00000130635,Collagen type V alpha 1 chain,9,134641774-134844843,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA030769,Approved,NA,Approved,Vesicles,Renal cancer:2.07e-12 (unfavourable),Expressed in all,Mixed,NA,NA,"cervix, uterine: 157.8",Cell line enhanced,NA,BJ: 370.0;fHDF/TERT166: 317.6;SiHa: 305.8
COL8A1,"C3orf7, MGC9568",ENSG00000144810,Collagen type VIII alpha 1 chain,3,99638475-99799226,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA053107,Enhanced,NA,Supported,Vesicles,Renal cancer:9.39e-8 (unfavourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 87.4,lung: 56.9,Cell line enhanced,NA,fHDF/TERT166: 930.0;LHCN-M2: 289.1;TIME: 423.8
COL9A2,"EDM2, MED",ENSG00000049089,Collagen type IX alpha 2 chain,1,40300487-40317816,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA056316, HPA075286",Approved,NA,Approved,Nucleus<br>Vesicles,Endometrial cancer:5.13e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 53.4,seminal vesicle: 32.4,Cell line enhanced,NA,HDLM-2: 91.5;HMC-1: 79.4;THP-1: 69.5
COLGALT1,"FLJ22329, GLT25D1",ENSG00000130309,Collagen beta(1-O)galactosyltransferase 1,19,17555594-17583162,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA047821,Approved,NA,Approved,Vesicles,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.65e-5 (unfavourable), Pancreatic cancer:1.92e-4 (unfavourable), Urothelial cancer:3.83e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 58.0,Expressed in all,NA,NA
COLGALT2,"C1orf17, GLT25D2, KIAA0584",ENSG00000198756,Collagen beta(1-O)galactosyltransferase 2,1,183929854-184037729,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031749, HPA031750",Approved,NA,Approved,Nucleus<br>Vesicles,NA,Tissue enhanced,Tissue enriched,5,cerebral cortex: 46.4,prostate: 8.8,Cell line enhanced,NA,Hep G2: 11.7;SK-MEL-30: 14.3;U-251 MG: 14.6;WM-115: 22.1
COMMD7,"C20orf92, dJ1085F17.3",ENSG00000149600,COMM domain containing 7,20,32702691-32743997,Predicted intracellular proteins,Evidence at protein level,HPA054119,NA,NA,Supported,Vesicles,"Liver cancer:1.46e-4 (unfavourable), Urothelial cancer:3.53e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 80.3,Expressed in all,NA,NA
COMT,NA,ENSG00000093010,Catechol-O-methyltransferase,22,19941607-19969975,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA001169, CAB011233",Enhanced,NA,Approved,Endoplasmic reticulum<br>Vesicles,"Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 172.6,Expressed in all,NA,NA
COPB1,COPB,ENSG00000129083,Coatomer protein complex subunit beta 1,11,14443440-14500027,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012338, HPA043954, HPA064403",Supported,NA,Enhanced,Golgi apparatus<br>Vesicles<br>Cytosol,"Liver cancer:5.63e-7 (unfavourable), Head and neck cancer:6.91e-4 (unfavourable), Pancreatic cancer:8.04e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 132.5,Expressed in all,NA,NA
COPS2,"ALIEN, CSN2, TRIP15",ENSG00000166200,COP9 signalosome subunit 2,15,49106068-49155661,Predicted intracellular proteins,Evidence at protein level,"HPA016867, HPA018271, HPA061071",Approved,NA,Enhanced,Vesicles<br>Cytokinetic bridge,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 103.5,Expressed in all,NA,NA
CPE,NA,ENSG00000109472,Carboxypeptidase E,4,165361194-165498320,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA003819, CAB024907",Supported,NA,Approved,Nucleoplasm<br>Vesicles<br>Centrosome,"Urothelial cancer:2.12e-4 (unfavourable), Renal cancer:2.60e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 1560.8,Group enriched,5,Hep G2: 211.8;SCLC-21H: 493.5;SH-SY5Y: 147.0;SiHa: 668.1
CPEB4,KIAA1673,ENSG00000113742,Cytoplasmic polyadenylation element binding protein 4,5,173888280-173961976,Predicted intracellular proteins,Evidence at protein level,HPA038394,NA,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:4.99e-8 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 119.8,Cell line enhanced,NA,U-266/70: 86.1;U-266/84: 121.7
CPLX1,CPX-I,ENSG00000168993,Complexin 1,4,784957-826198,Predicted intracellular proteins,Evidence at protein level,HPA071191,NA,NA,Uncertain,Vesicles,"Cervical cancer:4.20e-4 (unfavourable), Pancreatic cancer:5.05e-4 (favourable)",Expressed in all,Tissue enriched,11,cerebral cortex: 60.2,adipose tissue: 5.3,Cell line enriched,7,SCLC-21H: 95.0
CPLX2,"CPX-2, DKFZp547D155",ENSG00000145920,Complexin 2,5,175796310-175884020,Predicted intracellular proteins,Evidence at protein level,HPA071191,NA,NA,Uncertain,Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 236.4;epididymis: 145.5,adrenal gland: 44.3,Group enriched,19,A549: 549.3;Hep G2: 253.5;SCLC-21H: 296.3
CPM,NA,ENSG00000135678,Carboxypeptidase M,12,68842197-68971570,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA002657, HPA077243",Uncertain,NA,Uncertain,Vesicles,Endometrial cancer:1.00e-4 (favourable),Expressed in all,Tissue enhanced,NA,adipose tissue: 164.0,placenta: 101.2,Cell line enhanced,NA,ASC diff: 48.8;ASC TERT1: 35.1;HSkMC: 66.3;SiHa: 73.7
CPQ,"LDP, PGCP",ENSG00000104324,Carboxypeptidase Q,8,96645227-97149654,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA023235, HPA024490",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:5.40e-5 (favourable), Glioma:9.75e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 382.5,Cell line enhanced,NA,ASC TERT1: 92.2
CPSF2,KIAA1367,ENSG00000165934,Cleavage and polyadenylation specific factor 2,14,92121937-92172145,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA024238,Supported,NA,Approved,Nucleoplasm<br>Vesicles,Liver cancer:4.35e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 47.7,Expressed in all,NA,NA
CRB1,"LCA8, RP12",ENSG00000134376,"Crumbs 1, cell polarity complex component",1,197268204-197478455,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA061250, HPA063127",Approved,NA,Uncertain,Vesicles,NA,Tissue enriched,Group enriched,10,cerebral cortex: 12.2;testis: 5.0,ovary: 0.8,Cell line enriched,5,HeLa: 9.0
CREG1,CREG,ENSG00000143162,Cellular repressor of E1A stimulated genes 1,1,167529677-167553767,Predicted secreted proteins,Evidence at protein level,HPA056390,NA,NA,Approved,Vesicles<br>Microtubules,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 209.5,Expressed in all,NA,NA
CREM,hCREM-2,ENSG00000095794,CAMP responsive element modulator,10,35126791-35212958,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001818, CAB018352",Enhanced,NA,Supported,Nucleus<br>Vesicles,Renal cancer:1.23e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 339.8,Expressed in all,NA,NA
CROT,COT,ENSG00000005469,Carnitine O-octanoyltransferase,7,87345681-87399795,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA019052, HPA019364, HPA019365",Enhanced,NA,Supported,Vesicles,"Renal cancer:2.55e-6 (favourable), Urothelial cancer:4.02e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 68.4,Cell line enhanced,NA,RT4: 57.9
CSAG1,"CSAGE, CT24.1",ENSG00000198930,Chondrosarcoma associated gene 1,X,152727484-152733735,Predicted intracellular proteins,Evidence at transcript level,HPA078264,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 2.4,lymph node: 0.8,Cell line enhanced,NA,HMC-1: 57.5;K-562: 39.8;PC-3: 55.8;SH-SY5Y: 39.1;U-266/70: 79.2
CSAG2,"CSAG3B, CT24.2, TRAG3",ENSG00000268902,CSAG family member 2,X,152708261-152714549,Predicted intracellular proteins,Evidence at transcript level,HPA078264,NA,NA,Approved,Vesicles,NA,Mixed,Not detected,NA,NA,"lymph node,testis: 0.9",Cell line enhanced,NA,HMC-1: 13.5;SK-BR-3: 4.8;U-266/70: 3.9;U-266/84: 4.7
CSAG3,CSAG3A,ENSG00000268916,CSAG family member 3,X,152753921-152760222,Predicted intracellular proteins,Evidence at transcript level,HPA078264,NA,NA,Approved,Vesicles,NA,Mixed,Group enriched,10,lymph node: 1.7;skin: 1.2;spleen: 1.9;testis: 4.2,"adipose tissue,lung,placenta: 0.2",Cell line enhanced,NA,HDLM-2: 23.7;HMC-1: 22.9;SH-SY5Y: 35.8;SK-BR-3: 23.6;U-2 OS: 25.4;U-266/70: 61.5;U-266/84: 30.6
CSF2,"GM-CSF, GMCSF",ENSG00000164400,Colony stimulating factor 2,5,132073790-132076170,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,"HPA057404, HPA062006",NA,NA,Enhanced,Vesicles,NA,Mixed,Tissue enhanced,NA,lung: 3.0,urinary bladder: 0.9,Cell line enhanced,NA,BJ hTERT+: 74.1;hTEC/SVTERT24-B: 20.9
CSK,NA,ENSG00000103653,C-src tyrosine kinase,15,74782057-74803198,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011203, HPA026488, HPA028425",Approved,Approved,Approved,Vesicles<br>Cytosol,"Cervical cancer:5.14e-5 (favourable), Stomach cancer:1.07e-4 (favourable), Renal cancer:1.74e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 195.2,Expressed in all,NA,NA
CSMD1,"KIAA1890, PPP1R24",ENSG00000183117,CUB and Sushi multiple domains 1,8,2935353-4994972,Predicted membrane proteins,Evidence at protein level,HPA074707,NA,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 6.2;testis: 4.7,fallopian tube: 1.1,Cell line enhanced,NA,K-562: 4.4;U-2 OS: 2.3;U-266/70: 1.7;U-266/84: 1.5;U-698: 1.3
CSNK1G2,CK1g2,ENSG00000133275,Casein kinase 1 gamma 2,19,1941149-1981338,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034868, HPA056572",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 76.8,Expressed in all,NA,NA
CSNK2A2,"CK2alpha', CSNK2A1",ENSG00000070770,Casein kinase 2 alpha 2,16,58157907-58197920,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA077719,NA,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Head and neck cancer:1.40e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 237.6,Expressed in all,NA,NA
CSRNP1,"AXUD1, DKFZp566F164, FAM130B, TAIP-3, URAX1",ENSG00000144655,Cysteine and serine rich nuclear protein 1,3,39141855-39154562,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA045207, HPA058463",NA,NA,Enhanced,Nucleoplasm<br>Vesicles,"Renal cancer:1.07e-4 (favourable), Stomach cancer:6.47e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 123.5,Cell line enhanced,NA,SK-BR-3: 48.5
CST3,NA,ENSG00000101439,Cystatin C,20,23626706-23638473,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000118, HPA013143",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,"Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 1265.8,Cell line enhanced,NA,ASC diff: 1105.8
CTDP1,FCP1,ENSG00000060069,CTD phosphatase subunit 1,18,79679801-79756623,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB032641, HPA040394, HPA070389",Supported,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:5.51e-5 (favourable), Endometrial cancer:6.43e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 19.6,Expressed in all,NA,NA
CTDSPL,"C3orf8, HYA22, PSR1, RBSP3, SCP3",ENSG00000144677,CTD small phosphatase like,3,37861960-37984469,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA048325,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:6.22e-14 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 65.7,Mixed,NA,NA
CTNS,"CTNS-LSB, PQLC4",ENSG00000040531,"Cystinosin, lysosomal cystine transporter",17,3636468-3661542,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA046947,NA,NA,Supported,Vesicles<br>Intermediate filaments,"Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 42.6,Expressed in all,NA,NA
CTSA,"GSL, PPGB",ENSG00000064601,Cathepsin A,20,45890144-45898820,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB024930, HPA031068",Enhanced,NA,Enhanced,Vesicles,Liver cancer:1.95e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,adrenal gland: 243.4,Expressed in all,NA,NA
CTSB,NA,ENSG00000164733,Cathepsin B,8,11842524-11869448,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000457, HPA018156",Uncertain,NA,Supported,Nucleoli<br>Vesicles,"Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 2894.5,Expressed in all,NA,NA
CTSC,"DPP1, PALS, PLS",ENSG00000109861,Cathepsin C,11,88293592-88337787,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025364, HPA066610, HPA068434",Enhanced,NA,Supported,Vesicles,"Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lung: 390.4,Expressed in all,NA,NA
CTSH,"ACC-4, ACC-5, ACC4, ACC5, CPSB",ENSG00000103811,Cathepsin H,15,78921058-78949574,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000458, HPA003524",Enhanced,NA,Supported,Vesicles<br>Cytosol<br>Cytoplasmic bodies,Endometrial cancer:6.90e-4 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 570.6,Cell line enhanced,NA,CAPAN-2: 219.5;HaCaT: 161.7;RT4: 558.6
CTSK,"CTSO, CTSO2, PKND, PYCD",ENSG00000143387,Cathepsin K,1,150796208-150808323,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA050346,NA,NA,Supported,Vesicles,Renal cancer:7.12e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 575.0",Group enriched,6,ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7
CTSS,NA,ENSG00000163131,Cathepsin S,1,150730196-150765957,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000460, HPA002988",Supported,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,spleen: 374.8,Cell line enhanced,NA,HMC-1: 238.0;U-698: 410.8
CTSZ,CTSX,ENSG00000101160,Cathepsin Z,20,58995185-59007247,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB025114, HPA049876, HPA053504",Supported,NA,Supported,Vesicles,Renal cancer:5.72e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 476.8,Cell line enhanced,NA,fHDF/TERT166: 693.2
CUZD1,"ERG-1, UO-44",ENSG00000138161,CUB and zona pellucida like domains 1,10,122832149-122850793,Predicted membrane proteins,Evidence at protein level,"HPA068479, HPA068660, HPA074117",Enhanced,NA,Approved,Nucleoli<br>Vesicles,NA,Tissue enriched,Tissue enriched,173,pancreas: 380.6,testis: 2.1,Mixed,NA,NA
CXCL16,"CXCLG16, SR-PSOX, SRPSOX",ENSG00000161921,C-X-C motif chemokine ligand 16,17,4733526-4739922,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA053253, HPA066315",Approved,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,lung: 106.0,Cell line enhanced,NA,A-431: 84.5;CACO-2: 54.2;HaCaT: 93.1
CXorf21,FLJ11577,ENSG00000120280,Chromosome X open reading frame 21,X,30558824-30577844,Predicted intracellular proteins,Evidence at protein level,HPA001185,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,appendix: 14.4,Cell line enriched,6,THP-1: 107.8
CYB5A,CYB5,ENSG00000166347,Cytochrome b5 type A,18,74250847-74292016,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB006333, HPA047548, HPA058547",Enhanced,NA,Approved,Vesicles<br>Cytosol,"Liver cancer:4.15e-4 (favourable), Colorectal cancer:5.23e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,liver: 1260.1,Cell line enhanced,NA,ASC diff: 766.9
CYP27C1,FLJ16008,ENSG00000186684,Cytochrome P450 family 27 subfamily C member 1,2,127184120-127220078,Predicted intracellular proteins,Evidence at protein level,"HPA062460, HPA068731",NA,NA,Supported,Vesicles,NA,Mixed,Tissue enhanced,NA,skin: 6.8,"cervix, uterine: 2.4",Cell line enhanced,NA,HDLM-2: 13.5;TIME: 11.6;U-138 MG: 13.8
CYP2U1,SPG49,ENSG00000155016,Cytochrome P450 family 2 subfamily U member 1,4,107931369-107953457,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA041622, HPA046754, HPA064827",Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Renal cancer:2.75e-5 (favourable), Stomach cancer:6.97e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,prostate: 15.7,Mixed,NA,NA
CYP4B1,NA,ENSG00000142973,Cytochrome P450 family 4 subfamily B member 1,1,46757838-46819413,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA004331,Approved,NA,Supported,Vesicles,Cervical cancer:5.99e-4 (favourable),Tissue enhanced,Tissue enhanced,NA,lung: 382.2,fallopian tube: 79.0,Cell line enriched,9,RT4: 234.9
CYSRT1,"C9orf169, MGC59937",ENSG00000197191,Cysteine rich tail 1,9,137224635-137226311,Predicted intracellular proteins,Evidence at protein level,"HPA021883, HPA021886",Approved,NA,Approved,Nuclear speckles<br>Vesicles<br>Midbody,NA,Expressed in all,Tissue enhanced,NA,esophagus: 45.6;skin: 12.2,tonsil: 6.3,Cell line enhanced,NA,A-431: 11.7;CAPAN-2: 14.5;HaCaT: 16.3;MCF7: 20.0
DAAM2,KIAA0381,ENSG00000146122,Dishevelled associated activator of morphogenesis 2,6,39792298-39904877,Predicted intracellular proteins,Evidence at protein level,"HPA051300, HPA054630",Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.79e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 110.8,Cell line enhanced,NA,HSkMC: 39.9;LHCN-M2: 46.3;SK-MEL-30: 54.3;WM-115: 26.5
DAB1,NA,ENSG00000173406,"DAB1, reelin adaptor protein",1,56994778-58546734,Predicted intracellular proteins,Evidence at protein level,"CAB032329, HPA052033, HPA067495",Enhanced,NA,Supported,Vesicles,NA,Mixed,Tissue enhanced,NA,duodenum: 15.9;seminal vesicle: 13.8;small intestine: 24.8,prostate: 6.4,Cell line enhanced,NA,fHDF/TERT166: 41.8;HeLa: 12.9;NTERA-2: 23.4;RT4: 25.5;WM-115: 26.3
DACH1,DACH,ENSG00000276644,Dachshund family transcription factor 1,13,71437966-71867192,Predicted intracellular proteins,Evidence at protein level,HPA012672,Approved,NA,Supported,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,"cervix, uterine: 15.0",Cell line enhanced,NA,HAP1: 23.2;HL-60: 30.0;SCLC-21H: 43.5;SH-SY5Y: 31.4;THP-1: 18.1
DACT3,"DAPPER3, MGC15476, RRR1",ENSG00000197380,Dishevelled binding antagonist of beta catenin 3,19,46647612-46661138,Predicted intracellular proteins,Evidence at protein level,HPA043053,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:7.97e-8 (unfavourable), Urothelial cancer:6.66e-4 (unfavourable)",Mixed,Mixed,NA,NA,smooth muscle: 46.6,Cell line enhanced,NA,SH-SY5Y: 26.8
DAG1,"156DAG, A3a, AGRNR, DAG",ENSG00000173402,Dystroglycan 1,3,49468703-49535618,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB001960, CAB016353",Enhanced,NA,Supported,Vesicles,Renal cancer:2.59e-4 (favourable),Expressed in all,Expressed in all,NA,NA,placenta: 109.3,Expressed in all,NA,NA
DAP,NA,ENSG00000112977,Death associated protein,5,10679230-10761272,Predicted intracellular proteins,Evidence at protein level,HPA029456,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Mitochondria,Liver cancer:2.15e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 156.6,Expressed in all,NA,NA
DAPK2,"DRP-1, MGC119312",ENSG00000035664,Death associated protein kinase 2,15,63907036-64072033,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA071581,NA,NA,Supported,Golgi apparatus<br>Vesicles,Lung cancer:5.63e-4 (favourable),Tissue enriched,Tissue enhanced,NA,thyroid gland: 49.1,lung: 29.9,Cell line enhanced,NA,HMC-1: 16.0
DBH,DBM,ENSG00000123454,Dopamine beta-hydroxylase,9,133636360-133659344,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002130, HPA005960, HPA070789",Enhanced,NA,Enhanced,Endoplasmic reticulum<br>Vesicles,NA,Mixed,Tissue enriched,28,adrenal gland: 356.8,liver: 12.6,Cell line enriched,370,SH-SY5Y: 1924.2
DCAF15,"C19orf72, MGC99481",ENSG00000132017,DDB1 and CUL4 associated factor 15,19,13952492-13961449,Predicted intracellular proteins,Evidence at protein level,HPA068351,NA,NA,Approved,Vesicles<br>Mitochondria,"Renal cancer:1.34e-5 (unfavourable), Pancreatic cancer:7.97e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 59.9,Expressed in all,NA,NA
DCP1B,FLJ31638,ENSG00000151065,Decapping mRNA 1B,12,1946054-2004535,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039709, HPA058778",Approved,NA,Supported,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 36.7,Mixed,NA,NA
DCUN1D4,KIAA0276,ENSG00000109184,Defective in cullin neddylation 1 domain containing 4,4,51843000-51916837,Predicted intracellular proteins,Evidence at protein level,"HPA036483, HPA036484",Uncertain,NA,Supported,Nucleus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 28.9,Expressed in all,NA,NA
DDX31,"FLJ13633, FLJ14578, FLJ23349, PPP1R25",ENSG00000125485,DEAD-box helicase 31,9,132592997-132670401,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020891,NA,NA,Supported,Nucleoli<br>Golgi apparatus<br>Vesicles,Liver cancer:1.68e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 23.0,Expressed in all,NA,NA
DENND1A,"FAM31A, FLJ21129, KIAA1608",ENSG00000119522,DENN domain containing 1A,9,123379654-123930152,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA020481,NA,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:4.11e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 21.8,Expressed in all,NA,NA
DENND3,KIAA0870,ENSG00000105339,DENN domain containing 3,8,141117278-141195808,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA024491, HPA041668",NA,Approved,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,bone marrow: 68.5,Cell line enhanced,NA,HDLM-2: 60.7;HeLa: 52.8
DENND4C,"bA513M16.3, C9orf55, C9orf55B, FLJ20686, RAB10GEF",ENSG00000137145,DENN domain containing 4C,9,19230435-19373545,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014917, HPA015096",Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Cytosol,Renal cancer:3.51e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 47.6,Expressed in all,NA,NA
DENND5A,"FLJ22354, FLJ33829, FLJ43455, KIAA1091, RAB6IP1",ENSG00000184014,DENN domain containing 5A,11,9138825-9265390,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA052923, HPA055009",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.14e-6 (unfavourable), Liver cancer:5.05e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 126.7,Mixed,NA,NA
DENND6A,"AFI1A, FAM116A, FLJ34969",ENSG00000174839,DENN domain containing 6A,3,57625457-57693089,Predicted intracellular proteins,Evidence at protein level,"HPA062618, HPA069725, HPA071711",Approved,NA,Supported,Vesicles,"Renal cancer:7.77e-6 (favourable), Liver cancer:6.36e-4 (unfavourable), Colorectal cancer:9.21e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 25.6,Expressed in all,NA,NA
DERL3,"C22orf14, derlin-3, FLJ43842, IZP6, MGC71803",ENSG00000099958,Derlin 3,22,23834503-23839128,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB037234, HPA049306",Uncertain,NA,Uncertain,Vesicles,"Renal cancer:7.76e-13 (unfavourable), Cervical cancer:8.70e-5 (favourable), Head and neck cancer:8.01e-4 (favourable)",Expressed in all,Mixed,NA,NA,stomach: 39.0,Group enriched,5,Karpas-707: 58.5;RPMI-8226: 33.7;U-266/70: 66.4;U-698: 14.5
DESI2,"C1orf121, CGI-146, FAM152A, FLJ21998, PNAS-4, PPPDE1",ENSG00000121644,Desumoylating isopeptidase 2,1,244652935-244709033,Predicted intracellular proteins,Evidence at protein level,HPA049950,NA,NA,Approved,Vesicles,Renal cancer:4.25e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 95.0,Expressed in all,NA,NA
DGKA,"DAGK, DAGK1, DGK-alpha",ENSG00000065357,Diacylglycerol kinase alpha,12,55927319-55954027,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041645, HPA045462",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Mitochondria,Renal cancer:1.66e-5 (unfavourable),Expressed in all,Mixed,NA,NA,skin: 97.4,Cell line enhanced,NA,HBEC3-KT: 93.1;hTERT-HME1: 102.8
DHRS12,"FLJ13639, SDR40C1",ENSG00000102796,Dehydrogenase/reductase 12,13,51767993-51804157,Predicted intracellular proteins,Evidence at protein level,"CAB034238, HPA057028, HPA058315",Uncertain,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Renal cancer:2.22e-16 (favourable), Breast cancer:1.41e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 22.0,Mixed,NA,NA
DHRS13,"MGC23280, SDR7C5",ENSG00000167536,Dehydrogenase/reductase 13,17,28897781-28903071,Predicted intracellular proteins,Evidence at protein level,HPA022991,Uncertain,NA,Approved,Vesicles,Liver cancer:3.39e-6 (unfavourable),Expressed in all,Mixed,NA,NA,bone marrow: 25.2,Mixed,NA,NA
DHRS4,"FLJ11008, humNRDR, SCAD-SRL, SDR-SRL, SDR25C2",ENSG00000157326,Dehydrogenase/reductase 4,14,23953586-23969279,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023972,Uncertain,NA,Approved,Nuclear membrane<br>Vesicles,Renal cancer:4.55e-6 (favourable),Expressed in all,Expressed in all,NA,NA,kidney: 149.0,Mixed,NA,NA
DHRS4L2,SDR25C3,ENSG00000187630,Dehydrogenase/reductase 4 like 2,14,23969874-24006408,Predicted intracellular proteins,Evidence at protein level,HPA023972,Uncertain,NA,Uncertain,Nuclear membrane<br>Vesicles,Ovarian cancer:3.21e-4 (favourable),Expressed in all,Expressed in all,NA,NA,kidney: 123.6,Mixed,NA,NA
DIAPH2,"DIA, DIA2, POF, POF2",ENSG00000147202,Diaphanous related formin 2,X,96684663-97604997,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005647, CAB015461, CAB068183, CAB068184",Enhanced,NA,Supported,Nucleoli<br>Endoplasmic reticulum<br>Vesicles,"Endometrial cancer:2.16e-5 (unfavourable), Pancreatic cancer:2.12e-4 (unfavourable), Renal cancer:3.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 17.8,Mixed,NA,NA
DIDO1,"BYE1, C20orf158, DATF1, DIO-1, DIO1, dJ885L7.8, FLJ11265, KIAA0333",ENSG00000101191,Death inducer-obliterator 1,20,62877738-62937952,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004374, HPA049904",Supported,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Pancreatic cancer:3.88e-4 (favourable), Head and neck cancer:5.13e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 48.2,Expressed in all,NA,NA
DIP2C,KIAA0934,ENSG00000151240,Disco interacting protein 2 homolog C,10,274190-689668,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA030264, HPA059325",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:2.46e-6 (favourable), Endometrial cancer:8.92e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 23.4,Cell line enhanced,NA,U-2197: 30.9
DIRC2,"FLJ14784, RCC4",ENSG00000138463,Disrupted in renal carcinoma 2,3,122794795-122881139,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA072579,NA,NA,Supported,Vesicles,"Renal cancer:8.81e-11 (favourable), Pancreatic cancer:5.81e-5 (unfavourable), Liver cancer:7.48e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 16.2,Mixed,NA,NA
DISP2,"C15orf36, DISPB, HsT16908, KIAA1742, LINC00594",ENSG00000140323,Dispatched RND transporter family member 2,15,40358235-40378639,Predicted membrane proteins,Evidence at protein level,HPA059903,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 7.4,thyroid gland: 1.8,Group enriched,5,HaCaT: 5.9;SCLC-21H: 15.8
DKK3,"REIC, RIG",ENSG00000050165,Dickkopf WNT signaling pathway inhibitor 3,11,11963106-12009769,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA011868, CAB024949",Approved,NA,Approved,Vesicles,Renal cancer:6.31e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 373.5;heart muscle: 805.5,"cervix, uterine: 138.8",Cell line enhanced,NA,BJ: 355.1;BJ hTERT+: 524.6;fHDF/TERT166: 475.8;TIME: 285.3
DKKL1,"CT34, SGY-1",ENSG00000104901,Dickkopf like acrosomal protein 1,19,49361783-49375116,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025410, HPA047194",Enhanced,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enriched,149,testis: 265.5,"endometrium,fallopian tube: 1.7",Cell line enhanced,NA,AF22: 5.0;AN3-CA: 8.9
DLC1,"ARHGAP7, DLC-1, HP, p122-RhoGAP, STARD12",ENSG00000164741,DLC1 Rho GTPase activating protein,8,13083361-13604610,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA017753,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Endometrial cancer:1.11e-4 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 78.7,Cell line enhanced,NA,U-2197: 120.6
DLG4,"PSD-95, PSD95, SAP-90, SAP90",ENSG00000132535,Discs large MAGUK scaffold protein 4,17,7189890-7219702,"Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB001999, CAB002000, HPA010122",Enhanced,NA,Approved,Vesicles,"Pancreatic cancer:8.82e-6 (favourable), Renal cancer:1.70e-4 (unfavourable)",Expressed in all,Tissue enriched,6,cerebral cortex: 178.6,endometrium: 28.9,Cell line enhanced,NA,HMC-1: 57.4
DMPK,"DM, DM1, DM1PK, DMK, MDPK, MT-PK",ENSG00000104936,Dystrophia myotonica protein kinase,19,45769717-45782552,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007164, HPA008905",Enhanced,NA,Approved,Vesicles<br>Cytosol,Pancreatic cancer:9.39e-5 (favourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 97.3,Cell line enhanced,NA,RH-30: 99.0
DMRTA1,NA,ENSG00000176399,DMRT like family A1,9,22446841-22455740,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA044764, HPA062253",Uncertain,NA,Approved,Vesicles,Renal cancer:1.14e-6 (favourable),Mixed,Tissue enhanced,NA,parathyroid gland: 6.5,liver: 4.3,Cell line enhanced,NA,BJ hTERT+: 5.1
DNAJC13,"KIAA0678, RME8",ENSG00000138246,DnaJ heat shock protein family (Hsp40) member C13,3,132417526-132539032,Predicted membrane proteins,Evidence at protein level,"HPA036923, HPA036924",Approved,NA,Supported,Vesicles<br>Cytosol,"Liver cancer:7.49e-4 (unfavourable), Pancreatic cancer:8.36e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 28.9,Expressed in all,NA,NA
DNAJC16,KIAA0962,ENSG00000116138,DnaJ heat shock protein family (Hsp40) member C16,1,15526813-15592379,Predicted membrane proteins,Evidence at protein level,HPA043643,Approved,NA,Approved,Vesicles,"Colorectal cancer:6.77e-4 (favourable), Renal cancer:7.24e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 16.8,Expressed in all,NA,NA
DNAJC21,"DNAJA5, GS3, JJJ1",ENSG00000168724,DnaJ heat shock protein family (Hsp40) member C21,5,34929593-34958964,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA040789, HPA049208",Approved,NA,Approved,Vesicles,Liver cancer:2.36e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 101.6,Expressed in all,NA,NA
DNAJC22,"FLJ13236, wus",ENSG00000178401,DnaJ heat shock protein family (Hsp40) member C22,12,49346917-49357546,Predicted membrane proteins,Evidence at protein level,HPA039953,NA,NA,Approved,Vesicles,"Endometrial cancer:4.56e-5 (favourable), Melanoma:7.54e-4 (unfavourable)",Mixed,Mixed,NA,NA,thyroid gland: 17.9,Cell line enhanced,NA,CACO-2: 24.1;EFO-21: 28.4;MCF7: 19.7;T-47d: 21.2
DNAJC5B,"CSP-beta, MGC26226",ENSG00000147570,DnaJ heat shock protein family (Hsp40) member C5 beta,8,66021560-66100526,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA077389,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,13,testis: 114.3,lung: 9.1,Group enriched,6,HDLM-2: 17.3;RPTEC TERT1: 15.6;THP-1: 8.8;U-266/70: 8.7;U-937: 8.8
DNASE1,DNL1,ENSG00000213918,Deoxyribonuclease 1,16,3611728-3680143,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA010703,Enhanced,NA,Supported,Vesicles,Urothelial cancer:1.14e-4 (favourable),Expressed in all,Tissue enhanced,NA,small intestine: 37.8,duodenum: 29.9,Mixed,NA,NA
DNM1L,"DRP1, DVLP, DYMPLE, HDYNIV, VPS1",ENSG00000087470,Dynamin 1 like,12,32679200-32745650,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB009952, HPA039324",Enhanced,NA,Enhanced,Vesicles<br>Cytosol,Liver cancer:6.27e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 88.1,Expressed in all,NA,NA
DNMT3B,NA,ENSG00000088305,DNA methyltransferase 3 beta,20,32762385-32809356,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001595, CAB069896",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.87e-7 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)",Tissue enriched,Tissue enhanced,NA,testis: 9.2,skin: 4.5,Cell line enhanced,NA,BEWO: 236.9;NTERA-2: 333.3
DOK4,FLJ10488,ENSG00000125170,Docking protein 4,16,57471922-57487327,Predicted intracellular proteins,Evidence at protein level,HPA055849,Supported,NA,Approved,Vesicles<br>Microtubules<br>Cytokinetic bridge,NA,Expressed in all,Expressed in all,NA,NA,small intestine: 54.7,Cell line enhanced,NA,SH-SY5Y: 254.2
DOLPP1,LSFR2,ENSG00000167130,Dolichyldiphosphatase 1,9,129081100-129090438,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA019179,Approved,NA,Approved,Vesicles<br>Intermediate filaments,NA,Expressed in all,Expressed in all,NA,NA,duodenum: 25.8,Expressed in all,NA,NA
DOPEY1,"dJ202D23.2, KIAA1117",ENSG00000083097,Dopey family member 1,6,83067666-83171350,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA027902, HPA027904",Enhanced,NA,Approved,Nucleus<br>Vesicles,Pancreatic cancer:7.36e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 25.5,Mixed,NA,NA
DPP10,"DPL2, DPPY, DPRP3",ENSG00000175497,Dipeptidyl peptidase like 10,2,114442299-115845752,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048767,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,NA,Mixed,Group enriched,7,adrenal gland: 14.1;cerebral cortex: 34.7,pancreas: 3.6,Cell line enhanced,NA,AF22: 4.1;HAP1: 6.4;HMC-1: 3.8;NTERA-2: 3.7;RT4: 5.3;SCLC-21H: 11.4;SH-SY5Y: 4.1
DPP7,"DPP2, DPPII",ENSG00000176978,Dipeptidyl peptidase 7,9,137110542-137115177,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021282, CAB025541, HPA059381",Supported,NA,Enhanced,Golgi apparatus<br>Vesicles,"Colorectal cancer:6.07e-6 (unfavourable), Pancreatic cancer:8.31e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 70.7,Mixed,NA,NA
DPT,NA,ENSG00000143196,Dermatopontin,1,168695459-168729264,Predicted secreted proteins,Evidence at protein level,HPA065548,NA,NA,Approved,Vesicles,Renal cancer:4.74e-5 (unfavourable),Expressed in all,Mixed,NA,NA,adipose tissue: 330.3,Group enriched,10,ASC diff: 94.1;fHDF/TERT166: 44.4
DPY19L1,KIAA0877,ENSG00000173852,Dpy-19 like 1,7,34928876-35038271,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA059139,Uncertain,NA,Approved,Vesicles,Pancreatic cancer:2.99e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 69.5,Mixed,NA,NA
DPY19L4,NA,ENSG00000156162,Dpy-19 like 4 (C. elegans),8,94719703-94793836,Predicted membrane proteins,Evidence at protein level,HPA024780,Approved,NA,Approved,Vesicles,Endometrial cancer:3.73e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 36.9,Expressed in all,NA,NA
DPYSL4,"DRP-4, ULIP4",ENSG00000151640,Dihydropyrimidinase like 4,10,132186900-132205776,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA049066,Approved,NA,Approved,Vesicles<br>Mitochondria,Urothelial cancer:3.11e-4 (unfavourable),Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 30.0,heart muscle: 7.5,Cell line enhanced,NA,AF22: 51.3;AN3-CA: 63.4;SH-SY5Y: 74.6
DRAM2,"MGC54289, PRO180, RP5-1180E21.1, TMEM77, WWFQ154",ENSG00000156171,DNA damage regulated autophagy modulator 2,1,111117333-111140216,Predicted membrane proteins,Evidence at protein level,"HPA018036, HPA061701",Enhanced,NA,Enhanced,Golgi apparatus<br>Vesicles,"Liver cancer:3.45e-5 (unfavourable), Melanoma:6.43e-4 (unfavourable), Renal cancer:7.45e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 19.3,Mixed,NA,NA
DRG2,NA,ENSG00000108591,Developmentally regulated GTP binding protein 2,17,18087886-18107971,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA007716,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Endometrial cancer:1.56e-4 (favourable), Prostate cancer:7.34e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 29.4,Expressed in all,NA,NA
DTD2,"C14orf126, MGC9912",ENSG00000129480,D-tyrosyl-tRNA deacylase 2 (putative),14,31446036-31457510,Predicted intracellular proteins,Evidence at protein level,HPA001117,Approved,NA,Approved,Vesicles,"Urothelial cancer:5.74e-6 (unfavourable), Head and neck cancer:9.33e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 10.8,Expressed in all,NA,NA
DTWD1,"MDS009, MGC111207",ENSG00000104047,DTW domain containing 1,15,49620980-49656232,Predicted intracellular proteins,Evidence at protein level,HPA042214,Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 39.5",Expressed in all,NA,NA
DTX4,"KIAA0937, RNF155",ENSG00000110042,Deltex E3 ubiquitin ligase 4,11,59171430-59208587,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA056760, HPA059294",Uncertain,Approved,Approved,Vesicles,"Thyroid cancer:5.81e-4 (favourable), Renal cancer:8.94e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,lung: 27.3,Cell line enhanced,NA,BEWO: 63.2;RT4: 80.7
DUSP22,"JKAP, JSP1, MKPX, VHX",ENSG00000112679,Dual specificity phosphatase 22,6,291630-351355,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031394,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 85.1,Expressed in all,NA,NA
DYRK4,NA,ENSG00000010219,Dual specificity tyrosine phosphorylation regulated kinase 4,12,4562204-4615302,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028065, HPA056073",Enhanced,NA,Enhanced,Vesicles,Renal cancer:6.52e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 66.2,epididymis: 20.7,Mixed,NA,NA
DZIP3,"hRUL138, PPP1R66",ENSG00000198919,DAZ interacting zinc finger protein 3,3,108589682-108694846,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA035066, HPA049232",Approved,NA,Approved,Vesicles,Renal cancer:3.65e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 65.7,Mixed,NA,NA
EAF1,NA,ENSG00000144597,ELL associated factor 1,3,15427355-15450635,Predicted intracellular proteins,Evidence at protein level,"HPA059516, HPA060569, HPA069538",Enhanced,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles<br>Cytokinetic bridge,Lung cancer:6.87e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 33.7,Expressed in all,NA,NA
EBF1,"EBF, OLF1",ENSG00000164330,Early B-cell factor 1,5,158695916-159099761,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA061169,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:9.62e-7 (unfavourable), Stomach cancer:7.80e-4 (unfavourable)",Mixed,Tissue enhanced,NA,adipose tissue: 41.6,placenta: 16.2,Cell line enhanced,NA,ASC diff: 27.3;HSkMC: 22.6;REH: 81.2
EBF3,"COE3, DKFZp667B0210",ENSG00000108001,Early B-cell factor 3,10,129835283-129963841,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA061169,NA,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enhanced,NA,adipose tissue: 20.1,lymph node: 12.7,Cell line enhanced,NA,HAP1: 23.0;LHCN-M2: 29.6;NB-4: 29.2;RH-30: 18.6;SCLC-21H: 53.2
ECHDC1,dJ351K20.2,ENSG00000093144,Ethylmalonyl-CoA decarboxylase 1,6,127288710-127343609,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035445, HPA035446",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 98.5,Mixed,NA,NA
EDA,"ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2, EDA1, EDA2, HED, ODT1, XHED, XLHED",ENSG00000158813,Ectodysplasin A,X,69616067-70039469,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA037972, HPA037973",NA,NA,Supported,Vesicles<br>Lipid droplets,Renal cancer:1.04e-9 (favourable),Mixed,Tissue enhanced,NA,parathyroid gland: 19.4,thyroid gland: 10.0,Cell line enhanced,NA,EFO-21: 5.0;Hep G2: 12.2
EEA1,ZFYVE2,ENSG00000102189,Early endosome antigen 1,12,92770637-92929331,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005861, CAB018782, HPA038158, HPA038159",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 16.8,Expressed in all,NA,NA
EEF2KMT,"EFM3, FAM86A, MGC19636, SB153",ENSG00000118894,Eukaryotic elongation factor 2 lysine methyltransferase,16,5084304-5097808,Predicted intracellular proteins,Evidence at protein level,HPA041610,Approved,NA,Uncertain,Vesicles,"Urothelial cancer:2.35e-4 (unfavourable), Liver cancer:8.85e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 11.3,Expressed in all,NA,NA
EFNA4,"EPLG4, LERK4",ENSG00000243364,Ephrin A4,1,155063731-155069553,"Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB021350, HPA064952",Approved,NA,Uncertain,Nucleus<br>Vesicles,"Liver cancer:1.00e-5 (unfavourable), Stomach cancer:3.60e-5 (favourable), Renal cancer:3.14e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 24.5,Expressed in all,NA,NA
EFNA5,"AF1, EPLG7, LERK7",ENSG00000184349,Ephrin A5,5,107376889-107670895,"Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB013282, HPA054047",Approved,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:1.92e-7 (unfavourable), Stomach cancer:3.77e-4 (unfavourable)",Mixed,Mixed,NA,NA,"cervix, uterine: 17.1",Cell line enhanced,NA,RPTEC TERT1: 43.4
EGFL8,"C6orf8, NG3",ENSG00000241404,EGF like domain multiple 8,6,32164583-32168281,Predicted secreted proteins,Evidence at protein level,HPA061173,Uncertain,NA,Approved,Nuclear speckles<br>Vesicles,NA,Mixed,Mixed,NA,NA,skin: 2.7,Mixed,NA,NA
EGR3,PILOT,ENSG00000179388,Early growth response 3,8,22687659-22693302,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA006206, CAB009373",Uncertain,NA,Uncertain,Nucleus<br>Vesicles,"Breast cancer:1.83e-4 (favourable), Melanoma:4.78e-4 (favourable)",Mixed,Mixed,NA,NA,gallbladder: 49.6,Cell line enhanced,NA,HMC-1: 8.5;MCF7: 25.2;SK-MEL-30: 17.0
EIF1AD,"haponin, MGC11102",ENSG00000175376,Eukaryotic translation initiation factor 1A domain containing,11,65996545-66002176,Predicted intracellular proteins,Evidence at protein level,"HPA054991, HPA058735",Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,"Endometrial cancer:3.59e-5 (unfavourable), Liver cancer:8.63e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 34.9,Expressed in all,NA,NA
EIF2B3,"EIF-2B, EIF2Bgamma",ENSG00000070785,Eukaryotic translation initiation factor 2B subunit gamma,1,44850522-44986722,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA024213, HPA024218, HPA024219",Supported,NA,Supported,Vesicles<br>Cytosol,Liver cancer:1.73e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 49.4,Expressed in all,NA,NA
EIF4ENIF1,"2610509L04Rik, 4E-T, Clast4, FLJ21601",ENSG00000184708,Eukaryotic translation initiation factor 4E nuclear import factor 1,22,31436977-31496108,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001619, HPA002078",Enhanced,NA,Enhanced,Vesicles,Renal cancer:1.57e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 65.0,Expressed in all,NA,NA
EIF5A2,NA,ENSG00000163577,Eukaryotic translation initiation factor 5A2,3,170888415-170908693,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA029090,Approved,NA,Supported,Vesicles,Head and neck cancer:7.42e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,testis: 36.7,smooth muscle: 10.4,Mixed,NA,NA
ELAVL4,"HUD, PNEM",ENSG00000162374,ELAV like RNA binding protein 4,1,50048014-50203786,Predicted intracellular proteins,Evidence at protein level,"CAB004442, HPA043047",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Group enriched,Group enriched,9,adrenal gland: 10.7;cerebral cortex: 53.3;testis: 10.9,appendix: 2.9,Cell line enriched,21,SH-SY5Y: 131.1
ELFN2,"dJ63G5.3, KIAA1904, LRRC62, PPP1R29",ENSG00000166897,Extracellular leucine rich repeat and fibronectin type III domain containing 2,22,37367960-37427470,Predicted membrane proteins,Evidence at protein level,HPA000781,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:7.21e-4 (unfavourable),Mixed,Tissue enriched,7,cerebral cortex: 24.3,testis: 3.4,Cell line enhanced,NA,RPTEC TERT1: 16.3;U-2 OS: 25.4
ELOVL3,CIG-30,ENSG00000119915,ELOVL fatty acid elongase 3,10,102226328-102229589,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA036236,Supported,NA,Approved,Vesicles<br>Cytosol,Endometrial cancer:6.25e-5 (unfavourable),Tissue enhanced,Tissue enhanced,NA,adipose tissue: 3.6;breast: 4.4;skin: 3.4,testis: 2.3,Cell line enhanced,NA,HSkMC: 10.4;SiHa: 24.5
EML2,"ELP70, EMAP-2, EMAP2",ENSG00000125746,Echinoderm microtubule associated protein like 2,19,45606994-45645629,Predicted intracellular proteins,Evidence at protein level,HPA012757,Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 100.7,Mixed,NA,NA
EML6,FLJ42562,ENSG00000214595,Echinoderm microtubule associated protein like 6,2,54723499-54972025,Predicted intracellular proteins,Evidence at protein level,"HPA062808, HPA068759",Uncertain,NA,Approved,Vesicles<br>Mitochondria,NA,Mixed,Tissue enhanced,NA,lymph node: 7.5;tonsil: 8.3,appendix: 4.4,Cell line enhanced,NA,SCLC-21H: 32.4;U-698: 22.3
ENTPD4,"KIAA0392, LALP70, LAP70, LYSAL1, NTPDase-4, UDPase",ENSG00000197217,Ectonucleoside triphosphate diphosphohydrolase 4,8,23385783-23457695,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017655,Supported,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 47.3,Expressed in all,NA,NA
ENTPD8,"NTPDase-8, UNQ2492",ENSG00000188833,Ectonucleoside triphosphate diphosphohydrolase 8,9,137434364-137441816,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA021509,Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Stomach cancer:7.17e-4 (favourable),Mixed,Tissue enhanced,NA,colon: 21.7;duodenum: 28.7;small intestine: 31.6,rectum: 12.5,Cell line enhanced,NA,CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
EPHX4,"ABHD7, EPHXRP, FLJ90341",ENSG00000172031,Epoxide hydrolase 4,1,92029982-92063536,Predicted intracellular proteins,Evidence at protein level,HPA035067,Uncertain,NA,Approved,Vesicles,Pancreatic cancer:2.00e-4 (unfavourable),Mixed,Tissue enhanced,NA,cerebral cortex: 14.6,thyroid gland: 3.0,Cell line enhanced,NA,A-431: 13.4;CAPAN-2: 11.4;EFO-21: 24.3;RPTEC TERT1: 27.3
EPN2,"EHB21, KIAA1065",ENSG00000072134,Epsin 2,17,19215615-19336715,Predicted intracellular proteins,Evidence at protein level,"HPA049809, HPA053360",Approved,NA,Supported,Vesicles,"Urothelial cancer:8.15e-5 (unfavourable), Renal cancer:9.13e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 95.0,Mixed,NA,NA
EPN3,"FLJ20778, MGC129899",ENSG00000049283,Epsin 3,17,50532543-50543750,Predicted intracellular proteins,Evidence at protein level,"HPA055546, HPA063224",Approved,NA,Supported,Nucleoplasm<br>Vesicles,Renal cancer:1.53e-5 (favourable),Mixed,Mixed,NA,NA,stomach: 27.5,Cell line enhanced,NA,HaCaT: 24.3;HBEC3-KT: 27.4;MCF7: 48.0;RT4: 38.6;T-47d: 51.4
EPOR,NA,ENSG00000187266,Erythropoietin receptor,19,11377205-11384342,"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA077613,NA,NA,Supported,Vesicles,Pancreatic cancer:3.17e-5 (favourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 53.1,thyroid gland: 18.0,Mixed,NA,NA
EPS15,"AF-1P, MLLT5",ENSG00000085832,Epidermal growth factor receptor pathway substrate 15,1,51354263-51519328,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA008451, CAB010164, HPA061431",Approved,NA,Enhanced,Vesicles<br>Cytosol,Cervical cancer:6.44e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 84.6,Expressed in all,NA,NA
EPS15L1,eps15R,ENSG00000127527,Epidermal growth factor receptor pathway substrate 15 like 1,19,16355239-16472085,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019237, HPA055309",Uncertain,NA,Approved,Vesicles,Renal cancer:8.10e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 26.0,Expressed in all,NA,NA
EPS8L3,"FLJ21522, MGC16817",ENSG00000198758,EPS8 like 3,1,109750080-109764027,Predicted intracellular proteins,Evidence at protein level,HPA030998,Approved,NA,Approved,Vesicles,"Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable)",Group enriched,Group enriched,7,colon: 75.0;duodenum: 152.1;gallbladder: 59.8;rectum: 86.1;small intestine: 167.1;stomach: 53.4,appendix: 15.1,Group enriched,12,CACO-2: 13.3;CAPAN-2: 13.3;EFO-21: 5.8;Hep G2: 25.0
EREG,ER,ENSG00000124882,Epiregulin,4,74365143-74388751,Predicted membrane proteins,Evidence at protein level,HPA054373,NA,NA,Approved,Vesicles,"Cervical cancer:1.67e-7 (unfavourable), Lung cancer:1.45e-5 (unfavourable), Pancreatic cancer:6.57e-5 (unfavourable)",Tissue enhanced,Tissue enriched,6,bone marrow: 82.3,appendix: 14.4,Cell line enhanced,NA,BJ hTERT+: 218.4;U-2197: 168.6;U-87 MG: 300.8
ERGIC1,"ERGIC-32, ERGIC32, KIAA1181, NET24",ENSG00000113719,Endoplasmic reticulum-golgi intermediate compartment 1,5,172834275-172952685,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018666, HPA018900",Enhanced,NA,Enhanced,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,prostate: 238.2,Expressed in all,NA,NA
ERGIC2,"Erv41, PTX1",ENSG00000087502,ERGIC and golgi 2,12,29337352-29381189,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA049695,Approved,NA,Supported,Nucleoli<br>Vesicles,"Renal cancer:3.76e-6 (unfavourable), Pancreatic cancer:7.02e-6 (unfavourable), Liver cancer:8.06e-6 (unfavourable), Ovarian cancer:8.18e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 106.3,Expressed in all,NA,NA
ERI1,"3'HEXO, THEX1",ENSG00000104626,Exoribonuclease 1,8,9002147-9116746,Predicted intracellular proteins,Evidence at protein level,"CAB033838, HPA055548, HPA056074",Uncertain,NA,Approved,Vesicles<br>Microtubules,"Colorectal cancer:8.05e-5 (favourable), Renal cancer:1.42e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 16.8,Expressed in all,NA,NA
ERICH2,NA,ENSG00000204334,Glutamate rich 2,2,170783786-170798971,Predicted intracellular proteins,Evidence at protein level,HPA061010,NA,NA,Approved,Nucleoli fibrillar center<br>Vesicles,"Renal cancer:8.98e-7 (unfavourable), Endometrial cancer:9.49e-4 (favourable)",Expressed in all,Tissue enriched,8,testis: 233.8,thyroid gland: 30.5,Cell line enhanced,NA,hTCEpi: 44.3
ERV3-1,"envR, ERV-R, ERV3, H-PLK, HERV-R",ENSG00000213462,Endogenous retrovirus group 3 member 1,7,64990809-65006743,Predicted secreted proteins,Evidence at protein level,"HPA017209, HPA046508",Enhanced,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,adrenal gland: 39.8,Mixed,NA,NA
ESPL1,"ESP1, KIAA0165, SEPA",ENSG00000135476,"Extra spindle pole bodies like 1, separase",12,53268299-53293643,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB012185,Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable)",Mixed,Tissue enhanced,NA,esophagus: 11.4;testis: 10.6,lymph node: 4.8,Mixed,NA,NA
ESPN,DFNB36,ENSG00000187017,Espin,1,6424788-6461370,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028674, HPA060220",Enhanced,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,skin: 96.5;testis: 118.3,small intestine: 77.3,Cell line enhanced,NA,BEWO: 42.8;SK-BR-3: 110.9;T-47d: 47.8
ESR1,"Era, ESR, NR3A1",ENSG00000091831,Estrogen receptor 1,6,151656691-152129619,"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB000037, HPA000449, HPA000450, CAB055099, CAB072858",Enhanced,NA,Approved,Nucleus<br>Vesicles,Endometrial cancer:5.47e-7 (favourable),Group enriched,Group enriched,8,"breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5",seminal vesicle: 13.5,Group enriched,11,MCF7: 34.7;T-47d: 53.2
EVI5,NB4S,ENSG00000067208,Ecotropic viral integration site 5,1,92508696-92792404,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA027339, HPA053724",Approved,NA,Supported,Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 18.0,Mixed,NA,NA
EVL,RNB6,ENSG00000196405,Enah/Vasp-like,14,99971449-100144236,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA018849, HPA019536, CAB033987",Enhanced,NA,Approved,Vesicles<br>Cytosol,"Pancreatic cancer:4.07e-6 (favourable), Renal cancer:4.14e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 208.1,Cell line enhanced,NA,MOLT-4: 229.2
EXOC2,"FLJ11026, SEC5L1, Sec5p",ENSG00000112685,Exocyst complex component 2,6,485133-693111,"Predicted intracellular proteins, RAS pathway related proteins, Transporters",Evidence at protein level,HPA032093,NA,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 30.4,Expressed in all,NA,NA
EXOC6,"DKFZp761I2124, EXOC6A, FLJ1125, MGC33397, SEC15L, SEC15L1, Sec15p",ENSG00000138190,Exocyst complex component 6,10,92834713-93059493,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA036285, HPA059111",Approved,NA,Supported,Nucleoplasm<br>Vesicles,Renal cancer:4.66e-4 (favourable),Expressed in all,Expressed in all,NA,NA,placenta: 49.7,Cell line enhanced,NA,HUVEC TERT2: 87.5
F11,FXI,ENSG00000088926,Coagulation factor XI,4,186265945-186288806,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA039808,NA,NA,Approved,Vesicles,Liver cancer:3.29e-5 (favourable),Tissue enriched,Tissue enhanced,NA,liver: 180.1,kidney: 44.7,Cell line enriched,8,Hep G2: 6.0
F3,"CD142, TF",ENSG00000117525,"Coagulation factor III, tissue factor",1,94529225-94541800,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009438, HPA049292, HPA069132",Approved,NA,Enhanced,Vesicles,"Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 191.1,Cell line enhanced,NA,A-431: 929.2;HaCaT: 433.2;HBEC3-KT: 914.1;U-2197: 442.4
FAAP24,"C19orf40, FLJ46828, MGC32020",ENSG00000131944,Fanconi anemia core complex associated protein 24,19,32972209-32978222,Predicted intracellular proteins,Evidence at protein level,HPA041168,Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,"Renal cancer:4.00e-7 (unfavourable), Endometrial cancer:4.38e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 11.9,Expressed in all,NA,NA
FAM110A,"bA371L19.3, C20orf55",ENSG00000125898,Family with sequence similarity 110 member A,20,833715-857463,Predicted intracellular proteins,Evidence at protein level,"CAB034110, HPA069240",Uncertain,NA,Supported,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:4.42e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,skin: 31.3,spleen: 21.3,Cell line enhanced,NA,SK-BR-3: 62.8
FAM114A2,"133K02, C5orf3",ENSG00000055147,Family with sequence similarity 114 member A2,5,153990128-154038936,Predicted intracellular proteins,Evidence at protein level,"HPA035869, HPA035870",Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 68.7,Expressed in all,NA,NA
FAM155A,NA,ENSG00000204442,Family with sequence similarity 155 member A,13,107163510-107866735,Predicted membrane proteins,Evidence at protein level,"HPA039453, HPA058768",Enhanced,NA,Approved,Nucleus<br>Vesicles<br>Centrosome,NA,Mixed,Tissue enriched,6,cerebral cortex: 15.6,seminal vesicle: 2.4,Cell line enhanced,NA,RPTEC TERT1: 9.3;SCLC-21H: 8.9;SH-SY5Y: 18.1;U-87 MG: 10.5
FAM173B,JS-2,ENSG00000150756,Family with sequence similarity 173 member B,5,10226330-10249897,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA074513,NA,NA,Approved,Nucleus<br>Vesicles,Breast cancer:1.32e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 26.2,Expressed in all,NA,NA
FAM177A1,C14orf24,ENSG00000151327,Family with sequence similarity 177 member A1,14,35044907-35113130,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA053222, HPA055440",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Ovarian cancer:8.51e-5 (favourable), Head and neck cancer:9.70e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,prostate: 103.2,Expressed in all,NA,NA
FAM192A,"C16orf94, NIP30",ENSG00000172775,Family with sequence similarity 192 member A,16,57152466-57186116,Predicted intracellular proteins,Evidence at protein level,"HPA054382, HPA059652",Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 175.9,Expressed in all,NA,NA
FAM198A,"C3orf41, DKFZP434B172",ENSG00000144649,Family with sequence similarity 198 member A,3,42979267-43060211,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA047726,Approved,NA,Supported,Vesicles,NA,Mixed,Mixed,NA,NA,fallopian tube: 15.7,Cell line enhanced,NA,AN3-CA: 3.7;RPMI-8226: 3.0;T-47d: 7.5
FAM207A,"C21orf70, PRED56",ENSG00000160256,Family with sequence similarity 207 member A,21,44940010-44976989,Predicted intracellular proteins,Evidence at protein level,"CAB034178, HPA036354",Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Liver cancer:7.04e-4 (unfavourable), Renal cancer:7.80e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 20.8,Expressed in all,NA,NA
FAM212A,"C3orf54, INKA1",ENSG00000185614,Family with sequence similarity 212 member A,3,49803254-49805030,Predicted intracellular proteins,Evidence at protein level,HPA041879,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Head and neck cancer:1.96e-4 (favourable),Expressed in all,Tissue enhanced,NA,skin: 24.4,lung: 7.0,Cell line enhanced,NA,HEL: 60.9;HMC-1: 39.3;THP-1: 28.1;U-937: 27.1
FAM219A,"bA573M23.5, C9orf25, FLJ39031",ENSG00000164970,Family with sequence similarity 219 member A,9,34398184-34458570,Predicted intracellular proteins,Evidence at protein level,"HPA019338, HPA052909",Uncertain,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Liver cancer:1.98e-5 (unfavourable), Renal cancer:5.54e-5 (unfavourable), Pancreatic cancer:2.46e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 76.1,Expressed in all,NA,NA
FAM220A,"ACPIN1, C7orf70, MGC12966, SIPAR",ENSG00000178397,Family with sequence similarity 220 member A,7,6329409-6348981,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA055050,NA,NA,Approved,Vesicles,"Liver cancer:5.17e-6 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 102.3,Expressed in all,NA,NA
FAM3B,"2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44",ENSG00000183844,Family with sequence similarity 3 member B,21,41304212-41357431,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015885, HPA029777",Approved,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,duodenum: 162.1;small intestine: 166.8,stomach: 124.0,Cell line enhanced,NA,CACO-2: 16.2;CAPAN-2: 10.8;Hep G2: 22.1;RPMI-8226: 62.5
FAM43A,FLJ90022,ENSG00000185112,Family with sequence similarity 43 member A,3,194686544-194689037,Predicted intracellular proteins,Evidence at protein level,HPA048345,Uncertain,NA,Approved,Vesicles,Urothelial cancer:9.96e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,spleen: 34.0,placenta: 18.2,Cell line enhanced,NA,HUVEC TERT2: 113.2;NB-4: 52.7;PC-3: 59.3;TIME: 55.9
FAM69B,"C9orf136, MGC20262",ENSG00000165716,Family with sequence similarity 69 member B,9,136712570-136724050,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046812, HPA054443",Uncertain,NA,Approved,Nucleus<br>Nuclear bodies<br>Vesicles,"Colorectal cancer:1.77e-5 (unfavourable), Pancreatic cancer:9.48e-5 (favourable)",Expressed in all,Mixed,NA,NA,placenta: 29.6,Cell line enhanced,NA,EFO-21: 67.2;HEK93: 59.7;HUVEC TERT2: 67.6
FAM78A,"C9orf59, FLJ00024",ENSG00000126882,Family with sequence similarity 78 member A,9,131258076-131276547,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021472, HPA023914",Uncertain,NA,Uncertain,Nucleus<br>Vesicles,"Head and neck cancer:2.00e-4 (favourable), Cervical cancer:3.67e-4 (favourable)",Expressed in all,Mixed,NA,NA,lymph node: 27.4,Cell line enhanced,NA,BEWO: 37.7;HEL: 34.3;HL-60: 30.4;NB-4: 37.9;THP-1: 35.7;U-937: 27.8
FAM78B,NA,ENSG00000188859,Family with sequence similarity 78 member B,1,166057426-166166969,Predicted intracellular proteins,Evidence at transcript level,"HPA052789, HPA073246",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,NA,Mixed,Not detected,NA,NA,"adipose tissue,cerebral cortex,duodenum,stomach,testis: 0.2",Group enriched,7,HDLM-2: 8.8;SK-MEL-30: 6.5;U-2 OS: 2.3;WM-115: 2.2
FAM86B1,MGC16279,ENSG00000186523,Family with sequence similarity 86 member B1,8,12182096-12194133,Predicted intracellular proteins,Evidence at transcript level,"HPA041610, HPA055718",Uncertain,NA,Uncertain,Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 4.5,endometrium: 2.6,Mixed,NA,NA
FAM86B2,NA,ENSG00000145002,Family with sequence similarity 86 member B2,8,12425614-12436343,Predicted intracellular proteins,Evidence at protein level,"HPA041610, HPA055718",Uncertain,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,fallopian tube: 4.3,thyroid gland: 2.3,Cell line enhanced,NA,hTERT-HME1: 5.2;RPMI-8226: 11.6;SCLC-21H: 5.5
FAM89A,"C1orf153, MGC15887",ENSG00000182118,Family with sequence similarity 89 member A,1,231018958-231040246,Predicted intracellular proteins,Evidence at protein level,"HPA059052, HPA059578",Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:1.75e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 98.7,Cell line enhanced,NA,BEWO: 141.2
FAM98A,DKFZP564F0522,ENSG00000119812,Family with sequence similarity 98 member A,2,33583658-33599382,Predicted intracellular proteins,Evidence at protein level,"HPA036250, HPA036251",Uncertain,NA,Supported,Vesicles,"Liver cancer:4.86e-7 (unfavourable), Thyroid cancer:8.18e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 127.4,Expressed in all,NA,NA
FAM98B,FLJ38426,ENSG00000171262,Family with sequence similarity 98 member B,15,38454127-38487710,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008320, HPA008502",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 32.1,Expressed in all,NA,NA
FANCL,"FAAP43, FLJ10335, PHF9, Pog",ENSG00000115392,Fanconi anemia complementation group L,2,58159243-58241372,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033842, HPA036685, HPA036686",Supported,NA,Approved,Nuclear bodies<br>Vesicles,"Renal cancer:1.12e-7 (unfavourable), Liver cancer:2.81e-7 (unfavourable), Urothelial cancer:7.80e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 44.6,Expressed in all,NA,NA
FBXO46,"20D7-FC4, Fbx46, FBXO34L",ENSG00000177051,F-box protein 46,19,45710629-45730904,Predicted intracellular proteins,Evidence at protein level,HPA049390,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,"Urothelial cancer:5.09e-6 (favourable), Endometrial cancer:2.13e-5 (unfavourable), Liver cancer:1.11e-4 (unfavourable), Renal cancer:5.33e-4 (unfavourable), Head and neck cancer:5.44e-4 (favourable), Pancreatic cancer:8.11e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 17.7,Expressed in all,NA,NA
FBXW11,"BTRC2, BTRCP2, Fbw11, Fbw1b, FBXW1B, Hos, KIAA0696",ENSG00000072803,F-box and WD repeat domain containing 11,5,171861549-172006873,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA062578, HPA072204",Approved,NA,Approved,Nucleoli<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 72.6,Expressed in all,NA,NA
FBXW7,"AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10",ENSG00000109670,F-box and WD repeat domain containing 7,4,152321259-152536101,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB013793, CAB029987",Supported,NA,Supported,Nucleoplasm<br>Vesicles,Renal cancer:1.52e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,skin: 87.4,Expressed in all,NA,NA
FCHO2,NA,ENSG00000157107,FCH domain only 2,5,72955981-73090522,Predicted intracellular proteins,Evidence at protein level,"HPA037685, HPA037686, HPA077850",Enhanced,NA,Approved,Vesicles<br>Centrosome<br>Cytosol,Renal cancer:7.00e-5 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 39.6,Mixed,NA,NA
FERMT3,"KIND3, MGC10966, MIG-2, MIG2B, UNC112C, URP2",ENSG00000149781,Fermitin family member 3,11,64206678-64223886,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA065231,NA,NA,Approved,Vesicles,"Renal cancer:2.12e-5 (unfavourable), Endometrial cancer:9.89e-4 (favourable)",Expressed in all,Tissue enhanced,NA,bone marrow: 114.2,lymph node: 101.2,Cell line enhanced,NA,HEL: 276.6;HMC-1: 277.8
FES,FPS,ENSG00000182511,"FES proto-oncogene, tyrosine kinase",15,90883695-90895776,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001376,Approved,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,Colorectal cancer:5.78e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 96.5,Cell line enhanced,NA,HEL: 56.3;HL-60: 45.0;HMC-1: 100.9;NB-4: 46.6;THP-1: 73.8
FGD6,"FLJ11183, ZFYVE24",ENSG00000180263,"FYVE, RhoGEF and PH domain containing 6",12,95076749-95217482,Predicted intracellular proteins,Evidence at protein level,HPA007974,Approved,NA,Approved,Vesicles,"Renal cancer:5.46e-6 (unfavourable), Pancreatic cancer:4.62e-5 (unfavourable), Prostate cancer:9.83e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 9.4,Mixed,NA,NA
FGFR2,"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25",ENSG00000066468,Fibroblast growth factor receptor 2,10,121478334-121598458,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB010886, HPA035305, HPA056562",Uncertain,NA,Approved,Vesicles,"Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)",Expressed in all,Mixed,NA,NA,skin: 129.4,Cell line enhanced,NA,AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFRL1,NA,ENSG00000127418,Fibroblast growth factor receptor-like 1,4,1009936-1026897,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB026019, HPA068828",Approved,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 67.6,Mixed,NA,NA
FIG4,"ALS11, CMT4J, dJ249I4.1, hSac3, KIAA0274, SAC3",ENSG00000112367,FIG4 phosphoinositide 5-phosphatase,6,109691312-109825428,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017823, HPA068859",Approved,NA,Approved,Vesicles<br>Lipid droplets,"Liver cancer:4.73e-4 (unfavourable), Breast cancer:5.91e-4 (unfavourable), Renal cancer:8.19e-4 (favourable), Colorectal cancer:8.42e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 33.1,Expressed in all,NA,NA
FJX1,"FLJ22416, FLJ25593",ENSG00000179431,Four jointed box 1,11,35618419-35620868,Predicted secreted proteins,Evidence at protein level,HPA059220,Uncertain,NA,Approved,Vesicles,"Renal cancer:9.24e-9 (unfavourable), Urothelial cancer:6.56e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 22.4,endometrium: 8.8,Mixed,NA,NA
FKBP10,"FKBP6, FLJ20683, FLJ22041, FLJ23833, hFKBP65",ENSG00000141756,FK506 binding protein 10,17,41812680-41823217,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA051171, HPA057021",Enhanced,NA,Approved,Vesicles,"Renal cancer:0.00e+0 (unfavourable), Thyroid cancer:3.43e-5 (unfavourable), Cervical cancer:4.16e-4 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,placenta: 84.7,Mixed,NA,NA
FKBP1B,"FKBP12.6, FKBP1L, FKBP9, OTK4, PPIase",ENSG00000119782,FK506 binding protein 1B,2,24049701-24063681,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA045572, HPA051798",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 24.4,duodenum: 18.6,Cell line enhanced,NA,Hep G2: 30.2;NTERA-2: 41.7;SH-SY5Y: 31.9;TIME: 30.3
FKBP9,"FKBP60, FKBP63",ENSG00000122642,FK506 binding protein 9,7,32957404-33006931,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012595, HPA055256",Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Mitochondria,"Urothelial cancer:7.02e-6 (unfavourable), Head and neck cancer:2.02e-4 (unfavourable), Cervical cancer:4.22e-4 (unfavourable), Glioma:8.06e-4 (unfavourable), Liver cancer:8.69e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 110.4,Mixed,NA,NA
FLG,NA,ENSG00000143631,Filaggrin,1,152302175-152325203,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002210, HPA027505, HPA030188, HPA030189",Enhanced,NA,Supported,Vesicles,NA,Tissue enriched,Tissue enriched,26,skin: 548.3,breast: 21.1,Cell line enhanced,NA,HaCaT: 8.9;NTERA-2: 3.1;U-2 OS: 2.5;U-2197: 2.4
FNDC11,"C20orf195, MGC5356",ENSG00000125531,Fibronectin type III domain containing 11,20,63547891-63556708,Predicted intracellular proteins,Evidence at protein level,HPA041341,NA,NA,Approved,Nucleoplasm<br>Vesicles<br>Aggresome,NA,Mixed,Tissue enriched,19,testis: 53.0,epididymis: 2.8,Cell line enhanced,NA,CAPAN-2: 4.5;EFO-21: 2.5;SH-SY5Y: 3.4
FOSB,"AP-1, DKFZp686C0818, G0S3, GOS3, GOSB, MGC42291",ENSG00000125740,"FosB proto-oncogene, AP-1 transcription factor subunit",19,45467995-45475179,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB010267, HPA054663",Approved,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,gallbladder: 558.7,Cell line enhanced,NA,HMC-1: 11.7;SK-BR-3: 7.4
FOXI1,"FKHL10, FREAC6",ENSG00000168269,Forkhead box I1,5,170105897-170109725,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071469,Enhanced,NA,Uncertain,Nucleoli<br>Vesicles,NA,Group enriched,Tissue enhanced,NA,breast: 10.4;kidney: 20.0,salivary gland: 6.2,Cell line enhanced,NA,MCF7: 1.2
FOXJ3,KIAA1041,ENSG00000198815,Forkhead box J3,1,42176539-42335877,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA067284,NA,NA,Approved,Nucleoplasm<br>Nuclear speckles<br>Vesicles,"Renal cancer:4.51e-7 (unfavourable), Liver cancer:5.17e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 40.1,Expressed in all,NA,NA
FOXK2,"ILF, ILF1",ENSG00000141568,Forkhead box K2,17,82519713-82644662,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA027523,Approved,NA,Supported,Nucleoplasm<br>Vesicles,Liver cancer:1.24e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 53.2,Expressed in all,NA,NA
FOXN2,HTLF,ENSG00000170802,Forkhead box N2,2,48314637-48379294,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003485,Supported,NA,Supported,Nucleus<br>Vesicles,"Renal cancer:2.81e-5 (unfavourable), Glioma:5.14e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 36.4,Expressed in all,NA,NA
FPGT,GFPP,ENSG00000254685,Fucose-1-phosphate guanylyltransferase,1,74198212-74234086,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA072331,NA,NA,Uncertain,Vesicles,Liver cancer:2.30e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 32.8,Expressed in all,NA,NA
FPGT-TNNI3K,NA,ENSG00000259030,FPGT-TNNI3K readthrough,1,74198235-74543982,Predicted intracellular proteins,Evidence at protein level,HPA072331,NA,NA,Approved,Vesicles,NA,Not detected,Mixed,NA,NA,heart muscle: 5.7,Cell line enhanced,NA,SiHa: 3.3
FRAT1,NA,ENSG00000165879,"FRAT1, WNT signaling pathway regulator",10,97319267-97321915,Predicted intracellular proteins,Evidence at protein level,"CAB046472, HPA055258",Approved,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:6.36e-5 (favourable), Head and neck cancer:2.75e-4 (favourable), Cervical cancer:5.92e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 9.2,Mixed,NA,NA
FSTL1,"FRP, FSL1, OCC-1, OCC1, tsc36",ENSG00000163430,Follistatin like 1,3,120392293-120451253,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035251, HPA040815",Uncertain,NA,Approved,Vesicles<br>Cytosol,Renal cancer:1.33e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 656.3,Cell line enhanced,NA,BJ: 1888.8;fHDF/TERT166: 2153.3;HBF TERT88: 1729.6
FTCDNL1,FONG,ENSG00000226124,Formiminotransferase cyclodeaminase N-terminal like,2,199760544-199851173,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA065748,NA,NA,Uncertain,Vesicles,"Renal cancer:3.31e-4 (favourable), Thyroid cancer:5.74e-4 (unfavourable)",Mixed,Mixed,NA,NA,thyroid gland: 12.0,Mixed,NA,NA
FTO,"ALKBH9, KIAA1752, MGC5149",ENSG00000140718,"FTO, alpha-ketoglutarate dependent dioxygenase",16,53701692-54158512,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB017123, HPA041086, HPA068695",Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 87.0,Expressed in all,NA,NA
FUK,FLJ39408,ENSG00000157353,Fucokinase,16,70454421-70480274,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041971,Approved,NA,Approved,Vesicles,"Urothelial cancer:8.38e-4 (favourable), Renal cancer:8.91e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 13.9,Mixed,NA,NA
FUT4,"CD15, ELFT, FCT3A, FUC-TIV",ENSG00000196371,Fucosyltransferase 4,11,94543840-94549898,Predicted membrane proteins,Evidence at protein level,"CAB000014, CAB016129",Enhanced,NA,Enhanced,Vesicles,Lung cancer:3.64e-4 (unfavourable),Expressed in all,Tissue enriched,5,bone marrow: 62.9,duodenum: 12.4,Cell line enhanced,NA,HL-60: 29.6;THP-1: 31.3;U-937: 25.8
FXYD6-FXYD2,NA,ENSG00000255245,FXYD6-FXYD2 readthrough,11,117820163-117876667,Predicted membrane proteins,Evidence at transcript level,"HPA068838, HPA075209",Approved,NA,Approved,Nuclear membrane<br>Vesicles,NA,Not detected,Tissue enhanced,NA,kidney: 5.6,salivary gland: 2.1,Group enriched,6,MOLT-4: 5.2;RPTEC TERT1: 5.3
FYCO1,"FLJ13335, ZFYVE7",ENSG00000163820,FYVE and coiled-coil domain containing 1,3,45917899-45995824,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA035526, HPA057966",Uncertain,NA,Enhanced,Vesicles,Renal cancer:3.33e-11 (favourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 91.9,Expressed in all,NA,NA
G2E3,"FLJ20333, KIAA1333, PHF7B",ENSG00000092140,G2/M-phase specific E3 ubiquitin protein ligase,14,30559123-30620063,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001601,Approved,NA,Supported,Vesicles<br>Cytosol,NA,Expressed in all,Tissue enriched,6,testis: 80.4,thyroid gland: 12.9,Mixed,NA,NA
G6PD,G6PD1,ENSG00000160211,Glucose-6-phosphate dehydrogenase,X,154531391-154547572,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000247, HPA000834",Enhanced,NA,Approved,Vesicles<br>Microtubule organizing center<br>Cytosol,Liver cancer:9.45e-13 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 107.0,Expressed in all,NA,NA
GAB1,NA,ENSG00000109458,GRB2 associated binding protein 1,4,143336762-143474568,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB034333, HPA049599",Enhanced,NA,Approved,Vesicles,Renal cancer:3.91e-5 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 32.2,Cell line enhanced,NA,REH: 67.9
GABARAP,"ATG8A, MM46",ENSG00000170296,GABA type A receptor-associated protein,17,7240014-7242770,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA065883,NA,NA,Approved,Vesicles,Pancreatic cancer:9.52e-5 (favourable),Expressed in all,Expressed in all,NA,NA,epididymis: 763.1,Expressed in all,NA,NA
GABARAPL1,"APG8L, ATG8B, ATG8L, gec1",ENSG00000139112,GABA type A receptor associated protein like 1,12,10212458-10223130,Predicted intracellular proteins,Evidence at protein level,"HPA051386, HPA065883",Approved,NA,Approved,Vesicles,"Renal cancer:8.19e-8 (favourable), Liver cancer:2.36e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 432.0,Cell line enhanced,NA,HHSteC: 208.2;SiHa: 253.0
GABRD,NA,ENSG00000187730,Gamma-aminobutyric acid type A receptor delta subunit,1,2019298-2030758,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA044371,Enhanced,NA,Uncertain,Golgi apparatus<br>Vesicles,Renal cancer:4.12e-8 (unfavourable),Expressed in all,Tissue enriched,12,cerebral cortex: 34.0,testis: 2.7,Cell line enhanced,NA,EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
GAD1,GAD,ENSG00000128683,Glutamate decarboxylase 1,2,170813213-170861151,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004415, HPA031949, HPA058412, CAB078176",Enhanced,Supported,Approved,Vesicles,"Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)",Tissue enhanced,Tissue enriched,6,cerebral cortex: 75.3,parathyroid gland: 11.8,Cell line enhanced,NA,HEL: 55.7
GAK,DNAJC26,ENSG00000178950,Cyclin G associated kinase,4,849276-932373,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027405, HPA027459, HPA027463",Approved,NA,Enhanced,Golgi apparatus<br>Vesicles,"Renal cancer:1.70e-6 (favourable), Urothelial cancer:7.41e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,duodenum: 51.5,Expressed in all,NA,NA
GAL,"GAL-GMAP, GALN, GLNN, GMAP",ENSG00000069482,Galanin and GMAP prepropeptide,11,68683779-68691175,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA049864,Enhanced,Supported,Approved,Golgi apparatus<br>Vesicles,"Endometrial cancer:1.22e-4 (unfavourable), Lung cancer:8.17e-4 (unfavourable)",Mixed,Tissue enhanced,NA,appendix: 18.1;smooth muscle: 12.1,colon: 5.2,Cell line enhanced,NA,CACO-2: 193.9;K-562: 111.4;NB-4: 277.5;SH-SY5Y: 179.1
GAL3ST1,CST,ENSG00000128242,Galactose-3-O-sulfotransferase 1,22,30554635-30574587,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA001220,Approved,NA,Approved,Vesicles,Renal cancer:1.79e-4 (unfavourable),Tissue enriched,Tissue enhanced,NA,cerebral cortex: 18.0;duodenum: 23.2;small intestine: 27.0,kidney: 10.1,Cell line enhanced,NA,A549: 25.1;EFO-21: 13.7
GALNT4,GalNAc-T4,ENSG00000257594,Polypeptide N-acetylgalactosaminyltransferase 4,12,89519408-89524806,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA076116,NA,NA,Supported,Golgi apparatus<br>Vesicles,NA,Mixed,Mixed,NA,NA,stomach: 31.0,Cell line enhanced,NA,PC-3: 20.4
GALNT5,GalNAc-T5,ENSG00000136542,Polypeptide N-acetylgalactosaminyltransferase 5,2,157257598-157314211,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008963, HPA009035",Approved,NA,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol,NA,Mixed,Tissue enhanced,NA,lung: 18.4;rectum: 19.7;stomach: 16.8,colon: 13.9,Cell line enhanced,NA,A-431: 60.2;BJ hTERT+: 63.9;fHDF/TERT166: 72.0;HaCaT: 69.5;LHCN-M2: 65.2
GALNT8,GALNAC-T8,ENSG00000130035,Polypeptide N-acetylgalactosaminyltransferase 8,12,4720341-4851927,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012638, HPA014418, HPA073461",Approved,NA,Approved,Vesicles,NA,Tissue enhanced,Group enriched,7,cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5,appendix: 3.2,Cell line enhanced,NA,Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
GALNT9,GALNAC-T9,ENSG00000182870,Polypeptide N-acetylgalactosaminyltransferase 9,12,132196372-132329349,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA075016,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 29.4,thyroid gland: 6.3,Cell line enriched,6,U-87 MG: 30.6
GARNL3,"bA356B19.1, DKFZp761J1523",ENSG00000136895,GTPase activating Rap/RanGAP domain like 3,9,127224265-127393660,Predicted intracellular proteins,Evidence at protein level,"HPA022433, HPA028757, HPA074886",Uncertain,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,parathyroid gland: 15.5,Cell line enhanced,NA,SH-SY5Y: 3.7
GCG,"GLP1, GLP2, GRPP",ENSG00000115263,Glucagon,2,162142873-162152404,Predicted secreted proteins,Evidence at protein level,"CAB000040, HPA036760, HPA036761",Enhanced,NA,Supported,Endoplasmic reticulum<br>Vesicles,NA,Tissue enriched,Tissue enhanced,NA,pancreas: 346.3;rectum: 137.2;small intestine: 123.9,colon: 69.4,Group enriched,7,EFO-21: 100.6;U-2 OS: 158.1
GCM1,"GCMA, hGCMa",ENSG00000137270,Glial cells missing homolog 1,6,53126964-53148829,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA011343,Enhanced,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,21,placenta: 29.1,kidney: 1.3,Cell line enriched,25,BEWO: 38.0
GCNA,"ACRC, NAAR1",ENSG00000147174,Germ cell nuclear acidic peptidase,X,71578411-71613583,Predicted intracellular proteins,Evidence at protein level,HPA023476,Enhanced,NA,Approved,Vesicles,NA,Mixed,Group enriched,5,adrenal gland: 5.9;testis: 20.6,spleen: 2.4,Mixed,NA,NA
GCNT3,"C2/4GnT, C2GnT-M, C2GnT2",ENSG00000140297,"Glucosaminyl (N-acetyl) transferase 3, mucin type",15,59594875-59640239,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011154,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,"Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable)",Tissue enhanced,Tissue enhanced,NA,colon: 142.2;gallbladder: 118.0;rectum: 134.6;small intestine: 138.4,duodenum: 97.7,Cell line enriched,6,A549: 133.3
GCSH,NA,ENSG00000140905,Glycine cleavage system protein H,16,81081938-81096425,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041368,Approved,NA,Approved,Vesicles,Renal cancer:6.26e-6 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 157.3,Expressed in all,NA,NA
GDE1,MIR16,ENSG00000006007,Glycerophosphodiester phosphodiesterase 1,16,19501689-19522145,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA074747,NA,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,"Renal cancer:3.12e-5 (favourable), Liver cancer:7.52e-5 (unfavourable), Colorectal cancer:3.12e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 67.9,Expressed in all,NA,NA
GDF11,BMP-11,ENSG00000135414,Growth differentiation factor 11,12,55743280-55757278,Predicted secreted proteins,Evidence at protein level,"HPA060985, HPA069609",Enhanced,NA,Approved,Vesicles,Pancreatic cancer:1.08e-4 (favourable),Expressed in all,Mixed,NA,NA,"cerebral cortex,seminal vesicle: 13.3",Cell line enhanced,NA,HMC-1: 112.3
GDF6,"BMP13, KFS, KFS1, SGM1",ENSG00000156466,Growth differentiation factor 6,8,96142330-96160792,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA045206,Uncertain,NA,Supported,Nucleoplasm<br>Nuclear membrane<br>Vesicles,Renal cancer:2.17e-4 (unfavourable),Tissue enhanced,Tissue enhanced,NA,placenta: 15.1,gallbladder: 3.8,Cell line enriched,7,LHCN-M2: 27.7
GDI1,"FLJ41411, GDIL, MRX41, MRX48, OPHN2, RABGDIA, XAP-4",ENSG00000203879,GDP dissociation inhibitor 1,X,154436913-154443467,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012979, HPA049290, HPA057668",Enhanced,NA,Approved,Vesicles,"Colorectal cancer:3.83e-5 (unfavourable), Breast cancer:6.84e-4 (unfavourable)",Expressed in all,Tissue enriched,5,cerebral cortex: 532.0,smooth muscle: 101.3,Expressed in all,NA,NA
GDNF,"ATF1, ATF2, HFB1-GDNF",ENSG00000168621,Glial cell derived neurotrophic factor,5,37812677-37839686,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB005210, HPA070283",Supported,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,placenta: 7.0,Cell line enhanced,NA,hTEC/SVTERT24-B: 41.1;U-87 MG: 12.1;WM-115: 45.1
GFPT2,GFAT2,ENSG00000131459,Glutamine-fructose-6-phosphate transaminase 2,5,180300690-180353387,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA056892, HPA059910",Uncertain,NA,Supported,Vesicles,"Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 90.9,appendix: 25.7,Cell line enhanced,NA,ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1
GFRA2,"GDNFRB, NTNRA, RETL2, TRNR2",ENSG00000168546,GDNF family receptor alpha 2,8,21690403-21812357,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA024704, CAB032791",Uncertain,NA,Uncertain,Vesicles,NA,Tissue enriched,Tissue enhanced,NA,thyroid gland: 13.4,spleen: 9.5,Group enriched,12,HEL: 8.1;HMC-1: 17.5;WM-115: 3.6
GGA1,NA,ENSG00000100083,"Golgi associated, gamma adaptin ear containing, ARF binding protein 1",22,37608475-37633564,Predicted intracellular proteins,Evidence at protein level,"HPA048280, HPA051016",Supported,NA,Supported,Nucleoplasm<br>Vesicles,"Pancreatic cancer:4.86e-4 (favourable), Liver cancer:6.29e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 199.2,Expressed in all,NA,NA
GGT1,"CD224, D22S672, D22S732, GGT",ENSG00000100031,Gamma-glutamyltransferase 1,22,24583750-24629005,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA045635, HPA047534, HPA065444",Supported,NA,Approved,Vesicles,"Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable)",Expressed in all,Tissue enhanced,NA,kidney: 161.2,small intestine: 95.9,Cell line enhanced,NA,HDLM-2: 148.2;Karpas-707: 162.6;RPMI-8226: 159.9;RPTEC TERT1: 155.8
GGT2,GGT,ENSG00000133475,Gamma-glutamyltransferase 2,22,21207973-21227637,Predicted membrane proteins,Evidence at protein level,"HPA045635, HPA047534, HPA065444",Supported,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,lung: 1.3;thyroid gland: 1.5,"breast,salivary gland: 0.9",Cell line enhanced,NA,HDLM-2: 1.5;HeLa: 2.0;U-2197: 8.2
GGT7,"D20S101, dJ18C9.2, GGTL3, GGTL5",ENSG00000131067,Gamma-glutamyltransferase 7,20,34844720-34872860,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA013204, HPA013339",Approved,NA,Approved,Nucleus<br>Vesicles,Endometrial cancer:1.26e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,"cerebral cortex,parathyroid gland: 50.0",Mixed,NA,NA
GIGYF1,"GYF1, PERQ1",ENSG00000146830,GRB10 interacting GYF protein 1,7,100679507-100689448,Predicted intracellular proteins,Evidence at protein level,"HPA020999, HPA023995",Enhanced,NA,Approved,Vesicles<br>Microtubules,"Pancreatic cancer:1.35e-5 (favourable), Liver cancer:2.30e-4 (unfavourable), Head and neck cancer:7.42e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 35.8,Expressed in all,NA,NA
GIMAP7,"IAN7, MGC27027",ENSG00000179144,"GTPase, IMAP family member 7",7,150514830-150521073,Predicted intracellular proteins,Evidence at protein level,"HPA020266, HPA020268",Enhanced,NA,Approved,Vesicles<br>Cytosol,"Liver cancer:8.98e-5 (favourable), Head and neck cancer:7.43e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 181.4,Group enriched,12,HUVEC TERT2: 74.2;MOLT-4: 60.4
GLB1,"EBP, ELNR1",ENSG00000170266,Galactosidase beta 1,3,32996608-33097230,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB008382, HPA040610, HPA069503",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,Renal cancer:1.14e-5 (favourable),Expressed in all,Expressed in all,NA,NA,epididymis: 122.5,Cell line enriched,5,BEWO: 804.9
GLIPR2,"C9orf19, GAPR-1",ENSG00000122694,GLI pathogenesis related 2,9,36136536-36163913,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA029478,Approved,NA,Uncertain,Vesicles<br>Microtubules,Renal cancer:6.54e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 93.6,Cell line enhanced,NA,TIME: 103.7
GLTPD2,NA,ENSG00000182327,Glycolipid transfer protein domain containing 2,17,4788959-4790390,Predicted secreted proteins,Evidence at protein level,"HPA058295, HPA065267",Uncertain,NA,Approved,Vesicles,NA,Tissue enriched,Tissue enhanced,NA,duodenum: 11.0;kidney: 12.8;liver: 13.8,small intestine: 7.2,Cell line enhanced,NA,CACO-2: 8.6;Hep G2: 9.4
GNAZ,NA,ENSG00000128266,G protein subunit alpha z,22,23070361-23125037,Predicted intracellular proteins,Evidence at protein level,HPA003011,Enhanced,NA,Approved,Vesicles,Endometrial cancer:4.85e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 49.7,seminal vesicle: 23.0,Cell line enhanced,NA,SCLC-21H: 44.4;SH-SY5Y: 24.7
GNG2,NA,ENSG00000186469,G protein subunit gamma 2,14,51826195-51979342,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA003534, CAB018380",Uncertain,Supported,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:3.90e-6 (unfavourable), Pancreatic cancer:1.64e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 185.4,Cell line enhanced,NA,fHDF/TERT166: 108.6;MOLT-4: 89.8;SH-SY5Y: 94.7;WM-115: 245.1
GNL1,HSR1,ENSG00000204590,G protein nucleolar 1 (putative),6,30541377-30557174,Predicted intracellular proteins,Evidence at protein level,"CAB033575, HPA043338, HPA050455",Uncertain,NA,Supported,Vesicles,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 18.8,Mixed,NA,NA
GNPDA1,"GNPDA, GNPI, GPI, HLN, KIAA0060",ENSG00000113552,Glucosamine-6-phosphate deaminase 1,5,141991749-142013041,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000499, HPA046891",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,Liver cancer:2.60e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,kidney: 77.6,Mixed,NA,NA
GNPDA2,SB52,ENSG00000163281,Glucosamine-6-phosphate deaminase 2,4,44682200-44726595,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000499, HPA046891",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 32.4,Mixed,NA,NA
GOLGA4,"GCP2, GOLG, golgin-240, p230",ENSG00000144674,Golgin A4,3,37243177-37366751,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035102,Supported,NA,Supported,Golgi apparatus<br>Vesicles<br>Cytosol,Renal cancer:3.62e-6 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 81.0,Expressed in all,NA,NA
GOLPH3,"GOPP1, GPP34, MIDAS, Vps74",ENSG00000113384,Golgi phosphoprotein 3,5,32124704-32174350,Predicted intracellular proteins,Evidence at protein level,"HPA044564, HPA055841",Approved,NA,Supported,Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,gallbladder: 120.5,Expressed in all,NA,NA
GOLT1B,"CGI-141, GOT1, YMR292W",ENSG00000111711,Golgi transport 1B,12,21501781-21518408,Predicted membrane proteins,Evidence at protein level,"HPA055909, HPA066383",Approved,NA,Supported,Nucleoplasm<br>Vesicles,"Renal cancer:4.83e-10 (unfavourable), Liver cancer:1.99e-8 (unfavourable), Pancreatic cancer:2.32e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 42.4,Expressed in all,NA,NA
GPC4,K-glypican,ENSG00000076716,Glypican 4,X,133300103-133415490,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA030836,Approved,NA,Approved,Vesicles,"Renal cancer:1.25e-5 (favourable), Lung cancer:3.51e-4 (favourable)",Expressed in all,Mixed,NA,NA,placenta: 41.7,Cell line enhanced,NA,AF22: 206.9;HAP1: 125.3;NTERA-2: 110.1;RPTEC TERT1: 208.8
GPC6,NA,ENSG00000183098,Glypican 6,13,93226842-94407401,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA017671,Approved,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,gallbladder: 27.3,Cell line enhanced,NA,ASC diff: 42.9;HSkMC: 51.5;U-87 MG: 51.7
GPR108,LUSTR2,ENSG00000125734,G protein-coupled receptor 108,19,6729914-6737603,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041924, HPA041951, HPA063863",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 75.1,Mixed,NA,NA
GPR137C,"DKFZp762F0713, TM7SF1L2",ENSG00000180998,G protein-coupled receptor 137C,14,52553148-52637713,Predicted membrane proteins,Evidence at transcript level,"HPA003640, HPA030763",Uncertain,NA,Approved,Vesicles,NA,Mixed,Group enriched,6,cerebral cortex: 18.0;epididymis: 10.8;testis: 6.8,gallbladder: 2.1,Mixed,NA,NA
GPR17,NA,ENSG00000144230,G protein-coupled receptor 17,2,127645864-127652639,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA029766,Enhanced,Supported,Approved,Vesicles,NA,Tissue enriched,Mixed,NA,NA,spleen: 9.6,Cell line enhanced,NA,HeLa: 1.7;REH: 4.0;TIME: 3.5;U-2 OS: 1.8;U-2197: 1.8;U-251 MG: 2.1
GPR174,FKSG79,ENSG00000147138,G protein-coupled receptor 174,X,79170972-79172229,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA041025,Enhanced,NA,Uncertain,Vesicles,NA,Mixed,Tissue enhanced,NA,lymph node: 29.8;spleen: 16.7;tonsil: 17.2,appendix: 12.6,Cell line enriched,8,MOLT-4: 85.1
GPR180,ITR,ENSG00000152749,G protein-coupled receptor 180,13,94601903-94634645,Predicted membrane proteins,Evidence at protein level,HPA047250,Approved,NA,Approved,Vesicles,Renal cancer:3.18e-5 (unfavourable),Expressed in all,Mixed,NA,NA,adipose tissue: 6.3,Mixed,NA,NA
GPR183,EBI2,ENSG00000169508,G protein-coupled receptor 183,13,99294530-99307405,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA028847, CAB033690",Uncertain,NA,Approved,Nuclear membrane<br>Vesicles,Cervical cancer:9.77e-4 (favourable),Expressed in all,Mixed,NA,NA,appendix: 114.8,Group enriched,49,HDLM-2: 144.6;HL-60: 85.1
GPRC5B,RAIG-2,ENSG00000167191,G protein-coupled receptor class C group 5 member B,16,19856691-19886167,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015247,Enhanced,NA,Supported,Nucleus<br>Nucleoli<br>Vesicles,"Colorectal cancer:9.27e-5 (unfavourable), Renal cancer:6.30e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 308.3,testis: 66.2,Cell line enhanced,NA,EFO-21: 84.6;HHSteC: 50.7
GRASP,Tamalin,ENSG00000161835,General receptor for phosphoinositides 1 associated scaffold protein,12,52006940-52015889,Predicted intracellular proteins,Evidence at protein level,"HPA040664, HPA062028",Approved,NA,Approved,Nuclear bodies<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,adipose tissue: 21.6,Cell line enhanced,NA,HUVEC TERT2: 27.8;TIME: 19.7;WM-115: 43.6
GRB10,NA,ENSG00000106070,Growth factor receptor bound protein 10,7,50590063-50793462,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB019423, HPA027502, HPA031818",Approved,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 44.9,Mixed,NA,NA
GRHL1,"LBP-32, MGR, TFCP2L2",ENSG00000134317,Grainyhead like transcription factor 1,2,9951693-10002277,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA005798, HPA006420",Enhanced,NA,Enhanced,Nucleus<br>Golgi apparatus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,esophagus: 111.4;skin: 106.8,parathyroid gland: 50.3,Cell line enhanced,NA,BEWO: 205.8;SK-BR-3: 84.4
GRIPAP1,"DKFZp434P0630, GRASP-1, GRASP1, KIAA1167, MPMGp800B12492Q3",ENSG00000068400,GRIP1 associated protein 1,X,48973720-49002264,Predicted intracellular proteins,Evidence at protein level,"HPA000282, HPA000615",Enhanced,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:3.92e-7 (unfavourable), Urothelial cancer:4.63e-7 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 68.5,Expressed in all,NA,NA
GRK2,"ADRBK1, BARK1",ENSG00000173020,G protein-coupled receptor kinase 2,11,67266410-67286556,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005021, CAB037248, HPA048330",Approved,NA,Approved,Vesicles,Renal cancer:1.25e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 127.3,Expressed in all,NA,NA
GRK4,"GPRK2L, GPRK4",ENSG00000125388,G protein-coupled receptor kinase 4,4,2963608-3040747,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028737, HPA057023",Approved,NA,Supported,Vesicles,NA,Expressed in all,Tissue enriched,9,testis: 74.7,cerebral cortex: 8.1,Cell line enhanced,NA,SCLC-21H: 18.6
GRM1,"GPRC1A, mGlu1, MGLUR1, PPP1R85",ENSG00000152822,Glutamate metabotropic receptor 1,6,146027646-146437598,"Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA015701,Approved,NA,Approved,Vesicles,NA,Not detected,Group enriched,5,cerebral cortex: 7.0;heart muscle: 1.7,kidney: 0.8,Not detected,NA,NA
GSAP,"LOC54103, PION",ENSG00000186088,Gamma-secretase activating protein,7,77310751-77416400,Predicted intracellular proteins,Evidence at protein level,HPA023994,NA,NA,Supported,Vesicles,"Urothelial cancer:4.15e-5 (favourable), Breast cancer:3.36e-4 (favourable), Renal cancer:3.51e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,lung: 26.8,Cell line enhanced,NA,U-937: 13.1
GSKIP,C14orf129,ENSG00000100744,GSK3B interacting protein,14,96363452-96387288,Predicted intracellular proteins,Evidence at protein level,"HPA043054, HPA046782",Approved,NA,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,small intestine: 62.0,Expressed in all,NA,NA
GSPT1,"eRF3a, ETF3A, GST1",ENSG00000103342,G1 to S phase transition 1,16,11868128-11916082,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA052488,Approved,NA,Approved,Vesicles<br>Cytosol,"Colorectal cancer:2.10e-5 (favourable), Renal cancer:3.06e-5 (favourable), Liver cancer:7.94e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 131.6,Expressed in all,NA,NA
GTPBP2,NA,ENSG00000172432,GTP binding protein 2,6,43605316-43629162,Predicted intracellular proteins,Evidence at protein level,"HPA031418, HPA031419",Approved,NA,Enhanced,Vesicles,"Renal cancer:1.44e-15 (unfavourable), Liver cancer:1.08e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 47.4,Expressed in all,NA,NA
GUCY2C,"GUC2C, STAR",ENSG00000070019,Guanylate cyclase 2C,12,14612632-14696585,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA037655, HPA073759",Uncertain,NA,Uncertain,Vesicles,Liver cancer:1.37e-5 (unfavourable),Group enriched,Group enriched,13,colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2,appendix: 4.4,Cell line enhanced,NA,AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
GULP1,"CED-6, CED6, GULP",ENSG00000144366,"GULP, engulfment adaptor PTB domain containing 1",2,188291669-188595931,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA020587,Enhanced,NA,Approved,Vesicles,"Renal cancer:4.25e-6 (favourable), Stomach cancer:6.17e-4 (unfavourable)",Mixed,Mixed,NA,NA,epididymis: 99.9,Cell line enhanced,NA,AF22: 114.8;WM-115: 252.9
GUSB,NA,ENSG00000169919,Glucuronidase beta,7,65960684-65982314,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA036322, HPA036323",Approved,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,breast: 95.9,Expressed in all,NA,NA
GYG1,GYG,ENSG00000163754,Glycogenin 1,3,148991341-149027668,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA030497,Approved,NA,Supported,Vesicles,Liver cancer:6.15e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 210.0,Mixed,NA,NA
GYPC,"CD236, CD236R, Ge, GPC, GYPD",ENSG00000136732,Glycophorin C (Gerbich blood group),2,126655933-126696675,"Blood group antigen proteins, CD markers, Predicted membrane proteins",Evidence at protein level,"HPA008965, CAB009445",Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,bone marrow: 229.7,Cell line enhanced,NA,HHSteC: 315.4;SK-MEL-30: 452.6
HAND2,"bHLHa26, dHand, Hed, Thing2",ENSG00000164107,Heart and neural crest derivatives expressed 2,4,173524969-173530229,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA019591, CAB025576",Approved,NA,Supported,Nucleoplasm<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,endometrium: 83.9,smooth muscle: 77.9,Cell line enriched,21,SH-SY5Y: 660.2
HAPLN1,CRTL1,ENSG00000145681,Hyaluronan and proteoglycan link protein 1,5,83637805-83721613,Predicted secreted proteins,Evidence at protein level,"HPA019105, HPA019482, HPA025238",Enhanced,Approved,Supported,Vesicles,Renal cancer:4.81e-9 (unfavourable),Mixed,Tissue enriched,8,placenta: 103.4,cerebral cortex: 12.8,Group enriched,35,PC-3: 130.7;TIME: 73.5;U-2 OS: 149.3
HAVCR1,"CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1",ENSG00000113249,Hepatitis A virus cellular receptor 1,5,157029413-157059119,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007173, CAB075697",Approved,NA,Approved,Vesicles,"Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)",Tissue enriched,Group enriched,6,colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7,gallbladder: 0.8,Group enriched,5,A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8
HBB,"beta-globin, CD113t-C, HBD",ENSG00000244734,Hemoglobin subunit beta,11,5225464-5229395,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB009526, HPA043234",Enhanced,NA,Approved,Vesicles,NA,Expressed in all,Tissue enriched,9,bone marrow: 78046.6,placenta: 9082.6,Cell line enhanced,NA,HEL: 5.3;SCLC-21H: 5.9;SH-SY5Y: 6.7;U-266/70: 17.4
HBD,NA,ENSG00000223609,Hemoglobin subunit delta,11,5232678-5235370,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB037087, HPA043234",Supported,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,64,bone marrow: 1221.3,placenta: 19.0,Cell line enhanced,NA,HEL: 13.7;HMC-1: 14.7;U-266/70: 73.6;U-266/84: 12.8
HBE1,HBE,ENSG00000213931,Hemoglobin subunit epsilon 1,11,5268345-5505617,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA043234,Approved,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 1.0,placenta: 0.9,Cell line enriched,15,K-562: 5976.4
HBG1,HBG-T2,ENSG00000213934,Hemoglobin subunit gamma 1,11,5248083-5249892,Predicted intracellular proteins,Evidence at protein level,HPA043234,Approved,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,66,placenta: 1087.7,bone marrow: 16.4,Group enriched,298,HEL: 988.4;K-562: 1948.2
HBG2,HBG-T1,ENSG00000196565,Hemoglobin subunit gamma 2,11,5253190-5645789,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB016143, HPA043234",Approved,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,147,placenta: 18253.8,bone marrow: 124.0,Group enriched,301,HEL: 12101.5;K-562: 8442.3
HCST,"DAP10, DKFZP586C1522, KAP10, PIK3AP",ENSG00000126264,Hematopoietic cell signal transducer,19,35902480-35904377,Predicted membrane proteins,Evidence at protein level,"CAB034435, HPA063026",Enhanced,NA,Uncertain,Vesicles,"Renal cancer:1.59e-10 (unfavourable), Melanoma:6.70e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 154.3,Cell line enhanced,NA,HEL: 207.8;HL-60: 107.2;HMC-1: 130.2;THP-1: 117.5;U-937: 204.7
HDHD2,DKFZP564D1378,ENSG00000167220,Haloacid dehalogenase like hydrolase domain containing 2,18,47107403-47150520,Predicted intracellular proteins,Evidence at protein level,"HPA040697, CAB045978, HPA059818",Approved,NA,Approved,Vesicles,Renal cancer:3.52e-5 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 47.9,Expressed in all,NA,NA
HEBP1,"HBP, HEBP",ENSG00000013583,Heme binding protein 1,12,12974864-13000273,Predicted intracellular proteins,Evidence at protein level,"HPA056417, HPA075277",Approved,NA,Approved,Nucleus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,duodenum: 234.7,Expressed in all,NA,NA
HECTD4,"C12orf51, FLJ34154, KIAA0614",ENSG00000173064,HECT domain E3 ubiquitin protein ligase 4,12,112160188-112382439,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041062, HPA045473",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Head and neck cancer:2.97e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 19.4,Expressed in all,NA,NA
HEG1,"HEG, KIAA1237",ENSG00000173706,Heart development protein with EGF like domains 1,3,124965710-125055958,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA010952, HPA011559",Approved,NA,Approved,Vesicles,"Renal cancer:1.93e-5 (unfavourable), Urothelial cancer:1.16e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 65.0,Cell line enhanced,NA,HHSteC: 134.6
HELLS,"LSH, Nbla10143, PASG, SMARCA6",ENSG00000119969,"Helicase, lymphoid-specific",10,94501434-94613905,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004491, HPA063242",Enhanced,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Cervical cancer:1.36e-4 (favourable),Expressed in all,Tissue enhanced,NA,testis: 23.9,lymph node: 14.9,Expressed in all,NA,NA
HEPACAM,"FLJ25530, GLIALCAM, hepaCAM",ENSG00000165478,Hepatic and glial cell adhesion molecule,11,124919193-124936412,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA017613, CAB025486",Enhanced,NA,Approved,Vesicles,NA,Tissue enriched,Tissue enriched,5,cerebral cortex: 80.7,adipose tissue: 15.1,Cell line enriched,27,Hep G2: 18.8
HERC2,"D15F37S1, jdf2, p528",ENSG00000128731,HECT and RLD domain containing E3 ubiquitin protein ligase 2,15,28111040-28322152,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017188, HPA048389",Approved,NA,Approved,Vesicles,Renal cancer:1.41e-7 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 12.1,Cell line enhanced,NA,HEL: 48.6
HES4,bHLHb42,ENSG00000188290,Hes family bHLH transcription factor 4,1,998962-1000172,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA062465,NA,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:3.85e-4 (favourable), Renal cancer:6.27e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 7.5,Cell line enriched,8,HEK93: 180.2
HEXIM1,"CLP-1, EDG1, HIS1, MAQ1",ENSG00000186834,Hexamethylene bisacetamide inducible 1,17,45148502-45152101,Predicted intracellular proteins,Evidence at protein level,"HPA008926, CAB011625",Supported,NA,Enhanced,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,placenta: 36.2,Expressed in all,NA,NA
HFM1,"FLJ36760, FLJ39011, MER3, SEC63D1",ENSG00000162669,"HFM1, ATP dependent DNA helicase homolog",1,91260766-91404869,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035036, HPA035557",NA,NA,Supported,Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Tissue enriched,5,testis: 25.0,ovary: 4.7,Cell line enhanced,NA,AF22: 5.1;AN3-CA: 2.6;K-562: 2.6;SCLC-21H: 2.1;SH-SY5Y: 2.3
HHLA3,NA,ENSG00000197568,HERV-H LTR-associating 3,1,70354805-70385339,Predicted intracellular proteins,Evidence at protein level,HPA031323,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:2.03e-4 (unfavourable),Expressed in all,Mixed,NA,NA,epididymis: 21.7,Expressed in all,NA,NA
HIP1,ILWEQ,ENSG00000127946,Huntingtin interacting protein 1,7,75533300-75738962,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA013606, CAB015334, CAB016402, HPA017964",Enhanced,NA,Enhanced,Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 35.2,Mixed,NA,NA
HLA-DMA,"D6S222E, RING6",ENSG00000204257,"Major histocompatibility complex, class II, DM alpha",6,32948613-32969094,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012750, HPA017295",Enhanced,NA,Approved,Vesicles,"Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable)",Expressed in all,Tissue enhanced,NA,lung: 65.0,fallopian tube: 41.9,Cell line enhanced,NA,U-266/70: 22.0;U-266/84: 9.5;U-698: 52.4
HLA-DPA1,HLA-DP1A,ENSG00000231389,"Major histocompatibility complex, class II, DP alpha 1",6,33064569-33080775,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA017967,Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,lung: 120.6,Cell line enhanced,NA,Daudi: 26.7;HDLM-2: 107.3;REH: 26.8
HLA-E,NA,ENSG00000204592,"Major histocompatibility complex, class I, E",6,30489467-30494205,Predicted membrane proteins,Evidence at protein level,"CAB024589, HPA031454",Enhanced,NA,Approved,Vesicles,Renal cancer:3.86e-4 (unfavourable),Expressed in all,Mixed,NA,NA,skin: 153.4,Cell line enhanced,NA,U-266/70: 73.1
HMCN2,"DKFZp434P0216, FLJ23816",ENSG00000148357,Hemicentin 2,9,130265882-130434123,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA053903, HPA070647",Enhanced,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,small intestine: 11.4,Cell line enhanced,NA,HaCaT: 6.9;RH-30: 17.3;SH-SY5Y: 4.4;U-87 MG: 4.0
HMOX2,HO-2,ENSG00000103415,Heme oxygenase 2,16,4474690-4510347,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB025464, HPA040611",Supported,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 97.6,Expressed in all,NA,NA
HOOK2,HK2,ENSG00000095066,Hook microtubule tethering protein 2,19,12763003-12872740,Predicted intracellular proteins,Evidence at protein level,"HPA043519, HPA050351",Approved,NA,Supported,Vesicles<br>Cytosol,"Prostate cancer:7.59e-5 (unfavourable), Renal cancer:3.28e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 96.0,Expressed in all,NA,NA
HOXA2,HOX1K,ENSG00000105996,Homeobox A2,7,27100354-27102811,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA078220,NA,NA,Approved,Nucleus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 8.1,epididymis: 6.2,Cell line enhanced,NA,AN3-CA: 13.4;HaCaT: 5.3
HP,NA,ENSG00000257017,Haptoglobin,16,72054592-72061055,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB003787, HPA047750",Enhanced,NA,Approved,Vesicles,Renal cancer:6.94e-13 (unfavourable),Tissue enriched,Tissue enriched,182,liver: 28407.0,bone marrow: 155.8,Cell line enhanced,NA,Hep G2: 153.5;HSkMC: 88.2
HPR,NA,ENSG00000261701,Haptoglobin-related protein,16,72063224-72077246,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA047750,Supported,NA,Approved,Vesicles,NA,Tissue enriched,Tissue enriched,24,liver: 444.1,heart muscle: 18.7,Cell line enriched,14,Hep G2: 34.3
HPSE,"HPA, HPSE1, HSE1",ENSG00000173083,Heparanase,4,83292461-83335153,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB009813, HPA055344",NA,NA,Enhanced,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enhanced,NA,parathyroid gland: 20.0,testis: 10.0,Cell line enhanced,NA,Karpas-707: 27.7
HS3ST1,3OST1,ENSG00000002587,Heparan sulfate-glucosamine 3-sulfotransferase 1,4,11393150-11429765,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA002237,Approved,NA,Approved,Vesicles,"Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable)",Mixed,Tissue enhanced,NA,gallbladder: 13.9;ovary: 23.2,urinary bladder: 5.6,Cell line enhanced,NA,CAPAN-2: 12.2;RPTEC TERT1: 9.1;RT4: 8.0;SCLC-21H: 4.3
HS3ST3B1,"30ST3B1, 3OST3B1",ENSG00000125430,Heparan sulfate-glucosamine 3-sulfotransferase 3B1,17,14301083-14349404,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA064126,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,liver: 14.7,lymph node: 7.1,Cell line enhanced,NA,AF22: 20.5;BEWO: 14.3;HSkMC: 14.6;U-251 MG: 16.3
HSD11B1L,"SCDR10, SDR26C2",ENSG00000167733,Hydroxysteroid 11-beta dehydrogenase 1 like,19,5680604-5688523,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA049078,NA,NA,Approved,Vesicles,Head and neck cancer:4.38e-4 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 25.6,fallopian tube: 7.9,Cell line enhanced,NA,SH-SY5Y: 20.1
HSD11B2,SDR9C3,ENSG00000176387,Hydroxysteroid 11-beta dehydrogenase 2,16,67430652-67437553,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"CAB032443, HPA042186, HPA056385",Enhanced,NA,Approved,Vesicles,Renal cancer:9.51e-5 (favourable),Expressed in all,Tissue enhanced,NA,colon: 151.6;kidney: 173.3,salivary gland: 122.5,Cell line enhanced,NA,NTERA-2: 11.4;RPMI-8226: 9.6;RT4: 11.0;SCLC-21H: 17.5;SK-BR-3: 10.0
HSD17B13,"SCDR9, SDR16C3",ENSG00000170509,Hydroxysteroid 17-beta dehydrogenase 13,4,87303789-87322906,Predicted intracellular proteins,Evidence at protein level,HPA029125,Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,"Liver cancer:2.94e-4 (favourable), Lung cancer:7.80e-4 (favourable)",Tissue enriched,Tissue enriched,29,liver: 294.1,adipose tissue: 10.2,Not detected,NA,NA
HSD17B3,SDR12C2,ENSG00000130948,Hydroxysteroid 17-beta dehydrogenase 3,9,96235306-96302152,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA056833,Enhanced,NA,Supported,Vesicles,NA,Mixed,Tissue enriched,15,testis: 74.9,thyroid gland: 4.8,Cell line enhanced,NA,HBEC3-KT: 2.6;HEL: 3.2;U-2 OS: 5.8
HSD17B6,"HSE, RODH, SDR9C6",ENSG00000025423,Hydroxysteroid 17-beta dehydrogenase 6,12,56752161-56787790,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059141,Enhanced,NA,Approved,Nucleus<br>Vesicles,Liver cancer:6.32e-4 (favourable),Tissue enriched,Tissue enriched,10,liver: 930.6,seminal vesicle: 96.0,Cell line enhanced,NA,SCLC-21H: 12.9
HSPA1A,"HSP70-1, HSPA1",ENSG00000204389,Heat shock protein family A (Hsp70) member 1A,6,31815464-31817946,Predicted intracellular proteins,Evidence at protein level,"CAB017451, CAB032815, HPA052504",Supported,NA,Approved,Nucleoplasm<br>Vesicles,Colorectal cancer:1.54e-5 (unfavourable),Expressed in all,Mixed,NA,NA,adrenal gland: 49.9,Cell line enriched,10,HEK93: 3834.6
HSPA1B,HSP70-2,ENSG00000204388,Heat shock protein family A (Hsp70) member 1B,6,31827735-31830255,Predicted intracellular proteins,Evidence at protein level,"CAB008640, HPA052504",Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Tissue enhanced,NA,adrenal gland: 34.3,parathyroid gland: 14.6,Cell line enhanced,NA,A549: 74.8;Karpas-707: 175.2;U-266/70: 30.2
HSPA1L,"HSP70-HOM, hum70t",ENSG00000204390,Heat shock protein family A (Hsp70) member 1 like,6,31809619-31815065,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043285, HPA052504",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,"Ovarian cancer:1.02e-4 (favourable), Renal cancer:4.63e-4 (favourable)",Expressed in all,Tissue enriched,8,testis: 9.8,epididymis: 1.2,Cell line enhanced,NA,HEK93: 2.3
HSPA2,NA,ENSG00000126803,Heat shock protein family A (Hsp70) member 2,14,64535905-64546173,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000798, HPA052504",Enhanced,Approved,Approved,Nucleoplasm<br>Vesicles,"Breast cancer:1.78e-4 (favourable), Lung cancer:9.11e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 188.6,cerebral cortex: 96.4,Cell line enhanced,NA,A549: 67.9;BEWO: 110.2;BJ hTERT+: 80.5;SCLC-21H: 119.3
HSPA6,HSP70B',ENSG00000173110,Heat shock protein family A (Hsp70) member 6,1,161524540-161526910,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017452, HPA028549, HPA052504",Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.98e-5 (unfavourable), Liver cancer:7.26e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 27.8,spleen: 15.1,Cell line enriched,7,Karpas-707: 36.1
HSPA8,"HSC70, HSC71, HSP73, HSPA10",ENSG00000109971,Heat shock protein family A (Hsp70) member 8,11,123057489-123063230,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002056, HPA052504",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Colorectal cancer:6.14e-6 (favourable), Liver cancer:1.93e-4 (unfavourable), Renal cancer:3.81e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 1119.0,Expressed in all,NA,NA
HSPBP1,"FES1, HspBP1",ENSG00000133265,HSPA (Hsp70) binding protein 1,19,55262231-55280381,Predicted intracellular proteins,Evidence at protein level,"CAB005865, HPA071444",Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 40.1,Expressed in all,NA,NA
HTN3,HIS2,ENSG00000205649,Histatin 3,4,70028413-70036538,"Predicted secreted proteins, Transporters",Evidence at protein level,CAB073541,Enhanced,NA,Uncertain,Vesicles,NA,Tissue enhanced,Tissue enriched,1666,salivary gland: 47614.6,ovary: 28.5,Mixed,NA,NA
HTRA3,"Prsp, Tasp",ENSG00000170801,HtrA serine peptidase 3,4,8269765-8307111,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA021187, HPA063810",Approved,NA,Approved,Vesicles,"Renal cancer:1.61e-9 (unfavourable), Thyroid cancer:1.29e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,ovary: 60.9,Cell line enriched,6,U-2197: 168.9
HYKK,"AGPHD1, LOC123688",ENSG00000188266,Hydroxylysine kinase,15,78507564-78537372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040706,Approved,NA,Approved,Vesicles<br>Aggresome,NA,Mixed,Mixed,NA,NA,kidney: 12.5,Cell line enhanced,NA,HEK93: 20.5
ICA1,"ICA69, ICAp69",ENSG00000003147,Islet cell autoantigen 1,7,8113184-8262687,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017646, HPA061452",Approved,NA,Supported,Vesicles<br>Cytosol,Renal cancer:4.23e-8 (favourable),Expressed in all,Mixed,NA,NA,testis: 42.6,Cell line enhanced,NA,SCLC-21H: 73.0;SH-SY5Y: 109.7
IDUA,MPS1,ENSG00000127415,"Iduronidase, alpha-L-",4,986997-1004506,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025901, HPA046979, HPA054254",Enhanced,NA,Supported,Vesicles,"Renal cancer:7.87e-5 (unfavourable), Urothelial cancer:8.04e-5 (favourable), Colorectal cancer:3.13e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 16.5,Cell line enhanced,NA,U-266/70: 43.1
IFI30,"GILT, IFI-30, IP-30, IP30, MGC32056",ENSG00000216490,"IFI30, lysosomal thiol reductase",19,18173162-18178117,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA026650,Approved,NA,Supported,Vesicles<br>Cytosol,NA,Mixed,Expressed in all,NA,NA,appendix: 828.7,Cell line enhanced,NA,Daudi: 385.9;RPMI-8226: 408.1;U-266/84: 467.0
IFIT2,"cig42, G10P2, GARG-39, IFI-54, IFI54, ISG-54K",ENSG00000119922,Interferon induced protein with tetratricopeptide repeats 2,10,89283694-89309276,Predicted intracellular proteins,Evidence at protein level,HPA003408,Approved,NA,Approved,Vesicles,Renal cancer:6.99e-4 (unfavourable),Expressed in all,Mixed,NA,NA,spleen: 39.1,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+: 132.1;BJ hTERT+ SV40 Large T+ RasG12V: 108.9
IFT172,"BBS20, NPHP17, osm-1, SLB, wim",ENSG00000138002,Intraflagellar transport 172,2,27444371-27489789,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA044893,Uncertain,NA,Approved,Vesicles,Liver cancer:6.05e-6 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 33.5,Mixed,NA,NA
IGF1R,"CD221, IGFIR, IGFR, JTK13, MGC18216",ENSG00000140443,Insulin like growth factor 1 receptor,15,98648971-98964530,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB010268, HPA045563",Uncertain,NA,Uncertain,Vesicles,Renal cancer:3.75e-7 (favourable),Expressed in all,Mixed,NA,NA,prostate: 25.0,Mixed,NA,NA
IGF2,"C11orf43, FLJ44734, IGF-II",ENSG00000167244,Insulin like growth factor 2,11,2129112-2141238,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007556, HPA007993",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,Liver cancer:7.12e-4 (favourable),Group enriched,Tissue enriched,18,placenta: 3962.9,fallopian tube: 217.6,Cell line enhanced,NA,CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9
IGF2R,"CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI",ENSG00000197081,Insulin like growth factor 2 receptor,6,159969099-160113507,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009661, HPA011332",Supported,NA,Enhanced,Golgi apparatus<br>Vesicles,"Cervical cancer:2.92e-5 (unfavourable), Breast cancer:3.01e-4 (unfavourable), Urothelial cancer:6.08e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 50.5,Expressed in all,NA,NA
IGFBP3,"BP-53, IBP3",ENSG00000146674,Insulin like growth factor binding protein 3,7,45912245-45921874,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB010360,NA,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:5.07e-7 (unfavourable), Colorectal cancer:1.08e-4 (unfavourable), Liver cancer:1.64e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 2671.0,endometrium: 886.0,Cell line enhanced,NA,fHDF/TERT166: 6647.1;U-2197: 3223.6;U-87 MG: 1735.3
IGFBP5,NA,ENSG00000115461,Insulin like growth factor binding protein 5,2,216672105-216695525,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA059827,NA,NA,Approved,Nuclear bodies<br>Golgi apparatus<br>Vesicles,Endometrial cancer:1.78e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,"cervix, uterine: 2374.4;ovary: 1646.3",fallopian tube: 949.1,Cell line enhanced,NA,BJ: 704.3;BJ hTERT+: 1787.5;T-47d: 500.8;U-138 MG: 702.9
IGFBPL1,bA113O24.1,ENSG00000137142,Insulin like growth factor binding protein like 1,9,38408994-38424447,Predicted secreted proteins,Evidence at protein level,HPA051354,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enriched,8,thyroid gland: 31.5,cerebral cortex: 3.9,Group enriched,6,AF22: 359.4;NTERA-2: 100.5;RH-30: 101.1;SCLC-21H: 438.6;SH-SY5Y: 383.3
IGIP,"C5orf53, LOC492311",ENSG00000182700,IgA inducing protein,5,140125935-140129392,Predicted secreted proteins,Evidence at transcript level,"HPA041877, HPA048615",Approved,NA,Approved,Vesicles,"Renal cancer:6.25e-6 (favourable), Pancreatic cancer:3.94e-4 (favourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 28.6,Mixed,NA,NA
IL1RAP,"C3orf13, IL-1RAcP, IL1R3",ENSG00000196083,Interleukin 1 receptor accessory protein,3,190514051-190659750,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035293,Uncertain,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,liver: 113.0;placenta: 53.7,gallbladder: 19.8,Cell line enhanced,NA,SK-MEL-30: 193.6
IL1RL1,"DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1",ENSG00000115602,Interleukin 1 receptor like 1,2,102311502-102352037,"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007406, HPA007917",Uncertain,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enriched,12,placenta: 289.6,gallbladder: 23.7,Group enriched,6,HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2
IL20RB,"DIRS1, FNDC6, IL-20R2, MGC34923",ENSG00000174564,Interleukin 20 receptor subunit beta,3,136946230-137011085,Predicted membrane proteins,Evidence at protein level,HPA063914,NA,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.44e-4 (unfavourable)",Group enriched,Group enriched,9,esophagus: 56.6;skin: 165.5,breast: 12.4,Cell line enhanced,NA,HaCaT: 70.0;HBEC3-KT: 93.7;HHSteC: 70.6;hTCEpi: 372.4;hTERT-HME1: 73.1
IL2RG,"CD132, CIDX, IMD4, SCIDX1",ENSG00000147168,Interleukin 2 receptor subunit gamma,X,71107404-71112108,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046641, HPA049691",Enhanced,NA,Approved,Vesicles,"Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable)",Expressed in all,Tissue enhanced,NA,lymph node: 273.3;tonsil: 279.4,appendix: 182.3,Cell line enriched,5,Karpas-707: 1646.4
IL31RA,"CRL, CRL3, GLM-R, Glmr, IL-31RA",ENSG00000164509,Interleukin 31 receptor A,5,55851379-55922853,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA051532, HPA068114",Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 3.6,bone marrow: 1.2,Cell line enhanced,NA,hTERT-HME1: 10.7;U-2 OS: 21.6;U-87 MG: 23.4
IL37,"FIL1, FIL1(ZETA), FIL1Z, IL-1F7, IL-1H4, IL-1RP1, IL1F7",ENSG00000125571,Interleukin 37,2,112912971-112918882,Predicted intracellular proteins,Evidence at protein level,"HPA054371, HPA057950",Approved,NA,Supported,Nucleoplasm<br>Vesicles,NA,Tissue enriched,Tissue enriched,7,skin: 162.7,breast: 22.3,Cell line enhanced,NA,BJ hTERT+: 2.2;PC-3: 5.5;RT4: 2.5
IL6,"BSF2, HGF, HSF, IFNB2, IL-6",ENSG00000136244,Interleukin 6,7,22725884-22732002,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB023406, CAB072821",Supported,NA,Approved,Vesicles,Renal cancer:1.10e-11 (unfavourable),Mixed,Tissue enhanced,NA,adipose tissue: 136.4,urinary bladder: 73.6,Group enriched,7,BJ hTERT+: 1844.6;hTEC/SVTERT24-B: 429.5
ILVBL,"209L8, AHAS, FLJ39061, HACL1L, ILV2H, MGC1269, MGC19535",ENSG00000105135,IlvB acetolactate synthase like,19,15114984-15125785,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA067682,Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.91e-8 (favourable), Endometrial cancer:1.52e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 80.2,Expressed in all,NA,NA
INHA,NA,ENSG00000123999,Inhibin alpha subunit,2,219569162-219575713,Predicted secreted proteins,Evidence at protein level,"CAB000047, HPA019141",Enhanced,NA,Approved,Vesicles,Renal cancer:4.03e-5 (unfavourable),Mixed,Tissue enhanced,NA,adrenal gland: 51.5;ovary: 38.0;testis: 106.3,placenta: 14.9,Cell line enhanced,NA,HEL: 3.7;SK-BR-3: 6.8
INHBE,"activin, MGC4638",ENSG00000139269,Inhibin beta E subunit,12,57452323-57459280,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA016843, CAB034017",Enhanced,NA,Approved,Vesicles,Renal cancer:5.66e-8 (unfavourable),Tissue enriched,Tissue enriched,28,liver: 68.1,thyroid gland: 2.4,Cell line enhanced,NA,HHSteC: 43.4;Karpas-707: 57.3;U-266/70: 203.5
INMT,NA,ENSG00000241644,Indolethylamine N-methyltransferase,7,30697985-30757602,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA061343,NA,NA,Approved,Golgi apparatus<br>Vesicles,Liver cancer:5.72e-4 (favourable),Tissue enhanced,Tissue enhanced,NA,lung: 144.8,seminal vesicle: 66.2,Group enriched,6,CACO-2: 13.8;HHSteC: 5.7
INPP1,NA,ENSG00000151689,Inositol polyphosphate-1-phosphatase,2,190343470-190371665,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036698, HPA036699",Supported,NA,Approved,Vesicles,"Thyroid cancer:1.12e-5 (favourable), Urothelial cancer:5.70e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 73.6,Mixed,NA,NA
INSIG1,"CL-6, MGC1405",ENSG00000186480,Insulin induced gene 1,7,155297776-155310235,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA071524,NA,NA,Approved,Vesicles,Thyroid cancer:9.62e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,liver: 281.7,Cell line enhanced,NA,Karpas-707: 871.4
INSR,CD220,ENSG00000171105,Insulin receptor,19,7112255-7294034,"CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"HPA036302, HPA036303",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,ovary: 35.5,Cell line enhanced,NA,Karpas-707: 42.9
INTU,"KIAA1284, PDZD6, PDZK6",ENSG00000164066,Inturned planar cell polarity protein,4,127623271-127726737,Predicted intracellular proteins,Evidence at protein level,"HPA036714, HPA036715",Enhanced,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,epididymis: 6.4,Mixed,NA,NA
IPO9,"FLJ10402, Imp9",ENSG00000198700,Importin 9,1,201829141-201884294,"Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA059540,NA,NA,Approved,Vesicles<br>Cytosol,"Liver cancer:4.11e-5 (unfavourable), Renal cancer:2.86e-4 (unfavourable), Urothelial cancer:5.78e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 30.3,Expressed in all,NA,NA
IQCC,FLJ10547,ENSG00000160051,IQ motif containing C,1,32205661-32208687,Predicted intracellular proteins,Evidence at protein level,"HPA028602, HPA028686",Approved,NA,Supported,Vesicles,"Pancreatic cancer:8.23e-5 (favourable), Testis cancer:3.79e-4 (favourable), Lung cancer:5.65e-4 (favourable)",Expressed in all,Tissue enhanced,NA,testis: 11.6,thyroid gland: 6.0,Mixed,NA,NA
IQSEC1,"ARF-GEP100, BRAG2, GEP100, KIAA0763",ENSG00000144711,IQ motif and Sec7 domain 1,3,12897220-13073117,Predicted intracellular proteins,Evidence at protein level,"HPA038143, HPA038144",Uncertain,NA,Approved,Nucleoli<br>Vesicles,"Renal cancer:3.58e-6 (favourable), Breast cancer:3.03e-5 (unfavourable), Pancreatic cancer:9.07e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 83.3,Cell line enhanced,NA,BEWO: 75.1
IQSEC2,"KIAA0522, MRX1, MRX18, MRX78",ENSG00000124313,IQ motif and Sec7 domain 2,X,53225828-53321328,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA003973,NA,NA,Approved,Vesicles,"Renal cancer:2.00e-4 (unfavourable), Urothelial cancer:2.38e-4 (favourable)",Mixed,Mixed,NA,NA,cerebral cortex: 38.5,Cell line enhanced,NA,A549: 43.0
IRAK1BP1,"AIP70, SIMPL",ENSG00000146243,Interleukin 1 receptor associated kinase 1 binding protein 1,6,78867472-78946440,Predicted intracellular proteins,Evidence at protein level,"HPA035742, HPA035743",Uncertain,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,8,bone marrow: 59.8,"testis,thyroid gland: 7.0",Mixed,NA,NA
IRAK2,NA,ENSG00000134070,Interleukin 1 receptor associated kinase 2,3,10164865-10243743,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB013483, HPA050520",Uncertain,NA,Approved,Vesicles,"Urothelial cancer:6.60e-5 (favourable), Pancreatic cancer:2.26e-4 (unfavourable), Liver cancer:8.35e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,bone marrow: 14.6,Cell line enhanced,NA,BEWO: 31.5;BJ hTERT+: 28.0;CAPAN-2: 30.8;RT4: 38.6
IRAK3,IRAK-M,ENSG00000090376,Interleukin 1 receptor associated kinase 3,12,66188879-66254622,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA043097,Approved,NA,Approved,Vesicles,Renal cancer:6.23e-4 (unfavourable),Mixed,Tissue enhanced,NA,bone marrow: 51.0,adipose tissue: 19.3,Cell line enhanced,NA,HEL: 20.3;HL-60: 24.1;THP-1: 24.3;U-937: 20.5
IRGQ,"FKSG27, IRGQ1",ENSG00000167378,Immunity related GTPase Q,19,43584369-43596135,Predicted intracellular proteins,Evidence at protein level,"HPA043254, HPA050338",Enhanced,NA,Supported,Vesicles,"Pancreatic cancer:3.57e-5 (favourable), Renal cancer:3.92e-4 (favourable), Cervical cancer:5.17e-4 (favourable), Liver cancer:9.60e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 7.2,Mixed,NA,NA
IRX3,IRX-1,ENSG00000177508,Iroquois homeobox 3,16,54283304-54286763,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA062522,NA,NA,Approved,Vesicles,NA,Expressed in all,Tissue enhanced,NA,breast: 96.6,skin: 70.5,Cell line enhanced,NA,NB-4: 129.5;RPTEC TERT1: 178.7;T-47d: 115.6;THP-1: 136.2
IRX4,NA,ENSG00000113430,Iroquois homeobox 4,5,1877413-1887236,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA064094,NA,NA,Uncertain,Nucleus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,prostate: 5.8;skin: 6.9,esophagus: 1.4,Cell line enhanced,NA,BEWO: 43.3;HaCaT: 15.1;HBEC3-KT: 6.7
ISOC1,CGI-111,ENSG00000066583,Isochorismatase domain containing 1,5,129094751-129114028,Predicted intracellular proteins,Evidence at protein level,HPA070307,NA,NA,Approved,Endoplasmic reticulum<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,endometrium: 175.5,Expressed in all,NA,NA
IST1,KIAA0174,ENSG00000182149,"IST1, ESCRT-III associated factor",16,71845996-71931199,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041802, HPA054532",Approved,NA,Supported,Vesicles,"Renal cancer:4.55e-4 (favourable), Urothelial cancer:8.88e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 180.4,Expressed in all,NA,NA
ITIH1,"H1P, IATIH, ITIH",ENSG00000055957,Inter-alpha-trypsin inhibitor heavy chain 1,3,52777592-52792068,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041639, HPA042049",Approved,NA,Approved,Vesicles,Liver cancer:1.89e-5 (favourable),Tissue enriched,Tissue enriched,458,liver: 786.3,spleen: 1.7,Cell line enhanced,NA,ASC diff: 3.6;Hep G2: 1.1;HL-60: 1.0
ITIH4,"H4P, IHRP, ITIHL1",ENSG00000055955,Inter-alpha-trypsin inhibitor heavy chain family member 4,3,52812975-52831479,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001835, HPA003948, CAB072872",Enhanced,NA,Approved,Vesicles,NA,Tissue enriched,Tissue enriched,71,liver: 984.5,skeletal muscle: 13.8,Cell line enhanced,NA,HDLM-2: 2.2;U-266/70: 2.1
ITIH5,MGC10848,ENSG00000123243,Inter-alpha-trypsin inhibitor heavy chain family member 5,10,7559270-7666998,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA038305,Approved,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,placenta: 123.4,Cell line enriched,7,WM-115: 101.4
ITM2B,"BRI, BRI2, BRICD2B, E25B, E3-16",ENSG00000136156,Integral membrane protein 2B,13,48233158-48270357,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA029292, HPA071992",Approved,NA,Enhanced,Golgi apparatus<br>Vesicles,Renal cancer:3.73e-5 (favourable),Expressed in all,Expressed in all,NA,NA,epididymis: 1855.0,Expressed in all,NA,NA
ITPKA,"IP3-3KA, IP3KA",ENSG00000137825,Inositol-trisphosphate 3-kinase A,15,41493393-41503551,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040454,Enhanced,Approved,Approved,Vesicles,"Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)",Mixed,Tissue enhanced,NA,cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8,stomach: 8.9,Cell line enhanced,NA,Hep G2: 22.6
ITPR1,"ACV, Insp3r1, IP3R1, PPP1R94, SCA15, SCA16, SCA29",ENSG00000150995,"Inositol 1,4,5-trisphosphate receptor type 1",3,4493348-4847840,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014765, HPA016487",Approved,NA,Approved,Vesicles,Thyroid cancer:3.43e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 106.8,thyroid gland: 47.4,Cell line enhanced,NA,HDLM-2: 75.1;HeLa: 38.4;U-87 MG: 44.6
ITPR3,IP3R3,ENSG00000096433,"Inositol 1,4,5-trisphosphate receptor type 3",6,33620365-33696574,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA003915, HPA064704",Approved,NA,Uncertain,Vesicles,NA,Expressed in all,Mixed,NA,NA,skin: 65.1,Mixed,NA,NA
ITPRIP,"bA127L20.2, DANGER, KIAA1754",ENSG00000148841,"Inositol 1,4,5-trisphosphate receptor interacting protein",10,104309698-104338404,Predicted membrane proteins,Evidence at protein level,HPA043626,NA,NA,Uncertain,Vesicles,Lung cancer:3.59e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 135.2,Mixed,NA,NA
IZUMO4,C19orf36,ENSG00000099840,IZUMO family member 4,19,2096429-2099593,"Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA045099, HPA048496",Enhanced,NA,Uncertain,Nucleoplasm<br>Vesicles,"Pancreatic cancer:1.69e-4 (favourable), Endometrial cancer:7.08e-4 (favourable)",Mixed,Tissue enriched,52,testis: 341.9,ovary: 6.5,Cell line enhanced,NA,Karpas-707: 6.0;RPMI-8226: 7.2
JAG2,NA,ENSG00000184916,Jagged 2,14,105140981-105168824,Predicted membrane proteins,Evidence at protein level,"CAB025481, HPA030636, HPA050567",Approved,NA,Supported,Vesicles<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,skin: 22.5,adipose tissue: 6.5,Cell line enhanced,NA,HaCaT: 54.2;SCLC-21H: 36.3
JAGN1,"FLJ14602, GL009",ENSG00000171135,Jagunal homolog 1,3,9890554-9894349,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA067610,NA,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 37.9,Expressed in all,NA,NA
JKAMP,"C14orf100, CDA06, HSPC213, HSPC327, JAMP",ENSG00000050130,JNK1/MAPK8-associated membrane protein,14,59484443-59505410,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,"HPA031172, HPA071650",Supported,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:3.09e-6 (unfavourable), Renal cancer:1.36e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 76.2,Expressed in all,NA,NA
JTB,"hJT, PAR",ENSG00000143543,Jumping translocation breakpoint,1,153974269-153977688,"Cancer-related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA006514,Approved,NA,Approved,Vesicles<br>Actin filaments,"Renal cancer:6.65e-9 (unfavourable), Ovarian cancer:7.87e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 116.4,Expressed in all,NA,NA
KAT14,"ATAC2, CRP2BP, CSRP2BP, dJ717M23.1, PRO1194",ENSG00000149474,Lysine acetyltransferase 14,20,18138118-18188387,Predicted intracellular proteins,Evidence at protein level,"CAB034224, HPA068443",Uncertain,NA,Approved,Vesicles,Renal cancer:4.64e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 21.4,Expressed in all,NA,NA
KBTBD4,"BKLHD4, FLJ10450, HSPC252",ENSG00000123444,Kelch repeat and BTB domain containing 4,11,47572197-47579015,Predicted intracellular proteins,Evidence at protein level,"HPA037792, HPA037793",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:2.70e-7 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 48.6,Expressed in all,NA,NA
KCNC1,Kv3.1,ENSG00000129159,Potassium voltage-gated channel subfamily C member 1,11,17734774-17856804,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA047634, HPA048249",Enhanced,NA,Approved,Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol,NA,Tissue enhanced,Tissue enriched,8,cerebral cortex: 18.6,testis: 2.2,Cell line enhanced,NA,RH-30: 3.6;SCLC-21H: 4.2;SH-SY5Y: 2.3
KCNG1,"K13, KCNG, kH2, Kv6.1",ENSG00000026559,Potassium voltage-gated channel modifier subfamily G member 1,20,51003656-51023129,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA039530, HPA040024",Approved,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,endometrium: 23.4;seminal vesicle: 18.1,placenta: 10.1,Cell line enhanced,NA,hTCEpi: 38.3;U-138 MG: 39.5
KCNH1,"eag, eag1, h-eag, Kv10.1",ENSG00000143473,Potassium voltage-gated channel subfamily H member 1,1,210676823-211134180,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA014551, HPA019445",Enhanced,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,6,cerebral cortex: 6.2,testis: 1.0,Cell line enhanced,NA,RH-30: 4.9;SH-SY5Y: 6.8;SK-MEL-30: 4.8;T-47d: 4.3
KCNJ16,"BIR9, Kir5.1",ENSG00000153822,Potassium voltage-gated channel subfamily J member 16,17,70053429-70135608,"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA059563,Approved,NA,Uncertain,Vesicles,"Renal cancer:9.61e-7 (favourable), Thyroid cancer:6.58e-4 (favourable)",Group enriched,Group enriched,8,kidney: 209.1;parathyroid gland: 269.7;thyroid gland: 235.1,seminal vesicle: 31.5,Cell line enriched,18,RPTEC TERT1: 211.8
KCNK1,"DPK, K2p1.1, TWIK-1",ENSG00000135750,Potassium two pore domain channel subfamily K member 1,1,233614004-233672512,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA016049, CAB022588",Approved,NA,Approved,Vesicles,"Renal cancer:8.69e-8 (unfavourable), Liver cancer:3.84e-4 (favourable), Pancreatic cancer:7.29e-4 (unfavourable)",Mixed,Mixed,NA,NA,cerebral cortex: 46.4,Cell line enhanced,NA,SCLC-21H: 70.2;U-266/70: 104.5;U-266/84: 92.8
KCNQ5,Kv7.5,ENSG00000185760,Potassium voltage-gated channel subfamily Q member 5,6,72621792-73198851,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA016655,Enhanced,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 22.3,thyroid gland: 7.9,Cell line enhanced,NA,BJ: 29.6
KCNRG,NA,ENSG00000198553,Potassium channel regulator,13,50015254-50020922,Predicted intracellular proteins,Evidence at protein level,HPA001027,NA,NA,Uncertain,Vesicles,Endometrial cancer:2.61e-5 (favourable),Mixed,Tissue enriched,12,fallopian tube: 52.2,lung: 4.5,Mixed,NA,NA
KCNT2,"KCa4.2, SLICK, SLO2.1",ENSG00000162687,Potassium sodium-activated channel subfamily T member 2,1,196225779-196609225,"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA051218,Uncertain,NA,Approved,Vesicles,Renal cancer:1.67e-5 (unfavourable),Mixed,Tissue enhanced,NA,ovary: 6.0,cerebral cortex: 3.5,Cell line enhanced,NA,HHSteC: 2.7;NTERA-2: 2.6;SCLC-21H: 8.5;SH-SY5Y: 6.9
KCTD8,NA,ENSG00000183783,Potassium channel tetramerization domain containing 8,4,44173909-44448807,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA031562,Enhanced,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 11.5;thyroid gland: 5.2,testis: 2.4,Cell line enhanced,NA,HAP1: 2.2;NTERA-2: 1.5;SCLC-21H: 6.8;U-2 OS: 1.8
KDELC2,MGC33424,ENSG00000178202,KDEL motif containing 2,11,108472105-108498432,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039315, HPA039817, HPA066134",Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,"Urothelial cancer:6.27e-5 (unfavourable), Liver cancer:1.45e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 62.2,Mixed,NA,NA
KDELR1,"ERD2, ERD2.1, HDEL",ENSG00000105438,KDEL endoplasmic reticulum protein retention receptor 1,19,48382570-48391553,"Predicted membrane proteins, Transporters",Evidence at protein level,CAB017455,Approved,NA,Supported,Golgi apparatus<br>Vesicles,"Liver cancer:1.61e-4 (unfavourable), Head and neck cancer:3.49e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 264.3,Expressed in all,NA,NA
KIAA0319,NMIG,ENSG00000137261,KIAA0319,6,24544104-24646155,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA015607, HPA076313",Enhanced,NA,Uncertain,Vesicles,NA,Mixed,Tissue enriched,6,cerebral cortex: 15.8,fallopian tube: 2.8,Cell line enhanced,NA,HDLM-2: 2.6;SCLC-21H: 5.1;U-266/84: 2.6
KIAA0430,"LKAP, Marf1, PPP1R34",ENSG00000166783,KIAA0430,16,15594386-15643166,Predicted intracellular proteins,Evidence at protein level,HPA017992,Approved,NA,Supported,Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 20.6,Expressed in all,NA,NA
KIAA0895L,LOC653319,ENSG00000196123,KIAA0895 like,16,67175602-67184040,Predicted intracellular proteins,Evidence at transcript level,HPA065996,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Pancreatic cancer:3.16e-4 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 25.4,Expressed in all,NA,NA
KIAA0922,"DKFZp586H1322, TMEM131L",ENSG00000121210,KIAA0922,4,153466346-153636711,Predicted membrane proteins,Evidence at protein level,"HPA043472, HPA048443",Uncertain,NA,Approved,Nucleoli fibrillar center<br>Vesicles,Cervical cancer:6.69e-6 (favourable),Expressed in all,Expressed in all,NA,NA,lymph node: 56.4,Cell line enhanced,NA,Daudi: 75.0;MOLT-4: 79.8;U-698: 85.3
KIAA1328,NA,ENSG00000150477,KIAA1328,18,36829106-37232172,Predicted intracellular proteins,Evidence at protein level,HPA040946,Approved,NA,Approved,Nuclear speckles<br>Vesicles<br>Lipid droplets,NA,Mixed,Expressed in all,NA,NA,testis: 35.8,Expressed in all,NA,NA
KIAA1614,NA,ENSG00000135835,KIAA1614,1,180913154-180951614,Predicted intracellular proteins,Evidence at protein level,"HPA028227, HPA061684",Approved,NA,Approved,Nuclear membrane<br>Vesicles,NA,Mixed,Mixed,NA,NA,thyroid gland: 9.2,Cell line enhanced,NA,RH-30: 17.2;SH-SY5Y: 47.3
KIAA1644,NA,ENSG00000138944,KIAA1644,22,44243667-44312851,Predicted membrane proteins,Evidence at transcript level,HPA051178,Uncertain,NA,Approved,Vesicles<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 27.6;endometrium: 42.8;smooth muscle: 44.6,"cervix, uterine: 19.2",Cell line enhanced,NA,SiHa: 38.9;U-2197: 76.1;U-87 MG: 46.0;WM-115: 27.3
KIAA1755,RP5-1054A22.3,ENSG00000149633,KIAA1755,20,38210488-38260772,Predicted intracellular proteins,Evidence at protein level,HPA051064,Approved,NA,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Mixed,NA,NA,cerebral cortex: 33.6,Cell line enhanced,NA,AF22: 74.8;ASC TERT1: 11.9;WM-115: 19.1
KIAA2026,FLJ20375,ENSG00000183354,KIAA2026,9,5881596-6007901,Predicted intracellular proteins,Evidence at protein level,HPA002109,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:8.34e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 23.0,Expressed in all,NA,NA
KIF5C,NA,ENSG00000168280,Kinesin family member 5C,2,148875250-149026759,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035210, HPA062272",Enhanced,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 205.3,prostate: 44.3,Cell line enhanced,NA,AF22: 38.5;NTERA-2: 39.3;SCLC-21H: 236.2;SH-SY5Y: 49.2
KISS1,NA,ENSG00000170498,KiSS-1 metastasis-suppressor,1,204190341-204196486,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,"CAB017775, HPA035542",Enhanced,NA,Approved,Vesicles,Urothelial cancer:6.29e-6 (favourable),Tissue enhanced,Tissue enriched,87,placenta: 328.1,stomach: 3.7,Group enriched,21,BJ: 123.9;U-2 OS: 60.5
KITLG,"FPH2, Kitl, KL-1, MGF, SCF, SF",ENSG00000049130,KIT ligand,12,88492793-88580851,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,HPA070395,Approved,NA,Approved,Vesicles,"Renal cancer:5.81e-7 (favourable), Liver cancer:4.01e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,lung: 23.5,Cell line enhanced,NA,CACO-2: 199.5
KLF5,"BTEB2, CKLF, IKLF",ENSG00000102554,Kruppel like factor 5,13,73054976-73077542,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA040398,Approved,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Pancreatic cancer:2.55e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,skin: 279.6,esophagus: 216.2,Cell line enhanced,NA,HaCaT: 113.4;hTCEpi: 113.2;RT4: 108.4;SiHa: 121.1
KLF6,"BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9",ENSG00000067082,Kruppel like factor 6,10,3775996-3785281,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB013529, HPA069585",Supported,NA,Approved,Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol,Renal cancer:2.28e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 323.6,Expressed in all,NA,NA
KLHL12,C3IP1,ENSG00000117153,Kelch like family member 12,1,202891100-202928636,Predicted intracellular proteins,Evidence at protein level,HPA071324,NA,NA,Supported,Vesicles<br>Microtubule organizing center,NA,Expressed in all,Expressed in all,NA,NA,testis: 81.9,Expressed in all,NA,NA
KLHL2,MAV,ENSG00000109466,Kelch like family member 2,4,165207618-165323156,Predicted intracellular proteins,Evidence at protein level,HPA051637,NA,NA,Uncertain,Nucleoplasm<br>Vesicles,Renal cancer:3.77e-4 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 77.5,thyroid gland: 22.0,Mixed,NA,NA
KLHL38,C8ORFK36,ENSG00000175946,Kelch like family member 38,8,123645527-123652950,Predicted intracellular proteins,Evidence at protein level,"HPA024770, HPA027115",Uncertain,NA,Uncertain,Nucleoplasm<br>Vesicles,NA,Tissue enhanced,Group enriched,15,heart muscle: 35.8;skeletal muscle: 91.2,smooth muscle: 4.3,Cell line enhanced,NA,BJ hTERT+: 1.4;SK-BR-3: 2.1;U-2197: 4.6
KLK8,"HNP, neuropsin, ovasin, PRSS19, TADG14",ENSG00000129455,Kallikrein related peptidase 8,19,50996007-51002711,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB019393, HPA035761",Enhanced,NA,Approved,Vesicles,"Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable)",Tissue enhanced,Group enriched,6,esophagus: 77.9;fallopian tube: 20.9;skin: 96.8,breast: 11.0,Group enriched,7,A-431: 76.9;CAPAN-2: 98.5;HaCaT: 73.3
KLRC3,NKG2-E,ENSG00000205810,Killer cell lectin like receptor C3,12,10412312-10420595,Predicted membrane proteins,Evidence at transcript level,"HPA039910, HPA062570",Approved,NA,Uncertain,Vesicles,NA,Tissue enriched,Tissue enhanced,NA,cerebral cortex: 9.2;spleen: 6.2,lymph node: 2.3,Cell line enhanced,NA,HEL: 1.1;HeLa: 4.5;U-698: 1.3
KLRG1,"2F1, CLEC15A, MAFA, MAFA-L",ENSG00000139187,Killer cell lectin like receptor G1,12,8950044-9010760,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA051403, HPA076494",NA,NA,Supported,Vesicles,NA,Mixed,Tissue enhanced,NA,spleen: 15.8,lymph node: 13.5,Cell line enhanced,NA,HEL: 29.9;NTERA-2: 22.2;U-937: 16.1
KRIT1,"CAM, CCM1",ENSG00000001631,"KRIT1, ankyrin repeat containing",7,92198969-92246166,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049606,Supported,NA,Uncertain,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 48.7,Expressed in all,NA,NA
KRT222,"KA21, KRT222P, MGC45562",ENSG00000213424,Keratin 222,17,40654665-40665181,Predicted intracellular proteins,Evidence at protein level,"HPA043708, HPA054586, HPA069774",Uncertain,NA,Approved,Vesicles<br>Lipid droplets,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 10.0;epididymis: 6.0,gallbladder: 2.7,Cell line enriched,6,RPTEC TERT1: 8.8
KRT25,KRT25A,ENSG00000204897,Keratin 25,17,40748021-40755332,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA053977, HPA058943",Enhanced,NA,Approved,Vesicles,NA,Not detected,Group enriched,15,breast: 3.6;testis: 1.6,smooth muscle: 0.1,Cell line enriched,5,RPTEC TERT1: 1.0
KRT34,"Ha-4, KRTHA4",ENSG00000131737,Keratin 34,17,41377650-41382403,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA055194, HPA072208",Supported,NA,Approved,Nucleus<br>Vesicles,NA,Tissue enhanced,Tissue enriched,8,"cervix, uterine: 4.2",testis: 0.5,Cell line enhanced,NA,BJ: 170.4;BJ hTERT+ SV40 Large T+ RasG12V: 45.2;HBF TERT88: 41.4
L3HYPDH,"C14orf149, FLJ25436",ENSG00000126790,Trans-L-3-hydroxyproline dehydratase,14,59460363-59484430,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056694,Approved,NA,Uncertain,Vesicles,Renal cancer:1.72e-9 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 32.0,Expressed in all,NA,NA
L3MBTL4,"FLJ35936, HsT1031",ENSG00000154655,L(3)mbt-like 4 (Drosophila),18,5954706-6415237,Predicted intracellular proteins,Evidence at protein level,"HPA064194, HPA069042",Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,testis: 23.4,Cell line enhanced,NA,RPMI-8226: 8.0;SCLC-21H: 6.3;SH-SY5Y: 6.2
LAMA5,NA,ENSG00000130702,Laminin subunit alpha 5,20,62307955-62367312,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054609, CAB078157",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Tissue enhanced,NA,skin: 42.1,placenta: 28.9,Cell line enhanced,NA,CACO-2: 131.3
LAMB2,"LAMS, NPHS5",ENSG00000172037,Laminin subunit beta 2,3,49121114-49133118,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000053, HPA001895, HPA050033, CAB078160",Supported,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 207.4,Cell line enhanced,NA,fHDF/TERT166: 231.7
LAMP3,"CD208, DC-LAMP, DCLAMP, LAMP, TSC403",ENSG00000078081,Lysosomal associated membrane protein 3,3,183122213-183163839,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025133, HPA051467",Enhanced,NA,Enhanced,Vesicles,"Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable)",Mixed,Tissue enriched,7,lung: 319.3,appendix: 44.9,Group enriched,8,EFO-21: 154.0;HDLM-2: 40.5;HHSteC: 50.0;hTCEpi: 40.3
LAMTOR2,"ENDAP, MAPBPIP, MAPKSP1AP, p14, Ragulator2, ROBLD3",ENSG00000116586,"Late endosomal/lysosomal adaptor, MAPK and MTOR activator 2",1,156054752-156058510,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA004126,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:1.10e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,epididymis: 84.7,Expressed in all,NA,NA
LAMTOR4,C7orf59,ENSG00000188186,"Late endosomal/lysosomal adaptor, MAPK and MTOR activator 4",7,100148907-100155944,Predicted intracellular proteins,Evidence at protein level,HPA020998,Enhanced,NA,Enhanced,Vesicles,"Breast cancer:2.48e-4 (favourable), Cervical cancer:6.08e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,skin: 314.5,Expressed in all,NA,NA
LATS1,WARTS,ENSG00000131023,Large tumor suppressor kinase 1,6,149658153-149718256,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031804,Approved,NA,Uncertain,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 23.6,Expressed in all,NA,NA
LBH,NA,ENSG00000213626,Limb bud and heart development,2,30231531-30323730,Predicted intracellular proteins,Evidence at protein level,HPA034669,Approved,NA,Approved,Vesicles,Stomach cancer:8.24e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,lung: 197.1,Cell line enhanced,NA,fHDF/TERT166: 234.8;U-2 OS: 102.9
LCMT2,"KIAA0547, MGC9534, PPM2, TYW4",ENSG00000168806,Leucine carboxyl methyltransferase 2,15,43323649-43330605,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039401, HPA048176",Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:5.69e-9 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 13.2,Mixed,NA,NA
LDHA,NA,ENSG00000134333,Lactate dehydrogenase A,11,18394388-18408425,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB015336, CAB069404",Uncertain,NA,Supported,Vesicles<br>Cytosol,"Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 503.4,Expressed in all,NA,NA
LDLRAD4,C18orf1,ENSG00000168675,Low density lipoprotein receptor class A domain containing 4,18,13217498-13652755,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA047633, HPA054556, HPA065246",Approved,NA,Supported,Nucleoplasm<br>Vesicles,Renal cancer:4.58e-4 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 27.5,Cell line enhanced,NA,HEL: 34.2;MOLT-4: 94.8;REH: 32.0
LEPR,"CD295, OBR",ENSG00000116678,Leptin receptor,1,65420652-65641559,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA030899,Approved,NA,Approved,Vesicles,NA,Tissue enriched,Mixed,NA,NA,liver: 67.9,Cell line enhanced,NA,K-562: 102.4;RPTEC TERT1: 39.6
LGMN,"LGMN1, PRSC1",ENSG00000100600,Legumain,14,92703807-92748702,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001426,Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:4.70e-4 (favourable),Expressed in all,Expressed in all,NA,NA,placenta: 360.0,Cell line enhanced,NA,RPMI-8226: 587.9;U-266/70: 339.8
LGSN,"GLULD1, LGS",ENSG00000146166,"Lengsin, lens protein with glutamine synthetase domain",6,63275951-63319977,Predicted intracellular proteins,Evidence at protein level,"HPA030957, HPA039983",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,kidney: 2.8;liver: 2.4;placenta: 1.8,testis: 0.7,Cell line enhanced,NA,A549: 5.5;BEWO: 3.0;CACO-2: 1.6;HeLa: 1.5
LHFPL2,KIAA0206,ENSG00000145685,Lipoma HMGIC fusion partner-like 2,5,78485215-78770021,Predicted membrane proteins,Evidence at protein level,HPA042402,Uncertain,NA,Approved,Vesicles<br>Actin filaments,"Renal cancer:3.45e-7 (unfavourable), Liver cancer:2.73e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 36.4,Mixed,NA,NA
LHFPL3,LHFPL4,ENSG00000187416,Lipoma HMGIC fusion partner-like 3,7,104328656-104907232,Predicted membrane proteins,Evidence at transcript level,HPA069691,NA,NA,Approved,Vesicles,NA,Tissue enriched,Tissue enriched,10,cerebral cortex: 48.7,"cervix, uterine: 4.6",Cell line enhanced,NA,SCLC-21H: 1.8;SH-SY5Y: 2.1;SK-BR-3: 1.3
LIG1,NA,ENSG00000105486,DNA ligase 1,19,48115445-48170603,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB037015, HPA041431, HPA048071",Approved,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:5.75e-5 (unfavourable),Expressed in all,Mixed,NA,NA,bone marrow: 20.9,Mixed,NA,NA
LIMD2,MGC10986,ENSG00000136490,LIM domain containing 2,17,63695902-63701172,Predicted intracellular proteins,Evidence at protein level,HPA062867,NA,NA,Approved,Vesicles,Renal cancer:5.36e-11 (unfavourable),Expressed in all,Group enriched,5,appendix: 140.1;bone marrow: 71.2;lymph node: 255.5;spleen: 191.0;tonsil: 138.2,urinary bladder: 30.2,Cell line enhanced,NA,Daudi: 173.9;SH-SY5Y: 172.7;U-698: 174.0
LIPA,"CESD, LAL",ENSG00000107798,"Lipase A, lysosomal acid type",10,89213569-89414557,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB034892, HPA057052",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,spleen: 496.6,Mixed,NA,NA
LIPT2,NA,ENSG00000175536,Lipoyl(octanoyl) transferase 2 (putative),11,74491712-74493733,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040249,Approved,NA,Approved,Vesicles<br>Centrosome,Ovarian cancer:1.63e-4 (favourable),Expressed in all,Mixed,NA,NA,testis: 14.5,Mixed,NA,NA
LITAF,"FLJ38636, PIG7, SIMPLE, TP53I7",ENSG00000189067,Lipopolysaccharide induced TNF factor,16,11547722-11636381,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006960,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Glioma:1.78e-4 (unfavourable), Testis cancer:6.25e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,appendix: 225.8,Mixed,NA,NA
LIX1,"C5orf11, Lft",ENSG00000145721,Limb and CNS expressed 1,5,97091867-97142872,Predicted intracellular proteins,Evidence at transcript level,HPA058426,Uncertain,NA,Approved,Vesicles<br>Cytokinetic bridge<br>Cytosol,Endometrial cancer:2.48e-4 (unfavourable),Tissue enhanced,Tissue enriched,6,cerebral cortex: 32.8,seminal vesicle: 5.7,Cell line enriched,9,RPTEC TERT1: 24.5
LLGL2,"HGL, Hugl-2",ENSG00000073350,"LLGL2, scribble cell polarity complex component",17,75525080-75575208,Predicted intracellular proteins,Evidence at protein level,HPA022913,Uncertain,NA,Supported,Vesicles<br>Cytosol,"Renal cancer:6.14e-9 (favourable), Pancreatic cancer:6.00e-5 (favourable), Head and neck cancer:9.25e-4 (favourable)",Expressed in all,Mixed,NA,NA,stomach: 62.8,Cell line enhanced,NA,CAPAN-2: 118.0;MCF7: 101.3;SK-BR-3: 95.4;T-47d: 90.7
LMX1A,"LMX1, LMX1.1",ENSG00000162761,LIM homeobox transcription factor 1 alpha,1,165201867-165356715,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA028051, HPA030088",NA,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Not detected,Tissue enhanced,NA,duodenum: 1.0;testis: 2.2,"adipose tissue,rectum,small intestine: 0.6",Cell line enriched,11,SCLC-21H: 1.0
LNP1,NP3,ENSG00000206535,Leukemia NUP98 fusion partner 1,3,100401193-100456319,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA047926,NA,NA,Approved,Nuclear speckles<br>Vesicles<br>Cytosol,NA,Expressed in all,Tissue enriched,6,testis: 47.9,cerebral cortex: 7.6,Mixed,NA,NA
LOXL4,"FLJ21889, LOXC",ENSG00000138131,Lysyl oxidase like 4,10,98247690-98268250,Predicted secreted proteins,Evidence at protein level,"CAB033876, HPA037609",Approved,NA,Approved,Vesicles,"Glioma:5.36e-4 (unfavourable), Ovarian cancer:9.57e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,"cervix, uterine: 17.8",Cell line enhanced,NA,BJ hTERT+: 199.7;CAPAN-2: 260.1;U-2 OS: 57.0
LPL,LIPD,ENSG00000175445,Lipoprotein lipase,8,19901717-19967258,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048749,NA,NA,Supported,Vesicles,Urothelial cancer:6.07e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,adipose tissue: 976.8,heart muscle: 239.2,Cell line enriched,7,AF22: 363.8
LRFN2,"FIGLER2, KIAA1246, SALM1",ENSG00000156564,Leucine rich repeat and fibronectin type III domain containing 2,6,40391586-40587465,Predicted membrane proteins,Evidence at protein level,HPA076660,Enhanced,NA,Supported,Vesicles,NA,Not detected,Tissue enriched,5,cerebral cortex: 6.8,testis: 1.3,Cell line enhanced,NA,REH: 1.5;SH-SY5Y: 5.0
LRG1,LRG,ENSG00000171236,Leucine rich alpha-2-glycoprotein 1,19,4536409-4540474,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001888, HPA001889",Enhanced,NA,Approved,Vesicles,"Renal cancer:3.66e-6 (unfavourable), Thyroid cancer:3.49e-4 (favourable)",Tissue enriched,Tissue enriched,8,liver: 173.8,"appendix,esophagus: 21.1",Cell line enhanced,NA,THP-1: 15.8;U-937: 34.0
LRMP,JAW1,ENSG00000118308,Lymphoid restricted membrane protein,12,25004342-25108334,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA002967, HPA018505",Enhanced,NA,Supported,Nucleus<br>Vesicles<br>Cytosol,NA,Mixed,Tissue enhanced,NA,lymph node: 207.1;tonsil: 185.6,appendix: 63.4,Group enriched,7,Daudi: 453.9;REH: 202.5;U-698: 497.6
LRP1,"A2MR, APOER, APR, CD91, LRP, LRP1A",ENSG00000123384,LDL receptor related protein 1,12,57128493-57213351,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA004182, CAB018621, HPA022903",Supported,NA,Supported,Nucleoplasm<br>Vesicles,"Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adipose tissue: 123.8,Cell line enhanced,NA,ASC diff: 333.3;ASC TERT1: 342.9;HSkMC: 232.4
LRP1B,"LRP-DIT, LRPDIT",ENSG00000168702,LDL receptor related protein 1B,2,140231423-142131701,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA069094, HPA074788",Approved,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 16.4;thyroid gland: 9.6,epididymis: 2.7,Cell line enhanced,NA,ASC diff: 1.0;HEK93: 1.5;U-138 MG: 1.8
LRP2,"DBS, gp330",ENSG00000081479,LDL receptor related protein 2,2,169127109-169362685,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA005980, HPA064792",Enhanced,NA,Approved,Vesicles<br>Mitochondria,Renal cancer:3.43e-5 (favourable),Group enriched,Group enriched,6,kidney: 49.8;parathyroid gland: 155.8;thyroid gland: 37.0,breast: 14.2,Group enriched,11,AF22: 39.4;CACO-2: 56.2
LRR1,"LRR-1, MGC20689, PPIL5",ENSG00000165501,Leucine rich repeat protein 1,14,49598697-49614672,Predicted intracellular proteins,Evidence at protein level,"HPA065703, HPA069364",Approved,NA,Approved,Nucleoplasm<br>Nuclear membrane<br>Vesicles,"Renal cancer:4.90e-7 (unfavourable), Liver cancer:2.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 33.6,lymph node: 12.1,Expressed in all,NA,NA
LRRC24,LRRC14OS,ENSG00000254402,Leucine rich repeat containing 24,8,144522377-144527032,Predicted membrane proteins,Evidence at protein level,"HPA028171, HPA052250",Enhanced,NA,Approved,Vesicles,NA,Not detected,Tissue enhanced,NA,parathyroid gland: 3.6;prostate: 4.5,cerebral cortex: 3.1,Cell line enhanced,NA,SCLC-21H: 3.2;SH-SY5Y: 7.9
LRRC37A,KIAA0563,ENSG00000176681,Leucine rich repeat containing 37A,17,46292733-46337794,Predicted membrane proteins,Evidence at protein level,"HPA042121, HPA042701, HPA043056, HPA045090, HPA049080",Supported,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,8,testis: 13.4,skeletal muscle: 1.6,Cell line enhanced,NA,Daudi: 2.8
LRRC37A2,FLJ45049,ENSG00000238083,Leucine rich repeat containing 37 member A2,17,46511511-46555650,Predicted membrane proteins,Evidence at protein level,"HPA042121, HPA042701, HPA043056, HPA045090, HPA049080",Supported,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,25,testis: 13.0,"breast,lung: 0.5",Not detected,NA,NA
LRRC37A3,"FLJ34306, KIAA0563",ENSG00000176809,Leucine rich repeat containing 37 member A3,17,64854312-64919480,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042121, HPA042701, HPA043056, HPA045090",Supported,NA,Approved,Vesicles,Renal cancer:3.25e-6 (unfavourable),Mixed,Tissue enhanced,NA,testis: 31.6,thyroid gland: 12.5,Mixed,NA,NA
LRRC43,MGC35140,ENSG00000158113,Leucine rich repeat containing 43,12,122167738-122203471,Predicted intracellular proteins,Evidence at transcript level,"HPA039425, HPA047606",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,NA,Mixed,Group enriched,5,fallopian tube: 30.3;testis: 8.5,parathyroid gland: 3.6,Cell line enhanced,NA,HUVEC TERT2: 2.2;SCLC-21H: 2.5
LRRK2,"DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2",ENSG00000188906,Leucine rich repeat kinase 2,12,40196744-40369285,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA014293, CAB037160",Approved,NA,Approved,Nucleus<br>Vesicles,Renal cancer:3.02e-6 (favourable),Group enriched,Expressed in all,NA,NA,lung: 95.4,Cell line enhanced,NA,A549: 7.4;ASC TERT1: 5.6;RPTEC TERT1: 6.7
LRWD1,"CENP-33, DKFZp434K1815, ORCA",ENSG00000161036,Leucine rich repeats and WD repeat domain containing 1,7,102464929-102473168,Predicted intracellular proteins,Evidence at protein level,HPA021320,Enhanced,NA,Supported,Nucleus<br>Nucleoli<br>Vesicles,"Pancreatic cancer:8.71e-5 (favourable), Renal cancer:1.25e-4 (unfavourable)",Expressed in all,Tissue enriched,11,testis: 209.0,fallopian tube: 18.8,Expressed in all,NA,NA
LSM1,"CASM, YJL124C",ENSG00000175324,"LSM1 homolog, mRNA degradation associated",8,38163321-38176730,Predicted intracellular proteins,Evidence at protein level,HPA024601,NA,NA,Supported,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,placenta: 35.7,Expressed in all,NA,NA
LSM14B,"bA11M20.3, C20orf40, FAM61B, FLJ25473, FT005, LSM13, RAP55B",ENSG00000149657,LSM family member 14B,20,62122461-62135378,Predicted intracellular proteins,Evidence at protein level,"HPA041274, HPA061189",Approved,NA,Supported,Nucleoli fibrillar center<br>Vesicles,Liver cancer:3.61e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 78.8,Expressed in all,NA,NA
LSM4,YER112W,ENSG00000130520,"LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated",19,18306230-18323274,Predicted intracellular proteins,Evidence at protein level,HPA040932,Uncertain,NA,Approved,Vesicles,"Ovarian cancer:1.34e-4 (favourable), Renal cancer:2.22e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 102.4,Expressed in all,NA,NA
LSM8,YJR022W,ENSG00000128534,"LSM8 homolog, U6 small nuclear RNA associated",7,118184032-118192824,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA020116,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:7.46e-6 (unfavourable), Endometrial cancer:9.85e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 52.4,Expressed in all,NA,NA
LTK,TYK1,ENSG00000062524,Leukocyte receptor tyrosine kinase,15,41503638-41513887,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA059545,Uncertain,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,placenta: 15.2,Cell line enhanced,NA,HEL: 4.4;NB-4: 6.1;RH-30: 4.4;THP-1: 9.9
LURAP1,"C1orf190, FLJ25163, LRAP35a",ENSG00000171357,Leucine rich adaptor protein 1,1,46203334-46221261,Predicted intracellular proteins,Evidence at protein level,"HPA030060, HPA030061",Uncertain,NA,Approved,Vesicles,Renal cancer:8.81e-8 (favourable),Mixed,Tissue enhanced,NA,parathyroid gland: 18.1;thyroid gland: 17.6,testis: 9.2,Mixed,NA,NA
LUZP1,LUZP,ENSG00000169641,Leucine zipper protein 1,1,23084023-23177808,Predicted intracellular proteins,Evidence at protein level,"HPA028506, HPA028542",Enhanced,NA,Uncertain,Vesicles<br>Actin filaments<br>Cytosol,"Renal cancer:1.46e-7 (favourable), Cervical cancer:5.57e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 47.1,Mixed,NA,NA
LY96,MD-2,ENSG00000154589,Lymphocyte antigen 96,8,73991352-74029087,Predicted secreted proteins,Evidence at protein level,HPA053060,NA,NA,Approved,Vesicles,Renal cancer:6.38e-11 (unfavourable),Expressed in all,Mixed,NA,NA,spleen: 61.2,Cell line enhanced,NA,Karpas-707: 119.4;U-87 MG: 82.4
LYPD3,C4.4A,ENSG00000124466,LY6/PLAUR domain containing 3,19,43460787-43465660,Predicted membrane proteins,Evidence at protein level,"HPA041529, HPA041797, HPA077859",Enhanced,NA,Approved,Endoplasmic reticulum<br>Vesicles,Lung cancer:7.86e-5 (unfavourable),Tissue enhanced,Group enriched,6,esophagus: 673.8;skin: 593.4,tonsil: 114.6,Cell line enhanced,NA,HaCaT: 85.1;MCF7: 84.1;RT4: 83.0;SK-BR-3: 114.6
LZTS3,"KIAA0552, ProSAPiP1",ENSG00000088899,Leucine zipper tumor suppressor family member 3,20,3162617-3173592,Predicted intracellular proteins,Evidence at protein level,"HPA031008, HPA031009",Approved,NA,Approved,Vesicles,"Renal cancer:5.92e-8 (favourable), Endometrial cancer:7.26e-4 (unfavourable), Lung cancer:7.98e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 58.6,parathyroid gland: 20.3,Cell line enhanced,NA,SCLC-21H: 21.3
MAF1,DKFZp586G1123,ENSG00000179632,"MAF1 homolog, negative regulator of RNA polymerase III",8,144104499-144107611,Predicted intracellular proteins,Evidence at protein level,"HPA024821, HPA058548",Uncertain,NA,Supported,Nucleus<br>Nucleoli<br>Vesicles,Liver cancer:7.09e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 142.6,Expressed in all,NA,NA
MAGEB2,"CT3.2, DAM6, MAGE-XP-2, MGC26438",ENSG00000099399,MAGE family member B2,X,30215560-30220089,Predicted intracellular proteins,Evidence at protein level,"HPA065224, HPA074544, HPA075519",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Tissue enriched,Tissue enriched,74,testis: 54.2,placenta: 0.7,Group enriched,9,HL-60: 72.9;K-562: 59.4;Karpas-707: 55.2;U-2 OS: 93.7;U-266/70: 113.8;U-266/84: 116.9
MAK16,"MAK16L, RBM13",ENSG00000198042,MAK16 homolog,8,33484750-33501260,Predicted intracellular proteins,Evidence at protein level,"HPA044417, HPA050574",Uncertain,NA,Supported,Nucleoli<br>Vesicles,"Liver cancer:1.00e-4 (unfavourable), Renal cancer:3.66e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 12.6,Expressed in all,NA,NA
MAN1B1,"ERManI, MANA-ER, MRT15",ENSG00000177239,Mannosidase alpha class 1B member 1,9,137086927-137109187,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051516,Approved,NA,Uncertain,Vesicles,Liver cancer:1.45e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,fallopian tube: 33.4,Expressed in all,NA,NA
MAN1C1,HMIC,ENSG00000117643,Mannosidase alpha class 1C member 1,1,25617468-25786207,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048352,Uncertain,NA,Uncertain,Nucleus<br>Vesicles,"Pancreatic cancer:4.79e-4 (favourable), Lung cancer:7.55e-4 (favourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 40.7,Cell line enhanced,NA,AF22: 28.0;HSkMC: 74.2
MAN2B1,"LAMAN, MANB",ENSG00000104774,Mannosidase alpha class 2B member 1,19,12646511-12666742,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA041530, HPA053404",Supported,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:1.94e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 95.1,Expressed in all,NA,NA
MANBA,NA,ENSG00000109323,Mannosidase beta,4,102631488-102760994,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA053478,Approved,NA,Supported,Vesicles,"Liver cancer:3.74e-6 (unfavourable), Glioma:1.06e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 37.4,Expressed in all,NA,NA
MANSC1,"FLJ10298, LOH12CR3",ENSG00000111261,MANSC domain containing 1,12,12326056-12350541,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007955, HPA007956",Approved,NA,Approved,Golgi apparatus<br>Vesicles,Renal cancer:3.30e-5 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 24.7,Cell line enhanced,NA,HUVEC TERT2: 42.6
MAP3K14,"FTDCR1B, HS, HSNIK, NIK",ENSG00000006062,Mitogen-activated protein kinase kinase kinase 14,17,45263121-45317040,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027269, HPA027270",Approved,NA,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol,"Cervical cancer:5.27e-5 (favourable), Renal cancer:2.78e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 22.8,Mixed,NA,NA
MAP3K15,"ASK3, bA723P2.3, FLJ16518",ENSG00000180815,Mitogen-activated protein kinase kinase kinase 15,X,19360056-19515261,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004006,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,6,adrenal gland: 14.3,spleen: 2.2,Cell line enhanced,NA,A549: 1.8;HAP1: 5.1;HEK93: 3.8;REH: 2.4
MAP4K2,"BL44, GCK, RAB8IP",ENSG00000168067,Mitogen-activated protein kinase kinase kinase kinase 2,11,64784914-64803241,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA007330,Enhanced,NA,Approved,Vesicles,Liver cancer:3.10e-5 (unfavourable),Expressed in all,Mixed,NA,NA,spleen: 22.9,Mixed,NA,NA
MAPK8IP3,"JIP3, JSAP1, KIAA1066, syd",ENSG00000138834,Mitogen-activated protein kinase 8 interacting protein 3,16,1706183-1770317,Predicted intracellular proteins,Evidence at protein level,"CAB005580, HPA041785, HPA069311",Approved,NA,Approved,Vesicles,"Renal cancer:5.25e-5 (unfavourable), Urothelial cancer:3.95e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 83.9,Expressed in all,NA,NA
MARCH3,"MARCH-III, MGC48332, RNF173",ENSG00000173926,Membrane associated ring-CH-type finger 3,5,126867714-127030808,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA043406,Uncertain,NA,Supported,Vesicles,NA,Mixed,Mixed,NA,NA,testis: 10.9,Cell line enhanced,NA,hTEC/SVTERT24-B: 41.0;TIME: 27.2
MARCO,SCARA2,ENSG00000019169,Macrophage receptor with collagenous structure,2,118942166-118994660,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA063793,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,appendix: 123.2;lung: 288.2,adipose tissue: 78.0,Cell line enhanced,NA,HaCaT: 1.5;THP-1: 1.7;U-2 OS: 2.7;U-266/70: 1.1
MARVELD3,MRVLDC3,ENSG00000140832,MARVEL domain containing 3,16,71626161-71642114,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA043514, HPA045471",NA,NA,Approved,Vesicles<br>Intermediate filaments,Renal cancer:6.80e-10 (favourable),Mixed,Tissue enhanced,NA,small intestine: 37.1,duodenum: 31.5,Cell line enhanced,NA,BEWO: 29.9;CAPAN-2: 19.9;MCF7: 31.1;T-47d: 24.8
MAST1,"KIAA0973, SAST",ENSG00000105613,Microtubule associated serine/threonine kinase 1,19,12833951-12874951,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA028181, HPA073106",Enhanced,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enriched,12,cerebral cortex: 35.2,testis: 3.0,Cell line enhanced,NA,AN3-CA: 21.6;SCLC-21H: 47.7;SH-SY5Y: 21.4
MAX,"bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8",ENSG00000125952,MYC associated factor X,14,65006174-65102695,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB000328, HPA003474",Enhanced,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Thyroid cancer:2.12e-4 (favourable), Renal cancer:5.57e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 78.8,Expressed in all,NA,NA
MBD1,"CXXC3, PCM1",ENSG00000141644,Methyl-CpG binding domain protein 1,18,50266882-50281774,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB009017, CAB036003, HPA068850",Approved,NA,Enhanced,Nucleoplasm<br>Vesicles,"Prostate cancer:1.70e-6 (unfavourable), Liver cancer:5.08e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 109.0,Expressed in all,NA,NA
MBNL3,"CHCR, FLJ11316, MBLX39, MBXL",ENSG00000076770,Muscleblind like splicing regulator 3,X,132369317-132489968,Predicted intracellular proteins,Evidence at protein level,HPA001584,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,Endometrial cancer:1.57e-4 (unfavourable),Expressed in all,Group enriched,5,placenta: 242.1;testis: 81.4,liver: 30.6,Cell line enhanced,NA,CACO-2: 102.2;Hep G2: 116.6
MBOAT2,"FLJ14415, FLJ90298, OACT2",ENSG00000143797,Membrane bound O-acyltransferase domain containing 2,2,8852690-9003813,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014836,Uncertain,NA,Approved,Vesicles,"Endometrial cancer:2.13e-9 (unfavourable), Urothelial cancer:5.32e-4 (unfavourable)",Mixed,Tissue enhanced,NA,parathyroid gland: 50.1,cerebral cortex: 29.7,Mixed,NA,NA
MDK,"FLJ27379, MK, NEGF2",ENSG00000110492,Midkine (neurite growth-promoting factor 2),11,46380756-46383837,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,"CAB010055, HPA057126",Uncertain,NA,Approved,Vesicles,"Renal cancer:3.06e-6 (unfavourable), Glioma:9.54e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 524.3,Cell line enhanced,NA,NTERA-2: 890.9;REH: 1226.8;SH-SY5Y: 1163.1
MED17,"CRSP6, CRSP77, DRIP80, TRAP80",ENSG00000042429,Mediator complex subunit 17,11,93784227-93814963,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA064236,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:4.04e-6 (unfavourable), Breast cancer:4.94e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 3.2,Mixed,NA,NA
MED23,"CRSP130, CRSP3, DRIP130, Sur2",ENSG00000112282,Mediator complex subunit 23,6,131573966-131628229,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA070341,NA,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 32.2,Expressed in all,NA,NA
MED26,"CRSP7, CRSP70",ENSG00000105085,Mediator complex subunit 26,19,16574907-16629062,Predicted intracellular proteins,Evidence at protein level,"HPA057997, HPA071835",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:5.50e-5 (unfavourable), Cervical cancer:2.46e-4 (favourable)",Expressed in all,Tissue enriched,6,testis: 42.0,bone marrow: 6.8,Expressed in all,NA,NA
MEF2C,NA,ENSG00000081189,Myocyte enhancer factor 2C,5,88717117-88904257,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA005533, CAB068196, CAB068197",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles,Renal cancer:1.01e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 197.9,Cell line enhanced,NA,HEL: 205.2;REH: 238.4;WM-115: 143.4
MEMO1,"C2orf4, CGI-27, MEMO",ENSG00000162959,Mediator of cell motility 1,2,31865060-32011230,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042603, HPA057952",Approved,NA,Approved,Vesicles,NA,Mixed,Expressed in all,NA,NA,testis: 116.1,Expressed in all,NA,NA
METAP1D,"MAP1D, Metap1l",ENSG00000172878,"Methionyl aminopeptidase type 1D, mitochondrial",2,171999583-172082430,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030298, HPA030299",Uncertain,NA,Supported,Vesicles,NA,Expressed in all,Mixed,NA,NA,ovary: 9.3,Expressed in all,NA,NA
METTL6,MGC24132,ENSG00000206562,Methyltransferase like 6,3,15381275-15440566,Predicted intracellular proteins,Evidence at protein level,HPA035166,Uncertain,NA,Approved,Vesicles,Liver cancer:2.66e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 33.8,Expressed in all,NA,NA
METTL7B,"ALDI, MGC17301",ENSG00000170439,Methyltransferase like 7B,12,55681546-55684611,Predicted secreted proteins,Evidence at protein level,HPA038644,Enhanced,NA,Supported,Vesicles<br>Microtubules,"Thyroid cancer:2.37e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable)",Mixed,Tissue enhanced,NA,epididymis: 137.1;liver: 122.2,small intestine: 52.1,Cell line enhanced,NA,CAPAN-2: 42.8;EFO-21: 33.6;LHCN-M2: 33.5;U-87 MG: 35.3
MEX3C,"FLJ38871, RKHD2, RNF194",ENSG00000176624,Mex-3 RNA binding family member C,18,51174550-51218304,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA040603,Uncertain,NA,Approved,Vesicles,Liver cancer:8.49e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 81.7,Expressed in all,NA,NA
MFSD14A,"DKFZP564L0864, HIAT1",ENSG00000156875,Major facilitator superfamily domain containing 14A,1,100038097-100083377,Predicted membrane proteins,Evidence at protein level,HPA073681,NA,NA,Approved,Vesicles,Liver cancer:2.08e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 195.0,Expressed in all,NA,NA
MFSD3,NA,ENSG00000167700,Major facilitator superfamily domain containing 3,8,144509074-144511213,Predicted membrane proteins,Evidence at protein level,HPA056013,Uncertain,NA,Approved,Vesicles,"Renal cancer:5.44e-7 (favourable), Cervical cancer:5.08e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 14.5,Mixed,NA,NA
MFSD8,"CLN7, MGC33302",ENSG00000164073,Major facilitator superfamily domain containing 8,4,127917805-127965995,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA044802,Approved,NA,Supported,Nucleoplasm<br>Vesicles,Urothelial cancer:2.21e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 12.5,Mixed,NA,NA
MGAM2,NA,ENSG00000257743,Maltase-glucoamylase 2 (putative),7,142111749-142222324,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA055697,Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Group enriched,Group enriched,5,duodenum: 11.8;small intestine: 10.4,salivary gland: 2.1,Cell line enriched,7,RH-30: 1.1
MIA3,"FLJ39207, KIAA0268, TANGO, TANGO1, UNQ6077",ENSG00000154305,"MIA family member 3, ER export factor",1,222618086-222668012,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA055922, HPA056816",Enhanced,NA,Enhanced,Vesicles,Renal cancer:3.73e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 81.5,Expressed in all,NA,NA
MICB,PERB11.2,ENSG00000204516,MHC class I polypeptide-related sequence B,6,31494881-31511124,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA064618,NA,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:4.94e-9 (unfavourable), Liver cancer:7.04e-5 (unfavourable)",Mixed,Tissue enhanced,NA,lymph node: 3.2,spleen: 2.8,Cell line enhanced,NA,U-266/84: 26.2
MINDY4,"C7orf67, FAM188B, FLJ22374",ENSG00000106125,MINDY lysine 48 deubiquitinase 4,7,30771417-30892387,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019475, HPA030129, HPA030130",Approved,NA,Supported,Vesicles<br>Cytosol,NA,Mixed,Mixed,NA,NA,fallopian tube: 18.6,Cell line enhanced,NA,K-562: 17.1
MITD1,LOC129531,ENSG00000158411,Microtubule interacting and trafficking domain containing 1,2,99161427-99181058,Predicted intracellular proteins,Evidence at protein level,"HPA036162, HPA036163",Approved,NA,Enhanced,Vesicles,"Renal cancer:1.32e-11 (unfavourable), Urothelial cancer:5.46e-8 (favourable), Liver cancer:1.47e-6 (unfavourable), Breast cancer:5.96e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 42.2,Expressed in all,NA,NA
MMD,"MMA, PAQR11",ENSG00000108960,Monocyte to macrophage differentiation associated,17,55392613-55421992,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA026978,NA,NA,Approved,Vesicles,"Colorectal cancer:3.52e-5 (favourable), Liver cancer:6.39e-5 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Endometrial cancer:3.88e-4 (unfavourable), Thyroid cancer:8.62e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 141.5,cerebral cortex: 73.0,Expressed in all,NA,NA
MMP1,CLG,ENSG00000196611,Matrix metallopeptidase 1,11,102789920-102798160,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA004920,NA,NA,Approved,Vesicles,"Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,NA,appendix: 39.2;gallbladder: 126.4,urinary bladder: 29.1,Cell line enhanced,NA,BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
MMP16,"C8orf57, DKFZp761D112, MT3-MMP",ENSG00000156103,Matrix metallopeptidase 16,8,88032009-88328025,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA023693,Uncertain,NA,Approved,Vesicles<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 9.6,gallbladder: 4.2,Cell line enhanced,NA,AN3-CA: 27.2;SH-SY5Y: 17.2;WM-115: 28.4
MMP19,"MMP18, RASI-1",ENSG00000123342,Matrix metallopeptidase 19,12,55835433-55842966,"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA070804,NA,NA,Approved,Endoplasmic reticulum<br>Vesicles,Renal cancer:8.56e-9 (unfavourable),Expressed in all,Tissue enhanced,NA,adipose tissue: 64.2;gallbladder: 97.3,placenta: 28.2,Cell line enriched,7,BEWO: 141.1
MMP2,"CLG4, CLG4A, TBE-1",ENSG00000087245,Matrix metallopeptidase 2,16,55389700-55506691,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001939, CAB002788",Approved,NA,Uncertain,Vesicles<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,gallbladder: 1682.1,urinary bladder: 910.7,Cell line enhanced,NA,ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5
MMP3,"STMY, STMY1",ENSG00000149968,Matrix metallopeptidase 3,11,102835801-102843803,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007875,Uncertain,NA,Supported,Vesicles,"Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,NA,appendix: 26.5;endometrium: 58.6,urinary bladder: 9.0,Group enriched,15,BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8
MMP7,"MPSL1, PUMP-1",ENSG00000137673,Matrix metallopeptidase 7,11,102520508-102530753,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB025869, HPA051358",Supported,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,gallbladder: 820.8,breast: 201.7,Cell line enhanced,NA,A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4
MMRN2,"EMILIN3, EndoGlyx-1, FLJ13465",ENSG00000173269,Multimerin 2,10,86935540-86969481,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA020741,Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,placenta: 101.6,Cell line enhanced,NA,CAPAN-2: 78.1;HUVEC TERT2: 155.0;TIME: 182.9
MOSPD1,dJ473B4,ENSG00000101928,Motile sperm domain containing 1,X,134887626-134915267,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA031158,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 42.4,Expressed in all,NA,NA
MPLKIP,"C7orf11, ORF20, TTDN1",ENSG00000168303,M-phase specific PLK1 interacting protein,7,40126023-40134659,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA058457, HPA065463",Uncertain,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,liver: 4.3,Expressed in all,NA,NA
MPO,NA,ENSG00000005381,Myeloperoxidase,17,58269856-58280935,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000059, HPA021147, HPA061464",Enhanced,NA,Supported,Nucleus<br>Vesicles,NA,Tissue enhanced,Tissue enriched,82,bone marrow: 2499.6,salivary gland: 30.6,Group enriched,98,HL-60: 2786.8;NB-4: 2892.7
MPPED2,"239FB, C11orf8, D11S302E, dJ1024C24.1, dJ873F21.1, FAM1B, Hs.46638",ENSG00000066382,Metallophosphoesterase domain containing 2,11,30384493-30586872,Predicted intracellular proteins,Evidence at protein level,HPA062575,NA,NA,Approved,Nucleoli<br>Vesicles<br>Mitochondria,NA,Mixed,Tissue enhanced,NA,"cervix, uterine: 38.7;thyroid gland: 43.7",prostate: 20.9,Cell line enhanced,NA,HaCaT: 19.2;HAP1: 13.2;RT4: 7.3;SH-SY5Y: 7.2
MPV17L,"FLJ39599, MLPH1, MLPH2, MPV17L1",ENSG00000156968,MPV17 mitochondrial inner membrane protein like,16,15395754-15413268,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA041180,Uncertain,NA,Supported,Vesicles,Renal cancer:1.48e-11 (favourable),Mixed,Mixed,NA,NA,breast: 10.3,Cell line enhanced,NA,HMC-1: 35.5
MREG,"DSU, FLJ10116, WDT2",ENSG00000118242,Melanoregulin,2,215942805-216034096,Predicted intracellular proteins,Evidence at protein level,HPA068583,NA,NA,Approved,Vesicles,Thyroid cancer:4.20e-4 (favourable),Expressed in all,Mixed,NA,NA,esophagus: 29.4,Cell line enhanced,NA,MCF7: 74.2
MRPL17,"MRP-L26, RPML26",ENSG00000158042,Mitochondrial ribosomal protein L17,11,6680782-6683401,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA043666, HPA050552",Uncertain,NA,Uncertain,Nucleoli<br>Golgi apparatus<br>Vesicles,"Renal cancer:3.15e-7 (unfavourable), Liver cancer:2.59e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 37.0,Expressed in all,NA,NA
MRPL34,"L34mt, MGC24974, MGC2633",ENSG00000130312,Mitochondrial ribosomal protein L34,19,17292609-17306843,"Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins",Evidence at protein level,HPA049276,Uncertain,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,"Renal cancer:4.29e-6 (favourable), Pancreatic cancer:4.87e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,kidney: 76.6,Expressed in all,NA,NA
MRPL50,"FLJ20493, MRP-L50",ENSG00000136897,Mitochondrial ribosomal protein L50,9,101387633-101398614,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA022925, HPA056854",Approved,NA,Supported,Vesicles<br>Cytosol,Renal cancer:1.21e-10 (favourable),Expressed in all,Expressed in all,NA,NA,adrenal gland: 20.8,Expressed in all,NA,NA
MRPL55,NA,ENSG00000162910,Mitochondrial ribosomal protein L55,1,228106679-228109312,"Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins",Evidence at protein level,HPA027641,Supported,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.62e-6 (unfavourable), Ovarian cancer:6.76e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 40.9,Expressed in all,NA,NA
MRPS24,"HSPC335, MRP-S24",ENSG00000062582,Mitochondrial ribosomal protein S24,7,43866558-43869893,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA020983,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Lung cancer:1.91e-4 (unfavourable), Renal cancer:9.89e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,skeletal muscle: 147.5,Expressed in all,NA,NA
MSH2,"COCA1, HNPCC, HNPCC1",ENSG00000095002,MutS homolog 2,2,47402969-47562311,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009572, HPA066845, CAB070867",Supported,NA,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 32.2,Expressed in all,NA,NA
MSH5,G7,ENSG00000204410,MutS homolog 5,6,31739948-31762834,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA062688,NA,NA,Approved,Endoplasmic reticulum<br>Vesicles,NA,Mixed,Mixed,NA,NA,skin: 1.7,Mixed,NA,NA
MSH6,GTBP,ENSG00000116062,MutS homolog 6,2,47695530-47810101,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009091, HPA028376, HPA028446, CAB070870",Enhanced,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Renal cancer:1.06e-7 (unfavourable), Endometrial cancer:1.34e-4 (unfavourable), Liver cancer:7.86e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 74.5,Expressed in all,NA,NA
MSI1,NA,ENSG00000135097,Musashi RNA binding protein 1,12,120341330-120369180,Predicted intracellular proteins,Evidence at protein level,HPA064401,NA,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Pancreatic cancer:5.99e-4 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 17.5;testis: 14.6,skeletal muscle: 7.2,Cell line enhanced,NA,AF22: 118.2;HAP1: 57.0;NTERA-2: 62.4;SCLC-21H: 104.1;SH-SY5Y: 45.6
MSLN,"CAK1, MPF",ENSG00000102854,Mesothelin,16,760762-768865,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002216, HPA017172",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)",Tissue enhanced,Group enriched,9,fallopian tube: 445.8;lung: 105.4,epididymis: 29.1,Cell line enhanced,NA,CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2
MSMP,"PC-3, PSMP",ENSG00000215183,"Microseminoprotein, prostate associated",9,35752990-35756613,Predicted intracellular proteins,Evidence at protein level,HPA055174,Uncertain,NA,Supported,Vesicles<br>Cytosol,NA,Not detected,Tissue enriched,5,placenta: 1.8,appendix: 0.3,Group enriched,8,HUVEC TERT2: 72.1;PC-3: 101.9
MSS51,"FLJ39565, ZMYND17",ENSG00000166343,MSS51 mitochondrial translational activator,10,73423579-73433561,Predicted intracellular proteins,Evidence at protein level,HPA038564,NA,NA,Uncertain,Vesicles<br>Cytosol,NA,Mixed,Group enriched,15,parathyroid gland: 162.6;skeletal muscle: 81.4,heart muscle: 8.3,Mixed,NA,NA
MTA3,KIAA1266,ENSG00000057935,Metastasis associated 1 family member 3,2,42494569-42756947,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA039433,Approved,NA,Supported,Nucleus<br>Vesicles,"Endometrial cancer:2.30e-4 (unfavourable), Liver cancer:4.69e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 52.4,Mixed,NA,NA
MTFR2,"DUFD1, FAM54A",ENSG00000146410,Mitochondrial fission regulator 2,6,136231024-136250335,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA029792, HPA029794",Approved,NA,Uncertain,Vesicles,"Lung cancer:8.28e-4 (unfavourable), Endometrial cancer:9.64e-4 (unfavourable)",Mixed,Tissue enhanced,NA,testis: 12.7,bone marrow: 10.2,Mixed,NA,NA
MTHFSD,FLJ12998,ENSG00000103248,Methenyltetrahydrofolate synthetase domain containing,16,86530176-86555235,Predicted intracellular proteins,Evidence at protein level,HPA041333,Uncertain,NA,Approved,Nucleus<br>Vesicles,Colorectal cancer:9.88e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 33.0,Mixed,NA,NA
MTMR2,"CMT4B, KIAA1073",ENSG00000087053,Myotubularin related protein 2,11,95832882-95925315,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA049831,Approved,NA,Supported,Vesicles,"Liver cancer:1.61e-8 (unfavourable), Pancreatic cancer:3.60e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 57.8,Expressed in all,NA,NA
MTOR,"FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1",ENSG00000198793,Mechanistic target of rapamycin,1,11106535-11262507,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB069425, HPA071227",Approved,NA,Approved,Vesicles<br>Cytosol,Renal cancer:1.49e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 62.2,Expressed in all,NA,NA
MUC5AC,MUC5,ENSG00000215182,"Mucin 5AC, oligomeric mucus/gel-forming",11,1157953-1201138,Predicted secreted proteins,Evidence at protein level,"CAB002774, CAB009395, HPA040456, HPA040615",Enhanced,NA,Uncertain,Vesicles,NA,Tissue enhanced,Tissue enriched,61,stomach: 179.1,"cervix, uterine: 2.9",Cell line enriched,18,A549: 18.0
MUC5B,"MG1, MUC5",ENSG00000117983,"Mucin 5B, oligomeric mucus/gel-forming",11,1223066-1262172,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008246, CAB009396",Enhanced,NA,Supported,Vesicles,NA,Mixed,Group enriched,11,"cervix, uterine: 350.5;gallbladder: 344.7",colon: 31.8,Cell line enriched,7,PC-3: 111.2
MVB12B,"C9orf28, FAM125B, FLJ00001",ENSG00000196814,Multivesicular body subunit 12B,9,126326849-126507041,Predicted intracellular proteins,Evidence at protein level,"HPA043683, HPA049383",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,Pancreatic cancer:7.89e-4 (favourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 36.5,Cell line enhanced,NA,AF22: 34.2
MYBBP1A,"FLJ37886, P160, PAP2",ENSG00000132382,MYB binding protein 1a,17,4538897-4555631,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005466,Supported,NA,Supported,Nucleoli<br>Vesicles,"Pancreatic cancer:1.61e-4 (favourable), Renal cancer:5.95e-4 (unfavourable), Thyroid cancer:8.12e-4 (unfavourable), Melanoma:8.47e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 21.6,Expressed in all,NA,NA
MYCBP2,"FLJ10106, KIAA0916, PAM",ENSG00000005810,"MYC binding protein 2, E3 ubiquitin protein ligase",13,77044655-77327050,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA058807,NA,NA,Supported,Nucleus<br>Vesicles,Renal cancer:5.01e-5 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 82.7,Expressed in all,NA,NA
MYCBPAP,"AMAP-1, DKFZp434N1415",ENSG00000136449,MYCBP associated protein,17,50508384-50531501,Predicted intracellular proteins,Evidence at protein level,"HPA023257, HPA024405",Enhanced,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,12,testis: 91.5,fallopian tube: 7.5,Cell line enhanced,NA,HDLM-2: 3.7
MYD88,NA,ENSG00000172936,Myeloid differentiation primary response 88,3,38138478-38143022,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB009104,Approved,NA,Supported,Vesicles<br>Mitochondria<br>Cytosol,Breast cancer:8.45e-4 (favourable),Expressed in all,Mixed,NA,NA,lung: 57.1,Expressed in all,NA,NA
MYEOV,OCIM,ENSG00000172927,Myeloma overexpressed,11,69294138-69367726,Predicted membrane proteins,Evidence at transcript level,HPA012949,Uncertain,NA,Approved,Nucleus<br>Vesicles,"Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)",Mixed,Group enriched,5,adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8,appendix: 1.0,Cell line enhanced,NA,A-431: 154.1;A549: 74.9;U-2 OS: 38.7
MYL6B,MLC1SA,ENSG00000196465,Myosin light chain 6B,12,56152256-56159647,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038887, HPA046859, HPA063034",Enhanced,NA,Approved,Vesicles,Liver cancer:2.87e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,skeletal muscle: 149.6,Expressed in all,NA,NA
MYO16,"KIAA0865, Myo16b, MYR8, NYAP3, PPP1R107",ENSG00000041515,Myosin XVI,13,108596152-109208007,Predicted intracellular proteins,Evidence at protein level,"HPA040110, HPA058769, HPA071948",Uncertain,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 2.1,testis: 1.0,Cell line enhanced,NA,SH-SY5Y: 2.4;U-2197: 1.2
MYOM3,FLJ35961,ENSG00000142661,Myomesin 3,1,24056035-24112175,Predicted intracellular proteins,Evidence at protein level,"HPA028132, HPA029752",Uncertain,NA,Approved,Vesicles,Renal cancer:4.28e-6 (favourable),Tissue enhanced,Group enriched,5,heart muscle: 69.9;kidney: 31.8;skeletal muscle: 86.5,testis: 12.1,Cell line enhanced,NA,A549: 4.2;Hep G2: 12.2
MYPN,MYOP,ENSG00000138347,Myopalladin,10,68106117-68212017,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA036299, HPA061494",Enhanced,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,NA,Tissue enriched,Group enriched,27,heart muscle: 41.6;skeletal muscle: 99.9,prostate: 2.6,Cell line enhanced,NA,BJ: 33.6;fHDF/TERT166: 87.0;HBF TERT88: 24.6;LHCN-M2: 39.6
MYT1L,"KIAA1106, NZF1, ZC2H2C2, ZC2HC4B",ENSG00000186487,Myelin transcription factor 1 like,2,1789113-2331260,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA060245,NA,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,11,cerebral cortex: 60.0,testis: 5.3,Group enriched,12,SCLC-21H: 7.8;SH-SY5Y: 5.2
NAA35,"bA379P1.1, FLJ21613, FLJ22643, MAK10",ENSG00000135040,"N(alpha)-acetyltransferase 35, NatC auxiliary subunit",9,85941146-86022298,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021547, HPA051586",Approved,NA,Supported,Vesicles,Liver cancer:1.16e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 37.9,Expressed in all,NA,NA
NADK,FLJ13052,ENSG00000008130,NAD kinase,1,1751232-1780457,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048909, HPA053368",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,spleen: 77.4,Expressed in all,NA,NA
NAP1L3,"MB20, MGC26312, NPL3",ENSG00000186310,Nucleosome assembly protein 1 like 3,X,93670930-93673568,Predicted intracellular proteins,Evidence at protein level,HPA026075,NA,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 131.3,testis: 31.1,Cell line enhanced,NA,AF22: 13.4;HAP1: 13.7;NTERA-2: 24.0;U-2197: 15.0
NBPF1,"FLJ20719, KIAA1693",ENSG00000219481,Neuroblastoma breakpoint family member 1,1,16562319-16613562,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Approved,NA,Approved,Vesicles,Renal cancer:1.06e-4 (favourable),Expressed in all,Mixed,NA,NA,testis: 21.9,Mixed,NA,NA
NBPF10,AG1,ENSG00000271425,Neuroblastoma breakpoint family member 10,1,146064699-146144804,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Approved,NA,Approved,Vesicles,NA,Not detected,Mixed,NA,NA,skin: 8.1,Mixed,NA,NA
NBPF11,NBPF24,ENSG00000263956,Neuroblastoma breakpoint family member 11,1,148102046-148152322,Predicted intracellular proteins,Evidence at protein level,"HPA038748, HPA038752, HPA042595, HPA043105, HPA044023, HPA046971, HPA058050",Uncertain,NA,Approved,Vesicles,"Urothelial cancer:3.20e-5 (favourable), Lung cancer:6.87e-4 (favourable)",Mixed,Expressed in all,NA,NA,epididymis: 20.8,Mixed,NA,NA
NBPF12,"COAS1, KIAA1245",ENSG00000268043,Neuroblastoma breakpoint family member 12,1,146938744-146996202,Predicted intracellular proteins,Evidence at protein level,"HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Approved,NA,Approved,Vesicles,"Pancreatic cancer:9.01e-7 (favourable), Urothelial cancer:2.47e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 19.8,Expressed in all,NA,NA
NBPF14,DJ328E19.C1.1,ENSG00000270629,Neuroblastoma breakpoint family member 14,1,148531385-148679751,Predicted intracellular proteins,Evidence at protein level,"HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Uncertain,NA,Approved,Vesicles,NA,Mixed,Expressed in all,NA,NA,skin: 66.5,Mixed,NA,NA
NBPF15,"MGC8902, NBPF16",ENSG00000266338,Neuroblastoma breakpoint family member 15,1,144421386-144461674,Predicted intracellular proteins,Evidence at protein level,"HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Approved,NA,Approved,Vesicles,Renal cancer:4.11e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,epididymis: 25.4,Mixed,NA,NA
NBPF19,NA,ENSG00000271383,Neuroblastoma breakpoint family member 19,1,149390623-149556361,Predicted intracellular proteins,Evidence at protein level,"HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Uncertain,NA,Approved,Vesicles,NA,Mixed,Expressed in all,NA,NA,skin: 79.4,Expressed in all,NA,NA
NBPF20,NA,ENSG00000162825,Neuroblastoma breakpoint family member 20,1,145289900-145405778,Predicted intracellular proteins,Evidence at protein level,"HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Uncertain,NA,Approved,Vesicles,NA,Not detected,Mixed,NA,NA,parathyroid gland: 17.1,Mixed,NA,NA
NBPF26,NA,ENSG00000273136,Neuroblastoma breakpoint family member 26,1,120723923-120841481,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Uncertain,NA,Approved,Vesicles,NA,Mixed,Expressed in all,NA,NA,skin: 51.6,Mixed,NA,NA
NBPF9,AE01,ENSG00000269713,Neuroblastoma breakpoint family member 9,1,149054027-149103561,Predicted intracellular proteins,Evidence at protein level,"HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050",Approved,NA,Approved,Vesicles,NA,Mixed,Expressed in all,NA,NA,thyroid gland: 23.1,Expressed in all,NA,NA
NBR1,"1A1-3B, CA125, KIAA0049, M17S2",ENSG00000188554,"NBR1, autophagy cargo receptor",17,43170481-43211689,Predicted intracellular proteins,Evidence at protein level,"HPA022944, HPA022999, HPA023999",Approved,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles,Renal cancer:2.00e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 259.6,Expressed in all,NA,NA
NCAN,CSPG3,ENSG00000130287,Neurocan,19,19211973-19252233,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA036814,Enhanced,NA,Uncertain,Vesicles<br>Centrosome,NA,Tissue enriched,Tissue enriched,101,cerebral cortex: 183.5,testis: 1.8,Cell line enhanced,NA,AF22: 1.0;SCLC-21H: 2.7;SH-SY5Y: 1.7
NDFIP2,"KIAA1165, N4wbp5a",ENSG00000102471,Nedd4 family interacting protein 2,13,79481124-79556075,Predicted membrane proteins,Evidence at protein level,HPA009160,Uncertain,NA,Enhanced,Vesicles,"Renal cancer:4.18e-5 (favourable), Head and neck cancer:5.99e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 96.0,Mixed,NA,NA
NDNF,"C4orf31, FLJ23191",ENSG00000173376,Neuron derived neurotrophic factor,4,121035613-121073021,Predicted secreted proteins,Evidence at protein level,HPA048881,NA,NA,Supported,Vesicles,Renal cancer:3.26e-4 (unfavourable),Tissue enhanced,Tissue enhanced,NA,lung: 159.9;placenta: 86.6,ovary: 52.7,Cell line enhanced,NA,fHDF/TERT166: 37.8;U-266/70: 16.0;U-266/84: 60.4
NDP,"EVR2, norrin",ENSG00000124479,"NDP, norrin cystine knot growth factor",X,43948776-43973504,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA003095,Uncertain,NA,Supported,Nucleus<br>Nucleoli<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,ovary: 53.3,fallopian tube: 31.3,Cell line enriched,16,U-87 MG: 67.6
NECAB2,EFCBP2,ENSG00000103154,N-terminal EF-hand calcium binding protein 2,16,83968632-84002776,Predicted intracellular proteins,Evidence at protein level,"HPA013998, HPA014144, CAB068211",Enhanced,Supported,Approved,Vesicles,Renal cancer:1.58e-4 (unfavourable),Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 46.8,kidney: 10.6,Cell line enhanced,NA,AF22: 10.4;SCLC-21H: 47.1;U-87 MG: 13.8
NECAP1,DKFZP566B183,ENSG00000089818,NECAP endocytosis associated 1,12,8076939-8097859,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA053980, HPA063300",Uncertain,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 117.8,parathyroid gland: 34.8,Expressed in all,NA,NA
NEGR1,"IGLON4, KILON, MGC46680, Ntra",ENSG00000172260,Neuronal growth regulator 1,1,71395940-72282734,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA011894,Uncertain,NA,Approved,Vesicles<br>Actin filaments<br>Cytosol,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 54.3,gallbladder: 16.9,Mixed,NA,NA
NEIL2,"FLJ31644, MGC2832, MGC4505, NEH2",ENSG00000154328,Nei like DNA glycosylase 2,8,11769639-11787346,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA073029, HPA073916",NA,NA,Enhanced,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 45.4,Mixed,NA,NA
NEK10,FLJ32685,ENSG00000163491,NIMA related kinase 10,3,27110085-27369460,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038941,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Breast cancer:4.20e-4 (favourable),Tissue enriched,Tissue enhanced,NA,testis: 65.9,breast: 18.6,Cell line enhanced,NA,LHCN-M2: 6.8;U-2 OS: 7.1
NELFCD,"HSPC130, NELF-C, NELF-D, TH1, TH1L",ENSG00000101158,Negative elongation factor complex member C/D,20,58981208-58995133,Predicted intracellular proteins,Evidence at protein level,"HPA050641, HPA066262",NA,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles<br>Cytosol,"Endometrial cancer:4.98e-5 (unfavourable), Liver cancer:1.90e-4 (unfavourable), Prostate cancer:3.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 52.6,Expressed in all,NA,NA
NELL2,NRP2,ENSG00000184613,Neural EGFL like 2,12,44508275-44921848,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA035714, HPA035715",Uncertain,NA,Approved,Vesicles,Pancreatic cancer:5.56e-4 (favourable),Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 204.1;fallopian tube: 96.7,prostate: 46.5,Cell line enhanced,NA,AF22: 102.5;NTERA-2: 41.0;SCLC-21H: 88.2
NET1,"ARHGEF8, NET1A",ENSG00000173848,Neuroepithelial cell transforming 1,10,5412551-5458463,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA020068,Uncertain,NA,Approved,Nucleus<br>Vesicles,"Liver cancer:3.87e-5 (unfavourable), Pancreatic cancer:8.27e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,rectum: 96.4,Expressed in all,NA,NA
NEU3,NA,ENSG00000162139,Neuraminidase 3,11,74988134-75018893,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038729, HPA038730, HPA070381",Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,Pancreatic cancer:5.98e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 25.4,Expressed in all,NA,NA
NEURL1B,"DKFZP761M1511, Neur2",ENSG00000214357,Neuralized E3 ubiquitin protein ligase 1B,5,172641266-172691540,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037612,Approved,NA,Supported,Vesicles,Renal cancer:3.00e-6 (unfavourable),Expressed in all,Mixed,NA,NA,seminal vesicle: 45.0,Cell line enhanced,NA,REH: 39.9
NEURL2,"C20orf163, dJ337O18.6, FLJ30259, Ozz, Ozz-E3",ENSG00000124257,Neuralized E3 ubiquitin protein ligase 2,20,45888625-45891287,Predicted intracellular proteins,Evidence at transcript level,"HPA043402, HPA059842",Approved,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,ovary: 8.4,Mixed,NA,NA
NFE2L3,Nrf3,ENSG00000050344,"Nuclear factor, erythroid 2 like 3",7,26152240-26187125,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA055889,Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:7.58e-12 (unfavourable), Pancreatic cancer:6.62e-5 (unfavourable), Stomach cancer:2.14e-4 (favourable)",Expressed in all,Tissue enhanced,NA,placenta: 50.3,appendix: 14.3,Cell line enhanced,NA,BEWO: 132.0;NTERA-2: 115.5
NHLRC1,"bA204B7.2, EPM2B, malin",ENSG00000187566,NHL repeat containing E3 ubiquitin protein ligase 1,6,18120440-18122687,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA066030,NA,NA,Uncertain,Vesicles,"Urothelial cancer:5.30e-4 (favourable), Endometrial cancer:9.01e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 4.5,Cell line enhanced,NA,EFO-21: 6.4;SCLC-21H: 7.2
NIF3L1,"ALS2CR1, CALS-7, MDS015",ENSG00000196290,NGG1 interacting factor 3 like 1,2,200889327-200903930,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036335, HPA036336, HPA061466",Enhanced,NA,Approved,Vesicles,"Liver cancer:2.51e-6 (unfavourable), Endometrial cancer:9.52e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 40.6,Expressed in all,NA,NA
NIPBL,"DKFZp434L1319, FLJ11203, FLJ12597, FLJ13354, FLJ13648, IDN3, Scc2",ENSG00000164190,"NIPBL, cohesin loading factor",5,36876759-37066413,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040834, HPA058239",Approved,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 43.0,Expressed in all,NA,NA
NKG7,"GIG1, GMP-17",ENSG00000105374,Natural killer cell granule protein 7,19,51371606-51372715,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA071454,NA,NA,Approved,Vesicles,"Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable)",Expressed in all,Tissue enhanced,NA,bone marrow: 351.3;spleen: 151.2,lymph node: 122.0,Cell line enhanced,NA,NB-4: 109.5;THP-1: 34.5;U-937: 34.9
NKX2-1,"BCH, NKX2A, TITF1, TTF-1, TTF1",ENSG00000136352,NK2 homeobox 1,14,36516392-36521149,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB000078, CAB053633, HPA074316",Enhanced,NA,Uncertain,Golgi apparatus<br>Vesicles,NA,Group enriched,Group enriched,177,lung: 101.3;thyroid gland: 103.5,stomach: 0.5,Cell line enriched,36,SCLC-21H: 119.8
NLRP2,"CLR19.9, FLJ20510, NALP2, NBS1, PAN1, PYPAF2",ENSG00000022556,NLR family pyrin domain containing 2,19,54953130-55001142,Predicted intracellular proteins,Evidence at protein level,"HPA020765, HPA021183",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles<br>Cytosol,Pancreatic cancer:2.91e-4 (unfavourable),Tissue enriched,Mixed,NA,NA,testis: 5.6,Cell line enhanced,NA,BEWO: 33.1;K-562: 11.5;U-266/84: 11.6
NME6,"IPIA-ALPHA, NM23-H6",ENSG00000172113,NME/NM23 nucleoside diphosphate kinase 6,3,48293264-48301685,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017909,Approved,NA,Approved,Vesicles,"Liver cancer:2.17e-7 (unfavourable), Renal cancer:3.18e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 27.7,Expressed in all,NA,NA
NMRK2,"ITGB1BP3, MIBP, NRK2",ENSG00000077009,Nicotinamide riboside kinase 2,19,3933103-3942416,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049909, HPA054792, HPA072450",Approved,NA,Enhanced,Nucleoplasm<br>Vesicles,Renal cancer:1.19e-4 (favourable),Tissue enhanced,Group enriched,49,heart muscle: 374.4;skeletal muscle: 218.4,esophagus: 6.1,Group enriched,9,BEWO: 28.1;NTERA-2: 24.3
NOL12,"MGC3731, Nop25, RRP17",ENSG00000273899,Nucleolar protein 12,22,37681673-37693478,Predicted intracellular proteins,Evidence at protein level,HPA003547,Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,"Renal cancer:2.56e-6 (unfavourable), Cervical cancer:6.80e-5 (favourable), Urothelial cancer:3.24e-4 (favourable), Lung cancer:9.41e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 25.1,Expressed in all,NA,NA
NOS1AP,"CAPON, KIAA0464",ENSG00000198929,Nitric oxide synthase 1 adaptor protein,1,162069774-162370475,Predicted intracellular proteins,Evidence at protein level,"CAB018582, HPA030066, HPA055561",Approved,NA,Approved,Nucleus<br>Vesicles,NA,Mixed,Tissue enriched,6,cerebral cortex: 23.4,adrenal gland: 3.8,Cell line enhanced,NA,A-431: 3.6;HEL: 4.5
NOV,"CCN3, IGFBP9",ENSG00000136999,Nephroblastoma overexpressed,8,119416306-119424353,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA018449, HPA019684, CAB034423",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Tissue enriched,39,adrenal gland: 1392.1,prostate: 35.4,Cell line enhanced,NA,BJ hTERT+: 99.0;U-2197: 116.0
NOX3,GP91-3,ENSG00000074771,NADPH oxidase 3,6,155395370-155455903,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA073837,NA,NA,Uncertain,Vesicles,NA,Not detected,Not detected,NA,NA,adrenal gland: 0.1,Cell line enriched,7,MCF7: 2.9
NOXA1,"FLJ25475, NY-CO-31, SDCCAG31",ENSG00000188747,NADPH oxidase activator 1,9,137423350-137434406,Predicted intracellular proteins,Evidence at protein level,HPA044781,Uncertain,NA,Approved,Vesicles,Renal cancer:2.65e-4 (favourable),Expressed in all,Expressed in all,NA,NA,skin: 21.5,Cell line enhanced,NA,CAPAN-2: 11.1;EFO-21: 10.7;MCF7: 15.1;T-47d: 17.6
NPC1,NA,ENSG00000141458,NPC intracellular cholesterol transporter 1,18,23506184-23586898,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA026618, CAB070132, HPA077445",Approved,NA,Supported,Nucleus<br>Vesicles,Liver cancer:2.26e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 110.1,Expressed in all,NA,NA
NPHP1,"JBTS4, NPH1, SLSN1",ENSG00000144061,Nephrocystin 1,2,110122311-110205066,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA046093, HPA074071",Uncertain,NA,Uncertain,Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 46.0,fallopian tube: 28.4,Mixed,NA,NA
NR0B1,"AHC, AHCH, DAX1, DSS",ENSG00000169297,Nuclear receptor subfamily 0 group B member 1,X,30304206-30309598,"Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA061948, HPA067207",NA,NA,Supported,Nuclear speckles<br>Vesicles<br>Microtubule organizing center,NA,Tissue enhanced,Group enriched,8,adrenal gland: 27.8;testis: 35.0,ovary: 4.1,Cell line enhanced,NA,A549: 51.8;RT4: 14.5;U-87 MG: 7.9
NREP,"C5orf13, D4S114, P311, PRO1873, PTZ17, SEZ17",ENSG00000134986,Neuronal regeneration related protein,5,111662621-111997464,Predicted intracellular proteins,Evidence at protein level,HPA000545,Approved,NA,Approved,Vesicles,Stomach cancer:3.09e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 175.0,Cell line enhanced,NA,AF22: 411.4;SH-SY5Y: 475.7
NRG3,NA,ENSG00000185737,Neuregulin 3,10,81875314-82987179,"Cancer-related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA075789,NA,NA,Approved,Vesicles,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 30.3,fallopian tube: 7.3,Cell line enhanced,NA,HEK93: 1.4;SK-MEL-30: 2.6;U-2 OS: 2.9
NRSN1,"p24, VMP",ENSG00000152954,Neurensin 1,6,24126122-24154900,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA061006,Approved,NA,Approved,Nucleus<br>Vesicles,NA,Tissue enriched,Tissue enriched,14,cerebral cortex: 96.3,adrenal gland: 6.6,Cell line enhanced,NA,SCLC-21H: 14.0;SH-SY5Y: 10.0
NRSN2,"C20orf98, dJ1103G7.6",ENSG00000125841,Neurensin 2,20,346782-359660,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA015967,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Pancreatic cancer:1.61e-4 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 126.1,parathyroid gland: 69.0,Mixed,NA,NA
NSMCE1,NSE1,ENSG00000169189,"NSE1 homolog, SMC5-SMC6 complex component",16,27224991-27268794,Predicted intracellular proteins,Evidence at protein level,"HPA041567, HPA043091",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 122.9,Expressed in all,NA,NA
NSUN7,FLJ14001,ENSG00000179299,NOP2/Sun RNA methyltransferase family member 7,4,40749897-40809985,Predicted intracellular proteins,Evidence at protein level,HPA020653,Uncertain,NA,Supported,Vesicles,Renal cancer:2.76e-8 (favourable),Mixed,Tissue enhanced,NA,testis: 31.5,fallopian tube: 11.4,Cell line enhanced,NA,CAPAN-2: 5.0;Karpas-707: 2.9;T-47d: 3.9
NTRK1,"MTC, TRK, TRKA",ENSG00000198400,Neurotrophic receptor tyrosine kinase 1,1,156815640-156881850,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB004606, HPA035799, HPA076570",Approved,NA,Uncertain,Vesicles<br>Cytosol,NA,Tissue enhanced,Tissue enriched,6,adrenal gland: 9.5,testis: 1.6,Cell line enhanced,NA,HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1
NUDT5,"hYSAH1, YSA1H",ENSG00000165609,Nudix hydrolase 5,10,12165325-12196144,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019827,Approved,NA,Approved,Nucleus<br>Vesicles<br>Centrosome,Renal cancer:7.14e-12 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 45.6,Expressed in all,NA,NA
NUP214,"CAIN, CAN, D9S46E, N214",ENSG00000126883,Nucleoporin 214,9,131125561-131234670,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA048789,NA,NA,Supported,Nucleus<br>Vesicles<br>Focal adhesion sites,Renal cancer:2.39e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 123.0,Expressed in all,NA,NA
NUP98,NUP96,ENSG00000110713,Nucleoporin 98,11,3671083-3797792,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA074810,NA,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 150.7,Expressed in all,NA,NA
NXPE3,"FAM55C, MGC15606",ENSG00000144815,Neurexophilin and PC-esterase domain family member 3,3,101779202-101827392,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA036259,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:7.76e-6 (unfavourable),Mixed,Mixed,NA,NA,parathyroid gland: 34.5,Expressed in all,NA,NA
NYAP1,"C7orf51, FLJ37538, KIAA1486L",ENSG00000166924,Neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1,7,100483927-100494799,Predicted intracellular proteins,Evidence at protein level,HPA022251,Uncertain,NA,Supported,Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 25.1;testis: 7.7,adrenal gland: 3.3,Cell line enhanced,NA,HUVEC TERT2: 3.2;SH-SY5Y: 9.9
NYNRIN,"CGIN1, FLJ11811, KIAA1305",ENSG00000205978,NYN domain and retroviral integrase containing,14,24398786-24419288,Predicted intracellular proteins,Evidence at protein level,HPA018945,Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,ovary: 42.7,Cell line enhanced,NA,HUVEC TERT2: 28.9;RT4: 23.0
OAZ1,"AZI, MGC138338, OAZ",ENSG00000104904,Ornithine decarboxylase antizyme 1,19,2269509-2273490,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA009291,Uncertain,NA,Approved,Vesicles<br>Microtubule organizing center,"Pancreatic cancer:4.10e-5 (favourable), Liver cancer:1.73e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 268.1,Expressed in all,NA,NA
OLFM3,NOE3,ENSG00000118733,Olfactomedin 3,1,101802574-101997030,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA050297,NA,NA,Uncertain,Vesicles,NA,Mixed,Tissue enriched,15,cerebral cortex: 26.7,adrenal gland: 1.8,Group enriched,11,AF22: 5.5;HAP1: 4.0;HEL: 3.2;SCLC-21H: 2.6;SH-SY5Y: 2.3
OLFML3,"HNOEL-iso, OLF44",ENSG00000116774,Olfactomedin like 3,1,113979391-114035572,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA027991,NA,NA,Supported,Vesicles,Renal cancer:3.45e-5 (unfavourable),Expressed in all,Mixed,NA,NA,"cervix, uterine: 266.9",Cell line enhanced,NA,ASC diff: 395.8;BJ hTERT+: 302.6;HSkMC: 419.4;LHCN-M2: 496.4
ORM1,NA,ENSG00000229314,Orosomucoid 1,9,114323056-114326475,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB006265, HPA046438, HPA047725, HPA057726",Approved,NA,Approved,Golgi apparatus<br>Vesicles,Renal cancer:2.35e-4 (unfavourable),Tissue enriched,Tissue enriched,69,liver: 10591.2,bone marrow: 152.4,Cell line enriched,11,Hep G2: 797.0
ORM2,"AGP-B, AGP-B', AGP2",ENSG00000228278,Orosomucoid 2,9,114329869-114333252,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA046438, HPA047725, HPA057726",Approved,NA,Approved,Golgi apparatus<br>Vesicles,Renal cancer:1.23e-9 (unfavourable),Tissue enriched,Tissue enriched,96,liver: 3772.7,prostate: 39.2,Cell line enriched,195,Hep G2: 567.8
OSBPL5,"KIAA1534, ORP5",ENSG00000021762,Oxysterol binding protein like 5,11,3087116-3166739,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA038335, HPA038712, HPA058727",Approved,NA,Enhanced,Vesicles,NA,Expressed in all,Mixed,NA,NA,spleen: 19.8,Cell line enhanced,NA,NB-4: 47.3
OSBPL8,"MST120, MSTP120, ORP8, OSBP10",ENSG00000091039,Oxysterol binding protein like 8,12,76351797-76559809,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA001309,Uncertain,NA,Approved,Vesicles<br>Cytosol,Pancreatic cancer:9.79e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 39.5,Expressed in all,NA,NA
OSBPL9,NA,ENSG00000117859,Oxysterol binding protein like 9,1,51577179-51798427,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027378, HPA027397",Supported,Approved,Supported,Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 96.6,Expressed in all,NA,NA
OSTM1,"GL, HSPC019",ENSG00000081087,Osteopetrosis associated transmembrane protein 1,6,108041409-108165854,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA010851,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,"Renal cancer:1.34e-6 (unfavourable), Stomach cancer:1.20e-4 (unfavourable), Liver cancer:4.26e-4 (unfavourable), Breast cancer:4.36e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 33.6,Expressed in all,NA,NA
OXLD1,"C17orf90, MGC104712",ENSG00000204237,Oxidoreductase like domain containing 1,17,81665036-81666635,Predicted intracellular proteins,Evidence at protein level,"HPA056878, HPA057019",Uncertain,NA,Approved,Vesicles<br>Cytosol,Cervical cancer:2.91e-4 (favourable),Expressed in all,Mixed,NA,NA,testis: 10.7,Cell line enhanced,NA,A549: 54.5
OXR1,TLDC3,ENSG00000164830,Oxidation resistance 1,8,106359476-106752694,Predicted intracellular proteins,Evidence at protein level,"HPA027375, HPA027380, HPA027395",Enhanced,NA,Supported,Vesicles,"Renal cancer:5.82e-5 (favourable), Pancreatic cancer:3.85e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 110.7,Expressed in all,NA,NA
P3H1,"GROS1, LEPRE1, LEPRECAN, MGC117314",ENSG00000117385,Prolyl 3-hydroxylase 1,1,42746335-42767084,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA012113, HPA016980",Approved,NA,Approved,Nucleoli<br>Vesicles,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable)",Expressed in all,Tissue enhanced,NA,placenta: 53.5,smooth muscle: 28.8,Expressed in all,NA,NA
P4HA1,"C-P4Halpha(I), P4HA",ENSG00000122884,Prolyl 4-hydroxylase subunit alpha 1,10,73007217-73096974,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA007599, HPA026593",Enhanced,NA,Supported,Endoplasmic reticulum<br>Vesicles<br>Mitochondria,"Renal cancer:9.40e-9 (unfavourable), Head and neck cancer:1.19e-5 (unfavourable), Cervical cancer:3.19e-5 (unfavourable), Pancreatic cancer:2.85e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable), Breast cancer:9.01e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 91.7,Expressed in all,NA,NA
P4HA2,C-P4Halpha(II),ENSG00000072682,Prolyl 4-hydroxylase subunit alpha 2,5,132191838-132295315,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA016997, HPA027824, CAB062557",Enhanced,NA,Enhanced,Endoplasmic reticulum<br>Vesicles,"Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 95.3,Mixed,NA,NA
P4HTM,"EGLN4, FLJ20262, HIFPH4, P4H-TM, PH-4, PH4, PHD4",ENSG00000178467,"Prolyl 4-hydroxylase, transmembrane",3,48989886-49007154,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007199,Supported,NA,Uncertain,Vesicles<br>Cytosol,"Renal cancer:3.28e-5 (favourable), Endometrial cancer:8.18e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 50.0,Mixed,NA,NA
PACRGL,"C4orf28, MGC29898",ENSG00000163138,PARK2 coregulated like,4,20696282-20752907,Predicted intracellular proteins,Evidence at protein level,HPA054666,NA,NA,Approved,Nucleoplasm<br>Vesicles,Urothelial cancer:4.85e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 60.3,Expressed in all,NA,NA
PACSIN1,SDPI,ENSG00000124507,Protein kinase C and casein kinase substrate in neurons 1,6,34466061-34535231,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009929, HPA028852, HPA055491",Enhanced,NA,Approved,Nucleus<br>Vesicles,NA,Mixed,Tissue enriched,32,cerebral cortex: 133.6,lymph node: 4.1,Cell line enhanced,NA,MCF7: 9.2;RPMI-8226: 9.7;T-47d: 20.2;U-266/84: 11.7
PADI3,PDI3,ENSG00000142619,Peptidyl arginine deiminase 3,1,17249098-17284233,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043739,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.55e-11 (unfavourable), Endometrial cancer:3.22e-4 (unfavourable)",Tissue enhanced,Group enriched,10,esophagus: 3.7;seminal vesicle: 4.9;urinary bladder: 10.2,epididymis: 0.6,Cell line enhanced,NA,EFO-21: 13.2;RT4: 13.9;T-47d: 12.0
PAGE4,"CT16.7, GAGEC1, PAGE-4",ENSG00000101951,PAGE family member 4,X,49829260-49833973,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA023880,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,NA,Group enriched,Group enriched,6,epididymis: 1456.6;placenta: 2041.1,prostate: 269.4,Group enriched,9,CACO-2: 8.5;U-266/70: 9.3;U-266/84: 33.4
PAH,PH,ENSG00000171759,Phenylalanine hydroxylase,12,102836885-102958410,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028407, HPA031642",Enhanced,NA,Approved,Endoplasmic reticulum<br>Vesicles,Liver cancer:4.30e-4 (favourable),Tissue enriched,Tissue enhanced,NA,kidney: 504.6;liver: 722.4,gallbladder: 125.9,Cell line enriched,26,Hep G2: 161.3
PAIP2,PAIP2A,ENSG00000120727,Poly(A) binding protein interacting protein 2,5,139341587-139369720,Predicted intracellular proteins,Evidence at protein level,"HPA035945, CAB037212, HPA056766",Approved,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 306.7,Expressed in all,NA,NA
PAK2,"PAK65, PAKgamma",ENSG00000180370,P21 (RAC1) activated kinase 2,3,196739857-196832647,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,CAB007794,Approved,NA,Enhanced,Nucleus<br>Vesicles,"Pancreatic cancer:3.36e-4 (unfavourable), Prostate cancer:9.58e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 60.1,Expressed in all,NA,NA
PAPPA2,"PAPP-A2, PAPPE, PLAC3",ENSG00000116183,Pappalysin 2,1,176463171-176845605,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA018412, HPA018430",Enhanced,NA,Approved,Endoplasmic reticulum<br>Vesicles,NA,Mixed,Tissue enriched,8,placenta: 82.7,"cervix, uterine: 10.8",Cell line enriched,6,U-87 MG: 19.4
PAQR4,FLJ30002,ENSG00000162073,Progestin and adipoQ receptor family member 4,16,2969245-2973489,Predicted membrane proteins,Evidence at protein level,HPA068394,NA,NA,Approved,Vesicles,"Renal cancer:3.01e-6 (unfavourable), Stomach cancer:1.70e-4 (favourable), Liver cancer:6.86e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 54.0;parathyroid gland: 65.2,"prostate,skin: 19.2",Mixed,NA,NA
PAQR5,"FLJ20190, MPRG",ENSG00000137819,Progestin and adipoQ receptor family member 5,15,69298947-69407780,Predicted membrane proteins,Evidence at protein level,HPA076729,NA,NA,Approved,Vesicles,"Renal cancer:1.47e-14 (favourable), Pancreatic cancer:2.15e-5 (unfavourable)",Mixed,Tissue enhanced,NA,kidney: 55.8,adrenal gland: 20.8,Cell line enhanced,NA,A549: 34.9;CAPAN-2: 40.4;HMC-1: 69.7
PARG,NA,ENSG00000227345,Poly(ADP-ribose) glycohydrolase,10,49818279-49970203,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021819, HPA053007",Enhanced,NA,Enhanced,Nucleus<br>Vesicles,Liver cancer:5.57e-5 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 16.9,Expressed in all,NA,NA
PARM1,"Cipar1, DKFZP564O0823, WSC4",ENSG00000169116,Prostate androgen-regulated mucin-like protein 1,4,74933095-75050115,Predicted membrane proteins,Evidence at protein level,HPA038236,Approved,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,Thyroid cancer:1.78e-4 (unfavourable),Expressed in all,Mixed,NA,NA,thyroid gland: 206.6,Cell line enhanced,NA,ASC diff: 30.6;Karpas-707: 32.2;U-266/70: 37.9
PAX5,BSAP,ENSG00000196092,Paired box 5,9,36833275-37034185,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB026269, CAB026869, HPA056394, HPA068498",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Mixed,Tissue enhanced,NA,lymph node: 48.5;spleen: 26.2;tonsil: 33.2,appendix: 19.5,Group enriched,6,Daudi: 48.5;REH: 181.0;U-698: 61.2
PAXIP1,"CAGF28, CAGF29, PAXIP1L, PTIP, TNRC2",ENSG00000157212,PAX interacting protein 1,7,154943687-155003084,Predicted intracellular proteins,Evidence at protein level,"HPA006694, HPA016950",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 16.2,Expressed in all,NA,NA
PBLD,"FLJ14767, MAWBP, MAWDBP",ENSG00000108187,Phenazine biosynthesis like protein domain containing,10,68282660-68333049,Predicted intracellular proteins,Evidence at protein level,"HPA038035, HPA038036",Enhanced,NA,Approved,Vesicles,Liver cancer:1.44e-4 (favourable),Expressed in all,Expressed in all,NA,NA,kidney: 278.7,Expressed in all,NA,NA
PBX4,NA,ENSG00000105717,PBX homeobox 4,19,19561707-19618916,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA049859, HPA056469",Enhanced,NA,Enhanced,Vesicles,"Urothelial cancer:5.94e-7 (favourable), Cervical cancer:8.69e-6 (favourable)",Mixed,Tissue enhanced,NA,testis: 2.6;thyroid gland: 2.2,lymph node: 0.8,Cell line enhanced,NA,PC-3: 1.5;RT4: 1.6
PBXIP1,HPIP,ENSG00000163346,PBX homeobox interacting protein 1,1,154944076-154956123,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006949,Approved,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:9.22e-6 (favourable), Pancreatic cancer:2.64e-4 (favourable), Colorectal cancer:2.73e-4 (unfavourable), Head and neck cancer:7.19e-4 (favourable), Lung cancer:8.99e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 138.8,Cell line enriched,7,Karpas-707: 788.8
PCDH10,"KIAA1400, OL-PCDH",ENSG00000138650,Protocadherin 10,4,133149315-133208606,Predicted membrane proteins,Evidence at protein level,"HPA011220, HPA073462",Approved,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Group enriched,5,cerebral cortex: 62.0;placenta: 36.7;prostate: 17.6;seminal vesicle: 24.5,adrenal gland: 6.8,Cell line enhanced,NA,HUVEC TERT2: 23.1;MOLT-4: 19.4;TIME: 45.4;U-138 MG: 14.3
PCDH20,"FLJ22218, PCDH13",ENSG00000280165,Protocadherin 20,13,61409685-61415522,Predicted membrane proteins,Evidence at protein level,HPA062669,NA,NA,Approved,Vesicles<br>Cytokinetic bridge,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 14.5;smooth muscle: 13.0,lung: 5.0,Cell line enriched,12,RPTEC TERT1: 39.0
PCDHA6,"CNR2, CNRS2, CRNR2, PCDH-ALPHA6",ENSG00000081842,Protocadherin alpha 6,5,140827958-141012344,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA059326, HPA078110",Enhanced,NA,Approved,Vesicles,NA,Not detected,Tissue enhanced,NA,cerebral cortex: 4.8,parathyroid gland: 1.9,Cell line enhanced,NA,AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1
PCDHAC1,NA,ENSG00000248383,"Protocadherin alpha subfamily C, 1",5,140926369-141012344,Predicted membrane proteins,Evidence at transcript level,HPA052775,NA,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,NA,Not detected,Tissue enriched,27,parathyroid gland: 69.4,cerebral cortex: 2.5,Cell line enhanced,NA,A549: 5.7;hTCEpi: 5.8;PC-3: 4.2;SCLC-21H: 4.1
PCDHB14,PCDH-BETA14,ENSG00000120327,Protocadherin beta 14,5,141222932-141227759,Predicted membrane proteins,Evidence at protein level,"HPA007692, HPA045248",Uncertain,NA,Approved,Vesicles,Renal cancer:6.09e-4 (unfavourable),Mixed,Mixed,NA,NA,parathyroid gland: 7.6,Cell line enhanced,NA,SH-SY5Y: 15.2;SiHa: 12.6
PCDHB3,PCDH-BETA3,ENSG00000113205,Protocadherin beta 3,5,141100473-141103827,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA050296,Uncertain,NA,Supported,Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 6.9,"endometrium,prostate: 2.4",Cell line enhanced,NA,EFO-21: 10.7;SH-SY5Y: 16.1;U-138 MG: 5.2
PCED1B,"FAM113B, MGC16044",ENSG00000179715,PC-esterase domain containing 1B,12,47079603-47236662,Predicted intracellular proteins,Evidence at protein level,HPA043901,Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:4.55e-6 (unfavourable), Urothelial cancer:5.36e-5 (favourable)",Expressed in all,Mixed,NA,NA,lymph node: 42.3,Cell line enhanced,NA,A549: 57.4;K-562: 43.7
PCOLCE,"PCPE, PCPE1",ENSG00000106333,Procollagen C-endopeptidase enhancer,7,100602177-100608175,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB017623, HPA042927",Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.68e-5 (unfavourable), Melanoma:9.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,"cervix, uterine: 216.8",gallbladder: 145.9,Cell line enhanced,NA,ASC TERT1: 496.8;BJ hTERT+: 447.9;HSkMC: 595.6;SH-SY5Y: 617.5;U-2197: 961.3
PCP2,"GPSM4, MGC41903",ENSG00000174788,Purkinje cell protein 2,19,7631611-7633748,Predicted intracellular proteins,Evidence at protein level,HPA057428,NA,NA,Approved,Nuclear speckles<br>Vesicles,"Urothelial cancer:2.76e-5 (favourable), Breast cancer:7.93e-4 (favourable)",Mixed,Tissue enriched,9,testis: 72.6,skin: 8.1,Cell line enhanced,NA,HMC-1: 7.2;NB-4: 11.1
PCSK1N,"BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII",ENSG00000102109,Proprotein convertase subtilisin/kexin type 1 inhibitor,X,48831094-48835633,Predicted secreted proteins,Evidence at protein level,"HPA003925, HPA064734",Enhanced,NA,Approved,Vesicles,"Endometrial cancer:1.15e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 93.6;kidney: 65.7,adrenal gland: 28.5,Cell line enhanced,NA,HEK93: 52.2;PC-3: 133.3;SCLC-21H: 66.4;SH-SY5Y: 55.2;SiHa: 53.6;U-266/84: 49.2
PCSK2,"NEC2, PC2, SPC2",ENSG00000125851,Proprotein convertase subtilisin/kexin type 2,20,17226107-17484578,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049627,Enhanced,NA,Approved,Vesicles,NA,Group enriched,Tissue enhanced,NA,adrenal gland: 37.5;cerebral cortex: 31.7,skin: 16.5,Group enriched,6,AF22: 59.2;SCLC-21H: 18.5
PDCD11,"ALG-4, KIAA0185, RRP5",ENSG00000148843,Programmed cell death 11,10,103396648-103446292,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA017924, CAB026472",Approved,NA,Supported,Nucleoli<br>Vesicles,Liver cancer:2.79e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 27.9,Expressed in all,NA,NA
PDE9A,NA,ENSG00000160191,Phosphodiesterase 9A,21,42653636-42775509,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA011380,Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Tissue enhanced,NA,prostate: 56.8,spleen: 25.5,Cell line enhanced,NA,AF22: 29.5;EFO-21: 28.2;NTERA-2: 41.2;SCLC-21H: 26.8
PDGFA,"PDGF-A, PDGF1",ENSG00000197461,Platelet derived growth factor subunit A,7,497258-520296,"Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,CAB005579,Uncertain,NA,Approved,Vesicles<br>Microtubule organizing center,"Glioma:1.51e-4 (unfavourable), Head and neck cancer:1.78e-4 (unfavourable), Urothelial cancer:8.67e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 38.8,Cell line enhanced,NA,WM-115: 307.1
PDGFB,"SIS, SSV",ENSG00000100311,Platelet derived growth factor subunit B,22,39223359-39244751,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB011604, HPA011972, CAB018341",Supported,NA,Approved,Vesicles,Lung cancer:3.67e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,placenta: 59.7,lung: 28.6,Cell line enhanced,NA,EFO-21: 65.2;HUVEC TERT2: 45.3;SK-BR-3: 40.1;TIME: 55.5
PDGFD,"IEGF, MSTP036, SCDGF-B",ENSG00000170962,Platelet derived growth factor D,11,103907186-104164379,"Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA046183, HPA066271",Approved,NA,Approved,Golgi apparatus<br>Vesicles,Stomach cancer:9.60e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,adrenal gland: 140.5;ovary: 96.6,gallbladder: 53.7,Group enriched,6,ASC diff: 96.8;HHSteC: 36.1
PDGFRB,"CD140b, JTK12, PDGFR, PDGFR1",ENSG00000113721,Platelet derived growth factor receptor beta,5,150113837-150155872,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB003842, CAB018144, HPA028499",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,gallbladder: 193.8,Cell line enhanced,NA,ASC diff: 923.6;ASC TERT1: 324.4
PDPK1,PDK1,ENSG00000140992,3-phosphoinositide dependent protein kinase 1,16,2537964-2603188,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004272, HPA035199, HPA068961",Supported,NA,Approved,Vesicles,Renal cancer:1.29e-14 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 52.0,Expressed in all,NA,NA
PDXDC1,KIAA0251,ENSG00000179889,Pyridoxal dependent decarboxylase domain containing 1,16,14974591-15139339,Predicted intracellular proteins,Evidence at protein level,"HPA047369, HPA049121, HPA051484",Approved,NA,Enhanced,Golgi apparatus<br>Vesicles,Renal cancer:3.13e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 105.7,Expressed in all,NA,NA
PDZK1,"NHERF3, PDZD1",ENSG00000174827,PDZ domain containing 1,1,145670852-145708148,Predicted intracellular proteins,Evidence at protein level,"HPA005755, HPA006155, CAB008971",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.54e-7 (favourable),Group enriched,Tissue enhanced,NA,kidney: 561.5;small intestine: 127.1,duodenum: 69.0,Cell line enhanced,NA,CACO-2: 83.6;RPTEC TERT1: 168.6;T-47d: 547.9
PEF1,PEF1A,ENSG00000162517,Penta-EF-hand domain containing 1,1,31629862-31644896,Predicted intracellular proteins,Evidence at protein level,HPA061608,NA,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:2.88e-4 (unfavourable), Cervical cancer:3.95e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 183.0,Expressed in all,NA,NA
PELI3,MGC35521,ENSG00000174516,Pellino E3 ubiquitin protein ligase family member 3,11,66466327-66477337,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB033750, HPA038875, HPA062281",Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,Renal cancer:8.19e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 23.7,Mixed,NA,NA
PEX13,NA,ENSG00000162928,Peroxisomal biogenesis factor 13,2,61017225-61051990,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA032141, HPA032142, CAB032689",Enhanced,NA,Supported,Vesicles,Pancreatic cancer:8.07e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 27.5,Expressed in all,NA,NA
PEX2,"PAF-1, PMP35, PXMP3, RNF72, ZWS3",ENSG00000164751,Peroxisomal biogenesis factor 2,8,76980258-77001044,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA010983, HPA011410, HPA027729",Approved,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,seminal vesicle: 111.5,Expressed in all,NA,NA
PEX6,"PAF-2, PXAAA1",ENSG00000124587,Peroxisomal biogenesis factor 6,6,42963870-42979220,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA025924, HPA074179",Enhanced,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 36.5,Expressed in all,NA,NA
PEX7,"PTS2R, RD",ENSG00000112357,Peroxisomal biogenesis factor 7,6,136822564-136913937,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA049202,Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,"Renal cancer:1.85e-10 (favourable), Colorectal cancer:1.61e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 25.3,Mixed,NA,NA
PGBD2,NA,ENSG00000185220,PiggyBac transposable element derived 2,1,248906196-248919946,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029888, HPA029889, HPA029890",Uncertain,NA,Supported,Vesicles,"Urothelial cancer:2.05e-4 (favourable), Head and neck cancer:6.08e-4 (favourable), Renal cancer:7.86e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,thyroid gland: 13.4,Expressed in all,NA,NA
PHB,PHB1,ENSG00000167085,Prohibitin,17,49404049-49414905,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA003280,Supported,NA,Supported,Vesicles<br>Mitochondria,"Head and neck cancer:1.58e-4 (unfavourable), Renal cancer:3.77e-4 (favourable), Liver cancer:9.91e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,kidney: 202.4,Expressed in all,NA,NA
PHF14,KIAA0783,ENSG00000106443,PHD finger protein 14,7,10973872-11169630,Predicted intracellular proteins,Evidence at protein level,"HPA000538, HPA017376",Supported,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 20.8,Expressed in all,NA,NA
PHGR1,NA,ENSG00000233041,"Proline, histidine and glycine rich 1",15,40351033-40356434,Predicted intracellular proteins,Evidence at protein level,HPA068787,Enhanced,NA,Approved,Vesicles,Breast cancer:2.05e-4 (favourable),Group enriched,Group enriched,7,colon: 1448.4;duodenum: 892.1;rectum: 399.5;small intestine: 1777.5,stomach: 166.8,Cell line enhanced,NA,BEWO: 12.3;HaCaT: 16.0;SCLC-21H: 72.5
PHKA1,PHKA,ENSG00000067177,Phosphorylase kinase regulatory subunit alpha 1,X,72578814-72714319,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA001081,Enhanced,NA,Approved,Vesicles,Endometrial cancer:6.84e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,parathyroid gland: 40.1;skeletal muscle: 35.5,adrenal gland: 15.6,Mixed,NA,NA
PHLPP2,"KIAA0931, PHLPPL, PPM3B",ENSG00000040199,PH domain and leucine rich repeat protein phosphatase 2,16,71637835-71724701,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048598,Approved,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,small intestine: 24.2,Expressed in all,NA,NA
PHOSPHO2,MGC22679,ENSG00000144362,"Phosphatase, orphan 2",2,169694454-169701708,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034726, HPA034727",Uncertain,NA,Approved,Vesicles,"Liver cancer:3.82e-6 (unfavourable), Renal cancer:9.53e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 23.0,Expressed in all,NA,NA
PHOX2A,"ARIX, CFEOM2, FEOM2, PMX2A",ENSG00000165462,Paired like homeobox 2a,11,72239077-72245664,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA065621, HPA078004",Enhanced,NA,Approved,Nucleus<br>Nuclear membrane<br>Vesicles,NA,Tissue enriched,Tissue enriched,14,adrenal gland: 26.4,appendix: 1.8,Cell line enriched,240,SH-SY5Y: 603.9
PI15,P25TI,ENSG00000137558,Peptidase inhibitor 15,8,74824537-74855029,Predicted secreted proteins,Evidence at protein level,"HPA006593, HPA030057",Uncertain,NA,Approved,Vesicles<br>Cytosol,NA,Group enriched,Tissue enhanced,NA,appendix: 73.2;prostate: 50.5;smooth muscle: 67.8,endometrium: 33.0,Group enriched,9,AF22: 21.0;SH-SY5Y: 22.2;SK-MEL-30: 22.4;U-266/70: 5.5
PICALM,"CALM, CLTH",ENSG00000073921,Phosphatidylinositol binding clathrin assembly protein,11,85957684-86069882,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA019053, HPA019061",Enhanced,NA,Supported,Vesicles,"Renal cancer:2.02e-6 (favourable), Pancreatic cancer:6.61e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 297.2,Expressed in all,NA,NA
PIEZO2,"C18orf30, C18orf58, FAM38B, FAM38B2, FLJ23144, FLJ23403, FLJ34907, HsT748, HsT771",ENSG00000154864,Piezo type mechanosensitive ion channel component 2,18,10666483-11148762,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA015986, HPA031974, HPA031975, HPA040616",Enhanced,NA,Approved,Vesicles,Renal cancer:9.57e-7 (unfavourable),Mixed,Mixed,NA,NA,lung: 12.8,Cell line enhanced,NA,AF22: 17.1;BJ hTERT+ SV40 Large T+ RasG12V: 24.8;HeLa: 26.7;U-266/70: 19.5
PIGG,"FLJ20265, GPI7, LAS21",ENSG00000174227,Phosphatidylinositol glycan anchor biosynthesis class G,4,499210-540196,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015997,Uncertain,NA,Uncertain,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 35.6,Expressed in all,NA,NA
PIGP,"DCRC, DSCR5, DSRC",ENSG00000185808,Phosphatidylinositol glycan anchor biosynthesis class P,21,37059170-37073170,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026921,Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 125.7,Expressed in all,NA,NA
PIGQ,"GPI1, hGPI1",ENSG00000007541,Phosphatidylinositol glycan anchor biosynthesis class Q,16,566995-584136,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039105, HPA039828, HPA061414",Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:2.53e-6 (favourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 17.5,Expressed in all,NA,NA
PIGZ,"FLJ12768, MGC52163, SMP3",ENSG00000119227,Phosphatidylinositol glycan anchor biosynthesis class Z,3,196946343-196969060,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,"HPA058599, HPA059920",Approved,NA,Uncertain,Vesicles,Renal cancer:5.60e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,colon: 18.5;rectum: 18.1,cerebral cortex: 10.9,Mixed,NA,NA
PIK3CD,p110D,ENSG00000171608,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta",1,9651732-9729114,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB015420, HPA044953",Enhanced,NA,Approved,Vesicles<br>Cytokinetic bridge,NA,Expressed in all,Tissue enhanced,NA,lymph node: 56.4,spleen: 51.2,Cell line enhanced,NA,HDLM-2: 146.7;REH: 64.7;U-937: 63.7
PIK3R3,p55,ENSG00000117461,Phosphoinositide-3-kinase regulatory subunit 3,1,46040140-46133036,"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA005751, HPA071988",Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Endometrial cancer:1.93e-4 (favourable), Head and neck cancer:3.62e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 46.2,Expressed in all,NA,NA
PIK3R4,"p150, VPS15",ENSG00000196455,Phosphoinositide-3-kinase regulatory subunit 4,3,130678935-130746829,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036032, HPA036033",Approved,NA,Approved,Vesicles<br>Microtubules,Renal cancer:4.40e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 46.6,Expressed in all,NA,NA
PINLYP,NA,ENSG00000234465,Phospholipase A2 inhibitor and LY6/PLAUR domain containing,19,43576800-43583964,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA061218,Uncertain,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,fallopian tube: 27.7,Cell line enhanced,NA,HEL: 65.4;HMC-1: 40.9;REH: 27.1;THP-1: 24.6
PIP4K2C,"FLJ22055, PIP5K2C",ENSG00000166908,Phosphatidylinositol-5-phosphate 4-kinase type 2 gamma,12,57591174-57603418,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028658, HPA058551",Approved,NA,Approved,Vesicles,"Renal cancer:2.06e-6 (favourable), Liver cancer:7.98e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 109.1,Mixed,NA,NA
PIP5K1B,"MSS4, STM7",ENSG00000107242,Phosphatidylinositol-4-phosphate 5-kinase type 1 beta,9,68705414-69009176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA009687,Uncertain,NA,Approved,Nucleus<br>Vesicles,Renal cancer:1.03e-9 (favourable),Mixed,Mixed,NA,NA,testis: 50.3,Cell line enhanced,NA,AF22: 47.6;HEL: 16.8;U-266/70: 14.2
PITPNA,"PITPN, VIB1A",ENSG00000174238,Phosphatidylinositol transfer protein alpha,17,1517718-1562816,Predicted intracellular proteins,Evidence at protein level,HPA000528,Uncertain,NA,Approved,Vesicles<br>Cytosol,"Pancreatic cancer:1.80e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Renal cancer:9.35e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 117.9,Expressed in all,NA,NA
PITPNB,VIB1B,ENSG00000180957,Phosphatidylinositol transfer protein beta,22,27851669-27920134,Predicted intracellular proteins,Evidence at protein level,HPA000528,Uncertain,NA,Approved,Vesicles<br>Cytosol,Head and neck cancer:5.28e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 70.3,Expressed in all,NA,NA
PITPNM2,"NIR3, RDGB2, RDGBA2",ENSG00000090975,Phosphatidylinositol transfer protein membrane associated 2,12,122983480-123150015,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003414, HPA003978",Approved,NA,Supported,Vesicles,NA,Expressed in all,Mixed,NA,NA,ovary: 19.1,Cell line enhanced,NA,HEL: 26.5;MOLT-4: 44.3
PKN3,"PKNbeta, UTDP4-1",ENSG00000160447,Protein kinase N3,9,128702523-128720918,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA045390, HPA058305",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,adipose tissue: 7.6,Cell line enhanced,NA,HeLa: 45.8
PLA2G12B,PLA2G13,ENSG00000138308,Phospholipase A2 group XIIB,10,72935170-72954778,"Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA057745, HPA059562",Approved,NA,Approved,Vesicles,NA,Tissue enriched,Group enriched,10,duodenum: 35.2;kidney: 19.0;liver: 49.9;small intestine: 45.9,lung: 3.9,Group enriched,6,CACO-2: 10.3;Hep G2: 14.2
PLA2G15,"GXVPLA2, LLPL, LYPLA3",ENSG00000103066,Phospholipase A2 group XV,16,68245304-68261062,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA041702, HPA041727",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,placenta: 37.5,Expressed in all,NA,NA
PLA2G4F,PLA2G4F/Z,ENSG00000168907,Phospholipase A2 group IVF,15,42139034-42156636,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA042713, HPA056752",Enhanced,NA,Approved,Nucleus<br>Vesicles,Endometrial cancer:2.00e-4 (unfavourable),Mixed,Tissue enriched,5,skin: 92.5,lung: 18.4,Cell line enhanced,NA,hTCEpi: 1.4;RT4: 6.6
PLA2G7,"LDL-PLA2, PAFAH",ENSG00000146070,Phospholipase A2 group VII,6,46704201-46735693,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA035916,NA,NA,Uncertain,Vesicles,NA,Expressed in all,Mixed,NA,NA,spleen: 37.5,Cell line enhanced,NA,NTERA-2: 1.7;PC-3: 3.2;RT4: 1.3;U-2 OS: 1.7
PLAGL1,"LOT1, ZAC",ENSG00000118495,PLAG1 like zinc finger 1,6,143940300-144064599,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055706,NA,NA,Supported,Nuclear bodies<br>Golgi apparatus<br>Vesicles,"Renal cancer:4.94e-6 (unfavourable), Stomach cancer:6.61e-4 (unfavourable)",Mixed,Tissue enriched,5,placenta: 365.4,skin: 72.8,Cell line enhanced,NA,AF22: 105.6;RH-30: 105.2
PLCG2,NA,ENSG00000197943,Phospholipase C gamma 2,16,81739097-81962693,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004280, HPA020099, HPA020100",Enhanced,NA,Approved,Vesicles,"Renal cancer:4.88e-4 (favourable), Head and neck cancer:6.71e-4 (favourable)",Expressed in all,Tissue enhanced,NA,lymph node: 78.9,tonsil: 65.8,Cell line enhanced,NA,Daudi: 130.7;HMC-1: 74.1;U-698: 278.1
PLCH1,"DKFZp434C1372, KIAA1069, MGC117152, PLCeta1, PLCL3",ENSG00000114805,Phospholipase C eta 1,3,155375580-155745067,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036176, HPA057978",Uncertain,NA,Enhanced,Vesicles,Renal cancer:3.03e-5 (favourable),Mixed,Tissue enhanced,NA,testis: 20.6,fallopian tube: 13.0,Cell line enhanced,NA,AF22: 38.5;NTERA-2: 20.8
PLD5,FLJ40773,ENSG00000180287,Phospholipase D family member 5,1,242082986-242524696,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA028389, HPA050367",Uncertain,NA,Approved,Vesicles<br>Mitochondria<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,seminal vesicle: 4.2,cerebral cortex: 4.1,Cell line enhanced,NA,AF22: 10.2;HDLM-2: 5.0;SH-SY5Y: 3.0;U-2 OS: 3.6
PLEK2,NA,ENSG00000100558,Pleckstrin 2,14,67386983-67412200,Predicted intracellular proteins,Evidence at protein level,HPA001208,Enhanced,NA,Uncertain,Vesicles<br>Cytosol,"Pancreatic cancer:8.26e-5 (unfavourable), Lung cancer:1.58e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adrenal gland: 43.1,Cell line enhanced,NA,A-431: 77.9;CAPAN-2: 81.3;HBEC3-KT: 124.1
PLEKHM1,KIAA0356,ENSG00000225190,Pleckstrin homology and RUN domain containing M1,17,45435900-45490749,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA025018, HPA039473",Approved,NA,Supported,Nucleoli<br>Vesicles,"Endometrial cancer:1.28e-6 (favourable), Liver cancer:3.25e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,esophagus: 11.8,Mixed,NA,NA
PLEKHM3,"DAPR, PLEKHM1L",ENSG00000178385,Pleckstrin homology domain containing M3,2,207821288-208025560,Predicted intracellular proteins,Evidence at protein level,HPA035046,Uncertain,NA,Approved,Vesicles<br>Cytosol,NA,Mixed,Mixed,NA,NA,parathyroid gland: 18.9,Mixed,NA,NA
PLG,NA,ENSG00000122194,Plasminogen,6,160702238-160753315,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000668, CAB016678, HPA021602, HPA048823, HPA053770",Supported,NA,Uncertain,Vesicles,Renal cancer:4.22e-4 (favourable),Tissue enriched,Tissue enriched,6,liver: 1749.3,kidney: 313.4,Cell line enhanced,NA,RH-30: 1.0
PLGLB1,"PLGL, PRP-B",ENSG00000183281,Plasminogen-like B1,2,87002559-87021852,Predicted secreted proteins,Evidence at transcript level,HPA053770,NA,NA,Approved,Vesicles,NA,Tissue enriched,Tissue enriched,8,liver: 120.5,skin: 15.4,Mixed,NA,NA
PLGLB2,PLGP1,ENSG00000125551,Plasminogen-like B2,2,87748087-87758793,Predicted secreted proteins,Evidence at transcript level,HPA053770,NA,NA,Approved,Vesicles,NA,Tissue enriched,Tissue enriched,161,liver: 245.3,skin: 1.5,Mixed,NA,NA
PLOD1,"LH1, LLH, PLOD",ENSG00000083444,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",1,11934205-11975538,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA049137, HPA055799",Uncertain,NA,Uncertain,Nucleoplasm<br>Vesicles,"Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 122.3,Expressed in all,NA,NA
PLPP5,"DPPL1, HTPAP, PPAPDC1B",ENSG00000147535,Phospholipid phosphatase 5,8,38263130-38269243,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA055777,NA,NA,Approved,Vesicles,"Renal cancer:8.33e-10 (unfavourable), Endometrial cancer:1.48e-5 (favourable), Ovarian cancer:2.42e-5 (favourable), Lung cancer:8.72e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,prostate: 120.8,Mixed,NA,NA
PLPP6,"FLJ46512, FLJ90191, PDP1, PPAPDC2",ENSG00000205808,Phospholipid phosphatase 6,9,4662315-4665258,Predicted membrane proteins,Evidence at protein level,HPA018096,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:3.99e-4 (favourable),Expressed in all,Mixed,NA,NA,prostate: 26.7,Cell line enhanced,NA,HDLM-2: 92.6
PLPP7,"C9orf67, FLJ14662, MGC12921, NET39, PPAPDC3",ENSG00000160539,Phospholipid phosphatase 7 (inactive),9,131289694-131309262,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA070252,Uncertain,NA,Approved,Nucleus<br>Vesicles,NA,Mixed,Group enriched,5,heart muscle: 32.6;skeletal muscle: 72.2,cerebral cortex: 10.1,Cell line enhanced,NA,AN3-CA: 10.2;ASC diff: 7.8;SCLC-21H: 13.4;SH-SY5Y: 9.1
PMAIP1,"APR, NOXA",ENSG00000141682,Phorbol-12-myristate-13-acetate-induced protein 1,18,59899948-59904306,Predicted intracellular proteins,Evidence at protein level,HPA051063,Uncertain,NA,Approved,Vesicles,Renal cancer:3.15e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,bone marrow: 55.8,placenta: 18.4,Cell line enhanced,NA,U-138 MG: 194.4
PMEPA1,"STAG1, TMEPAI",ENSG00000124225,"Prostate transmembrane protein, androgen induced 1",20,57648392-57711536,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA072291,NA,NA,Supported,Vesicles,"Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,"cervix, uterine: 146.1;prostate: 179.6",endometrium: 60.3,Cell line enhanced,NA,SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9
PMF1,NA,ENSG00000160783,Polyamine modulated factor 1,1,156212993-156240042,Predicted intracellular proteins,Evidence at protein level,"HPA034583, HPA071854",NA,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 68.6,Expressed in all,NA,NA
PMF1-BGLAP,NA,ENSG00000260238,PMF1-BGLAP readthrough,1,156212982-156243332,Predicted intracellular proteins,Evidence at protein level,"HPA034583, HPA071854",NA,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:1.50e-4 (unfavourable), Renal cancer:3.22e-4 (unfavourable)",Mixed,Mixed,NA,NA,fallopian tube: 8.2,Expressed in all,NA,NA
PODXL2,"endoglycan, PODLX2",ENSG00000114631,Podocalyxin like 2,3,127629181-127672809,Predicted membrane proteins,Evidence at protein level,"CAB024934, HPA042265",Approved,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 77.1,testis: 35.9,Cell line enhanced,NA,SCLC-21H: 195.4
POGK,"BASS2, KIAA15131, KRBOX2, LST003",ENSG00000143157,Pogo transposable element with KRAB domain,1,166839447-166856344,Predicted intracellular proteins,Evidence at protein level,"HPA007838, HPA031630",Approved,NA,Supported,Nucleoplasm<br>Vesicles,Liver cancer:5.93e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 42.2,Expressed in all,NA,NA
POLB,NA,ENSG00000070501,DNA polymerase beta,8,42338454-42371808,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011616, HPA049104",Enhanced,NA,Approved,Vesicles,"Renal cancer:2.15e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Urothelial cancer:5.65e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 92.7,Expressed in all,NA,NA
POLE2,DPE2,ENSG00000100479,"DNA polymerase epsilon 2, accessory subunit",14,49643555-49688422,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA027555,Uncertain,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,bone marrow: 10.7,Mixed,NA,NA
POLR3H,"KIAA1665, RPC8",ENSG00000100413,RNA polymerase III subunit H,22,41525804-41544606,"Predicted intracellular proteins, RNA polymerase related proteins",Evidence at protein level,HPA046787,Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Centrosome,"Liver cancer:2.04e-4 (unfavourable), Pancreatic cancer:5.41e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 35.5,Expressed in all,NA,NA
POP7,"RPP2, RPP20",ENSG00000172336,"POP7 homolog, ribonuclease P/MRP subunit",7,100706053-100707495,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021007,Uncertain,NA,Supported,Nucleoli<br>Vesicles,"Liver cancer:4.99e-5 (unfavourable), Renal cancer:6.02e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 41.1,Expressed in all,NA,NA
POR,"CYPOR, FLJ26468",ENSG00000127948,Cytochrome p450 oxidoreductase,7,75899200-75986855,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004372, HPA010136",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Glioma:5.23e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 220.8,Expressed in all,NA,NA
PORCN,"DHOF, MG61, por, PORC, PPN",ENSG00000102312,Porcupine homolog (Drosophila),X,48508962-48520814,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA049215, HPA058413",Enhanced,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,adrenal gland: 31.4,Cell line enhanced,NA,HBEC3-KT: 126.7
POU2F1,"OCT1, OTF1",ENSG00000143190,POU class 2 homeobox 1,1,167220829-167427345,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB002608, HPA058559, HPA064323",Supported,NA,Supported,Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles,Renal cancer:2.98e-5 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 8.0,Mixed,NA,NA
POU2F2,"OCT2, OTF2",ENSG00000028277,POU class 2 homeobox 2,19,42086110-42196585,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB002513, HPA049056, HPA062096, HPA064404",Enhanced,NA,Enhanced,Nucleoplasm<br>Vesicles,Renal cancer:7.57e-11 (unfavourable),Mixed,Tissue enhanced,NA,lymph node: 62.3;tonsil: 44.4,"appendix,spleen: 37.6",Cell line enhanced,NA,BJ hTERT+: 42.5;Daudi: 81.0;hTEC/SVTERT24-B: 42.8;U-266/70: 57.7;U-266/84: 54.8;U-698: 61.5
PPA1,"IOPPP, PP, PP1, Ppase, SID6-8061",ENSG00000180817,Pyrophosphatase (inorganic) 1,10,70202830-70233911,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019878, HPA020096",Supported,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,breast: 226.6,Expressed in all,NA,NA
PPARG,"NR1C3, PPARG1, PPARG2, PPARgamma",ENSG00000132170,Peroxisome proliferator activated receptor gamma,3,12287368-12434356,"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB004282, HPA051239, HPA063663",Approved,NA,Enhanced,Nucleus<br>Vesicles,"Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable)",Expressed in all,Tissue enhanced,NA,adipose tissue: 173.3,placenta: 59.2,Cell line enhanced,NA,ASC diff: 131.6;BEWO: 223.4;RT4: 116.1
PPFIA3,"KIAA0654, LPNA3, MGC126567, MGC126569",ENSG00000177380,PTPRF interacting protein alpha 3,19,49119389-49151026,Predicted intracellular proteins,Evidence at protein level,"HPA043567, HPA050340",Enhanced,NA,Uncertain,Nucleoli fibrillar center<br>Vesicles,"Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable)",Expressed in all,Group enriched,6,cerebral cortex: 21.5;skin: 20.2,parathyroid gland: 3.6,Cell line enhanced,NA,PC-3: 33.5
PPIP5K2,"CFAP160, HISPPD1, KIAA0433, VIP2",ENSG00000145725,Diphosphoinositol pentakisphosphate kinase 2,5,103120149-103212799,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037895, HPA038442",Approved,NA,Approved,Vesicles,Thyroid cancer:1.12e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 34.3,Expressed in all,NA,NA
PPM1J,"DKFZp434P1514, FLJ35951, MGC19531, PP2Czeta, PPP2CZ",ENSG00000155367,"Protein phosphatase, Mg2+/Mn2+ dependent 1J",1,112709994-112715477,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046045,Uncertain,NA,Approved,Vesicles,NA,Mixed,Group enriched,6,epididymis: 22.8;skeletal muscle: 24.1;skin: 21.4;testis: 46.5,heart muscle: 4.7,Cell line enhanced,NA,T-47d: 18.2
PPM1N,FLJ40125,ENSG00000213889,"Protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)",19,45488777-45502510,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043577,NA,NA,Supported,Vesicles,NA,Tissue enhanced,Tissue enriched,5,skeletal muscle: 69.9,spleen: 12.9,Cell line enhanced,NA,RT4: 24.0
PPP1R11,"CFAP255, HCG-V, HCGV, TCTE5, Tctex5",ENSG00000204619,Protein phosphatase 1 regulatory inhibitor subunit 11,6,30066709-30070333,Predicted intracellular proteins,Evidence at protein level,"HPA043266, HPA060174",Approved,NA,Approved,Vesicles,NA,Expressed in all,Tissue enhanced,NA,epididymis: 38.2,fallopian tube: 17.0,Cell line enhanced,NA,A-431: 42.0;AN3-CA: 57.2;HEL: 34.3;RPTEC TERT1: 32.3;U-266/84: 30.5
PPP1R15A,GADD34,ENSG00000087074,Protein phosphatase 1 regulatory subunit 15A,19,48872392-48876057,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB018395, HPA020240",Approved,NA,Uncertain,Vesicles,Liver cancer:1.95e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 358.1,Expressed in all,NA,NA
PPP1R21,"CCDC128, FLJ16566, KLRAQ1",ENSG00000162869,Protein phosphatase 1 regulatory subunit 21,2,48440598-48515391,Predicted intracellular proteins,Evidence at protein level,"HPA036791, HPA036792",Approved,NA,Approved,Vesicles,"Renal cancer:4.59e-6 (favourable), Endometrial cancer:6.83e-4 (unfavourable), Pancreatic cancer:8.05e-4 (favourable), Thyroid cancer:9.87e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 62.3,Expressed in all,NA,NA
PPP1R3D,PPP1R6,ENSG00000132825,Protein phosphatase 1 regulatory subunit 3D,20,59936668-59940297,Predicted intracellular proteins,Evidence at protein level,HPA041146,Approved,NA,Approved,Nucleoli<br>Vesicles<br>Mitochondria,Stomach cancer:9.14e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 11.1,Mixed,NA,NA
PPP3CC,"CALNA3, PP2Bgamma",ENSG00000120910,Protein phosphatase 3 catalytic subunit gamma,8,22440819-22541142,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023396, CAB024950",Approved,NA,Approved,Vesicles,Lung cancer:6.80e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 101.2,Expressed in all,NA,NA
PPP5C,"PP5, PPP5",ENSG00000011485,Protein phosphatase 5 catalytic subunit,19,46346994-46392981,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB022641, HPA029065, HPA056933",Approved,NA,Supported,Vesicles<br>Cytosol,Liver cancer:3.45e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 44.3,Expressed in all,NA,NA
PPP6R2,"dJ579N16.1, KIAA0685, SAP190, SAPS2",ENSG00000100239,Protein phosphatase 6 regulatory subunit 2,22,50343304-50445090,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030656, CAB034919",Uncertain,NA,Supported,Vesicles<br>Cytosol,"Endometrial cancer:1.70e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 65.3,Expressed in all,NA,NA
PQLC2,FLJ20320,ENSG00000040487,PQ loop repeat containing 2,1,19312326-19329300,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA057810,Approved,NA,Enhanced,Vesicles,"Liver cancer:2.64e-5 (unfavourable), Endometrial cancer:3.50e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 16.3,Expressed in all,NA,NA
PRAF2,"JM4, Yip6a",ENSG00000243279,PRA1 domain family member 2,X,49071156-49074071,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA002859, HPA005504, CAB011655",Enhanced,NA,Approved,Endoplasmic reticulum<br>Vesicles,"Liver cancer:1.66e-6 (unfavourable), Pancreatic cancer:4.88e-6 (favourable), Renal cancer:5.83e-6 (unfavourable), Lung cancer:2.81e-4 (favourable), Cervical cancer:7.42e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 185.0,Expressed in all,NA,NA
PRDM10,"KIAA1231, MGC131802, PFM7",ENSG00000170325,PR/SET domain 10,11,129899706-130002835,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA026997,Approved,NA,Approved,Nucleoplasm<br>Nucleoli fibrillar center<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 7.6,Expressed in all,NA,NA
PREX1,"KIAA1415, P-REX1",ENSG00000124126,"Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1",20,48624252-48827883,Predicted intracellular proteins,Evidence at protein level,HPA001927,Supported,NA,Supported,Vesicles<br>Cytosol,Head and neck cancer:8.56e-4 (favourable),Expressed in all,Expressed in all,NA,NA,spleen: 60.8,Cell line enhanced,NA,MCF7: 124.7;SK-BR-3: 123.7;T-47d: 138.8
PRICKLE2,DKFZp686D143,ENSG00000163637,Prickle planar cell polarity protein 2,3,64092242-64445476,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035493,NA,NA,Approved,Golgi apparatus<br>Vesicles,NA,Mixed,Mixed,NA,NA,endometrium: 29.7,Cell line enhanced,NA,ASC diff: 16.5;HSkMC: 16.1;U-87 MG: 15.2
PRIM1,NA,ENSG00000198056,Primase (DNA) subunit 1,12,56731596-56752373,Predicted intracellular proteins,Evidence at protein level,HPA040010,Uncertain,NA,Supported,Vesicles,Liver cancer:2.40e-8 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 21.8,Expressed in all,NA,NA
PRKAR2A,PRKAR2,ENSG00000114302,Protein kinase cAMP-dependent type II regulatory subunit alpha,3,48744597-48847846,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005023, HPA038268",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles<br>Microtubule organizing center,"Colorectal cancer:4.27e-5 (favourable), Liver cancer:1.97e-4 (unfavourable), Renal cancer:2.07e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 124.3,Mixed,NA,NA
PRKCE,NA,ENSG00000171132,Protein kinase C epsilon,2,45651345-46187990,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB001948, HPA044496, HPA054252",Enhanced,NA,Approved,Vesicles,"Renal cancer:2.63e-7 (favourable), Endometrial cancer:2.42e-4 (unfavourable), Lung cancer:9.62e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 48.3,parathyroid gland: 20.5,Mixed,NA,NA
PRKG1,"PGK, PKG, PRKG1B, PRKGR1B",ENSG00000185532,"Protein kinase, cGMP-dependent, type I",10,50991358-52298350,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007699, CAB009629",Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Mixed,Mixed,NA,NA,smooth muscle: 25.1,Cell line enhanced,NA,AN3-CA: 19.3;BJ hTERT+: 17.6;fHDF/TERT166: 13.4
PRNP,"AltPrP, CD230, CJD, GSS, PRIP, PRP",ENSG00000171867,Prion protein,20,4686236-4701590,"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA042754, HPA043398",Enhanced,NA,Approved,Nuclear membrane<br>Vesicles<br>Cytosol,"Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 619.4,Cell line enhanced,NA,WM-115: 985.1
PRPS2,NA,ENSG00000101911,Phosphoribosyl pyrophosphate synthetase 2,X,12791355-12824222,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA067599, CAB070417",Enhanced,NA,Approved,Vesicles,Cervical cancer:1.90e-4 (favourable),Expressed in all,Tissue enhanced,NA,testis: 242.3,seminal vesicle: 117.1,Expressed in all,NA,NA
PRR22,MGC24975,ENSG00000212123,Proline rich 22,19,5782960-5784765,Predicted intracellular proteins,Evidence at protein level,HPA044157,Enhanced,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,testis: 21.9,skin: 4.9,Cell line enhanced,NA,HMC-1: 15.2
PRR4,"LPRP, PROL4",ENSG00000111215,Proline rich 4 (lacrimal),12,10845849-11171613,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042133,Enhanced,NA,Uncertain,Vesicles,NA,Mixed,Tissue enriched,23,salivary gland: 1528.2,stomach: 65.1,Cell line enhanced,NA,HDLM-2: 1.4;HHSteC: 1.7
PRRC1,FLJ32875,ENSG00000164244,Proline rich coiled-coil 1,5,127517609-127555089,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039212,Supported,NA,Approved,Vesicles,Breast cancer:9.35e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 54.1,Expressed in all,NA,NA
PRSS2,TRY2,ENSG00000275896,"Protease, serine 2",7,142760398-142774564,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA062452, HPA063471",Supported,NA,Approved,Endoplasmic reticulum<br>Vesicles,Breast cancer:2.32e-4 (favourable),Tissue enriched,Tissue enriched,53,pancreas: 30215.4,small intestine: 567.7,Group enriched,6,RPMI-8226: 46.1;U-2 OS: 14.3
PRSS3,"PRSS4, TRY3, TRY4",ENSG00000010438,"Protease, serine 3",9,33750466-33799231,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA062452, HPA063471",Supported,NA,Approved,Endoplasmic reticulum<br>Vesicles,Endometrial cancer:4.30e-4 (unfavourable),Group enriched,Tissue enriched,64,pancreas: 6301.2,small intestine: 99.1,Cell line enriched,9,PC-3: 632.8
PSAP,"GLBA, SAP1",ENSG00000197746,Prosaposin,10,71816298-71851375,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA004426, CAB004647",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 1912.4,Expressed in all,NA,NA
PSD3,"DKFZp761K1423, EFA6D, EFA6R, HCA67, KIAA0942",ENSG00000156011,Pleckstrin and Sec7 domain containing 3,8,18527301-19084730,Predicted intracellular proteins,Evidence at protein level,HPA002455,Enhanced,NA,Approved,Nucleus<br>Vesicles,"Endometrial cancer:5.76e-5 (unfavourable), Colorectal cancer:7.55e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 83.3,testis: 29.6,Cell line enhanced,NA,U-87 MG: 48.5
PSMA4,"HC9, HsT17706",ENSG00000041357,Proteasome subunit alpha 4,15,78540405-78552419,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004973, HPA055466, HPA060613",Supported,NA,Enhanced,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:6.74e-10 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 174.1,Expressed in all,NA,NA
PSMB8,"beta5i, D6S216E, LMP7, PSMB5i, RING10",ENSG00000204264,Proteasome subunit beta 8,6,32840717-32844703,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA046995, HPA050327",Enhanced,NA,Approved,Vesicles<br>Cytokinetic bridge,"Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable)",Expressed in all,Mixed,NA,NA,lymph node: 23.0,Mixed,NA,NA
PSMD6,"KIAA0107, p44S10, Rpn7, S10",ENSG00000163636,"Proteasome 26S subunit, non-ATPase 6",3,64010549-64024010,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036921, HPA036922",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles,Liver cancer:1.68e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 216.4,Cell line enriched,5,MCF7: 1051.2
PTGR2,"FLJ39091, ZADH1",ENSG00000140043,Prostaglandin reductase 2,14,73851844-73886827,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001125,Approved,NA,Approved,Vesicles,Renal cancer:4.55e-12 (favourable),Expressed in all,Mixed,NA,NA,thyroid gland: 21.2,Cell line enhanced,NA,T-47d: 39.4
PTGS1,"COX1, PGHS-1, PTGHS",ENSG00000095303,Prostaglandin-endoperoxide synthase 1,9,122370530-122395703,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002834, CAB020315",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,skin: 161.6,fallopian tube: 86.1,Cell line enhanced,NA,ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6
PTK2,"FADK, FAK, FAK1, PPP1R71",ENSG00000169398,Protein tyrosine kinase 2,8,140657900-141002216,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001842, CAB004036, HPA029671",Approved,NA,Supported,Vesicles<br>Focal adhesion sites<br>Cytosol,"Breast cancer:3.21e-4 (unfavourable), Endometrial cancer:9.11e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 107.1,Mixed,NA,NA
PTPN9,MEG2,ENSG00000169410,"Protein tyrosine phosphatase, non-receptor type 9",15,75463251-75579289,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041922,Approved,NA,Approved,Vesicles,Renal cancer:2.49e-6 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 54.8,Expressed in all,NA,NA
PTPRA,"HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA",ENSG00000132670,"Protein tyrosine phosphatase, receptor type A",20,2864184-3039076,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA029412, CAB034366, HPA069480",Approved,NA,Approved,Nucleus<br>Vesicles,Renal cancer:3.29e-6 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 167.4,Expressed in all,NA,NA
PTPRD,"HPTP, PTPD",ENSG00000153707,"Protein tyrosine phosphatase, receptor type D",9,8314246-10612723,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054829,Uncertain,NA,Approved,Vesicles,Renal cancer:7.45e-6 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 32.7;parathyroid gland: 47.0,ovary: 11.7,Cell line enhanced,NA,AF22: 27.3;RH-30: 9.9
PTPRN2,"IA-2beta, ICAAR, KIAA0387, phogrin",ENSG00000155093,"Protein tyrosine phosphatase, receptor type N2",7,157539056-158587788,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006900, HPA026656",Approved,NA,Supported,Vesicles,"Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 82.3,stomach: 38.9,Cell line enhanced,NA,AF22: 28.0;HDLM-2: 38.8;NB-4: 27.1;SCLC-21H: 26.6;SH-SY5Y: 24.3;U-87 MG: 27.1
PUSL1,FLJ90811,ENSG00000169972,Pseudouridylate synthase-like 1,1,1308567-1311677,Predicted intracellular proteins,Evidence at protein level,"HPA032057, HPA039999",Uncertain,NA,Enhanced,Vesicles,"Renal cancer:1.62e-5 (unfavourable), Liver cancer:1.33e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 9.1,Expressed in all,NA,NA
QRICH2,DKFZP434P0316,ENSG00000129646,Glutamine rich 2,17,76274049-76307998,Predicted intracellular proteins,Evidence at protein level,HPA052219,Enhanced,NA,Approved,Nucleoplasm<br>Nuclear membrane<br>Vesicles,NA,Expressed in all,Tissue enriched,11,testis: 22.2,thyroid gland: 1.9,Mixed,NA,NA
QRSL1,"DKFZP564C1278, FLJ10989, FLJ12189, FLJ13447, GatA",ENSG00000130348,Glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1,6,106629578-106668417,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA029585, HPA029587",Approved,NA,Approved,Vesicles<br>Centrosome,"Liver cancer:7.97e-5 (unfavourable), Renal cancer:3.83e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 18.6,Expressed in all,NA,NA
QSOX1,QSCN6,ENSG00000116260,Quiescin sulfhydryl oxidase 1,1,180154834-180204030,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA042127, HPA056243",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles,Renal cancer:1.86e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,gallbladder: 233.0,Expressed in all,NA,NA
RAB11A,YL8,ENSG00000103769,"RAB11A, member RAS oncogene family",15,65726054-65891991,Predicted intracellular proteins,Evidence at protein level,"CAB013097, HPA051697, HPA060686",Approved,NA,Enhanced,Vesicles<br>Microtubule organizing center,"Renal cancer:1.46e-5 (favourable), Pancreatic cancer:4.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 524.8,Expressed in all,NA,NA
RAB11B,H-YPT3,ENSG00000185236,"RAB11B, member RAS oncogene family",19,8389981-8404434,Predicted intracellular proteins,Evidence at protein level,HPA054396,NA,NA,Approved,Vesicles<br>Microtubule organizing center,"Pancreatic cancer:7.58e-5 (favourable), Renal cancer:2.06e-4 (favourable), Cervical cancer:2.08e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 151.9,Expressed in all,NA,NA
RAB11FIP1,"FLJ22524, FLJ22622, Rab11-FIP1, RCP",ENSG00000156675,RAB11 family interacting protein 1,8,37858618-37899467,Predicted intracellular proteins,Evidence at protein level,"CAB017037, HPA023904, HPA024010, HPA025960",Enhanced,NA,Enhanced,Vesicles,"Renal cancer:1.14e-6 (favourable), Head and neck cancer:6.61e-4 (favourable)",Mixed,Expressed in all,NA,NA,lung: 111.7,Cell line enhanced,NA,K-562: 65.6
RAB11FIP2,"KIAA0941, nRip11, Rab11-FIP2",ENSG00000107560,RAB11 family interacting protein 2,10,118004916-118046603,Predicted intracellular proteins,Evidence at protein level,HPA037726,Approved,NA,Supported,Nucleoplasm<br>Vesicles,Renal cancer:9.69e-5 (favourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 36.4,Expressed in all,NA,NA
RAB11FIP3,"eferin, KIAA0665, Rab11-FIP3",ENSG00000090565,RAB11 family interacting protein 3,16,425619-523011,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028088, HPA028631, HPA030086",Approved,NA,Supported,Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center,"Pancreatic cancer:3.16e-5 (favourable), Liver cancer:9.87e-5 (unfavourable), Endometrial cancer:1.22e-4 (favourable), Renal cancer:7.99e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,kidney: 56.9,Expressed in all,NA,NA
RAB11FIP5,"GAF1, KIAA0857, pp75, RIP11",ENSG00000135631,RAB11 family interacting protein 5,2,73073382-73156721,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036406, HPA036407",Enhanced,NA,Enhanced,Vesicles<br>Microtubule organizing center,"Renal cancer:2.26e-5 (favourable), Ovarian cancer:3.87e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 73.1,parathyroid gland: 26.9,Mixed,NA,NA
RAB12,NA,ENSG00000206418,"RAB12, member RAS oncogene family",18,8609445-8639381,Predicted intracellular proteins,Evidence at protein level,HPA040727,Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,skeletal muscle: 67.4,Expressed in all,NA,NA
RAB14,"FBP, RAB-14",ENSG00000119396,"RAB14, member RAS oncogene family",9,121178137-121223014,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA026419, CAB037066",Approved,NA,Supported,Vesicles,Renal cancer:1.79e-8 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 83.4,Expressed in all,NA,NA
RAB15,NA,ENSG00000139998,"RAB15, member RAS oncogene family",14,64945814-64972776,Predicted intracellular proteins,Evidence at protein level,HPA041177,Uncertain,NA,Approved,Vesicles<br>Microtubule organizing center,Liver cancer:4.68e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 62.9,Cell line enhanced,NA,HAP1: 153.9;RH-30: 186.0;RT4: 173.7
RAB20,FLJ20429,ENSG00000139832,"RAB20, member RAS oncogene family",13,110523066-110561733,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA052111, HPA068647",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles,"Urothelial cancer:4.48e-4 (favourable), Renal cancer:8.57e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 42.0,Cell line enhanced,NA,SK-BR-3: 63.7;T-47d: 50.6
RAB30,NA,ENSG00000137502,"RAB30, member RAS oncogene family",11,82973133-83071923,Predicted intracellular proteins,Evidence at protein level,"HPA054514, HPA060565",Approved,NA,Enhanced,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,"cerebral cortex,tonsil: 28.4",Cell line enhanced,NA,U-698: 116.4
RAB33A,RabS10,ENSG00000134594,"RAB33A, member RAS oncogene family",X,130171649-130184870,Predicted intracellular proteins,Evidence at protein level,HPA059737,Uncertain,NA,Approved,Vesicles,NA,Group enriched,Tissue enhanced,NA,cerebral cortex: 31.9,lymph node: 9.1,Cell line enhanced,NA,HMC-1: 70.4;Karpas-707: 65.9;U-266/70: 50.9
RAB36,NA,ENSG00000100228,"RAB36, member RAS oncogene family",22,23145326-23164350,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA059631,NA,NA,Approved,Vesicles,Renal cancer:4.55e-4 (favourable),Mixed,Tissue enhanced,NA,fallopian tube: 52.9;thyroid gland: 29.6,testis: 10.4,Cell line enhanced,NA,SCLC-21H: 20.4
RAB3D,"D2-2, GOV, RAB16, RAD3D",ENSG00000105514,"RAB3D, member RAS oncogene family",19,11322046-11346270,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB018067, HPA063283",Approved,NA,Approved,Vesicles,Glioma:3.30e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,skin: 62.5,esophagus: 28.1,Cell line enhanced,NA,SK-BR-3: 51.2
RAB5B,NA,ENSG00000111540,"RAB5B, member RAS oncogene family",12,55973913-55996683,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010224, HPA068337",Approved,NA,Supported,Vesicles,Breast cancer:2.24e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 175.6,Expressed in all,NA,NA
RAB8B,NA,ENSG00000166128,"RAB8B, member RAS oncogene family",15,63189469-63267782,Predicted intracellular proteins,Evidence at protein level,HPA074534,NA,NA,Supported,Nucleoplasm<br>Vesicles,Renal cancer:2.44e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 50.6,Expressed in all,NA,NA
RABEP1,"neurocrescin, RAB5EP, rabaptin-5, RABPT5",ENSG00000029725,"Rabaptin, RAB GTPase binding effector protein 1",17,5282265-5385812,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004549, HPA019669, HPA024235, HPA024691",Enhanced,NA,Enhanced,Vesicles,Pancreatic cancer:6.43e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 88.9,Expressed in all,NA,NA
RABEP2,"FLJ23282, FRA",ENSG00000177548,"Rabaptin, RAB GTPase binding effector protein 2",16,28904421-28936526,Predicted intracellular proteins,Evidence at protein level,HPA047641,Approved,NA,Supported,Vesicles<br>Cytosol,"Renal cancer:1.24e-6 (favourable), Head and neck cancer:5.84e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 57.1,Expressed in all,NA,NA
RABGGTB,NA,ENSG00000137955,Rab geranylgeranyltransferase beta subunit,1,75786197-75795079,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026585, HPA027167, HPA030793",Approved,Approved,Supported,Vesicles,"Renal cancer:1.12e-5 (unfavourable), Liver cancer:9.80e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,kidney: 69.4,Expressed in all,NA,NA
RABL2A,NA,ENSG00000144134,"RAB, member of RAS oncogene family-like 2A",2,113627229-113643396,Predicted intracellular proteins,Evidence at protein level,"HPA042642, HPA042700, HPA044007",Approved,NA,Approved,Vesicles<br>Centrosome,Renal cancer:1.20e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,fallopian tube: 31.5,cerebral cortex: 8.1,Mixed,NA,NA
RABL2B,NA,ENSG00000079974,"RAB, member of RAS oncogene family-like 2B",22,50767501-50783663,Predicted intracellular proteins,Evidence at protein level,"HPA042642, HPA042700, HPA044007",Approved,NA,Approved,Vesicles<br>Centrosome,"Liver cancer:4.58e-5 (unfavourable), Endometrial cancer:5.58e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 110.4,Expressed in all,NA,NA
RAD1,"HRAD1, REC1",ENSG00000113456,RAD1 checkpoint DNA exonuclease,5,34905264-34918989,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006692,Approved,NA,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:1.06e-5 (unfavourable), Breast cancer:6.30e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 11.9,Expressed in all,NA,NA
RAET1G,ULBP5,ENSG00000203722,Retinoic acid early transcript 1G,6,149916878-149923121,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA062673,NA,NA,Approved,Vesicles,Lung cancer:5.35e-4 (unfavourable),Mixed,Tissue enhanced,NA,adrenal gland: 8.2;esophagus: 9.5,skin: 3.4,Cell line enhanced,NA,HeLa: 21.4;hTCEpi: 18.1;SiHa: 13.3;U-87 MG: 9.8
RALBP1,"RIP, RIP1, RLIP76",ENSG00000017797,RalA binding protein 1,18,9475009-9538116,"Predicted intracellular proteins, RAS pathway related proteins, Transporters",Evidence at protein level,"CAB046010, HPA046651",Approved,NA,Approved,Nuclear membrane<br>Vesicles<br>Cytosol,"Renal cancer:5.39e-6 (favourable), Ovarian cancer:8.47e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 70.4,Expressed in all,NA,NA
RAMP2,NA,ENSG00000131477,Receptor activity modifying protein 2,17,42758447-42763041,"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA052020,NA,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,lung: 178.6,Cell line enhanced,NA,ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7
RANBP6,NA,ENSG00000137040,RAN binding protein 6,9,6011043-6015625,Predicted intracellular proteins,Evidence at protein level,"HPA043748, HPA052684",Approved,NA,Supported,Vesicles,Renal cancer:1.34e-7 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 26.2,Expressed in all,NA,NA
RANGAP1,"Fug1, KIAA1835, SD",ENSG00000100401,Ran GTPase activating protein 1,22,41245611-41286251,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB004293, HPA050110, HPA062034",Enhanced,NA,Enhanced,Nuclear membrane<br>Vesicles<br>Cytosol,"Liver cancer:1.08e-4 (unfavourable), Stomach cancer:5.39e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 206.1,Expressed in all,NA,NA
RAPGEF2,"DKFZP586O1422, KIAA0313, PDZ-GEF1, PDZGEF1, RA-GEF",ENSG00000109756,Rap guanine nucleotide exchange factor 2,4,159104178-159360169,Predicted intracellular proteins,Evidence at protein level,HPA057169,NA,NA,Supported,Nucleoplasm<br>Vesicles<br>Centrosome,Renal cancer:1.76e-7 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 109.8,Mixed,NA,NA
RASA2,GAP1M,ENSG00000155903,RAS p21 protein activator 2,3,141487047-141615342,"Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA035374, HPA035375",Approved,NA,Approved,Vesicles,"Renal cancer:7.62e-7 (unfavourable), Urothelial cancer:4.34e-5 (favourable)",Expressed in all,Mixed,NA,NA,lymph node: 25.0,Expressed in all,NA,NA
RASA4,"CAPRI, GAPL, KIAA0538",ENSG00000105808,RAS p21 protein activator 4,7,102573807-102616757,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at transcript level,HPA043010,Uncertain,NA,Uncertain,Vesicles,NA,Not detected,Expressed in all,NA,NA,skeletal muscle: 85.0,Cell line enhanced,NA,SH-SY5Y: 34.2;U-138 MG: 44.7
RASGEF1B,"FLJ31695, GPIG4",ENSG00000138670,RasGEF domain family member 1B,4,81426393-82044244,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA044574,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:4.21e-6 (favourable), Head and neck cancer:1.49e-5 (favourable), Cervical cancer:6.40e-4 (favourable)",Expressed in all,Mixed,NA,NA,skin: 31.6,Cell line enhanced,NA,CACO-2: 12.9;Daudi: 13.1;Karpas-707: 9.0;NTERA-2: 11.1;SCLC-21H: 10.7
RASL10B,"RRP17, VTS58635",ENSG00000270885,RAS like family 10 member B,17,35731649-35743521,Predicted intracellular proteins,Evidence at protein level,"HPA046842, HPA057092",Enhanced,NA,Approved,Vesicles,Endometrial cancer:6.38e-6 (unfavourable),Tissue enhanced,Tissue enhanced,NA,adipose tissue: 16.0;seminal vesicle: 21.0,skeletal muscle: 11.1,Cell line enhanced,NA,HAP1: 25.2;HHSteC: 22.5;NTERA-2: 41.3
RASSF10,NA,ENSG00000189431,Ras association domain family member 10,11,13009577-13012106,Predicted intracellular proteins,Evidence at transcript level,HPA040406,NA,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:4.12e-5 (favourable), Head and neck cancer:2.76e-4 (favourable)",Mixed,Tissue enhanced,NA,fallopian tube: 5.4,parathyroid gland: 3.8,Cell line enhanced,NA,A549: 8.6;CAPAN-2: 7.5;HaCaT: 11.6;HMC-1: 5.6;RPTEC TERT1: 9.8
RBMS3,NA,ENSG00000144642,RNA binding motif single stranded interacting protein 3,3,28574791-30010391,Predicted intracellular proteins,Evidence at protein level,HPA034719,Uncertain,NA,Approved,Vesicles,Renal cancer:1.85e-4 (unfavourable),Mixed,Mixed,NA,NA,thyroid gland: 28.0,Mixed,NA,NA
RBP5,CRBPIII,ENSG00000139194,Retinol binding protein 5,12,7123684-7128942,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA038723,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,"Urothelial cancer:3.68e-4 (favourable), Lung cancer:8.37e-4 (favourable)",Group enriched,Tissue enhanced,NA,kidney: 455.7;liver: 204.9,spleen: 102.0,Cell line enhanced,NA,Hep G2: 17.0;K-562: 46.6
RBSN,ZFYVE20,ENSG00000131381,"Rabenosyn, RAB effector",3,15070073-15099163,Predicted intracellular proteins,Evidence at protein level,HPA044878,Approved,NA,Enhanced,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 30.7,Expressed in all,NA,NA
RC3H2,"FLJ20301, FLJ20713, MNAB, RNF164",ENSG00000056586,Ring finger and CCCH-type domains 2,9,122844556-122905341,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA042863, HPA062144",Approved,NA,Supported,Vesicles,Renal cancer:5.50e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 25.5,Expressed in all,NA,NA
RCN3,RLP49,ENSG00000142552,Reticulocalbin 3,19,49527618-49546962,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA043134, HPA050402",Uncertain,NA,Approved,Endoplasmic reticulum<br>Vesicles,Renal cancer:5.80e-12 (unfavourable),Expressed in all,Expressed in all,NA,NA,small intestine: 45.0,Cell line enhanced,NA,ASC diff: 170.1;BJ: 238.6;fHDF/TERT166: 192.6
RCOR2,NA,ENSG00000167771,REST corepressor 2,11,63911221-63916844,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA021638,Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Midbody,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 13.2,testis: 3.7,Cell line enhanced,NA,AF22: 39.9;NTERA-2: 52.3;SCLC-21H: 95.8;SH-SY5Y: 57.5
RDH5,"HSD17B9, RDH1, SDR9C5",ENSG00000135437,Retinol dehydrogenase 5,12,55720367-55724705,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA063345,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,adipose tissue: 97.7,liver: 30.0,Cell line enhanced,NA,ASC diff: 19.5;ASC TERT1: 17.1;hTEC/SVTERT24-B: 15.2;LHCN-M2: 12.8;U-87 MG: 26.2
RELL2,"C5orf16, FLJ90583",ENSG00000164620,RELT like 2,5,141636950-141641077,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA077928,NA,NA,Uncertain,Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 13.2;parathyroid gland: 23.3,testis: 4.3,Mixed,NA,NA
RFC3,"MGC5276, RFC38",ENSG00000133119,Replication factor C subunit 3,13,33818049-33966558,Predicted intracellular proteins,Evidence at protein level,HPA030149,Approved,NA,Supported,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,lymph node: 26.8,Expressed in all,NA,NA
RFFL,"CARP-2, CARP2, fring, rififylin, RNF189, RNF34L",ENSG00000092871,Ring finger and FYVE like domain containing E3 ubiquitin protein ligase,17,35005990-35089319,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008096, HPA017910, HPA019492",Approved,NA,Approved,Vesicles,"Renal cancer:2.43e-5 (unfavourable), Colorectal cancer:4.92e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 54.1,Expressed in all,NA,NA
RFT1,CDG1N,ENSG00000163933,RFT1 homolog,3,53088483-53130462,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA060327, HPA069022",Approved,NA,Approved,Vesicles,Liver cancer:1.69e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 25.8,Expressed in all,NA,NA
RFX3,NA,ENSG00000080298,Regulatory factor X3,9,3218297-3526004,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA035689,Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,Breast cancer:1.47e-4 (favourable),Mixed,Tissue enhanced,NA,testis: 38.6,fallopian tube: 18.3,Cell line enhanced,NA,AF22: 26.0;SCLC-21H: 16.6
RGL1,RGL,ENSG00000143344,Ral guanine nucleotide dissociation stimulator like 1,1,183636085-183928531,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA019788,Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Liver cancer:1.49e-5 (unfavourable), Lung cancer:4.32e-4 (favourable)",Expressed in all,Mixed,NA,NA,spleen: 62.6,Cell line enhanced,NA,HSkMC: 39.9
RGPD1,RGP1,ENSG00000187627,RANBP2-like and GRIP domain containing 1,2,86907953-87013981,Predicted intracellular proteins,Evidence at transcript level,"HPA049497, HPA051675, HPA067564",Uncertain,NA,Approved,Nuclear membrane<br>Vesicles,NA,Not detected,Group enriched,12,"cervix, uterine: 11.8;placenta: 9.0;testis: 24.5",parathyroid gland: 1.2,Cell line enhanced,NA,BEWO: 6.0;MOLT-4: 8.6;NTERA-2: 3.1
RGPD2,"RANBP2L2, RGP2",ENSG00000185304,RANBP2-like and GRIP domain containing 2,2,87755955-87825952,Predicted intracellular proteins,Evidence at transcript level,"HPA049497, HPA051675, HPA067564",Uncertain,NA,Approved,Nuclear membrane<br>Vesicles,NA,Not detected,Tissue enhanced,NA,placenta: 14.3;testis: 33.3,bone marrow: 6.3,Cell line enhanced,NA,BEWO: 10.9;MOLT-4: 10.5;NTERA-2: 5.4;SiHa: 4.7
RGPD3,RGP3,ENSG00000153165,RANBP2-like and GRIP domain containing 3,2,106391290-106468376,Predicted intracellular proteins,Evidence at transcript level,"HPA049497, HPA051675, HPA067564",Uncertain,NA,Approved,Nuclear membrane<br>Vesicles,NA,Not detected,Tissue enriched,13,testis: 11.7,"cerebral cortex,kidney: 0.8",Cell line enhanced,NA,HEL: 1.4;MOLT-4: 4.1
RGPD4,"DKFZp686P0288, RGP4",ENSG00000196862,RANBP2-like and GRIP domain containing 4,2,107826937-107890841,Predicted intracellular proteins,Evidence at transcript level,"HPA049497, HPA051675, HPA067564",Uncertain,NA,Uncertain,Nuclear membrane<br>Vesicles,NA,Not detected,Tissue enriched,57,testis: 5.7,all non-specific tissues: 0.0,Not detected,NA,NA
RGPD5,"BS-63, DKFZp686I1842, RGP5",ENSG00000015568,RANBP2-like and GRIP domain containing 5,2,109792758-109857695,Predicted intracellular proteins,Evidence at protein level,"HPA045704, HPA049497, HPA051675, HPA067564",Uncertain,NA,Uncertain,Nuclear membrane<br>Vesicles,NA,Not detected,Tissue enhanced,NA,testis: 6.6,duodenum: 3.2,Mixed,NA,NA
RGPD6,RGP6,ENSG00000183054,RANBP2-like and GRIP domain containing 6,2,110513812-110577185,Predicted intracellular proteins,Evidence at protein level,"HPA045704, HPA049497, HPA051675, HPA067564",Uncertain,NA,Uncertain,Nuclear membrane<br>Vesicles,NA,Not detected,Expressed in all,NA,NA,testis: 83.3,Mixed,NA,NA
RGPD8,"RanBP2alpha, RANBP2L1",ENSG00000169629,RANBP2-like and GRIP domain containing 8,2,112370092-112434488,Predicted intracellular proteins,Evidence at protein level,"HPA045704, HPA049497, HPA051675, HPA067564",Uncertain,NA,Uncertain,Nuclear membrane<br>Vesicles,NA,Not detected,Tissue enriched,5,testis: 31.7,cerebral cortex: 5.8,Cell line enhanced,NA,HEL: 14.4
RGS14,NA,ENSG00000169220,Regulator of G-protein signaling 14,5,177357837-177372601,Predicted intracellular proteins,Evidence at protein level,"HPA046847, HPA061819",Enhanced,NA,Enhanced,Nucleoplasm<br>Vesicles,"Liver cancer:1.84e-6 (unfavourable), Glioma:9.11e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 21.7,Cell line enhanced,NA,HDLM-2: 101.9;HMC-1: 82.1;RPMI-8226: 39.1
RGS17,"RGS-17, RGSZ2",ENSG00000091844,Regulator of G-protein signaling 17,6,153004459-153131249,Predicted intracellular proteins,Evidence at protein level,"HPA022276, HPA056493",Approved,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,cerebral cortex: 5.5,Cell line enhanced,NA,hTERT-HME1: 13.2;LHCN-M2: 14.6;U-87 MG: 14.3
RHBDF1,"C16orf8, Dist1, EGFR-RS, FLJ2235, iRhom1",ENSG00000007384,Rhomboid 5 homolog 1,16,58059-76355,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA077399,NA,NA,Uncertain,Vesicles,Renal cancer:2.49e-5 (unfavourable),Expressed in all,Mixed,NA,NA,placenta: 39.8,Mixed,NA,NA
RHOBTB3,KIAA0878,ENSG00000164292,Rho related BTB domain containing 3,5,95713522-95824383,Predicted intracellular proteins,Evidence at protein level,HPA000265,NA,NA,Uncertain,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,ovary: 99.0,Cell line enhanced,NA,HaCaT: 281.3
RHOQ,"ARHQ, RASL7A, TC10",ENSG00000119729,Ras homolog family member Q,2,46541806-46583121,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044938,NA,NA,Approved,Vesicles<br>Cytosol,Liver cancer:9.60e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 167.5,Expressed in all,NA,NA
RINL,FLJ45909,ENSG00000187994,Ras and Rab interactor like,19,38867834-38878279,Predicted intracellular proteins,Evidence at protein level,"HPA042083, HPA042103",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Cervical cancer:6.49e-5 (favourable), Head and neck cancer:1.64e-4 (favourable)",Expressed in all,Mixed,NA,NA,lymph node: 13.9,Cell line enhanced,NA,HMC-1: 20.0;Karpas-707: 19.3
RNASE1,"RAC1, RNS1",ENSG00000129538,"Ribonuclease A family member 1, pancreatic",14,20801228-20803278,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001140,Supported,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,pancreas: 1946.8,Group enriched,6,HUVEC TERT2: 239.6;RT4: 91.0;TIME: 122.8
RNASE12,RAI1,ENSG00000258436,Ribonuclease A family member 12 (inactive),14,20590193-20590823,Predicted secreted proteins,Evidence at protein level,"HPA044175, HPA059465",Enhanced,NA,Uncertain,Vesicles<br>Microtubules,NA,Not detected,Tissue enriched,252,epididymis: 1052.1,seminal vesicle: 4.1,Not detected,NA,NA
RNF121,FLJ11099,ENSG00000137522,Ring finger protein 121,11,71928701-71997597,Predicted membrane proteins,Evidence at protein level,HPA046041,Uncertain,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Renal cancer:2.72e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 28.5,Expressed in all,NA,NA
RNF13,RZF,ENSG00000082996,Ring finger protein 13,3,149812708-149962139,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA064784,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.00e-8 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 94.4,Expressed in all,NA,NA
RNF135,MGC13061,ENSG00000181481,Ring finger protein 135,17,30968785-30999911,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021576, HPA052404",Approved,NA,Approved,Vesicles,Renal cancer:7.51e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 28.7,Mixed,NA,NA
RNF144A,"KIAA0161, RNF144, UBCE7IP4",ENSG00000151692,Ring finger protein 144A,2,6917392-7068286,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA049939,Approved,NA,Approved,Vesicles,"Stomach cancer:7.32e-5 (unfavourable), Endometrial cancer:6.00e-4 (unfavourable), Head and neck cancer:6.96e-4 (favourable)",Expressed in all,Mixed,NA,NA,endometrium: 43.1,Cell line enhanced,NA,HMC-1: 112.4
RNF157,KIAA1917,ENSG00000141576,Ring finger protein 157,17,76142453-76240373,Predicted intracellular proteins,Evidence at protein level,"HPA021854, HPA021991, HPA023922",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 60.6;testis: 57.3,skeletal muscle: 24.9,Cell line enhanced,NA,HDLM-2: 92.0;U-266/70: 38.2
RNF182,MGC33993,ENSG00000180537,Ring finger protein 182,6,13924446-13980302,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012309,Approved,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Endometrial cancer:4.66e-5 (unfavourable),Mixed,Tissue enhanced,NA,cerebral cortex: 14.6,testis: 6.9,Cell line enhanced,NA,HeLa: 57.3;RPTEC TERT1: 51.0
RNF26,MGC2642,ENSG00000173456,Ring finger protein 26,11,119334527-119337313,Predicted membrane proteins,Evidence at transcript level,HPA027620,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:3.45e-6 (favourable), Liver cancer:3.19e-4 (unfavourable), Urothelial cancer:7.73e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 33.9,Mixed,NA,NA
ROS1,"c-ros-1, MCF3, ROS",ENSG00000047936,"ROS proto-oncogene 1, receptor tyrosine kinase",6,117288300-117425855,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA049098, HPA072424",Uncertain,NA,Approved,Vesicles,NA,Tissue enriched,Group enriched,18,epididymis: 70.9;lung: 47.2,seminal vesicle: 3.2,Cell line enhanced,NA,HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7
RP11-195F19.5,NA,ENSG00000187186,NA,9,34664163-34666112,Predicted intracellular proteins,Evidence at protein level,HPA069617,Enhanced,NA,Approved,Nucleoli<br>Endoplasmic reticulum<br>Vesicles,Glioma:5.81e-5 (unfavourable),Mixed,Tissue enriched,5,testis: 138.9,cerebral cortex: 25.6,Cell line enhanced,NA,HeLa: 31.7
RP11-303E16.10,NA,ENSG00000284512,NA,16,81022316-81096284,Predicted secreted proteins,Evidence at protein level,HPA041368,Uncertain,NA,Approved,Vesicles,NA,NA,Tissue enriched,7,testis: 12.0,cerebral cortex: 1.6,Mixed,NA,NA
RP11-303E16.8,NA,ENSG00000260643,NA,16,81053587-81096296,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA041368,Approved,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,thyroid gland: 17.3,cerebral cortex: 11.3,Mixed,NA,NA
RP11-310K10.1,NA,ENSG00000197991,NA,13,61409858-61427849,Predicted membrane proteins,No evidence,HPA062669,NA,NA,Approved,Vesicles<br>Cytokinetic bridge,NA,Not detected,Not detected,NA,NA,testis: 0.5,Not detected,NA,NA
RP11-606E8.2,NA,ENSG00000284057,NA,11,93741664-93812378,Predicted intracellular proteins,Evidence at protein level,"HPA040511, HPA064236",Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,NA,Tissue enhanced,NA,kidney: 6.9,duodenum: 3.1,Mixed,NA,NA
RP4-714D9.5,NA,ENSG00000283761,NA,1,99970011-100083321,Predicted membrane proteins,Evidence at transcript level,HPA073681,NA,NA,Approved,Vesicles,NA,NA,Mixed,NA,NA,lung: 1.0,Mixed,NA,NA
RPL11,L11,ENSG00000142676,Ribosomal protein L11,1,23691779-23696425,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA002734, HPA074839",Approved,NA,Approved,Vesicles,"Renal cancer:5.93e-6 (unfavourable), Breast cancer:2.55e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 4915.9,Expressed in all,NA,NA
RPL7A,"L7A, SURF3, TRUP",ENSG00000148303,Ribosomal protein L7a,9,133348214-133351426,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA046794,NA,NA,Approved,Nucleoli<br>Vesicles,"Ovarian cancer:3.60e-5 (unfavourable), Liver cancer:8.99e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,ovary: 2618.0,Expressed in all,NA,NA
RPRD2,"FLJ32145, HSPC099, KIAA0460",ENSG00000163125,Regulation of nuclear pre-mRNA domain containing 2,1,150363091-150476566,Predicted intracellular proteins,Evidence at protein level,HPA061693,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 38.5,Expressed in all,NA,NA
RPS12,S12,ENSG00000112306,Ribosomal protein S12,6,132814441-132817564,"Plasma proteins, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA006124, HPA006365",Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Cytosol,Renal cancer:1.06e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,ovary: 3959.0,Expressed in all,NA,NA
RRAGA,"FIP-1, RAGA",ENSG00000155876,Ras related GTP binding A,9,19049395-19050983,Predicted intracellular proteins,Evidence at protein level,HPA003734,Supported,NA,Approved,Golgi apparatus<br>Vesicles,Head and neck cancer:7.43e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 128.1,Expressed in all,NA,NA
RRAGB,NA,ENSG00000083750,Ras related GTP binding B,X,55717739-55758774,Predicted intracellular proteins,Evidence at protein level,HPA003734,Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Lung cancer:3.64e-6 (favourable), Glioma:5.36e-5 (favourable), Colorectal cancer:7.60e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 42.3,Expressed in all,NA,NA
RRAGC,"FLJ13311, GTR2",ENSG00000116954,Ras related GTP binding C,1,38838198-38859823,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA018247, HPA055489",Enhanced,NA,Supported,Nucleus<br>Vesicles,Liver cancer:9.97e-9 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 40.4,Expressed in all,NA,NA
RRAS,NA,ENSG00000126458,Related RAS viral (r-ras) oncogene homolog,19,49635292-49640201,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010160, HPA060364, CAB069439",Uncertain,NA,Approved,Vesicles,"Renal cancer:1.54e-9 (unfavourable), Glioma:6.03e-5 (unfavourable), Lung cancer:5.28e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,seminal vesicle: 209.2,Mixed,NA,NA
RSBN1,"FLJ11220, ROSBIN",ENSG00000081019,Round spermatid basic protein 1,1,113761832-113812476,Predicted intracellular proteins,Evidence at protein level,"HPA042124, HPA049484",Approved,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 22.0,Expressed in all,NA,NA
RSU1,"FLJ31034, RSP-1",ENSG00000148484,Ras suppressor protein 1,10,16590611-16817528,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA025927,Uncertain,NA,Approved,Vesicles,Renal cancer:9.32e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,smooth muscle: 58.8,Expressed in all,NA,NA
RTCB,"C22orf28, FAAP, HSPC117",ENSG00000100220,"RNA 2',3'-cyclic phosphate and 5'-OH ligase",22,32387582-32412255,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000535, HPA001103",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:4.25e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 104.2,Expressed in all,NA,NA
RUBCN,"KIAA0226, rubicon, rundataxin",ENSG00000145016,RUN and cysteine rich domain containing beclin 1 interacting protein,3,197671393-197749727,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA050908, HPA054497",Approved,NA,Supported,Vesicles<br>Cytosol,"Liver cancer:9.91e-5 (unfavourable), Prostate cancer:1.62e-4 (unfavourable), Colorectal cancer:6.65e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"spleen,testis: 24.3",Expressed in all,NA,NA
RUFY1,"FLJ22251, RABIP4, ZFYVE12",ENSG00000176783,RUN and FYVE domain containing 1,5,179550558-179610026,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038804, HPA057614",Approved,NA,Supported,Nucleus<br>Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,spleen: 20.2,Expressed in all,NA,NA
RUNDC3A,"RAP2IP, RPIP8",ENSG00000108309,RUN domain containing 3A,17,44308413-44318671,Predicted intracellular proteins,Evidence at protein level,"HPA023548, HPA070733",Enhanced,Supported,Approved,Vesicles,NA,Tissue enhanced,Tissue enriched,10,cerebral cortex: 178.0,adrenal gland: 18.2,Group enriched,8,SCLC-21H: 72.5;SH-SY5Y: 41.7
RUNX1,"AML1, AMLCR1, CBFA2, PEBP2A2",ENSG00000159216,Runt related transcription factor 1,21,34787801-36004667,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004176, HPA037912",Enhanced,NA,Enhanced,Nucleoplasm<br>Vesicles,Renal cancer:3.44e-15 (unfavourable),Expressed in all,Mixed,NA,NA,breast: 34.0,Cell line enhanced,NA,HEL: 225.2
RYR1,"CCO, MHS, MHS1, PPP1R137, RYR",ENSG00000196218,Ryanodine receptor 1,19,38433699-38587564,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA056416,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles<br>Cytosol,NA,Mixed,Tissue enriched,31,skeletal muscle: 572.4,esophagus: 18.6,Cell line enhanced,NA,HaCaT: 16.8;RH-30: 14.8;SiHa: 32.7;U-2 OS: 13.2
RYR3,NA,ENSG00000198838,Ryanodine receptor 3,15,33310945-33866121,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA062004,NA,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,parathyroid gland: 29.1,cerebral cortex: 7.0,Cell line enhanced,NA,A549: 3.9;RH-30: 6.3;RPTEC TERT1: 2.3
S100B,S100beta,ENSG00000160307,S100 calcium binding protein B,21,46598962-46605208,"Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB000073, HPA015768, CAB078196",Enhanced,NA,Approved,Nucleus<br>Vesicles,NA,Group enriched,Group enriched,8,adipose tissue: 208.2;cerebral cortex: 626.3,seminal vesicle: 49.5,Group enriched,6,SK-MEL-30: 519.7;WM-115: 1274.2
S1PR1,"CD363, D1S3362, edg-1, EDG1",ENSG00000170989,Sphingosine-1-phosphate receptor 1,1,101236888-101241518,"Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB010104, HPA075568",Supported,NA,Supported,Vesicles,Urothelial cancer:8.78e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 86.8,Cell line enhanced,NA,BJ: 53.9;HUVEC TERT2: 149.1;TIME: 81.9;U-251 MG: 103.4
SAFB2,KIAA0138,ENSG00000130254,Scaffold attachment factor B2,19,5586999-5624046,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA050894,Approved,NA,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles,"Urothelial cancer:2.12e-4 (favourable), Pancreatic cancer:2.53e-4 (favourable), Endometrial cancer:7.10e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,ovary: 40.0,Expressed in all,NA,NA
SALL2,"Hsal2, KIAA0360, ZNF795",ENSG00000165821,Spalt like transcription factor 2,14,21521081-21537216,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA004162,Approved,NA,Approved,Nucleus<br>Vesicles,"Pancreatic cancer:1.23e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)",Mixed,Tissue enhanced,NA,parathyroid gland: 67.9,cerebral cortex: 42.4,Cell line enhanced,NA,AF22: 123.9;NTERA-2: 95.1;SCLC-21H: 50.0
SAMD11,MGC45873,ENSG00000187634,Sterile alpha motif domain containing 11,1,923928-944581,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA030110,NA,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:3.35e-5 (unfavourable),Expressed in all,Tissue enhanced,NA,seminal vesicle: 27.6,fallopian tube: 20.4,Cell line enhanced,NA,HEK93: 98.5;HeLa: 80.1;SCLC-21H: 89.8
SAMD5,dJ875H10.1,ENSG00000203727,Sterile alpha motif domain containing 5,6,147508927-147737547,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067811,Uncertain,NA,Supported,Vesicles,Liver cancer:2.23e-4 (unfavourable),Mixed,Tissue enhanced,NA,parathyroid gland: 22.5,placenta: 18.1,Cell line enhanced,NA,Hep G2: 44.5;K-562: 40.0;RH-30: 28.7;WM-115: 20.8
SAMD9,"C7orf5, FLJ20073, KIAA2004",ENSG00000205413,Sterile alpha motif domain containing 9,7,93099513-93118023,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021318, HPA021319",Approved,NA,Enhanced,Vesicles<br>Cytosol,"Renal cancer:8.40e-7 (unfavourable), Pancreatic cancer:8.31e-5 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Endometrial cancer:3.14e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,esophagus: 43.2,spleen: 24.2,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+ RasG12V: 64.9
SARM1,"KIAA0524, SAMD2, SARM",ENSG00000004139,Sterile alpha and TIR motif containing 1,17,28364356-28404049,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA024359, HPA024759",Uncertain,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,duodenum: 7.5,Cell line enhanced,NA,CACO-2: 26.9
SAYSD1,"C6orf64, FLJ11101",ENSG00000112167,SAYSVFN motif domain containing 1,6,39104064-39115189,Predicted membrane proteins,Evidence at protein level,HPA007959,NA,Approved,Enhanced,Vesicles,NA,Expressed in all,Tissue enriched,6,testis: 85.8,prostate: 14.6,Mixed,NA,NA
SBSN,"HLAR698, UNQ698",ENSG00000189001,Suprabasin,19,35523367-35528351,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA062568, HPA067734",Enhanced,NA,Approved,Vesicles,NA,Group enriched,Group enriched,12,esophagus: 1055.9;skin: 2690.8,tonsil: 151.8,Cell line enhanced,NA,ASC diff: 42.6;ASC TERT1: 75.3;HSkMC: 106.4;U-2197: 48.0;U-87 MG: 117.4
SBSPON,"C8orf84, RPESP",ENSG00000164764,Somatomedin B and thrombospondin type 1 domain containing,8,73064540-73124088,Predicted secreted proteins,Evidence at protein level,"HPA029595, CAB034214, CAB034332",Uncertain,NA,Approved,Vesicles,"Breast cancer:7.18e-4 (favourable), Renal cancer:8.82e-4 (unfavourable)",Mixed,Tissue enhanced,NA,prostate: 23.8,urinary bladder: 16.2,Group enriched,6,BJ: 7.6;RPTEC TERT1: 12.1
SCAMP2,NA,ENSG00000140497,Secretory carrier membrane protein 2,15,74843730-74873365,Predicted membrane proteins,Evidence at protein level,"HPA014699, HPA019194",Approved,NA,Supported,Golgi apparatus<br>Vesicles,Renal cancer:1.12e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 128.7,Expressed in all,NA,NA
SCAMP3,C1orf3,ENSG00000116521,Secretory carrier membrane protein 3,1,155255979-155262430,Predicted membrane proteins,Evidence at protein level,HPA071167,NA,NA,Supported,Vesicles,Liver cancer:2.92e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 46.9,Expressed in all,NA,NA
SCARB1,"CD36L1, CLA-1, CLA1, SR-BI, SRB1",ENSG00000073060,Scavenger receptor class B member 1,12,124776856-124882668,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA066285, CAB070124, HPA072449",Enhanced,NA,Approved,Vesicles,"Renal cancer:1.49e-5 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Lung cancer:4.02e-4 (unfavourable)",Expressed in all,Group enriched,7,adrenal gland: 758.4;placenta: 287.5,liver: 72.3,Mixed,NA,NA
SCCPDH,"CGI-49, NET11",ENSG00000143653,Saccharopine dehydrogenase (putative),1,246724047-246768137,Predicted membrane proteins,Evidence at protein level,HPA050775,Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 241.5,Mixed,NA,NA
SCG3,"FLJ90833, SgIII",ENSG00000104112,Secretogranin III,15,51681353-51721031,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA006880, CAB033274, HPA053715",Enhanced,Approved,Enhanced,Vesicles,NA,Group enriched,Tissue enriched,13,cerebral cortex: 278.4,adrenal gland: 21.9,Group enriched,8,NTERA-2: 50.4;SCLC-21H: 140.8;SH-SY5Y: 60.1
SCRN3,FLJ23142,ENSG00000144306,Secernin 3,2,174395730-174429575,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034689, HPA034690",Approved,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 48.4,Mixed,NA,NA
SDCBP2,"SITAC18, ST-2",ENSG00000125775,Syndecan binding protein 2,20,1309909-1329239,Predicted intracellular proteins,Evidence at protein level,"HPA054554, HPA064490",Enhanced,NA,Approved,Vesicles<br>Cytosol,"Lung cancer:2.42e-4 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable), Urothelial cancer:3.37e-4 (favourable)",Expressed in all,Tissue enhanced,NA,duodenum: 135.1;small intestine: 143.9,stomach: 94.5,Cell line enhanced,NA,CAPAN-2: 16.0
SDF2,NA,ENSG00000132581,Stromal cell derived factor 2,17,28648356-28662189,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042799,NA,NA,Approved,Vesicles,Liver cancer:1.16e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,adrenal gland: 27.8,Expressed in all,NA,NA
SEC13,"D3S1231E, npp-20, SEC13L1, SEC13R",ENSG00000157020,"SEC13 homolog, nuclear pore and COPII coat complex component",3,10293131-10321178,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA035292, HPA057943",Approved,NA,Supported,Nucleoplasm<br>Vesicles,Liver cancer:1.73e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 120.0",Expressed in all,NA,NA
SEC23A,NA,ENSG00000100934,"Sec23 homolog A, coat complex II component",14,39031919-39109646,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043806, HPA069974",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.69e-4 (unfavourable), Stomach cancer:2.94e-4 (unfavourable), Colorectal cancer:3.56e-4 (favourable), Cervical cancer:5.75e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 140.0,Expressed in all,NA,NA
SEC23B,"CDA-II, CDAII, CDAN2, HEMPAS",ENSG00000101310,"Sec23 homolog B, coat complex II component",20,18507493-18561415,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA008216, HPA069974",Uncertain,NA,Supported,Vesicles,Endometrial cancer:8.25e-4 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 85.7,Expressed in all,NA,NA
SEC23IP,p125,ENSG00000107651,SEC23 interacting protein,10,119892711-119944658,Predicted intracellular proteins,Evidence at protein level,"HPA038403, HPA043305",Approved,NA,Enhanced,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,smooth muscle: 30.5,Expressed in all,NA,NA
SEC24A,NA,ENSG00000113615,"SEC24 homolog A, COPII coat complex component",5,134648789-134727823,Predicted intracellular proteins,Evidence at protein level,"HPA038901, HPA056825",Approved,NA,Approved,Nucleoli fibrillar center<br>Vesicles,Cervical cancer:3.70e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 25.8,Expressed in all,NA,NA
SEC24B,NA,ENSG00000138802,"SEC24 homolog B, COPII coat complex component",4,109433772-109540896,Predicted intracellular proteins,Evidence at protein level,HPA038181,Approved,NA,Approved,Nucleus<br>Vesicles,Renal cancer:2.33e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 42.8,Expressed in all,NA,NA
SEC24C,KIAA0079,ENSG00000176986,"SEC24 homolog C, COPII coat complex component",10,73744384-73772161,Predicted intracellular proteins,Evidence at protein level,"HPA040196, HPA040213",Supported,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 85.5,Expressed in all,NA,NA
SEC24D,KIAA0755,ENSG00000150961,"SEC24 homolog D, COPII coat complex component",4,118722823-118838683,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA041626, HPA053486",Approved,NA,Approved,Vesicles,Renal cancer:3.42e-6 (unfavourable),Expressed in all,Mixed,NA,NA,"cervix, uterine: 76.6",Expressed in all,NA,NA
SEC31A,"ABP125, ABP130, KIAA0905, SEC31L1",ENSG00000138674,"SEC31 homolog A, COPII coat complex component",4,82818661-82901166,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA005457,Approved,NA,Supported,Vesicles<br>Cytosol,"Urothelial cancer:2.69e-4 (unfavourable), Liver cancer:3.32e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 281.0,Expressed in all,NA,NA
SEC31B,"DKFZP434M183, SEC31B-1, SEC31L2",ENSG00000075826,"SEC31 homolog B, COPII coat complex component",10,100486642-100519864,Predicted intracellular proteins,Evidence at protein level,"HPA035882, HPA040819, HPA060052",Uncertain,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol,Renal cancer:6.41e-7 (unfavourable),Mixed,Mixed,NA,NA,testis: 3.2,Mixed,NA,NA
SEMA3A,"coll-1, Hsema-I, SEMA1, SEMAD, SemD",ENSG00000075213,Semaphorin 3A,7,83955777-84492724,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA029447, HPA052235",Approved,NA,Approved,Nucleoplasm<br>Vesicles,Cervical cancer:2.69e-5 (unfavourable),Mixed,Mixed,NA,NA,placenta: 14.5,Cell line enhanced,NA,AF22: 127.3;BJ: 86.5;fHDF/TERT166: 86.7
SEMA3E,"coll-5, KIAA0331, M-SemaK, SEMAH",ENSG00000170381,Semaphorin 3E,7,83363906-83649010,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA029419, HPA063804",Uncertain,Supported,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,prostate: 8.7,Cell line enhanced,NA,SK-BR-3: 29.4;U-2 OS: 21.3
SEMA4D,"C9orf164, CD100, coll-4, FLJ39737, SEMAJ",ENSG00000187764,Semaphorin 4D,9,89360787-89498130,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA015662, HPA023277",Approved,NA,Supported,Endoplasmic reticulum<br>Vesicles,"Urothelial cancer:4.06e-5 (favourable), Cervical cancer:4.17e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,lymph node: 72.4,Cell line enhanced,NA,HDLM-2: 124.4;HMC-1: 86.7;MOLT-4: 98.7
SEMA4G,"FLJ20590, KIAA1619",ENSG00000095539,Semaphorin 4G,10,100969518-100985871,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA038362, HPA077752",Uncertain,NA,Uncertain,Vesicles<br>Lipid droplets,NA,Mixed,Tissue enhanced,NA,rectum: 92.7,duodenum: 53.8,Cell line enhanced,NA,A549: 28.9;CACO-2: 25.3;Hep G2: 76.9
SEMA7A,"CD108, H-Sema-L, SEMAL",ENSG00000138623,Semaphorin 7A (John Milton Hagen blood group),15,74409289-74434467,"Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008210, HPA042273",Uncertain,NA,Uncertain,Vesicles,Renal cancer:2.45e-11 (unfavourable),Expressed in all,Tissue enhanced,NA,spleen: 59.6;testis: 56.9,placenta: 44.8,Cell line enhanced,NA,HMC-1: 510.6;hTEC/SVTERT24-B: 213.0;U-251 MG: 310.7
SENP8,"DEN1, HsT17512, NEDP1, PRSC2",ENSG00000166192,"SUMO/sentrin peptidase family member, NEDD8 specific",15,72114258-72143688,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036273,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 27.7,thyroid gland: 8.3,Expressed in all,NA,NA
SEPSECS,"SLA, SLA/LP",ENSG00000109618,Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase,4,25120014-25160442,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA070409,NA,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,liver: 16.7,Expressed in all,NA,NA
SERGEF,"DelGEF, Gnefr",ENSG00000129158,Secretion regulating guanine nucleotide exchange factor,11,17788048-18013162,Predicted intracellular proteins,Evidence at protein level,"HPA037811, HPA037812, HPA074086",Supported,NA,Enhanced,Nucleoplasm<br>Vesicles<br>Cytosol,Glioma:7.92e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 52.9,Expressed in all,NA,NA
SERINC5,"C5orf12, TPO1",ENSG00000164300,Serine incorporator 5,5,80111651-80256079,Predicted membrane proteins,Evidence at protein level,"HPA037898, HPA037899",Supported,NA,Uncertain,Nucleus<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 55.4,Mixed,NA,NA
SERPINA1,"A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1",ENSG00000197249,Serpin family A member 1,14,94376747-94390693,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA000927, HPA001292, CAB013211, CAB016648, CAB073396",Enhanced,NA,Enhanced,Vesicles,"Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable)",Tissue enriched,Tissue enriched,20,liver: 17144.0,small intestine: 857.0,Cell line enriched,6,Hep G2: 3254.2
SERPINB5,"maspin, PI5",ENSG00000206075,Serpin family B member 5,18,63476761-63505085,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009570, HPA019025, HPA019132, HPA020136",Enhanced,NA,Supported,Vesicles,"Pancreatic cancer:5.71e-6 (unfavourable), Lung cancer:1.54e-4 (unfavourable)",Tissue enhanced,Group enriched,5,esophagus: 220.2;skin: 261.8,breast: 44.2,Cell line enhanced,NA,HaCaT: 1048.4;HBEC3-KT: 281.3;hTCEpi: 583.7
SERPIND1,"D22S673, HC-II, HC2, HCF2, HLS2",ENSG00000099937,Serpin family D member 1,22,20773879-20787720,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB008639, HPA055767",Supported,NA,Approved,Vesicles,Endometrial cancer:4.09e-4 (favourable),Tissue enriched,Tissue enriched,16,liver: 585.3,parathyroid gland: 36.2,Cell line enriched,8,Hep G2: 126.1
SERPINF2,"A2AP, AAP, ALPHA-2-PI, API, PLI",ENSG00000167711,Serpin family F member 2,17,1742836-1755268,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001885, CAB024863",Approved,NA,Uncertain,Nucleoplasm<br>Vesicles,Liver cancer:2.26e-5 (favourable),Tissue enriched,Tissue enhanced,NA,epididymis: 117.4;liver: 452.5,kidney: 63.3,Cell line enriched,24,Hep G2: 99.1
SERTM1,C13orf36,ENSG00000180440,Serine rich and transmembrane domain containing 1,13,36673912-36697839,Predicted membrane proteins,Evidence at protein level,"HPA054814, HPA070485",Uncertain,NA,Supported,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 47.6;endometrium: 37.7;fallopian tube: 29.6,smooth muscle: 24.8,Cell line enhanced,NA,HAP1: 1.2;HEK93: 1.3;NTERA-2: 3.5;SH-SY5Y: 2.1
SEZ6L,NA,ENSG00000100095,Seizure related 6 homolog like,22,26169474-26383597,Predicted membrane proteins,Evidence at protein level,HPA045135,NA,NA,Approved,Vesicles,NA,Group enriched,Tissue enriched,7,cerebral cortex: 89.2,adrenal gland: 13.6,Group enriched,8,SCLC-21H: 49.2;SH-SY5Y: 11.9
SFXN4,NA,ENSG00000183605,Sideroflexin 4,10,119140767-119165667,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018028, HPA020872",Approved,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 47.3,Expressed in all,NA,NA
SGK3,"SGK2, SGKL",ENSG00000104205,Serum/glucocorticoid regulated kinase family member 3,8,66712418-66862022,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006699, HPA027146",Supported,NA,Approved,Nucleoplasm<br>Vesicles,"Breast cancer:5.52e-6 (favourable), Cervical cancer:8.28e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 48.5,Mixed,NA,NA
SH2B1,"FLJ30542, SH2B",ENSG00000178188,SH2B adaptor protein 1,16,28846600-28874212,Predicted intracellular proteins,Evidence at protein level,HPA076175,NA,NA,Approved,Vesicles,"Renal cancer:2.81e-6 (favourable), Urothelial cancer:1.60e-4 (favourable), Pancreatic cancer:4.38e-4 (favourable), Lung cancer:9.40e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 105.8,Expressed in all,NA,NA
SH3BGRL,MGC117402,ENSG00000131171,SH3 domain binding glutamate rich protein like,X,81201943-81298547,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051248,Approved,NA,Approved,Vesicles,Stomach cancer:4.08e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,seminal vesicle: 360.6,Mixed,NA,NA
SH3BP5L,KIAA1720,ENSG00000175137,SH3 binding domain protein 5 like,1,248810446-248826633,Predicted intracellular proteins,Evidence at protein level,"HPA038067, HPA038068",Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 19.7,Expressed in all,NA,NA
SH3RF1,"KIAA1494, POSH, RNF142, SH3MD2",ENSG00000154447,SH3 domain containing ring finger 1,4,169094256-169271105,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA074783,NA,NA,Supported,Vesicles<br>Intermediate filaments,Renal cancer:5.51e-8 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 32.1,Mixed,NA,NA
SHISA2,"bA398O19.2, C13orf13, hShisa, PRO28631, TMEM46, WGAR9166",ENSG00000180730,Shisa family member 2,13,26044597-26051031,Predicted membrane proteins,Evidence at protein level,"HPA049752, HPA050172",Uncertain,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,"Renal cancer:2.43e-4 (favourable), Lung cancer:3.30e-4 (favourable)",Mixed,Tissue enhanced,NA,breast: 22.3;thyroid gland: 48.3,epididymis: 13.1,Cell line enhanced,NA,LHCN-M2: 21.2;NTERA-2: 18.4;RH-30: 56.6;U-2197: 34.1
SHOX,"GCFX, PHOG, SHOXY, SS",ENSG00000185960,Short stature homeobox,X,624344-659411,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA035141, HPA060931",NA,NA,Enhanced,Nucleoplasm<br>Vesicles,NA,Not detected,Mixed,NA,NA,spleen: 1.0,Cell line enhanced,NA,BJ: 19.3;BJ hTERT+: 9.5
SHROOM1,"APXL2, KIAA1960",ENSG00000164403,Shroom family member 1,5,132822141-132830898,Predicted intracellular proteins,Evidence at protein level,"HPA037690, HPA037691",Uncertain,NA,Approved,Vesicles,Renal cancer:5.72e-6 (unfavourable),Expressed in all,Tissue enhanced,NA,prostate: 54.5,seminal vesicle: 21.3,Mixed,NA,NA
SIAH2,NA,ENSG00000181788,Siah E3 ubiquitin protein ligase 2,3,150741127-150763477,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA061293, CAB069930",Approved,NA,Supported,Nucleoplasm<br>Vesicles,"Pancreatic cancer:8.21e-5 (unfavourable), Breast cancer:1.17e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 95.3,Expressed in all,NA,NA
SIKE1,"FLJ21168, SIKE",ENSG00000052723,Suppressor of IKBKE 1,1,114769479-114780685,Predicted intracellular proteins,Evidence at protein level,"HPA024177, HPA025726",Supported,NA,Approved,Vesicles<br>Focal adhesion sites,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 19.4,Expressed in all,NA,NA
SIRPB1,"CD172b, SIRP-BETA-1",ENSG00000101307,Signal regulatory protein beta 1,20,1563521-1620061,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA047463,Uncertain,NA,Uncertain,Vesicles,NA,Mixed,Tissue enhanced,NA,appendix: 38.7;bone marrow: 33.7,lung: 28.0,Cell line enhanced,NA,HMC-1: 46.6;NB-4: 46.7;THP-1: 38.2
SIRT7,NA,ENSG00000187531,Sirtuin 7,17,81911939-81921323,Predicted intracellular proteins,Evidence at protein level,"CAB037261, HPA053669",Enhanced,NA,Supported,Nucleoli fibrillar center<br>Vesicles,"Renal cancer:1.69e-7 (unfavourable), Liver cancer:1.97e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,esophagus: 21.6,Expressed in all,NA,NA
SLA2,"C20orf156, FLJ21992, SLAP-2",ENSG00000101082,Src like adaptor 2,20,36612318-36646216,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA053746, HPA058217",NA,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Renal cancer:6.77e-8 (unfavourable), Cervical cancer:7.36e-4 (favourable)",Mixed,Tissue enhanced,NA,lymph node: 11.8,spleen: 8.9,Cell line enriched,9,HEL: 81.2
SLAMF7,"19A, CD319, CRACC, CS1",ENSG00000026751,SLAM family member 7,1,160739057-160754821,"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB015445, HPA055945, HPA061654",Enhanced,NA,Approved,Vesicles,"Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)",Mixed,Mixed,NA,NA,spleen: 58.3,Group enriched,7,SK-MEL-30: 45.6;U-266/70: 216.2
SLC12A1,NKCC2,ENSG00000074803,Solute carrier family 12 member 1,15,48191664-48304078,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014967, HPA018107",Enhanced,NA,Approved,Nucleus<br>Vesicles,NA,Tissue enhanced,Tissue enriched,477,kidney: 780.2,testis: 1.6,Cell line enriched,19,RPTEC TERT1: 19.2
SLC12A6,"ACCPN, KCC3",ENSG00000140199,Solute carrier family 12 member 6,15,34229996-34338060,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA034563,Uncertain,NA,Approved,Vesicles<br>Cytosol,Renal cancer:3.33e-6 (favourable),Expressed in all,Mixed,NA,NA,testis: 46.4,Cell line enhanced,NA,HaCaT: 38.6
SLC14A1,"HsT1341, JK, RACH1, RACH2",ENSG00000141469,Solute carrier family 14 member 1 (Kidd blood group),18,45724127-45752520,"Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA058353, HPA059570",Supported,NA,Supported,Vesicles,NA,Group enriched,Group enriched,5,prostate: 137.8;urinary bladder: 49.9,cerebral cortex: 18.1,Cell line enriched,14,RT4: 97.7
SLC15A3,"hPTR3, PHT2",ENSG00000110446,Solute carrier family 15 member 3,11,60937084-60952530,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA047880, HPA057642",Approved,NA,Supported,Vesicles,Cervical cancer:4.07e-5 (favourable),Expressed in all,Expressed in all,NA,NA,lung: 102.2,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+: 91.0;BJ hTERT+ SV40 Large T+ RasG12V: 114.5;HHSteC: 47.3
SLC16A6,"MCT6, MCT7",ENSG00000108932,Solute carrier family 16 member 6,17,68267026-68291267,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA054459, HPA066328",Uncertain,NA,Approved,Vesicles,NA,Group enriched,Tissue enhanced,NA,epididymis: 39.4,esophagus: 12.1,Cell line enriched,11,SK-MEL-30: 392.2
SLC20A1,"Glvr-1, GLVR1, PiT-1",ENSG00000144136,Solute carrier family 20 member 1,2,112645857-112663827,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB019279, HPA035834",Approved,NA,Approved,Vesicles,"Renal cancer:3.44e-5 (unfavourable), Head and neck cancer:6.56e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,colon: 51.1,Expressed in all,NA,NA
SLC22A23,"C6orf85, FLJ22174",ENSG00000137266,Solute carrier family 22 member 23,6,3268962-3457022,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014697,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:2.39e-4 (unfavourable), Endometrial cancer:6.57e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,stomach: 27.9,Mixed,NA,NA
SLC22A3,"EMT, OCT3",ENSG00000146477,Solute carrier family 22 member 3,6,160348268-160452581,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA029750,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Cervical cancer:7.19e-5 (unfavourable), Urothelial cancer:7.26e-4 (unfavourable)",Mixed,Mixed,NA,NA,seminal vesicle: 70.8,Cell line enhanced,NA,A549: 24.2;HeLa: 24.0;Hep G2: 15.5;RPTEC TERT1: 10.1
SLC23A2,"KIAA0238, SLC23A1, SVCT2, YSPL2",ENSG00000089057,Solute carrier family 23 member 2,20,4852356-5010293,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052825, HPA059314",Approved,NA,Supported,Golgi apparatus<br>Vesicles,"Urothelial cancer:6.08e-5 (favourable), Pancreatic cancer:7.14e-5 (favourable), Liver cancer:3.35e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 98.2,Expressed in all,NA,NA
SLC25A25,"KIAA1896, MCSC, PCSCL",ENSG00000148339,Solute carrier family 25 member 25,9,128068201-128109245,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA020381,Uncertain,NA,Supported,Vesicles<br>Mitochondria,"Renal cancer:4.65e-6 (favourable), Liver cancer:1.01e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,gallbladder: 62.9,Expressed in all,NA,NA
SLC25A35,FLJ40217,ENSG00000125434,Solute carrier family 25 member 35,17,8287763-8295343,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA051720,Uncertain,NA,Approved,Vesicles<br>Mitochondria,"Endometrial cancer:3.37e-7 (favourable), Renal cancer:1.14e-6 (favourable), Urothelial cancer:1.91e-5 (favourable)",Expressed in all,Mixed,NA,NA,testis: 19.3,Mixed,NA,NA
SLC26A11,NA,ENSG00000181045,Solute carrier family 26 member 11,17,80219699-80253500,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA029893,Approved,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Liver cancer:1.82e-6 (unfavourable), Pancreatic cancer:1.43e-5 (favourable), Endometrial cancer:1.55e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 34.4,Mixed,NA,NA
SLC26A2,"DTD, DTDST",ENSG00000155850,Solute carrier family 26 member 2,5,149960737-149993455,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA041957, HPA058090",Enhanced,NA,Approved,Vesicles,"Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable)",Expressed in all,Tissue enhanced,NA,colon: 213.0;rectum: 207.1,parathyroid gland: 82.7,Expressed in all,NA,NA
SLC27A4,"ACSVL4, FATP4",ENSG00000167114,Solute carrier family 27 member 4,9,128340646-128361470,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA007293, CAB009771",Approved,NA,Supported,Vesicles,Renal cancer:2.61e-5 (favourable),Expressed in all,Expressed in all,NA,NA,duodenum: 72.1,Expressed in all,NA,NA
SLC29A3,"ENT3, FLJ11160",ENSG00000198246,Solute carrier family 29 member 3,10,71319258-71363385,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA046085, HPA054976, HPA057905",Approved,NA,Supported,Golgi apparatus<br>Vesicles,"Liver cancer:6.07e-6 (unfavourable), Renal cancer:5.53e-5 (unfavourable), Thyroid cancer:1.16e-4 (favourable)",Expressed in all,Mixed,NA,NA,placenta: 18.8,Cell line enhanced,NA,BEWO: 35.2
SLC2A10,GLUT10,ENSG00000197496,Solute carrier family 2 member 10,20,46709487-46736347,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA041015,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,prostate: 49.3,Cell line enhanced,NA,SK-MEL-30: 45.7
SLC2A8,"GLUT8, GLUTX1",ENSG00000136856,Solute carrier family 2 member 8,9,127397138-127408424,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA011935,Uncertain,NA,Approved,Vesicles,"Cervical cancer:2.57e-6 (favourable), Renal cancer:6.55e-6 (favourable), Pancreatic cancer:9.86e-6 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 50.0,Cell line enhanced,NA,CACO-2: 101.8
SLC30A2,ZNT2,ENSG00000158014,Solute carrier family 30 member 2,1,26037252-26046133,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA017979,NA,NA,Approved,Vesicles,Renal cancer:2.86e-6 (favourable),Tissue enhanced,Tissue enhanced,NA,kidney: 22.0;thyroid gland: 42.4,pancreas: 16.5,Group enriched,5,BEWO: 2.4;RPTEC TERT1: 4.3;WM-115: 3.5
SLC30A3,ZNT3,ENSG00000115194,Solute carrier family 30 member 3,2,27253684-27275817,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA060505, HPA067637, CAB079044",Enhanced,Approved,Approved,Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol,NA,Mixed,Group enriched,12,cerebral cortex: 36.6;epididymis: 55.4;testis: 43.5,heart muscle: 3.6,Cell line enhanced,NA,HAP1: 10.6;Hep G2: 9.5;REH: 20.7;RH-30: 11.0
SLC35B1,UGTREL1,ENSG00000121073,Solute carrier family 35 member B1,17,49700943-49709014,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA048655, HPA057418",Approved,NA,Approved,Nucleus<br>Endoplasmic reticulum<br>Vesicles,Renal cancer:5.69e-7 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 52.2,Expressed in all,NA,NA
SLC35B2,UGTrel4,ENSG00000157593,Solute carrier family 35 member B2,6,44254096-44257890,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA029638,Approved,NA,Approved,Vesicles,"Liver cancer:8.59e-5 (unfavourable), Prostate cancer:6.07e-4 (favourable), Breast cancer:7.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 59.2,Expressed in all,NA,NA
SLC35F6,"ANT2BP, C2orf18, FLJ20555, TANGO9",ENSG00000213699,Solute carrier family 35 member F6,2,26764284-26781231,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA034655,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:1.11e-4 (unfavourable), Lung cancer:3.71e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 26.2,Expressed in all,NA,NA
SLC38A2,"ATA2, KIAA1382, SAT2, SNAT2",ENSG00000134294,Solute carrier family 38 member 2,12,46358189-46372867,Predicted membrane proteins,Evidence at protein level,HPA035180,Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,skin: 238.8,Mixed,NA,NA
SLC38A9,FLJ90709,ENSG00000177058,Solute carrier family 38 member 9,5,55625845-55773194,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA043785,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Endometrial cancer:7.24e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 80.4,Expressed in all,NA,NA
SLC39A3,ZIP3,ENSG00000141873,Solute carrier family 39 member 3,19,2732204-2740152,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA042139, HPA058526",Uncertain,NA,Approved,Vesicles,Endometrial cancer:9.76e-5 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 110.2,Cell line enhanced,NA,U-937: 326.0
SLC39A5,NA,ENSG00000139540,Solute carrier family 39 member 5,12,56230049-56237846,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA018423,NA,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:5.05e-4 (favourable),Tissue enhanced,Group enriched,12,colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4,gallbladder: 10.0,Group enriched,62,CACO-2: 33.1;Hep G2: 39.7
SLC45A3,"IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein",ENSG00000158715,Solute carrier family 45 member 3,1,205657851-205680459,"Cancer-related genes, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA019073, HPA019075",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,"Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable)",Tissue enriched,Tissue enriched,30,prostate: 505.2,stomach: 16.5,Cell line enriched,28,HMC-1: 749.2
SLC48A1,"FLJ20489, hHRG-1, HRG1",ENSG00000211584,Solute carrier family 48 member 1,12,47753916-47782753,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA073994,NA,NA,Supported,Vesicles,"Renal cancer:1.34e-6 (favourable), Liver cancer:9.39e-5 (unfavourable), Cervical cancer:4.27e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 79.5,Expressed in all,NA,NA
SLC4A11,"BTR1, CDPD1, CHED2, dJ794I6.2, FECD4, NaBC1",ENSG00000088836,Solute carrier family 4 member 11,20,3227417-3239190,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018120, HPA058377",Uncertain,NA,Uncertain,Nucleoplasm<br>Vesicles,"Renal cancer:6.21e-6 (favourable), Cervical cancer:9.03e-4 (favourable)",Expressed in all,Tissue enhanced,NA,thyroid gland: 27.7,salivary gland: 19.2,Cell line enhanced,NA,HaCaT: 55.7
SLC51B,OSTbeta,ENSG00000186198,Solute carrier family 51 beta subunit,15,65045370-65053396,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA008398, HPA008533",Enhanced,NA,Approved,Vesicles<br>Mitochondria,Renal cancer:8.46e-5 (favourable),Tissue enhanced,Tissue enhanced,NA,"cervix, uterine: 59.7;duodenum: 85.4;small intestine: 118.4",colon: 40.7,Group enriched,9,CACO-2: 15.0;EFO-21: 11.0;Hep G2: 10.4
SLC5A1,"D22S675, NAGT, SGLT1",ENSG00000100170,Solute carrier family 5 member 1,22,32043032-32113029,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB015467, HPA051805, HPA055106",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable)",Mixed,Group enriched,10,duodenum: 505.0;small intestine: 313.4,gallbladder: 40.2,Cell line enhanced,NA,CACO-2: 2.1;RPMI-8226: 1.3;SH-SY5Y: 1.0
SLC6A12,BGT-1,ENSG00000111181,Solute carrier family 6 member 12,12,190077-214570,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA034973,Approved,NA,Approved,Vesicles,"Renal cancer:2.70e-6 (favourable), Endometrial cancer:1.59e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,NA,kidney: 29.5;liver: 43.6,cerebral cortex: 14.8,Group enriched,10,Hep G2: 4.9;RPTEC TERT1: 10.5
SLC6A14,NA,ENSG00000268104,Solute carrier family 6 member 14,X,116436622-116461458,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA003193,Uncertain,NA,Approved,Vesicles,Pancreatic cancer:9.74e-4 (unfavourable),Mixed,Tissue enhanced,NA,"cervix, uterine: 11.0;lung: 23.9",breast: 9.1,Cell line enhanced,NA,HeLa: 1.0;Hep G2: 2.3
SLC6A15,"FLJ10316, hv7-3, NTT73, SBAT1, V7-3",ENSG00000072041,Solute carrier family 6 member 15,12,84859488-84913615,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA008609,Uncertain,NA,Approved,Nucleoli<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 23.0,placenta: 5.5,Cell line enhanced,NA,ASC diff: 62.0;hTERT-HME1: 99.4;SCLC-21H: 104.6
SLC6A3,"DAT, DAT1",ENSG00000142319,Solute carrier family 6 member 3,5,1392790-1445430,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA012763, HPA013602, CAB016249, CAB078172",Supported,Supported,Approved,Vesicles,Renal cancer:3.40e-7 (unfavourable),Tissue enriched,Not detected,NA,NA,thyroid gland: 0.3,Not detected,NA,NA
SLC6A4,"5-HTT, HTT, OCD1, SERT1",ENSG00000108576,Solute carrier family 6 member 4,17,30194319-30236002,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA071354, HPA074728",NA,Supported,Supported,Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Group enriched,10,duodenum: 10.4;lung: 44.2;placenta: 26.4;small intestine: 45.3,esophagus: 3.1,Cell line enhanced,NA,BEWO: 1.9;CACO-2: 3.2;Hep G2: 7.1
SLC7A11,xCT,ENSG00000151012,Solute carrier family 7 member 11,4,138164097-138242349,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA064215,NA,NA,Supported,Vesicles,Ovarian cancer:1.77e-4 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 22.4,epididymis: 8.2,Expressed in all,NA,NA
SLC9A6,"KIAA0267, NHE6",ENSG00000198689,Solute carrier family 9 member A6,X,135973841-136047269,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA059445, HPA059590",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Tissue enhanced,NA,cerebral cortex: 67.9,parathyroid gland: 16.6,Mixed,NA,NA
SLC9A7,NHE7,ENSG00000065923,Solute carrier family 9 member A7,X,46599252-46759172,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA048938, HPA075385",Approved,NA,Supported,Vesicles,Endometrial cancer:8.58e-4 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 14.4,Mixed,NA,NA
SLF2,"C10orf6, FAM178A, FLJ10512, FLJ25012",ENSG00000119906,SMC5-SMC6 complex localization factor 2,10,100912569-100965136,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038499, HPA057568",Approved,NA,Supported,Nucleus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 56.9,Expressed in all,NA,NA
SLFN5,MGC19764,ENSG00000166750,Schlafen family member 5,17,35243036-35273655,Predicted intracellular proteins,Evidence at protein level,HPA017760,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,lymph node: 37.4,Cell line enhanced,NA,hTERT-HME1: 113.0
SMARCA1,"hSNF2L, ISWI, NURF140, SNF2L, SNF2L1, SNF2LB, SWI",ENSG00000102038,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1",X,129446501-129523500,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003335, HPA064712",Uncertain,NA,Supported,Nucleoplasm<br>Vesicles,"Pancreatic cancer:3.03e-4 (favourable), Renal cancer:5.09e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 113.1,Mixed,NA,NA
SMARCA2,"BAF190, BRM, hBRM, hSNF2a, SNF2, SNF2L2, SNF2LA, Sth1p, SWI2",ENSG00000080503,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2",9,1980290-2193624,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA029981, CAB037276",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles<br>Intermediate filaments,Renal cancer:1.26e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 328.7,Cell line enriched,7,HDLM-2: 1364.0
SMARCD1,"BAF60A, CRACD1, Rsc6p",ENSG00000066117,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1",12,50084972-50100712,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA004101,Supported,NA,Approved,Nucleoplasm<br>Vesicles,Liver cancer:2.53e-8 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 86.5,Expressed in all,NA,NA
SMIM17,NA,ENSG00000268182,Small integral membrane protein 17,19,56643145-56655766,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA071857, HPA071861",Enhanced,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 8.7,epididymis: 2.0,Cell line enhanced,NA,AF22: 2.3;HEK93: 2.1;SCLC-21H: 2.5
SMIM3,"C5orf62, MSTP150, NID67",ENSG00000256235,Small integral membrane protein 3,5,150777946-150796734,Predicted membrane proteins,Evidence at protein level,HPA075345,NA,NA,Approved,Vesicles,Renal cancer:1.15e-8 (unfavourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 109.0,Cell line enhanced,NA,ASC diff: 172.4;U-87 MG: 184.9
SMIM5,C17orf109,ENSG00000204323,Small integral membrane protein 5,17,75633434-75641404,Predicted membrane proteins,Evidence at protein level,"HPA065332, HPA071268",Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.12e-4 (favourable), Cervical cancer:5.52e-4 (favourable)",Mixed,Mixed,NA,NA,thyroid gland: 14.3,Cell line enhanced,NA,MCF7: 8.0;SK-BR-3: 3.4
SMIM8,"C6orf162, dJ102H19.2, DKFZP586E1923",ENSG00000111850,Small integral membrane protein 8,6,87322583-87399749,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007401, HPA067453",Approved,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,cerebral cortex: 13.9,Expressed in all,NA,NA
SMOX,"C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO",ENSG00000088826,Spermine oxidase,20,4120980-4187747,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA047117, HPA060198",Approved,NA,Supported,Nucleoplasm<br>Nuclear membrane<br>Vesicles,"Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,cerebral cortex: 49.7,gallbladder: 23.5,Cell line enhanced,NA,A549: 104.6;Karpas-707: 139.7
SMU1,"BWD, FLJ10805, fSAP57, SMU-1",ENSG00000122692,DNA replication regulator and spliceosomal factor,9,33041764-33076659,Predicted intracellular proteins,Evidence at protein level,"HPA019228, HPA019708",Supported,NA,Approved,Vesicles,"Renal cancer:1.67e-5 (favourable), Ovarian cancer:1.25e-4 (favourable), Cervical cancer:2.66e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 27.4,Expressed in all,NA,NA
SMUG1,"FDG, HMUDG, UNG3",ENSG00000123415,Single-strand-selective monofunctional uracil-DNA glycosylase 1,12,54121277-54189008,Predicted intracellular proteins,Evidence at protein level,"HPA051149, HPA071486",NA,NA,Approved,Vesicles<br>Centrosome,"Ovarian cancer:1.31e-4 (favourable), Liver cancer:6.96e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 48.8,Expressed in all,NA,NA
SMYD4,"KIAA1936, ZMYND21",ENSG00000186532,SET and MYND domain containing 4,17,1779485-1830634,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030059,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 10.8,Expressed in all,NA,NA
SNX16,NA,ENSG00000104497,Sorting nexin 16,8,81799581-81842866,Predicted intracellular proteins,Evidence at protein level,"HPA024730, HPA024731, HPA024817",Approved,NA,Supported,Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 27.7,Expressed in all,NA,NA
SNX17,KIAA0064,ENSG00000115234,Sorting nexin 17,2,27370496-27377533,Predicted intracellular proteins,Evidence at protein level,HPA043867,Supported,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 97.8,Expressed in all,NA,NA
SNX21,"C20orf161, dJ337O18.4, SNX-L",ENSG00000124104,Sorting nexin family member 21,20,45833810-45843275,Predicted intracellular proteins,Evidence at protein level,HPA046359,Approved,NA,Approved,Vesicles<br>Microtubule organizing center,NA,Expressed in all,Mixed,NA,NA,skin: 25.5,Cell line enhanced,NA,PC-3: 28.8;U-87 MG: 27.0
SNX22,FLJ13952,ENSG00000157734,Sorting nexin 22,15,64151715-64157481,Predicted intracellular proteins,Evidence at protein level,HPA038470,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Breast cancer:2.89e-5 (favourable), Thyroid cancer:2.19e-4 (favourable)",Tissue enriched,Tissue enhanced,NA,cerebral cortex: 16.2;thyroid gland: 14.4,lymph node: 9.0,Cell line enhanced,NA,Daudi: 13.5;SCLC-21H: 4.9
SNX24,SBBI31,ENSG00000064652,Sorting nexin 24,5,122843439-123029354,Predicted intracellular proteins,Evidence at protein level,"HPA044566, HPA073934",Approved,NA,Approved,Vesicles,"Endometrial cancer:7.93e-6 (unfavourable), Renal cancer:1.28e-4 (favourable), Liver cancer:8.88e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 39.4,Mixed,NA,NA
SNX25,SBBI31,ENSG00000109762,Sorting nexin 25,4,185204237-185370185,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA036928,NA,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,lung: 42.7,Expressed in all,NA,NA
SNX8,Mvp1,ENSG00000106266,Sorting nexin 8,7,2251770-2354318,Predicted intracellular proteins,Evidence at protein level,"HPA057296, HPA060194",Approved,NA,Supported,Vesicles,Liver cancer:8.47e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,spleen: 38.0,Expressed in all,NA,NA
SOBP,FLJ10159,ENSG00000112320,Sine oculis binding protein homolog,6,107489958-107660167,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA029242,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Pancreatic cancer:1.55e-5 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 26.4,ovary: 13.7,Cell line enhanced,NA,AF22: 12.5;AN3-CA: 15.3
SOS2,NA,ENSG00000100485,SOS Ras/Rho guanine nucleotide exchange factor 2,14,50117120-50231558,"Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004577, HPA047368, HPA052689",Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:8.48e-8 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 80.7,Expressed in all,NA,NA
SOX15,"SOX20, SOX26, SOX27",ENSG00000129194,SRY-box 15,17,7588178-7590170,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA067196, HPA074049",Enhanced,NA,Supported,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,skin: 40.5,esophagus: 17.5,Group enriched,8,A-431: 108.6;HaCaT: 120.2;HBEC3-KT: 39.0;hTCEpi: 38.2
SP2,KIAA0048,ENSG00000167182,Sp2 transcription factor,17,47896150-47928957,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003357, CAB010245",Supported,NA,Enhanced,Nucleoplasm<br>Vesicles,Renal cancer:1.82e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 40.3,Expressed in all,NA,NA
SPA17,"CT22, SP17",ENSG00000064199,Sperm autoantigenic protein 17,11,124673798-124697518,Predicted intracellular proteins,Evidence at protein level,HPA037568,Enhanced,NA,Approved,Vesicles,Endometrial cancer:1.03e-4 (favourable),Expressed in all,Group enriched,7,fallopian tube: 124.1;testis: 430.2,epididymis: 38.3,Mixed,NA,NA
SPANXA1,"CT11.1, NAP-X, SPAN-Xa, SPAN-Xb, SPANX",ENSG00000198021,"Sperm protein associated with the nucleus, X-linked, family member A1",X,141583674-141585011,Predicted intracellular proteins,Evidence at protein level,"HPA046423, HPA073647",Supported,NA,Supported,Nucleoplasm<br>Vesicles,NA,Not detected,Tissue enriched,93,testis: 9.2,all non-specific tissues: 0.0,Cell line enhanced,NA,U-2 OS: 1.6
SPANXA2,SPANX,ENSG00000203926,SPANX family member A2,X,141589435-141590772,Predicted intracellular proteins,Evidence at protein level,"HPA046423, HPA073647",Supported,NA,Supported,Nucleoplasm<br>Vesicles,NA,Not detected,Tissue enriched,93,testis: 9.2,all non-specific tissues: 0.0,Cell line enhanced,NA,U-2 OS: 1.6
SPANXB1,"CT11.2, SPANXB2, SPANXF1, SPANXF2",ENSG00000227234,SPANX family member B1,X,141002591-141003706,Predicted intracellular proteins,Evidence at protein level,"HPA046423, HPA073647",Supported,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enriched,370,testis: 42.5,kidney: 0.1,Group enriched,26,A-431: 70.8;U-2 OS: 28.0
SPANXC,"CT11.3, CTp11",ENSG00000198573,SPANX family member C,X,141241463-141242496,Predicted intracellular proteins,Evidence at protein level,"HPA046423, HPA073647",Supported,NA,Supported,Nucleoplasm<br>Vesicles,NA,Tissue enhanced,Tissue enriched,187,testis: 18.7,all non-specific tissues: 0.0,Cell line enhanced,NA,A-431: 7.8;U-2 OS: 4.3
SPANXD,"CT11.4, SPANXE",ENSG00000196406,SPANX family member D,X,141697411-141698739,Predicted intracellular proteins,Evidence at protein level,"HPA046423, HPA073647",Supported,NA,Approved,Nucleoplasm<br>Vesicles,NA,Not detected,Tissue enriched,193,testis: 19.3,all non-specific tissues: 0.0,Group enriched,10,A-431: 2.2;U-2 OS: 4.8
SPATA21,"spergen-2, spergen2",ENSG00000187144,Spermatogenesis associated 21,1,16387117-16437424,Predicted intracellular proteins,Evidence at transcript level,HPA032080,NA,NA,Approved,Vesicles<br>Cytosol,NA,Not detected,Tissue enriched,13,testis: 8.0,skin: 0.6,Cell line enriched,7,Hep G2: 3.7
SPATA33,"C16orf55, FLJ31606",ENSG00000167523,Spermatogenesis associated 33,16,89657802-89671272,Predicted intracellular proteins,Evidence at protein level,"HPA045648, HPA073096",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,Cervical cancer:1.06e-4 (favourable),Expressed in all,Tissue enhanced,NA,testis: 77.2,fallopian tube: 25.6,Expressed in all,NA,NA
SPATA6,"FLJ10007, SRF-1, SRF1",ENSG00000132122,Spermatogenesis associated 6,1,48295372-48472208,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA028234,NA,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,testis: 89.0,fallopian tube: 24.6,Cell line enhanced,NA,ASC TERT1: 14.7
SPCS1,"HSPC033, SPC1, SPC12, YJR010C-A",ENSG00000114902,Signal peptidase complex subunit 1,3,52704955-52711146,Predicted membrane proteins,Evidence at protein level,"HPA046091, HPA055273",Supported,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:2.90e-4 (favourable), Colorectal cancer:9.28e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 216.1,Expressed in all,NA,NA
SPEG,"APEG1, BPEG, KIAA1297, MGC12676, SPEGalpha, SPEGbeta",ENSG00000072195,SPEG complex locus,2,219434846-219498287,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA018904,Enhanced,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,skeletal muscle: 43.2,Cell line enhanced,NA,U-2 OS: 22.8;U-87 MG: 23.6
SPG21,"ACP33, BM-019, GL010, MAST",ENSG00000090487,"SPG21, maspardin",15,64963021-64990310,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA040407, HPA040436",Approved,NA,Supported,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 182.9,Expressed in all,NA,NA
SPHK2,NA,ENSG00000063176,Sphingosine kinase 2,19,48619291-48630717,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA065508,NA,NA,Supported,Vesicles,"Renal cancer:2.59e-5 (favourable), Endometrial cancer:5.19e-4 (unfavourable), Pancreatic cancer:9.30e-4 (favourable)",Expressed in all,Mixed,NA,NA,duodenum: 22.1,Expressed in all,NA,NA
SPINK4,"MGC133107, PEC-60",ENSG00000122711,"Serine peptidase inhibitor, Kazal type 4",9,33218365-33248567,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007286,Enhanced,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Colorectal cancer:8.85e-5 (favourable),Group enriched,Group enriched,6,colon: 631.8;duodenum: 266.4;rectum: 1071.3;small intestine: 734.5,appendix: 107.1,Cell line enriched,8,HMC-1: 152.9
SPINK5,"DKFZp686K19184, FLJ21544, FLJ97536, FLJ97596, FLJ99794, LEKTI, LETKI, NETS, NS, VAKTI",ENSG00000133710,"Serine peptidase inhibitor, Kazal type 5",5,148025683-148137289,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA009067, HPA011351, CAB015347",Enhanced,NA,Enhanced,Vesicles,NA,Tissue enhanced,Group enriched,26,esophagus: 1130.0;skin: 383.9;tonsil: 270.0,breast: 22.9,Cell line enhanced,NA,HaCaT: 13.2;HeLa: 14.7;Karpas-707: 13.8
SPIRE2,"KIAA1832, spir-2",ENSG00000204991,Spire type actin nucleation factor 2,16,89818179-89871319,Predicted intracellular proteins,Evidence at protein level,"HPA041413, HPA049415",Uncertain,NA,Approved,Nucleus<br>Vesicles<br>Intermediate filaments,Liver cancer:9.77e-5 (unfavourable),Expressed in all,Mixed,NA,NA,stomach: 14.0,Mixed,NA,NA
SPNS1,"HSpin1, LAT, nrs, PP2030, SPIN1, SPINL",ENSG00000169682,Sphingolipid transporter 1 (putative),16,28974221-28984548,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA041995, HPA042988",Enhanced,NA,Approved,Nucleoli fibrillar center<br>Golgi apparatus<br>Vesicles<br>Cytosol,NA,Mixed,Expressed in all,NA,NA,parathyroid gland: 37.1,Expressed in all,NA,NA
SPOCK1,"SPOCK, testican-1, TIC1",ENSG00000152377,"SPARC/osteonectin, cwcv and kazal like domains proteoglycan 1",5,136975298-137598379,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA007450, HPA026770",Uncertain,NA,Approved,Vesicles,"Head and neck cancer:1.93e-5 (unfavourable), Renal cancer:3.77e-5 (unfavourable), Colorectal cancer:1.93e-4 (unfavourable), Ovarian cancer:4.72e-4 (unfavourable), Lung cancer:9.08e-4 (unfavourable), Stomach cancer:9.40e-4 (unfavourable)",Tissue enriched,Tissue enhanced,NA,cerebral cortex: 209.2,prostate: 108.0,Cell line enhanced,NA,AF22: 299.3;ASC diff: 403.2;HUVEC TERT2: 508.1;U-138 MG: 298.1
SPON2,DIL1,ENSG00000159674,Spondin 2,4,1166932-1208962,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040170, HPA066095",Uncertain,NA,Approved,Vesicles,"Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable)",Tissue enriched,Tissue enhanced,NA,endometrium: 105.2;prostate: 113.0,"cervix, uterine: 53.6",Group enriched,6,HHSteC: 216.0;HSkMC: 330.1
SPOPL,BTBD33,ENSG00000144228,Speckle type BTB/POZ protein like,2,138501801-138573547,Predicted intracellular proteins,Evidence at protein level,HPA034687,Uncertain,NA,Approved,Vesicles,Renal cancer:3.63e-4 (favourable),Expressed in all,Expressed in all,NA,NA,breast: 16.2,Mixed,NA,NA
SPPL2A,"IMP3, PSL2",ENSG00000138600,Signal peptide peptidase like 2A,15,50702266-50765808,"Enzymes, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036062, HPA067304",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 291.5,Expressed in all,NA,NA
SPRYD7,"C13orf1, CLLD6",ENSG00000123178,SPRY domain containing 7,13,49912706-49936490,Predicted intracellular proteins,Evidence at protein level,HPA043934,Approved,NA,Approved,Vesicles,Cervical cancer:8.48e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 18.7,Mixed,NA,NA
SPTAN1,NA,ENSG00000197694,"Spectrin alpha, non-erythrocytic 1",9,128552558-128633662,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004581, HPA007927",Enhanced,NA,Approved,Vesicles<br>Microtubules,Renal cancer:1.84e-12 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 201.9,Expressed in all,NA,NA
SQLE,NA,ENSG00000104549,Squalene epoxidase,8,124998497-125022283,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018038, HPA020762",Enhanced,NA,Uncertain,Vesicles<br>Cytosol,"Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 107.8,Expressed in all,NA,NA
SQSTM1,"A170, OSIL, p60, p62, p62B, PDB3",ENSG00000161011,Sequestosome 1,5,179806398-179838078,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004587, HPA064165, HPA068843",Supported,NA,Enhanced,Vesicles<br>Cytosol,Liver cancer:2.31e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 371.5,Expressed in all,NA,NA
SREBF2,"bHLHd2, SREBP2",ENSG00000198911,Sterol regulatory element binding transcription factor 2,22,41833079-41907308,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,"HPA031962, HPA031963",Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Mitochondria,Renal cancer:1.37e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 118.4,Expressed in all,NA,NA
SRFBP1,"BUD22, FLJ25286, p49, Rlb1, STRAP",ENSG00000151304,Serum response factor binding protein 1,5,121961961-122075570,Predicted intracellular proteins,Evidence at protein level,"HPA042737, HPA058150",Approved,NA,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,Pancreatic cancer:5.31e-4 (unfavourable),Expressed in all,Mixed,NA,NA,thyroid gland: 13.8,Expressed in all,NA,NA
SRR,"ILV1, ISO1",ENSG00000167720,Serine racemase,17,2303383-2325260,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007529, CAB015343",Approved,NA,Approved,Vesicles,"Renal cancer:2.45e-6 (favourable), Endometrial cancer:6.20e-5 (favourable), Pancreatic cancer:8.16e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 25.5,Expressed in all,NA,NA
ST14,"HAI, MT-SP1, PRSS14, SNC19, TMPRSS14",ENSG00000149418,Suppression of tumorigenicity 14,11,130159562-130210376,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA047014,NA,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:5.03e-11 (favourable),Expressed in all,Mixed,NA,NA,small intestine: 149.0,Cell line enhanced,NA,CAPAN-2: 361.3;HaCaT: 255.1;RPMI-8226: 192.2;T-47d: 268.8
ST3GAL2,"SIAT4B, ST3GalA.2, ST3GALII",ENSG00000157350,"ST3 beta-galactoside alpha-2,3-sialyltransferase 2",16,70375978-70439237,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA017270,Approved,NA,Approved,Vesicles,"Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:2.33e-4 (favourable), Liver cancer:2.79e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,appendix: 15.2,Mixed,NA,NA
ST3GAL5,"SIAT9, SIATGM3S, ST3GalV",ENSG00000115525,"ST3 beta-galactoside alpha-2,3-sialyltransferase 5",2,85837120-85905199,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034708, HPA040425, HPA068928",Uncertain,NA,Approved,Vesicles,"Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable)",Expressed in all,Tissue enhanced,NA,thyroid gland: 44.7,cerebral cortex: 40.7,Cell line enhanced,NA,AN3-CA: 50.3;RT4: 37.4
ST6GALNAC5,"MGC3184, SIAT7E, ST6GalNAcV",ENSG00000117069,"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5",1,76867441-77065711,Predicted secreted proteins,Evidence at protein level,"HPA065593, HPA070354",Uncertain,NA,Approved,Vesicles,NA,Tissue enhanced,Mixed,NA,NA,lung: 8.8,Cell line enhanced,NA,AF22: 7.6;fHDF/TERT166: 7.3;SH-SY5Y: 7.0;U-2 OS: 7.8
STAC2,24b2,ENSG00000141750,SH3 and cysteine rich domain 2,17,39210536-39225872,Predicted intracellular proteins,Evidence at protein level,HPA017288,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Endometrial cancer:4.05e-5 (unfavourable), Glioma:5.04e-4 (unfavourable), Ovarian cancer:6.66e-4 (unfavourable)",Group enriched,Group enriched,6,breast: 32.0;cerebral cortex: 30.1;epididymis: 13.8;seminal vesicle: 35.6,skin: 4.5,Cell line enhanced,NA,HeLa: 22.2;hTEC/SVTERT24-B: 4.8;U-87 MG: 14.4
STAM,STAM1,ENSG00000136738,Signal transducing adaptor molecule,10,17644125-17715914,Predicted intracellular proteins,Evidence at protein level,"CAB034399, HPA043882",Supported,NA,Supported,Vesicles,Liver cancer:3.44e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 41.9,Expressed in all,NA,NA
STAM2,Hbp,ENSG00000115145,Signal transducing adaptor molecule 2,2,152116801-152175992,Predicted intracellular proteins,Evidence at protein level,"HPA035528, HPA035529",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 22.8,Expressed in all,NA,NA
STAP1,"BRDG1, STAP-1",ENSG00000035720,Signal transducing adaptor family member 1,4,67558728-67607337,Predicted intracellular proteins,Evidence at protein level,HPA038529,Enhanced,NA,Uncertain,Nucleoplasm<br>Vesicles,NA,Tissue enriched,Group enriched,6,appendix: 23.8;kidney: 13.2;lymph node: 59.6;spleen: 26.6;tonsil: 56.3,testis: 6.1,Cell line enhanced,NA,Daudi: 141.5;U-698: 60.7;U-937: 22.3
STARD3NL,"MENTHO, MGC3251",ENSG00000010270,STARD3 N-terminal like,7,38178222-38230671,Predicted membrane proteins,Evidence at protein level,HPA019204,Enhanced,NA,Supported,Vesicles,"Liver cancer:1.44e-5 (unfavourable), Head and neck cancer:2.20e-4 (unfavourable), Pancreatic cancer:8.48e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,placenta: 70.6,Expressed in all,NA,NA
STARD5,MGC10327,ENSG00000172345,StAR related lipid transfer domain containing 5,15,81309053-81324183,Predicted intracellular proteins,Evidence at protein level,HPA040662,Approved,NA,Approved,Vesicles<br>Cytosol,NA,Mixed,Mixed,NA,NA,skin: 9.4,Cell line enhanced,NA,HMC-1: 5.2;U-266/70: 5.5;U-937: 5.4
STEAP2,"IPCA-1, PCANAP1, STAMP1, STMP",ENSG00000157214,STEAP2 metalloreductase,7,90167590-90238137,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA029115, HPA055603",Uncertain,NA,Supported,Vesicles,NA,Tissue enriched,Tissue enriched,11,prostate: 208.0,parathyroid gland: 18.7,Cell line enhanced,NA,A549: 20.3;CAPAN-2: 42.2;U-138 MG: 26.9
STK11IP,"KIAA1898, LIP1, LKB1IP, STK11IP1",ENSG00000144589,Serine/threonine kinase 11 interacting protein,2,219597860-219616451,Predicted intracellular proteins,Evidence at protein level,"HPA036837, HPA036838, HPA053192",Approved,NA,Enhanced,Vesicles,Pancreatic cancer:1.63e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 39.7,Expressed in all,NA,NA
STK39,"DCHT, SPAK",ENSG00000198648,Serine/threonine kinase 39,2,167954020-168248141,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB046022, HPA061803, HPA062802",Enhanced,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:5.67e-5 (unfavourable), Breast cancer:3.96e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 71.4,Mixed,NA,NA
STMN2,"SCG10, SCGN10",ENSG00000104435,Stathmin 2,8,79610814-79666175,Predicted intracellular proteins,Evidence at protein level,HPA026922,NA,Supported,Approved,Endoplasmic reticulum<br>Vesicles,NA,Group enriched,Tissue enriched,6,cerebral cortex: 489.4,adrenal gland: 88.0,Cell line enriched,10,SH-SY5Y: 696.7
STMN4,RB3,ENSG00000015592,Stathmin 4,8,27235323-27258420,Predicted intracellular proteins,Evidence at protein level,HPA027765,NA,NA,Uncertain,Golgi apparatus<br>Vesicles,NA,Tissue enriched,Tissue enriched,25,cerebral cortex: 338.4,adrenal gland: 13.3,Cell line enriched,29,SCLC-21H: 102.2
STPG3,"C9orf173, FLJ40246",ENSG00000197768,Sperm-tail PG-rich repeat containing 3,9,137251261-137253483,Predicted intracellular proteins,Evidence at transcript level,HPA044352,NA,NA,Uncertain,Vesicles,NA,Mixed,Tissue enriched,7,testis: 27.7,duodenum: 3.9,Cell line enhanced,NA,HDLM-2: 3.0;T-47d: 1.8
STT3A,"ITM1, MGC9042, STT3-A, TMC",ENSG00000134910,"STT3A, catalytic subunit of the oligosaccharyltransferase complex",11,125591712-125625215,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA030735,Approved,NA,Uncertain,Nucleoplasm<br>Vesicles<br>Cytosol,"Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable)",Expressed in all,Tissue enriched,7,parathyroid gland: 1131.8,epididymis: 173.0,Expressed in all,NA,NA
STX12,"STX13, STX14",ENSG00000117758,Syntaxin 12,1,27773183-27824452,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041038, HPA055300",Approved,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 156.0,Expressed in all,NA,NA
STX16,"hsyn16, SYN16",ENSG00000124222,Syntaxin 16,20,58651253-58679526,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041019, HPA042033",Uncertain,NA,Enhanced,Vesicles,"Renal cancer:1.11e-16 (unfavourable), Liver cancer:4.18e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 63.9,Expressed in all,NA,NA
SULT2B1,HSST2,ENSG00000088002,Sulfotransferase family 2B member 1,19,48552075-48599425,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB033013, HPA041724, HPA043539",Approved,NA,Supported,Vesicles<br>Cytosol,NA,Mixed,Tissue enhanced,NA,esophagus: 152.2;skin: 152.4,"cervix, uterine: 45.8",Cell line enhanced,NA,CAPAN-2: 59.3;MCF7: 32.5;T-47d: 31.4
SUSD4,FLJ10052,ENSG00000143502,Sushi domain containing 4,1,223220819-223364202,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058296,Uncertain,NA,Approved,Vesicles,Endometrial cancer:4.28e-4 (unfavourable),Mixed,Tissue enhanced,NA,esophagus: 42.4,cerebral cortex: 38.5,Cell line enriched,5,SCLC-21H: 46.1
SUSD5,KIAA0527,ENSG00000173705,Sushi domain containing 5,3,33150042-33219215,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA052788,Uncertain,NA,Uncertain,Golgi apparatus<br>Vesicles,NA,Tissue enhanced,Mixed,NA,NA,cerebral cortex: 11.0,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+: 26.7;HUVEC TERT2: 60.2;LHCN-M2: 23.3;TIME: 23.4
SV2C,NA,ENSG00000122012,Synaptic vesicle glycoprotein 2C,5,76083172-76353939,Predicted membrane proteins,Evidence at protein level,"HPA040722, HPA040770",Supported,NA,Supported,Nucleoplasm<br>Vesicles,NA,Not detected,Tissue enhanced,NA,adrenal gland: 1.6;cerebral cortex: 3.4,"fallopian tube,ovary: 0.6",Cell line enhanced,NA,Karpas-707: 6.5;SCLC-21H: 4.3;SH-SY5Y: 9.0
SYBU,"FLJ20366, GOLSYN, KIAA1472, OCSYN, SNPHL",ENSG00000147642,Syntabulin,8,109573978-109691791,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA053057,Uncertain,NA,Supported,Vesicles,Liver cancer:7.74e-4 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 76.0,adrenal gland: 40.7,Cell line enhanced,NA,HaCaT: 20.2;PC-3: 23.7;SCLC-21H: 20.0;SK-BR-3: 38.8
SYNDIG1,"C20orf39, FLJ14220, IFITMD5, SynDIG1, TMEM90B",ENSG00000101463,Synapse differentiation inducing 1,20,24469199-24666616,Predicted membrane proteins,Evidence at protein level,"HPA044271, HPA059267",NA,NA,Supported,Vesicles,Thyroid cancer:6.16e-6 (unfavourable),Mixed,Tissue enhanced,NA,cerebral cortex: 26.9,heart muscle: 14.4,Group enriched,9,Karpas-707: 9.0;RH-30: 34.5;RPMI-8226: 24.4;SCLC-21H: 9.7;U-87 MG: 21.0
SYNPO2,MYOPODIN,ENSG00000172403,Synaptopodin 2,4,118850688-119061247,Predicted intracellular proteins,Evidence at protein level,"HPA030665, CAB037231, HPA049707, HPA068563",Enhanced,NA,Supported,Vesicles<br>Actin filaments<br>Cytosol,"Renal cancer:5.67e-5 (unfavourable), Urothelial cancer:3.91e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,seminal vesicle: 421.3,smooth muscle: 342.7,Cell line enhanced,NA,fHDF/TERT166: 44.3;SH-SY5Y: 89.5
SYT10,NA,ENSG00000110975,Synaptotagmin 10,12,33374238-33439819,Predicted membrane proteins,Evidence at transcript level,HPA055426,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Tissue enriched,Tissue enhanced,NA,fallopian tube: 3.5,seminal vesicle: 1.1,Cell line enhanced,NA,AF22: 1.6;MCF7: 2.7;RT4: 1.1;SCLC-21H: 2.0
SYT13,KIAA1427,ENSG00000019505,Synaptotagmin 13,11,45240301-45286319,Predicted intracellular proteins,Evidence at protein level,"HPA046224, HPA056602",Uncertain,NA,Supported,Vesicles,Endometrial cancer:7.79e-5 (unfavourable),Mixed,Tissue enhanced,NA,cerebral cortex: 69.9;gallbladder: 32.9,small intestine: 14.4,Group enriched,9,A549: 17.3;NTERA-2: 8.8;RPTEC TERT1: 43.3;SCLC-21H: 17.8
SYT14,"FLJ34198, sytXIV",ENSG00000143469,Synaptotagmin 14,1,209938174-210171389,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA036963,NA,NA,Supported,Vesicles,NA,Tissue enhanced,Group enriched,5,cerebral cortex: 3.0;testis: 6.7;thyroid gland: 9.8,adrenal gland: 1.3,Cell line enhanced,NA,BJ hTERT+: 10.5;SCLC-21H: 7.8;TIME: 8.9;U-138 MG: 7.9
SYT2,NA,ENSG00000143858,Synaptotagmin 2,1,202590596-202710417,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA030372, HPA063655",Enhanced,Supported,Approved,Vesicles,NA,Tissue enriched,Tissue enhanced,NA,adrenal gland: 1.8;cerebral cortex: 2.1,"epididymis,testis: 1.0",Cell line enhanced,NA,AF22: 8.4;NTERA-2: 5.8;U-2 OS: 1.8
SYT6,NA,ENSG00000134207,Synaptotagmin 6,1,114089291-114153919,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058362,NA,NA,Uncertain,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 6.5,kidney: 1.5,Group enriched,7,NTERA-2: 23.0;WM-115: 16.3
SYTL3,"exophilin-6, SLP3",ENSG00000164674,Synaptotagmin like 3,6,158650014-158764876,Predicted intracellular proteins,Evidence at protein level,"HPA030584, HPA030585, HPA030586",Approved,NA,Approved,Nucleoli fibrillar center<br>Vesicles,Cervical cancer:8.84e-5 (favourable),Mixed,Tissue enhanced,NA,thyroid gland: 44.5,fallopian tube: 22.9,Cell line enhanced,NA,HMC-1: 21.4;SCLC-21H: 19.1;U-2 OS: 20.9;U-266/70: 21.7
SZT2,"C1orf84, FLJ10387, FLJ34502, KIAA0467, RP11-506B15.1, SZT2A, SZT2B",ENSG00000198198,Seizure threshold 2 homolog (mouse),1,43389882-43454247,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA029012,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Actin filaments,"Head and neck cancer:1.47e-7 (favourable), Liver cancer:2.53e-4 (unfavourable), Lung cancer:6.20e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 21.4,Expressed in all,NA,NA
TAC3,"NKB, NKNB, ZNEUROK1",ENSG00000166863,Tachykinin 3,12,57010000-57028883,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA045919,Supported,Approved,Approved,Vesicles,NA,Tissue enriched,Tissue enriched,23,placenta: 617.0,cerebral cortex: 27.2,Cell line enhanced,NA,K-562: 13.1;SCLC-21H: 2.7
TACC3,ERIC1,ENSG00000013810,Transforming acidic coiled-coil containing protein 3,4,1721490-1745176,Predicted intracellular proteins,Evidence at protein level,"HPA005781, HPA006050, CAB010111, HPA022039",Enhanced,NA,Enhanced,Vesicles<br>Mitotic spindle<br>Microtubule organizing center<br>Centrosome<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.30e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 74.9,lymph node: 55.8,Expressed in all,NA,NA
TAOK1,"FLJ14314, KIAA1361, MAP3K16, MARKK, PSK2, TAO1",ENSG00000160551,TAO kinase 1,17,29390464-29551904,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007669,Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 41.5,Expressed in all,NA,NA
TAPT1,FLJ90013,ENSG00000169762,Transmembrane anterior posterior transformation 1,4,16160505-16227410,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA042567, HPA048658",Approved,NA,Approved,Vesicles,"Urothelial cancer:4.18e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable), Renal cancer:8.52e-4 (favourable), Endometrial cancer:9.75e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 21.5,Expressed in all,NA,NA
TAX1BP3,TIP-1,ENSG00000213977,Tax1 binding protein 3,17,3662896-3668682,Predicted intracellular proteins,Evidence at protein level,"HPA046410, HPA063078",Approved,NA,Approved,Nucleoli fibrillar center<br>Vesicles<br>Actin filaments,"Glioma:1.66e-4 (unfavourable), Lung cancer:1.76e-4 (unfavourable), Renal cancer:7.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 228.1",Expressed in all,NA,NA
TBC1D14,KIAA1322,ENSG00000132405,TBC1 domain family member 14,4,6909242-7033118,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036930, HPA067398",Approved,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:5.28e-10 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 67.5,Expressed in all,NA,NA
TBC1D22A,C22orf4,ENSG00000054611,TBC1 domain family member 22A,22,46762617-47175699,Predicted intracellular proteins,Evidence at protein level,HPA001173,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Liver cancer:2.42e-4 (unfavourable), Ovarian cancer:6.94e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,spleen: 22.1,Expressed in all,NA,NA
TBC1D3,"DKFZp434P2235, PRC17, TBC1D3A",ENSG00000274611,TBC1 domain family member 3,17,38181659-38192541,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,small intestine: 4.0;testis: 6.8,endometrium: 3.6,Cell line enhanced,NA,AF22: 7.5;REH: 4.5;U-138 MG: 6.4;U-266/70: 7.8;U-266/84: 3.0;U-698: 3.6
TBC1D3B,"PRC17, TBC1D3I",ENSG00000274808,TBC1 domain family member 3B,17,36165681-36176636,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,skin: 6.3;testis: 6.0,spleen: 2.9,Cell line enhanced,NA,CAPAN-2: 7.5;T-47d: 5.6
TBC1D3C,MGC44903,ENSG00000278299,TBC1 domain family member 3C,17,38057693-38068592,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,testis: 3.3,skin: 2.1,Cell line enhanced,NA,CAPAN-2: 30.1;HeLa: 4.4;T-47d: 6.5
TBC1D3D,NA,ENSG00000274419,TBC1 domain family member 3D,17,38003976-38014902,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,small intestine: 5.5;testis: 3.4,skin: 3.2,Cell line enhanced,NA,CAPAN-2: 8.4;HaCaT: 6.1;HeLa: 5.2;RT4: 3.7
TBC1D3E,NA,ENSG00000278599,TBC1 domain family member 3E,17,38127951-38138862,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,bone marrow: 1.1;gallbladder: 1.8;testis: 3.1,lymph node: 0.9,Cell line enhanced,NA,HHSteC: 3.4
TBC1D3F,NA,ENSG00000275954,TBC1 domain family member 3F,17,36428618-36439566,Predicted membrane proteins,Evidence at protein level,HPA046969,NA,NA,Uncertain,Vesicles,NA,Not detected,Tissue enriched,14,testis: 1.9,"bone marrow,gallbladder: 0.1",Not detected,NA,NA
TBC1D3G,NA,ENSG00000260287,TBC1 domain family member 3G,17,36323884-36334759,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Supported,NA,Approved,Vesicles,NA,Not detected,Tissue enriched,33,testis: 6.1,duodenum: 0.1,Cell line enhanced,NA,SiHa: 1.4
TBC1D3H,NA,ENSG00000274226,TBC1 domain family member 3H,17,36377531-36388423,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Approved,Vesicles,NA,Not detected,Tissue enhanced,NA,testis: 2.7;urinary bladder: 1.1,"cervix, uterine: 0.6",Cell line enriched,10,CAPAN-2: 5.1
TBC1D3I,NA,ENSG00000274933,TBC1 domain family member 3I,17,36253456-36264553,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,testis: 1.1,skin: 0.3,Cell line enriched,6,CAPAN-2: 4.7
TBC1D3K,NA,ENSG00000273513,TBC1 domain family member 3K,17,37924415-37935365,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Not detected,Tissue enhanced,NA,testis: 1.6,lymph node: 0.3,Cell line enhanced,NA,T-47d: 1.3
TBC1D3L,NA,ENSG00000274512,TBC1 domain family member 3L,17,37977972-37989048,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,NA,Uncertain,Vesicles,NA,Mixed,Mixed,NA,NA,skin: 42.2,Cell line enhanced,NA,BEWO: 37.5
TBC1D5,KIAA0210,ENSG00000131374,TBC1 domain family member 5,3,17157162-18444817,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA035125, HPA035126",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles,Renal cancer:1.75e-7 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 56.9,Expressed in all,NA,NA
TBX4,NA,ENSG00000121075,T-box 4,17,61452404-61485110,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB032413, HPA044457",Uncertain,NA,Approved,Vesicles,NA,Mixed,Group enriched,6,lung: 43.6;placenta: 29.8;prostate: 14.9,urinary bladder: 4.8,Cell line enhanced,NA,BJ: 2.4;THP-1: 3.9
TBXAS1,"CYP5, CYP5A1, THAS, TS, TXAS, TXS",ENSG00000059377,Thromboxane A synthase 1,7,139777051-140020325,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA031257, HPA031258, HPA031259",Enhanced,NA,Supported,Vesicles,Renal cancer:1.14e-4 (unfavourable),Expressed in all,Mixed,NA,NA,spleen: 56.3,Cell line enhanced,NA,NB-4: 48.5;PC-3: 22.1;U-937: 48.2
TCEA3,TFIIS.H,ENSG00000204219,Transcription elongation factor A3,1,23381061-23424740,Predicted intracellular proteins,Evidence at protein level,"HPA044960, HPA055811",Approved,NA,Approved,Nucleoplasm<br>Vesicles,Head and neck cancer:2.56e-4 (favourable),Expressed in all,Tissue enhanced,NA,skeletal muscle: 157.4,ovary: 62.8,Cell line enhanced,NA,Hep G2: 43.0;SiHa: 21.8;T-47d: 30.3
TCEANC2,"C1orf83, FLJ32112",ENSG00000116205,Transcription elongation factor A N-terminal and central domain containing 2,1,54053587-54112519,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046918,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 12.5,Expressed in all,NA,NA
TCTE1,"D6S46, DRC5, FAP155, MGC33600",ENSG00000146221,T-complex-associated-testis-expressed 1,6,44278743-44297688,Predicted intracellular proteins,Evidence at transcript level,HPA031739,NA,NA,Uncertain,Vesicles,NA,Tissue enhanced,Group enriched,13,fallopian tube: 23.1;testis: 35.3,lung: 2.2,Cell line enhanced,NA,SCLC-21H: 1.0
TCTN2,"C12orf38, FLJ12975, JBTS24, MKS8, TECT2",ENSG00000168778,Tectonic family member 2,12,123671113-123708403,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA039900,Enhanced,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,fallopian tube: 46.6,Mixed,NA,NA
TDRD10,DKFZp434M202,ENSG00000163239,Tudor domain containing 10,1,154502219-154548147,"Cancer-related genes, Predicted intracellular proteins",Evidence at transcript level,HPA054327,NA,NA,Approved,Vesicles,Thyroid cancer:8.04e-5 (favourable),Tissue enhanced,Tissue enriched,12,testis: 77.3,lung: 6.3,Cell line enhanced,NA,HUVEC TERT2: 2.5;TIME: 1.3
TDRP,"C8orf42, INM01, TDRP1, TDRP2",ENSG00000180190,Testis development related protein,8,489792-545781,Predicted intracellular proteins,Evidence at protein level,HPA008462,Approved,NA,Supported,Vesicles<br>Cytosol,"Endometrial cancer:1.52e-4 (unfavourable), Pancreatic cancer:9.37e-4 (favourable)",Expressed in all,Mixed,NA,NA,placenta: 46.8,Cell line enhanced,NA,BEWO: 48.4
TECPR1,"DKFZP434B0335, FLJ23419, FLJ90593, KIAA1358",ENSG00000205356,Tectonin beta-propeller repeat containing 1,7,98214624-98252251,Predicted intracellular proteins,Evidence at protein level,HPA021061,Approved,NA,Supported,Vesicles,Pancreatic cancer:8.12e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 19.1,Expressed in all,NA,NA
TEP1,"p240, TLP1, TP1, TROVE1, VAULT2",ENSG00000129566,Telomerase associated protein 1,14,20365667-20413429,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA029206,NA,NA,Supported,Nucleoplasm<br>Vesicles,Endometrial cancer:9.58e-4 (favourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 46.9,Expressed in all,NA,NA
TET3,"hCG_40738, MGC22014",ENSG00000187605,Tet methylcytosine dioxygenase 3,2,73986404-74108176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050845,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:3.58e-5 (unfavourable),Expressed in all,Mixed,NA,NA,skin: 17.9,Mixed,NA,NA
TFDP2,Dp-2,ENSG00000114126,Transcription factor Dp-2,3,141944428-142149544,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,CAB018396,Supported,NA,Supported,Nucleus<br>Vesicles,"Cervical cancer:6.32e-4 (favourable), Renal cancer:9.84e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 127.5,Expressed in all,NA,NA
TFG,"FLJ36137, SPG57, TF6",ENSG00000114354,TRK-fused gene,3,100709331-100748966,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA019473, HPA052206",Approved,NA,Approved,Vesicles<br>Cytosol,"Pancreatic cancer:1.50e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 164.5,Expressed in all,NA,NA
TGFA,NA,ENSG00000163235,Transforming growth factor alpha,2,70447280-70554193,"Cancer-related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA042297,Approved,NA,Approved,Vesicles,"Pancreatic cancer:1.20e-5 (unfavourable), Thyroid cancer:1.52e-4 (favourable)",Expressed in all,Mixed,NA,NA,esophagus: 27.2,Cell line enhanced,NA,A-431: 58.1;CAPAN-2: 69.9;HBEC3-KT: 50.1;RPTEC TERT1: 52.1;U-87 MG: 63.0
TGFB3,"ARVD, ARVD1",ENSG00000119699,Transforming growth factor beta 3,14,75958099-75982991,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA063582,NA,NA,Approved,Vesicles,Renal cancer:4.01e-7 (unfavourable),Expressed in all,Mixed,NA,NA,placenta: 84.9,Group enriched,5,SCLC-21H: 28.0;SK-BR-3: 99.2;T-47d: 87.5
TGFBR3L,NA,ENSG00000260001,Transforming growth factor beta receptor 3 like,19,7916145-7919097,Predicted membrane proteins,Evidence at protein level,HPA074356,Supported,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,duodenum: 1.7;small intestine: 1.8,kidney: 1.0,Cell line enhanced,NA,PC-3: 3.7;REH: 9.0
TGFBRAP1,"TRAP-1, TRAP1, VPS3",ENSG00000135966,Transforming growth factor beta receptor associated protein 1,2,105264391-105330034,Predicted intracellular proteins,Evidence at protein level,"HPA037672, HPA038397",Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 20.9,Expressed in all,NA,NA
THAP7,MGC10963,ENSG00000184436,THAP domain containing 7,22,20999104-21002196,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003083,Approved,NA,Approved,Nucleus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 20.4,Expressed in all,NA,NA
THBS3,NA,ENSG00000169231,Thrombospondin 3,1,155195588-155209051,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA006293, HPA073242",Approved,NA,Approved,Vesicles,"Renal cancer:2.38e-12 (unfavourable), Endometrial cancer:1.44e-4 (unfavourable), Colorectal cancer:2.43e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 41.6,Cell line enhanced,NA,SCLC-21H: 49.1
THBS4,NA,ENSG00000113296,Thrombospondin 4,5,79991311-80083287,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB004597, HPA042426",Approved,NA,Approved,Vesicles,Urothelial cancer:3.33e-4 (unfavourable),Expressed in all,Group enriched,6,adipose tissue: 234.3;heart muscle: 113.6;smooth muscle: 388.9,thyroid gland: 44.6,Cell line enhanced,NA,AF22: 3.1;SCLC-21H: 2.9;THP-1: 4.7;U-2 OS: 3.0
TIAL1,TIAR,ENSG00000151923,TIA1 cytotoxic granule associated RNA binding protein like 1,10,119571802-119597029,Predicted intracellular proteins,Evidence at protein level,HPA060962,NA,NA,Approved,Nucleus<br>Vesicles,Liver cancer:7.81e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 86.8,Expressed in all,NA,NA
TIGD6,DKFZp761E2110,ENSG00000164296,Tigger transposable element derived 6,5,149993118-150001167,Predicted intracellular proteins,Evidence at protein level,HPA044599,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Actin filaments,"Colorectal cancer:5.35e-4 (favourable), Pancreatic cancer:5.88e-4 (favourable)",Expressed in all,Tissue enhanced,NA,parathyroid gland: 21.4,testis: 6.7,Mixed,NA,NA
TIPIN,FLJ20516,ENSG00000075131,TIMELESS interacting protein,15,66336206-66386746,Predicted intracellular proteins,Evidence at protein level,"HPA039704, HPA058799",Enhanced,NA,Supported,Nucleus<br>Vesicles,"Liver cancer:2.47e-4 (unfavourable), Cervical cancer:4.15e-4 (favourable), Prostate cancer:9.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,testis: 36.9,parathyroid gland: 12.6,Expressed in all,NA,NA
TIPRL,"dJ69E11.3, MGC3794, TIP41, TIPRL1",ENSG00000143155,TOR signaling pathway regulator,1,168178933-168202114,Predicted intracellular proteins,Evidence at protein level,"HPA027995, HPA054282",Approved,NA,Supported,Vesicles<br>Cytosol,"Renal cancer:1.45e-8 (unfavourable), Liver cancer:1.60e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 38.5,Expressed in all,NA,NA
TLCD2,NA,ENSG00000185561,TLC domain containing 2,17,1702790-1710438,Predicted membrane proteins,Evidence at transcript level,HPA046063,Uncertain,NA,Approved,Nucleoli<br>Vesicles,Renal cancer:4.36e-5 (unfavourable),Expressed in all,Mixed,NA,NA,adipose tissue: 6.0,Cell line enhanced,NA,SiHa: 6.2
TLL1,NA,ENSG00000038295,Tolloid like 1,4,165873258-166103895,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA060767,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,placenta: 10.5,gallbladder: 4.4,Cell line enhanced,NA,HeLa: 4.3;Karpas-707: 7.1;PC-3: 3.3
TM4SF18,L6D,ENSG00000163762,Transmembrane 4 L six family member 18,3,149318498-149334414,"Predicted membrane proteins, Transporters",Evidence at transcript level,"HPA053639, HPA069378",Approved,NA,Uncertain,Nucleoli<br>Vesicles,Liver cancer:8.63e-4 (favourable),Expressed in all,Mixed,NA,NA,spleen: 47.0,Group enriched,6,A549: 86.7;EFO-21: 184.5;HUVEC TERT2: 55.1;NTERA-2: 47.1
TM7SF2,"ANG1, DHCR14A, NET47",ENSG00000149809,Transmembrane 7 superfamily member 2,11,65111845-65116384,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA030691, HPA072704",Approved,NA,Supported,Endoplasmic reticulum<br>Vesicles,Renal cancer:8.49e-8 (favourable),Expressed in all,Expressed in all,NA,NA,adrenal gland: 160.5,Cell line enhanced,NA,T-47d: 122.6
TM9SF3,SMBP,ENSG00000077147,Transmembrane 9 superfamily member 3,10,96518109-96587452,Predicted membrane proteins,Evidence at protein level,HPA039609,Approved,NA,Approved,Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,stomach: 180.7,Expressed in all,NA,NA
TMBIM1,"LFG3, PP1201, RECS1",ENSG00000135926,Transmembrane BAX inhibitor motif containing 1,2,218274192-218292586,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012093, HPA070824",Approved,NA,Supported,Vesicles,"Renal cancer:3.38e-4 (favourable), Pancreatic cancer:4.22e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,esophagus: 269.0,Expressed in all,NA,NA
TMC7,FLJ21240,ENSG00000170537,Transmembrane channel like 7,16,18983934-19063942,Predicted membrane proteins,Evidence at protein level,HPA029465,Uncertain,NA,Approved,Vesicles,"Lung cancer:3.20e-4 (unfavourable), Pancreatic cancer:7.64e-4 (unfavourable), Urothelial cancer:9.20e-4 (favourable)",Mixed,Tissue enhanced,NA,testis: 17.8,cerebral cortex: 10.7,Mixed,NA,NA
TMCC3,KIAA1145,ENSG00000057704,Transmembrane and coiled-coil domain family 3,12,94567124-94650562,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014272,Approved,NA,Approved,Endoplasmic reticulum<br>Vesicles,Endometrial cancer:4.87e-4 (unfavourable),Expressed in all,Mixed,NA,NA,placenta: 25.7,Cell line enhanced,NA,HUVEC TERT2: 26.1;Karpas-707: 30.1;U-266/84: 20.9
TMED2,"P24A, p24b1, p24beta1, RNP24",ENSG00000086598,Transmembrane p24 trafficking protein 2,12,123584531-123598577,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA014060,Approved,NA,Supported,Vesicles,"Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 328.1,Expressed in all,NA,NA
TMEM102,"CBAP, FLJ36878",ENSG00000181284,Transmembrane protein 102,17,7435443-7437679,Predicted intracellular proteins,Evidence at protein level,HPA024433,Uncertain,NA,Approved,Vesicles,Renal cancer:9.90e-4 (favourable),Expressed in all,Mixed,NA,NA,adrenal gland: 3.5,Mixed,NA,NA
TMEM123,"KCT3, PORIMIN",ENSG00000152558,Transmembrane protein 123,11,102396332-102470384,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB026001, HPA062862",NA,NA,Supported,Golgi apparatus<br>Vesicles<br>Cytosol,"Pancreatic cancer:2.66e-4 (unfavourable), Melanoma:5.36e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 575.8,Mixed,NA,NA
TMEM129,D4S2561E,ENSG00000168936,Transmembrane protein 129,4,1715952-1721358,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA060920,NA,NA,Approved,Vesicles,Renal cancer:9.64e-8 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 36.1,Expressed in all,NA,NA
TMEM131,"CC28, KIAA0257, PRO1048, RW1, YR-23",ENSG00000075568,Transmembrane protein 131,2,97756333-97995891,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017678, HPA017682",Approved,NA,Uncertain,Vesicles<br>Intermediate filaments,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 47.6,Expressed in all,NA,NA
TMEM135,FLJ22104,ENSG00000166575,Transmembrane protein 135,11,87037844-87323758,Predicted membrane proteins,Evidence at protein level,"HPA056685, HPA069473",Uncertain,NA,Supported,Vesicles,Renal cancer:9.02e-4 (favourable),Expressed in all,Expressed in all,NA,NA,adipose tissue: 31.7,Expressed in all,NA,NA
TMEM136,MGC17839,ENSG00000181264,Transmembrane protein 136,11,120325129-120333682,Predicted membrane proteins,Evidence at transcript level,HPA074432,NA,NA,Approved,Vesicles<br>Cytosol,Endometrial cancer:6.65e-4 (unfavourable),Expressed in all,Mixed,NA,NA,adrenal gland: 12.6,Mixed,NA,NA
TMEM145,FLJ90805,ENSG00000167619,Transmembrane protein 145,19,42313325-42325062,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA060462,Enhanced,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enriched,6,cerebral cortex: 38.3,adrenal gland: 5.9,Cell line enhanced,NA,SCLC-21H: 32.9;SH-SY5Y: 14.2
TMEM150A,"FLJ90024, TM6P1, TMEM150, TTN1",ENSG00000168890,Transmembrane protein 150A,2,85598548-85603196,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA019015,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,placenta: 33.4,Mixed,NA,NA
TMEM159,promethin,ENSG00000011638,Transmembrane protein 159,16,21158377-21180616,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018033, HPA063509",Approved,NA,Approved,Vesicles,"Renal cancer:8.11e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,skin: 45.2,Mixed,NA,NA
TMEM165,"GDT1, TMPT27, TPARL",ENSG00000134851,Transmembrane protein 165,4,55395957-55453397,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA038299, HPA062424",Supported,NA,Enhanced,Golgi apparatus<br>Vesicles,"Renal cancer:1.18e-8 (unfavourable), Liver cancer:2.08e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 87.1,Expressed in all,NA,NA
TMEM178A,"MGC33926, TMEM178",ENSG00000152154,Transmembrane protein 178A,2,39664982-39717963,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at transcript level,HPA052128,Uncertain,NA,Approved,Nucleus<br>Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 55.4,kidney: 19.3,Cell line enhanced,NA,AF22: 137.1;NTERA-2: 17.7;SCLC-21H: 30.2
TMEM178B,DKFZp547G036,ENSG00000261115,Transmembrane protein 178B,7,141074232-141480380,Predicted membrane proteins,Evidence at protein level,HPA048771,Uncertain,NA,Uncertain,Nucleoli<br>Vesicles,Renal cancer:4.10e-4 (favourable),Mixed,Tissue enhanced,NA,cerebral cortex: 19.3;parathyroid gland: 28.9;thyroid gland: 14.4,heart muscle: 7.2,Cell line enhanced,NA,HAP1: 6.3;RPTEC TERT1: 6.3;SCLC-21H: 7.7;WM-115: 8.9
TMEM181,"GPR178, KIAA1423",ENSG00000146433,Transmembrane protein 181,6,158536436-158635428,Predicted membrane proteins,Evidence at protein level,HPA040189,Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Ovarian cancer:1.09e-4 (unfavourable), Cervical cancer:7.26e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 41.5",Expressed in all,NA,NA
TMEM182,FLJ30294,ENSG00000170417,Transmembrane protein 182,2,102736905-103019900,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045861,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Group enriched,9,heart muscle: 56.8;skeletal muscle: 44.4,prostate: 5.8,Mixed,NA,NA
TMEM184C,"FLJ10846, TMEM34",ENSG00000164168,Transmembrane protein 184C,4,147617383-147672044,Predicted membrane proteins,Evidence at protein level,HPA054013,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:2.31e-7 (favourable), Pancreatic cancer:6.37e-4 (unfavourable)",Expressed in all,Group enriched,6,parathyroid gland: 253.9;thyroid gland: 53.2,placenta: 27.6,Expressed in all,NA,NA
TMEM198,"MGC99813, TMEM198A",ENSG00000188760,Transmembrane protein 198,2,219543663-219550595,Predicted membrane proteins,Evidence at protein level,"HPA042385, HPA056598",Uncertain,NA,Approved,Vesicles,Pancreatic cancer:6.89e-4 (favourable),Expressed in all,Tissue enhanced,NA,cerebral cortex: 15.7,duodenum: 8.9,Cell line enhanced,NA,SCLC-21H: 23.4;SH-SY5Y: 18.3
TMEM2,NA,ENSG00000135048,Transmembrane protein 2,9,71683366-71816690,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA044889,Approved,NA,Approved,Vesicles<br>Cytosol,Renal cancer:1.31e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,placenta: 94.6,Cell line enhanced,NA,AF22: 107.2
TMEM209,"FLJ14803, NET31",ENSG00000146842,Transmembrane protein 209,7,130164715-130207770,Predicted membrane proteins,Evidence at protein level,HPA031678,Uncertain,NA,Approved,Nuclear membrane<br>Nuclear speckles<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 27.5,Expressed in all,NA,NA
TMEM215,NA,ENSG00000188133,Transmembrane protein 215,9,32783499-32787399,Predicted membrane proteins,Evidence at protein level,"HPA052804, HPA063207",Uncertain,NA,Supported,Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles,NA,Tissue enriched,Group enriched,5,"cervix, uterine: 1.0;endometrium: 4.8;testis: 4.2;thyroid gland: 1.8",cerebral cortex: 0.5,Cell line enhanced,NA,NTERA-2: 1.9
TMEM231,"ALYE870, FLJ22167, JBTS20, MKS11, PRO1886",ENSG00000205084,Transmembrane protein 231,16,75536744-75556286,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA042081,Enhanced,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,8,fallopian tube: 77.5,thyroid gland: 9.8,Mixed,NA,NA
TMEM234,"C1orf91, dJ622L5.7, FLJ90779, RP4-622L5",ENSG00000160055,Transmembrane protein 234,1,32214472-32222359,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA015049,Uncertain,NA,Approved,Vesicles,"Liver cancer:2.35e-5 (unfavourable), Renal cancer:4.12e-5 (unfavourable)",Expressed in all,Mixed,NA,NA,epididymis: 12.8,Expressed in all,NA,NA
TMEM241,"C18orf45, FLJ44259, MGC11386",ENSG00000134490,Transmembrane protein 241,18,23197144-23437961,Predicted membrane proteins,Evidence at protein level,"HPA029489, HPA059922",Uncertain,NA,Approved,Golgi apparatus<br>Vesicles,Urothelial cancer:5.80e-4 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 4.2,Mixed,NA,NA
TMEM248,"C7orf42, FLJ10099, FLJ13090",ENSG00000106609,Transmembrane protein 248,7,66921225-66958551,Predicted membrane proteins,Evidence at protein level,HPA016495,Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 93.8,Expressed in all,NA,NA
TMEM25,FLJ14399,ENSG00000149582,Transmembrane protein 25,11,118531041-118547280,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012163, HPA051562",Approved,NA,Approved,Golgi apparatus<br>Vesicles,Renal cancer:0.00e+0 (favourable),Expressed in all,Expressed in all,NA,NA,duodenum: 47.0,Cell line enhanced,NA,T-47d: 41.7
TMEM256,"C17orf61, MGC40107",ENSG00000205544,Transmembrane protein 256,17,7402975-7404137,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA062732,NA,NA,Approved,Vesicles,Renal cancer:9.36e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,duodenum: 68.3,Expressed in all,NA,NA
TMEM27,NX17,ENSG00000147003,Transmembrane protein 27,X,15627318-15665031,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA048543,Enhanced,NA,Approved,Endoplasmic reticulum<br>Vesicles,"Renal cancer:6.78e-9 (favourable), Ovarian cancer:5.65e-4 (favourable)",Tissue enriched,Tissue enriched,16,kidney: 422.0,parathyroid gland: 26.6,Cell line enhanced,NA,HaCaT: 6.8;RPTEC TERT1: 5.3
TMEM35A,"FLJ14084, TMEM35",ENSG00000126950,Transmembrane protein 35A,X,101078720-101096364,Predicted membrane proteins,Evidence at protein level,HPA048583,Enhanced,NA,Supported,Vesicles<br>Focal adhesion sites<br>Cytosol,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 42.4;seminal vesicle: 65.5,prostate: 33.7,Cell line enhanced,NA,HUVEC TERT2: 40.2;SH-SY5Y: 12.9
TMEM39A,FLJ10902,ENSG00000176142,Transmembrane protein 39A,3,119429500-119468830,Predicted membrane proteins,Evidence at protein level,HPA039140,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.00e-5 (unfavourable), Liver cancer:3.26e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"cervix, uterine: 32.3",Expressed in all,NA,NA
TMEM39B,FLJ10315,ENSG00000121775,Transmembrane protein 39B,1,32072031-32102866,Predicted membrane proteins,Evidence at protein level,"HPA040191, HPA040224",Approved,NA,Approved,Vesicles,"Renal cancer:5.11e-9 (unfavourable), Liver cancer:2.82e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,"cervix, uterine: 10.1",Expressed in all,NA,NA
TMEM45A,"DERP7, FLJ10134",ENSG00000181458,Transmembrane protein 45A,3,100492619-100577444,Predicted membrane proteins,Evidence at protein level,HPA062101,Uncertain,NA,Approved,Endoplasmic reticulum<br>Vesicles,"Renal cancer:6.18e-11 (unfavourable), Lung cancer:7.42e-4 (unfavourable)",Expressed in all,Tissue enriched,10,skin: 563.0,placenta: 58.7,Cell line enhanced,NA,ASC diff: 279.1
TMEM54,CAC-1,ENSG00000121900,Transmembrane protein 54,1,32894594-32901438,Predicted membrane proteins,Evidence at transcript level,HPA061992,NA,NA,Approved,Vesicles,Liver cancer:3.08e-4 (unfavourable),Expressed in all,Mixed,NA,NA,colon: 222.7,Mixed,NA,NA
TMEM63A,KIAA0792,ENSG00000196187,Transmembrane protein 63A,1,225845536-225882369,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA066504, HPA066936, HPA068918",NA,NA,Enhanced,Vesicles<br>Microtubule organizing center,Endometrial cancer:8.79e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 77.2,Mixed,NA,NA
TMEM68,FLJ32370,ENSG00000167904,Transmembrane protein 68,8,55696424-55773407,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018216, HPA019173",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,fallopian tube: 36.8,Expressed in all,NA,NA
TMEM87B,FLJ14681,ENSG00000153214,Transmembrane protein 87B,2,112055223-112119318,Predicted membrane proteins,Evidence at protein level,HPA035183,Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.52e-7 (unfavourable), Cervical cancer:3.78e-4 (unfavourable), Head and neck cancer:4.28e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,prostate: 44.5,Expressed in all,NA,NA
TMEM8B,"C9orf127, NAG-5, NGX6",ENSG00000137103,Transmembrane protein 8B,9,35814451-35854847,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052130, HPA062701",Approved,NA,Approved,Vesicles,"Renal cancer:1.89e-15 (favourable), Pancreatic cancer:3.14e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 27.1,Mixed,NA,NA
TMIE,DFNB6,ENSG00000181585,Transmembrane inner ear,3,46701333-46710886,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038298,Uncertain,NA,Uncertain,Vesicles<br>Cytosol,NA,Tissue enriched,Tissue enhanced,NA,adrenal gland: 7.4;cerebral cortex: 5.2,testis: 1.6,Cell line enhanced,NA,CAPAN-2: 2.2;EFO-21: 2.1;SH-SY5Y: 2.3
TMSB4X,"TB4X, TMSB4",ENSG00000205542,"Thymosin beta 4, X-linked",X,12975108-12977227,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB033806,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:6.20e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,lymph node: 11540.2,Expressed in all,NA,NA
TMTC4,"FLJ14624, FLJ22153",ENSG00000125247,Transmembrane and tetratricopeptide repeat containing 4,13,100603927-100675093,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA016489,Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 26.4,Mixed,NA,NA
TMUB2,MGC3123,ENSG00000168591,Transmembrane and ubiquitin like domain containing 2,17,44186970-44191731,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA043137,Approved,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 48.4,Expressed in all,NA,NA
TNFAIP3,"A20, OTUD7C",ENSG00000118503,TNF alpha induced protein 3,6,137867188-137883312,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002116, HPA067479",Approved,NA,Supported,Vesicles,Renal cancer:6.05e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 345.2,Cell line enhanced,NA,Karpas-707: 118.8;REH: 135.9
TNFAIP8L2,FLJ23467,ENSG00000163154,TNF alpha induced protein 8 like 2,1,151156629-151159749,Predicted intracellular proteins,Evidence at protein level,HPA062742,NA,NA,Uncertain,Vesicles,"Renal cancer:3.53e-7 (unfavourable), Melanoma:3.64e-4 (favourable)",Expressed in all,Tissue enhanced,NA,lymph node: 34.7;spleen: 39.1,appendix: 25.8,Group enriched,6,HEL: 26.1;HL-60: 13.6;HMC-1: 38.0;NB-4: 15.6;THP-1: 62.9;U-937: 28.8
TNFSF4,"CD252, gp34, OX-40L, TXGP1",ENSG00000117586,Tumor necrosis factor superfamily member 4,1,173183734-173207313,"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA059579,Approved,NA,Approved,Nucleus<br>Vesicles,NA,Expressed in all,Tissue enhanced,NA,testis: 7.5,appendix: 3.1,Cell line enhanced,NA,fHDF/TERT166: 32.7;HUVEC TERT2: 68.0;LHCN-M2: 56.4
TNNC2,NA,ENSG00000101470,"Troponin C2, fast skeletal type",20,45823214-45833745,Predicted intracellular proteins,Evidence at protein level,"HPA043174, HPA058481",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Tissue enriched,78,skeletal muscle: 9898.9,esophagus: 126.3,Group enriched,6,Hep G2: 6.4;HSkMC: 10.1;SCLC-21H: 12.6
TNNI3,"CMD2A, CMH7, TNNC1",ENSG00000129991,"Troponin I3, cardiac type",19,55151767-55157773,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009349, HPA046428",Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Mixed,Tissue enriched,174,heart muscle: 3607.1,breast: 20.7,Cell line enhanced,NA,HEK93: 11.1;HMC-1: 17.7;K-562: 34.7
TNPO3,"IPO12, LGMD1F, MTR10A, TRN-SR, TRN-SR2",ENSG00000064419,Transportin 3,7,128954180-129055173,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039555, HPA041537",Approved,NA,Enhanced,Vesicles,Liver cancer:3.29e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 48.4,Expressed in all,NA,NA
TNRC6A,"CAGH26, GW182, KIAA1460, TNRC6",ENSG00000090905,Trinucleotide repeat containing 6A,16,24610209-24827632,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA015305, HPA017869",Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 68.2,Expressed in all,NA,NA
TOB1,"APRO5, TOB, TROB, TROB1",ENSG00000141232,"Transducer of ERBB2, 1",17,50862223-50867978,Predicted intracellular proteins,Evidence at protein level,HPA047839,Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Pancreatic cancer:5.04e-5 (unfavourable), Prostate cancer:3.37e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,adrenal gland: 278.7,Expressed in all,NA,NA
TOP3B,NA,ENSG00000100038,Topoisomerase (DNA) III beta,22,21957025-21982816,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA069678,NA,NA,Approved,Vesicles,NA,Not detected,Mixed,NA,NA,spleen: 18.9,Expressed in all,NA,NA
TOR1A,"DQ2, DYT1",ENSG00000136827,Torsin family 1 member A,9,129812944-129824134,"Disease related genes, Predicted secreted proteins",Evidence at protein level,"CAB012473, HPA051195",Approved,NA,Supported,Nuclear membrane<br>Vesicles,Lung cancer:5.45e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 39.9,Expressed in all,NA,NA
TOX4,"C14orf92, KIAA0737, LCP1",ENSG00000092203,TOX high mobility group box family member 4,14,21476597-21499175,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA017880, HPA027551",Approved,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,"Renal cancer:8.38e-5 (favourable), Liver cancer:3.46e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 35.4,Expressed in all,NA,NA
TP53I3,PIG3,ENSG00000115129,Tumor protein p53 inducible protein 3,2,24077433-24085861,Predicted intracellular proteins,Evidence at protein level,"CAB017479, HPA022012, HPA028742",Enhanced,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,esophagus: 97.1,Cell line enriched,7,T-47d: 553.5
TPD52L2,"D54, hD54",ENSG00000101150,Tumor protein D52 like 2,20,63865228-63891545,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA047489,Approved,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:1.74e-8 (unfavourable), Liver cancer:1.39e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,smooth muscle: 105.2,Expressed in all,NA,NA
TPK1,"HTPK1, PP20",ENSG00000196511,Thiamin pyrophosphokinase 1,7,144451941-144836395,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021545, HPA021849",Approved,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,duodenum: 14.4,Cell line enhanced,NA,AN3-CA: 65.0;EFO-21: 19.9
TPRA1,"FLJ32197, GPR175, TMEM227, TPRA40",ENSG00000163870,Transmembrane protein adipocyte associated 1,3,127573069-127598251,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA019784,Approved,NA,Approved,Vesicles,Liver cancer:6.46e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 38.5,Expressed in all,NA,NA
TPRG1L,"FAM79A, FLJ21811, RP11-46F15.3",ENSG00000158109,Tumor protein p63 regulated 1 like,1,3625002-3630127,Predicted intracellular proteins,Evidence at protein level,"HPA063163, CAB079051",NA,Supported,Approved,Vesicles<br>Cytosol,Renal cancer:1.76e-9 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 102.1,Expressed in all,NA,NA
TRA2A,"AWMS1, htra-2-alpha, tra2a",ENSG00000164548,Transformer 2 alpha homolog,7,23504780-23532041,Predicted intracellular proteins,Evidence at protein level,HPA054018,Uncertain,NA,Supported,Nucleoli<br>Vesicles,"Renal cancer:1.79e-6 (unfavourable), Liver cancer:2.07e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,endometrium: 67.7,Expressed in all,NA,NA
TRAF3IP2,"ACT1, C6orf2, C6orf4, C6orf5, C6orf6, CIKS, DKFZP586G0522",ENSG00000056972,TRAF3 interacting protein 2,6,111556454-111606278,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA036352,Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Endometrial cancer:4.73e-5 (favourable), Renal cancer:5.16e-5 (unfavourable), Cervical cancer:3.21e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 50.8,Cell line enhanced,NA,U-2197: 94.7
TRAF3IP3,T3JAM,ENSG00000009790,TRAF3 interacting protein 3,1,209756032-209782320,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040796,Enhanced,NA,Approved,Vesicles,"Breast cancer:4.11e-4 (favourable), Lung cancer:8.15e-4 (favourable)",Mixed,Tissue enhanced,NA,lymph node: 114.8;spleen: 82.5;tonsil: 82.8,appendix: 67.8,Cell line enhanced,NA,HDLM-2: 106.9;Karpas-707: 33.1;MOLT-4: 48.2;NB-4: 43.3;THP-1: 43.1;U-266/70: 51.7
TRAK2,"ALS2CR3, CALS-C, GRIF-1, KIAA0549, MILT2, OIP98",ENSG00000115993,Trafficking kinesin protein 2,2,201377207-201451579,Predicted intracellular proteins,Evidence at protein level,"HPA015827, HPA062163",Uncertain,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,Renal cancer:7.42e-5 (favourable),Expressed in all,Expressed in all,NA,NA,thyroid gland: 52.1,Expressed in all,NA,NA
TRAPPC2,"hYP38334, MIP-2A, SEDL, SEDT, TRS20, ZNF547L",ENSG00000196459,Trafficking protein particle complex 2,X,13712244-13734635,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004665, HPA063308",Approved,NA,Approved,Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles,"Urothelial cancer:7.89e-5 (favourable), Ovarian cancer:6.35e-4 (favourable), Cervical cancer:8.09e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 16.5,Expressed in all,NA,NA
TRAPPC2B,"MIP-2A, SEDLP, SEDLP1, TRAPPC2P1",ENSG00000256060,Trafficking protein particle complex 2B,19,57363511-57365353,Predicted intracellular proteins,Evidence at protein level,HPA063308,NA,NA,Approved,Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles,Renal cancer:1.28e-4 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 28.8,Mixed,NA,NA
TRAPPC2L,HSPC176,ENSG00000167515,Trafficking protein particle complex 2 like,16,88856220-88862686,Predicted intracellular proteins,Evidence at protein level,HPA041714,Approved,NA,Supported,Vesicles<br>Cytosol,Endometrial cancer:3.75e-4 (favourable),Expressed in all,Expressed in all,NA,NA,adrenal gland: 91.5,Expressed in all,NA,NA
TRAPPC5,"MGC52424, TRS31",ENSG00000181029,Trafficking protein particle complex 5,19,7680843-7687703,Predicted intracellular proteins,Evidence at protein level,"HPA042221, HPA049064",Uncertain,NA,Approved,Vesicles,NA,Mixed,Expressed in all,NA,NA,testis: 69.8,Expressed in all,NA,NA
TRAPPC9,"IKBKBBP, KIAA1882, MRT13, NIBP, T1, TRS120",ENSG00000167632,Trafficking protein particle complex 9,8,139730343-140458579,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA026579,NA,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:5.11e-6 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 49.7,Expressed in all,NA,NA
TRIM17,"RBCC, RNF16, terf",ENSG00000162931,Tripartite motif containing 17,1,228407940-228416861,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA054908,Uncertain,NA,Approved,Vesicles,Breast cancer:1.86e-4 (favourable),Mixed,Tissue enhanced,NA,testis: 27.8,cerebral cortex: 6.1,Cell line enhanced,NA,BEWO: 8.7;SH-SY5Y: 5.0;T-47d: 10.6
TRIM33,"FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA",ENSG00000197323,Tripartite motif containing 33,1,114392777-114511160,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA004345,Supported,NA,Approved,Nucleoplasm<br>Vesicles,"Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 46.2,Expressed in all,NA,NA
TRIM51,"SPRYD5, TRIM51A",ENSG00000124900,Tripartite motif-containing 51,11,55883297-55891810,Predicted intracellular proteins,Evidence at transcript level,"HPA044988, HPA077883",Uncertain,NA,Approved,Nucleoli<br>Vesicles,NA,Tissue enriched,Not detected,NA,NA,testis: 0.4,Group enriched,101,SK-MEL-30: 45.9;WM-115: 14.6
TRIM62,"DEAR1, FLJ10759",ENSG00000116525,Tripartite motif containing 62,1,33145402-33182059,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050061,NA,NA,Approved,Vesicles<br>Focal adhesion sites,Renal cancer:7.08e-5 (unfavourable),Expressed in all,Mixed,NA,NA,skin: 11.6,Expressed in all,NA,NA
TRIM65,NA,ENSG00000141569,Tripartite motif containing 65,17,75880335-75897003,Predicted intracellular proteins,Evidence at protein level,"HPA021575, HPA021578, HPA064820",Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:4.74e-6 (unfavourable), Renal cancer:1.82e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 20.4,Expressed in all,NA,NA
TRIM7,"GNIP, RNF90",ENSG00000146054,Tripartite motif containing 7,5,181193924-181205293,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA039213,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Mixed,Group enriched,5,skeletal muscle: 67.7;skin: 22.1,esophagus: 8.6,Cell line enhanced,NA,HDLM-2: 34.1;PC-3: 18.2
TRIM8,"GERP, RNF27",ENSG00000171206,Tripartite motif containing 8,10,102644496-102658407,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023560, HPA023561",Approved,NA,Enhanced,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,adipose tissue: 60.9,Expressed in all,NA,NA
TRIO,ARHGEF23,ENSG00000038382,Trio Rho guanine nucleotide exchange factor,5,14143702-14532128,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008157, HPA064664",Supported,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 47.2,Cell line enhanced,NA,hTEC/SVTERT24-B: 190.1;U-87 MG: 248.3
TRIP10,"CIP4, HSTP, STOT, STP",ENSG00000125733,Thyroid hormone receptor interactor 10,19,6737925-6751526,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041934, HPA072625, HPA073886",Approved,NA,Supported,Nucleoplasm<br>Vesicles,"Head and neck cancer:1.76e-4 (favourable), Colorectal cancer:3.61e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skeletal muscle: 129.0,Mixed,NA,NA
TRPC1,HTRP-1,ENSG00000144935,Transient receptor potential cation channel subfamily C member 1,3,142724074-142807888,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"CAB009387, HPA021130",Supported,NA,Approved,Vesicles,Renal cancer:2.72e-5 (unfavourable),Mixed,Mixed,NA,NA,endometrium: 18.6,Mixed,NA,NA
TRUB1,PUS4,ENSG00000165832,TruB pseudouridine synthase family member 1,10,114938193-114977676,Predicted intracellular proteins,Evidence at protein level,"HPA037914, HPA057552",Approved,NA,Supported,Vesicles<br>Actin filaments,NA,Expressed in all,Expressed in all,NA,NA,adrenal gland: 38.5,Expressed in all,NA,NA
TSPAN1,"NET-1, TSPAN-1",ENSG00000117472,Tetraspanin 1,1,46175073-46185958,Predicted membrane proteins,Evidence at protein level,HPA011909,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:9.28e-6 (favourable),Expressed in all,Tissue enhanced,NA,colon: 525.0;rectum: 651.6,prostate: 311.2,Cell line enhanced,NA,CAPAN-2: 191.2;HaCaT: 134.4;hTCEpi: 125.3;RPTEC TERT1: 474.4;RT4: 246.2
TSPAN11,NA,ENSG00000110900,Tetraspanin 11,12,30926428-30996599,Predicted membrane proteins,Evidence at protein level,HPA066789,NA,NA,Approved,Vesicles,"Lung cancer:3.43e-4 (favourable), Head and neck cancer:5.28e-4 (favourable)",Mixed,Mixed,NA,NA,cerebral cortex: 17.9,Group enriched,5,AF22: 26.8;HSkMC: 19.0;NTERA-2: 21.6;SCLC-21H: 12.2;SH-SY5Y: 21.8
TSPAN12,"NET-2, TM4SF12",ENSG00000106025,Tetraspanin 12,7,120787320-120858402,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA051570, HPA058244",Uncertain,NA,Approved,Vesicles<br>Microtubules,NA,Expressed in all,Mixed,NA,NA,kidney: 91.5,Cell line enhanced,NA,HEK93: 47.4;HUVEC TERT2: 48.1;RH-30: 50.5;RPTEC TERT1: 63.2;RT4: 52.1
TSPAN14,"DC-TM4F2, MGC11352, TM4SF14",ENSG00000108219,Tetraspanin 14,10,80454166-80533123,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014773, HPA057174",Uncertain,NA,Supported,Vesicles,"Cervical cancer:3.56e-4 (favourable), Renal cancer:4.20e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,placenta: 129.4,Mixed,NA,NA
TSPO,"BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS",ENSG00000100300,Translocator protein,22,43151514-43163242,"Cancer-related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB011232, HPA046260",Uncertain,NA,Approved,Vesicles<br>Mitochondria<br>Cytosol,Liver cancer:1.61e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 300.6,Mixed,NA,NA
TTC33,OSRF,ENSG00000113638,Tetratricopeptide repeat domain 33,5,40512333-40755975,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038252, HPA038253",Approved,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:1.83e-4 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 25.6,Expressed in all,NA,NA
TTI1,"KIAA0406, smg-10",ENSG00000101407,TELO2 interacting protein 1,20,37983007-38033468,Predicted intracellular proteins,Evidence at protein level,"CAB034230, HPA068338",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:2.40e-7 (unfavourable), Endometrial cancer:3.30e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,"testis,thyroid gland: 20.3",Expressed in all,NA,NA
TTL,MGC46235,ENSG00000114999,Tubulin tyrosine ligase,2,112482154-112541739,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA066819,NA,NA,Approved,Nucleoplasm<br>Vesicles,Liver cancer:5.65e-4 (unfavourable),Expressed in all,Mixed,NA,NA,cerebral cortex: 4.4,Mixed,NA,NA
TTLL6,FLJ35808,ENSG00000170703,Tubulin tyrosine ligase like 6,17,48762235-48817214,Predicted intracellular proteins,Evidence at protein level,HPA052397,Enhanced,NA,Approved,Vesicles<br>Microtubules,NA,Mixed,Tissue enhanced,NA,testis: 26.0,fallopian tube: 5.8,Cell line enriched,5,HDLM-2: 4.1
TUFT1,NA,ENSG00000143367,Tuftelin 1,1,151540305-151583583,Predicted intracellular proteins,Evidence at protein level,"HPA028112, HPA054301",Approved,Approved,Approved,Vesicles,Endometrial cancer:4.83e-4 (unfavourable),Expressed in all,Tissue enhanced,NA,skin: 92.8,esophagus: 25.8,Mixed,NA,NA
TUSC1,TSG-9,ENSG00000198680,Tumor suppressor candidate 1,9,25676389-25678440,Predicted intracellular proteins,Evidence at protein level,HPA051426,Approved,NA,Approved,Nucleus<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 16.5,Cell line enhanced,NA,HEL: 34.6
TUSC2,"C3orf11, FUS1, PAP, PDAP2",ENSG00000114383,Tumor suppressor candidate 2,3,50320027-50328251,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA030116,NA,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:8.70e-7 (favourable), Liver cancer:2.84e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 42.1,Expressed in all,NA,NA
TVP23A,"FAM18A, YDR084C",ENSG00000166676,Trans-golgi network vesicle protein 23 homolog A,16,10760919-10818794,Predicted membrane proteins,Evidence at transcript level,HPA060582,Uncertain,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,cerebral cortex: 6.3,ovary: 3.2,Cell line enhanced,NA,SH-SY5Y: 2.2
TXK,"BTKL, PSCTK5, PTK4, RLK, TKL",ENSG00000074966,TXK tyrosine kinase,4,48066393-48134256,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA062482,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enhanced,NA,lymph node: 17.9,epididymis: 15.1,Cell line enhanced,NA,HMC-1: 12.2;WM-115: 31.5
TYR,"OCA1, OCA1A, OCAIA",ENSG00000077498,Tyrosinase,11,89177452-89295759,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB000079, HPA043241, HPA050889",Enhanced,NA,Enhanced,Vesicles,NA,Tissue enriched,Tissue enriched,33,skin: 29.8,breast: 0.9,Cell line enriched,1211,SK-MEL-30: 256.2
TYRP1,"b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP",ENSG00000107165,Tyrosinase related protein 1,9,12685439-12710290,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA000937, CAB002520",Enhanced,NA,Supported,Vesicles,NA,Tissue enriched,Group enriched,6,heart muscle: 40.2;skin: 169.1,kidney: 17.0,Cell line enriched,51,SK-MEL-30: 1084.9
UBA5,"FLJ23251, UBE1DC1",ENSG00000081307,Ubiquitin like modifier activating enzyme 5,3,132654446-132678097,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017235,Uncertain,NA,Enhanced,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 64.2,Expressed in all,NA,NA
UBA7,"D8, UBA1B, UBE1L, UBE2",ENSG00000182179,Ubiquitin like modifier activating enzyme 7,3,49805207-49813946,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB015444, HPA058182",Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:1.48e-4 (favourable), Breast cancer:1.55e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,spleen: 65.5,Cell line enhanced,NA,BJ hTERT+ SV40 Large T+ RasG12V: 55.3;HMC-1: 91.3
UBIAD1,"SCCD, TERE1",ENSG00000120942,UbiA prenyltransferase domain containing 1,1,11273206-11296049,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA044862,NA,NA,Approved,Vesicles,Renal cancer:6.80e-5 (favourable),Expressed in all,Expressed in all,NA,NA,fallopian tube: 15.8,Expressed in all,NA,NA
UBR1,NA,ENSG00000159459,Ubiquitin protein ligase E3 component n-recognin 1,15,42942897-43106113,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038838,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 27.4,Expressed in all,NA,NA
UCN2,"SRP, UCN-II, UCNI, URP",ENSG00000145040,Urocortin 2,3,48561727-48563773,Predicted secreted proteins,Evidence at protein level,HPA066841,Uncertain,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enriched,8,skin: 15.5,endometrium: 2.0,Cell line enhanced,NA,hTCEpi: 19.9;hTEC/SVTERT24-B: 21.7;SiHa: 20.5;WM-115: 55.5
UGT3A1,FLJ34658,ENSG00000145626,UDP glycosyltransferase family 3 member A1,5,35951010-36001028,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA047697, HPA056290",Uncertain,NA,Approved,Vesicles<br>Cytosol,NA,Group enriched,Tissue enhanced,NA,kidney: 53.4;liver: 29.2,duodenum: 9.5,Cell line enriched,51,RH-30: 26.5
ULBP3,RAET1N,ENSG00000131019,UL16 binding protein 3,6,150063150-150069095,Predicted secreted proteins,Evidence at protein level,"HPA056541, HPA063007",Approved,NA,Uncertain,Vesicles<br>Microtubule organizing center,NA,Mixed,Tissue enhanced,NA,testis: 11.9;thyroid gland: 8.8,fallopian tube: 3.9,Mixed,NA,NA
UNC13B,"hmunc13, UNC13, Unc13h2",ENSG00000198722,Unc-13 homolog B,9,35161992-35405338,Predicted intracellular proteins,Evidence at protein level,"HPA024493, HPA062300",Approved,NA,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Renal cancer:4.34e-11 (favourable), Lung cancer:6.59e-5 (favourable), Head and neck cancer:8.51e-5 (favourable), Pancreatic cancer:3.71e-4 (favourable), Colorectal cancer:4.96e-4 (favourable)",Expressed in all,Mixed,NA,NA,lung: 58.2,Mixed,NA,NA
UNC13D,Munc13-4,ENSG00000092929,Unc-13 homolog D,17,75827225-75844717,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA067117, HPA073525",Enhanced,NA,Supported,Vesicles<br>Cytosol,"Renal cancer:5.28e-12 (unfavourable), Endometrial cancer:3.62e-4 (unfavourable), Pancreatic cancer:6.01e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,spleen: 38.6,Cell line enhanced,NA,HEL: 219.6;HMC-1: 213.8;SK-BR-3: 125.9
UNC80,"C2orf21, FLJ33496, KIAA1843, UNC-80",ENSG00000144406,"Unc-80 homolog, NALCN activator",2,209771993-209999300,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042472,Enhanced,NA,Approved,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,adrenal gland: 5.1;cerebral cortex: 15.8;testis: 5.2,gallbladder: 1.9,Cell line enhanced,NA,AF22: 2.4;SCLC-21H: 4.7;SH-SY5Y: 2.4
UPF3A,"HUPF3A, RENT3A, UPF3",ENSG00000169062,UPF3 regulator of nonsense transcripts homolog A (yeast),13,114281584-114305817,Predicted intracellular proteins,Evidence at protein level,"HPA018325, HPA061316",Approved,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,"Pancreatic cancer:7.09e-5 (favourable), Urothelial cancer:3.71e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 84.4,Expressed in all,NA,NA
UPK3B,"FLJ32198, MGC10902, p35, UPIIIb",ENSG00000243566,Uroplakin 3B,7,76510428-76516521,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA010506,Approved,NA,Approved,Nucleus<br>Vesicles<br>Cytosol,NA,Group enriched,Group enriched,11,esophagus: 12.4;lung: 29.8;urinary bladder: 11.0,tonsil: 1.6,Group enriched,8,A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4
UPP2,"UDRPASE2, UP2, UPASE2",ENSG00000007001,Uridine phosphorylase 2,2,157876702-158136154,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035225, HPA035226",NA,NA,Approved,Nucleus<br>Vesicles<br>Mitochondria,NA,Tissue enriched,Group enriched,14,kidney: 52.2;liver: 14.3,cerebral cortex: 2.4,Not detected,NA,NA
UPRT,"DKFZp781E1243, FUR1, MGC23937, RP11-311P8.3",ENSG00000094841,Uracil phosphoribosyltransferase homolog,X,75274085-75304600,Predicted intracellular proteins,Evidence at protein level,HPA000805,Uncertain,NA,Approved,Vesicles,Renal cancer:4.14e-4 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 21.4,Mixed,NA,NA
URM1,"C9orf74, MGC2668",ENSG00000167118,Ubiquitin related modifier 1,9,128371319-128392016,Predicted intracellular proteins,Evidence at protein level,"HPA053645, HPA065160",Approved,NA,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:7.43e-6 (favourable), Liver cancer:6.91e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,fallopian tube: 25.1,Expressed in all,NA,NA
USF2,"bHLHb12, FIP",ENSG00000105698,"Upstream transcription factor 2, c-fos interacting",19,35268978-35279821,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA029764, HPA046567",NA,NA,Supported,Nucleoplasm<br>Vesicles,"Pancreatic cancer:5.12e-5 (favourable), Urothelial cancer:3.28e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 215.5,Expressed in all,NA,NA
USP27X,USP27,ENSG00000273820,"Ubiquitin specific peptidase 27, X-linked",X,49879948-49882565,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA077264,NA,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:6.14e-4 (unfavourable), Pancreatic cancer:9.31e-4 (favourable)",Expressed in all,Tissue enhanced,NA,placenta: 19.7,cerebral cortex: 10.3,Mixed,NA,NA
USP40,FLJ10785,ENSG00000085982,Ubiquitin specific peptidase 40,2,233475520-233566782,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA005821,Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 31.5,Mixed,NA,NA
USP6,"HRP1, Tre-2, TRE17, Tre2, TRESMCR",ENSG00000129204,Ubiquitin specific peptidase 6,17,5116438-5175034,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046969,NA,NA,Uncertain,Vesicles,NA,Tissue enriched,Group enriched,5,ovary: 3.5;skeletal muscle: 7.5;testis: 17.1,smooth muscle: 1.8,Mixed,NA,NA
USP9X,"DFFRX, FAF, MRX99",ENSG00000124486,"Ubiquitin specific peptidase 9, X-linked",X,41085635-41236579,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB011618, HPA047417, CAB070164",Approved,NA,Uncertain,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,parathyroid gland: 90.1,Expressed in all,NA,NA
USP9Y,DFFRY,ENSG00000114374,"Ubiquitin specific peptidase 9, Y-linked",Y,12701231-12860839,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057687,NA,NA,Uncertain,Vesicles,NA,Tissue enhanced,Tissue enhanced,NA,prostate: 9.9,seminal vesicle: 6.9,Cell line enhanced,NA,RPTEC TERT1: 13.3
UTP3,"CRLZ1, DKFZp761F222, FLJ23256, SAS10",ENSG00000132467,"UTP3, small subunit processome component homolog (S. cerevisiae)",4,70688479-70690551,Predicted intracellular proteins,Evidence at protein level,"HPA035655, HPA041453",Approved,NA,Supported,Nucleoli<br>Vesicles,Renal cancer:3.16e-4 (favourable),Expressed in all,Expressed in all,NA,NA,spleen: 43.2,Expressed in all,NA,NA
VAC14,"ArPIKfyve, FLJ10305, TAX1BP2",ENSG00000103043,"Vac14, PIKFYVE complex component",16,70687439-70801161,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA027766,Approved,NA,Approved,Vesicles<br>Cytosol,"Renal cancer:1.56e-6 (favourable), Cervical cancer:8.33e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 31.6,Expressed in all,NA,NA
VAMP7,"SYBL1, TI-VAMP, VAMP-7",ENSG00000124333,Vesicle associated membrane protein 7,X,155881293-155943769,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA036733,Approved,NA,Supported,Vesicles,Renal cancer:2.83e-4 (favourable),Expressed in all,Expressed in all,NA,NA,placenta: 57.2,Expressed in all,NA,NA
VAV2,NA,ENSG00000160293,Vav guanine nucleotide exchange factor 2,9,133761894-133992604,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003224,Uncertain,NA,Approved,Vesicles,"Renal cancer:7.39e-7 (favourable), Thyroid cancer:4.33e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,adrenal gland: 32.2,Mixed,NA,NA
VBP1,"PFD3, PFDN3",ENSG00000155959,VHL binding protein 1,X,155197007-155239817,Predicted intracellular proteins,Evidence at protein level,"CAB006260, HPA023230",Approved,NA,Supported,Vesicles<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,cerebral cortex: 85.3,Expressed in all,NA,NA
VCAN,"CSPG2, PG-M",ENSG00000038427,Versican,5,83471465-83582303,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA004726, CAB008979",Enhanced,NA,Supported,Vesicles,"Stomach cancer:1.41e-4 (unfavourable), Renal cancer:5.17e-4 (unfavourable), Melanoma:7.59e-4 (unfavourable)",Expressed in all,Tissue enhanced,NA,appendix: 105.5;placenta: 104.6,smooth muscle: 67.1,Cell line enhanced,NA,AF22: 296.8;RPTEC TERT1: 288.7;U-2197: 156.9
VGF,"SCG7, SgVII",ENSG00000128564,VGF nerve growth factor inducible,7,101162509-101165593,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA055177, HPA072505",Enhanced,NA,Supported,Golgi apparatus<br>Vesicles,"Endometrial cancer:4.25e-4 (unfavourable), Glioma:4.43e-4 (unfavourable)",Tissue enriched,Tissue enriched,22,cerebral cortex: 46.1,adipose tissue: 2.0,Group enriched,11,SH-SY5Y: 182.3;SK-MEL-30: 372.7;U-2 OS: 87.3;WM-115: 139.3
VLDLR,"CARMQ1, CHRMQ1, VLDLRCH",ENSG00000147852,Very low density lipoprotein receptor,9,2621834-2660053,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB032462, HPA051312",Uncertain,NA,Approved,Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center,Endometrial cancer:5.95e-4 (favourable),Expressed in all,Tissue enhanced,NA,ovary: 110.0;parathyroid gland: 124.0,fallopian tube: 43.7,Cell line enhanced,NA,BEWO: 60.5
VN1R1,"V1RL1, VNR19I1, ZVNH1, ZVNR1",ENSG00000178201,Vomeronasal 1 receptor 1,19,57454790-57457142,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA062209,NA,NA,Uncertain,Nucleus<br>Vesicles,NA,Mixed,Mixed,NA,NA,epididymis: 2.7,Cell line enhanced,NA,HEK93: 2.6;U-266/70: 1.9;U-266/84: 2.3
VPS13D,"FLJ10619, KIAA0453",ENSG00000048707,Vacuolar protein sorting 13 homolog D,1,12230067-12512047,Predicted intracellular proteins,Evidence at protein level,"HPA027332, HPA051621",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:7.42e-12 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 29.5,Expressed in all,NA,NA
VPS29,"DC15, DC7, PEP11",ENSG00000111237,"VPS29, retromer complex component",12,110491097-110502117,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039748,Uncertain,NA,Supported,Vesicles<br>Cytosol,"Liver cancer:2.79e-5 (unfavourable), Ovarian cancer:7.70e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 109.0,Expressed in all,NA,NA
VPS37A,"FLJ32642, HCRP1, PQBP2, SPG53",ENSG00000155975,"VPS37A, ESCRT-I subunit",8,17246571-17302427,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA024705, HPA024781",Enhanced,NA,Approved,Vesicles<br>Centrosome<br>Cytosol,NA,Expressed in all,Expressed in all,NA,NA,testis: 57.3,Expressed in all,NA,NA
VPS37C,FLJ20847,ENSG00000167987,"VPS37C, ESCRT-I subunit",11,61130256-61161617,Predicted intracellular proteins,Evidence at protein level,HPA043348,Approved,NA,Approved,Nucleus<br>Vesicles,"Renal cancer:2.37e-7 (favourable), Liver cancer:5.85e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,skin: 25.2,Expressed in all,NA,NA
VPS37D,"MGC35352, WBSCR24",ENSG00000176428,"VPS37D, ESCRT-I subunit",7,73667825-73672112,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA040978,Uncertain,NA,Approved,Vesicles,"Renal cancer:5.80e-9 (favourable), Pancreatic cancer:2.07e-5 (favourable)",Expressed in all,Mixed,NA,NA,cerebral cortex: 6.3,Cell line enhanced,NA,SH-SY5Y: 12.4
VPS4B,"SKD1, SKD1B, VPS4-2",ENSG00000119541,Vacuolar protein sorting 4 homolog B,18,63389190-63422483,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040393, CAB046445, HPA057649",Approved,NA,Approved,Vesicles<br>Intermediate filaments,Renal cancer:1.23e-4 (favourable),Expressed in all,Expressed in all,NA,NA,esophagus: 82.7,Expressed in all,NA,NA
VPS51,"ANG2, ANG3, C11orf2, C11orf3, FFR",ENSG00000149823,"VPS51, GARP complex subunit",11,65089324-65111860,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039650, HPA061447",Uncertain,NA,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles,Renal cancer:2.41e-9 (favourable),Expressed in all,Expressed in all,NA,NA,ovary: 101.9,Expressed in all,NA,NA
VRK3,NA,ENSG00000105053,Vaccinia related kinase 3,19,49976467-50025946,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA056489,Approved,NA,Supported,Nucleus<br>Vesicles,"Renal cancer:1.83e-4 (favourable), Urothelial cancer:5.66e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 168.6,Expressed in all,NA,NA
VSIG1,MGC44287,ENSG00000101842,V-set and immunoglobulin domain containing 1,X,108044970-108079184,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA001445, HPA036310, HPA036311",Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Group enriched,Group enriched,10,stomach: 185.7;testis: 91.1,gallbladder: 14.3,Cell line enhanced,NA,HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2
VSTM1,UNQ3033,ENSG00000189068,V-set and transmembrane domain containing 1,19,54040825-54063953,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA059365,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,38,bone marrow: 35.4,urinary bladder: 0.9,Not detected,NA,NA
VSTM4,"C10orf72, FLJ31737",ENSG00000165633,V-set and transmembrane domain containing 4,10,49014245-49115509,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA017279,Uncertain,NA,Approved,Nucleus<br>Vesicles,Urothelial cancer:4.25e-4 (unfavourable),Tissue enriched,Mixed,NA,NA,adrenal gland: 54.8,Cell line enhanced,NA,RH-30: 9.1;U-138 MG: 10.5;U-2197: 22.4;U-87 MG: 11.4
VTA1,"C6orf55, HSPC228, My012",ENSG00000009844,Vesicle trafficking 1,6,142147162-142224689,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030968, HPA030969",Approved,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:6.58e-6 (unfavourable), Breast cancer:7.02e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 60.9,Expressed in all,NA,NA
VTI1A,"MVti1, Vti1-rp2, Vti1a",ENSG00000151532,Vesicle transport through interaction with t-SNAREs 1A,10,112446998-112818744,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA054108,Supported,NA,Supported,Golgi apparatus<br>Vesicles,"Liver cancer:6.50e-5 (unfavourable), Renal cancer:7.27e-5 (favourable)",Expressed in all,Mixed,NA,NA,parathyroid gland: 12.1,Expressed in all,NA,NA
VTI1B,VTI2,ENSG00000100568,Vesicle transport through interaction with t-SNAREs 1B,14,67647075-67674831,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA044121, HPA048150, HPA060118",Approved,NA,Enhanced,Golgi apparatus<br>Vesicles,Renal cancer:3.53e-12 (favourable),Expressed in all,Expressed in all,NA,NA,epididymis: 64.9,Expressed in all,NA,NA
VTN,VN,ENSG00000109072,Vitronectin,17,28367276-28373091,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016695, CAB016765, HPA060933",Supported,NA,Supported,Endoplasmic reticulum<br>Vesicles,"Renal cancer:4.10e-11 (unfavourable), Liver cancer:3.74e-4 (favourable)",Tissue enriched,Tissue enriched,28,liver: 2554.5,gallbladder: 91.2,Cell line enriched,9,CACO-2: 1044.7
VWA8,KIAA0564,ENSG00000102763,Von Willebrand factor A domain containing 8,13,41566837-41961120,Predicted intracellular proteins,Evidence at protein level,"HPA039075, HPA045478",Uncertain,NA,Approved,Vesicles<br>Lipid droplets,"Renal cancer:6.38e-14 (favourable), Liver cancer:8.56e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 21.8,Mixed,NA,NA
VWCE,"FLJ32009, URG11, VWC1",ENSG00000167992,Von Willebrand factor C and EGF domains,11,61258286-61295424,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040401, HPA043921",Uncertain,NA,Supported,Nucleus<br>Vesicles<br>Cytosol,NA,Group enriched,Tissue enhanced,NA,fallopian tube: 5.1;ovary: 5.8,liver: 3.7,Cell line enhanced,NA,Hep G2: 14.6;HSkMC: 8.6;REH: 11.0
WASHC1,"FAM39E, FLJ00038, WASH1",ENSG00000181404,WASH complex subunit 1,9,14521-29739,Predicted intracellular proteins,Evidence at protein level,HPA002689,Uncertain,NA,Supported,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,epididymis: 24.5,Expressed in all,NA,NA
WASHC2A,"bA56A21.1, bA98I6.1, FAM21A, FAM21B, FLJ10824",ENSG00000099290,WASH complex subunit 2A,10,50067888-50133506,Predicted intracellular proteins,Evidence at protein level,"HPA047844, HPA060975, HPA061022",Supported,NA,Supported,Nucleoli<br>Vesicles<br>Cytosol,Liver cancer:6.75e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 42.7,Expressed in all,NA,NA
WASHC2C,"Em:AC012044.3, FAM21C, KIAA0592",ENSG00000172661,WASH complex subunit 2C,10,45727200-45792961,Predicted intracellular proteins,Evidence at protein level,"HPA047844, HPA060975, HPA061022",Supported,NA,Supported,Nucleoli<br>Vesicles<br>Cytosol,"Liver cancer:1.35e-5 (unfavourable), Lung cancer:4.69e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 41.9,Expressed in all,NA,NA
WASHC3,"CCDC53, CGI-116",ENSG00000120860,WASH complex subunit 3,12,102012927-102062149,Predicted intracellular proteins,Evidence at protein level,"HPA038338, HPA038339",Approved,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 165.7,Expressed in all,NA,NA
WBSCR28,MGC26719,ENSG00000175877,Williams-Beuren syndrome chromosome region 28,7,73861159-73865893,Predicted membrane proteins,Evidence at transcript level,HPA077196,NA,NA,Approved,Vesicles,NA,Mixed,Tissue enriched,99,testis: 36.2,duodenum: 0.3,Cell line enhanced,NA,MCF7: 1.2
WDR48,"KIAA1449, P80, SPG60",ENSG00000114742,WD repeat domain 48,3,39051998-39096671,Predicted intracellular proteins,Evidence at protein level,"HPA038421, HPA058015",Approved,NA,Supported,Vesicles,Renal cancer:1.63e-7 (favourable),Expressed in all,Expressed in all,NA,NA,testis: 72.5,Expressed in all,NA,NA
WDR54,FLJ12953,ENSG00000005448,WD repeat domain 54,2,74421678-74425755,Predicted intracellular proteins,Evidence at protein level,"HPA043257, HPA053558",Enhanced,NA,Approved,Vesicles<br>Cytosol,NA,Expressed in all,Tissue enhanced,NA,fallopian tube: 113.2,testis: 48.2,Expressed in all,NA,NA
WDR72,FLJ38736,ENSG00000166415,WD repeat domain 72,15,53513741-53762878,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA048212, HPA057410, HPA059819",Uncertain,NA,Approved,Vesicles,"Renal cancer:3.33e-16 (favourable), Thyroid cancer:1.80e-4 (unfavourable)",Mixed,Group enriched,6,kidney: 104.7;thyroid gland: 92.1,liver: 16.9,Cell line enhanced,NA,A549: 8.9;EFO-21: 5.9;NTERA-2: 5.9;RPMI-8226: 11.9;RPTEC TERT1: 8.1;U-266/70: 5.7
WDR83,MORG1,ENSG00000123154,WD repeat domain 83,19,12666800-12675832,Predicted intracellular proteins,Evidence at protein level,"HPA042629, HPA042838",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Centrosome,"Urothelial cancer:3.12e-4 (favourable), Pancreatic cancer:5.44e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 9.4,Mixed,NA,NA
WDTC1,"ADP, DCAF9, KIAA1037",ENSG00000142784,WD and tetratricopeptide repeats 1,1,27234516-27308633,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA028177, HPA028180, HPA028182",Uncertain,NA,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:8.84e-8 (favourable), Cervical cancer:4.51e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 73.7,Expressed in all,NA,NA
WDYHV1,"C8orf32, FLJ10204",ENSG00000156795,WDYHV motif containing 1,8,123416725-123467230,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA024823, HPA053680",Approved,NA,Supported,Nucleoplasm<br>Vesicles,"Endometrial cancer:4.93e-5 (unfavourable), Liver cancer:3.47e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 18.5,Expressed in all,NA,NA
WNK3,PRKWNK3,ENSG00000196632,WNK lysine deficient protein kinase 3,X,54192823-54358642,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA077678,NA,NA,Approved,Vesicles,NA,Mixed,Group enriched,6,epididymis: 14.3;testis: 18.6,ovary: 2.6,Cell line enhanced,NA,AF22: 4.4;HAP1: 5.4;NTERA-2: 9.1;SiHa: 4.8;U-2 OS: 4.1
WNT2,"INT1L1, IRP",ENSG00000105989,Wnt family member 2,7,117276631-117323289,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,HPA020920,NA,NA,Approved,Vesicles,NA,Mixed,Group enriched,6,endometrium: 23.8;placenta: 93.2,lung: 9.2,Cell line enriched,6,U-2197: 19.1
WNT2B,"WNT13, XWNT2",ENSG00000134245,Wnt family member 2B,1,112466541-112530165,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA047274, HPA060696, HPA066368",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Tissue enhanced,Mixed,NA,NA,seminal vesicle: 20.0,Cell line enhanced,NA,HSkMC: 6.3
WNT4,WNT-4,ENSG00000162552,Wnt family member 4,1,22117305-22143969,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011397,Uncertain,NA,Approved,Vesicles,"Pancreatic cancer:4.90e-4 (favourable), Melanoma:5.34e-4 (unfavourable)",Mixed,Tissue enhanced,NA,skin: 49.2,ovary: 15.3,Cell line enhanced,NA,HaCaT: 7.6;SCLC-21H: 12.2;SK-BR-3: 6.6
WNT5B,NA,ENSG00000111186,Wnt family member 5B,12,1529891-1647243,Predicted secreted proteins,Evidence at protein level,HPA061991,NA,NA,Approved,Vesicles,NA,Expressed in all,Tissue enhanced,NA,prostate: 34.7,seminal vesicle: 27.9,Cell line enhanced,NA,BJ: 195.3;BJ hTERT+ SV40 Large T+: 154.0;BJ hTERT+ SV40 Large T+ RasG12V: 132.9;HBF TERT88: 139.5;hTEC/SVTERT24-B: 144.8;U-138 MG: 140.4
XAB2,"HCNP, HCRN, NTC90, SYF1",ENSG00000076924,XPA binding protein 2,19,7619525-7629565,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA048751,NA,NA,Approved,Nucleus<br>Vesicles,"Cervical cancer:4.04e-4 (favourable), Endometrial cancer:4.96e-4 (favourable), Pancreatic cancer:7.47e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,testis: 39.3,Expressed in all,NA,NA
XAGE5,"CT12.5, GAGED5, XAGE-5",ENSG00000171405,X antigen family member 5,X,52812204-52818301,Predicted intracellular proteins,Evidence at transcript level,"HPA052507, HPA055941, HPA059045",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Tissue enhanced,Tissue enriched,10,testis: 2.1,skin: 0.2,Cell line enriched,47,U-2 OS: 22.9
XK,"Kx, NA, NAC, X1k, XKR1",ENSG00000047597,X-linked Kx blood group,X,37685759-37732130,"Blood group antigen proteins, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA019036,Approved,NA,Approved,Nucleoplasm<br>Vesicles<br>Mitochondria,NA,Mixed,Mixed,NA,NA,rectum: 12.1,Cell line enhanced,NA,HEL: 39.5;K-562: 25.8
XPO1,"CRM1, emb",ENSG00000082898,Exportin 1,2,61477849-61538626,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB010184, HPA042933",Supported,NA,Enhanced,Nucleoplasm<br>Nuclear membrane<br>Vesicles<br>Cytosol,"Liver cancer:1.84e-5 (unfavourable), Renal cancer:3.74e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 139.1,Expressed in all,NA,NA
XRCC2,FANCU,ENSG00000196584,X-ray repair cross complementing 2,7,152644779-152676165,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA065153,NA,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,testis: 3.7,Mixed,NA,NA
YBX1,"BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1",ENSG00000065978,Y-box binding protein 1,1,42682427-42702349,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB005875, HPA040304, HPA057159",Supported,NA,Enhanced,Vesicles<br>Cytosol,"Liver cancer:9.87e-10 (unfavourable), Renal cancer:3.59e-7 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 1542.9,Expressed in all,NA,NA
YIF1A,"54TM, FinGER7, YIF1, YIF1P",ENSG00000174851,"Yip1 interacting factor homolog A, membrane trafficking protein",11,66284580-66289170,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014840,Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Microtubule organizing center,Urothelial cancer:8.70e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 62.3,Expressed in all,NA,NA
YIF1B,FinGER8,ENSG00000167645,"Yip1 interacting factor homolog B, membrane trafficking protein",19,38305104-38317273,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039328, HPA055257, HPA062675",Approved,NA,Approved,Golgi apparatus<br>Vesicles,"Liver cancer:4.53e-5 (unfavourable), Pancreatic cancer:1.88e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,cerebral cortex: 49.5,Expressed in all,NA,NA
YIPF5,"FinGER5, SMAP-5",ENSG00000145817,Yip1 domain family member 5,5,144158159-144170714,Predicted membrane proteins,Evidence at protein level,"HPA042338, HPA073622",Enhanced,NA,Supported,Nucleoplasm<br>Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles,"Head and neck cancer:1.12e-5 (unfavourable), Liver cancer:3.26e-5 (unfavourable), Breast cancer:7.83e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 43.2,Expressed in all,NA,NA
YIPF6,"FinGER6, MGC21416",ENSG00000181704,Yip1 domain family member 6,X,68498323-68537285,Predicted membrane proteins,Evidence at protein level,HPA003720,Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Expressed in all,NA,NA,thyroid gland: 32.8,Mixed,NA,NA
YY1,"DELTA, INO80S, NF-E1, UCRBP, YIN-YANG-1",ENSG00000100811,YY1 transcription factor,14,100238298-100282792,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001119, CAB009392",Supported,NA,Supported,Nucleoplasm<br>Nucleoli fibrillar center<br>Vesicles,"Liver cancer:3.44e-4 (unfavourable), Endometrial cancer:6.13e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 65.8,Expressed in all,NA,NA
ZADH2,MGC45594,ENSG00000180011,Zinc binding alcohol dehydrogenase domain containing 2,18,75195108-75209348,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021468, HPA053646",Uncertain,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,"Renal cancer:1.02e-6 (favourable), Thyroid cancer:1.94e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,placenta: 52.3,Expressed in all,NA,NA
ZBED6CL,C7orf29,ENSG00000188707,ZBED6 C-terminal like,7,150329789-150332721,Predicted intracellular proteins,Evidence at transcript level,"HPA019724, HPA055805",Approved,NA,Approved,Nuclear membrane<br>Vesicles,"Renal cancer:1.38e-5 (unfavourable), Pancreatic cancer:2.44e-5 (favourable), Glioma:5.65e-5 (unfavourable), Breast cancer:9.48e-5 (favourable)",Expressed in all,Tissue enhanced,NA,adrenal gland: 31.7;parathyroid gland: 30.4,lymph node: 9.8,Cell line enhanced,NA,HDLM-2: 80.9;K-562: 33.8
ZBTB39,"KIAA0352, ZNF922",ENSG00000166860,Zinc finger and BTB domain containing 39,12,56998834-57006446,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA016866, HPA020306",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 13.4,Expressed in all,NA,NA
ZC3H10,"FLJ14451, ZC3HDC10",ENSG00000135482,Zinc finger CCCH-type containing 10,12,56118159-56127514,Predicted intracellular proteins,Evidence at protein level,"HPA039236, HPA062265",Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,testis: 10.3,Expressed in all,NA,NA
ZC3H12B,"CXorf32, MCPIP2",ENSG00000102053,Zinc finger CCCH-type containing 12B,X,65366638-65507887,Predicted intracellular proteins,Evidence at transcript level,HPA000836,Uncertain,NA,Approved,Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 4.6,endometrium: 2.2,Cell line enhanced,NA,AF22: 2.1
ZC4H2,"HCA127, KIAA1166, WWS",ENSG00000126970,Zinc finger C4H2-type containing,X,64915802-65034713,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049584,Approved,NA,Approved,Vesicles<br>Microtubules,Thyroid cancer:3.51e-5 (unfavourable),Mixed,Mixed,NA,NA,parathyroid gland: 17.5,Cell line enhanced,NA,NTERA-2: 51.9;REH: 36.2
ZCCHC3,"C20orf99, dJ1103G7.7",ENSG00000247315,Zinc finger CCHC-type containing 3,20,296968-300321,Predicted intracellular proteins,Evidence at protein level,HPA042972,NA,NA,Approved,Vesicles,Pancreatic cancer:1.29e-4 (favourable),Expressed in all,Expressed in all,NA,NA,placenta: 23.2,Expressed in all,NA,NA
ZDHHC13,"FLJ10852, FLJ10941, HIP14L",ENSG00000177054,Zinc finger DHHC-type containing 13,11,19117099-19176422,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA016759, HPA018791",Uncertain,NA,Enhanced,Vesicles,NA,Expressed in all,Mixed,NA,NA,esophagus: 40.4,Expressed in all,NA,NA
ZDHHC17,"HIP14, HYPH, KIAA0946",ENSG00000186908,Zinc finger DHHC-type containing 17,12,76763588-76853696,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA016807, HPA058674",Approved,NA,Supported,Golgi apparatus<br>Vesicles<br>Aggresome,Renal cancer:7.11e-5 (unfavourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 45.2,Expressed in all,NA,NA
ZDHHC24,NA,ENSG00000174165,Zinc finger DHHC-type containing 24,11,66520637-66546238,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA016619,Approved,NA,Approved,Vesicles<br>Cytosol,Glioma:2.39e-4 (unfavourable),Expressed in all,Mixed,NA,NA,parathyroid gland: 10.9,Expressed in all,NA,NA
ZFAND3,"FLJ13222, TEX27",ENSG00000156639,Zinc finger AN1-type containing 3,6,37819499-38154624,Predicted intracellular proteins,Evidence at protein level,HPA016755,Approved,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Expressed in all,NA,NA,testis: 185.0,Expressed in all,NA,NA
ZFP36,"G0S24, NUP475, RNF162A, TIS11, TTP",ENSG00000128016,ZFP36 ring finger protein,19,39406813-39409412,Predicted intracellular proteins,Evidence at transcript level,HPA006009,Approved,NA,Approved,Vesicles<br>Intermediate filaments,NA,Expressed in all,Expressed in all,NA,NA,gallbladder: 928.0,Expressed in all,NA,NA
ZFP37,ZNF906,ENSG00000136866,ZFP37 zinc finger protein,9,113038380-113056759,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA049112,Uncertain,NA,Approved,Nucleus<br>Vesicles,Glioma:9.22e-5 (favourable),Mixed,Mixed,NA,NA,ovary: 8.8,Mixed,NA,NA
ZFYVE16,"KIAA0305, PPP1R69",ENSG00000039319,Zinc finger FYVE-type containing 16,5,80408013-80479350,Predicted intracellular proteins,Evidence at protein level,"HPA035935, HPA035936",Supported,NA,Enhanced,Vesicles<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,"cervix, uterine: 24.0",Expressed in all,NA,NA
ZFYVE9,"MADHIP, PPP1R173, SARA, SMADIP",ENSG00000157077,Zinc finger FYVE-type containing 9,1,52142094-52346686,Predicted intracellular proteins,Evidence at protein level,"CAB017702, HPA065852, HPA065862",Approved,NA,Enhanced,Vesicles<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 45.2,Mixed,NA,NA
ZG16B,"HRPE773, JCLN2, PRO1567",ENSG00000162078,Zymogen granule protein 16B,16,2830169-2839585,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041125, HPA053549",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,Endometrial cancer:3.48e-6 (favourable),Tissue enhanced,Tissue enriched,225,salivary gland: 19471.0,prostate: 86.7,Cell line enhanced,NA,MCF7: 20.7;SK-BR-3: 18.1;T-47d: 20.8
ZGLP1,"GATAD3, GLP-1, GLP1",ENSG00000220201,"Zinc finger, GATA-like protein 1",19,10304803-10309880,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA049855,Uncertain,NA,Approved,Nucleus<br>Vesicles,NA,Mixed,Mixed,NA,NA,testis: 3.1,Cell line enhanced,NA,NB-4: 20.8
ZIC5,NA,ENSG00000139800,Zic family member 5,13,99962964-99971909,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA074045,NA,NA,Uncertain,Nucleoplasm<br>Vesicles,NA,Mixed,Group enriched,45,cerebral cortex: 2.3;testis: 6.6,all non-specific tissues: 0.0,Cell line enhanced,NA,AF22: 21.7;NTERA-2: 15.0;SCLC-21H: 100.6
ZMIZ1,"FLJ13541, hZIMP10, KIAA1224, MIZ, RAI17, RP11-519K18.1, Zimp10",ENSG00000108175,Zinc finger MIZ-type containing 1,10,79069035-79316528,Predicted intracellular proteins,Evidence at protein level,HPA045144,Approved,NA,Approved,Nucleoplasm<br>Vesicles,Renal cancer:3.64e-7 (favourable),Expressed in all,Expressed in all,NA,NA,cerebral cortex: 65.3,Mixed,NA,NA
ZMYND19,MIZIP,ENSG00000165724,Zinc finger MYND-type containing 19,9,137582079-137590490,Predicted intracellular proteins,Evidence at protein level,"HPA020642, HPA050761",Supported,NA,Approved,Golgi apparatus<br>Vesicles,Liver cancer:1.70e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,testis: 46.1,Expressed in all,NA,NA
ZNF132,pHZ-12,ENSG00000131849,Zinc finger protein 132,19,58432814-58440222,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA008726,Uncertain,NA,Approved,Vesicles<br>Intermediate filaments,"Renal cancer:7.26e-13 (favourable), Pancreatic cancer:1.92e-4 (favourable)",Mixed,Mixed,NA,NA,parathyroid gland: 11.6,Mixed,NA,NA
ZNF133,"pHZ-13, pHZ-66, ZNF150",ENSG00000125846,Zinc finger protein 133,20,18288283-18316996,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA001493,Enhanced,NA,Approved,Nucleus<br>Vesicles,"Liver cancer:4.46e-6 (unfavourable), Renal cancer:2.20e-5 (unfavourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 20.1,Mixed,NA,NA
ZNF143,"pHZ-1, SBF, STAF",ENSG00000166478,Zinc finger protein 143,11,9460319-9528524,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003263, HPA074818",Supported,NA,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,"Liver cancer:1.76e-5 (unfavourable), Renal cancer:6.78e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 31.1,Expressed in all,NA,NA
ZNF213,"CR53, ZKSCAN21, ZSCAN53",ENSG00000085644,Zinc finger protein 213,16,3129777-3142805,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA035000, HPA056750",Uncertain,NA,Approved,Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol,Liver cancer:6.74e-4 (unfavourable),Expressed in all,Mixed,NA,NA,testis: 16.3,Expressed in all,NA,NA
ZNF215,"ZKSCAN11, ZSCAN43",ENSG00000149054,Zinc finger protein 215,11,6926404-7001004,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA047243, HPA051010",Enhanced,NA,Approved,Nucleoplasm<br>Vesicles,NA,Mixed,Mixed,NA,NA,lymph node: 4.5,Cell line enhanced,NA,U-698: 14.5
ZNF232,ZSCAN11,ENSG00000167840,Zinc finger protein 232,17,5105541-5123116,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA027309, HPA028611",Uncertain,NA,Supported,Nucleus<br>Vesicles<br>Cytosol,"Liver cancer:4.66e-4 (unfavourable), Pancreatic cancer:6.55e-4 (favourable)",Expressed in all,Mixed,NA,NA,ovary: 4.3,Mixed,NA,NA
ZNF266,HZF1,ENSG00000174652,Zinc finger protein 266,19,9412598-9435578,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA026836, HPA054110",Uncertain,NA,Enhanced,Nucleus<br>Vesicles<br>Rods & Rings,"Head and neck cancer:3.94e-6 (favourable), Pancreatic cancer:3.03e-5 (favourable), Urothelial cancer:9.15e-5 (favourable), Cervical cancer:1.41e-4 (favourable), Renal cancer:1.82e-4 (unfavourable), Lung cancer:4.47e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,epididymis: 117.7,Mixed,NA,NA
ZNF302,"ZNF135L, ZNF140L, ZNF327",ENSG00000089335,Zinc finger protein 302,19,34677639-34686397,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059503,NA,NA,Approved,Vesicles<br>Cytokinetic bridge,"Endometrial cancer:2.03e-5 (unfavourable), Urothelial cancer:9.85e-5 (favourable), Renal cancer:5.41e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 42.1,Mixed,NA,NA
ZNF326,"FLJ20403, ZAN75, Zfp326, ZIRD",ENSG00000162664,Zinc finger protein 326,1,89995112-90035531,Predicted intracellular proteins,Evidence at protein level,"HPA028450, HPA028461, HPA028466",Supported,NA,Enhanced,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Urothelial cancer:2.84e-4 (favourable), Breast cancer:9.46e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 29.5,Expressed in all,NA,NA
ZNF341,dJ553F4.3,ENSG00000131061,Zinc finger protein 341,20,33731657-33792269,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA023240, HPA024607, HPA067108",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:1.87e-4 (unfavourable), Head and neck cancer:3.93e-4 (favourable)",Expressed in all,Mixed,NA,NA,testis: 2.3,Mixed,NA,NA
ZNF365,"KIAA0844, UAN",ENSG00000138311,Zinc finger protein 365,10,62374192-62672011,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA052446,Enhanced,NA,Supported,Vesicles<br>Microtubule organizing center,NA,Mixed,Tissue enhanced,NA,cerebral cortex: 54.5,parathyroid gland: 10.9,Cell line enhanced,NA,HaCaT: 18.7;PC-3: 12.7;U-251 MG: 14.7
ZNF37A,"KOX21, ZNF37",ENSG00000075407,Zinc finger protein 37A,10,38094334-38150293,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003172,Approved,NA,Approved,Vesicles,"Renal cancer:2.31e-4 (unfavourable), Liver cancer:2.83e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 18.1,Expressed in all,NA,NA
ZNF442,FLJ14356,ENSG00000198342,Zinc finger protein 442,19,12345949-12365905,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA045738, HPA053407",Uncertain,NA,Approved,Nuclear membrane<br>Vesicles,NA,Mixed,Mixed,NA,NA,ovary: 6.0,Mixed,NA,NA
ZNF469,KIAA1858,ENSG00000225614,Zinc finger protein 469,16,88427471-88440757,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA069784,NA,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,"cervix, uterine: 2.2",Cell line enhanced,NA,SiHa: 5.3;THP-1: 4.3
ZNF526,"KIAA1951, MGC4267",ENSG00000167625,Zinc finger protein 526,19,42220271-42228201,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA023070, HPA056609",Uncertain,NA,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,skin: 6.2,Expressed in all,NA,NA
ZNF530,KIAA1508,ENSG00000183647,Zinc finger protein 530,19,57599885-57612722,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA045868,Uncertain,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,spleen: 3.1,Cell line enhanced,NA,HEK93: 68.7;U-266/84: 40.3
ZNF540,DKFZp547B0714,ENSG00000171817,Zinc finger protein 540,19,37551406-37614097,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003444,Supported,NA,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Mixed,Mixed,NA,NA,thyroid gland: 13.3,Mixed,NA,NA
ZNF550,MGC41917,ENSG00000251369,Zinc finger protein 550,19,57535257-57559863,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003251,Uncertain,NA,Approved,Vesicles<br>Microtubules,Prostate cancer:2.21e-4 (unfavourable),Expressed in all,Mixed,NA,NA,ovary: 12.7,Mixed,NA,NA
ZNF569,"FLJ32053, ZAP1",ENSG00000196437,Zinc finger protein 569,19,37411155-37469275,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA052994,Uncertain,NA,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,NA,Mixed,Mixed,NA,NA,testis: 20.5,Mixed,NA,NA
ZNF586,FLJ20070,ENSG00000083828,Zinc finger protein 586,19,57769655-57819939,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA030306, HPA060782",Approved,NA,Approved,Nucleoli fibrillar center<br>Vesicles,"Breast cancer:9.83e-5 (favourable), Urothelial cancer:5.36e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,bone marrow: 16.3,Mixed,NA,NA
ZNF605,NA,ENSG00000196458,Zinc finger protein 605,12,132918308-132956306,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA061970, HPA062655",Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,NA,Expressed in all,Mixed,NA,NA,parathyroid gland: 11.3,Mixed,NA,NA
ZNF613,FLJ13590,ENSG00000176024,Zinc finger protein 613,19,51927147-51948759,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA026833,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles,Urothelial cancer:1.92e-6 (favourable),Expressed in all,Tissue enhanced,NA,prostate: 32.4,placenta: 9.8,Mixed,NA,NA
ZNF614,FLJ21941,ENSG00000142556,Zinc finger protein 614,19,52012765-52030240,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA021197,Uncertain,NA,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,NA,Expressed in all,Mixed,NA,NA,prostate: 14.0,Expressed in all,NA,NA
ZNF624,KIAA1349,ENSG00000197566,Zinc finger protein 624,17,16620737-16653856,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA023157, HPA023244",Uncertain,NA,Approved,Vesicles,NA,Mixed,Mixed,NA,NA,testis: 9.0,Mixed,NA,NA
ZNF626,NA,ENSG00000188171,Zinc finger protein 626,19,20620061-20661596,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA045631,Uncertain,NA,Approved,Nucleoplasm<br>Nuclear membrane<br>Vesicles,NA,Mixed,Expressed in all,NA,NA,parathyroid gland: 52.8,Mixed,NA,NA
ZNF638,"MGC26130, NP220, ZFML, Zfp638",ENSG00000075292,Zinc finger protein 638,2,71276561-71435069,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036784, HPA057395",Supported,NA,Enhanced,Nucleoplasm<br>Vesicles,Urothelial cancer:8.73e-5 (favourable),Expressed in all,Expressed in all,NA,NA,parathyroid gland: 58.9,Expressed in all,NA,NA
ZNF644,"BM-005, KIAA1221, MGC60165, MGC70410",ENSG00000122482,Zinc finger protein 644,1,90915298-91022272,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA057795,Uncertain,NA,Uncertain,Vesicles,"Colorectal cancer:4.27e-4 (favourable), Endometrial cancer:8.39e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,thyroid gland: 31.0,Expressed in all,NA,NA
ZNF691,Zfp691,ENSG00000164011,Zinc finger protein 691,1,42846573-42852477,"Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA062527,Approved,NA,Approved,Nucleus<br>Nucleoli<br>Vesicles,"Liver cancer:7.33e-6 (unfavourable), Pancreatic cancer:6.25e-5 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 21.5,Expressed in all,NA,NA
ZNF768,FLJ23436,ENSG00000169957,Zinc finger protein 768,16,30524001-30526821,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA024630, HPA066512",Supported,NA,Approved,Nucleus<br>Vesicles,"Renal cancer:9.30e-6 (favourable), Urothelial cancer:6.46e-4 (favourable)",Expressed in all,Expressed in all,NA,NA,parathyroid gland: 55.9,Expressed in all,NA,NA
ZNF813,FLJ16542,ENSG00000198346,Zinc finger protein 813,19,53467735-53496255,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA056406,Uncertain,NA,Approved,Vesicles,NA,Expressed in all,Mixed,NA,NA,prostate: 8.1,Cell line enhanced,NA,RT4: 14.6
ZNHIT6,"BCD1, C1orf181, FLJ20729, NY-BR-75",ENSG00000117174,Zinc finger HIT-type containing 6,1,85649423-85708433,Predicted intracellular proteins,Evidence at protein level,HPA018132,Uncertain,NA,Approved,Nuclear speckles<br>Vesicles,Liver cancer:6.08e-6 (unfavourable),Expressed in all,Expressed in all,NA,NA,"cervix, uterine,endometrium: 21.1",Expressed in all,NA,NA
ZPR1,ZNF259,ENSG00000109917,ZPR1 zinc finger,11,116773799-116788050,Predicted intracellular proteins,Evidence at protein level,"CAB022596, HPA030979",Uncertain,NA,Approved,Vesicles,"Liver cancer:5.87e-6 (unfavourable), Head and neck cancer:8.01e-4 (unfavourable)",Expressed in all,Expressed in all,NA,NA,testis: 43.9,Expressed in all,NA,NA
ZSWIM3,"C20orf164, dJ337O18.7, PPP1R174",ENSG00000132801,Zinc finger SWIM-type containing 3,20,45857617-45879122,Predicted intracellular proteins,Evidence at protein level,"HPA055692, HPA060508",Uncertain,NA,Approved,Nucleoli fibrillar center<br>Vesicles<br>Cytosol,"Breast cancer:9.32e-5 (unfavourable), Endometrial cancer:4.21e-4 (unfavourable)",Expressed in all,Mixed,NA,NA,testis: 5.2,Mixed,NA,NA
ZXDC,"FLJ13861, MGC11349",ENSG00000070476,ZXD family zinc finger C,3,126437601-126475919,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA049593,NA,NA,Supported,Nucleoli<br>Vesicles,Liver cancer:2.27e-4 (unfavourable),Expressed in all,Expressed in all,NA,NA,bone marrow: 25.4,Expressed in all,NA,NA
